[
  {
    "id": "EP2287161B1",
    "text": "Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders AbstractA heterocyclic compound or a salt thereof represented by the formula (I): where R 2  represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or a lower alkenylene group; and R 1  represents a cylo C3-C8 alkyl group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. Claims (\n13\n)\n\n\n\n\n \n\n\nA heterocyclic compound or a salt thereof represented by the formula (1):\n\n \n \n\nwhere R\n2\n represents a hydrogen atom or a C1-C6 alkyl group;\n\nA represents a C1-C6 alkylene group or a C2-C6 alkenylene group; and\n\nR\n1\n represents a heterocyclic group selected from a saturated or unsaturated heteromonocyclic group having 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, oxygen atom and sulfur atom;\n\nwherein at least one group selected from the group consisting of the groups (1) to (66) below may be present as a substituent on the heterocyclic group represented by R\n1\n:\n\n(1) a C1-C6 alkyl group,\n\n\n(2) a C2-C6 alkenyl group,\n\n\n(3) a halogen substituted C1-C6 alkyl group,\n\n\n(4) a C1-C6 alkoxy group,\n\n\n(5) an aryloxy group,\n\n\n(6) a C1-C6 alkylthio group,\n\n\n(7) a halogen substituted C1-C6 alkoxy group,\n\n\n(8) a hydroxy group,\n\n\n(9) a protected hydroxy group,\n\n\n(10) a hydroxy C1-C6 alkyl group,\n\n\n(11) a protected hydroxy C1-C6 alkyl group,\n\n\n(12) a halogen atom,\n\n\n(13) a cyano group,\n\n\n(14) an aryl group,\n\n\n(15) a nitro group,\n\n\n(16) an amino group,\n\n\n(17) an amino group having a group(s) selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkanoyl group, a C1-C6 alkoxycarbonyl group, a C1-C6 alkylsulfonyl group, a carbamoyl group, a C1-C6 alkyl carbamoyl group, an amino C1-C6 alkanoyl group, a C1-C6 alkanoylamino C1-C6 alkanoyl group and a C1-C6 alkoxy carbonylamino C1-C6 alkanoyl group as a substituent,\n\n\n(18) a C1-C6 alkanoyl group,\n\n\n(19) an arylsulfonyl group that may have a C1-C6 alkyl group(s) on the aryl group,\n\n\n(20) a carboxy group,\n\n\n(21) a C1-C6 alkoxycarbonyl group,\n\n\n(22) a carboxy C1-C6 alkyl group,\n\n\n(23) a C1-C6 alkoxycarbonyl C1-C6 alkyl group,\n\n\n(24) a C1-C6 alkanoylamino C1-C6 alkanoyl group,\n\n\n(25) a carboxy C2-C6 alkenyl group,\n\n\n(26) a C1-C6 alkoxycarbonyl C2-C6 alkenyl group,\n\n\n(27) a carbamoyl C2-C6 alkenyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group and a halogen substituted C1-C6 alkyl group as a substituent,\n\n\n(28) a carbamoyl group that may have a group(s) selected from the group consisting of the groups (i) to (lxxviii) below as a substituent:\n\n(i) a C1-C6 alkyl group,\n\n\n(ii) a C1-C6 alkoxy group,\n\n\n(iii) a hydroxy C1-C6 alkyl group,\n\n\n(iv) a C1-C6 alkoxy C1-C6 alkyl group,\n\n\n(v) an aryloxy C1-C6 alkyl group,\n\n\n(vi) a halogen substituted C1-C6 alkyl group,\n\n\n(vii) an amino C1-C6 alkyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkanoyl group, an aroyl group and a carbamoyl group,\n\n\n(viii) a cyclo C3-C8 alkyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group, a hydroxy group, a C1-C6 alkoxycarbonyl group and a phenyl C1-C6 alkoxy group as a substituent,\n\n\n(ix) a cyclo C3-C8 alkyl substituted C1-C6 alkyl group,\n\n\n(x) a C2-C6 alkenyl group,\n\n\n(xi) a carbamoyl C1-C6 alkyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group, phenyl group that may have a C1-C6 alkyl group(s) and a phenyl group(s) that may have a C1-C6 alkoxy group(s) as a substituent,\n\n\n(xii) a C1-C6 alkoxycarbonyl C1-C6 alkyl group,\n\n\n(xiii) a furyl C1-C6 alkyl group (that may have a C1-C6 alkyl group(s) as a substituent) on the furyl group,\n\n\n(xiv) a tetrahydrofuryl C1-C6 alkyl group,\n\n\n(xv) a 1,3-dioxolanyl C1-C6 alkyl group,\n\n\n(xvi) a tetrahydropyranyl C1-C6 alkyl group,\n\n\n(xvii) a pyrrolyl C1-C6 alkyl group (that may have a C1-C6 alkyl group(s) as a substituent on the pyrrolyl group),\n\n\n(xviii) a C1-C6 alkyl group substituted with a dihydropyrazolyl group that may have an oxo group(s),\n\n\n(xix) a pyrazolyl C1-C6 alkyl group (that may have a C1-C6 alkyl group(s) as a substituent on the pyrazolyl group),\n\n\n(xx) an imidazolyl C1-C6 alkyl group,\n\n\n(xxi) a pyridyl C1-C6 alkyl group,\n\n\n(xxii) a pyrazinyl C1-C6 alkyl group (that may have a C1-C6 alkyl group(s) as a substituent on the pyrazinyl group),\n\n\n(xxiii) a pyrrolidinyl C1-C6 alkyl group (that may have a group(s) selected from the group consisting of an oxo group(s) and a C1-C6 alkyl group as a substituent on the pyrrolidinyl group),\n\n\n(xxiv) a piperidyl C1-C6 alkyl group (that may have a group(s) selected from the group consisting of a benzoyl group and a C1-C6 alkanoyl group as a substituent on the piperidyl group),\n\n\n(xxv) a piperazinyl C1-C6 alkyl group (that may have a C1-C6 alkyl group(s) as a substituent on the piperazinyl group),\n\n\n(xxvi) a morpholinyl C1-C6 alkyl group,\n\n\n(xxvii) a thienyl C1-C6 alkyl group (that may have a C1-C6 alkyl group(s) as a substituent on the thienyl group),\n\n\n(xxviii) a thiazolyl C1-C6 alkyl group,\n\n\n(xxix) a dihydrobenzofuryl C1-C6 alkyl group,\n\n\n(xxx) a benzopyranyl C1-C6 alkyl group (that may have an oxo group(s) as a substituent on the benzopyranyl group),\n\n\n(xxxi) a benzimidazolyl C1-C6 alkyl group,\n\n\n(xxxii) an indolyl C1-C6 alkyl group (that may have a C1-C6 alkoxycarbonyl group(s) on the C1-C6 alkyl group),\n\n\n(xxxiii) an imidazolyl C1-C6 alkyl group that has a substituent(s) selected from the group consisting of a carbamoyl group and a C1-C6 alkoxycarbonyl group on the C1-C6 alkyl group,\n\n\n(xxxiv) a pyridyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkoxy group and a C1-C6 alkylthio C1-C6 alkyl group as a substituent,\n\n\n(xxxv) a pyrrolidinyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkoxycarbonyl group, a C1-C6 alkanoyl group and an aroyl group as a substituent,\n\n\n(xxxvi) a piperidyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkoxycarbonyl group, a C1-C6 alkanoyl group and an aroyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group and a halogen atom as a substituent,\n\n\n(xxxvii) a tetrahydrofuryl group that may have an oxo group(s),\n\n\n(xxxviii) a hexahydroazepinyl group that may have an oxo group(s),\n\n\n(xxxix) a pyrazolyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group, an aryl group and a furyl group as a substituent,\n\n\n(xl) a thiazolyl group,\n\n\n(xli) a thiadiazolyl group that may have a C1-C6 alkyl group(s),\n\n\n(xlii) an isoxazolyl group that may have a C1-C6 alkyl group(s),\n\n\n(xliii) an indazolyl group,\n\n\n(xliv) an indolyl group,\n\n\n(xlv) a tetrahydrobenzothiazolyl group,\n\n\n(xlvi) a tetrahydroquinolyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkoxy group, a halogen atom and an oxo group as a substituent,\n\n\n(xlvii) a quinolyl group that may have a C1-C6 alkyl group(s),\n\n\n(xlviii) a benzodioxolyl C1-C6 alkyl group,\n\n\n(xlix) an aryl group that may have a group(s) as a substituent, selected from the group consisting of a halogen atom; a C1-C6 alkyl group; a C1-C6 alkoxy group; a halogen substituted C1-C6 alkyl group; a halogen substituted C1-C6 alkoxy group; a C2-C6 alkenyl group; an amino group that may have a group selected from the group consisting of a C1-C6 alkanoyl group, a C1-C6 alkyl sulfonyl group, a C1-C6 alkyl group and an aryl group; a sulfamoyl group; a C1-C6 alkylthio group; a C1-C6 alkanoyl group; a C1-C6 alkoxycarbonyl group; a pyrrolyl group; a C2-C6 alkynyl group; a cyano group; a nitro group; an aryloxy group; an aryl C1-C6 alkoxy group; a hydroxy group; a hydroxy C1-C6 alkyl group; a carbamoyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group and an aryl group; a pyrazolyl group; a pyrrolidinyl group that may have an oxo group(s); an oxazolyl group; an imidazolyl group that may have a C1-C6 alkyl group(s); a dihydrofuryl group that may have an oxo group(s); a thiazolidinyl C1-C6 alkyl group that may have an oxo group(s); an imidazolyl C1-C6 alkanoyl group and a piperidinylcarbonyl group,\n\n\n(l) a cyano C1-C6 alkyl group,\n\n\n(li) a dihydroquinolyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group and an oxo group,\n\n\n(lii) a halogen substituted C1-C6 alkylamino group,\n\n\n(liii) a C1-C6 alkylthio C1-C6 alkyl group,\n\n\n(liv) an amidino group that may have a C1-C6 alkyl group(s),\n\n\n(lv) an amidino C1-C6 alkyl group,\n\n\n(lvi) a C2-C6 alkenyloxy C1-C6 alkyl group,\n\n\n(lvii) an arylamino group that may have a substituent(s) selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkoxy group, a halogen substituted C1-C6 alkyl group and a halogen substituted C1-C6 alkoxy group, on the aryl group,\n\n\n(lviii) an aryl C2-C6 alkenyl group,\n\n\n(lix) a pyridylamino group that may have a C1-C6 alkyl group(s),\n\n\n(lx) an aryl C1-C6 alkyl group (that may have on the aryl group and/or the C1-C6 alkyl group a group(s) selected from the group consisting of a halogen atom, a C1-C6 alkyl group, a halogen substituted C1-C6 alkyl group, a halogen substituted C1-C6 alkoxy group, a C1-C6 alkoxy group, a carbamoyl group and a C1-C6 alkoxycarbonyl group as a substituent),\n\n\n(lxi) a C2-C6 alkynyl group,\n\n\n(lxii) an aryloxy C1-C6 alkyl group (that may have as a substituent on the aryl group a group(s) selected from the group consisting of a C1-C6 alkoxy group; a carbamoyl group that may have a group(s) selected from the group consisting of a C1-C6 alkoxy group and a C1-C6 alkyl group; and a pyrrolidinyl group that may have an oxo group(s)),\n\n\n(lxiii) an isoxazolidinyl group that may have an oxo group(s),\n\n\n(lxiv) a dihydroindenyl group,\n\n\n(lxv) an aryl C1-C6 alkoxy C1-C6 alkyl group,\n\n\n(lxvi) a tetrahydropyranyl group,\n\n\n(lxvii) an azetidinyl group that may have a group(s) selected from the group consisting of a C1-C6 alkanoyl group and an aroyl group,\n\n\n(lxviii) an azetidinyl C1-C6 alkyl group that may have a group(s) selected from the group consisting of a C1-C6 alkanoyl group and aroyl group,\n\n\n(lxix) a tetrazolyl group,\n\n\n(lxx) an indolinyl group that may have an oxo group(s),\n\n\n(lxxi) a triazolyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group and a C1-C6 alkylthio group,\n\n\n(lxxii) an imidazolyl group that may have a carbamoyl group(s),\n\n\n(lxxiii) an oxazolyl group that may have a C1-C6 alkyl group(s),\n\n\n(lxxiv) an isothiazolyl group that may have a C1-C6 alkyl group(s),\n\n\n(lxxv) a benzimidazolyl group,\n\n\n(lxxvi) a dihydrobenzothiazolyl group that may have an oxo group(s),\n\n\n(lxxvii) a thienyl group that may have a C1-C6 alkoxycarbonyl group(s), and\n\n\n(lxxviii) an oxazolyl C1-C6 alkyl group that may have a C1-C6 alkyl group(s)\n \n\n\n(29) an amino C1-C6 alkyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group, a halogen substituted C1-C6 alkyl group, a C1-C6 alkoxycarbonyl group, a C1-C6 alkanoyl group, an aryl group, an aryl C1-C6 alkyl group, an aroyl group and an amino substituted alkyl group (that may have a C1-C6 alkyl group(s) as a substituent on the amino group) on the amino group,\n\n\n(30) a C1-C6 alkyl group substituted with a carbamoyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group and a halogen substituted C1-C6 alkyl group,\n\n\n(31) a thiocarbamoyl group that may have a C1-C6 alkyl group(s),\n\n\n(32) a sulfamoyl group,\n\n\n(33) an oxazolidinyl group that may have an oxo group(s),\n\n\n(34) an imidazolidinyl group that may have a substituent(s) selected from the group consisting of an oxo group and a C1-C6 alkyl group,\n\n\n(35) a pyrrolidinyl group that may have an oxo group(s),\n\n\n(36) an imidazolyl group,\n\n\n(37) a triazolyl group,\n\n\n(38) an isoxazolyl group,\n\n\n(39) a piperidyl group that may have a substituent(s) selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkanoyl group, an arylsulfonyl group, an oxo group, a hydroxy group, and an amino group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkanoyl group, a C1-C6 alkoxycarbonyl group and C1-C6 alkanoylamino C1-C6 alkanoyl group,\n\n\n(40) a piperidylcarbonyl group that may have a substituent(s) selected from the group consisting of a C1-C6 alkyl group, a hydroxy group, a hydroxy C1-C6 alkyl group, a C1-C6 alkanoyl group, a carboxy C1-C6 alkyl group, a C1-C6 alkyl carbamoyl C1-C6 alkyl group, a carbamoyl group, a C1-C6 alkoxy group, a carboxy group, a C1-C6 alkoxycarbonyl group, an amino group (on which 1 to 2 groups selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkanoyl group, a C1-C6 alkoxycarbonyl group and an aroyl group may be present), a piperidyl group (on which a group(s) selected from the group consisting of a C1-C6 alkanoyl group, a C1-C6 alkoxycarbonyl group and an aroyl group may be present), piperazinyl group (on which a C1-C6 alkyl group(s) may be present as a substituent), a 1,4-dioxa-8-azaspiro[4.5]decyl group, a morpholinyl group, a hexahydro-1,4-diazepinyl group (on which a C1-C6 alkyl group(s) may be present as a substituent), a pyridyl group, a pyridyloxy group, a pyridyl C1-C6 alkoxy group, a tetrahydroquinolyl group (on which an oxo group(s) may be present), a benzodioxolyl group, an aryl C1-C6 alkoxy group (that may have a group(s) selected from the group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group and a halogen substituted C1-C6 alkoxy group on the aryl group), an aryl group (on which a group(s) selected from the group consisting of a halogen atom, a C1-C6 alkoxy group, hydroxy group may be present), an aryloxy group (that may have on the aryl group a group(s) selected from the group consisting of a cyano group, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group and a halogen substituted C1-C6 alkyl group), an aryl C1-C6 alkyl group (that may have on the aryl group a group(s) selected from the group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group and a halogen substituted C1-C6 alkyl group), and an aroyl group (that may have on the aryl group a group(s) selected from the group consisting of a halogen atom and a C1-C6 alkoxy group),\n\n\n(41) a pyrrolidinylcarbonyl group that may have a group as a substituent, selected from the group consisting of a hydroxy C1-C6 alkyl group, a carbamoyl group, a hydroxy group, an amino group (that may have on the amino group a group(s) selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkanoyl group and an aroyl group), a morpholinyl C1-C6 alkyl group, a pyrrolidinyl C1-C6 alkyl group, a piperidyl C1-C6 alkyl group, a piperazinyl C1-C6 alkyl group (that may have a C1-C6 alkyl group(s) as a substituent on the piperazinyl group), an amino C1-C6 alkyl group (that may have a C1-C6 alkyl group(s) as a substituent on the amino group), an aryloxy group (that may have a halogen substituted C1-C6 alkoxy group(s) on the aryl group), an aryloxy C1-C6 alkyl group (that may have a halogen substituted C1-C6 alkoxy group(s) on the aryl group) and a tetrahydroquinolyl group (on which an oxo group(s) may be present),\n\n\n(42) a piperazinylcarbonyl group that may have a group(s) as a substituent, selected from the group consisting of a C1-C6 alkyl group, a cyclo C3-C8 alkyl group, a C1-C6 alkanoyl group, a hydroxy C1-C6 alkyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C1-C6 alkoxycarbonyl group, an amino C1-C6 alkyl group (that may have a C1-C6 alkyl group(s) as a substituent on the amino group), a piperidyl C1-C6 alkyl group (that may have a C1-C6 alkyl group(s) as a substituent on the piperidyl group), a morpholinyl C1-C6 alkyl group, a pyrrolidinyl C1-C6 alkyl group, a 1,3-dioxolanyl C1-C6 alkyl group, a tetrahydrofuryl C1-C6 alkyl group, a pyridyl C1-C6 alkyl group (that may have a phenyl group(s) as a substituent on the C1-C6 alkyl group), a imidazolyl C1-C6 alkyl group, a furyl C1-C6 alkyl group, a pyrrolidinylcarbonyl C1-C6 alkyl group, a piperidyl group that may have a C1-C6 alkyl group(s) as a substituent, a pyridyl group (that may have on the pyridyl group a group(s) selected from the group consisting of a C1-C6 alkyl group, a cyano group and a halogen substituted C1-C6 alkyl group as a substituent), a thieno[2,3-b]pyridyl group, an aryl group (on which a group(s) selected from the group consisting of a halogen atom and a C1-C6 alkyl group may be present), an aroyl group, a furyl carbonyl group, an aryl C1-C6 alkoxycarbonyl group and an oxo group,\n\n\n(43) a hexahydroazepinylcarbonyl group,\n\n\n(44) a hexahydro-1,4-diazepinylcarbonyl group that may have a substituent(s) selected from the group consisting of a C1-C6 alkyl group and a pyridyl group,\n\n\n(45) a dihydropyrrolylcarbonyl group that may have a C1-C6 alkyl group(s),\n\n\n(46) a thiomorpholinylcarbonyl group,\n\n\n(47) a morpholinylcarbonyl group that may have a group(s) selected from the group consisting of a C1-C6 alkyl group, a piperidyl C1-C6 alkyl group and an aryl group,\n\n\n(48) a thiazolidinyl carbonyl group that may have an aryl group(s) that may have a group(s) selected from the group consisting of a C1-C6 alkoxy group and a cyano group,\n\n\n(49) an azabicyclo[3.2.2]nonylcarbonyl group,\n\n\n(50) an 8-azabicyclo[3.2.1]octylcarbonyl group that may have a halogen substituted or unsubstituted aryloxy group(s),\n\n\n(51) an indolinylcarbonyl group,\n\n\n(52) a tetrahydroquinolylcarbonyl group,\n\n\n(53) a tetrahydropyrido[3.4-b]indolylcarbonyl group,\n\n\n(54) a morpholinyl C1-C6 alkyl group,\n\n\n(55) a piperazinyl C1-C6 alkyl group that may have a C1-C6 alkyl group(s) on the piperazinyl group,\n\n\n(56) a morpholinylcarbonyl C1-C6 alkyl group,\n\n\n(57) a piperazinylcarbonyl C1-C6 alkyl group that may have a C1-C6 alkyl group(s) on the piperazinyl group,\n\n\n(58) an oxo group,\n\n\n(59) an amino C1-C6 alkoxy group (that may have a C1-C6 alkyl group(s) on the amino group),\n\n\n(60) a C1-C6 alkoxy C1-C6 alkoxy group,\n\n\n(61) a piperazinyl group that may have a group(s) selected from the group consisting of an oxo group, a C1-C6 alkyl group, a C1-C6 alkanoyl group and a C1-C6 alkoxycarbonyl group,\n\n\n(62) a morpholinyl group,\n\n\n(63) a 1,3,8-triazaspiro[4.5]decanylcarbonyl group that may have a group(s) selected from the group consisting of an oxo group and an aryl group,\n\n\n(64) a tetrahydropyridylcarbonyl group that may have a pyridyl group(s),\n\n\n(65) an imidazolidinylcarbonyl group that may have a thioxo group(s), and\n\n\n(66) a 1,4-dioxa-8-azaspiro[4.5]decanyl group.\n \n\n\n\n\n \n \n\n\nThe compound according to claim 1, wherein R\n1\n represents a heterocyclic group selected from a saturated or unsaturated heteromonocyclic group that has 1 to 2 hetero atoms selected from the group consisting of a nitrogen atom, oxygen atom and sulfur atom, and that is selected from the group consisting of a pyrrolidinyl group, piperidyl group, pyrazolyl group, pyridyl group, pyrimidinyl group, pyrazinyl group, isoxazolyl group, thiazolyl group, pyranyl group, and thienyl group;\n\nwherein, on the heterocyclic group represented by R\n1\n, 1 to 5 groups selected from the group consisting of the groups (1) to (66) below may be present as a substituent(s):\n\n(1) a C1-C6 alkyl group,\n\n\n(2) a C2-C6 alkenyl group,\n\n\n(3) a halogen substituted C1-C6 alkyl group,\n\n\n(4) a C1-C6 alkoxy group,\n\n\n(5) a phenoxy group,\n\n\n(6) a C1-C6 alkylthio group,\n\n\n(7) a halogen substituted C1-C6 alkoxy group,\n\n\n(8) a hydroxy group,\n\n\n(9) a phenyl C1-C6 alkoxy group,\n\n\n(10) a hydroxy C1-C6 alkyl group,\n\n\n(11) a C1-C6 alkoxy C1-C6 alkyl group,\n\n\n(12) a halogen atom,\n\n\n(13) a cyano group,\n\n\n(14) a phenyl group,\n\n\n(15) a nitro group,\n\n\n(16) an amino group,\n\n\n(17) an amino group having 1 to 2 groups selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkanoyl group, a C1-C6 alkoxycarbonyl group, a C1-C6 alkylsulfonyl group, a carbamoyl group, a C1-C6 alkyl carbamoyl group, an amino C1-C6 alkanoyl group, a C1-C6 alkanoylamino C1-C6 alkanoyl group and a C1-C6 alkoxycarbonylamino C1-C6 alkanoyl group as a substituent(s),\n\n\n(18) a C1-C6 alkanoyl group,\n\n\n(19) a phenylsulfonyl group that may have a single C1-C6 alkyl group on the phenyl group,\n\n\n(20) a carboxy group,\n\n\n(21) a C1-C6 alkoxycarbonyl group,\n\n\n(22) a carboxy C1-C6 alkyl group,\n\n\n(23) a C1-C6 alkoxycarbonyl C1-C6 alkyl group,\n\n\n(24) a C1-C6 alkanoylamino C1-C6 alkanoyl group,\n\n\n(25) a carboxy C2-C6 alkenyl group,\n\n\n(26) a C1-C6 alkoxycarbonyl C2-C6 alkenyl group,\n\n\n(27) a carbamoyl C2-C6 alkenyl group that may have 1 to 2 groups selected from the group consisting of a C1-C6 alkyl group and a C1-C6 alkyl group substituted with 1 to 3 halogen atoms as a substituent (s),\n\n\n(28) a carbamoyl group that may have 1 to 2 groups selected from the group consisting of the groups (i) to (lxxviii) below as a substituent(s):\n\n(i) a C1-C6 alkyl group,\n\n\n(ii) a C1-C6 alkoxy group,\n\n\n(iii) a hydroxy C1-C6 alkyl group,\n\n\n(iv) a C1-C6 alkoxy C1-C6 alkyl group,\n\n\n(v) an phenoxy C1-C6 alkyl group,\n\n\n(vi) a halogen substituted C1-C6 alkyl group,\n\n\n(vii) an amino C1-C6 alkyl group that may have 1 to 2 groups selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkanoyl group, a benzoyl group and a carbamoyl group,\n\n\n(viii) a cyclo C3-C8 alkyl group that may have 1 to 3 groups selected from the group consisting of a C1-C6 alkyl group, a hydroxy group, a C1-C6 alkoxycarbonyl group and a phenyl C1-C6 alkoxy group as a substituent(s),\n\n\n(ix) a cyclo C3-C8 alkyl substituted C1-C6 alkyl group,\n\n\n(x) a C2-C6 alkenyl group,\n\n\n(xi) a C1-C6 alkyl group having 1 to 2 carbamoyl groups that may have 1 to 2 groups as a substituent(s) selected from the group consisting of a C1-C6 alkyl group, a phenyl group that may have a single C1-C6 alkyl group and a phenyl group that may have a single C1-C6 alkoxy group,\n\n\n(xii) a C1-C6 alkyl group having 1 to 2 C1-C6 alkoxy carbonyl groups,\n\n\n(xiii) a furyl C1-C6 alkyl group (that may have 1 to 2 C1-C6 alkyl groups as a substituent(s) on the furyl group),\n\n\n(xiv) a tetrahydrofuryl C1-C6 alkyl group,\n\n\n(xv) a 1,3-dioxolanyl C1-C6 alkyl group,\n\n\n(xvi) a tetrahydropyranyl C1-C6 alkyl group,\n\n\n(xvii) a pyrrolyl C1-C6 alkyl group (that may have 1 to 2 C1-C6 alkyl groups on the pyrrolyl group as a substituent(s)),\n\n\n(xviii) a C1-C6 alkyl group substituted with a dihydropyrazolyl group that may have a single oxo group,\n\n\n(xix) a pyrazolyl C1-C6 alkyl group (that may have 1 to 3 C1-C6 alkyl groups as a substituent(s) on the pyrazolyl group),\n\n\n(xx) an imidazolyl C1-C6 alkyl group,\n\n\n(xxi) a pyridyl C1-C6 alkyl group,\n\n\n(xxii) a pyrazinyl C1-C6 alkyl group (that may have 1 to 3 (preferably 1) C1-C6 alkyl groups as a substituent(s) on the pyrazinyl group),\n\n\n(xxiii) a pyrrolidinyl C1-C6 alkyl group (that may have 1 to 2 groups selected from the group consisting of an oxo group and a C1-C6 alkyl group as a substituent(s) on the pyrrolidinyl group),\n\n\n(xxiv) a piperidyl C1-C6 alkyl group (that may have 1 to 3 groups selected from the group consisting of a benzoyl group and a C1-C6 alkanoyl group as a substituent(s) on the piperidyl group),\n\n\n(xxv) a piperazinyl C1-C6 alkyl group (that may have 1 to 3 C1-C6 alkyl groups as a substituent(s) on the piperazinyl group),\n\n\n(xxvi) a morpholinyl C1-C6 alkyl group,\n\n\n(xxvii) a thienyl C1-C6 alkyl group (that may have 1 to 3 C1-C6 alkyl groups as a substituent(s) on the thienyl group),\n\n\n(xxviii) a thiazolyl C1-C6 alkyl group,\n\n\n(xxix) a dihydrobenzofuryl C1-C6 alkyl group,\n\n\n(xxx) a benzopyranyl C1-C6 alkyl group (that may have a single oxo group as a substituent on the benzopyranyl group),\n\n\n(xxxi) a benzimidazolyl C1-C6 alkyl group,\n\n\n(xxxii) an indolyl C1-C6 alkyl group that may have 1 to 3 C1-C6 alkoxycarbonyl groups on the C1-C6 alkyl group),\n\n\n(xxxiii) an imidazolyl C1-C6 alkyl group that has 1 to 3 substituents selected from the group consisting of a carbamoyl group and a C1-C6 alkoxycarbonyl group, on the C1-C6 alkyl group,\n\n\n(xxxiv) a pyridyl group that may have 1 to 3 groups selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkoxy group and a C1-C6 alkylthio C1-C6 alkyl group as a substituent(s),\n\n\n(xxxv) a pyrrolidinyl group that may have 1 to 3 groups selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkoxycarbonyl group, a C1-C6 alkanoyl group and a benzoyl group as a substituent(s),\n\n\n(xxxvi) a piperidyl group that may have 1 to 3 groups selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkoxycarbonyl group, a C1-C6 alkanoyl group and a benzoyl group (that may have 1 to 3 groups selected from the group consisting of a C1-C6 alkyl group and a halogen atom as a substituent(s) on the phenyl group),\n\n\n(xxxvii) a tetrahydrofuryl group that may have a single oxo group\n\n\n(xxxviii) a hexahydroazepinyl group that may have a single oxo group,\n\n\n(xxxix) a pyrazolyl group that may have 1 to 3 groups selected from the group consisting of a C1-C6 alkyl group, a phenyl group and a furyl group as a substituent(s),\n\n\n(xl) a thiazolyl group,\n\n\n(xli) a thiadiazolyl group that may have 1 to 3 C1-C6 alkyl groups,\n\n\n(xlii) an isoxazolyl group that may have 1 to 3 C1-C6 alkyl groups,\n\n\n(xliii) an indazolyl group,\n\n\n(xliv) an indolyl group,\n\n\n(xlv) a tetrahydrobenzothiazolyl group,\n\n\n(xlvi) a tetrahydroquinolyl group that may have 1 to 3 groups selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkoxy group, a halogen atom and an oxo group as a substituent(s),\n\n\n(xlvii) a quinolyl group that may have 1 to 3 C1-C6 alkyl groups,\n\n\n(xlviii) a benzodioxolyl C1-C6 alkyl group,\n\n\n(xlix) a phenyl group or naphthyl group that may have 1 to 3 groups as a substituent(s), selected from the group consisting of a halogen atom; a C1-C6 alkyl group; a C1-C6 alkoxy group; a halogen substituted C1-C6 alkyl group; a halogen substituted C1-C6 alkoxy group; a C2-C6 alkenyl group; an amino group that may have 1 to 2 groups selected from the group consisting of a C1-C6 alkanoyl group, a C1-C6 alkyl sulfonyl group, a C1-C6 alkyl group and an aryl group; a sulfamoyl group; a C1-C6 alkylthio group; a C1-C6 alkanoyl group; a C1-C6 alkoxycarbonyl group; a pyrrolyl group; a C2-C6 alkynyl group; a cyano group; a nitro group; a phenyloxy group; a phenyl C1-C6 alkoxy group; a hydroxy group; a hydroxy C1-C6 alkyl group; a carbamoyl group that may have 1 to 2 groups selected from the group consisting of a C1-C6 alkyl group and a phenyl group; a pyrazolyl group; a pyrrolidinyl group that may have a single oxo group; an oxazolyl group; an imidazolyl group that may have 1 to 3 C1-C6 alkyl groups; a dihydrofuryl group that may have a single oxo group; thiazolidinyl C1-C6 alkyl group that may have two oxo groups; imidazolyl C1-C6 alkanoyl group and a piperidinylcarbonyl group,\n\n\n(l) a cyano C1-C6 alkyl group,\n\n\n(li) a dihydroquinolyl group that may have 1 to 3 group(s) selected from the group consisting of a C1-C6 alkyl group and an oxo group,\n\n\n(lii) a halogen substituted C1-C6 alkylamino group,\n\n\n(liii) a C1-C6 alkylthio C1-C6 alkyl group,\n\n\n(liv) an amidino group that may have a C1-C6 alkyl group,\n\n\n(lv) an amidino C1-C6 alkyl group,\n\n\n(lvi) a C2-C6 alkenyloxy C1-C6 alkyl group,\n\n\n(lvii) a phenylamino group that may have 1 to 3 substituents selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkoxy group, a halogen substituted C1-C6 alkyl group and a halogen substituted C1-C6 alkoxy group on the phenyl group,\n\n\n(lviii) a phenyl C2-C6 alkenyl group,\n\n\n(lix) a pyridylamino group that may have 1 to 3 C1-C6 alkyl groups,\n\n\n(lx) a phenyl C1-C6 alkyl group (that may have as a substituent(s) on the phenyl group and/or the C1-C6 alkyl group 1 to 3 groups selected from the group consisting of a halogen atom, a C1-C6 alkyl group, a halogen substituted C1-C6 alkyl group, a halogen substituted C1-C6 alkoxy group, a C1-C6 alkoxy group, a carbamoyl group and a C1-C6 alkoxycarbonyl group),\n\n\n(lxi) a C2-C6 alkynyl group,\n\n\n(lxii) a phenyloxy C1-C6 alkyl group (that may have 1 to 3 groups selected from the group consisting of a C1-C6 alkoxy group, N-C1-C6 alkoxy-N-C1-C6 alkylcarbamoyl group and oxopyrrolidinyl group as a substituent(s) on the phenyl group),\n\n\n(lxiii) an isoxazolidinyl group that may have a single oxo group,\n\n\n(lxiv) a dihydroindenyl group,\n\n\n(lxv) a phenyl C1-C6 alkoxy C1-C6 alkyl group,\n\n\n(lxvi) a tetrahydropyranyl group,\n\n\n(lxvii) an azetidinyl group that may have 1 to 3 groups selected from the group consisting of a C1-C6 alkanoyl group and benzoyl group,\n\n\n(lxviii) an azetidinyl C1-C6 alkyl group that may have 1 to 3 groups selected from the group consisting of a C1-C6 alkanoyl group and benzoyl group,\n\n\n(lxix) a tetrazolyl group,\n\n\n(lxx) an indolinyl group that may have a single oxo group,\n\n\n(lxxi) a triazolyl group that may have 1 to 3 groups selected from the group consisting of a C1-C6 alkyl group and a C1-C6 alkylthio group,\n\n\n(lxxii) an imidazolyl group that may have 1 to 3 carbamoyl groups,\n\n\n(lxxiii) an oxazolyl group that may have 1 to 3 C1-C6 alkyl groups,\n\n\n(lxxiv) an isothiazolyl group that may have 1 to 3 C1-C6 alkyl groups,\n\n\n(lxxv) a benzimidazolyl group,\n\n\n(lxxvi) a dihydrobenzothiazolyl group that may have a single oxo group,\n\n\n(lxxvii) a thienyl group that may have 1 to 3 C1-C6 alkoxycarbonyl groups, and\n\n\n(lxxviii) an oxazolyl C1-C6 alkyl group that may have 1 to 3 C1-C6 alkyl groups,\n \n\n\n(29) an amino C1-C6 alkyl group that may have 1 to 2 groups selected from the group consisting of a C1-C6 alkyl group, a halogen substituted C1-C6 alkyl group, a C1-C6 alkoxycarbonyl group, a C1-C6 alkanoyl group, a phenyl group, a phenyl C1-C6 alkyl group, a benzoyl group and an amino substituted alkyl group (that may have 1 to 2 C1-C6 alkyl groups as a substituent(s) on the amino group), on the amino group,\n\n\n(30) a C1-C6 alkyl group substituted with a single carbamoyl group that may have 1 to 2 groups selected from the group consisting of a C1-C6 alkyl group and a halogen substituted C1-C6 alkyl group,\n\n\n(31) a thiocarbamoyl group that may have 1 to 2 C1-C6 alkyl groups,\n\n\n(32) a sulfamoyl group,\n\n\n(33) an oxazolidinyl group that may have a single oxo group,\n\n\n(34) an imidazolidinyl group that may have 1 to 2 substituents selected from the group consisting of an oxo group and a C1-C6 alkyl group,\n\n\n(35) a pyrrolidinyl group that may have a single oxo group,\n\n\n(36) an imidazolyl group,\n\n\n(37) a triazolyl group,\n\n\n(38) an isoxazolyl group,\n\n\n(39) a piperidyl group that may have 1 to 3 substituents selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkanoyl group, a C1-C6 alkylphenylsulfonyl group, an oxo group, a hydroxy group, and an amino group that may have 1 to 2 groups selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkanoyl group, a C1-C6 alkoxycarbonyl group and a C1-C6 alkanoylamino C1-C6 alkanoyl group,\n\n\n(40) a piperidylcarbonyl group that may have 1 to 3 substituent(s) selected from the group consisting of a C1-C6 alkyl group, a hydroxy group, a hydroxy C1-C6 alkyl group, a C1-C6 alkanoyl group, a carboxy C1-C6 alkyl group, a C1-C6 alkyl carbamoyl C1-C6 alkyl group, a carbamoyl group, a C1-C6 alkoxy group, a carboxy group, a C1-C6 alkoxycarbonyl group, an amino group (on which 1 to 2 groups selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkanoyl group, a C1-C6 alkoxycarbonyl group and a benzoyl group may be present), a piperidyl group (on which 1 to 3 groups selected from the group consisting of a C1-C6 alkanoyl group, a C1-C6 alkoxycarbonyl group and a benzoyl group may be present), a piperazinyl group (on which 1 to 3 C1-C6 alkyl groups may be present as a substituent(s)), a 1,4-dioxa-8-azaspiro[4.5]decyl group, a morpholinyl group, a hexahydro-1,4-diazepynyl group (on which a single C1-C6 alkyl group may be present as a substituent), a pyridyl group, a pyridyloxy group, a pyridyl C1-C6 alkoxy group, a tetrahydroquinolyl group (on which a single oxo group may be present), a benzodioxolyl group, a phenyl C1-C6 alkoxy group (that may have on the phenyl group 1 to 3 groups selected from the group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group and a halogen substituted C1-C6 alkoxy group), a phenyl group (on which 1 to 3 groups selected from the group consisting of a halogen atom, a C1-C6 alkoxy group and a hydroxy group may be present), a phenyloxy group (that may have on the phenyl group 1 to 3 groups selected from the group consisting of a cyano group, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group and a halogen substituted C1-C6 alkyl group), a phenyl C1-C6 alkyl group (on the phenyl group, 1 to 3 groups selected from the group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group and a halogen substituted C1-C6 alkyl group may be present), and a benzoyl group (that may have 1 to 3 groups selected from the group consisting of a halogen atom and a C1-C6 alkoxy group on the phenyl group),\n\n\n(41) a pyrrolidinylcarbonyl group that may have 1 to 3 groups as a substituent(s) selected from the group consisting of a hydroxy C1-C6 alkyl group, a carbamoyl group, a hydroxy group, an amino group (that may have 1 to 2 groups selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkanoyl group and a benzoyl group on the amino group), a morpholinyl C1-C6 alkyl group, a pyrrolidinyl C1-C6 alkyl group, a piperidyl C1-C6 alkyl group, a piperazinyl C1-C6 alkyl group (that may have a single C1-C6 alkyl group as a substituent on the piperazinyl group), an amino C1-C6 alkyl group (that may have 1 to 2 C1-C6 alkyl groups may be present as a substituent on the amino group), a phenyloxy group (that may have 1 to 3 halogen substituted C1-C6 alkoxy groups on the phenyl group), a phenyloxy C1-C6 alkyl group (that may have 1 to 3 halogen substituted C1-C6 alkoxy groups on the phenyl group) and a tetrahydroquinolyl group (on which an oxo group may be present),\n\n\n(42) a piperazinylcarbonyl group that may have 1 to 3 groups as a substituent(s) selected from the group consisting of a C1-C6 alkyl group, a cyclo C3-C8 alkyl group, a Cl-C6 alkanoyl group, a hydroxy C1-C6 alkyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C1-C6 alkoxycarbonyl group, an amino C1-C6 alkyl group (that may have 1 to 2 C1-C6 alkyl groups as a substituent(s) on the amino group), a piperidyl C1-C6 alkyl group (that may have 1 to 2 C1-C6 alkyl groups as a substituent(s) on the piperidyl group), a morpholinyl C1-C6 alkyl group, a pyrrolidinyl C1-C6 alkyl group, a 1,3-dioxoranyl C1-C6 alkyl group, a tetrahydrofuryl C1-C6 alkyl group, a pyridyl C1-C6 alkyl group (that may have 1 to 2 phenyl groups as a substituent(s) on the C1-C6 alkyl group), an imidazolyl C1-C6 alkyl group, a furyl C1-C6 alkyl group, a pyrrolidinylcarbonyl C1-C6 alkyl group, a piperidyl group that may have 1 to 2 C1-C6 alkyl groups as a substituent(s)), a pyridyl group (that may have 1 to 3 groups selected from the group consisting of a C1-C6 alkyl group, a cyano group and a halogen substituted C1-C6 alkyl group as a substituent(s) on the pyridyl group), a thieno[2,3-b]pyridyl group, a phenyl group (on which 1 to 3 groups selected from the group consisting of a halogen atom and a C1-C6 alkyl group may be present), a benzoyl group, a furyl carbonyl group, a phenyl C1-C6 alkoxycarbonyl group and an oxo group,\n\n\n(43) a hexahydroazepinylcarbonyl group,\n\n\n(44) a hexahydro-1,4-diazepinylcarbonyl group that may have 1 to 3 substituents selected from the group consisting of a C1-C6 alkyl group and a pyridyl group,\n\n\n(45) a dihydropyrrolylcarbonyl group that may have 1 to\n\n\n3 C1-C6 alkyl groups,\n\n\n(46) a thiomorpholinylcarbonyl group,\n\n\n(47) a morpholinylcarbonyl group that may have 1 to 3 groups selected from the group consisting of a C1-C6 alkyl group, a piperidyl C1-C6 alkyl group and a phenyl group,\n\n\n(48) a thiazolidinyl carbonyl group that may have 1 to 3 phenyl groups that may have 1 to 3 groups selected from the group consisting of a C1-C6 alkoxy group and a cyano group,\n\n\n(49) an azabicyclo[3.2.2]nonylcarbonyl group,\n\n\n(50) an 8-azabicyclo[3.2.1]octylcarbonyl group that may have 1 to 3 halogen substituted or unsubstituted phenyloxy groups,\n\n\n(51) an indolinylcarbonyl group,\n\n\n(52) a tetrahydroquinolylcarbonyl group,\n\n\n(53) a tetrahydropyrido[3.4-b]indolylcarbonyl group,\n\n\n(54) a morpholinyl C1-C6 alkyl group,\n\n\n(55) a piperazinyl C1-C6 alkyl group that may have 1 to\n\n\n3 C1-C6 alkyl groups on the piperazinyl group,\n\n\n(56) a morpholinylcarbonyl C1-C6 alkyl group,\n\n\n(57) a piperazinylcarbonyl C1-C6 alkyl group that may have 1 to 3 C1-C6 alkyl groups on the piperazinyl group,\n\n\n(58) an oxo group,\n\n\n(59) an amino C1-C6 alkoxy group (that may have 1 to 2 C1-C6 alkyl groups on the amino group),\n\n\n(60) a C1-C6 alkoxy C1-C6 alkoxy group,\n\n\n(61) a piperazinyl group that may have 1 to 3 groups selected from the group consisting of an oxo group, a C1-C6 alkyl group, a C1-C6 alkanoyl group and a C1-C6 alkoxycarbonyl group,\n\n\n(62) a morpholinyl group,\n\n\n(63) a 1,3,8-triazaspiro[4.5]decanylcarbonyl group that may have 1 to 3 groups selected from the group consisting of an oxo group and a phenyl group,\n\n\n(64) a tetrahydropyridylcarbonyl group that may have 1 to 3 pyridyl groups,\n\n\n(65) an imidazolidinylcarbonyl group that may have a single thioxo group, and\n\n\n(66) a 1,4-dioxa-8-azaspiro[4.5]decanyl group.\n \n\n\n\n\n \n \n\n\nThe compound according to claim 1 or 2, wherein A is a C1-C6 alkylene group.\n\n\n\n\n \n \n\n\nThe compound according to claim 3, wherein R\n1\n represents a heterocyclic group selected from\n\na saturated or unsaturated heteromonocyclic group having 1 to 2 nitrogen atoms selected from the group consisting of a pyrrolidinyl group, a piperidyl group, a pyrazolyl group, a pyridyl group, pyrimidinyl group and a thiazolyl group, and on the heterocyclic group represented by R\n1\n, 1 to 5 groups selected from the group consisting of (1) to (66) defined in claim 2 may be present as a substituent(s).\n\n\n\n\n \n \n\n\nThe compound according to claim 4, wherein R\n1\n represents a heterocyclic group selected from\n\na saturated or unsaturated heteromonocyclic group having 1 to 2 nitrogen atoms selected from a pyrrolidinyl group, a piperidyl group, a pyrazolyl group, a pyridyl group, a pyrimidinyl group and a thiazolyl group, and on the heterocyclic group represented by R\n1\n, 1 to 5 groups selected from the group consisting of (1), (4), (10), (17), (18), (21), (28), (29), (30), (33), (34), (35), (36), (39), (61) and (62) shown below may be present as a substituent(s):\n\n(1) a C1-C6 alkyl group,\n\n\n(4) a C1-C6 alkoxy group,\n\n\n(10) a hydroxy C1-C6 alkyl group,\n\n\n(17) an amino group having 1 to 2 groups selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkanoyl group, a C1-C6 alkoxycarbonyl group, a C1-C6 alkylsulfonyl group, a carbamoyl group, a C1-C6 alkyl carbamoyl group, an amino C1-C6 alkanoyl group, a C1-C6 alkanoylamino C1-C6 alkanoyl group and a C1-C6 alkoxycarbonylamino C1-C6 alkanoyl group, as a substituent(s),\n\n\n(18) a C1-C6 alkanoyl group,\n\n\n(21) a C1-C6 alkoxycarbonyl group,\n\n\n(28) a carbamoyl group that may have 1 to 2 groups selected from the group consisting of the groups (i), (ii), (iv), (xii) and (xxi) below as a substituent(s):\n\n(i) a C1-C6 alkyl group,\n\n\n(ii) a C1-C6 alkoxy group,\n\n\n(iv) a C1-C6 alkoxy C1-C6 alkyl group,\n\n\n(xii) a C1-C6 alkyl group having 1 to 2 C1-C6 alkoxy carbonyl groups,\n\n\n(xxi) a pyridyl C1-C6 alkyl group,\n \n\n\n(29) an amino C1-C6 alkyl group that may have, on the amino group, 1 to 2 groups selected from the group consisting of a C1-C6 alkyl group, a halogen substituted C1-C6 alkyl group, a C1-C6 alkoxycarbonyl group, a C1-C6 alkanoyl group, a phenyl group, a phenyl C1-C6 alkyl group, a benzoyl group and an amino substituted C1-C6 alkyl group (which may have 1 to 2 C1-C6 alkyl groups may be present as a substituent(s) on the amino group),\n\n\n(30) a C1-C6 alkyl group substituted with a single carbamoyl group that may have 1 to 2 groups selected from the group consisting of a C1-C6 alkyl group and a halogen substituted C1-C6 alkyl group,\n\n\n(33) an oxazolidinyl group that may have a single oxo group,\n\n\n(34) an imidazolidinyl group that may have 1 to 2 substituents selected from the group consisting of an oxo group and a C1-C6 alkyl group,\n\n\n(35) a pyrrolidinyl group that may have a single oxo group,\n\n\n(36) an imidazolyl group,\n\n\n(39) a piperidyl group that may have 1 to 3 substituents selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkanoyl group, a C1-C6 alkyl phenylsulfonyl group, an oxo group, a hydroxy group, and an amino group that may have 1 to 2 groups selected from the group consisting of a C1-C6 alkyl group, a C1-C6 alkanoyl group, a C1-C6 alkoxycarbonyl group and a C1-C6 alkanoylamino C1-C6 alkanoyl group,\n\n\n(61) a piperazinyl group that may have 1 to 3 groups selected from the group consisting of an oxo group, a C1-C6 alkyl group, a C1-C6 alkanoyl group and a C1-C6 alkoxycarbonyl group, and\n\n\n(62) a morpholinyl group.\n \n\n\n\n\n \n \n\n\nThe compound according to claim 5, wherein R\n1\n represents a saturated or unsaturated heteromonocyclic group having 1 to 2 nitrogen atoms selected from a piperidyl group, pyrazolyl group and thiazolyl group, and, on the heterocyclic group represented by R\n1\n, 1 to 3 groups selected from the group consisting of (1), (4), (10), (17), (18), (21), (28), (29), (30), (33), (34), (35), (36), (39), (61) and (62) defined in claim 5 may be present as a substituent(s).\n\n\n\n\n \n \n\n\nThe compound according to claim 6, wherein R\n1\n represents a saturated or unsaturated heteromonocyclic group having 1 to 2 nitrogen atoms selected from a piperidyl group, pyrazolyl group and thiazolyl group, and, on the heterocyclic group represented by R\n1\n, 1 to 3 groups selected from the group consisting of (1), (17) and (28) shown below may be present as a substituent(s).\n\n(1) a C1-C6 alkyl group;\n\n\n(17) an amino group having 1 to 2 groups selected from the group consisting of a C1-C6 alkyl group and a C1-C6 alkanoyl group, as a substituent(s); and\n\n\n(28) a carbamoyl group that may have 1 to 2 C1-C6 alkyl groups.\n \n\n\n\n\n \n \n\n\nThe compound according to claim 7, wherein R\n1\n represents\n\na pyrazolyl group having a single C1-C6 alkyl group and a single C1-C6 alkanoyl amino group;\n\n\na pyrazolyl group having a single C1-C6 alkyl group and a single N,N-di-C1-C6 alkyl amino group;\n\n\na piperidyl group having a single N,N-di-C1-C6 alkyl carbamoyl group; or\n\n\na thiazolyl group having a single N,N-di-C1-C6 alkyl carbamoyl group.\n \n\n\n\n\n \n \n\n\nA pharmaceutical composition comprising a heterocyclic compound of the formula (1) or a salt thereof according to any one of claims 1 to 8, as an active ingredient and a pharmaceutically acceptable carrier.\n\n\n\n\n \n \n\n\nA heterocyclic compound of the formula (1) or a salt thereof according to any one of claims 1 to 8 for use as a drug.\n\n\n\n\n \n \n\n\nA heterocyclic compound of the formula (1) or a salt thereof according to any one of claims 1 to 5 for use in a method for treating or preventing a central nervous system disorder\n\n\n\n\n \n \n\n\nThe compound for use according to claim 8, wherein the central nervous system disorder is selected from the group consisting of schizophrenia; refractory, intractable or chronic schizophrenia; emotional disturbance; psychotic disorder; mood disorder; bipolar I type disorder; bipolar II type disorder; depression; endogenous depression; major depression; melancholy and refractory depression; dysthymic disorder; cyclothymic disorder; panic attack; panic disorder; agoraphobia; social phobia; obsessive-compulsive disorder; post-traumatic stress disorder; generalized anxiety disorder; acute stress disorder; hysteria; somatization disorder; conversion disorder; pain disorder; hypochondriasis; factitious disorder; dissociative disorder; sexual dysfunction; sexual desire disorder; sexual arousal disorder; erectile dysfunction; anorexia nervosa; bulimia nervosa; sleep disorder; adjustment disorder; alcohol abuse; alcohol intoxication; drug addiction; stimulant intoxication; narcotism; anhedonia; iatrogenic anhedonia; anhedonia of a psychic or mental cause; anhedonia associated with depression; anhedonia associated with schizophrenia; delirium; cognitive impairment; cognitive impairment associated with Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases; cognitive impairment caused by Alzheimer's disease; Parkinson's disease and associated neurodegenerative diseases; cognitive impairment of schizophrenia; cognitive impairment caused by refractory, intractable or chronic schizophrenia; vomiting; motion sickness; obesity; migraine; pain (ache); mental retardation; autism disorder (autism); Tourette's disorder; tic disorder; attention-deficit/hyperactivity disorder; conduct disorder; and Down's syndrome.\n\n\n\n\n \n \n\n\nA process for producing a heterocyclic compound represented by the formula (1) :\n\n \n \n\n[wherein R\n1\n, R\n2\n and A are the same as defined in claim 1] or a salt thereof, \ncharacterized by\n comprising a reaction of a compound represented by the formula:\n\n\n\n        R\n1\n-O-A-X\n1\n \n\n\n\n[wherein R\n1\n and A are the same as defined above, and X\n1\n represents a halogen atom or a group which causes a substitution reaction the same as in a halogen atom] or a salt thereof with a compound represented by the formula:\n\n \n \n\n[wherein R\n2\n is the same as defined above] or a salt thereof. Description\n\n\n\n\nTECHNICAL FIELD\n\n\n \n \n \nThe present invention relates to a novel heterocyclic compound.\n\n\n \nBACKGROUND ART\n\n\n \n \n \nSince causal factor of schizophrenia as well as of bipolar disorder, mood disorders and emotional disorders is heterogeneous, it is desirable that a drug has multiple pharmacological effects so as to develop wide treatment spectrum.\n\n\n \n \n \n \n \n \nWO2004/026864A1\n \n discloses that a carbostyril derivative represented by the general formula:\n\n \n \n\n(wherein A' represents -(CH\n2\n)\nm\nCH\n2\n-, -(CH\n2\n)\nm\nO-, etc.; m represents an integer of 1 to 4; and R\nA\n represents a hydrogen atom, a C\n1-4\n alkyl group which may be substituted with 1 to 3 fluorine atoms, etc.) has D\n2\n receptor antagonist activity and serotonin 2A (5-HT\n2A\n) receptor antagonist activity and it is effective for treatment of schizophrenia and other central nervous system disorders).\n\n\n \n \n \n \nHowever, there is no description in \n \nWO2004/026864A1\n \n that carbostyril derivatives described in the document have D\n2\n receptor partial agonist activity, 5'-HT\n2A\n receptor antagonist activity, α\n1\n receptor antagonist activity and serotonin uptake inhibitory activity together and have a wide treatment spectrum.\n\n\n \n \n \n \n \n \nWO 2005/019215 A1\n \n discloses the compounds represented by the following formula:\n\n \n \n\n(wherein A is -(CH\n2\n)\nm\nCH\n2\n-, -(CH\n2\n)\nm\nO- or the like; m is an integer of 2 to 5; D is N, C or the like; Z and Q are independently N, C or CH, provided that at least one of Z and Q is N; X and Y are independently C, N or the like, and the bond between X and Y is a single or double bond; R\n1\n is hydrogen, (C\n1\n-C\n3\n) alkyl group or the like; R\n4\n, R\n5\n, R\n6\n and R\n7\n each represents hydrogen, alkyl group or the like; and G represents a group of monocyclic or bicyclic compound), which bind to dopamine D\n2\n receptors. \n \nWO 2005/019215 A1\n \n teaches that some compounds disclosed therein have an activity as partial agonists of D\n2\n receptors or an activity as antagonists of D\n2\n receptors, and may be effective for the treatment of schizophrenia and other central nervous system.\n\n\n \n \n \n \nHowever, \n \nWO 2005/019215 A1\n \n does not specifically disclose the compounds of the present invention.\n\n\n \nDISCLOSURE OF THE INVENTION\n\n\n \n \n \nAn object of the present invention is to provide an antipsychotic drug which has a wider treatment spectrum, less side effects and excellent tolerability and safety as compared with well-known typical and atypical antipsychotic drugs.\n\n\n \n \n \n \nThe present inventors have conducted intensive studies on the above-described problem and consequently succeeded in synthesizing a novel compound which has dopamine D\n2\n receptor partial agonist activity (D\n2\n receptor partial agonist activity), serotonin 5-HT\n2A\n receptor antagonist activity (5-HT\n2A\n receptor antagonist activity) and adrenalin α\n1\n receptor antagonist activity (α\n1\n receptor antagonist activity) and further has serotonin uptake inhibitory effect (or serotonin reuptake inhibitory effect) together in addition to these effects. The present invention has been completed based on this finding.\n\n\n \n \n \n \nThere is provided a heterocyclic compound or a salt thereof represented by the formula (1):\n\n \n \n\nwhere R\n2\n represents a hydrogen atom or a lower alkyl group;\n\nA represents a lower alkylene group or a lower alkenylene group; and\n\nR\n1\n represents a heterocyclic group selected from the group\n\na saturated or unsaturated heteromonocyclic group having 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom; and\n\nwherein at least one group selected from the group consisting of the groups (1) to (66) below may be present as a substituent on the heterocyclic group represented by R\n1\n:\n\n \n \n \n(1) a lower alkyl group,\n \n(2) a lower alkenyl group,\n \n(3) a halogen substituted lower alkyl group,\n \n(4) a lower alkoxy group,\n \n(5) an aryloxy group,\n \n(6) a lower alkylthio group,\n \n(7) a halogen substituted lower alkoxy group,\n \n(8) a hydroxy group,\n \n(9) a protected hydroxy group,\n \n(10) a hydroxy lower alkyl group,\n \n(11) a protected hydroxy lower alkyl group,\n \n(12) a halogen atom,\n \n(13) a cyano group,\n \n(14) an aryl group,\n \n(15) a nitro group,\n \n(16) an amino group,\n \n(17) an amino group having a group(s) selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkoxycarbonyl group, a lower alkylsulfonyl group, a carbamoyl group, a lower alkyl carbamoyl group, an amino lower alkanoyl group, a lower alkanoylamino lower alkanoyl group and a lower alkoxy carbonylamino lower alkanoyl group as a substituent,\n \n(18) a lower alkanoyl group,\n \n(19) an arylsulfonyl group that may have a lower alkyl group(s) on the aryl group,\n \n(20) a carboxy group,\n \n(21) a lower alkoxycarbonyl group,\n \n(22) a carboxy lower alkyl group,\n \n(23) a lower alkoxycarbonyl lower alkyl group,\n \n(24) a lower alkanoylamino lower alkanoyl group,\n \n(25) a carboxy lower alkenyl group,\n \n(26) a lower alkoxycarbonyl lower alkenyl group,\n \n(27) a carbamoyl lower alkenyl group that may have a group(s) selected from the group consisting of a lower alkyl group and a halogen substituted lower alkyl group as a substituent,\n \n(28) a carbamoyl group that may have a group(s) selected from the group consisting of the groups (i) to (lxxviii) below as a substituent:\n\n \n(i) a lower alkyl group,\n \n(ii) a lower alkoxy group,\n \n(iii) a hydroxy lower alkyl group,\n \n(iv) a lower alkoxy lower alkyl group,\n \n(v) an aryloxy lower alkyl group,\n \n(vi) a halogen substituted lower alkyl group,\n \n(vii) an amino lower alkyl group that may have a group(s) selected from the group consisting of a lower alkyl group, a lower alkanoyl group, an aroyl group and a carbamoyl group,\n \n(viii) a cyclo C3-C8 alkyl group that may have a group(s) selected from the group consisting of a lower alkyl group, a hydroxy group, a lower alkoxycarbonyl group and a phenyl lower alkoxy group as a substituent,\n \n(ix) a cyclo C3-C8 alkyl substituted lower alkyl group,\n \n(x) a lower alkenyl group,\n \n(xi) a carbamoyl lower alkyl group that may have a group(s) selected from the group consisting of a lower alkyl group, phenyl group that may have a lower alkyl group(s) and a phenyl group(s) that may have a lower alkoxy group(s) as a substituent,\n \n(xii) a lower alkoxycarbonyl lower alkyl group,\n \n(xiii) a furyl lower alkyl group (that may have a lower alkyl group(s) as a substituent) on the furyl group,\n \n(xiv) a tetrahydrofuryl lower alkyl group,\n \n(xv) a 1,3-dioxolanyl lower alkyl group,\n \n(xvi) a tetrahydropyranyl lower alkyl group,\n \n(xvii) a pyrrolyl lower alkyl group (that may have a lower alkyl group(s) as a substituent on the pyrrolyl group),\n \n(xviii) a lower alkyl group substituted with a dihydropyrazolyl group that may have an oxo group(s),\n \n(xix) a pyrazolyl lower alkyl group (that may have a lower alkyl group(s) as a substituent on the pyrazolyl group),\n \n(xx) an imidazolyl lower alkyl group,\n \n(xxi) a pyridyl lower alkyl group,\n \n(xxii) a pyrazinyl lower alkyl group (that may have a lower alkyl group(s) as a substituent on the pyrazinyl group),\n \n(xxiii) a pyrrolidinyl lower alkyl group (that may have a group(s) selected from the group consisting of an oxo group(s) and a lower alkyl group as a substituent on the pyrrolidinyl group),\n \n(xxiv) a piperidyl lower alkyl group (that may have a group(s) selected from the group consisting of a benzoyl group and a lower alkanoyl group as a substituent on the piperidyl group),\n \n(xxv) a piperazinyl lower alkyl group (that may have a lower alkyl group(s) as a substituent on the piperazinyl group),\n \n(xxvi) a morpholinyl lower alkyl group,\n \n(xxvii) a thienyl lower alkyl group (that may have a lower alkyl group(s) as a substituent on the thienyl group),\n \n(xxviii) a thiazolyl lower alkyl group,\n \n(xxix) a dihydrobenzofuryl lower alkyl group,\n \n(xxx) a benzopyranyl lower alkyl group (that may have an oxo group(s) as a substituent on the benzopyranyl group),\n \n(xxxi) a benzimidazolyl lower alkyl group,\n \n(xxxii) an indolyl lower alkyl group that may have a lower alkoxycarbonyl group(s) on the lower alkyl group),\n \n(xxxiii) an imidazolyl lower alkyl group that has a substituent(s) selected from the group consisting of a carbamoyl group and a lower alkoxycarbonyl group on the lower alkyl group,\n \n(xxxiv) a pyridyl group that may have a group(s) selected from the group consisting of a lower alkyl group, a lower alkoxy group and a lower alkylthio lower alkyl group as a substituent,\n \n(xxxv) a pyrrolidinyl group that may have a group(s) selected from the group consisting of a lower alkyl group, a lower alkoxycarbonyl group, a lower alkanoyl group and an aroyl group as a substituent,\n \n(xxxvi) a piperidyl group that may have a group(s) selected from the group consisting of a lower alkyl group, a lower alkoxycarbonyl group, a lower alkanoyl group and an aroyl group that may have a group(s) selected from the group consisting of a lower alkyl group and a halogen atom as a substituent,\n \n(xxxvii) a tetrahydrofuryl group that may have an oxo group(s),\n \n(xxxviii) a hexahydroazepinyl group that may have an oxo group(s),\n \n(xxxix) a pyrazolyl group that may have a group(s) selected from the group consisting of a lower alkyl group, an aryl group and a furyl group as a substituent,\n \n(xl) a thiazolyl group,\n \n(xli) a thiadiazolyl group that may have a lower alkyl group(s),\n \n(xlii) an isoxazolyl group that may have a lower alkyl group(s),\n \n(xliii) an indazolyl group,\n \n(xliv) an indolyl group,\n \n(xlv) a tetrahydrobenzothiazolyl group,\n \n(xlvi) a tetrahydroquinolyl group that may have a group(s) selected from the group consisting of a lower alkyl group, a lower alkoxy group, a halogen atom and an oxo group as a substituent,\n \n(xlvii) a quinolyl group that may have a lower alkyl group(s),\n \n(xlviii) a benzodioxolyl lower alkyl group,\n \n(xlix) an aryl group that may have a group(s) as a substituent, selected from the group consisting of\n\na halogen atom; a lower alkyl group; a lower alkoxy group; a halogen substituted lower alkyl group; a halogen substituted lower alkoxy group; a lower alkenyl group; an amino group that may have a group(s) selected from the group consisting of a lower alkanoyl group, a lower alkyl sulfonyl group, a lower alkyl group and an aryl group; a sulfamoyl group; a lower alkylthio group; a lower alkanoyl group; a lower alkoxycarbonyl group; a pyrrolyl group; a lower alkynyl group; a cyano group; a nitro group; an aryloxy group; an aryl lower alkoxy group; a hydroxy group; a hydroxy lower alkyl group; a carbamoyl group that may have a group(s) selected from the group consisting of a lower alkyl group and an aryl group; a pyrazolyl group; a pyrrolidinyl group that may have an oxo group(s); an oxazolyl group; an imidazolyl group that may have a lower alkyl group(s); a dihydrofuryl group that may have an oxo group(s); a thiazolidinyl lower alkyl group that may have an oxo group(s); an imidazolyl lower alkanoyl group and a piperidinylcarbonyl group,\n \n(l) a cyano lower alkyl group,\n \n(li) a dihydroquinolyl group that may have a group(s) selected from the group consisting of a lower alkyl group and an oxo group,\n \n(lii) a halogen substituted lower alkylamino group,\n \n(liii) a lower alkylthio lower alkyl group,\n \n(liv) an amidino group that may have a lower alkyl group(s),\n \n(lv) an amidino lower alkyl group,\n \n(lvi) a lower alkenyloxy lower alkyl group,\n \n(lvii) an arylamino group that may have a substituent(s) selected from the group consisting of a lower alkyl group, a lower alkoxy group, a halogen substituted lower alkyl group and a halogen substituted lower alkoxy group, on the aryl group,\n \n(lviii) an aryl lower alkenyl group,\n \n(lix) a pyridylamino group that may have a lower alkyl group(s),\n \n(lx) an aryl lower alkyl group (that may have on the aryl group and/or the lower alkyl group a group(s) selected from the group consisting of a halogen atom, a lower alkyl group, a halogen substituted lower alkyl group, a halogen substituted lower alkoxy group, a lower alkoxy group, a carbamoyl group and a lower alkoxycarbonyl group as a substituent),\n \n(lxi) a lower alkynyl group,\n \n(lxii) an aryloxy lower alkyl group (that may have as a substituent on the aryl group a group(s) selected from the group consisting of a lower alkoxy group; a carbamoyl group that may have a group(s) selected from the group consisting of a lower alkoxy group and a lower alkyl group; and a pyrrolidinyl group that may have an oxo group(s)),\n \n(lxiii) an isoxazolidinyl group that may have an oxo group(s),\n \n(lxiv) a dihydroindenyl group,\n \n(lxv) an aryl lower alkoxy lower alkyl group,\n \n(lxvi) a tetrahydropyranyl group,\n \n(lxvii) an azetidinyl group that may have a group(s) selected from the group consisting of a lower alkanoyl group and an aroyl group,\n \n(lxviii) an azetidinyl lower alkyl group that may have a group(s) selected from the group consisting of a lower alkanoyl group and aroyl group,\n \n(lxix) a tetrazolyl group,\n \n(lxx) an indolinyl group that may have an oxo group(s),\n \n(lxxi) a triazolyl group that may have a group(s) selected from the group consisting of a lower alkyl group and a lower alkylthio group,\n \n(lxxii) an imidazolyl group that may have a carbamoyl group(s),\n \n(lxxiii) an oxazolyl group that may have a lower alkyl group(s),\n \n(lxxiv) an isothiazolyl group that may have a lower alkyl group(s),\n \n(lxxv) a benzimidazolyl group,\n \n(lxxvi) a dihydrobenzothiazolyl group that may have an oxo group(s),\n \n(lxxvii) a thienyl group that may have a lower alkoxycarbonyl group(s), and\n \n(lxxviii) an oxazolyl lower alkyl group that may have a lower alkyl group(s)\n \n \n \n(29) an amino lower alkyl group that may have a group(s) selected from the group consisting of a lower alkyl group, a halogen substituted lower alkyl group, a lower alkoxycarbonyl group, a lower alkanoyl group, an aryl group, an aryl lower alkyl group, an aroyl group and an amino substituted alkyl group (that may have a lower alkyl group(s) as a substituent on the amino group) on the amino group,\n \n(30) a lower alkyl group substituted with a carbamoyl group that may have a group(s) selected from the group consisting of a lower alkyl group and a halogen substituted lower alkyl group,\n \n(31) a thiocarbamoyl group that may have a lower alkyl group(s),\n \n(32) a sulfamoyl group,\n \n(33) an oxazolidinyl group that may have an oxo group(s),\n \n(34) an imidazolidinyl group that may have a substituent(s) selected from the group consisting of an oxo group and a lower alkyl group,\n \n(35) a pyrrolidinyl group that may have an oxo group(s),\n \n(36) an imidazolyl group,\n \n(37) a triazolyl group,\n \n(38) an isoxazolyl group,\n \n(39) a piperidyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group, a lower alkanoyl group, an arylsulfonyl group, an oxo group, a hydroxy group, and an amino group that may have a group(s) selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkoxycarbonyl group and a lower alkanoylamino lower alkanoyl group,\n \n(40) a piperidylcarbonyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group, a hydroxy group, a hydroxy lower alkyl group, a lower alkanoyl group, a carboxy lower alkyl group, a lower alkyl carbamoyl lower alkyl group, a carbamoyl group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, an amino group (on which 1 to 2 groups selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkoxycarbonyl group and an aroyl group may be present), a piperidyl group (on which a group(s) selected from the group consisting of a lower alkanoyl group, a lower alkoxycarbonyl group and an aroyl group may be present), piperazinyl group (on which a lower alkyl group(s) may be present as a substituent), a 1,4-dioxa-8-azaspiro[4.5]decyl group, a morpholinyl group, a hexahydro-1,4-diazepinyl group (on which a lower alkyl group(s) may be present as a substituent), a pyridyl group, a pyridyloxy group, a pyridyl lower alkoxy group, a tetrahydroquinolyl group (on which an oxo group(s) may be present), a benzodioxolyl group, an aryl lower alkoxy group (that may have a group(s) selected from the group consisting of a halogen atom, a lower alkyl group, a lower alkoxy group and a halogen substituted lower alkoxy group on the aryl group), an aryl group (on which a group(s) selected from the group consisting of a halogen atom, a lower alkoxy group, a hydroxy group may be present), an aryloxy group (that may have on the aryl group a group(s) selected from the group consisting of a cyano group, a halogen atom, a lower alkyl group, a lower alkoxy group and a halogen substituted lower alkyl group), an aryl lower alkyl group (that may have on the aryl group a group(s) selected from the group consisting of a halogen atom, a lower alkyl group, a lower alkoxy group and a halogen substituted lower alkyl group), and an aroyl group (that may have on the aryl group a group(s) selected from the group consisting of a halogen atom and a lower alkoxy group),\n \n(41) a pyrrolidinylcarbonyl group that may have a group as a substituent, selected from the group consisting of a hydroxy lower alkyl group, a carbamoyl group, a hydroxy group, an amino group (that may have on the amino group a group(s) selected from the group consisting of a lower alkyl group, a lower alkanoyl group and an aroyl group), a morpholinyl lower alkyl group, a pyrrolidinyl lower alkyl group, a piperidyl lower alkyl group, a piperazinyl lower alkyl group (that may have a lower alkyl group(s) as a substituent on the piperazinyl group), an amino lower alkyl group (that may have a lower alkyl group(s) as a substituent on the amino group), an aryloxy group (that may have a halogen substituted lower alkoxy group(s) on the aryl group), an aryloxy lower alkyl group (that may have a halogen substituted lower alkoxy group(s) on the aryl group) and a tetrahydroquinolyl group (on which an oxo group(s) may be present),\n \n(42) a piperazinylcarbonyl group that may have a group(s) as a substituent, selected from the group consisting of a lower alkyl group, a cyclo C3-C8 alkyl group, a lower alkanoyl group, a hydroxy lower alkyl group, a lower alkoxy lower alkyl group, a lower alkoxycarbonyl group, an amino lower alkyl group (that may have a lower alkyl group(s) as a substituent on the amino group), a piperidyl lower alkyl group (that may have a lower alkyl group(s) as a substituent on the piperidyl group), a morpholinyl lower alkyl group, a pyrrolidinyl lower alkyl group, a 1,3-dioxolanyl lower alkyl group, a tetrahydrofuryl lower alkyl group, a pyridyl lower alkyl group (that may have a phenyl group(s) as a substituent on the lower alkyl group), an imidazolyl lower alkyl group, a furyl lower alkyl group, a pyrrolidinylcarbonyl lower alkyl group, a piperidyl group that may have a lower alkyl group(s) as a substituent, pyridyl group (that may have on the pyridyl group a group(s) selected from the group consisting of a lower alkyl group, a cyano group and a halogen substituted lower alkyl group as a substituent), a thieno[2,3-b]pyridyl group, an aryl group (on which a group(s) selected from the group consisting of a halogen atom and a lower alkyl group may be present), an aroyl group, a furyl carbonyl group, an aryl lower alkoxycarbonyl group and an oxo group,\n \n(43) a hexahydroazepinylcarbonyl group,\n \n(44) a hexahydro-1,4-diazepinylcarbonyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and a pyridyl group,\n \n(45) a dihydropyrrolylcarbonyl group that may have a lower alkyl group(s),\n \n(46) a thiomorpholinylcarbonyl group,\n \n(47) a morpholinylcarbonyl group that may have a group(s) selected from the group consisting of a lower alkyl group, a piperidyl lower alkyl group and an aryl group,\n \n(48) a thiazolidinyl carbonyl group that may have an aryl group(s) that may have a group(s) selected from the group consisting of a lower alkoxy group and a cyano group,\n \n(49) an azabicyclo[3.2.2]nonylcarbonyl group,\n \n(50) an 8-azabicyclo[3.2.1]octylcarbonyl group that may have a halogen substituted or unsubstituted aryloxy group(s),\n \n(51) an indolinylcarbonyl group,\n \n(52) a tetrahydroquinolylcarbonyl group,\n \n(53) a tetrahydropyrido[3.4-b]indolylcarbonyl group,\n \n(54) a morpholinyl lower alkyl group,\n \n(55) a piperazinyl lower alkyl group that may have a lower alkyl group(s) on the piperazinyl group,\n \n(56) a morpholinylcarbonyl lower alkyl group,\n \n(57) a piperazinylcarbonyl lower alkyl group that may have a lower alkyl group(s) on the piperazinyl group,\n \n(58) an oxo group,\n \n(59) an amino lower alkoxy group (that may have a lower alkyl group(s) on the amino group),\n \n(60) a lower alkoxy lower alkoxy group,\n \n(61) a piperazinyl group that may have a group(s) selected from the group consisting of an oxo group, a lower alkyl group, a lower alkanoyl group and a lower alkoxycarbonyl group,\n \n(62) a morpholinyl group,\n \n(63) a 1,3,8-triazaspiro[4.5]decanylcarbonyl group that may have a group(s) selected from the group consisting of an oxo group and an aryl group,\n \n(64) a tetrahydropyridylcarbonyl group that may have a pyridyl group(s),\n \n(65) an imidazolidinylcarbonyl group that may have a thioxo group(s), and\n \n(66) a 1,4-dioxa-8-azaspiro[4.5]decanyl group.\n \n\n\n \n \n \nThe present invention provides a compound represented by the general formula (1), wherein\n\nR\n1\n represents a heterocyclic group selected from\n\na saturated or unsaturated heteromonocyclic group that has 1 to 2 hetero atoms selected from the group consisting of a nitrogen atom, oxygen atom and sulfur atom, and that is selected from the group consisting of a pyrrolidinyl group, piperidyl group, pyrazolyl group, pyridyl group, pyrimidinyl group, pyrazinyl group, isoxazolyl group, thiazolyl group, pyranyl group, and thienyl group;\n\nwherein, on the aromatic group and the heterocyclic group represented by R\n1\n, 1 to 5 groups selected from the group consisting of the groups (1) to (66) below may be present as a substituent(s):\n\n \n \n \n(1) a lower alkyl group,\n \n(2) a lower alkenyl group,\n \n(3) a halogen substituted lower alkyl group,\n \n(4) a lower alkoxy group,\n \n(5) a phenoxy group,\n \n(6) a lower alkylthio group,\n \n(7) a halogen substituted lower alkoxy group,\n \n(8) a hydroxy group,\n \n(9) a phenyl lower alkoxy group,\n \n(10) a hydroxy lower alkyl group,\n \n(11) a lower alkoxy lower alkyl group,\n \n(12) a halogen atom,\n \n(13) a cyano group,\n \n(14) a phenyl group,\n \n(15) a nitro group,\n \n(16) an amino group,\n \n(17) an amino group having 1 to 2 groups selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkoxycarbonyl group, a lower alkylsulfonyl group, a carbamoyl group, a lower alkyl carbamoyl group, an amino lower alkanoyl group, a lower alkanoylamino lower alkanoyl group and a lower alkoxycarbonylamino lower alkanoyl group as a substituent(s),\n \n(18) a lower alkanoyl group,\n \n(19) a phenylsulfonyl group that may have a single lower alkyl group on the phenyl group,\n \n(20) a carboxy group,\n \n(21) a lower alkoxycarbonyl group,\n \n(22) a carboxy lower alkyl group,\n \n(23) a lower alkoxycarbonyl lower alkyl group,\n \n(24) a lower alkanoylamino lower alkanoyl group,\n \n(25) a carboxy lower alkenyl group,\n \n(26) a lower alkoxycarbonyl lower alkenyl group,\n \n(27) a carbamoyl lower alkenyl group that may have 1 to 2 groups selected from the group consisting of a lower alkyl group and a lower alkyl group substituted with 1 to 3 halogen atoms as a substituent(s),\n \n(28) a carbamoyl group that may have 1 to 2 groups selected from the group consisting of the groups (i) to (lxxviii) below as a substituent(s):\n\n \n(i) a lower alkyl group,\n \n(ii) a lower alkoxy group,\n \n(iii) a hydroxy lower alkyl group,\n \n(iv) a lower alkoxy lower alkyl group,\n \n(v) an phenoxy lower alkyl group,\n \n(vi) a halogen substituted lower alkyl group,\n \n(vii) an amino lower alkyl group that may have 1 to 2 groups selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a benzoyl group and a carbamoyl group,\n \n(viii) a cyclo C3-C8 alkyl group that may have 1 to 3 groups selected from the group consisting of a lower alkyl group, a hydroxy group, a lower alkoxycarbonyl group and a phenyl lower alkoxy group as a substituent(s),\n \n(ix) a cyclo C3-C8 alkyl substituted lower alkyl group,\n \n(x) a lower alkenyl group,\n \n(xi) a lower alkyl group having 1 to 2 carbamoyl groups that may have 1 to 2 groups as a substituent(s) selected from the group consisting of a lower alkyl group, a phenyl group that may have a single lower alkyl group and a phenyl group that may have a single lower alkoxy group,\n \n(xii) a lower alkyl group having 1 to 2 lower alkoxy carbonyl groups,\n \n(xiii) a furyl lower alkyl group (that may have 1 to 2 lower alkyl groups as a substituent(s) on the furyl group),\n \n(xiv) a tetrahydrofuryl lower alkyl group,\n \n(xv) a 1,3-dioxolanyl lower alkyl group,\n \n(xvi) a tetrahydropyranyl lower alkyl group,\n \n(xvii) a pyrrolyl lower alkyl group (that may have 1 to 2 lower alkyl groups on the pyrrolyl group as a substituent(s)),\n \n(xviii) a lower alkyl group substituted with a dihydropyrazolyl group that may have a single oxo group,\n \n(xix) a pyrazolyl lower alkyl group (that may have 1 to 3 lower alkyl groups as a substituent(s) on the pyrazolyl group),\n \n(xx) an imidazolyl lower alkyl group,\n \n(xxi) a pyridyl lower alkyl group,\n \n(xxii) a pyrazinyl lower alkyl group (that may have 1 to 3 (preferably 1) lower alkyl groups as a substituent(s) on the pyrazinyl group),\n \n(xxiii) a pyrrolidinyl lower alkyl group (that may have 1 to 2 groups selected from the group consisting of an oxo group and a lower alkyl group as a substituent(s) on the pyrrolidinyl group),\n \n(xxiv) a piperidyl lower alkyl group (that may have 1 to 3 groups selected from the group consisting of a benzoyl group and a lower alkanoyl group as a substituent(s) on the piperidyl group),\n \n(xxv) a piperazinyl lower alkyl group (that may have 1 to 3 lower alkyl groups as a substituent(s) on the piperazinyl group),\n \n(xxvi) a morpholinyl lower alkyl group,\n \n(xxvii) a thienyl lower alkyl group (that may have 1 to 3 lower alkyl groups as a substituent(s) on the thienyl group),\n \n(xxviii) a thiazolyl lower alkyl group,\n \n(xxix) a dihydrobenzofuryl lower alkyl group,\n \n(xxx) a benzopyranyl lower alkyl group (that may have a single oxo group as a substituent on the benzopyranyl group),\n \n(xxxi) a benzimidazolyl lower alkyl group,\n \n(xxxii) an indolyl lower alkyl group that may have 1 to 3 lower alkoxycarbonyl groups on the lower alkyl group),\n \n(xxxiii) an imidazolyl lower alkyl group that has 1 to 3 substituents selected from the group consisting of a carbamoyl group and a lower alkoxycarbonyl group, on the lower alkyl group,\n \n(xxxiv) a pyridyl group that may have 1 to 3 groups selected from the group consisting of a lower alkyl group, a lower alkoxy group and a lower alkylthio lower alkyl group as a substituent(s),\n \n(xxxv) a pyrrolidinyl group that may have 1 to 3 groups selected from the group consisting of a lower alkyl group, a lower alkoxycarbonyl group, a lower alkanoyl group and a benzoyl group as a substituent(s),\n \n(xxxvi) a piperidyl group that may have 1 to 3 groups selected from the group consisting of a lower alkyl group, a lower alkoxycarbonyl group, a lower alkanoyl group and a benzoyl group (that may have 1 to 3 groups selected from the group consisting of a lower alkyl group and a halogen atom as a substituent(s) on the phenyl group),\n \n(xxxvii) a tetrahydrofuryl group that may have a single oxo group\n \n(xxxviii) a hexahydroazepinyl group that may have a single oxo group,\n \n(xxxix) a pyrazolyl group that may have 1 to 3 groups selected from the group consisting of a lower alkyl group, a phenyl group and a furyl group as a substituent(s),\n \n(xl) a thiazolyl group,\n \n(xli) a thiadiazolyl group that may have 1 to 3 lower alkyl groups,\n \n(xlii) an isoxazolyl group that may have 1 to 3 lower alkyl groups,\n \n(xliii) an indazolyl group,\n \n(xliv) an indolyl group,\n \n(xlv) a tetrahydrobenzothiazolyl group,\n \n(xlvi) a tetrahydroquinolyl group that may have 1 to 3 groups selected from the group consisting of a lower alkyl group, a lower alkoxy group, a halogen atom and an oxo group as a substituent(s),\n \n(xlvii) a quinolyl group that may have 1 to 3 lower alkyl groups,\n \n(xlviii) a benzodioxolyl lower alkyl group,\n \n(xlix) a phenyl group or naphthyl group that may have 1 to 3 groups as a substituent(s), selected from the group consisting of\n\na halogen atom; a lower alkyl group; a lower alkoxy group; a halogen substituted lower alkyl group; a halogen substituted lower alkoxy group; a lower alkenyl group; an amino group that may have 1 to 2 groups selected from the group consisting of a lower alkanoyl group, a lower alkyl sulfonyl group, a lower alkyl group and an aryl group; a sulfamoyl group; a lower alkylthio group; a lower alkanoyl group; a lower alkoxycarbonyl group; pyrrolyl group; a lower alkynyl group; a cyano group; a nitro group; a phenyloxy group; a phenyl lower alkoxy group; a hydroxy group; a hydroxy lower alkyl group; a carbamoyl group that may have 1 to 2 groups selected from the group consisting of a lower alkyl group and a phenyl group; a pyrazolyl group; a pyrrolidinyl group that may have a single oxo group; oxazolyl group; an imidazolyl group that may have 1 to 3 lower alkyl groups; a dihydrofuryl group that may have a single oxo group; thiazolidinyl lower alkyl group that may have two oxo groups; imidazolyl lower alkanoyl group and piperidinylcarbonyl group,\n \n(1) a cyano lower alkyl group,\n \n(li) a dihydroquinolyl group that may have 1 to 3 group(s) selected from the group consisting of a lower alkyl group and oxo group,\n \n(lii) a halogen substituted lower alkylamino group,\n \n(liii) a lower alkylthio lower alkyl group,\n \n(liv) an amidino group that may have a lower alkyl group,\n \n(lv) an amidino lower alkyl group,\n \n(lvi) a lower alkenyloxy lower alkyl group,\n \n(lvii) a phenylamino group that may have 1 to 3 substituents selected from the group consisting of a lower alkyl group, a lower alkoxy group, a halogen substituted lower alkyl group and a halogen substituted lower alkoxy group on the phenyl group,\n \n(lviii) a phenyl lower alkenyl group,\n \n(lix) a pyridylamino group that may have 1 to 3 lower alkyl groups,\n \n(lx) a phenyl lower alkyl group (that may have as a substituent(s) on the phenyl group and/or the lower alkyl group 1 to 3 groups selected from the group consisting of a halogen atom, a lower alkyl group, a halogen substituted lower alkyl group, a halogen substituted lower alkoxy group, a lower alkoxy group, carbamoyl group and a lower alkoxycarbonyl group),\n \n(lxi) a lower alkynyl group,\n \n(lxii) a phenyloxy lower alkyl group (that may have 1 to 3 groups selected from the group consisting of a lower alkoxy group, N-lower alkoxy-N-lower alkylcarbamoyl group and oxopyrrolidinyl group as a substituent(s) on the phenyl group),\n \n(lxiii) an isoxazolidinyl group that may have a single oxo group,\n \n(lxiv) a dihydroindenyl group,\n \n(lxv) a phenyl lower alkoxy lower alkyl group,\n \n(lxvi) a tetrahydropyranyl group,\n \n(lxvii) an azetidinyl group that may have 1 to 3 groups selected from the group consisting of a lower alkanoyl group and benzoyl group,\n \n(lxviii) an azetidinyl lower alkyl group that may have 1 to 3 groups selected from the group consisting of a lower alkanoyl group and benzoyl group,\n \n(lxix) a tetrazolyl group,\n \n(lxx) an indolinyl group that may have a single oxo group,\n \n(lxxi) a triazolyl group that may have 1 to 3 groups selected from the group consisting of a lower alkyl group and a lower alkylthio group,\n \n(lxxii) an imidazolyl group that may have 1 to 3 carbamoyl groups,\n \n(lxxiii) an oxazolyl group that may have 1 to 3 lower alkyl groups,\n \n(lxxiv) an isothiazolyl group that may have 1 to 3 lower alkyl groups,\n \n(lxxv) a benzimidazolyl group,\n \n(lxxvi) a dihydrobenzothiazolyl group that may have a single oxo group,\n \n(lxxvii) a thienyl group that may have 1 to 3 lower alkoxycarbonyl groups, and\n \n(lxxviii) an oxazolyl lower alkyl group that may have 1 to 3 lower alkyl groups,\n \n \n \n(29) an amino lower alkyl group that may have 1 to 2 groups selected from the group consisting of a lower alkyl group, a halogen substituted lower alkyl group, a lower alkoxycarbonyl group, a lower alkanoyl group, a phenyl group, a phenyl lower alkyl group, a benzoyl group and an amino substituted alkyl group (that may have 1 to 2 lower alkyl groups as a substituent(s) on the amino group), on the amino group,\n \n(30) a lower alkyl group substituted with a single carbamoyl group that may have 1 to 2 groups selected from the group consisting of a lower alkyl group and a halogen substituted lower alkyl group,\n \n(31) a thiocarbamoyl group that may have 1 to 2 lower alkyl groups,\n \n(32) a sulfamoyl group,\n \n(33) an oxazolidinyl group that may have a single oxo group,\n \n(34) an imidazolidinyl group that may have 1 to 2 substituents selected from the group consisting of an oxo group and a lower alkyl group,\n \n(35) a pyrrolidinyl group that may have a single oxo group,\n \n(36) an imidazolyl group,\n \n(37) a triazolyl group,\n \n(38) an isoxazolyl group,\n \n(39) a piperidyl group that may have 1 to 3 substituents selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkylphenylsulfonyl group, an oxo group, a hydroxy group, and an amino group that may have 1 to 2 groups selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkoxycarbonyl group and a lower alkanoylamino lower alkanoyl group,\n \n(40) a piperidylcarbonyl group that may have 1 to 3 substituent(s) selected from the group consisting of a lower alkyl group, a hydroxy group, a hydroxy lower alkyl group, a lower alkanoyl group, a carboxy lower alkyl group, a lower alkyl carbamoyl lower alkyl group, a carbamoyl group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, an amino group (on which 1 to 2 groups selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkoxycarbonyl group and a benzoyl group may be present), a piperidyl group (on which 1 to 3 groups selected from the group consisting of a lower alkanoyl group, a lower alkoxycarbonyl group and a benzoyl group may be present), a piperazinyl group (on which 1 to 3 lower alkyl groups may be present as a substituent(s)), a 1,4-dioxa-8-azaspiro[4.5]decyl group, a morpholinyl group, a hexahydro-1,4-diazepynyl group (on which a single lower alkyl group may be present as a substituent), a pyridyl group, a pyridyloxy group, a pyridyl lower alkoxy group, a tetrahydroquinolyl group (on which a single oxo group may be present), a benzodioxolyl group, a phenyl lower alkoxy group (that may have on the phenyl group 1 to 3 groups selected from the group consisting of a halogen atom, a lower alkyl group, a lower alkoxy group and a halogen substituted lower alkoxy group), a phenyl group (on which 1 to 3 groups selected from the group consisting of a halogen atom, a lower alkoxy group and a hydroxy group may be present), phenyloxy group (that may have on the phenyl group 1 to 3 groups selected from the group consisting of a cyano group, a halogen atom, a lower alkyl group, a lower alkoxy group and a halogen substituted lower alkyl group), a phenyl lower alkyl group (on the phenyl group, 1 to 3 groups selected from the group consisting of a halogen atom, a lower alkyl group, a lower alkoxy group and a halogen substituted lower alkyl group may be present), and a benzoyl group (that may have 1 to 3 groups selected from the group consisting of a halogen atom and a lower alkoxy group on the phenyl group),\n \n(41) a pyrrolidinylcarbonyl group that may have 1 to 3 groups as a substituent(s) selected from the group consisting of a hydroxy lower alkyl group, carbamoyl group, a hydroxy group, an amino group (that may have 1 to 2 groups selected from the group consisting of a lower alkyl group, a lower alkanoyl group and a bemzoyl group on the amino group), a morpholinyl lower alkyl group, a pyrrolidinyl lower alkyl group, a piperidyl lower alkyl group, a piperazinyl lower alkyl group (that may have a single lower alkyl group as a substituent on the piperazinyl group), an amino lower alkyl group (that may have 1 to 2 lower alkyl groups may be present as a substituent on the amino group), phenyloxy group (that may have 1 to 3 halogen substituted lower alkoxy groups on the phenyl group), a phenyloxy lower alkyl group (that may have 1 to 3 halogen substituted lower alkoxy groups on the phenyl group) and a tetrahydroquinolyl group (on which an oxo group may be present),\n \n(42) a piperazinylcarbonyl group that may have 1 to 3 groups as a substituent(s) selected from the group consisting of a lower alkyl group, a cyclo C3-C8 alkyl group, a lower alkanoyl group, a hydroxy lower alkyl group, a lower alkoxy lower alkyl group, a lower alkoxycarbonyl group, an amino lower alkyl group (that may have 1 to 2 lower alkyl groups as a substituent(s) on the amino group), a piperidyl lower alkyl group (that may have 1 to 2 lower alkyl groups as a substituent(s) on the piperidyl group), a morpholinyl lower alkyl group, a pyrrolidinyl lower alkyl group, a 1,3-dioxoranyl lower alkyl group, a tetrahydrofuryl lower alkyl group, a pyridyl lower alkyl group (that may have 1 to 2 phenyl groups as a substituent(s) on the lower alkyl group), an imidazolyl lower alkyl group, a furyl lower alkyl group, a pyrrolidinylcarbonyl lower alkyl group, a piperidyl group that may have 1 to 2 lower alkyl groups as a substituent(s)), a pyridyl group (that may have 1 to 3 groups selected from the group consisting of a lower alkyl group, a cyano group and a halogen substituted lower alkyl group as a substituent(s) on the pyridyl group), a thieno[2,3-b]pyridyl group, a phenyl group (on which 1 to 3 groups selected from the group consisting of a halogen atom and a lower alkyl group may be present), a benzoyl group, a furyl carbonyl group, a phenyl lower alkoxycarbonyl group and an oxo group,\n \n(43) a hexahydroazepinylcarbonyl group,\n \n(44) a hexahydro-1,4-diazepinylcarbonyl group that may have 1 to 3 substituents selected from the group consisting of a lower alkyl group and a pyridyl group,\n \n(45) a dihydropyrrolylcarbonyl group that may have 1 to 3 lower alkyl groups,\n \n(46) a thiomorpholinylcarbonyl group,\n \n(47) a morpholinylcarbonyl group that may have 1 to 3 groups selected from the group consisting of a lower alkyl group, a piperidyl lower alkyl group and a phenyl group,\n \n(48) a thiazolidinyl carbonyl group that may have 1 to 3 phenyl groups that may have 1 to 3 groups selected from the group consisting of a lower alkoxy group and a cyano group,\n \n(49) an azabicyclo[3.2.2]nonylcarbonyl group,\n \n(50) an 8-azabicyclo[3.2.1]octylcarbonyl group that may have 1 to 3 halogen substituted or unsubstituted phenyloxy groups,\n \n(51) an indolinylcarbonyl group,\n \n(52) a tetrahydroquinolylcarbonyl group,\n \n(53) a tetrahydropyrido[3.4-b]indolylcarbonyl group,\n \n(54) a morpholinyl lower alkyl group,\n \n(55) a piperazinyl lower alkyl group that may have 1 to 3 lower alkyl groups on the piperazinyl group,\n \n(56) a morpholinylcarbonyl lower alkyl group,\n \n(57) a piperazinylcarbonyl lower alkyl group that may have 1 to 3 lower alkyl groups on the piperazinyl group,\n \n(58) an oxo group,\n \n(59) an amino lower alkoxy group (that may have 1 to 2 lower alkyl groups on the amino group),\n \n(60) a lower alkoxy lower alkoxy group,\n \n(61) a piperazinyl group that may have 1 to 3 groups selected from the group consisting of an oxo group, a lower alkyl group, a lower alkanoyl group and a lower alkoxycarbonyl group,\n \n(62) a morpholinyl group,\n \n(63) a 1,3,8-triazaspiro[4.5]decanylcarbonyl group that may have 1 to 3 groups selected from the group consisting of an oxo group and a phenyl group,\n \n(64) a tetrahydropyridylcarbonyl group that may have 1 to 3 pyridyl groups,\n \n(65) an imidazolidinylcarbonyl group that may have a single thioxo group, and\n \n(66) a 1,4-dioxa-8-azaspiro[4.5]decanyl group.\n \n\n\n \n \n \nThe present invention provides a compound represented by the general formula (1), wherein A is a lower alkylene group.\n\n\n \n \n \n \nThe present invention provides a compound represented by the general formula (1), wherein R\n1\n represents a saturated or unsaturated heteromonocyclic group having 1 to 2 nitrogen atoms selected from a pyrrolidinyl group, a piperidyl group, pyrazolyl group, a pyridyl group, a pyrimidinyl group and a thiazolyl group, and, on heterocyclic group represented by R\n1\n, 1 to 5 groups selected from the group consisting of (1) to (66) defined in claim 2 may be present as a substituent(s).\n\n\n \n \n \n \nThe present invention provides a compound represented by the general formula (1), wherein R\n1\n represents a heterocyclic group selected from\n\na saturated or unsaturated heteromonocyclic group having 1 to 2 nitrogen atoms selected from a pyrrolidinyl group, a piperidyl group, a pyrazolyl group, a pyridyl group, a pyrimidinyl group and a thiazolyl group, and\n\non the and heterocyclic group represented by R\n1\n, 1 to 5 groups selected from the group consisting of (1), (4), (10), (17), (18), (21), (28), (29), (30), (33), (34), (35), (36), (39), (61) and (62) shown below may be present as a substituent(s):\n\n \n \n \n(1) a lower alkyl group,\n \n(4) a lower alkoxy group,\n \n(10) a hydroxy lower alkyl group,\n \n(17) an amino group having 1 to 2 groups selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkoxycarbonyl group, a lower alkylsulfonyl group, a carbamoyl group, a lower alkyl carbamoyl group, an amino lower alkanoyl group, a lower alkanoylamino lower alkanoyl group and a lower alkoxycarbonylamino lower alkanoyl group, as a substituent(s),\n \n(18) a lower alkanoyl group,\n \n(21) a lower alkoxycarbonyl group,\n \n(28) a carbamoyl group that may have 1 to 2 groups selected from the group consisting of the groups (i), (ii), (iv), (xii) and (xxi) below as a substituent(s):\n\n \n(i) a lower alkyl group,\n \n(ii) a lower alkoxy group,\n \n(iv) a lower alkoxy lower alkyl group,\n \n(xii) a lower alkyl group having 1 to 2 lower alkoxy carbonyl groups,\n \n(xxi) a pyridyl lower alkyl group,\n \n \n \n(29) an amino lower alkyl group that may have, on the amino group, 1 to 2 groups selected from the group consisting of a lower alkyl group, a halogen substituted lower alkyl group, a lower alkoxycarbonyl group, a lower alkanoyl group, a phenyl group, a phenyl lower alkyl group, a benzoyl group and an amino substituted lower alkyl group (which may have 1 to 2 lower alkyl groups may be present as a substituent(s) on the amino group),\n \n(30) a lower alkyl group substituted with a single carbamoyl group that may have 1 to 2 groups selected from the group consisting of a lower alkyl group and a halogen substituted lower alkyl group,\n \n(33) an oxazolidinyl group that may have a single oxo group,\n \n(34) an imidazolidinyl group that may have 1 to 2 substituents selected from the group consisting of an oxo group and a lower alkyl group,\n \n(35) a pyrrolidinyl group that may have a single oxo group,\n \n(36) an imidazolyl group,\n \n(39) a piperidyl group that may have 1 to 3 substituents selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkyl phenylsulfonyl group, an oxo group, hydroxy group, and an amino group that may have 1 to 2 groups selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkoxycarbonyl group and a lower alkanoylamino lower alkanoyl group,\n \n(61) a piperazinyl group that may have 1 to 3 groups selected from the group consisting of an oxo group, a lower alkyl group, a lower alkanoyl group and a lower alkoxycarbonyl group, and\n \n(62) a morpholinyl group.\n \n\n\n \n \n \nThe present invention provides a compound represented by the general formula (1), wherein R\n1\n represents a saturated or unsaturated heteromonocyclic group having 1 to 2 nitrogen atoms selected from a piperidyl group, pyrazolyl group and thiazolyl group, and, on the heterocyclic group represented by R\n1\n, 1 to 3 groups selected from the group consisting of (1), (4), (10), (17), (18), (21), (28), (29), (30), (33), (34), (35), (36), (39), (61) and (62) defined in claim 5 may be present as a substituent(s).\n\n\n \n \n \n \nThe present invention provides a compound represented by the general formula (1), wherein R\n1\n represents a saturated or unsaturated heteromonocyclic group having 1 to 2 nitrogen atoms selected from a piperidyl group, pyrazolyl group and thiazolyl group, and, on the heterocyclic group represented by R\n1\n, 1 to 3 groups selected from the group consisting of (1), (17) and (28) shown below may be present as a substituent(s).\n\n \n \n \n(1) a lower alkyl group;\n \n(17) an amino group having 1 to 2 groups selected from the group consisting of a lower alkyl group and a lower alkanoyl group, as a substituent(s); and\n \n(28) a carbamoyl group that may have 1 to 2 lower alkyl groups.\n \n\n\n \n \n \nThe present invention provides a compound represented by the general formula (1), wherein R\n1\n represents\n\na pyrazolyl group having a single lower alkyl group and a single lower alkanoyl amino group;\n\na pyrazolyl group having a single lower alkyl group and a single N,N-di-lower alkyl amino group;\n\na piperidyl group having a single N,N-di-lower alkyl carbamoyl group; or\n\na thiazolyl group having a single N,N-di-lower alkyl carbamoyl group.\n\n\n \n \n \n \nThe present invention provides a pharmaceutical composition comprising a heterocyclic compound of the general formula (1) or a salt thereof according to the present invention, as an active ingredient and a pharmaceutically acceptable carrier.\n\n\n \n \n \n \nThe present invention provides a pharmaceutical composition according to the present invention can be used as a pharmaceutical composition for treating or preventing central nervous system disorders.\n\n\n \n \n \n \nThe pharmaceutical composition according to the present invention can be used as a pharmaceutical composition for treating or preventing central nervous system disorders selected from the group consisting of schizophrenia; refractory, intractable or chronic schizophrenia; emotional disturbance; psychotic disorder; mood disorder; bipolar I type disorder; bipolar II type disorder; depression; endogenous; depression; major depression; melancholy and refractory depression; dysthymic disorder; cyclothymic disorder; panic attack; panic disorder; agoraphobia; social phobia; obsessive-compulsive disorder; post-traumatic stress disorder; generalized anxiety disorder; acute stress disorder; hysteria; somatization disorder; conversion disorder; pain disorder; hypochondriasis; factitious disorder; dissociative disorder; sexual dysfunction; sexual desire disorder; sexual arousal disorder; erectile dysfunction; anorexia nervosa; bulimia nervosa; sleep disorder; adjustment disorder; alcohol abuse; alcohol intoxication; drug addiction; stimulant intoxication; narcotism; anhedonia; iatrogenic anhedonia; anhedonia of a psychic or mental cause; anhedonia associated with depression; anhedonia associated with schizophrenia; delirium; cognitive impairment; cognitive impairment associated with Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases; cognitive impairment caused by Alzheimer's disease; Parkinson's disease and associated neurodegenerative diseases; cognitive impairment of schizophrenia; cognitive impairment caused by refractory, intractable or chronic schizophrenia; vomiting; motion sickness; obesity; migraine; pain (ache); mental retardation; autism disorder (autism); Tourette's disorder; tic disorder; attention-deficit/hyperactivity disorder; conduct disorder; and Down's syndrome.\n\n\n \n \n \n \nThe present invention provides a process for producing a pharmaceutical composition comprising mixing a heterocyclic compound represented by the formula (1) or a salt thereof with a pharmaceutically acceptable carrier.\n\n\n \n \n \n \nThe present invention provides use of a heterocyclic compound represented by the formula (1) or a salt thereof as a drug.\n\n\n \n \n \n \nSpecifically provided is of a heterocyclic compound represented by the formula (1) or a salt thereof, as a dopamine D\n2\n receptor partial agonist and/or serotonin 5-HT\n2A\n receptor antagonist and/or an adrenaline α\n1\n receptor antagonist and/or a serotonin uptake inhibitor (or a serotonin reuptake inhibitor).\n\n\n \n \n \n \nThe present invention provides a process for producing a heterocyclic compound represented by the formula (1):\n\n \n \n\n[wherein R\n1\n, R\n2\n and A are the same as defined in claim 1) or a salt thereof, characterized by comprising a reaction of a compound represented by the formula:\n\n\n\n        R\n1\n-Q-A-X\n1\n \n\n\n\n[wherein R\n1\n and A are the same as defined above, and X\n1\n represents a halogen atom or a group which causes a substitution reaction the same as in a halogen atom] or a salt thereof with a compound represented by the formula:\n\n \n \n\n[wherein R\n2\n is the same as defined above] or a salt thereof.\n\n\n \nBEST MODE FOR CARRYING OUT THE INVENTION\n\n\n \n \n \nSpecific examples of each of the groups shown in the general formula (1) are as follows.\n\n\n \n \n \n \nSpecific examples of each of the groups shown in the general formula are as follows.\n\n\n \n \n \n \nThe lower alkyl group is a linear or branched alkyl group having 1 to 6 carbon atoms. Specific examples thereof include a methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, tert-butyl group, sec-butyl group, n-pentyl group, 1-ethylpropyl group, isopentyl group, neo-pentyl group, n-hexyl group, 1,2,2-trimethylpropyl group, 2,3-dimethylbutyl group, 2-ethylbutyl group, isohexyl group, and 5-methylpentyl group.\n\n\n \n \n \n \nThe lower alkylene group is a linear or branched alkylene group having 1 to 6 carbon atoms. Specific examples thereof include a methylene group, ethylene group, trimethylene group, 2-methyltrimethylene group, 2,2-dimethylethylene group, 2,2-dimethyltrimethylene group, 1-methyltrimethylene group, methylmethylene group, ethylmethylene group, tetramethylene group, pentamethylene group, and hexamethylene group.\n\n\n \n \n \n \nThe lower alkenylene group is a linear or branched alkenylene group having 1 to 3 double bonds and 2 to 6 carbon atoms. Specific examples thereof include a vinylene group, 1-propenylene group, 1-methyl-1-propenylene group, 2-methyl-1-propenylene group, 2-propenylene group, 2-butenylene group, 1-butenylene group, 3-butenylene group, 2-pentenylene group, 1-pentenylene group, 3-pentenylene group, 4-pentenylene group, 1,3-butadienylene group, 1,3-pentadienylene group, 2-penten-4-ynylene group, 2-hexenylene group, 1-hexenylene group, 5-hexenylene group, 3-hexenylene group, 4-hexenylene group, 3,3-dimethyl-1-propenylene group, 2-ethyl-1-propenylene group, 1, 3, 5-hexatrienylene group, 1,3-hexadienylene group, and 1,4-hexadienylene group.\n\n\n \n \n \n \nThe lower alkenyl group is a linear or branched alkenyl group having 1 to 3 double bonds and 2 to 6 carbon atoms, including both a trans and cis-configurations. Specific examples thereof include a vinyl group, 1-propenyl group, 2-propenyl group, 1-methyl-1-propenyl group, 2-methyl-1-propenyl group, 2-methyl-2-propenyl group, 2-propenyl group, 2-butenyl group, 1-butenyl group, 3-butenyl group, 2-pentenyl group, 1-pentenyl group, 3-pentenyl group, 4-pentenyl group, 1,3-butadienyl group, 1,3-pentadienyl group, 2-penten-4-yl group, 2-hexenyl group, 1-hexenyl group, 5-hexenyl group, 3-hexenyl group, 4-hexenyl group, 3,3-dimethyl-1-propenyl group, 2-ethyl-1-propenyl group, 1,3,5-hexatrienyl group, 1,3-hexadienyl group, and 1,4-hexadienyl group.\n\n\n \n \n \n \nExamples of the halogen atom include a fluorine atom, chlorine atom, bromine atom and iodine atom.\n\n\n \n \n \n \nExamples of the halogen substituted lower alkyl group include a lower alkyl group as illustrated above substituted with 1 to 7, more preferably, 1 to 3 halogen atoms. Specific examples thereof include a fluoromethyl group, difluoromethyl group, trifluoromethyl group, chloromethyl group, dichloromethyl group, trichloromethyl group, bromomethyl group, dibromomethyl group, dichlorofluoromethyl group, 2,2-difluoroethyl group, 2,2,2-trifluoroethyl group, pentafluoroethyl group, 2-fluoroethyl group, 2-chloroethyl group, 3,3,3-trifluoropropyl group, heptafluoropropyl group, 2,2,3,3,3-pentafluoropropyl group, heptafluoroisopropyl group, 3-chloropropyl group, 2-chloropropyl group, 3-bromopropyl group, 4,4,4-trifluorobutyl group, 4,4,4,3,3-pentafluorobutyl group, 4-chlorobutyl group, 4-bromobutyl group, 2-chlorobutyl group, 5,5,5-trifluoropentyl group, 5-chloropentyl group, 6,6,6-trifluorohexyl group, 6-chlorohexyl group, and perfluorohexyl group.\n\n\n \n \n \n \nThe lower alkoxy group is a linear or branched alkoxy group having 1 to 6 carbon atoms. Specific examples thereof include a methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group, isobutoxy group, tert-butoxy group, sec-butoxy group, n-pentyloxy group, isopentyloxy group, neopentyloxy group, n-hexyloxy group, isohexyloxy group, and 3-methylpentyloxy group.\n\n\n \n \n \n \nExamples of the aryl group include a phenyl group, substituted phenyl group, biphenyl group, substituted biphenyl group, naphthyl group, and substituted naphthyl group. Examples of the substituent for an aryl group include a lower alkyl group as illustrated above (a linear or branched lower alkyl group having 1 to 6 carbon atoms), a halogen atom as illustrated above, and an amino group. On the aryl group, 1 to 7, preferably 1 to 5, more preferably, 1 to 2 substituents of at least one type of these may be present. Specific examples of the aryl group may include a phenyl group, (2-, 3-, or 4-)biphenyl group, (1- or 2-)naphthyl group, (2-, 3-, or 4-)methylphenyl group, (2-, 3-, or 4-)ethylphenyl group, (2-, 3-, or 4-)n-propylphenyl group, (2-, 3-, or 4-)n-butylphenyl group, (2-, 3-, or 4-)n-pentylphenyl group, (2-, 3-, or 4-)n-hexylphenyl group, (2-, 3-, or 4-)isobutylphenyl group, (2-, 3-, or 4-)tert-butylphenyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)methyl-2-biphenyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)methyl-3-biphenyl group, (2-, 3-,-5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)methyl-4-biphenyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)ethyl-2-biphenyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)ethyl-3-biphenyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)ethyl-4-biphenyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-propyl-2-biphenyl group, -(2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-propyl-3-biphenyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-propyl-4-biphenyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-butyl-2-biphenyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-butyl-3-biphenyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-butyl-4-biphenyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-pentyl-2-biphenyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-pentyl-3-biphenyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-pentyl-4-biphenyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-hexyl-2-biphenyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-hexyl-3-biphenyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-hexyl-4-biphenyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)isobutyl-2-biphenyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)isobutyl-3-biphenyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)isobutyl-4-biphenyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)tert-butyl-2-biphenyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)tert-butyl-3-biphenyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)tert-butyl-4-biphenyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)methyl-1-naphthyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)methyl-2-naphthyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)ethyl-1-naphthyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)ethyl-2-naphthyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-propyl-1-naphthyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-propyl-2-naphthyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-butyl-1-naphthyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-butyl-2-naphthyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-pentyl-1-naphthyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-pentyl-2-naphthyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-hexyl-1-naphthyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-hexyl-2-naphthyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)isobutyl-1-naphthyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)isobutyl-2-naphthyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)tert-butyl-1-naphthyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)tert-butyl-2-naphthyl group, (2-, 3-, or 4-)chlorophenyl group, (2-, 3-, or 4-)fluorophenyl group, (2-, 3-, or 4-)bromophenyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)chloro-1-naphthyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)chloro-2-naphthyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)fluoro-1-naphthyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)fluoro-2-naphthyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)bromo-1-naphthyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)bromo-2-naphthyl group, (2-, 3-, or 4-)aminophenyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)amino-1-naphthyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)amino-2-naphthyl group, 2,3-dimethylphenyl group, 3,4-dimethylphenyl group, 2,4-dimethylphenyl group, 2,5-dimethylphenyl group, 2,6-dimethylphenyl group, 2,4,6-trimethylphenyl group, 3,4,5-trimethylphenyl group, 2,3,4,5-tetraethylphenyl group, pentamethylphenyl group, 2,4-dimethyl-1-naphthyl group, 2,3-dimethyl-1-naphthyl group, 3,4-dimethyl-1-naphthyl group, 3,5,7-triethylnaphthyl group, 3,4,5,7-tetramethyl-1-naphthyl group, 2,3,4,5,7-pentamethyl-1-naphthyl group, 2,3,4,5,6,7-hexaethyl-1-naphthyl group, heptamethyl-1-naphthyl group, 2,3-diaminophenyl group, 2,4,6-triaminophenyl group, and 2-methyl-5-chloro-1-naphthyl group.\n\n\n \n \n \n \nExamples of the aryloxy group include a phenyloxy group, substituted phenyloxy group, biphenyloxy group, substituted biphenyloxy group, naphthyloxy group, and substituted naphthyloxy group. Examples of the substituent for an aryloxy group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms), a halogen atom as illustrated above, and an amino groups. On the aryl group, 1 to 7, preferably 1 to 5, more preferably, 1 to 2 substituents of at least one type of these may be present. Specific examples of the aryloxy groups include a phenyloxy group, (2-, 3-, or 4-)biphenyloxy group, (1- or 2-)naphthyloxy group, (2-, 3-, or 4-)methylphenyloxy group, (2-, 3-, or 4-)ethylphenyloxy group, (2-, 2-, or 4-)n-propylphenyloxy group, (2-, 3-, or 4-)n-butylphenyloxy group, (2-, 3-, or 4-) n-pentylphenyloxy group, (2-, 3-, or 4-)n-hexylphenyloxy group, (2-, 3-, or 4-)isobutylphenyloxy group, (2-, 3-, or 4-)tert-butylphenyloxy group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)methyl-2-biphenyloxy group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)methyl-3-biphenyloxy group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 5'-)methyl-4-biphenyloxy group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)ethyl-2-biphenyloxy group, (2-, 4-, 3-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)ethyl-3-biphenyloxy group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)ethyl-4-biphenyloxy group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-propyl-2-biphenyloxy group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-propyl-3-biphenyloxy group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-propyl-4-biphenyloxy group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-butyl-2-biphenyloxy group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-butyl-3-biphenyloxy group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-butyl-4-biphenyloxy group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-pentyl-2-biphenyloxy group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-pentyl-3-biphenyloxy group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-pentyl-4-biphenyloxy group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-hexyl-2-biphenyloxy group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-hexyl-3-biphenyloxy group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-hexyl-4-biphenyloxy group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)isobutyl-2-biphenyloxy group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)isobutyl-3-biphenyloxy group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)isobutyl-4-biphenyloxy group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)tert-butyl-2-biphenyloxy group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)tert-butyl-3-biphenyloxy group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)tert-butyl-4-biphenyloxy group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)methyl-1-naphthyloxy group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)methyl-2-naphthyloxy group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)ethyl-1-naphthyloxy group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)ethyl-2-naphthyloxy group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-propyl-1-naphthyloxy group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-propyl-2-naphthyloxy group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-butyl-1-naphthyloxy group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-butyl-2-naphthyloxy group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-pentyl-1-naphthyloxy group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-pentyl-2-naphthyloxy group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-hexyl-1-naphthyloxy group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-hexyl-2-naphthyloxy group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)isobutyl-1-naphthyloxy group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)isobutyl-2-naphthyloxy group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)tert-butyl-1-naphthyloxy group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)tert-butyl-2-naphthyloxy group, (2-, 3-, or 4-)chlorophenyloxy group, (2-, 3-, or 4-)fluorophenyloxy group, (2-, 3-, or 4-)bromophenyloxy group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)chloro-1-naphthyloxy group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)chloro-2-naphthyloxy group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)fluoro-1-naphthyloxy group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)fluoro-2-naphthyloxy group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)bromo-1-naphthyloxy group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)bromo-2-naphthyloxy group, (2-, 3-, or 4-)aminophenyloxy group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)amino-1-naphthyloxy group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)amino-2-naphthyloxy group, 2,3-dimethylphenyloxy group, 3,4-dimethylphenyloxy group, 2,4-dimethylphenyloxy group, 2,5-dimethylphenyloxy group, 2,6-dimethylphenyloxy group, 2,4,6-trimethylphenyloxy group, 3,4,5-trimethylphenyloxy group, 2,3,4,5-tetraethylphenyloxy group, pentamethylphenyloxy group, 2,4-dimethyl-1-naphthyloxy group, 2,3-dimethyl-1-naphtyloxy group, 3,4-dimethyl-1-naphthyloxy group, 3,5,7-triethyl-1-naphthyloxy group, 3,4,5,7-tetramethyl-1-naphthyloxy group, 2,3,4,5,7-pentamethyl-1-naphthyloxy group, 2,3,4,5,6,7-hexaethyl-1-naphthyloxy group, heptamethyl-1-naphthyloxy group, 2,3-diaminophenyloxy group, 2,4,6-triaminophenyloxy group, and 2-methyl-5-chloro-1-naphthyloxy group.\n\n\n \n \n \n \nThe lower alkylthio group is a linear or branched alkylthio group having 1 to 6 carbon atoms. Specific examples thereof include a methylthio group, ethylthio group, n-propylthio group, isopropylthio group, n-butylthio group, tert-butylthio group, n-pentylthio group, and n-hexylthio group.\n\n\n \n \n \n \nExamples of the halogen-substituted lower alkoxy group include a lower alkoxy group as illustrated above substituted with 1 to 7, preferably, 1 to 3 halogen atoms. Specific examples thereof include a fluoromethoxy group, difluoromethoxy group, trifluoromethoxy group, chloromethoxy group, dichloromethoxy group, trichloromethoxy group, bromomethoxy group, dibromomethoxy group, dichlorofluoromethoxy group, 2,2,2-trifluoroethoxy group, pentafluoroethoxy group, 2-chloroethoxy group, 3,3,3-trifluoropropoxy group, heptafluoropropoxy group, heptafluoroisopropoxy group, 3-chloropropoxy group, 2-chloropropoxy group, 3-bromopropoxy group, 4,4,4-trifluorobutoxy group, 4,4,4,3,3-pentafluorobutoxy group, 4-chlorobutoxy group, 4-bromobutoxy group, 2-chlorobutoxy group, 5,5,5-trifluoropentoxy group, 5-chloropentoxy group, 6,6,6-trifluorohexyloxy group, and 6-chlorohexyloxy group.\n\n\n \n \n \n \nExamples of the protecting group of a hydroxy group include a linear or branched alkyl group having 1 to 6 carbon atoms, a lower alkanoyl group (a linear or branched alkanoyl group having 1 to 6 carbon atoms), and a phenyl lower alkyl group whose lower alkyl moiety is a linear or branched alkyl group having 1 to 6 carbon atoms.\n\n\n \n \n \n \nExamples of the hydroxy group protected include a methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group, isobutoxy group, tert-butoxy group, sec-butoxy group, n-pentyloxy group, isopentyloxy group, neopentyloxy group, n-hexyloxy group, isohexyloxy group, 3-methylpentyloxy group, lower alkanoyloxy group and phenyl lower alkoxy group. Specific examples include a formyloxy group, acetyloxy group, propionyloxy group, butyryloxy group, isobutyryloxy group, pentanoyloxy group, tert-butylcarbonyloxy group, hexanoyloxy group, benzyloxy group, 2-phenylethoxy group, 1-phenylethoxy group, 3-phenylpropoxy group, 4-phenylbutoxy group, 5-phenylpentyloxy group, 6-phenylhexyloxy group, 1,1-dimethyl-2-phenylethoxy group, and 2-methyl-3-phenylpropoxy group.\n\n\n \n \n \n \nExamples of the hydroxy lower alkyl group include a lower alkyl group as illustrated above having 1 to 5, preferably 1 to 3 hydroxy groups (a linear or branched alkyl group having 1 to 6 carbon atoms). Specific examples thereof include a hydroxymethyl group, 2-hydroxyethyl group, 1-hydroxyethyl group, 3-hydroxypropyl group, 2,3-dihydroxypropyl group, 4-hydroxybutyl group, 3,4-dihydroxybutyl group, 1,1-dimethyl-2-hydroxyethyl group, 5-hydroxypentyl group, 6-hydroxyhexyl group, 3,3-dimethyl-3-hydroxypropyl group, 2-methyl-3-hydroxypropyl group, 2,3,4-trihydroxybutyl group, and perhydroxyhexyl group.\n\n\n \n \n \n \nExample of a protecting group of a hydroxy lower alkyl group include a linear or branched alkyl group having 1 to 6 carbon atoms, a lower alkanoyl group (a linear or branched alkanoyl group having 1 to 6 carbon atoms), and a phenyl lower alkyl group whose lower alkyl moiety is a linear or branched alkyl group having 1 to 6 carbon atoms.\n\n\n \n \n \n \nExamples of the hydroxy lower alkyl group protected included a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 5, preferably 1 to 3 projected hydroxy groups as illustrated above (preferably a lower alkoxy group, lower alkanoyloxy group or phenyl lower alkoxy group). Specific examples thereof include a methoxymethyl group, 2-methoxyethyl group, 2-ethoxyethyl group, 2-n-propoxyethyl group, 2-isopropoxyethyl group, 2-n-butoxyethyl group, 2-isobutoxyethyl group, 2-tert-butoxyethyl group, 2-sec-butoxyethyl group, 2-n-pentyloxyethyl group, 2-isopentyloxyethyl group, 2-neopentyloxyethyl group, 2-n-hexyloxyethyl group, 2-isohexyloxyethyl group, 2-(3-methylpentyloxy)ethyl group, 2-formyloxyethyl group, 2-acetyloxyethyl group, 2-propionyloxyethyl group, 2-butyryloxyethyl group, 2-isobutyryloxyethyl group, 2-pentanoyloxyethyl group, 2-tert-butylcarbonyloxyethyl group, 2-hexanoyloxyethyl group, 2-benzyloxyethyl group, 2-(2-phenylethoxy)ethyl group, 2-(1-phenylethoxy)ethyl group, 2-(3-phenylpropoxy)ethyl group, 2-(4-phenylbutoxy)ethyl group, 2-(5-phenylpentyloxy)ethyl group, 2-(6-phenylhexyloxy)ethyl group, 2-(1,1-dimethyl-2-phenylethoxy)ethyl group, 2-(2-methyl-3-phenylpropoxy)ethyl group, 3-ethoxypropyl group, 2,3-diethoxypropyl group, 4-ethoxybutyl group, 3,4-diethoxybutyl group, 1,1-dimethyl-2-ethoxyethyl group, 5-ethoxypentyl group, 6-ethoxyhexyl group, 3,3-dimethyl-3-ethoxypropyl group, 2-methyl-3-ethoxypropyl group, and 2,3,4-triethoxybutyl group.\n\n\n \n \n \n \nThe lower alkanoyl group is a linear or branched alkanoyl group having 1 to 6 carbon atoms. Specific examples thereof include a formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, pentanoyl group, tert-butylcarbonyl group, and hexanoyl group.\n\n\n \n \n \n \nThe lower alkoxycarbonyl group is a linear or branched alkoxycarbonyl group whose lower alkoxy moiety is one as illustrated above, and has 1 to 6 carbon atoms. Specific examples thereof include a methoxycarbonyl group, ethoxycarbonyl group, n-propoxycarbonyl group, isopropoxycarbonyl group, n-butoxycarbonyl group, isobutoxy carbonyl group, tert-butoxycarbonyl group, sec-butoxycarbonyl group, n-pentyloxycarbonyl group, neopentyloxy group, n-hexyloxycarbonyl group, isohexyloxycarbonyl group, and 3-methylpentyloxycarbonyl group.\n\n\n \n \n \n \nThe lower alkylsulfonyl group is a linear or branched alkylsulfonyl group whose lower alkyl moiety is one as illustrated above, and has 1 to 6 carbon atoms. Specific examples thereof include a methylsulfonyl group, ethylsulfonyl group, n-propylsulfonyl group, isopropylsulfonyl group, n-butylsulfonyl group, isobutylsulfonyl group, tert-butylsulfonyl group, sec-butylsulfonyl group, n-pentylsulfonyl group, isopentylsulfonyl group, neopentylsulfonyl group, n-hexylsulfonyl group, isohexylsulfonyl group, and 3-methylpentylsufonyl group.\n\n\n \n \n \n \nThe lower alkylcarbamoyl group is a carbamoyl group having 1 to 2 lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms) as a substituent(s). Specific examples thereof include a N-methylcarbamoyl group, N,N-dimethylcarbamoyl group, N-ethylcarbamoyl group, N,N-diethylcarbamoyl group, N-n-propylcarbamoyl group, N-n-butylcarbamoyl group, N-n-pentylcarbamoyl group, N-n-hexylcarbamoyl group, N-isobutylcarbamoyl group, N-tert-butylcarbamoyl group, and N,N-di-n-propylcarbamoyl group.\n\n\n \n \n \n \nExamples of the aminoalkanoyl group include a lower alkanoyl group as illustrated above (a linear or branched alkanoyl group having 1 to 6 carbon atoms) having 1 to 3 (preferably 1) amino groups. Specific examples thereof include an aminoacetyl group, 3-aminopropionyl group, 4-aminobutyryl group, 3,4-diaminobutyryl group, 3,3-dimethyl-3-aminopropionyl group, 4-aminobutyryl group and 5-aminovaleryl group.\n\n\n \n \n \n \nExamples of the lower alkanoyl amino lower alkanoyl group include a lower alkanoyl group as illustrated above (a linear or branched alkanoyl group having 1 to 6 carbon atoms) whose lower alkanoyl moiety has 1 to 3 (preferably 1) lower alkanoylamino groups as illustrated above. Specific examples thereof include an N-formylaminoacetyl group, K-acetylaminoacetyl group, N-propionylaminoacetyl group, 3-(N-acetylamino)propionyl group, 4-(N-acetylamino)butyryl group, 3,4-di(N-acetylamino)butyryl group, 3,3-dimethyl-3-(N-propinylamino)propionyl group, 4-(N-formylamino)butyryl group, and 5-(N-acetylamino)valeryl group.\n\n\n \n \n \n \nExamples of the lower alkoxy carbonylamino lower alkanoyl group include a lower alkanoyl group as illustrated above (a linear or branched alkanoyl group having 1 to 6 carbon atoms) whose lower alkoxycarbonyl moiety has 1 to 3 (preferably 1) lower alkoxy carbonylamino groups as illustrated above. Specific examples thereof include an N-methoxycarbonylaminoacetyl group, N-ethoxycarbonylaminoacetyl group, N-tert-butoxycarbonylaminocacetyl group, 3-(N-methoxycarbonylamino)propionyl group, 4-(N-acetylamino)butyryl group, 3,4-di(N-acetylamino)butyryl group, 3,3-dimethyl-3-(N-propinylamino)propionyl group, 4-(N-formylamino)butyryl group and 5-(N-acetylamino)valeryl group. Examples of the amino group having, as a substituent, a group selected from the group consisting of a lower alkyl group, lower alkanoyl group, lower alkoxycarbonyl group, lower alkylsulfonyl group, carbamoyl group, lower alkylcarbamoyl group, amino lower alkanoyl group, lower alkanoylamino lower alkanoyl group, and lower alkoxycarbonylamino lower alkanoyl group include an amino group having, as a substituent, 1 to 2 groups selected from the group consisting of\n\na lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms);\n\na lower alkanoyl group as illustrated above (preferably a linear or branched alkanoyl group having 1 to 6 carbon atoms);\n\na lower alkoxycarbonyl group as illustrated above ;\n\na lower alkylsulfonyl group as illustrated above (a linear or branched alkylsulfonyl group having 1 to 6 carbon atoms) ;\n\na carbamoyl group;\n\na lower alkylcarbamoyl group as illustrated above (preferably a carbamoyl group having, as a substituent, 1 to 2 lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms)); an amino lower alkanoyl group as illustrated above; a lower alkanoylamino lower alkanoyl group as illustrated above; and a lower alkoxycarbonylamino lower alkanoyl group as illustrated above. Specific examples thereof include an amino group, N-mathylamino group, N,N-dimethylamino group, N-ethylamino group, N-n-propylamino group, N-isopropylamino group, K-formylamino group, N-acetylamino group, N-tert-butoxycarbonylamino group, N-methoxycarbonylamino group, N-methylsulfonylamino group, N-ethylsulfonylamino group, N-methyl-N-acetylamino group, N-methyl-N-methoxycarbonylamino group, N-[N,N-dimethylcarbamoyl]amino group, N-carbamoylamino group, N-[N-methylcartamoyl]amino group, N-[N,N-diethylcarbamoyl]amino group, N-[aminoacetyl]amino group, N-[[N-formylamino]acetyl]amino group, N-[[N-acetylamino]acetyl]amino group, N-[[N- , methoxycarbonylamino]acetyl]amino group, and N-[[N-tert-butoxycarbonylamino]acetyl]amino group.\n\n\n \n \n \n \nExamples of the arylsulfonyl group that may have a lower alkyl group on an aryl group include an arylsulfonyl group whose aryl moiety is phenyl, biphenyl, naphthyl or the like and on which 1 to 7, preferably 1 to 5, more preferably, 1 to 2 linear or branched alkyl groups having 1 to 6 carbon atoms. Specific examples of the arylsulfonyl group that may have a lower alkyl group on an aryl group include a phenylsulfonyl group, (2-, 3-, or 4-)biphenylsulfonyl group, (1- or 2-)naphthylsulfonyl group, (2-, 3-, or 4-)methylphenylsulfonyl group, (2-, 3-, or 4-)ethylphenylsulfonyl group, (2-, 3-, or 4-)n-propylphenylsulfonyl group, (2-, 3-, or 4-)n-butylphenylsulfonyl group, (2-, 3-, or 4-)n-pentylphenylsulfonyl group, (2-, 3-, or 4-)n-hexylphenylsulfonyl group, (2-, 3-, or 4-)isobutylphenylsulfonyl group, (2-, 3-, or 4-)tert-butylphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)methyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)methyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)methyl-4-biphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)ethyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)ethyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)ethyl-4-biphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-propyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-propyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-propyl-4-biphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-butyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-butyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-butyl-4-biphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-pentyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, z5'-, or 6'-) n-pentyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-pentyl-4-biphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-hexyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-hexyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-hexyl-4-biphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)isobutyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)isobutyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)isobutyl-4-biphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)tert-butyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)tert-butyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, z'-, 5'-, or 6'-)tert-butyl-4-biphenylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)methyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)methyl-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)ethyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)ethyl-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-propyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-propyl-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-butyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-butyl-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-) n-pentyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-pentyl-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-hexyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-hexyl-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)isobutyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)isobutyl-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)tert-butyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)tert-butyl-2-naphthylsulfonyl group, 2,3-dimethylphenylsulfonyl group, 3,4-dimethylphenylsulfonyl group, 2,4-dimethylphenylsulfonyl group, 2,5-dimethylphenylsulfonyl group, 2,6-dimethylphenylsulfonyl group, 2,4,6-trimethylphenylsulfonyl group, 3,4,5-trimethylphenylsulfonyl group, 2,3,4,5-tetraethylphenylsulfonyl group, pentamethylphenylsulfonyl group, 2,4-dimethyl-1-naphthylsulfonyl group, 2,3-dimethyl-l-naphthylsulfonyl Group, 3,4-dimethyl-1-naphthylsulfonyl group, 3,5,7-triethyl-1-naphthylsulfonyl group, 3,4,5,7-tetramethyl-1-naphthylsulfonyl group, 2,3,4,5,7-pentamethyl-1-naphthylsulfonyl group, 2,3,4,5,6,7-hexaethyl-1-naphthylsulfonyl group, and heptamethyl-1-naphthylsulfonyl group.\n\n\n \n \n \n \nExamples of a carboxyl lower alkyl group include a lover alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 3 (preferably 1) carboxyl groups. Specific examples thereof include carboxymethyl group, 2-carboxyethyl group, 1-carboxyethyl group, 1-carboxy-1-methylethyl group, 3-carboxypropyl group, 2,3-dicarboxypropyl group, 4-carboxybutyl group, 3,4-dicarboxybutyl group, 1,1-dimethyl-2-carboxyethyl group, 5-carboxypentyl group, 6-carboxyhexyl group, 3,3-dimethyl-3-carboxypropyl group, 2-methyl-3-carboxypropyl group, and 2,3,4-tricarboxybutyl group.\n\n\n \n \n \n \nExamples of a lower alkoxycarbonyl lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 3 (preferably 1 to 2) lower alkoxycarbonyl groups as illustrated above . Specific examples thereof include a methoxycarbonylmethyl group, ethoxycarbonylmethyl group, 1-methoxycarbonylethyl group, 2-methoxycarbonylethyl group, 2-ethoxycarbonylethyl group, 1-ethoxycarbonylethyl group, 3-methoxycarbonylpropyl group, 3-ethoxycarbonylpropyl group, 4-ethoxycarbonylbutyl group, 5-isopropoxycarbonylpentyl group, 6-n-propoxycarbonylhexyl group, 1,1-dimethyl-2-n-butoxycarbonylethyl group, 1-methyl-1-methoxycarbonylethyl group, 2-methyl-1-methoxycarbonylpropyl group, 2-methyl-3-tert-butoxycarbonylpropyl group, 3-methyl-1-methoxycarbonylbutyl group, diethoxycarbonylmethyl group, 1,2-diethoxycarbonylethyl group, 2-n-pentyloxycarbonylethyl group, and n-hexyloxycarbonylmethyl group.\n\n\n \n \n \n \nExamples of the carbamoyl lower alkyl group that may have a group, as a substituent, selected from the group consisting of a lower alkyl group, a phenyl group that may have a lower alkyl group and a phenyl group that may have a lower alkoxy group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 3 (preferably 1 to 2) carbamoyl groups. The carbamoyl moiety, may have 1 to 2 groups selected from the group consisting of a phenyl group that may have 1 to 3 (preferably 1) lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms) and a phenyl group that may have 1 to 3 (preferably 1) lower alkoxy groups as illustrated above (linear or branched alkoxy groups having 1 to 6 carbon atoms). Specific examples of the carbamoyl lower alkyl group include a carbamoylmethyl group, dicarbamoylmethyl group, 2-carbamoylethyl group, 1-carbamoylethyl group, 1-carbamoyl-2-methylpropyl group, 3-carbamoylpropyl group, 4-carbamoylbutyl group, 5-carbamoylpentyl group, 6-carbamoylhexyl group, 1,1-dimethyl-2-carbamoylethyl group, 2-methyl-3-carbamoylpropyl group, N-methylcarbamoylmethyl group, N,N-dimethylcarbamoylmethyl group, N-methyl-N-ethylcarbamoylmethyl group, N-methylcarbamoylmethyl group, 2-(N-methylcarbamoyl)ethyl group, 2-(N-ethylcarbamoyl) ethyl group, N-phenylcarbamoylmethyl group, N-(2-methoxyphenyl)carbamoylmethyl group, and N-(4-methylphenyl) carbamoylmethyl group.\n\n\n \n \n \n \nExamples of the carboxyl lower alkenyl group include a lower alkenyl group as illustrated above having 1 to 3, preferably 1, carboxyl groups and including both trans and cis configurations (a linear or branched alkenyl group having 1 to 3 double bonds and 2 to 6 carbon atoms). Specific examples thereof include a 2-carboxyethenyl group, 3-carboxy-2-propenyl group, 4-carboxy-2-butenyl group, 4-carboxy-3-butenyl group, 4-carboxy-1,3-butadienyl group, 5-carboxy-1,3,5-hexatrienyl group, 5-carboxy-2,4-hexadienyl group, 5-carboxy-3-pentenyl group, and 3-carboxy-1-propenyl group.\n\n\n \n \n \n \nExamples of the lower alkoxycarbonyl lower alkenyl group include a lower alkenyl group as illustrated above (a linear or branched alkenyl group having 1 to 3 double bonds and 2 to 6 carbon atoms) having 1 to 3 lower alkoxycarbonyl groups as illustrated above and including both trans and cis configurations. Specific example of the lower alkoxycarbonyl lower alkenyl group include a 2-methoxycarbonylethenyl group, 2-ethoxycarbonylethenyl group, 1-ethoxycarbonylethenyl group, 3-methoxycarbonyl-2-propenyl group, 3-ethoxycarbonyl-2-propenyl group, 4-ethoxycarbonyl-2-butenyl group, 4-ethoxycarbonyl-1,3-buthadienyl group, 5-isopropoxycarbonyl-3-pentenyl group, 6-n-propoxycarbonyl-1,3,5-hexatrienyl group, 1,1-dimethyl-2-n-butoxycarbonylethenyl group, 2-methyl-3-tert-butoxycarbonyl-2-propenyl group, and 2-n-pentyloxycarbonylethenyl group.\n\n\n \n \n \n \nExamples of the carbamoyl lower alkenyl group include a lower alkenyl group as illustrated above (a linear or branched alkenyl group having 2 to 6 carbon atoms and 1 to 3 double bonds) having 1 to 3, preferably 1, carbamoyl groups. Specific examples thereof include a 2-carbamoylethenyl group, 3-carbamoyl-2-propenyl group, 4-carbamoyl-2-butenyl group, 4-carbamoyl-3-butenyl group, 4-carbamoyl-1,3-butadienyl group, 5-carbamoyl-1,3,5-hexatrienyl group, 5-carbamoyl-2,4-hexadienyl group, 5-carbamoyl-3-pentenyl group, and 3-carbamoyl-1-propenyl group.\n\n\n \n \n \n \nExamples of the carbamoyl lower alkenyl group that may have, as a substituent, a group selected from the group consisting of a lower alkyl group and a halogen-substituted lower alkyl group include a lower alkenyl group as illustrated above (a linear or branched alkenyl group having 1 to 3 double bonds and to 6 carbon atoms) having 1 to 3, preferably 1 carbamoyl group that may have, on the carbamoyl group, 1 to 2 substituents selected from the group consisting of\n\na lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms); and\n\na halogen-substituted lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 5 carbon atoms preferably having 1 to 7, more preferably 1 to 3 substituents of halogen atoms). Specific examples thereof include a 2-carbamoylethenyl group, 2-(N-methylcarbamoyl)ethenyl group, 2-(N-ethylcarbamoy)ethenyl group, 2-(N,N-dimethylcarbamoyl)ethenyl group, and 2-[N-(2,2,2-trifluoroethyl)carbamoyl]ethenyl group.\n\n\n \n \n \n \nExamples of the lower alkoxy lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 3, preferably 1, lower alkoxy groups as illustrated above (a linear or branched alkoxy group having 1 to 6 carbon atoms). Specific examples thereof include a methoxymethyl group, 2-methoxyethyl group, 1-ethoxyethyl group, 2-ethoxyethyl group, 2-isobutoxyethyl group, 2,2-dimethoxyethyl group, 2-methoxy-1-methylethyl group, 2-methoxy-1-ethylethyl group, 2-methoxypropyl group, 3-ethoxypropyl group, 2-isopropoxyethyl group, 3-isopropoxypropyl group, 3-n-butoxypropyl group, 4-n-propoxybutyl group, 1-methyl-3-isobutoxy propyl group, 1,1-dimethyl-2-n-pentyloxyethyl group, 5-n-hexyloxypentyl group, 6-methoxyhexyl group, 1-ethoxyisopropyl group, and 2-methyl-3-methoxypropyl group.\n\n\n \n \n \n \nExamples of the aryloxy lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 3, preferably 1 aryloxy groups whose aryl moiety is phenyl, biphenyl, naphthyl or the like. Examples of a substituent for an aryl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms), a halogen atom was illustrated above, and an amino group. One to seven substituents of at least one type of these may be present on an aryl ring. Specific examples of the aryloxy lower alkyl include a phenoxymethyl group, 2-phenoxyethyl group, 2-[(1- or 2-)naphthyloxy]ethyl group, 2-[(2-, 3-, or 4-)methylphenoxy]ethyl group, 2-[(2-, 3-, or 4-)ethylphenoxy]ethyl group, 2-[(2-, 3-, or 4-)n-propylphenoxy]ethyl group, 2-[(2-, 3-, or 4-)n-butylphenoxy]ethyl group, 2-[(2-, 3-, or 4-)n-pentylphenoxy]ethyl group, 2-[(2-, 3-, or 4-)n-hexylphenoxy]ethyl group, 2-[(2-, 3-, or 4-)isobutylphenoxy]ethyl group, 2-[(2-, 3-, or 4-)tert-butylphenoxy]ethyl group2-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)methyl-1-naphthyloxy]ethyl group, 2-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)methyl-2-naphthyloxy)ethyl group, 2-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-) ethyl-1-naphthyloxy]ethyl group, 2-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)ethyl-2-naphthyloxy]ethyl group, 2-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-propyl-1-naphthyloxy]ethyl group, 2-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-propyl-2-naphthyloxy]ethyl group, 2-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-butyl-1-naphthyloxy]ethyl group, 2-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-butyl-2-naphthyloxy]ethyl group, 2-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-pentyl-l-naphthyloxy]ethyl group, 2-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-pentyl-2-naphthyloxy]ethyl group, 2-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-hexyl-1-naphthyloxy]ethyl group, 2-L(1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-hexyl-2-naphthyloxy]ethyl group, 2-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)isobutyl-1-naphthyloxy]ethyl group, 2-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)isobutyl-2-naphthyloxy]ethyl group, 2-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)tert-butyl-1-naphthyloxy]ethyl group, 2-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)tert-butyl-2-naphthyloxy]ethyl group, 2-[(2-, 3-, or 4-)chlorophenoxy]ethyl group, 2-[(2-, 3-, or 4-)fluorophenoxy]ethyl group, 2-[(2-, 3-, or 4-)bromophenoxy]ethyl group, 2-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)chloro-1-naphthyloxy]ethyl group, 2-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)chloro-2-naphthyloxy]ethyl group, 2-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)fluoro-1-naphthyloxy]ethyl group, 2-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)fluoro-2-naphthyloxy]ethyl group, 2-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)bromo-1-naphthyloxy]ethyl group, 2-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)bromo-2-naphthyloxy]ethyl group, 2-[(2-, 3-, or 4-)aminophenoxy]ethyl group, 2-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)amino-1-naphthyloxy]ethyl group, 2-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)amino-2-naphthyloxy]ethyl group, 2-(2,3-dimethylphenoxy)ethyl group, 2-(3,4-dimethylphenoxy)ethyl group, 2-(2,4-dimethylphenoxy)ethyl group, 2-(2,5-dimethylphenoxy)ethyl group, 2-(2,6-dimethylphenoxy)ethyl group, 2-(2,4,6-trimethylphenoxy)ethyl group, 2-(3,4,5-trimethylphenoxy)ethyl group, 2-(2,3,4,5-tetraethylphenoxy)ethyl group, 2-(pentamethylphenoxy)ethyl group, 2-(2,4-dimethyl-1-naphthyloxy)ethyl group, 2-(2,3-dimethyl-1-naphthyloxy)ethyl group, 2-(3,4-dimethyl-1-naphthyloxy)ethyl group, 2-(3,5,7-triethyl-1-naphthyloxy)ethyl group, 2-(3,4,5,7-tetramethyl-1-naphthyloxy)ethyl group, 2-(2,3,4,5,7-pentamethyl-1-naphthyloxy)ethyl group, 2-(2,3,4,5,6,7-hexaethyl-1-naphthyloxy)ethyl group, 2-(heptamethyl-1-naphthyloxy)ethyl group, 2-(2,3-diaminophenoxy)ethyl group, 2-(2,4,6-triaminophenoxy)ethyl group, 2-(2-methyl-5-chloro-1-naphthyl)ethyl group, 3-phenoxypropyl group, 2,3-diphenoxypropyl group, 4-phenoxybutyl group, 3,4-diphenoxybutyl group, 1,1-dimethyl-2-phenoxyethyl group, 5-phenoxypentyl group, 6-phenoxyhexyl group, 3,3-dimethyl-3-phenoxypropyl group, 2-methyl-3-phenoxypropyl group, and 2,3,4-triphenoxybutyl group, 3-[(1- or 2-)naphthyloxy]propyl group, 2,3-di[(1- or 2-)naphthyloxy]propyl group, 4-[(1- or 2-)naphthyloxy]butyl group, 3,4-di[(1- or 2-)naphthyloxy]butyl group, 1,1-dimethyl-2-[(1- or 2-)naphthyloxy]ethyl group, 5-[(1- or 2-)naphthyloxy]pentyl group, 6-[(1- or 2-)naphthyloxy]hexyl group, 3,3-dimethyl-3-[(1- or 2-)naphthyloxy]propyl group, 2-methyl-3-[(1- or 2-)naphthyloxy]propyl group, and 2,3,4-tri[(1- or 2-)naphthyloxy]butyl group.\n\n\n \n \n \n \nExamples of the amino lower alkyl group that may have a group selected from the group consisting of a lower alkyl group, lower alkanoyl group, aroyl group and carbamoyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 5 carbon atoms) having 1 to 5 (preferably 1) amino groups thar may have 1 to 2 groups selected from the group consisting of a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms), lower alkanoyl group as illustrated above (a linear or branched alkanoyl group having 1 to 6 carbon atoms), aroyl group as illustrated above (preferably benzoyl group) as illustrated above and carbamoyl group, Specific examples of the amino lower alkyl group include an aminomethyl group, 2-aminoethyl group, 1-aminoethyl group, 3-aminopropyl group, 4-aminobutyl group, 5-aminopentyl group, 6-aminohexyl group, 1,1-dimethyl-2-aminoethyl group, 2-methyl-2-aminopropyl group, N,N-dimethylaminomethyl group, N-methyl-N-ethylaminomethyl group, N-methylaminomethyl group, 2-(N-methylamino)e-thyl group, 1-methyl-2-(N,N-dimethylamino) ethyl group, 1-methyl-2-(N,N-diethylamino)ethyl group, 2-(N,N-dimethylamino) ethyl group, 2-(N,N-diethylamino)ethyl group, 2-(N,N-diisopropylamino)ethyl group, 3-(N,N-dimethylamino)propyl group, 3-(N,N-diethylamino)propyl group, 2-(N-acetylamino)ethyl group, 2-(N-methyl-N-acetylamino)ethyl group, 2-(N-methyl-N-n-butyrylamino)ethyl group, 2-(N-methyl-N-benzoylamino)ethyl group, and 2-(N-carbamoylamino)ethyl group.\n\n\n \n \n \n \nExamples of the cyclo C3-C8 alkyl group include a cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, and cyclooctyl group.\n\n\n \n \n \n \nExamples of the cyclo C\n3\n-C\n8\n alkyl group that may have a group, as a substituent, selected from the group consisting of a lower alkyl group, hydroxy group, lower alkoxy carbonyl group and phenyl lower alkoxy group include a cyclo C\n3\n-C\n8\n alkyl group that may have 1 to 3 (preferably 1) groups, as a substituent(s), selected from the group consisting of\n\na lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms); a hydroxy group:\n\na lower alkoxy carbonyl group as illustrated above ; and\n\na lower alkoxy group (a linear or branched alkoxy group having 1 to 6 carbon atoms) having 1 to 3 (preferably 1) phenyl groups. Specific examples thereof include a cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group, 1-methylcyclopropyl group, 1-methylcyclopentyl group, 1-methylcyclohexyl group, 2-methylcyclohexyl group, 4-hydroxycyclohexyl group, 4-methoxycarbonylcyclohexyl group, 2-benzyloxypentyl group, and 2-benzyloxyhexyl group.\n\n\n \n \n \n \nExample of the cyclo C3-C8 alkyl substituted lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 3, preferably 1 cycle C3-C8 alkyl group as illustrated above. Specific examples thereof include a cyclopropylmethyl group, cyclohexylmethyl group, 2-cyclopropylethyl group, 1-cyclobutylethyl group, cyclopentylmethyl group, 3-cyclopentylpropyl group, 4-cyclohexylbutyl group, 5-cycloheptylpentyl group, 6-cyclooctylhexyl group, 1,1-dimethyl-2-cyclohexylethyl group, and 2-methyl-3-cyclopropylpropyl group.\n\n\n \n \n \n \nExamples of the furyl lower alkyl group (that may have a substituent of a lover alkyl group on the furyl group) include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) furyl groups on which 1 to 3 (preferably 1 to 2) lower alkyl groups as illustrated above ( linear or branched alkyl groups having 1 to 6 carbon atoms) may be present as a substituent. Specific examples thereof include a [(2- or 3-)furyl]methyl group, 2-[(2- or 3-)furyl]ethyl group, 1-[(2- or 3-)furyl]ethyl group, 3-[(2- or 3-)furyl]propyl group, 4-[(2- or 3-)furyl]butyl group, 5-[(2- or 3-)furyl]pentyl group, 6-[(2- or 3-)furyl]hexyl group, 1,1-dimethyl-2-[(2- or 3-)furyl]ethyl group, 2-methyl-3-[(2- or 3-)furyl]propyl group, [5-ethyl-(2-, 3-, or 4-)furyl]methyl group, [5-methyl-(2-, 3-, or 4-)furyl]methyl group, [2-n-propyl-(3-, 4-, or 5-)furyl]methyl group, [5-tert-butyl-(2 -, 4-, or 5-)furyl]methyl group, [4-n-pentyl-(2-, 3-, or 5-)furyl]methyl group, [2-n-hexyl-(3-, 4-, or 5-)furyl]methyl group, [2,5-dimethyl-(3- or 4-)furyl]methyl group, [2, 5-diethyl- (3- or 4-)furyl]methyl group, and [2,4,5-triethyl-3-furyl]methyl group.\n\n\n \n \n \n \nExamples of the tetrahydrofuryl lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) tetrahydrofuryl groups. Specific examples thereof include a (2- or 3-) (2,3,4,5-tetrahydrofuryl)methyl group, 2-[(2- or 3-) (2,3,4,5-tetrahydrofuryl)]ethyl group, 1-[(2- or 3-) (2,3,4,5-tetrahydrofuryl)]ethyl group, 3-[(2- or 2-) (2,3,4,5-tetrahydrofuryl)]propyl group, 2,3-di[(2- or 3-) (2,3,4,5-tetrahydrofuryl)]propyl group, 4-[(2- or 3-) (2,3,4,5-tetrahydrofuryl)]butyl group, 3,4-di[(2- or 3-) (2,3,4,5-tetrahydrofuryl)]butyl group, 1,1-dimethyl-2-[(2- or 3-) (2,3,4,5-tetrahydrofuryl)]ethyl group, 5-[(2- or 3-) (2,3,4,5-tetrahydrofuryl)]pentyl group, 6-[(2- or 3-) (2,3,4,5-tetrahydrofuryl)]hexyl group, 3,3-dimethyl-3-[(2- or 3-)(2,3,4,5-tetrahydrofuryl)]propyl group, 2-methyl-3-[(2- or 3-) (2,3,4,5-tetrahydrofuryl)]propyl group, and 2,3,4-tri[(2- or 3-) (2,3,4,5-tetrahydrofuryl)]butyl group.\n\n\n \n \n \n \nExamples of a 1,3-dioxolanyl lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) 1,3-dioxolanyl groups. Specific examples thereof include a [(2- or 4-)1,3-dioxolanyl]methyl group, 2-[(2- or 4-)1,3-dioxolanyl]ethyl group, 1-[(2- or 4-)1,3-dioxolanyl]ethyl group, 3-[(2- or 4-)1,1-dioxolanyl]propyl group, 4-[(2- or 4-)1,3-dioxolanyl]butyl group, 1,1,-dimethyl-2-[(2- or 4-)1,3-dioxolanyl]ethyl group, 5-[(2- or 4-)1,3-dioxolanyl]pentyl group, 6-[(2- or 4-)1,3-dioxolanyl]hexyl group, 1-[(2- or 4-)1,3-dioxolanyl]isopropyl group, and 2-methyl-3-[(1-, 2-, or 4-)imidazolyl]propyl group.\n\n\n \n \n \n \nExamples of the tetrahydropyranyl lower alkyl group include a lower alkyl group was illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) tetrahydropyranyl groups. Specific examples thereof include a [(2-, 3-, or 4-)tetrahydropyranyl] methyl group, 2-[(2-, 3-, or 4-)tetrahydropyranyl]ethyl group, 1-[(2-, 3-, or 4-)tetrahydropyranyl]ethyl group, 3-[(2-, 3-, or 4-)tetrahydropyranyl]propyl group, 4-[(2-, 3-, or 4-)tetrahydropyranyl]butyl group, 1,1-dimethyl-2-[(2-, 3-, or 4-)tetrahydropyranyl]ethyl group, 5-[(2-, 3-, or 4-)tetrahydropyranyl]pentyl group, 6-[(2-, 3-, or 4-)tetrahydropyranyl]hexyl group, 1-[(2-, 3-, or 4-)tetrahydropyranyl]isopropyl group, and 2-methyl-3-[(2-, 3-, or 4-)tetrahydropyranyl]propyl group.\n\n\n \n \n \n \nExamples of the pyrrolyl lower alkyl group (that may have a substituent of a lower alkyl group on the pyrrolyl group) include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) pyrrolyl groups on which 1 to 3 (preferably 1 to 2) lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms) may be present as a substituent (s). Specific examples thereof include a [(1-, 2-, or 3-)pyrrolyl]methyl group, 2-[(1-, 2-, or 3-)pyrrolyl]ethyl group, 1-[(1-, 2-, or 3-)pyrrolyl]ethyl group, 3-[(1-, 2-, or 3-)pyrrolyl]propyl group, 4-[(1-, 2-, or 3-)pyrrolyl]butyl group, 1,1-dimethyl-2-[(1-, 2-, or 3-)pyrrolyl]ethyl group, 5-[(1-, 2-, or 3-)pyrrolyl]pentyl group, 6-[(1-, 2-, or 3-)pyrrolyl]hexyl group, 1-[(1-, 2-, or 3-)pyrrolyl]isopropyl group, 2-methyl-3-[(1-, 2-, or 3-)pyrrolyl]propyl group, [1-methyl-(2- or 3-)pyrrolyl]methyl group, [1-ethyl-(2- or 3-)pyrrolyl]methyl group, [1-n-propyl-(2- or 3-)pyrrolyl]methyl group, [1-n-butyl-(2- or 3-)pyrrolyl]methyl group, [1-n-pentyl-(2- or 3-)pyrrolyl]methyl group, [1-n-hexyl-(2- or 3-)pyrrolyl]methyl group, 2-[5-methyl-(1-, 2-, 3-, or 4-)pyrrolyl]ethyl group, 1-[1-ethyl-(2- or 3-)pyrrolyl]ethyl group, 3-[1-ethyl-(2- or 3-)pyrrolyl]propyl group, 6-[1-n-propyl-(2- or 3-)pyrrolyl]butyl group, 5-[1-n-butyl-(2- or 3-)pyrrolyl]butyl group, 5-[1-n-butyl- (2- or 3-)pyrrolyl]pentyl group, 6-[1-n-pentyl-(2- or 3-)pyrrolyl]hexyl group, [1,5-dimethyl-(2-, 3-, or 4-)pyrrolyl]methyl group, [1,3,5-trimethyl-1-pyrrolyl]methyl group, and [1,2,4-trimethyl-3-pyrrolyl]methyl group.\n\n\n \n \n \n \nExamples of the lower alkyl group substituted witch a dihydropyrazolyl group that may have an oxo group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having a 2,3-dihydropyraxolyl group) or 4,5-dihydropyrazolyl group as a dihydropyrazolyl group, on which an oxo group may be present. Specific examples thereof include a 3-(2,3- or 4,5-)dihydropyrazolylmethyl group, 2-[4-(2,3- or 4,5-)dihydropyrazolyl]ethyl group, 1-[5-(2,3- or 4,5-)dihydropyrazolyl]ethyl group, 3-[3-(2,3- or 4,5-)dihydropyrazolyl]propyl group, 4-[4-(2,3- or 4,3-)dihydropyrazolyl]butyl group, 5-[1-(2,3- or 4,5-)dihydropyrazolyl]pentyl group, 6-[5-(2,3- or 4,5-)dihydropyrazolyl]hexyl group, 2-methyl-3-(1-(2,3- or 4,5-dihydropyrazolyl]propyl group, 1,1-dimethyl-2-[3-(2,3-or 4,5-)dihydropyrazolyl]ethyl group, 5-oxo-4-(4,5-dihydropyrazolyl) methyl group, 2-[5-oxo-4-(4,5-dihydropyrazolyl)]ethyl group, and 3-[5-oxo-4-(4,5-dihydropyrazolyl)]propyl group.\n\n\n \n \n \n \nExamples of the pyrazolyl lower alkyl group (that may have a substituent of a lower alkyl group on the pyrazolyl group) include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) pyrazolyl groups, on which 1 to 3 (preferably 1 to 2) lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms) may be present as a substituent(s). Specific examples thereof include a 3-pyrazolylmethyl group, 2-(4-pyrazolyl)ethyl group, 2-(1-pyrazolyl)ethyl group, 1-(5-pyrazolyl)etnyl group, 3-(3-pyrazclyl)propyl group, 4-(4-pyrazolyl)butyl group, 5-(1-pyrazolyl)pentyl group, 6-(5-pyrazolyl)hexyl group, 2-methyl-3-(1-pyrazolyl)propyl group, 1,1-dimethyl-2-(3-pyrazolyl)ethyl group, 1-methyl-3-pyrazolylmethyl group, 1-ethyl-3-pyrazolylmethyl group, 1-n-propyl-3-pyrazolylmethyl group, 1-n-butyl-3-pyrazolylmethyl group, 1-n-pentyl-3-pyrazolylmethyl group, 1-methyl-4-pyrazolylmethyl group, 5-methyl-3-pyrazolylmethyl group, 1-ethyl-4-pyrazolylmethyl group, 1-n-propyl-4-pyrazolylmethyl group, 1-n-butyl-4-pyrazolylmethyl group, 1-n-hexyl-4-pyrazolylmethyl group, 3-methyl-1-pyrazolylmethyl group, 3-ethyl-1-pyrazolylmethyl group, 3-n-propyl-1-pyrazolylmethyl group, 3-n-butyl-1-pyrazolylmethyl group, 1,5-dimethyl-3-pyrazolylmethyl group, 3,5-dimethyl-4-pyrazolylmethyl group, 3,4-dimethyl-1-pyrazolylmethyl group, 1,3-dimethyl-5-pyrazolylmethyl group, 3,4-diethyl-1-pyrazolylmethyl group, 3,4-di-n-propyl-1-pyrazolylmethyl group, 3,4-di-n-butyl-1-pyrazolylmethyl group, 1,3,5-trimethyl-4-pyrazolylmethyl group, 3,4,5-trimethyl-1-pyrazolylmethyl group, 3,4,5-triethyl-1-pyrazolylmethyl group, 3,4,5-tri-n-propyl-1-pyrazolylmethyl group, 3,4,5-tri-n-butyl-1-pyrazolylmethyl group, 1-methyl-5-pyrazolylmethyl group, 1-ethyl-5-pyrazolylmethyl group, 1-n-propyl-5-pyrazolylmethyl group, 1-n-butyl-5-pyrazolylmethyl group, 2-(3-pyrazolyl)ethyl group, 3-(3-pyrazolyl)propyl group, 4-(3-pyrazolyl)butyl group, 5-(3-pyrazolyl)pentyl group, 6-(3-pyrazolyl)hexyl group, 2-(1-(4-chlorophenyl)-3-pyrazolyl)ethyl group, 3-(1-methyl-3-pyrazolyl)propyl group, 3-(3-methyl-4-pyrazolyl)propyl group, 3-(5-methyl-4-pyrazolyL)propyl group, 3-(1,5-dimethyl-3-pyrazolyl)propyl group, 3-(1-ethyl-3-pyrazolyl)propyl group, 3-(1-n-propyl-3-pyrazolyl)propyl group, 3-(1-n-butyl-3-pyrazolyl)propyl group, 4-(1-methyl-3-pyrazolyl)butyl group, 4-(1-ethyl-3-pyrazolyl)butyl group, 4-(1-n-propyl-3-pyrazolyl)butyl group, 4-(1-n-butyl-3-pyrazolyl)butyl group, 5-(1-methyl-3-pyrazolyl)pentyl group, 5-(1-ethyl-3-pyrazolyl)pentyl group, 5-(1-n-propyl-3-pyrazolyl)pentyl group, 5-(1-n-butyl-3-pyrazolyl)pentyl group, 6-(1-methyl-3-pyrazolyl)hexyl group, 6-(1-ethyl-3-pyrazolyl)hexyl group, 6-(1-n-propyl-3-pyrazolyl)hexyl group, and 6-[1-(3-butyl)-3-pyrazolyl]hexyl group.\n\n\n \n \n \n \nExamples of the imidazolyl lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) imidazolyl groups. Specific examples thereof include a [(1-, 2-, 4- or 5-)imidazolyl]methyl 2-[(1-, 2-, 4- or 5-)imidazolyl]ethyl group, 1-[(1-, 2-, 4- or 5-)imidazolyl]ethyl group, 3-[(1-, 2-, 4- or 5-)imidazolyl]propyl group, 4-[(1-, 2-, 4- or 5-) imidazolyl]butyl group, 1,1-dimemyl-2-[(1-, 2-, 4- or 5-)imidazolyl]ethyl group, 5-[(1-, 2-, 4- or 5-)imidazolyl]pentyl group, 6-[(1-, 2-, 4- or 5-)imidazolyl]hexyl group, 1-[(1-, 2-, 4- or 5-)imidazolyl]isopropyl group, and 2-methyl-3-[(1-, 2-, 4- or 5-)imidazolyl]propyl group.\n\n\n \n \n \n \nExamples of the pyridyl lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) pyridyl groups. Specific examples thereof include a (2-, 3- or 4-)pyridylmethyl group, 2-[(2-, 3- or 4-)pyridyl]methyl group, 1-[(2-, 3- or 4-)pyridyl]ethyl group, 3-[(2-, 3- or 4-)pyridyl]propyl group, 4-[(2-, 3- or 4-)pyridyl]butyl group, 1,1-dimethyl-2-[(2-, 3- or 4-)pyridyl]ethyl group, 5-[(2-, 3- or 4-)pyridyl]pentyl group, 6-[(2-, 3- or 4-)pyridyl]hexyl group, 1-[(2-, 3- or 4-)pyridyl]isopropyl group, 2-methyl-3-[(2-, 3- or 4-)pyridyl]propyl group.\n\n\n \n \n \n \nExamples of the pyrazinyl lower alkyl group (a lower alkyl group may be present as a substituent on the pyrazinyl group) include lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) pyrazinyl groups on which 1 to 3 (preferably 1) lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms) may be present as a substituent(s). Specific examples thereof include a 2-pyrazinylmethyl group, 2-(2-pyrarinyl)ethyl group, 1-(2-pyrazinyl)ethyl group, 3-(2-pyrazinyl)propyl group, 4-(2-pyrazinyl)butyl group, 3-(2-pyrazinyl)pentyl group, 6-(2-pyrarinyl)hexyl group, 3-methyl-3-(2-pyrazinyl)propyl group, 1,1-dimethyl-2-(2-pyrazinyl)ethyl group, 3-methyl-2-pyrazinylmethyl group, 3-ethyl-2-pyrazinylmethyl group, 3-n-propyl-2-pyrazinylmethyl group, 3-n-butyl-2-pyrazinylmethyl group, 3-n-penyl-2-pyrazinylmethyl group, 5-methyl-2-pyrazinylmethyl group, 5-ethyl-2-pyrarinylmethyl group, 5-n-propyl-2-pyrazinylmethyl group, 5-n-butyl-2-pyrazinylmethyl group, 6-methyl-2-pyrazinylmethyl group, 6-ethyl-2-pyrazinylmethyl group, 6-n-propyl-2-pyrazinylmethyl group, 6-n-butyl-2-pyrazinylmethyl group, 3,5-dimethyl-2-pyrazinylmetyl group, 3,5-diethyl-2-pyrazinylmethyl group, 3,5-di-n-propyl-2-pyrazinylmethyl group, 3,5-di-n-butyl-2-pyrazinylmethyl group, 2-(5-methyl-2-pyrazinyl)ethyl group, 2-(5-ethyl-2-pyrazinyl)ethyl group, 2-(5-n-propyl-2-pyrazinyl)ethyl group, 2-(5-n-butyl-2-pyrazinyl)ethyl group, 3-(5-methyl-2-pyrazinyl)propyl group, 3-(5-ethyl-2-pyrazinyl)propyl group, 3-(5-n-propyl-2-pyrazinyl)propyl group, 3-(5-n-butyl-2-pyrazinyl)propyl group, 4-(5-methyl-2-pyrazinyl)butyl group, 4-(5-ethyl-2-pyrazinyl)butyl group, 4-(5-n-propyl-2-pyrazinyl)butyl group, 4-(5-n-butyl-2-pyrazinyl)butyl group, 5-(5-methyl-2-pyrazinyl)pentyl group, 5-(5-ethyl-2-pyrazinyl)pentyl group, 5-(5-n-propyl-2-pyrazinyl)pentyl group, 5-(5-n-butyl-2-pyrazinyl)pentyl group, 6-(5-methyl-2-pyrazinyl)hexyl group, 6-(5-ethyl-2-pyrazinyl)hexyl group, -6-(5-n-propyl-2-pyrazinyl)hexyl group, and 6-(5-n-butyl-2-pyrazinyl)hexyl group.\n\n\n \n \n \n \nExamples of the pyrrolidinyl lower alkyl group (a group selected from the group consisting of an oxo group and a lower alkyl group may be present as a substituent on the pyrrolidinyl group) include a lower alkyl group as illustrated above (a linear or branched alkyl-group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) pyrrolidinyl groups, on which 1 to 3 (preferably 1) groups selected from the group consisting of an oxo group and a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) may be present as a substituent(s). Specific examples thereof include a [(1-, 2-, or 3-)pyrrolidinyl]methyl group, 2-[(1-, 2-, or 3-)pyrrolidinyl]ethyl group, 1-[(1-, 2-, or 3-)pyrrolidinyl]ethyl group, 3-[(1-, 2-, or 3-)pyrrolidinyl]propyl group, 4-[(1-, 2-, or 3-)pyrrolidinyl]butyl group, 5-[(1-, 2-, or 3-)pyrrolidinyl]pentyl group, 6-[(1-, 2-, or 3-)pyrrolidinyl]hexyl group, 1-methyl-2-[(1-, 2-, or 3-)pyrrolidicyl]ethyl group, 1,1-dimethyl-2-[1'-, 2-, or 3-)pyrrolidinyl]ethyl group, 2-methyl-3-[(1-, 2-, or 3-)pyrrolidinyl]propyl group, 1-methyl-(2- or 3-)pyrrolidinylmethyl group, 1-ethyl-(2- or 3-)pyrrolidinylmethyl group, 1-n-propyl-(2- or 3-)pyrrolidinylmethyl group, 1-n-butyl-(2- or 3-)pyrrolidinylmethyl group, 1-n-pentyl-(2- or 3-)pyrrolidinylmethyl group, 1-n-hexyl-(2- or 3-)pyrrolidinylmethyl group, 2-methyl-1-pyrrolidinylmethyl group, 2-ethyl-1-pyrrolidinylmethyl group, 2-n-propyl-1-pyrrolidinylmethyl group, 2-n-butyl-1-pyrrolidinylmethyl group, 2-n-pentyl-1-pyrrolidinylmethyl group, 2-n-hexyl-1-pyrrolidinylmethyl group, 3-methyl-2-pyrrolidinylmethyl group, 3-ethyl-2-pyrrolidinylmethyl group, 3-n-propyl-2-pyrrolidinylmethyl group, 3-n-butyl-2-pyrrolidinylmethyl group, 1,5-dimethyl-(2- or 3-)pyrrolidinylmethyl group, 1,5-di-ethyl-(2- or 3-)pyrrolodinylmethyl group, 1,5-di-n-propyl-(2- or 3-)pyrrolidinylmethyl group, 1,5-di-n-butyl-(2- or 3-)pyrrolidinylmethyl group, 1,4,5-triethyl-(2- or 3-)pyrrolidinyimethyl group, 1,4,5-tri-n-propyl-(2- or 3-)pyrrolidinylmethyl group, 1,4,5-tri-n-butyl-(2- or 3-)pyrrolidinylmethyl group, 3-[2-oxo-(1-pyrrolidinyl)propyl]group, 3-[5-oxo-(2-, 3-, or 4-)pyrrolidinyl]propyl group, and 3-[1-methyl-5-oxo-(2-, 3-, or 4-)pyrrolidinyl]propyl group.\n\n\n \n \n \n \nExamples of the piperidyl lower alkyl group (that may have as a substituent on the piperidyl group, a group selected from the group consisting of a benzoyl group and a lower alkanoyl group) include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) piperidyl groups having 1 to 3 (preferably 1) groups, as a substituent (s), selected from the group consisting of a benzoyl group and a lower alkanoyl group as illustrated above (preferably a linear or branched alkyl group having 1 to 6 carbon atoms) on the piperidyl group(s). Specific examples thereof include a (1-, 2-, 3-, or 4-)piperidylmethyl group, 2-[(1-, 2-, 3-, or 4-)piperidyl]ethyl group, 2-[1-benzoyl-(2-, 3-, or 4-)piperidyl]ethyl group, 2-[1-acetyl-[2-, 3-, or 4-)piperidyl]ethyl group, 2-[1-butyryl-(2-, 3-, or 4-)piperidyl]ethyl group, 1-[(1-, 2-, 3-, or 4-)piperidyl]ethyl group, 3-[(1-, 2-, 3-, or 4-)piperidyl]propyl group, 4-[(1-, 2-, 3-, or 4-)piperioyl]butyl group, 1,1-dimethyl-2-(1-, 2-, 3-, or 4-)piperidyl]ethyl group, 5-[(1-, 2-, 3-, or 4-)piperidyl]pentyl group, 6-[(1-, 2-, 3-, or 4-)piperidyl]hexyl group, 1-[(1-, 2-, 3-, or 4-)piperidyl]isopropyl group, and 2-methyl-3-[(1-, 2-, 3-, or 4-)piperidyljpropyl group.\n\n\n \n \n \n \nExamples of the piperazinyl lower alkyl group (that may have a lower alkyl group as a substituent on the piperazinyl group) include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) piperazinyl groups, on which 1 to 3 (preferably 1) lower alkyl groups as illustrated above (a linear or branched alkyl groups having 1 to 6 carbon atom) may be present as a substituent (s). Specific examples thereof include a 1-piperazinylmethyl group, 2-piperazinylmethyl group, 2-(1-piperazinyl)ethyl group, 2-(2-piperazinyl)ethyl group, 1-d-piperazinyl)ethyl group, 1-(2-piperazinyl)ethyl group, 3-(1-piperazinyl)propyl group, 3-(2-piperazinyl)propyl group, 4-(1-piperazinyl)butyl group, 4-(2-piperazinyl)butyl group, 2-(4-ethyl-2-piperazinyl)ethyl group, 1-(4-n-propyl-2-piperazinyl)ethyl group, 2-(4-n-butyl-2-piperazinyl)ethyl group, 2-(4-n-pentyl-2-piperazinyl)ethyl group, (4-n-hexyl-2-piperazinyl)ethyl group, 2-(5-methyl-2-piperazinyl)ethyl group, 1-(5-ethyl-2-piperazinyl)ethyl group, 2-(5-n-propyl-2-piperazinyl)ethyl group, 1-(5-n-butyl-2-piperazinyl)ethyl group, 2-(5-n-pentyl-2-piperazinyl)ethyl group, 1-(5-n-hexyl-2-piperazinyl)ethyl group, 2-(6-methyl-2-piperazinyl)ethyl group, 1-(6-ethyl-2-piperazinyl)ethyl group, 2-(6-n-propyl-2-piperazinyl)ethyl group, 1-(6-n-butyl-2-piperazinyl)ethyl group, 2-(6-n-pentyl-2-piperazinyl)ethyl group, 2-(6-n-hexyl-2-piperazinyl)ethyl group, 3-(2-methyl-1-piperazinyl)propyl group, 3-(2-ethyl-1-piperazinyl)propyl group, 3-(2-n-propyl-1-piperazinyl)propyl group, 3-(2-n-butyl-1-piperazinyl)propyl group, 3-(2-n-pentyl-1-piperazinyl)propyl group, 3-(2-n-hexyl-1-piperazinyl)propyl group, 3-(3-methyl-1-piperazinyl)propyl group, 3-(3-ethyl-1-piperazinyl)propyl group, 3-(3-n-propyl-1-piperazinyl)propyl group, 3-(3-n-butyl-1-piperazinyl)propyl group, 3-(3-n-pentyl-1-piperazinyl)propyl group, 3-(3-n-hexyl-1-piperazinyl)propyl group, 3-(4-methyl-1-piperazinyl)propyl group, 3-(4-ethyl-1-piperazinyl)propyl group, 3-(4-n-propyl-1-piperazinyl)propyl group, 3-(4-n-butyl-1-piperazinyl)propyl group, 3-(4-n-pentyl-1-piperazinyl)propyl group, 6-(5-n-butyl-2-piperazinyl)hexyl group, 6-(5-n-pentyl-2-piperazinyl)hexyl group, 6-(5-n-hexyl-2-piperazinyl)hexyl group, 6-(6-methyl-2-piperazinyl)hexyl group, 6-(6-ethyl-2-piperazinyl)hexyl group, 6-(6-n-propyl-2-piperazinyl)hexyl group, 6-(6-n-butyl-2-piperazinyl)hexyl group, 6-(6-n-pentyl-2-piperaziny)hexyl group, 6-(6-n-hexyl-2-piperazinyl)hexyl group, 2,3-dimethyl-1-piperazinylmethyl group, 3,3-dimethyl-1-piperazinylmethyl group, and 2-(1,3,4-trimethyl-2-piperazinyl)ethyl group.\n\n\n \n \n \n \nExamples or the morpholinyl lower alkyl group included a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) morpholinyl groups. Specific examples thereof include a 2-morpholinylmethyl group, 5-morpholinylmethyl group, 4-morpholinylmethyl group, 2-(2-morpholinyl)ethyl group, 2-(3-morpholinyl)ethyl group, 2-(4-morpholinyl)ethyl group, 1-(2-morphclinyl)ethyl group, 1-(3-morpholinyl)ethyl group, 1-(4-morpholinyl)ethyl group, 3-(2-morpholinyl)propyl group, 3-(3-morpholinyl)propyl group, 3-(4-morpholnyl)propyl group, 4-(2-morpholinyl)butyl group, 4-(3-morpholinyl)butyl group, 4-(4-morpnolinyl)butyl group, 5-(2-morpholinyl)pentyl group, 5-(3-morpholinyl)pentyl group, 5-(4-morpholinyl)pentyl group, 6-(2-morpholinyl)hexyl group, 6-(3-morpholinyl)hexyl group, 6-(4-morpholinyl)hexyl group, 3-methyl-3-(2-morpholinyl)propyl group, 3-methyl-3-(3-morpholinyl)propyl group, 3-methyl-3-(4-morpholinyl)propyl group, 1,1-dimethyl-2-(2-morpholinyl)ethyl group, 1,1-dimethyl-2-(3-morpholinyl)ethyl group, and 1,1-dimethyl-2-(4-morpholinyl)ethyl group.\n\n\n \n \n \n \nExample of a thienyl lower alkyl group (that may have a lower alkyl group as a substituent on the thienyl group) include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) thienyl groups, on which 1 to 3 (preferably 1) lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms) may be present as a substituent (s). Specific examples thereof include a (2- or 3-)thienylmethyl group, 2-[(2- or 3-)thienyl]ethyl group, 1-[(2- or 3-) thienyl]ethyl group, 3-[(2- or 3-)thienyl]propyl group, 4-[(2- or 3-)thienyl]butyl group, 5-[(2- or 3-) thienyl]pentyl group, 6-[(2- or 3-)thienyl]hexyl group, 1,1-dimethyl-2-[(2- or 3-)thienyl]ethyl group, 2-methyl-3-[(2- or 3-)thienyl]propyl group, 3-methyl-(2-, 4-, or 5-)-thienylmethyl group, [5-methyl-(2, 3- or 4-)thienyl]methyl group, [4-ethyl-(2- or 3-) thienyl]methyl group, [5-n-propyl-(2, 3- or 4-)thienyl]methyl group, [3-n-butyl-(2-, 4-, or 5-)-thienyl]]]methyl group, [4,5-dimethyl-(2- or 3-)thienyl]methyl group, (3,4,5-trimethyl-2-thienyl)methyl group, 2-[3-methyl-(2-, 4-, or 5-)-thienyl]ethyl group, 1-[4-n-pentyl-(2- or 3-)thienyl]ethyl group, 3-[3-hexyl-2-thienyl]propyl group, 4-[4,5-dimethyl-(2- or 3-) thienyl]butyl group, 5-(2,4,5-trimethyl-3-thienyl)pentyl group, and 6-[5-ethyl-(2-, 3-, or 4-)thienyl]hexyl group.\n\n\n \n \n \n \nExamples of the thiazolyl group include a (2-, 4- or 5-) thiazolyl group.\n\n\n \n \n \n \nExamples of the thiazolyl lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) thiazolyl groups. Specific examples thereof include a (2-, 4-, or 5-) thiazolylmethyl group, 2-[(2-, 4-, or 5-)thiazolyl)ethyl group, 1-[(2-, 4-, or 5-)thiazolyl]ethyl group, 3-[(2-, 4-, or 5-)thiazolyl]propyl group, 4-[(2-, 4-, or 5-)thiazolyl]butyl group, 5-[(2-, 4-, or 5-)thiazolyl)]pentyl group, 6-[(2-, 4-, or 5-)thiazolyl)]hexyl group, 1,1-dimethyl-2-[(2-, 4- or 5-)thiazolyl]ethyl group, and [2-methyl-3-[(2-, 4-, or 5-)thiazolyl]propyl group.\n\n\n \n \n \n \nExamples of the dihydrobenzofuryl group include a 2,3-dihydro-(2-, 3-, 4-, 5-, 6- or 7-)benzofuryl group.\n\n\n \n \n \n \nExamples of the dihydrobenzofuryl lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) dihydrobenzofuryl groups. Specific examples thereof include a 2,3-dihydro-4-benzofurylmethyl group, 2-(2,3-dihydro-4-benzofuryl)ethyl group, 3-(2,3-dihydro-4-benzofuryl)propyl group, 4-(2,3-dihydzo-4-benzofuryl)butyl group, 5-(2,3-dihydro-4-benzofuryl)pentyl group, 6-(2,3-dihydro-4-benzofuryl)hexyl group, 2,3-dihydro-5-benzofurylmethyl group, 2-(2,3-dihydro-5-benzofuryl)ethyl group, 3-(2,3-dihydro-5-benzofuryl)propyl group, 4-(2,3-dihydro-5-benzofuryl)butyl group, 2,3-dihydro-6-benzofurylmethyl group, 2-(2,3-dihydro-6-benzofuryl)ethyl group, 3-(2,3-dihydro-6-benzofuryl)propyl group, 4-(2,3-dihydro-6-benzofuryl)butyl group, 5-(2,3-dihydro-5-benzofuryl)pentyl group, 2,3-dihydro-7-benzofurylmethyl group, 2,3-dihydro-7-benzofurylethyl group, 3-(2,3-dihydro-7-benzofuryl)propyl group, 4-(2,3-dihydro-7-benzofuryl)butyl group, and 6-(2,3-dihydro-7-benzofuryl)hexyl group.\n\n\n \n \n \n \nExamples of the benzopyranyl lower alkyl group (that may have an oxo group as a substituent on the benzopyranyl group) include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) benzopyranyl groups on which an oxo group may be present as a substituent. Specific examples thereof include a (4H-1-benzopyran-2-yl)methyl group, 2-(4H-1-benzopyran-2-yl)ethyl group, 3-(4H-1-benzopyran-2-yl)propyl group, 4-(4H-1-benzopyran-2-yl)butyl group, 5-(4H-1-benzopyran-2-yl)pentyl group, 6-(4H-1-benzopyran-2-yl)hexyl group, (4H-1-benzopyran-3-yl)methyl group, 2-(4H-1-benzopyran-3-yl)ethyl group, 3-(4H-1-benzopyran-3-yl)propyl group, 4-(4H-1-benzopyran-3-yl)butyl group, 5-(4H-1-benzopyran-3-yl)pentyl group, 6-(4H-1-benzopyran-3-yl)hexyl group, (4H-1-benzopyran-4-yl)methyl group, 2-(4H-1-benzopyran-4-yl)ethyl group, 3-(4H-1-benzopyran-4-yl)propyl group, 4-(4H-1-benzopyran-4-yl)butyl group, 5-(4H-1-benzopyran-4-yl)pentyl group, 6-(4H-1-benzopyran-4-yl)hexyl group, (2H-1-benzopyran-2-yl)methyl group, 2-(2H-1-benzopyran-2-yl)ethyl group, 3-(2H-1-benzopyran-2-yl)propyl group, 4-(2H-1-benzopyran-2-yl)butyl group, 5-(2H-1-benzopyran-2-yl)pentyl group, 6-(2H-1-benzopyran-2-yl)hexyl group, (2H-1-benzopyran-3-yl)methyl group, 2-(2H-1-benzopyran-3-yl)ethyl group, 3-(2H-1-benzopyran-3-yl)propyl group, 4-(2H-1-benzopyran-3-yl)butyl group, 5-(2H-1-benzopyran-3-yl)pentyl group, 6-(2H-1-benzopyran-3-yl)hexyl group, (2H-1-benzopyran-4-yl)methyl group, 2-(2H-1-benzopyran-4-yl)ethyl group, 3-(2H-1-benzopyran-4-yl)propyl group, 4-(2H-1-benzopyran-4-yl)butyl group, 5-(2H-1-benzopyran-4-yl)pentyl group, 6-(2H-1-benzopyran-4-yl)hexyl group, (1H-2-benzopyran-1-yl)methyl group, 2-(1H-2-benzopyran-1-yl)ethyl group, 3-(1H-2-benzopyran-1-yl)propyl group, 4-(1H-2-benzopyran-1-yl)butyl group, 5-(1H-2-benzopyran-1-yl)pentyl group, 6-(1H-2-benzopyran-1-yl)hexyl group, (1H-2-benzopyran-3-yl)methyl group, 2-(1H-2-benzopyran-3-yl)ethyl group, 3-(1H-2-benzopyran-3-yl)propyl group, 4-(1H-2-benzopyran-3-yl)butyl group, 5-(1H-2-benzopyran-3-yl)pentyl group, 6-(1H-2-benzopyran-3-yl)hexyl group, (1H-2-benzopyran-3-yl)methyl group, 2-(1H-2-benzopyran-4-yl)ethyl group, 3-(1H-2-benzopyran-4-yl)propyl group, 4-(1H-2-benzopyran-4-yl)butyl group, 5-(1H-2-benzopyran-4-yl)pentyl group, 6-(1H-2-benzopyran-4-yl)hexyl group, (4-oxo-4H-1-benzopyran-2-yl)methyl group, 2-(4-oxo-4H-1-benzopyran-2-yl)ethyl group, 3-(4-oxo-4H-1-benzopyran-2-yl)propyl group, 4-(4-oxo-4H-1-benzopyran-2-yl)butyl group, 5-(4-oxo-4H-1-benzopyran-2-yl)pentyl group, 6-(4-oxo-4H-1-benzopyran-2-yl)hexyl group, (4-oxo-4H-1-benzopyran-3-yl)methyl group, 2-(4-oxo-4H-1-benzopyran-3-yl)ethyl group, 3-(4-oxo-4H-1-benzopyran-3-yl)propyl group, 4-(4-oxo-4H-1-benzopyran-3-yl)butyl group, 5-(4-oxo-4H-1-benzopyran-3-yl)pentyl group, 6-(4-oxo-4H-1-benzopyran-3-yl)hexyl group, (4-oxo-4H-1-benzopyran-4-yl)methyl group, (2-oxo-2H-1-benzopyran-3-yl)methyl group, 2-(2-oxo-2H-1-benzopyran-3-yl)ethyl group, 3-(2-oxo-2H-1-benzopyran-3-yl)propyl group, 4-(2-oxo-2H-1-benzopyran-3-yl)butyl group, 5-(2-oxo-2H-1-benzopyran-3-yl)pentyl group, 6-(2-oxo-2H-1-benzopyran-3-yl)hexyl group, (2-oxo-2H-1-benzopyran-4-yl)methyl group, 2-(2-oxo-2H-1-benzopyran-4-yl)ethyl group, 3-(2-oxo-2H-1-benzopyran)-4-yl)propyl group, 4-(2-oxo-2H-1-benzopyran-4-yl)butyl group, 5-(2-oxo-2H-1-benzopyran-4-yl)pentyl group, 6-(2-oxo-2H-1-benzopyran-4-yl)hexyl group, (1-oxo-1H-2-benzopyran-3-yl)methyl group, 2-(1-oxo-1H-2-benzopyran-1-yl)ethyl group, 3-(1-oxo-1H-2-benzopyran-3-yl)propyl group, 4-(1-oxo-1H-2-benzopyran-3-yl)butyl group, 5-(1-oxo-1H-2-benzopyran-3-yl)pentyl group, 6-(1-oxo-1H-2-benzopyran-3-yl)hexyl group, (1-oxo-1H-2-benzopyran-4-yl)methyl group, 2-(1-oxo-1H-2-benzopyran-4-yl)ethyl group, 3-(1-oxo-1H-2-benzopyran-4-yl)propyl group, 4-(1-oxo-1H-2-benzopyran-4-yl)butyl group, 5-(1-oxo-1H-2-benzopyran-4-yl)pentyl group, and 6-(1-oxo-1H-2-benzopyran-4-yl)hexyl group.\n\n\n \n \n \n \nExamples of the benzimidazolyl lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) benzimidazolyl groups. Specific examples thereof include a 1-benzimidazolylmethyl group, 2-(1-benzimidazolyl) ethyl group, 3-(1-benzimidazolyl)propyl group, 4-(1-benzimidazolyl)butyl group, 5-(1-benzimidazolyl)pentyl group, 6-(1-benzimidazolyl)hexyl group, 2-benzimidazolylmethyl group, 2-(2-benzimidazolyl)ethyl group, 3-(2-benzimidazolyl)propyl group, 4-(2-benzimidazolyl)butyl group, 5-(2-benzimidazolyl)pentyl group, and 6-(2-benzimidazolyl)hexyl group.\n\n\n \n \n \n \nExamples of the indolyl lower alkyl group that may have a lower alkoxycarbonyl group on the lower alkyl group include a lower alkyl group (a linear or branched alkyl group having 1 to 6 carbon atoms) as illustrated above that may have 1 to 3 (preferably 1) lower alkoxycarbonyl groups as illustrated above that may have 1 to 2 (preferably 1) indolyl groups. Specific examples thereof include an indol (-1-, -2-, - 3-, -4-, -5-, -6-, or -7-)ylmethyl group, 2-indol(-1-, -2-, -3-, -4-, -5-, -6-, or -7-)ylethyl group, 3-indol(-1-, -2-, -3-, -4-, -5-, -6-, or -7-)ylpropyl group, 4-indol (-1-, -2-, -3-, -4-, -5-, -6-, or -7-)ylbutyl group, 5-indol(-1-, -2-, -3-, -4-, -3-, -5-, or -7-)ylpentyl group, 6-indol(-1-, -2-, -3-, -4-, -5-, -6-, or -7-)ylhexyl group, 3-methyl-3-indol(-1-, -2-, -3-, -4-, -5-, -6-, or -7-)ylpropyl group, 1,1-dimethyl-2-indol(-1-, -2-, -3-, -4-, -5-, -6-, or - 7-)ylethyl group, and 1-methoxycarbonyl-2-indol(-1-, - 2-, -3-, -4-, -5-, -6-, or -7-)ylethyl group.\n\n\n \n \n \n \nExamples of the imidazolyl lower alkyl group having an substituent selected from the group consisting of a carbamoyl group and a lower alkoxycarbonyl group on the lower alkyl group include an imidazolyl lower alkyl group having a 1 to 3, preferably 1, substituents selected from the group consisting of a carbamoyl group and a lower alkoxycarbonyl group as illustrated above on the alkyl group whose lower alkyl moiety is the same as that illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms). Specific examples thereof include a carbamoyl-[(1-, 2-, 4-, or 5-)imidazolyl]methyl group, methoxycarbonyl-[(1-, 2-, 4-, or 3-)imidazolyl]methyl group, ethoxycarbonyl-[(1-, 2-, 4-, or 5-)imidazolyl]methyl group, n-butoxycarbonyl-[(1-, 2-, 4-, or 5-)imidazolyl]methyl group, isobutoxycarbonyl-[(1-, 2-, 4-, or 5-)imidazolyl]methyl group, tert-butoxycarbonyl-[(1-, 2-, 4-, or 5-)imidazolyl]methyl group, sec-butoxycarbonyl-[(1-, 2-, 4-, or 5-)imidazolyl]methyl group, n-pentyloxycarbonyl-[(1-, 2-, 4-, or 5-)imidazolyl]methyl group, neopentyloxy-[(1-, 2-, 4-, or 5-) imidazolyl]methyl group, n-hexyloxycarbonyl-[(1-, 2-, 4-, or 5-)imidazolyl]methyl group, isohexyloxycarbonyl-[(1-, 2-, 4-, or 5-)imidazolyl]methyl group, 3-methylpentyloxycarbonyl-[(1-, 2-, 4-, or 5-)imidazolyl]methyl group, 1-carbamoyl-2-[(1-, 2-, 4-, or 5-)imidazolyl]ethyl group, 1-methoxycarbonyl-2-[(1-, 2-, 4-, or 5-)imidazolyl]ethyl group, 1,1-dimethoxycarbonyl-2-[(1-, 2-, 4-, or 5-)imidazolyl]ethyl group, 1,1-dicarbamoyl-2-[(1-, 2-, 4-, or 5-)imidazolyl]ethyl group, 2-carbamoyl-1-[(1-, 2-, 4-, or 5-)imidazolyl]ethyl group, 2-methoxycarbonyl-3-[(1-, 2-, 4-, or 5-)imidazolyl]propyl group, 2-carbamoyl-4-[(1-, 2-, 4-, or 5-)imidazolyl]butyl group, 1-methyl-1-carbamoylmethyl-2-[(1-, 2-, 4-, or 5-)imidazolyl]ethyl group, 2-methoxycarbonyl-5-[(1-, 2-, 4-, or 5-)imidazolyl]pentyl group, 3-carbamoyl-6-[(1-, 2-, 4-, or 5-)imidazolyl]hexyl group, 2-methoxycarbonyl-1-[(1-, 2-, 4-, or 5-)imidazolyl]isopropyl group, and 2-carbamoylmethyl-3-[(1-, 2-, 4-, or 5-)imidazolyl]propyl group.\n\n\n \n \n \n \nExamples of the pyridyl group that may have a group selected from the group consisting of a lower alkyl group, lower alkoxy group, and lower alkylthio lower alkyl group, as a substituent include a pyridyl group that may have 1 to 4 (preferably 1) groups, as a substituent (s), which are selected from the group consisting of a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms), a lower alkoxy group as illustrated above (a linear or branched alkoxy group having 1 to 6 carbon atoms), and a lower alkylthio lower alkyl group in which the two lower alkyl moieties each are composed of a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) . Specific examples thereof include a 2-pyridyl group, 3-pyridyl group, 4-pyridyl group, 4-methyl-2-pyridyl group, 5-methyl-2-pyridyl group, 5-ethyl-3-pyridyl group, 2-n-propyl-3-pyridyl group, 4-n-butyl-2-pyridyl group, 4-tert-butyl-2-pyridyl group, 5-n-pentyl-3-pyridyl group, 4-n-hexyl-2-pyridyl group, 4-methoxy-2-pyridyl group, 5-methoxy-2-pyridyl group, 2-methylthiomethyl-3-pyridyl group, 5-ethylthiomethyl-2-pyridyl group, 4-n-propylthiomethyl-2-pyridyl group, 3-n-butylthiomethyl-2-pyridyl group, 5-n-pentylthiomethyl-3-pyridyl group, 4-n-hexylthiomethyl-3-pyridyl group, 2-(2-methylthioethyl)-3-pyridyl group, 2-(3-methylthiopropyl)-4-pyridyl group, 3-(4-methylthiobutyl)-4-pyridyl group, 3-(5-methylthiopentyl)-2-pyridyl group, 4-(6-methylthiohexyl)-2-pyridyl group, 3,4-dimethyl-2-pyridyl group, 2,4,6-triethyl-3-pyridyl group, 2,3,5,6-tetramethyl-4-pyridyl group, and 2-methyl-3-methylthiomethyl-4-pyridyl group.\n\n\n \n \n \n \nExamples of the pyrrolidinyl group that may have a group selected from the group consisting of a lower alkyl group, lower alkoxycarbonyl group, lower alkanoyl group, and aroyl group as a substituent include a pyrrolidinyl group that may have 1 to 3, preferably 1 group, as a substituent(s), which is selected from the group consisting of a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms), a lower alkoxycarbonyl group as illustrated above a lower alkanoyl group as described above (a linear or branched alkanoyl group having 1 to 6 carbon atoms), and an aroyl group (preferably a benzoyl group). Specific examples thereof include a pyrrolidin-1-yl group, pyrrolidin-2-yl group, pyrrolidin-3-yl group, 1-methylpyrrolidin-3-yl group, 2-ethylpyrrolidin-3-yl group, 3-n-propylpyrrolidin-3-yl group, 4-n-butylpyrrolidin-3-yl group, 1-tert-butylpyrrolidin-3-yl group, 5-n-pentylpyrrolidin-3-yl group, 1-n-hexylpyrrolidin-2-yl group, 2-methoxycarbonyl-2-yl group, 3-ethoxycarbonylpyrrolidin-2-yl group, 1-tert-butoxycarbonylpyrrolidin-3-yl group, 4-propoxycarbonylpyrrolidin-2-yl group, 5-butoxycarbonylpyrrolidin-2-yl group, 1-pentoxycarbonyl-2-yl group, 2-hexyloxycarbonylpyrrolidin-2-yl group, 1,3-dimethoxycarbonylpyrrolidin-2-yl group, 3,4,5-triethylpyrrolidin-2-yl group, 2,3,4,5-tetramethylpyrrolidin-1-yl group, 2,4-dimethoxycarbonylpyrrolidin-1-yl group, 3,4,5-triethoxycarbonylpyrrolidin-1-yl group, 2-methyl-4-methoxycarbonylpyrrolidin-1-yl group, 1-benzoylpyrrolidin-3-yl group, 1-acetylpyrrolidin-3-yl group, and 1-butyrylpyrrolidin-3-yl group.\n\n\n \n \n \n \nExamples of the piperidyl group that may have a group as a substituent selected from the group consisting of a lower alkyl group, a lower alkoxycarbonyl group, a lower alkanoyl group, and an aroyl group that may have a group selected from the group consisting of a lower alkyl group and a halogen atom include a piperidyl group that may have 1 to 5 (preferably 1 to 4) groups, as a substituent(s), which are selected from the group consisting of\n\na lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms);\n\na lower alkoxy group as illustrated above (a linear or branched alkoxy group having 1 to 6 carbon atoms);\n\na lower alkanoyl group as illustrated above ( a linear or branched alkanoyl group having 1 to 6 carbon atoms); and\n\nan aroyl group that may have 1 to 3 groups (preferably 1 group) selected from the group consisting of a lower alkyl group as illustrated above and a halogen atom as illustrated above (preferably a benzoyl group). Specific examples thereof include a 1-piperidyl group, 2-piperidyl group, 3-piperidyl group, 4-piperidyl group, 1-methyl-4-piperidyl group, 2-ethyl-4-piperidyl group, 3-n-propyl-4-piperidyl group, 4-n-butyl-4-piperidyl group, 1-n-pentyl-4-piperidyl group, 2-n-hexyl -4-piperidyl group, 1-methoxycarbonyl-4-piperidyl group, 1-ethoxycarbonyl-4-piperidyl group, 4-n-propoxycarbonyl-4-piperidyl group, 5-n-butoxycarbonyl-4-piperidyl group, 1-tert-butoxycarbonyl-4-piperidyl group, 1-formyl-4-piperidyl group, 1-acetyl-4-piperidyl group, 1-butyryl-4-piperidyl group, 1-butyryl-3-piperidyl group, 2-propionyl-4-piperidyl group, 3-butyryl-4-piperidyl group, 4-isobutyryl-4-piperidyl group, 1-n-pentanoyl-4-piperidyl group, 2-tert-butylcarbonyl-4-piperidyl group, 3-n-hexanoyl-4-piperidyl group, 1-benzoyl-4-piperidyl group, 1-benzoyl-3-piperidyl group, 1-(2-, 3-, or 4-chlorobenzoyl)-4-piperidyl group, 1-(2-, 3-, or 4-fluorobenzoyl)-4-piperidyl group, 1-(2-, 3-, or 4-methylbenzoyl)-4-piperidyl group, 2,6-dimethyl-4-piperidyl group, 2,4,6-trimethyl-3-piperidyl group, 2,2,6,6-tetramethyl-4-piperidyl group, and 2,2,4,4,6-pentamethyl-3-piperidyl group.\n\n\n \n \n \n \nExamples of the tetrahydrofuryl group that may have an oxo group include a 2-tetrahydrofuryl group, 3-tetrahydrofuryl group, 3-oxo-2-tetrahydrofuryl group, 4-oxo-2-tetrahydrofuryl group, 5-oxo-2-tetrahydrofuryl group, 2-oxo-3-tetrahydrofuryl group, 4-oxo-3-tetrahydrofuryl group, and 5-oxo-4-tetrahydrofuryl group.\n\n\n \n \n \n \nExamples of the hexahydroazepinyl group that may have an oxo group include 2-hexahydroazepinyl group, 3-hexahydroazepinyl group, 4-hexahydroazepinyl group, 2-oxo-3-hexahydroazepinyl group, 3-oxo-2-hexahydroazepinyl group, 4-oxo-2-hexahydroazepinyl group, 5-oxo-2-hexahydroazepinyl group, and 6-oxo-2-hexahydroazepinyl group.\n\n\n \n \n \n \nExamples of the pyrazolyl group that may have a group selected from the group consisting of a lower alkyl group, aryl group, and furyl group as a substituent include a pyrazolyl group that may have 1 to 3 (preferably 1 to 2) groups, as a substituent(s), which are selected from the group consisting of\n\na lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) ;\n\nan aryl group as illustrated above; and a furyl group. Specific examples thereof include a 1-pyrazolyl group, 3-pyrazolyl group, 4-pyrazolyl group, 1-metbyl-5-pyrazolyl group, 1-ethyl-5-pyrazolyl group, 3-n-propyl-5-pyrazolyl group, 4-n-butyl-5-pyrazolyl group, 1-tert-butyl-4-pyrazolyl group, 1-n-pentyl-4-pyrazolyl group, 3-n-hexyl-4-pyrazolyl group, 3-phenyl-5-pyrazolyl group, 1-(2-naphthyl)-3-pyrazolyl group, 4-(2-methylphenyl)-3-pyrasolyl group, 5-(3-ethylphenyl)-3-pyrazolyl group, 1-(4-n-propylphenyl)-4-pyrazolyl group, 3-(2-n-butylphenyl)-4-pyrazolyl group, 5-(3-n-pentylphenyl)-4-pyrazolyl group, 1-(4-n-hexylphenyl)-5-pyrazolyl group, 3-(2-isobutylphenyl)-5-pyrazolyl group, 4-(3-tert-butylphenyl)-5-pyrazolyl group, 3-(2-chlorophenyl)-1-pyrazolyl group, 4-(3-fluorophenyl)-1-pyrazolyl group, 5-(4-bromopnenyl)-1-pyrazolyl group, 1-(2-aminophenyl)-3-pyrazolyl group, 4-(2,3-dimethylphenyl)-3-pyrazolyl group, 5-(3,4,5-trimethylphenyl)-3-pyrazolyl group, 1-(2,3-diaminophenyl)-4-pyrazolyl group, 3-(2-furyl)-5-pyrazolyl group, 1,3-dimethyl-5-pyrazolyl group, 1,3,4-triethyl-5-pyrazolyl group, 1,3,5-trimethyl-4-pyrazolyl group, and 1-methyl-3-phenyl-5-pyrazolyl group.\n\n\n \n \n \n \nExamples of the thiadiazolyl group include a 1,2,3-thiadiazolyl group, 1,2,4-thiadiazolyl group, 1,2,5-thiadiazolyl group or 1,3,4-thiadiazolyl group.\n\n\n \n \n \n \nExamples of the thiadiazolyl group that may have a lover alkyl group include a thiadiazolyl group as illustrated above that may have 1 to 3, preferably 1, lower alkyl groups as illustrated above ( linear or branched alkyl groups having 1 to 6 carbon atoms). Specific examples thereof include a 4- or 5-(1, 2, 3-thiadiazolyl) group, 3- or 5-(1, 2, 4-thiadiazolyl) group, 3-(1, 2, 5-thiadiazolyl) group, 2-(1, 3, 4-thiadiazolyl) group, 5-methyl-1,3,4-thiadiazol-2-yl group, 4-ethyl-1,2,3-thiadiazol-5-yl group, 5-n-propyl-1,2,4-thiadiazol-5-yl group, 5-n-butyl-1,2,4-thiadiazol-2-yl group, 4-tert-butyl-1,2,3-thiadiazol-5-yl group, 5-n-pentyl-1,2,4-thiadiazol-3-yl group, and 5-n-hexyl-1,3,4-thiadiazol-2-yl group.\n\n\n \n \n \n \nExamples of an isoxazolyl group that may have a lower alkyl group include an isoxazolyl group that may have 1 to 2 lower alkyl group as illustrated above (linear or branched alkyl group having 1 to 6 carbon atoms). Specific examples thereof include a 3-isoxazolyl group, 4-isoxazolyl group, 5-isoxazolyl group, 2-methyl-5-isoxazolyl group, 4-ethyl-5-isoxazolyl group, 4-n-propyl-3-isoxazolyl group, 5-methyl-3-isoxazolyl group, 5-n-butyl-3-isoxazolyl group, 3-tert-butyl-4-isoxazolyl group, 5-n-pentyl-4-isoxazolyl group, 3-n-hexyl-5-isoxazolyl group, and 3,4-dimethyl-5-isoxazolyl group.\n\n\n \n \n \n \nExamples of the indazolyl group include a (1-, 3-, 4-, 5-, 6- or 7-)indazolyl group.\n\n\n \n \n \n \nExamples of the tetrahydrobenzothiazolyl group include a (2-, 4-, 5-, 6-, or 7-) (4, 5,6,7-tetrahydrobenthiazolyl) group.\n\n\n \n \n \n \nExamples of the tetrahydroquinolyl group include a (1-, 2-, 4-, 5-, 6- or -8)(1, 2, 3, 4-tetrahydroquinolyl group.\n\n\n \n \n \n \nExample of a tetrahydroquinolyl group that may have a group selected from the group consisting of a lower alkyl group, lower alkoxy group, halogen atom and oxo group as a substituent include a tetrahydroquinolyl group as illustrated above that may have 1 to 3 (preferably 2 to 2) groups, as a substituent(s), which are selected from the group consisting of\n\na lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) ;\n\na lower alkoxy group as illustrated above (a linear or branched alkoxy group having 2 to 6 carbon atoms); a halogen atom; and\n\nan oxo group. Specific examples thereof include a 1-(1,2,3,4-tetrahydroquinolyl) group, 2-(1,2,3,4-tetrahydroquinolyl) group, 3-(1,2,3,4-tetrahydroquinolyl) group, 4-(1,2,3,4-tetrahydroquinolyl) group, 5-(1, 2, 3, 4 tetrahydroquinolyl) group, 6-(1, 2, 3, 4-tetrahydroquinolyl) group, 7-(1,2, 3, 4-tetrahydroquinolyl) group, 8-(1,2,3,4-tetrahydroquinolyl) group, 2-methyl-3-(1,2,3,4-tetrahydroquinolyl) group, 3-ethyl-2-(1,2,3,4-tetrahydroquinolyl) group, 4-n-propyl-2-(1,2,3,4-tetrahydroquinolyl) group, 5-n-butyl-3-(1,2,3,4-tetrahydroquinolyl) group, 6-tert-butyl-3-(1,2,3,4-tetrahydroquinolyl) group, 7-n-pentyl-2-(1,2,3,4-tetrahydroquinolyl) group, 8-n-hexyl-2-(1,2,3,4-tetrahydroquinolyl) group, 2-methoxy-4-(1,2,3,4-tetrahydroquinolyl) group, 3-ethoxy-4-(1,2,3,4-tetrahydroquinolyl) group, 4-propoxy-5-(1,2,3,4-tetrahydroquinolyl) group, 5-butoxy-6-(1,2,3,4-tetrahydroquinolyl) group, 6-pentoxy-7-(1,2,3,4-tetrahydroquinolyl) group, 7-hexyloxy-8-(1,2,3,4-tetrahydroquinolyl) group, 4-oxo-3-(1,2,3,4-tetrahydroquinolyl) group, 2-oxo-(1-, 3-, 4-, 5-, 6-, 7-, or 8-)-(1,2,3,4-tetrahydroquinolyl) group, 2-oxo-8-methyl-(3-, 4-, 5-, 6-, or 7-)-(1,2,3,4-tetrahydroquinolyl) group, 2-oxo-8-methoxy-3-(1,2,3,4-tetrahydroquinolyl) group, 2-oxo-5-methoxy-(1-, 3-, 4-, 6-, 7-, or 8-)-(1,2,3,4-tetrahydroquinolyl) group, 2-oxo-8-fluoro-(3-, 4-, 5-, 6-, or 7-)-(1,2,3,4-tetrahydroquinolyl)group, and 2-oxo-6,8-dimethyl-3-(1,2,3,4-tetrahydroquinolyl) group.\n\n\n \n \n \n \nExamples of the quinolyl group include a 2-quinolyl group, 3-quinolyl group, 4-quinolyl group, 5-quinolyl group, 6-quinolyl group, 7-quinolyl group, and 8-quinolyl group. Examples of the quinolyl group that may have a lower alkyl group include a quinolyl group that may have 1 to 2 lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms). Specific examples thereof include a 2-, 3-, 4-, 5-, 6-, 7- or 6-quinolyl group, 2-methyl-6-quinolyl group, 4-ethyl-5-quinolyl group, 4-n-propyl-3-quinolyl group, 5-methyl-3-quinolyl group, 5-n-butyl-3-quinolyl group, 3-tert-butyl-4-quinolyl group, 5-n-pentyl-4-quinolyl group, 3-n-hexyl-5-quinolyl group and 3,4-dimethyl-5-quinolyl group.\n\n\n \n \n \n \nExamples of the benzodioxolyl lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 2 (preferably 1) benzodioxolyl groups. Specific examples thereof include a 2-, 4- or 5-(1,3-benzodioxolyl)methyl group, 2-(2-, 4- or 5-) (1,3-benzodioxolyl) ethyl group and 3-(2-, 4- or 5-) (1, 3-benzodioxolyl) propyl group.\n\n\n \n \n \n \nExamples of the aryl group that may have a group selected from the group consisting of a halogen atom; a lower alkyl group; a lower alkoxy group; a halogen substituted lower alkyl group; a halogen substituted lower alkoxy group; a lower alkenyl group; an amino group that may have a group selected from the group consisting of a lower alkylsulfonyl group, lower alkyl group, and aryl group; a sulfamoyl group; a lower alkylthio group; a lower alkanoyl group; a lower alkoxycarbonyl group; a pyrrolyl group; lower alkynyl group; cyano group, nitro group; aryloxy group; aryl lower alkoxy group; hydroxy group; hydroxy lower alkyl group; carbamoyl group that may have a group selected from the group consisting of a lower alkyl group and an aryl group; pyrazolyl group; pyrrolidinyl group that may have an oxo group; oxazolyl group; imidazolyl group that may have a lower alkyl group; dihydrofuryl group that may have an oxo group; thiazolidinyl lower alkyl group that may have an oxo group; imidazolyl lower alkanoyl group; and piperidinylcarbonyl group include an aryl group as illustrated above that may have 1 to 7, preferably 1 to 5, more preferably, 1 to 2 groups, as a substituent (s) , which are selected from the group consisting of\n\na halogen atom as illustrated above;\n\na lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) ;\n\na lower alkoxy group as illustrated above (a linear or branched alkoxy group having 1 to 6 carbon atoms);\n\na halogen substituted lower alkyl group as illustrated above (preferably a linear or branched alkyl group having 1 to 6 carbon atoms substituted with 1 to 7 halogen atoms) ;\n\na halogen substituted lower alkoxy group as illustrated above (preferably a linear or branched alkoxy group, having 1 to 6 carbon atoms substituted with 1 to 7 halogen atoms);\n\na lower alkenyl group as illustrated above ( a linear or branched alkenyl group having 1 to 3 double bonds and 2 to 6 carbon atoms (including both trans and cis configurations));\n\nam amino group having 1 to 2 lower alkanoyl groups as illustrated above, lower alkyl groups as illustrated above, and aryl groups as illustrated above; a sulfamoyl group;\n\na lower alkylthio group whose lower alkyl moiety is a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 5 carbon atoms);\n\na lower alkanoyl group as illustrated above ( a linear or branched alkanoyl group having 1 to 6 carbon atoms)\n\na lower alkoxycarbonyl group as illustrated above ; a pyrrolyl group; an alkynyl group as illustrated below, cyano group; nitro group; aryloxy group whose aryl moiety is as illustrated above; aryl lower alkoxy group whose aryl moiety and lower alkoxy moiety are as illustrated above; hydroxy croup; a hydroxy lower alkyl group whose lower alkyl moiety is as illustrated above; a carbamoyl group that may have 1 to groups selected from the group consisting of a lower alkyl group as illustrated above and aryl group as illustrated above; pyrazolyl group; pyrrolidinyl group that may have 1 to 2 (preferably 1) oxo groups; oxazolyl group; imidazolyl group that may have 1 to 3 (preferably 1 to 2) lower alkyl groups as illustrated above; dihydrofuryl group that may have 1 to 2 (preferably 1) oxo groups; thiazolidinyl group that may have 1 to 2 (preferably 1) oxo groups and having an lower alkyl moiety as illustrated above; imidazolyl lower alkanoyl group whose alkanoyl moiety is as illustrated above and piperidinylcarbonyl group. Specific examples thereof include a phenyl group, 1-naphthyl group, 2- naphthyl group, (2-, 3-, or 4-)biphenyl group, (2-, 3-, or 4-)chlorophenyl group, (2-, 3-, or 4-)fluorophenyl group, (2-, 3-, or 4-)bromophenyl group, (2-, 3-, or 4-)methylphenyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)ethyl-1-naphthyl group, (2-, 3-, or 4-)n-propylphenyl group, (2-, 3-, or 4-)n-butylphenyl group, (2-, 3-, or 4-)n-pentylphenyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-hexyl-1-naphthyl group, (2-, 3-, or 4-)isobutylphenyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)tert-butyl-1-naphthyl group, (2-, 3-, or 4-)methoxyphenyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)ethoxy-1-naphthyl group, (2-, 3-, or 4-)n-propoxyphenyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)isopropoxy-1-naphthyl group; (2-, 3-, or 4-)n-butoxyphenyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)isobutoxy-2-naphthyl group, (2-, 3-, or 4-)tert-butoxyphenyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)sec-butoxy-1-naphthyl group, (2-, 3-, or 4-)n-pentyloxyphenyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)isopentyloxy-1-naphthyl group, (2-, 3-, or 4-)neopentyloxyphenyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-hexyloxy-2-naphthyl group, (2-, 3-, or 4-)isohexyloxyphenyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)(3-methylpentyloxy)-1-naphthyl group, (2-, 3-, or 4-)chloromethylphenyl group, (2-, 3-, or 4-)trifluoromethylphenyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)fluoroethyl-1-naphthyl group, (2-, 3-, or 4-)(3-bromopropyl)phenyl group, (2-, 3-, or 4-)(4-chlorobutyl)phenyl group, (2-, 3-, or 4-)(5-fluoropentyl)phenyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)(6-bromohexyl)-1-naphthyl group, (2-, 3-, or 4-)(1,1-dimethyl-2-chloroethyl)phenyl.group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)(2-methyl-3-fluoropropyl)-2-naphthyl group, (2-, 3-, or 4-)chloromethoxyphenyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)(2-fluoroethoxy)-1-naphthyl group, (2-, 3-, or 4-)(3-bromopropoxy)phenyl group, (2-, 3-, or 4-)(4-chlorobutoxy)phenyl group, (2-, 3-, or 4-)(5-fluoropentyloxy)phenyl group, (2-, 3-, or 4-)trifluoromethoxyphenyl group, 4-(6-bromohexyloxy)-1-naphthyl group, (2-, 3-, or 4-)(1,1-dimethyl-2-chloroethoxy)phenyl group, 7-(2-methyl-3-fluoropropoxy)-2-naphthyl group, 2-vinylphenyl group, 2-(1-methylvinyl)phenyl group, 2-(1-propenyl)-1-naphthyl group, (2-, 3-, or 4-)(1-methyl-1-propenyl)phenyl group, 3-(2-methyl-1-propenyl)-1-naphthyl group, (2-, 3-, or 4-)(1-propenyl)phenyl group, (2-, 3-, or 4-)(2-propenyl)phenyl group, 4-(2-butenyl)-1-naphthyl group, (2-, 3-, or 4-)(1-butenyl)phenyl group, 5-(3-butenyl)-1-naphthyl group, (2-, 3-, or 4-)(2-pentenyl)phenyl group, 6-(1-pentenyl)-1-naphthyl group, (2-, 3-, or 4-) (3-pentenyl)phenyl group, 7-(4-pentenyl)-1-naphthyl group, (2-, 3-, or 4-)(1,3-butadienyl)phenyl group, 8-(1,3-pentadienyl)-1-naphthyl group, (2-, 3-, or 4-) (2-penten-4-ynyl)phenyl group, 1-(2-hexenyl)-2-naphthyl group, 4-(1-hexenyl)phenyl group, a 3-(5-hexenyl)-2-naphthyl group, (2-, 3-, or 4-)(3-hexenyl) group, 4-(4-hexenyl)-2-naphthyl group, (2-, 3-, or 4-)(3,3-dimethyl-1-propenyl)phenyl group, 5-(2-ethyl-1-propenyl)-2-naphthyl group, 4-(1,3,5-hexatrienyl)phenyl group, 6-(1,3-hexadienyl)-2-naphthyl group, (2-, 3-, or 4-)(1,4-hexadienyl)phenyl group, (2-, 3-, or 4-)(N-formylamino)phenyl group, (2-, 3-, or 4-)(N-acetylamino)phenyl group, 7-(N-acetylamino)-2-naphthyl group, (2-, 3-, or 4-)(N-propionylamino)phenyl group, 8-(N-butyrylamino)-2-naphthyl group, (2-, 3-, or 4-)(N-isobutyrylamino)phenyl group, 2-(N-pentanoylamino)-1-naphthyl group, (2-, 3-, or 4-)(N-tert-butylcarbonylamino)phenyl group, 3-(N-hexanoylamino)-1-naphthyl group, (2-, 3-, or 4-)(N,N-diformylamino)phenyl group, 4-(N,N-diacetylamino)-1-naphthyl group, (2-, 3-, or 4-)(N,N-dimethylamino)phenyl group, (2-, 3-, or 9-) (N-phenylamino)phenyl group, (2-, 3-, or 4-)sulfamoylphenyl group, 5-sulfamoyl-1-naphthyl group, (2-, 3-, or 4-)methylthiophenyl group, 6-ethylthio-1-naphthyl group, (2-, 3-, or 4-)n-propylthiophenyl group, 7-isopropylthio-1-naphthyl group, (2-, 3-, or 4-)n-butylthiophenyl group, 8-tert-butylthio-1-naphthyl group, (2-, 3-, or 4-)n-pentylthiophenyl group, 1-n-hexylthio-2-naphthyl group, (2-, 3-, or 4-)(N-methyl(sulfonylamino)phenyl group, (2-, 3-, or 4-)formylphenyl group, (2-, 3-, or 4-)acetylphenyl group, (2-, 3-, or 4-) butyrylphenyl group, 3-acetyl-2-naphthyl group, (2-, 3-, or 4-)propionylphenyl group, 4-butyryl-2-naphthyl group, (2-, 3-, or 4-)isobutyrylphenyl group, 5-pentanoyl-2-naphthyl group, (2-, 3-, or 4-)cyanophenyl group, (2-, 3-, or 4-)methoxycarbonylphenyl group, (2-, 3-, or 4-)tert-butylcarbonylphenyl group, 6-hexanoyl-2-naphthyl group, (2-, 3-, or 4-)ethoxycarbonylphenyl group, 7-ethoxycarbonyl-2-naphthyl group, (2-, 3-, or 4-)n-propoxycarbonylphenyl group, 8-isopropoxycarbonyl-2-naphthyl group, (2-, 3-, or 4-)n-butoxycarbonylphenyl group, 2-isobutoxycarbonyl-1-naphthyl group, (2-, 3-, or 4-)tert-butoxycarbonylphenyl group, 3-sec-butoxycarbonyl-1-naphthyl group, (2-, 3-, or 4-)n-pentyloxycarbonylphenyl group, 4-neopentyloxy-1-naphthyl group, (2-, 3-, or 4-)n-hexyloxycarbonylphenyl group, 5-isohexyloxycarbonyl-1-naphthyl group, (2-, 3-, or 4-)(3-methylpentyloxycarbonyl)phenyl group, 6-(1-pyrrolyl)-1-naphthyl group, (2-, 3-, or 4-)(1-pyrrolyl)phenyl group, (2-, 3-, or 4-)ethynylphenyl group, (2-, 3-, or 4-)(N-methylcarbamoyl)phenyl group, (2-, 3-, or 4-)(N-phenylcarbamoyl)phenyl group, (2-, 3-, or 4-)(2-hydroxyethyl)phenyl group, (2-, 3-, or 4-)phenoxyphenyl group, (2-, 3-, or 4-)nitrophenyl group, (2-, 3-, or 4-)benzyloxyphenyl group, (2-, 3-, or 4-)hydroxyphenyl group, (2-, 3-, or 4-)(2-oxo-2,5-dihydrofuran-4-yl)phenyl group, (2-, 3-, or 4-)(1-imidazolylacetyl)phenyl group, (2-, 3-, or 4-)(2,4-dioxothiazolidin-5-ylmethyl)phenyl group, (2-, 3-, or 4-)[(1-, 2-, 3-, or 4-)piperidylcarbonyl]phenyl group, (2-, 3-, or 4-)[(1-, 3-, 4-, or 5-)pyrazolyl]phenyl group, (2-, 3-, or 4-)[2-oxo-(1- or 3-)pyrrolidinyl]phenyl group, (2-, 3-, or 4-)[(2-, 4-, or 5-)oxazolyl]phenyl group, (2-, 3-, or 4-)(2-ethyl-4-methylimidazol-1-yl)phenyl group, (2-, 3-, or 4-)biphenyl group, 2,3-dimethoxyphenyl group, 2,4-dimethoxyphenyl group, 2,5-dimethoxyphenyl group, 2,6-dimethoxyphenyl group, 3,4-dimethoxyphenyl group, 3,5-dimethoxyphenyl group, 2,3-dichlorophenyl group, 2,4-dichlorophenyl group, 3,4-dichlorophenyl group, 2-methoxy-5-chlorophenyl group, 2-methoxy-5-methylphenyl group, 2-methoxy-5-acetylaminophenyl group, 2-vinyl-4-methylphenyl group, 2-vinyl-5-ethylphenyl group, 2,6-disulfamoylphenyl group, 2,4,6-trimethoxyphenyl group, 3,4,5-triethoxyphenyl group, 2-vinyl-3,4,5-triethylphenyl group, pentamethoxyphenyl group, 2-vinylnaphthyl group, 2,3-dimethoxy-1-naphthyl coup, 3,4-diethoxyphenyl group, 2-methoxy-5-methoxycarbonylphenyl group, 3,5-dimethoxycarbonylphenyl group, 3-chloro-4-hydroxyphenyl group, 2-chloro-5-(N-acetylamino)phenyl group, 2-chloro-5-cyanophenyl group, 2-chloro-5-carbamoylphenyl group, 2-methoxy-5-(N-acetylamino)phenyl group, 2-chloro-5-ethoxycarbonylphenyl group, 3,5,7-triethoxy-1-naphthyl group, 3,4,5,7-7.tetramethyl-1-naphthyl group, 2,3,4,5-tetramethyl-7-(N-pentaacetylamino)-1-naphthyl group, 2,3,4,5,5,7-hexaethoxy-1-naphthyl group, and heptamethoxy-1-naphthyl group.\n\n\n \n \n \n \nExamples of the cyano lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having a single cyano group-Specific examples thereof include a cyanomethyl group, 2-cyanoethyl group, 1-cyanoethyl group, 3-cyanopropyl group, 4-cyanobutyl group, 1,1-dimethyl-2-cyanoethyl group, 5-cyanopentyl group, 6-cyanohexyl group, 2-cyanoisopropyl group, and 2-methyl-3-cyanopropyl group.\n\n\n \n \n \n \nExamples of the lower alkanoylamino lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atom) having 1 to 3, preferably 1, amino groups which has 1 to 2 lower alkanoyl groups as illustrated, above (a linear or branched alkanoyl group having 1 to 6 carbon atoms). Specific examples thereof include a 2-(N-formylamino)ethyl group, 2-(N-acetylamino)ethyl group, 2-(N-propionylamino)ethyl group, 2-(N-butyrylamino)ethyl group, 2-(N-isobutyrylamino)ethyl group, 2-(N-pentanoylamino)ethyl group, 2-(N-tert-butylcarbonylamino)ethyl group, 2-(N-hexanoylamino)ethyl group, N-acetylaminomethyl group, 1-(N-acetylamino)ethyl group, 3-(N-acetylamino)propyl group, 4-(N-acetylamino)butyl group, 5-(N-acetylamino)pentyl group, 6-(N-acetylamino)hexyl group, 1,1-dimethyl-2-(N- acetylamino)ethyl group, 2-methyl-3-(N-acetylamino)propyl group, and 2-(N,N-diacetylamino)ethyl group.\n\n\n \n \n \n \nExamples of a halogen substituted lower alkylamino group include an amino group having 1 to 2 (preferably 1) halogen substituted lower alkyl groups as illustrated above (preferably a linear or branched halogen substituted alkyl group having 1 to 6 carbon atoms with 1 to 7 (preferably 1 to 3) halogen atoms). Specific examples thereof include an N-fluoromethylamino group, N-difluoromethylamino group, N-trifluoromethylamino group, N-chloromethylamino group, N-dichloromethylamino group, N-trichloromethylamino group, N-bromomethylaminogroup, N-dibromomethylamino group, N-dichlorofluoromethylamino group, N-2,2,2-trifluoroethylamino group, N-pentafluoroethylamino group, N-2-chloroethylamino group, N-3,3,3-trifluoropropylamino group, N-heptafluoropropylamino group, N-heptafluoroisopropylamino group, N-3-chloropropylamino group, N-2-chloropropylamino group, N-3-bromopropylamino group, N-4,4,4-trifluorobutylamino group, N-4,4,4,3,3-pentafluorobutylamino group, N-4-chlorobutylamino group, N-4-bromobutylamino group, N-2-chlorobutylamino group, N-5,5,5-trifluoropentylamino group, N-5-chloropentylamino group, N-6,6,6-trifluorohexylamino group, N-6-chlorohexylamino group, N-(1,1-dimethyl-2-chloroethyl) amino group, N-(2-methyl-3-fluoropropyl)amino group, and N,N-di(fluoromethyl) amino group.\n\n\n \n \n \n \nExamples of the lower alkylthio lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 3 lower alkylthio groups whose alkyl moiety, is a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms). Specific examples thereof include a 2-methylthioethyl group, 2-ethylthioethyl group, 2-n-propylthioethyl group, 2-n-butylthioethyl group, 2-tert-butylthioethyl group, 2-n-pentylthioethyl group, 2-n-hexylthioethyl group, methylthiomethyl group, 1-methylthioethyl group, 3-methylthiopropyl group, 4-methylthiobutyl group, 5-methylthiopentyl group, 6-methylthiohexyl group, 1,1-dimethyl-2-methylthioethyl group, 2-methyl-3-methylthiopropyl group, 2,2-diethylthioethyl group, and 2,2,2-triethylthioethyl group.\n\n\n \n \n \n \nExamples of the amidino group that may have a lower alkyl group include an amidino group that may have 1 to 2 lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms). Specific examples thereof include an amidinc group, N-methylamidino group, K-ethylamidino group, N-n-propylamidino group, N-n-butylamidino group, N-n-pentylamidino group, K-n-hexylamidino group, N-isopropylamidino group, N-tert-butylamidino goup, N,N-dimethylamidino group, M,N'-dimethylamidino group, and N-methyl-N'-ethyl-amidino group.\n\n\n \n \n \n \nExamples of the amidino lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 3 amidino groups. Specific examples thereof include an amidinomethyl group, 2-amidinoethyl group, 3-amicinopropyl group, 4-amidinobutyl group, 5-amidinopropyl group, 6-amidinohexyl group, 1-amidinoethyl group, 1,1-dimethyl-2-amidinoethyl group, 2-methyl-3-amidinopropyl group, 2,2-diamidinoethyl group, and 2,2,2-triamidinoethyl group.\n\n\n \n \n \n \nExamples of the lower alkenyloxy group include a lower alkenyloxy group whose lower alkenyl moiety is one as illustrates above (a linear or branched alkenyloxy group having 1 to 3 double bonds and 2 to 6 carbon atoms.). Specific examples thereof include a vinyloxy croup, 1-propenyloxy group, 1-methyl-1-propenyloxy group, 2-methyl-1-propenyloxy group, 2-propenyloxy group, 2-butenyloxy group, 1-butenyloxy group, 3-butenyloxy group, 2-pentenyloxy group, 1-pentenyloxy group, 3-pentenyloxy group, 4-pentenyloxy group, 1,3-butadienyloxy group, 1, 3-pentadienyloxy group, 2-penten-4-ynyloxy group, 2-hexenyloxy group, -1-hexenyloxy group, 5-hexenyloxy group, 3-hexenyloxy group, 4-hexenyloxy group, 3,3-dimethyl-1-propenyloxy group, 2-ethyl-1-propenyloxy group, 1,3,5-hexatrienyloxy group, 1,3-hexadienyloxy group, and 1,4-hexadienyloxy group.\n\n\n \n \n \n \nExamples of the loser alkenyloxy lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 3 lower alkenyloxy groups whose lower alkenyloxy moiety is a lower alkenyloxy group as illustrated above (a linear or branched alkenyl group having 2 so 6 carbon atoms and 1 to 3 double bonds) Specific examples whereof include a vinyloxymethyl group, 2-vinyloxyethyl group, 2-(1-propenyloxy)ethyl group, 2-(1-methyl-1-propenyloxy)ethyl group, 2-(2-methyl-1-propenyloxy)ethyl group, 2-(2-propenyloxy)ethyl group, 2-(2-butenyloxy)ethyl group, 2-(1-butenyloxy)ethyl group, 2-(3-butenyloxy)ethyl group, 2-(2-pentenyloxy)ethyl group, 2-(1-pentenyloxy)ethyl group, 2-(3-pentenyloxy) ethyl group 2-(4-pentenyloxy)ethyl group, 2-(1,3-butadienyloxy)ethyl group, 2-(1,3-pentadienyloxy)ethyl group, 2-(2-penten-4-ynyloxy)ethyl group, 2-(2-hexenyloxy)ethyl group, 2-(1-hexenyloxy)ethyl group, 2-(5-hexenyloxy)ethyl group, 2-(3-hexenyloxy)ethyl group, 2-(4-hexenyloxy)etyl group, 2-(3,3-dimethyl-1-propenyloxy)ethyl group, 2-(2-ethyl-1-propenyloxy)ethyl group, 2-(1,3,5-0hexatrienyloxy)ethyl group, 2-(1,3-hexadienyloxy)ethyl group, 2-(1,4-hexadienyloxy)ethyl group, 5-vinyloxypropyl group, 6-vinyloxybutyl group, 5-vinyloxypropyl group, 6-vinyloxyhexyl group, 1-vinyloxyethyl group, 1,1-dimethyl-2-vinyloxyethyl group, 2-methyl-3-vinylorypropyl group, 2,2-divinyloxyethyl group, and 2,2,2-trivinyloxyethyl group.\n\n\n \n \n \n \nExamples of the arylamino group that may have a substituent selected from the group consisting of a lower alkyl group, lower alkoxy group, halogen substituted lower alkyl group, and halogen substituted lower alkoxy group on the aryl group include an amine group having 1 to 2 aryl groups as illustrated above that may have 1 to 7, preferably 1. to 5, more preferably 1 to 2 substituent, on the aryl group, which are selected from the group consisting of a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) ;\n\na lower alkoxy croup as illustrated above (a linear or branched alkoxy group having 1 to 6 carbon atoms);\n\na halogen substituted alkyl group as illustrated above (preferably a linear or branched alkyl group having 1 to 6 carbon atoms with 1 to 7, preferably 1 to 3 halogen atoms); and\n\nhalogen substituted lower alkoxy group as illustrated above (a linear or branched alkoxy group having 1 to 6 carbon atoms with preferably 1 to 7, more preferably 1 to 3 halogen atoms). Specific examples thereof include an N-phenylamino group, N-2-naphthylamino group, N-(2-methylphenyl)amino group, N-(3-ethyl-1-naphthyl)amino group, N-(4-n-propylphenyl)amino group, N-(2-n-butyl-1-phenyl)amino group, N-(3-n-pentylphenyl)amino group, N-(4-n-hexyl-1-naphthyl)amino group, N-(2-isobutylphenyl)amino group, N-(3-tert-butyl-1-naphthyl)amino group, N-(2-methoxyphenyl)amino group, N-(3-ethoxy-1-naphthyl)amino group, N-(4-n-propoxyphenyl)amino group, N-(3-isopropoxy-1-naphthyl)amino group, N-(n-butoxyphenyl)amino group, N-(1-isobutoxy-2-naphthyl)amino group, N-(tert-butoxyphenyl)amino group, N-(5-sec-butoxy-1-naohthyl)amino group, N-(n-pentyloxyphenyl) amino group, N-(5-isopentyloxy-1-naphthyl)amino group, N-(1-neopentyloxyphenyl)amino group, N-(6-n-hexyloxy-2-naphthyl)amino group, N-(isohexyloxyphenyl)amino group, N-(5-methylpentyloxy-1-naphthyl)amino group, N-(2-trifluoromethylphenyl)amino group, N-(4-trifluoromethylphenyl)amino group, N-(2-chloromethylphenyl)amino group, N-[3-(2-fluoroethyl)-1-naphthyl]amino group, N-[4-(3-bromopropyl)phenyl]amino group, N-[2-(4-chlorobutyl)-1-phenyl]amino group, N-[3-(5-fluoropentyl)phenyl]amino group, N-[4-(6-bromohexyl)-1-naphthyl]amino group, N-[2-(1,1-dimethyl-2-chloroethyl)phenyl]amino group, N-[7-(2-methyl-3-fluoropropyl)-2-naphthyl]amino group, N-(2-chloromethoxyphenyl)amino group, N-(4-trifluoromethoxyphenyl)amino group, N-(3-(2-fluoroethoxy)-1-naphthyl)amino group, N-[4-(3-bromopropoxy)phenyl]amino group, N-[2-(4-chlorobutoxy)-1-phenyl]amino group, N-[3-(5-fluoropentyloxy)phenyl]amino group, N-[4-(6-bromohexyloxy)-1-naphthyl]amino group, N-[2-(1,1-dimethyl-2-chloroethoxy)phenyl]amino group, N-[7-(2-methyl-3-fluoropropoxy)-2-naphthyl]amino group, N-(2-chloromethoxyphenyl)amino group, N-[3-(2-fluoroethoxy)-1-naphthyl]amino group, N-[4-(3-bromopropoxy)phenyl]amino group, N-[2-(4-chlorobutoxy)-1-phenyl]amino group, N-[3-(5-fluoropentyloxy)phenyl]amino group, N-[4-(6-bromohexyloxy)-1-naphthyl]amino group, N-[2-(1,1-dimethyl-2-chloroethoxy)phenyl]amino group, N-[7-(2-methyl-3-fluoropropoxy)-2-naphthyl]amino group, and N,N-diphenylamino group.\n\n\n \n \n \n \nExamples of the aryl lower alkenyl group include a lower alkenyl group as illustrated above having an aryl group as illustrated above (preferably a linear or branched alkenyl group having 1 to 3 aryl groups and 1 to 6 carbon atoms). Specific examples thereof include a 2-phenylethenyl group, 3-phenyl-2-propenyl group, 3-[(1- or 2-)naphthyl]-2-propenyl group, 4-[(2-, 3-, or 4-)methylphenyl]-2-butenyl group, 4-[(2-, 3-, or 4-)ethylphenyl]-3-butenyl group, 4-[(2-, 3-, or 4-)n-propylphenyl]-1,3-butadienyl group, 5-[(2-, 3-, or 4-)n-butylphenyl]-1,3,5-hexatrienyl group, 5-[(2-, 3-, or 4-)n-pentylphenyl]-2,4-hexadienyl group, 5-[(2-, 3-, or 4-)n-hexylphenyl]-3-pentenyl group, 3-[(2-, 3-, or 4-)isobutylphenyl]-2-propenyl group, 2-[(2-, 3-, or 4-)tert-butylphenyl]phenyl group, 3-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)methyl-1-naphthyl]-2-propenyl group, 4-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)methyl-2-naphthyl]-2-butenyl group, 4-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)ethyl-1-naphthyl]-3-butenyl group, 4-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)ethyl-2-naphthyl]-1,3-butadienyl group, 5-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-propyl-1-naphthyl]-1,3,5-hexatrienyl group, 5-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-propyl-2-naphthyl]-2,4-hexadienyl group, 5-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-butyl-1-naphthyl]-3-pentenyl group, 3-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-butyl-2-naphthyl]-2-propenyl group, 2-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-pentyl-1-naphthyl]ethenyl group, 3-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-pentyl-2-naphthyl]-2-propenyl group, 4-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-hexyl-1-naphthyl]-2-butenyl group, 4-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-hexyl-2-naphthyl]-3-butenyl group, 4-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)isobutyl-1-naphthyl]-1,3-butadienyl group, 5-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)isobutyl-2-naphthyl]-1,3,5-hexatrienyl group, 5-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)tert-butyl-1-naphthyl]-2,4-hexadienyl group, 5-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)tert-butyl-2-naphthyl]-1,3,5-hexatrienyl group, 5-[(2-, 3-, or 4-)chlorophenyl group, (2-, 3-, or 4-)fluorophenyl]-2,4-hexadienyl group, 5-[(2-, 3-, or 4-)bromophenyl]-3-pentenyl group, 3-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)chloro-1-naphthyl]-2-propenyl group, 2-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)chloro-2-naphthyl]ethenyl group, 3-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)fluoro-1-naphthyl]-2-propenyl group, 4-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)fluoro-2-naphthyl]-2-butenyl group, 4-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)bromo-1-naphthyl]-3-butenyl group, 4-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)bromo-2-naphthyl]-1,3-butadienyl group, 5-[(2-, 3-, or 4-)aminophenyl]-1,3,5-hexatrienyl group, 5-[(2-, 3-, 4-, 5-, 6-, 7-, or 8-)amino-1-naphthyl]-2,4-hexadienyl group, 5-[(1-, 3-, 4-, 5-, 6-, 7-, or 8-)amino-2-naphthyl]-3-pentenyl group, 3-(2,3-dimethylphenyl)-2-propenyl group, 2-(3,4-dimethylphenyl)vinyl group, 3-(2,4-dimethylphenyl)-2-propenyl group, 4-(2,5-dimethylphenyl)-2-butenyl group, 4-(2,6-dimethylphenyl)-3-butenyl group, 4-(2,4,6-trimethylphenyl)-1,3-butadienyl group, 5-(3,4,5-trimethylphenyl)-1,3,5-hexatrienyl group, 5-(2,3,4,5-tetraethylphenyl)-2,4-hexadienyl group, 5-(pentamethylpnenyl)-3-pentenyl group, 3-(2-methylnaphthyl)-2-propenyl group, 2-(2,3-dimethylnaphthyl)ethenyl group, 3-(3,4-dimethylphenyl)-2-propenyl group, 4-(3,5,7-triethylnaphthyl)-2-butenyl group, 4-(3,4,5,7-tetramethylnaphthyl)-3-butenyl group, 4-(2,3,4,5,7-pentamethylnephthyl)-1,3-butadienyl group, 5-(2,3,4,6,7-hexaethylnaphthyl)-1,3,5-hexatrienyl group, 5-(heptemethylnaphthyl)-2,4-hexadienyl group, 5-(2,3-diaminophenyl)-3-pentenyl group, 3-(2,4,6-triaminophenyl)-2-propenyl group, and 2-(2-methyl-5-chloronaphthyl)ethenyl group.\n\n\n \n \n \n \nExamples of the pyridylamino group that may have a lower alkyl group include a pyridylamino group that may have 1 to 3, preferably 1 to 2 lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms), on the pyridyl group and/or amino group. Specific examples thereof include an N-(2-, 3-, or 4-)pyridylamino group, N-3-methyl-2-pyridylamino group, N-(4-methyl-2-pyridyl)amino group, N-(5-methyl-2-pyridyl)amino group, N-(6-methyl-2-pyridyl)amino group, N-(2-methyl-3-pyridyl)amino group, N-(4-methyl-3-pyridyl)amino group, N-(5-methyl-3-pyridyl)amino group, N-(6-methyl-3-pyridyl)amino group, N-(2-methyl-4-pyridyl)amino group, N-(3-methyl-4-pyridyl)amino group, N-(3-ethyl-2-pyridyl)amino group, N-(4-n-propyl-2-pyridyl)amino group, N-(5-n-propyl-2-pyridyl)amino group, N-(2-n-butyl-3-pyridyl)amino group, N-(4-n-pentyl-3-pyridyl)amino group, N-(5-n-hexyl-3-pyridyl)amino group, N-(2-isopropyl-4-pyridyl)amino group, N-(3-tert-butyl-4-pyridyl)amino group, N-(3-methyl-2-pyridyl)-N-methyl-amino group, and N-(2,4-diethyl-3-pyridyl)-N-methyl-amino group.\n\n\n \n \n \n \nExamples of the aryl lower alkyl group (that may have a group selected from the group consisting of halogen atom, lower alkyl group, halogen substituted alkyl group, halogen substituted lower alkoxy group, lower alkoxy group, carbamoyl group, and lower alkoxycarbonyl group, as a substituent, on the aryl group and/or the lower alkyl group) include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 3 (preferably 1) aryl groups as illustrated above. Note that, on the aryl group and/or the alkyl moiety, there may be 1 to 7, preferably 1 to 5, more preferably, 1 to 2 substituents selected from the group consisting of\n\na halogen atom as illustrated above;\n\na lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms);\n\na halogen substituted lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 5 carbon atoms preferably substituted with 1 to 7 halogen atoms);\n\na lower alkoxy group as illustrated above (a linear or branched alkoxy group having 1 to 6 carbon atoms substituted with 1 to 7 halogen atoms);\n\na lower alkoxy group as illustrated above (a linear or branched alkoxy group having 1 to 6 carbon atoms);\n\na carbamoyl group; and\n\na lower alkoxy-carbonyl group as illustrated above . Specific examples of the aryl lower alkyl group (that may have a substituent selected from the group consisting of a halogen atom, lower alkyl group, halogen substituted lower alkyl group, halogen substituted lower alkoxy group, lower alkoxy group, carbamoyl group and lower alkoxycarbonyl group, on the aryl group and/or the lower alkyl group) include a benzyl group, 1-phenylethyl group, 2-phenylethyl group, 1-methyl-1-phenylethyl group, 1,1-dimethyl-2-phenylethyl group, 1,1-dimethyl-3-phenylpropyl group, (2-, 3-, or 4-)fluorobenzyl group, 2-[(2-, 3-, or 4-)fluorophenyl]ethyl group, 1-[(2-, 3-, or 4-)fluorophenyl]ethyl group, 1-[(2-, 3-, or 4-)fluorophenyl]propyl group, 2-[(2, 6- or 3,5-)difluorophenyl]ethyl group, 1-(3,5-difluorophenyl)ethyl group, 1-(3,5-difluorophenyl)propyl group, (2-, 3-, or 4-)chlorobensyl group, 2-[(2-, 3-, or 4-)chlorophenyl]ethyl group, 2-(3,4-dichlorophenyl)ethyl group, 1-(3-chlorophenyl)butyl group, 1-(4-chlorophenyl)butyl group, (2-, 3-, or 4-)trifluoromethylphenylbenzyl group, 1-[(2-, 3-, or 4-)trifluoromethylphenyl]ethyl group, 1-[(2-, 3-, or 4-)trifluoromethylphenyl]propyl group, (2-, 3-, or 4-)methylbenzyl group, 2-[(2- 3-, or 4-)methylphenyl]ethyl group, (2-, 3-, or 4-)trifluoromethoxybenzyl group, 1-[(2-, 3-, or 4-)trifluoromethylphenyl]ethyl group, (2-, 3-, or 4-)methoxybenzyl group, 2-[(2-, 3-, or 4-)methylphenyl]ethyl group, 1-[(2-, 3-, or 4-)methoxyphenyl]propyl group, (2-, 3-, or 4-)ethoxybenzyl group, (3,4- or 3,5-)dimethoxybenzyl group, (3,4- or 3,5-)di(n-butoxy)benzyl group, 2-[(3,5- or 3,4-)dimethoxyphenyl]ethyl group, 2-(2-ethoxyphenyl)ethyl group, 1-(4-methoxyphenyl)butyl group, 1-phenyl-1-methoxycarbonylmethyl group, 1-carbamoyl-2-phenylethyl group, 1-methoxycarbonyl-2-phenylethyl group, 2-methoxycarbonyl-2-phenylethyl group, 2-phenyl-2-hydroxyethyl group, 2-(4-hydroxyphenyl)-1-methoxycarbonylethyl group, 3-chloro-4-difluoromethoxyphenylmethyl group, and naphthylmethyl group.\n\n\n \n \n \n \nExamples of the lower alkynyl group include a linear or branched alkynyl group having 2 to 6 carbon atoms. Specific examples thereof include an ethynyl group, 2-propynyl group, 2-butynyl group, 3-butynyl group, 1-methyl-2-propynyl group, 2-pentynyl group, and 2-hexynyl group.\n\n\n \n \n \n \nExamples of the aryloxy lower alkyl group (on the aryl group, a group selected from the group consisting of a lower alkoxy group; a carbamoyl group that may have a group selected from the group consisting of a lower alkoxy group and a lower alkyl group; and a pyrrolidinyl group that may have an cxo group, may be present, include an aryl lower alkyl group whose aryl moiety and lower alkyl group are as illustrated above. On the aryl group herein, 1 to 5 (preferably 1 to 2) groups selected from the group consisting of a lower alkoxy group as illustrated above; a carbamoyl group that may have 1 to 2 groups selected from the group consisting of a lower alkoxy group as illustrated above and a lower alkyl group as illustrated above: and oxo group may be present as a substituent(s). Specific examples thereof include a 2-[(2-, 3 or 4-)methoxyphenoxy]ethyl group, 2-[(2-, 3- or 4-)carbamoylphenoxy]ethyl group, 2-[(2-, 3- or 4-) (N-methyl-N-ethoxycarbamoyl)phenoxy]ethyl group and 2-[(2-, 3- or 4-)(2-oxo-1-pyrolidinyl)phenoxy]ethyl group.\n\n\n \n \n \n \nExamples of the isoxazolidinyl group that may have an oxo group include an isoxazolidinyl group that may have 1 to 2 (preferably 1) oxo groups. Specific examples thereof include a 3-oxoisooxazolidin-4- or 5-yl group and 3,5-dioxoisoxazolidin-4-yl group.\n\n\n \n \n \n \nExamples of the dihydroindenyl group include a (1-, 2-, 4- or 5-)-1,2-dihydroindenyl group.\n\n\n \n \n \n \nExamples of the aryl lower alkoxy lower alkyl group include an aryl lower alkoxy lower alkyl group whose aryl moiety, lower alkoxy moiety and lower alkyl group moiety are as illustrated above. Specific examples thereof include a benzyloxymethyl group, 2-benzyloxyethyl group and 2-benzyloxybutyl group.\n\n\n \n \n \n \nExamples of the azetidinyl group that may have a group selected from the group consisting of a lower alkanoyl group and an aroyl group include an azetidinyl group that may have a 1 to 3 (preferably 1) groups selected from a lower alkanoyl group as illustrated above and an aroyl group as illustrated above. Specific examples thereof include a 2- or 3-azetinyl group, 1-acetyl-(2- or 3-)azetidinyl group, 1-butyryl-(2- or 3-)azetidinyl group and 1-benzoyl-(2- or 3-)azetidinyl group.\n\n\n \n \n \n \nExamples of the azetidinyl lower alkyl group that may have a group selected from the group consisting of a lower alkanoyl group and an aroyl group include an azetidinyl lower alkyl group that may have 1 to 3 (preferable 1) groups selected from the group consisting of a lower alkanoyl group as illustrated above and an aroyl group as illustrated above and have a lower alkyl moiety as illustrated above. Specific examples thereof include a 2- or 3-azetidinylmethyl group, 2-(2- or 3-azetidinyl)ethyl group, 1-acetyl-(2- or 3-)azetidinylmethyl group, 1-butyryl-(2- or 3-)azetidinylmethyl group, 1-benzoyl-(2- or 3-)azetidinylmethyl group, 2-[1-acetyl-(2- or 3-)azetidinyl]ethyl group, 2-[1-butyryl-(2- or 3-)azetidinyl]ethyl group and 2-[1-benzoyl-(2- or 3-)azetidinyl]ethyl group.\n\n\n \n \n \n \nExamples of the tetrazolyl group include a (1- or 5-)tetrazolyl group.\n\n\n \n \n \n \nExamples of the indolinyl group that may have an oxo group include an indolinyl group that may have 1 to 2 (preferably 1) oxo groups. Specific examples thereof include a (1-, 3-, 5-, 6-, 7- or 8-)indolinyl group, 2-oxo-(1-, 3-, 5-, 6-, 7- or 8-) indolinyl group and 2,3-dioxo-(1-, 5-, 6-, 7- or 8-) indolinyl group.\n\n\n \n \n \n \nExamples of the triazolyl group include a 1, 2, 4, -triazolyl group and a 1, 3, 5, -triazolyl group.\n\n\n \n \n \n \nExamples of the triazolyl group that may have a group selected from the group consisting of a lower alkyl group and a lower alkylthio group include a triazolyl group as illustrated above that may have 1 to 3 (more preferably 1 to 2) groups selected from the group consisting of a lower alkyl group as illustrated above and a lower alkylthio, group as illustrated above. Specific examples thereof include a (1-, 3- or 5-)-1,2,4-triazolyl group, (1-, 2- or 5-)-1,3,5-triazolyl group, 1-methyl-5-methylthio-1,2,4-triazol-3-yl group and 1-methyl-5-methylthio-1,2,3-triazol-2-yl group.\n\n\n \n \n \n \nExamples of the imidazolyl group that may have a carbamoyl group include an imidazolyl group that may have 1 to 2 (preferably 1) carbamoyl groups. Specific examples thereof include a (1-, 2-, 4- or 5-)imidazolyl group and a 4-carbamoyl-(1, 2- or 5-)imidazolyl group.\n\n\n \n \n \n \nExamples of the oxazolyl group that may have a lower alkyl group include an oxazolyl group that may have 1 to 2 (preferably 1) lower alkyl groups as illustrated above. Specific examples thereof include a (2-, 3- or 4-)oxazolyl group and a 4-methyl-(2- or 3-)oxazolyl group.\n\n\n \n \n \n \nExamples of the isothiazolyl group that may have a lower alkyl group include an isothiazolyl group that may have 1 to 2 (preferably 1) lower alkyl groups as illustrated above. Specific examples thereof include a (3-, 4- or 5-)isothiazolyl group and a (3- or 4-)methyl-2-isothiazolyl group.\n\n\n \n \n \n \nExamples of the dihydrobenzothiazolyl group include a (1-,2-,4-, 5-, 6- or 7-)2,3-dihydrobenzothiazolyl group.\n\n\n \n \n \n \nExamples of the dihydrobenzothiazolyl group that may have an oxo group include a dihydrobenzothiazolyl group that may have a single oxo group. Specific examples thereof include a (1-, 2-, 5-, 6-, 7- or 8-)2,3-dihydrobenzothiazolyl group and a 2-oxo-(1-, 5-, 6-, 7- or 8-)2,3-dihydrobenzothiazolyl group.\n\n\n \n \n \n \nExamples of the thienyl group that may have a lower alkoxycarbonyl group include a thienyl group that may have 1 to 2 (preferably 1) lower alkoxycarbonyl groups as illustrated above. Specific examples thereof include a (2- or 3-)thienyl group and a 3-methoxycarbonyl-2-thienyl group.\n\n\n \n \n \n \nExamples of the oxazolyl lower alkyl group that may have a lower alkyl group include an oxazolyl lower alkyl group as illustrated above, whose alkyl group as illustrated above, having 1 to 3 (more preferably to 2) lower alkyl groups as illustrated above on the oxazole ring. Specific examples whereof include e (2-, 4- or 5-)oxazolylmethyl group, 2-(2-, 4- or 5-)oxazolylmethyl group, [2-methyl-(4- or 5-)oxazolyl]methyl group and (2,5-dimethyl-4-oxazolyl)methyl group.\n\n\n \n \n \n \nExamples of the amino lower alkyl group that may have a group, non the amino group, which is selected from the group consisting of a lower alkyl group, halogen substituted lower alkyl group, lower alkoxycarbonyl group, lower alkanoyl group, aryl group, aryl lower alkyl group, aroyl group, and amino substituted alkyl group (on the amino group of the amino substituted alkyl group, a lower alkyl group may be present as a Substituent) include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 5, preferable 1 to 3, more preferably 1, amino groups. Note that, on the amino group, 1 to 2 substituents may be present which are selected from the group consisting of\n\na lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms);\n\na halogen substituted lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms with 1 to 13, preferably 1 to 7, more preferably 1 to 3 halogen atoms);\n\na lower alkoxy-carbonyl group as illustrated above ;\n\na lower alkancyl group as illustrated above ( a linear or branched alkanoyl group having 1 to 6 carbon atoms);\n\nan aryl group as illustrated above;\n\nan aryl lower alkyl group as illustrated above;\n\nan aroyl group as illustrated above; and\n\na lower alkyl group as illustrated above ( a linear or branched alkyl group having 1 to 6 carbon atoms) having 1 to 5, preferably 1 to 3, more preferably 1, amino groups (1 to 2 lower alkyl groups as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) may be present on the amino group, as a substituent(s)). Specific examples of the amino lower alkyl group that may have, on the amino group, a group selected from the group consisting of a lower alkyl group, halogen substituted lower alkyl group, lower alkoxycarbonyl group, lower alkanoyl group, aryl group, aryl lower alkyl group, aroyl group, and amino substituted alkyl group ((on the amino group of the amino substituted alkyl group, a lower alkyl group may be present as a substituent) include an N-methylaminomethyl group, N-ethylaminomethyl group, N-n-propylaminomethyl group, N,N-dimethylaminomethyl group, N,N-diethylaminomethyl group, N-methyl-N-n-propylaminomethyl group, N-methyl-N-ethylaminomethyl group, N-(2,2,2-trifluoroethyl)aminomethyl group, N-methyl-N-benzylaminomethyl group, N-phenylaminomethyl group, N-methyl-N-phenylaminomethyl group, N-formylaminomethyl group, N-methyl-N-acetylaminomethyl group, N-methyl-N-propionylaminomethyl group, N-(2-(N,N-diethylamino)ethyl)aminomethyl group, N-methyl-N-benzoylaminomethyl group, N-methylaminoethyl group, N-ethylaminoethyl group, N-(2,2,2-trifluoroethyl)aminoethyl group, N,N-dimethylaminoethyl group, N,N-diethylaminoethyl group, N-methyl-N-acetylaminoethyl group, N-methyl-N-benzoylaminoethyl group, N-methyl-N-propionylaminoethyl group, N-methyl-N-benzylaminoethyl group, and N-methyl-N-tert-butoxycarbonylaminoethyl group.\n\n\n \n \n \n \nExamples of the lower alkyl group substituted with a carbamoyl group that may have a group selected from the group consisting of a lower alkyl group and a halogen substituted lower alkyl group include a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) and substituted with 1 to 3 (preferably 1) carbamoyl groups that may have 1 to 2 groups selected from the group consisting of\n\na lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms); and\n\na halogen substituted lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms and 1 to 13, preferably 1 to 7, more preferably 1 to 3 halogen atoms). Specific examples thereof include a carbamoylmethyl group, 2-carbamoylethyl group, 1-carbamoylethyl group, 3-carbamoylpropyl group, 4-carbamoylbutyl group, 5-carbamoylpentyl group, 6-carbamoylhexyl group, 1,1-dimethyl-2-carbamoylethyl group, 2-methyl-3-carbamoylpropyl group, 1,2-dicarbamoylethyl group, 2,2-dicarbamoylethyl group, 1,2,3-tricarbamoylpropyl group, N-methylcarbamoylmethyl group, N-ethylcarbamoylmethyl group, 2-(N-n-propylcarbamoyl)ethyl group, 3-(N-n-butylcarbamoyl)propyl group, 4-(N-isobutylcarbamoyl)butyl group, 5-(N-tert-butylcarbamoyl)pentyl group, 6-(N-penthylcarbamoyl)hexyl group, N,N-dimethylcarbamoylmethyl group, N,N-diethylcarbamoylmethyl group, 2-(N-2-fluoroethylcarbamoyl) ethyl group, 3-(N-2-chloroethylcarbamoyl) propyl group, 4-(N-2-bromoethylcarbamoyl)butyl group, 2-(N-2,2-dichloroethylcarbamoyl)ethyl group, N-2,2,2-trifluoroethylcarbamoylmethyl group, and N-heptafluoropropylcarbamoylmethyl group.\n\n\n \n \n \n \nExamples of the thiocarbamoyl group that may have a lower alkyl group include a thiocarbamoyl group that may have 1 to 2 lower alkyl groups as illustrated above (linear or branched alkyl groups having to 6 carbon atoms). Specific examples thereof include a thiocarbamoyl group, N-methyl-thiocarbamoyl group, N-ethyl-thiocarbomoyl group, N-n-propylthiocarbamoyl group, N-n-butyl-thiocarbamoyl group, N-n-pentyl-thiocarbamoyl group, N-n-hexyl-thiocarbamoyl group, N-isobutyl-thiocarbamoyl group, N-tert-butyl-thiocarbamoyl group, N,N-dimethyl-thiocarbamoyl group, and N-methyl-N-ethyl-thiocarbamoyl group.\n\n\n \n \n \n \nExamples of the oxazolidinyl group that may have an oxo group include an oxazolidinyl group that may have 1 to 2 (preferably 1) oxo groups. Specific examples thereof include ain oxazolidin-3-yl group, oxazolidin-4-yl group, oxazclidin-5-yl group, 2-oxo-oxazolidin-4-yl group, 2-oxo-oxazolidin-3-yl group, and 2-oxo-exazolidin-5-yl group.\n\n\n \n \n \n \nExamples of the imidazolidinyl group that may have a substituent selected from the group consisting of an oxo group and a lower alkyl group include an imidazolidinyl group that may have 1 to 3, preferably 1 to 2 substituents selected from the group consisting of oxo group and a lower alkyl group as illustrated above (preferably a linear or branched alkyl group having 1 to 6 carbon atoms). Specific examples thereof include an imidazolidin-1-yl group, imidazolidin-2-yl group, imidazolidin-4-yl group, 2-oxo-imidazolidin-1-yl group, 4-oxo-imidazolidin-1-yl group, 5-oxo-imidazolidin-1-yl group, 4-oxo-imidazolidin-2-yl group, 2-oxo-imidazolidin-4-yl group, 2-methyl-imidazolidin-1-yl group, 4-ethyl-imidazolidin-1-yl group, 5-n-propylimidazolidin-1-yl group, 4-n-butyl-imidazolidin-2-yl group, 2-n-pentyl-imidazolidin-4-yl group, 2-n-hexylimidazolidin-1-yl group, 4-isobutyl-imidazolidin-2-yl group, 2-tert-butyl-imidazolidin-4-yl group, 2-oxo-3-methyl-imidazolidin-1-yl group, and 2-oxo-3,4-dimethylimidazolidin-1-yl group.\n\n\n \n \n \n \nExamples of the pyrrolidinyl group that may have an oxo group include a pyrrolidinyl group that may have 1 to 2 (preferably 1) oxo groups. Specific examples thereof include a (1-, 2- or 3-)pyrrolidinyl group, (2- or 3-)oxo-1-pyrrolidinyl group, (3-, 4- or 5-)oxo-2-pyrrolidinyl group, and (2-, 4- or 5-)oxo-3-pyrrolidinyl group.\n\n\n \n \n \n \nExamples of the imidazolyl group include a (1-,2-, 4- or -5)imidazolyl group.\n\n\n \n \n \n \nExamples of the isoxazolyl group include a (3-, 4- or 5-)isoxazolyl group.\n\n\n \n \n \n \nExamples of the arylsulfonyl group include an arylsulfonyl group whose aryl moiety is phenyl, biphenyl, substituted biphenyl, substituted phenyl, naphthyl and substituted naphthyl, and which may have, on the aryl moiety, 1 to 7, preferably 1 to 5, more preferably 1 to 2 linear or branched alkyl groups having 1 to 6 carbon atoms. Examples of the substituent such as phenyl, biphenyl and naphthyl include a linear or branched alkyl group having 1 to 6 carbon atoms, a halogen atom, an amino group and the like. One to seven, preferably 1 to 5, more preferably 1 to 2 substituents of at least one type of these may be present on the phenyl, biphenyl, naphthyl ring and the like. Specific Examples of the arylsulfonyl group that may have a lower alkyl group on the aryl group include a phenylsulfonyl group, (2-, 3-, or 4-)biphenylsulfonyl group, (1- or 2-)naphthylsulfonyl group, (2-, 3-, or 4-)methylphenylsulfonyl group, (2-, 3-, or 4-)ethylphenylsulfonyl group, (2-, 3-, or 4-)n-propylphenylsulfonyl group, (2-, 3-, or 4-)n-butylphenylsulfonyl group, (2-, 3-, or 4-)n-pentylphenylsulfonyl group, (2-, 3-, or 4-)n-hexylphenylsulfonyl group, (2-, 3-, or 4-)isobutylphenylsulfonyl group, (2-, 3-, or 4-)tert-butylphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)methyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)methyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)methyl-4-biphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)ethyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)ethyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)ethyl-4-biphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-propyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-propyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-propyl-4-biphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-butyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-butyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-butyl-4-biphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-pentyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-pentyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-pentyl-4-biphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-hexyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-hexyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)n-hexyl-4-biphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)isobutyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)isobutyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)isobutyl-4-biphenylsulfonyl group, (3-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)tert-butyl-2-biphenylsulfonyl group, (2-, 4-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)tert-butyl-3-biphenylsulfonyl group, (2-, 3-, 5-, 6-, 2'-, 3'-, 4'-, 5'-, or 6'-)tert-butyl-4-biphenylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)methyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)methyl-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)ethyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)ethyl-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-propyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-propyl-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-butyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-butyl-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-pentyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-pentyl-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)n-hexyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)n-hexyl-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)isobutyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)isobutyl-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)tert-butyl-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)tert-butyl-2-naphthylsulfonyl group, (2-, 3-, or 4-)chlorophenylsulfonyl group, (2-, 3-, or 4-)fluorophenylsulfonyl group, (2-, 3-, or 4-)bromophenylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)chloro-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)chloro-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)fluoro-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)fluoro-2-naphthylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)bromo-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)bromo-2-naphthylsulfonyl group, (2-, 3-, or 4-)aminophenylsulfonyl group, (2-, 3-, 4-, 5-, 6-, 7-, or 8-)amino-1-naphthylsulfonyl group, (1-, 3-, 4-, 5-, 6-, 7-, or 8-)amino-2-naphthylsulfonyl group, 2,3-dimethylphenylsulfonyl group, 3,4-dimethylphenylsulfonyl group, 2,4-dimethylphenylsulfonyl group, 2,5-dimethylphenylsulfonyl group, 2,6-dimethylphenylsulfonyl group, 2,4,6-trimethylphenylsulfonyl group, 3,4,5-trimethylphenylsulfonyl group, 2,3,4,5-tetraethylphenylsulfonyl group, pentamethylphenylsulfonyl group, 2-methylnaphthylsulfonyl group, 2,3-dimethylnaphthylsulfonyl group, 3,4-dimethylphenylsulfonyl group, 3,5,7-triethylnaphthylsulfonyl group, 3,4,5,7-tetramethylnaphthylsulfonyl group, 2,3,4,5,7-pentamethylnaphthylsulfonyl group, 2,3,4,5,6,7-hexaethylnaphthylsulfonyl group, heptamethylnaphthylsulfonyl group, 2,3-diaminophenylsulfonyl group, 2,4,6-triaminophenylsulfonyl group, and 2-methyl-5-chloronaphthylsulfonyl group.\n\n\n \n \n \n \nExamples of the piperidyl group that may have a substituent selected from the group consisting of a lower alkyl group; lower alkanoyl group; arylsulfonyl group; oxo group; hydroxy group and amino group that may have a group selected from the group consisting of a lower alkyl group, lower alkanoyl group, lower alkoxycarbonyl group and lower alkanoylamino lower alkanoyl group include a piperidyl group that may have 1 to 6, preferably 1 to 3, more preferably 1 substituent selected from the group consisting of a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 5 carbon atoms) ;\n\na lower alkanoyl group as illustrated above ( a linear or branched alkanoyl group having 1 to 6 carbon atoms) ; and\n\nan arylsulfonyl group as illustrated above; an oxo group; a hydroxy group; and an amino group that may have to 2 groups selected from the group consisting of a lower alkyl group as illustrated above, lower alkanoyl group as illustrated above, lower alkoxycarbonyl group as illustrated above and lower alkanoyl amino lower alkanoyl group as illustrated above. Specific examples thereof include a (1-, 2-, 3-, or 4-)piperidyl group, 1-methyl-4-piperidyl group, 2-ethyl-4-piperidyl group, 3-n-propyl-4-piperidyl group, 4-isoproryl-4-piperidyl group, 2-n-butyl-1-piperidyl group, 3-isobutyl-1-piperidyl group, 4-tert-butyl-1-piperidyl group, 1-sec-butyl-2-piperidyl group, 2-n-pentyl-2-piperidyl group, 3-(1-ethylpropyl)-2-piperidyl group, 4-iso-pentyl-2-piperidyl group, 5-neopentyl-2-piperidyl group, 6-n-hexyl-2-piperidyl group, 1-(1,2,2-trimethylpropyl)-3-piperidyl group, 2-(3,3-dimethylbutyl)-3-piperidyl group, 3-(2-ethylbutyl)-3-piperidyl group, 4-isohexyl-3-piperidyl group, 5-(3-methylpentyl group)-3-piperidyl group, 6-formyl-3-piperidyl group, 1-acetyl-4-piperidyl group, 2-propionyl-4-piperidyl group, 3-butyryl-4-piperidyl group, 4-isobutyryl-4-piperidyl group, 2-pentanoyl-1-piperidyl group, 3-tert-butylcarbonyl-1-piperidyl group, 4-hexanoyl-1-piperidyl group, 1-phenylsulfonyl-2-piperidyl group, 2-(2-biphenylsulfonyl)-2-piperidyl group, 3-(1-naphthylsulfonyl)-2-piperidyl group, 1-tosyl-4-piperidyl group, 4-(4-ethylphenylsulfonyl)-2-piperidyl group, 5-(2-n-propylphenylsulfonyl)-2-piperidyl group, 6-(3-n-butylphenylsulfonyl)-2-piperidyl group, 1-(4-n-pentylphenylsulfonyl)-3-piperidyl group, 2-(2-n-hexylphenylsulfonyl)-3-piperidyl group, 3-(3-isobutylphenylsulfonyl)-3-piperidyl group, 4-(4-tert-butylphenylsulfonyl)-3-piperidyl group, 5-(2-chlorophenylsulfonyl)-3-piperidyl group, 6-(4-fluorophenylsulfonyl)-3-piperidyl group, 1-(3-bromophenylsulfonyl)-4-piperidyl group, 2-(2-aminophenylsulfonyl)-4-piperidyl group, 3-(2,3-dimethylphenylsulfonyl)-4-piperidyl group, 4-(3,4,5-trimethylphenylsulfonyl)-4-piperidyl group, 2-(2,3-diaminophenylsulfonyl)-1-piperidyl group, 4-oxo-1-piperidyl group, 2-oxo-3-piperidyl group, 4-hydroxy-1-piperidyl group, 2-hydroxy-3-piperidyl group, 4-amino-1-piperidyl group, 2-amino-4-piperidyl group, 4-methylamino-1-piperidyl group, 2-methylamino-4-piperidyl group, 4-ethylamino-1-piperidyl group, 2-ethylamino-4-piperidyl group, 2-dimethylamino-4-piperidyl group, 4-diethylamino-1-piperidyl group, 4-formylamino-1-piperidyl group, 4-acetylamino-1-piperidyl group, 4-(N-methyl-N-acetylamino)-1-piperidyl group, 4-(N-methyl-N-methoxycarbonylamino)-1-piperidyl group, 4-(N-methyl-N-tert-butoxycarbonylamino)-1-piperidyl group, 4-[N-methyl-N-(N-acetylamino)acetylamino]-1-piperidyl group.\n\n\n \n \n \n \nExamples of the piperidylcarbonyl group that may have a substituent selected from the group consisting of\n\na lower alkyl group, hydroxy group, hydroxy lower alkyl group, lower alkanoyl group, carboxy lower alkyl group, lower alkyl carbamoyl lower alkyl group, carbamoyl group, lower alkoxy group, carboxy group, lower alkoxycarbonyl group, amino group (on which 1 to 2 groups selected from the group consisting of a lower alkyl group, lower alkanoyl group, lower alkoxycarbonyl group and aroyl group may be present), piperidyl group (on which a group selected from the group consisting of a lower alkanoyl group, lower alkoxycarbonyl group and aroyl group may be present), piperazinyl group (on which a lower alkyl group may be present as a substituent), 1,4-dioxa-B-azasprio(4.5)decyl group, morpholinyl group, hexahydro-1,4-diazepinyl group (on which a lower alkyl group may be present as a substituent), pyridyl group, pyridyloxy group, pyridyl lower alkoxy group, tetrahydroquinolyl group (on which an oxo group may be present), benzodioxolyl group, aryl lower alkoxy group (that may have on the aryl group a group selected from the group consisting of a halogen atom, lower alkyl group, lower alkoxy group and halogen substituted lower alkoxy group), aryl group (on which a group selected from the group consisting of a halogen atom, lower alkoxy group and hydroxy group may be present) , aryloxy group (that may have on the aryl group a group selected from the group consisting of a cyano group, halogen atom, lower alkyl group, lower alkoxy group and halogen substituted lower alkyl group), aryl lower alkyl group (that may have on the aryl group a group selected from the group consisting of a halogen atom, lower alkyl group, lower alkoxy group and halogen substituted lower alkyl group) and aroyl group (that may have on the aryl group a group selected from the group consisting of a halogen atom and a lower alkoxy group) include\n\na piperidylcarbonyl group that may have 1 to 3 (preferably 1) substituents, on the piperidyl group, selected from the group consisting of\n\na lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms);\n\na hydroxy group;\n\na hydroxy lower alkyl group as illustrated above (preferably a linear or branched alkyl group having 1 to 6 carbon atoms and having 1 to 3 hydroxy groups);\n\na lower alkanoyl group as illustrated above;\n\na carboxy lower alkyl group as illustrated above having a lower alkyl moiety as illustrated above;\n\na linear or branched alkyl group having 1 to 6 carbon atoms and substituted with a carbamoyl group having 1 to 2 lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms);\n\na carbamoyl group;\n\na lower alkoxy group as illustrated above (a linear or branched alkoxy group having 1 to 6 carbon atoms);\n\na carboxy group;\n\na lower alkoxycarbonyl group as illustrated above ,\n\nan amine group (on which 1 to 2 groups selected from the group consisting of a lower alkyl group as illustrated above, a lower alkanoyl group as illustrated above, lower alkoxycarbonyl group as illustrated above and aroyl group as illustrated above may be present);\n\na piperidyl group (on which 1 to 3 groups (preferably 1) selected from the group consisting of a lower alkanoyl group as illustrated above, lower alkoxycarbonyl group as illustrated above and aroyl group as illustrated above may be present);\n\na piperazinyl group (on which 1 to 3 lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms) may be present as a substituent(s));\n\na 1,4-dioxa-8-azesprio[4.5] decyl group;\n\na morpholinyl group;\n\na hexahydro-1,4-diazepinyl group (on which 1 to 3 lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms) may be present as a substituent(s));\n\na pyridyl group;\n\na pyridyloxy group;\n\na pyridyl lower alkoxy group having a lower alkoxy moiety as illustrated above;\n\na tetrahydroquinolyl group (on which 1 to 2 (preferably 1) oxo groups may be present);\n\na benzodioxolyl group (preferably benzo[1.3]dioxolyl group);\n\nan aryl lower alkoxy group having an aryl moiety and lower alkoxy moiety as illustrated above (that may have on the aryl group 1 to 3 (preferably 1 to 2) groups selected from the group consisting of a halogen atom as illustrated above, lower alkyl group as illustrated above, lower alkoxy group as illustrated above and halogen substituted lower alkoxy group as illustrated above);\n\nan aryl group as illustrated above (that may have on the aryl group 1 to 3 (preferably 1 to 2) groups selected from the group consisting of a halogen atom as illustrated above, lower alkoxy group as illustrated above and hydroxy group);\n\nan aryloxy group having an aryl moiety as illustrated above (that may have on the aryl group 1 to 3 (preferably 1 to 2) groups selected from the group consisting of a cyano group, halogen atom, lower alkyl group as illustrated above, lower alkoxy group as illustrated above and halogen substituted lower alkyl group as illustrated above);\n\nan aryl lower alkyl group having an aryl moiety and lower alkyl moiety as illustrated above (that may have on the aryl group 1 to 3 (preferably 1 to 2) groups selected from the group consisting of a halogen atom, lower alkyl group, lower alkoxy group and halogen substituted lower alkyl group); and\n\nan aroyl group as illustrated above (that may have on the aryl group 1 to 3 (preferably 1 to 2) groups selected from the group consisting of a halogen atom as illustrated above and a lower alkoxy group as illustrated above). Specific examples thereof include a (1-, 2-, 3-, or 4-)piperidylcarbonyl group, (1-, 2-, 3-, or 4-)ethyl-4-piperidylcarbonyl group, (2-, 3-, or 4-)methyl-1-piperidylcarbon group, (1-, 2-, 3-, 4-, 5-, or 6-)methyl-2-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)methyl-3-piperidylcarbonyl group, (1-, 2-, 3-, or 4-)methyl-4-piperidylcarbonyl group, (2-, 3-, or 4-)hydroxy-1-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)hydroxy-2-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)hydroxy-3-piperidylcarbonyl group, (1-, 2-, 3-, or 4-)hydroxy-4-piperidylcarbonyl group, (2-, 3-, or 4-)hydroxymethyl-1-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)hydroxymethyl-2-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)hydroxymethyl-3-piperidylcarbonyl group, (1-, 2-, 3-, or 4-)hydroxymethyl-4-piperidylcarbonyl group, (1-, 2-, 3-, or 4-)(2-hydroxyethyl)-4-piperidylcarbonyl group, (2-, 3-, or 4-)(N-ethyl-carbamoylmethyl)-1-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(N-ethyl-carbamoylmethyl)-2-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(N-ethyl-carbamoylmethyl)-3-piperidylcarbonyl group, (1-, 2-, 3-, or 4-)N-ethyl-carbamoylmethyl-4-piperidylcarbonyl group, (2-, 3-, or 4-)carbamoyl-1-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)carbamoyl-2-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)carbamoyl-3-piperidylcarbonyl group, (1-, 2-, 3-, or 4-)carbamoyl-4-piperidylcarbonyl group, (2-, 3-, or 4-)carboxy-1-piperidylcarbonyl group, (2-, 3-, or 4-)carboxymethyl-1-piperidylcarbonyl group, (2-, 3-, or 4-)ethoxycarbonyl-1-piperidylcarbonyl group, (2-, 3-, or 4-)methoxy-1-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)methoxy-2-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)methoxy-3-piperidylcarbonyl group, (1-, 2-, 3-, or 4-)methoxy-4-piperidylcarbonyl group, (2-, 3-, or 4-)methoxycarbonyl-1-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)methoxycarbonyl-2-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)methoxycarbonyl-3-piperidylcarbonyl group, (1-, 2-, 3-, or 4-)methoxycarbonyl-4-piperidylcarbonyl group, (2-, 3-, or 4-)ethoxycarbonyl-1-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)ethoxycarbonyl-2-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)ethoxycarbonyl-3-piperidylcarbonyl group, (1-, 2-, 3-, or 4-)ethoxycarbonyl-4-piperidylcarbonyl group, (2-, 3-, or 4-)acetylamino-1-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)acetylamino-2-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)acetylamino-3-piperidylcarbonyl group, (1-, 2-, 3-, or 4-)acetylamino-4-piperidylcarbonyl group, (2-, 3-, or 4-)tert-butoxycarbonylamino-1-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)tert-butoxycarbonylamino-2-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)tert-butoxycarbonylamino-3-piperidylcarbonyl group, (1-, 2-, 3-, or 4-)tert-butoxycarbonylamino-4-piperidylcarbonyl group, (2-, 3-, or 4-)butyrylamino-1-piperidylcarbonyl group, (2-, 3-, or 4-)benzoylamino-1-piperidylcarbonyl group, (2-, 3-, or 4-)(N-methyl-N-acetylamino)-1-piperidylcarbonyl group, (2-, 3-, or 4-)(N-methyl-N-butyrylamino)-1-piperidylcarbonyl group, (2-, 3-, or 4-)(N-methyl-N-tert-butoxycarbonylamino)-1-piperidylcarbonyl group, (2-, 3-, or 4-)(N-methyl-N-benzoylamino)-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(1-, 2-, 3-, or 4-)piperidyl]-1-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)[(1-, 2-, 3-, or 4-)piperidyl)-2-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)[(1-, 2-, 3-, or 4-)piperidyl]-3-piperidylcarbonyl group, (1-, 2-, 3-, or 4-)[(1-, 2-, 3-, or 4-)piperidyl]-4-piperidylcarbonyl group, (2-, 3-, or 4-)[1-acetyl-(2-, 3-, or 4-)piperidyl]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[1-butyryl-(2-, 3-, or 4-)piperidyl]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[1-tert-butoxycarbonyl-(2-, 3-, or 4-)piperidyl]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[1-benzoyl-(2-, 3-, or 4-)piperidyl]-1-piperidylcarbonyl group, (2-, 3-, or 4-)(1-piperazinyl)-1-piperidylcarbonyl group, (2-, 3-, or 4-)[1-(3,4-dimethylpiperazinyl)]-1-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-) [1-(3,4-dimethylpiperazinyl)]-2-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)[1-(3,4-dimethylpiperazinyl)]-3-piperidylcarbonyl group, (1-, 2-, 3-, or 4-)[1-(3,4-dimethylpiperazinyl)]-4-piperidylcarbonyl group, (2-, 3-, or 4-)[1-(4-methylpiperazinyl)]-1-piperidylcarbonyl group, (1-, 3-, or 4-)[1-(4-methylpiperazinyl)]-2-piperidylcarbonyl group, (1-, 2-, or 4-)[1-(4-methylpiperazinyl)]-3-piperidylcarbonyl group, (1-, 2-, or 3-)[1-(4-methylpiperazinyl)]-4-piperidylcarbonyl group, (2-, 3-, or 4-) [(2-, 3-, or 4-)morpholinyl]-1-piperidylcarbonyl group, (1-, 3-, or 4-)[(2-, 3-, or 4-)morpholinyl]-2-piperidylcarbonyl group, (1-, 2-, 4-, 5-, or 6-) [(2-, 3-, or 4-)morpholinyl]-3-piperidylcarbonyl group, (1-, 2-, or 3-)[(2-, 3-, or 4-)morpholinyl]-4-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, 6-, or 7-)(4-methyl-hexahydro-1,4-diazepinyl)-1-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(4-methyl-hexahydro-1,4-diazepinyl)-2-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(4-methyl-hexahydro-1,4-diazepinyl)-3-piperidylcarbonyl group, (1-, 2-, 3-, or 4-)(4-methyl-hexahydro-1,4-diazepinyl)-4-piperidylcarbonyl group, (2-, 3-, or 4-)(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1-piperidylcarbonyl group, (1-, 2-, 3-,'4-, 5-, or 6-)(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-2-piperidylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-piperidylcarbonyl group, (1-, 2-, 3-, or 4-)(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-4-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 4-, or 5-)benzo[1.3]dioxolyl]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[2-oxo-(1-, 3-, 4-, 5-, 6-, 7-, or 8-)-1,2,3,4-tetrahydroquinolyl]-1-piperidylcarbonyl group, 4-[2-oxo-(1-, 3-, 4-, 5-, 6-, 7-, or 8-)-1,2,3,4-tetrahydroquinolyl]-(2- or 3-methyl)-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)pyridyl]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)pyridyloxy]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)pyridylmethoxy]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)fluorobenzyloxy]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)chlorobenzyloxy]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)bromobenzyloxy]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)methylbenzyloxy]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)trifluoromethoxybenzyloxy]-1-piperidylcarbonyl group, (2-, 3-, or 4-)(3,4-dichlorobenzyloxy)-1-piperidylcarbonyl group, (2-, 3-, or 4-)(3,4-dimethoxybenzyloxy)-1-piperidylcarbonyl group, (2-, 3-, or 4-)(3-chloro-4-methoxybenzyloxy)-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)fluorophenoxy]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)chlorophenoxy]-1-piperidylcarbonyl group; (2-, 3-, or 4-)[(2-, 3-, or 4-)cyanophenoxy]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)methoxyphenoxy]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)methylphenoxy]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)trifluoromethoxyphenoxy]-1-piperidylcarbonyl group, (2-, 3-, or 4-)phenyl-1-piperidylcarbonyl group, 4-hydroxy-(2-, 3-, or 4-)phenyl-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)chlorophenyl]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)methoxyphenyl]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)hydroxyphenoxy]-1-piperidylcarbonyl group, 4-hydroxy-(2-, 3-, or 4-)phenyl-1-piperidylcarbonyl group, 4-ethoxycarbonyl-(2-, 3-, or 4-)phenyl-1-piperidylcarbonyl group, 4-hydroxy-(2-, 3-, or 4-)[(2-, 3-, or 4-)chlorophenyl]-1-piperidylcarbonyl group, (2-, 3-, or 4-)benzyl-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)chlorobenzyl]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)methylbenzyl]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)methoxybenzyl]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)trifluoromethoxybenzyl]-1-piperidylcarbonyl group, 4-hydroxy-(2-, 3-, or 4--)benzyl-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)chlorobenzoyl]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)methoxybenzoyl]-1-piperidylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)fluorobenzoyl]-1-piperidylcarbonyl group, and (2-, 3-, or 4-)[(2-, 3-, or 4-)trifluoromethoxybenzyl]-1-piperidylcarbonyl group.\n\n\n \n \n \n \nExamples of the pyrrolidinylcarbonyl group that may have a substituent selected from the group consisting of a hydroxy lower alkyl group, carbamoyl group, hydroxy group, amino group (that may have a group selected from the group consisting of a lower alkyl group, lower alkanoyl group, and aroyl group thereon) morpholinyl lower alkyl group, pyrrolidinyl lower alkyl group, piperidyl lower alkyl group, piperazinyl lower alkyl group (that may have a lower alkyl group thereon as a substituent), amino lower alkyl group (that may have a lower alkyl group thereon as a substituent) and aryl oxy group (that may have on the aryl group a halogen substituted lower alkoxy group), aryloxy lower alkyl group (on the aryl group, a halogen substituted lower alkoxy group may be present) and a tetrahydroquinolyl group (on which as oxo group may be present) include a pyrrolidinylcarbonyl group that may have 1 to 3 (preferably 1) substituents, on the pyrrolidinyl group, which are selected from the group consisting of\n\na lower alkyl group as illustrated above having 1 to 3 hydroxy groups (a linear or branched alkyl group having 1 to 6 carbon atoms) ;\n\na carbamoyl group;\n\na hydroxy group;\n\nan amino group (that may have 1 to 2 groups selected from the group consisting of a lower alkyl group as illustrated above, a lower alkanoyl group as illustrated above, and an aroyl group as illustrated above);\n\na morpholinyl lower alkyl group whose lower alkyl moiety is one as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms); a pyrrolidinyl lower alkyl group whose lower alkyl moiety is one as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms);\n\na piperidyl lower alkyl group whose lower alkyl moiety is one as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms);\n\na piperazinyl lower alkyl group whose lower alkyl moiety is one was illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) (1 to 3 (preferably 1) lower alkyl groups as illustrated above (linear or branched alkyls group having 1 to 5 carbon atoms) may be present non the piperazinyl group, as a substituent(s));\n\nan amino lower alkyl group whose lower alkyl moiety is one as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) (1 to 2 lower alkyl groups as illustrated above ( linear or branched alkyl groups having 1 to 6 carbon atoms) may be present on the amino group, as a substituent(s)), aryloxy group having an aryl moiety as illustrated above (which may have on the aryl group, 1 to 3 (preferably 1) halogen substituted lower alkoxy groups), aryloxy lower alkyl group having an aryl moiety and lower alkyl moiety as illustrated above (which may have on the aryl group, 1 to 3 (preferably 1) halogen substituted lower alkoxy groups) and a tetrahydroquinolyl group (on which a single oxo group may be present). Specific examples thereof include a (1-, 2-, or 3-)pyrrolidinylcarbonyl group, (2- or 3-)hydroxymethyl-1-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)hydroxymethyl-2-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)hydroxymethyl-3-pyrrolidinylcarbonyl group, (2- or 3-)carbamoyl-1-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)carbamoyl-2-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)carbamoyl-3-pyrrolidinylcarbonyl group, (2- or 3-)hydroxy-1-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)hydroxy-2-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)hydroxy-3-pyrrolidinylcarbonyl group, (2- or 3-)amino-1-pyrrolidinylcarbonyl group, (2- or 3-)acetamido-1-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)acetamido-2-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)acetamido-3-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)butyrylamino-3-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)(N-methyl-N-acetylamino)-3-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)(N-methyl-N-butyrylamino)-3-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)benzoylamino-3-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)(N-methyl-N-benzoylamino)-3-pyrrolidinylcarbonyl group, (2- or 3-)[(2-, 3-, or 4-)morpholinylmethyl]-1-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)[(2-, 3-, or 4-)morpholinylmethyl]-2-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)[(2-, 3-, or 4-)morpholinylmethyl]-3-pyrrolidinylcarbonyl group, (2- or 3-)[(1-, 2-, or 3-)pyrrolidinylmethyl]-1-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)[(1-, 2-, or 3-)pyrrolidinylmethyl]]-2-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)[(1-, 2-, or 3-)pyrrolidinylmethyl]]-3-pyrrolidinylcarbonyl group, (2- or 3-)[(1-, 2-, 3-, or 4-)piperidylmethyl]]-1-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)[(1-, 2-, 3-, or 4-)piperidylmethyl]]-2-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)[(1-, 2-, 3-, or 4-)piperidylmethyl)]-3-pyrrolidinylcarbonyl group, (2- or 3-)(4-methyl-1-piperazinylmethyl)-1-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)(4-methyl-1-piperazinylmethyl)-2-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)(4-methyl-1-piperazinylmethyl)-3-pyrrolidinylcarbonyl group, (2- or 3-)N,N-dimethylaminomethyl-1-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)N,N-dimethylaminomethyl-2-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)N,N-dimethylaminomethyl-3-pyrrolidinylcarbonyl group, (2- or 3-)N,N-diethylaminomethyl-1-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)N,N-diethylaminomethyl-2-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)N,N-diethylaminomethyl-3-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)(4-trifluoromethoxyphenoxymethyl)-3-pyrrolidinylcarbonyl group, (1-, 2-, 3-, 4-, or 5-)(4-trifluoromethoxyphenoxy)-3-pyrrolidinylcarbonyl group, and (1-, 3-, 4-, 5-, 6-, 7-, or 8-)(2-oxy-1,2,3,4-tetrahydroquinolyl)-3-pyrrolidinylcarbonyl group.\n\n\n \n \n \n \nExamples of a piperazinylcarbonyl group that may have a substituent selected from the group consisting of a lower alkyl group, cycle C3-C9 alkyl group, lower alkanoyl group, hydroxy lower alkyl group, lower alkoxy lower alkyl group, lower alkoxycarbonyl group, amino lower alkyl group (a lower alkyl group may be present on the amino group, as a substituent), piperidyl lower alkyl group (a lower alkyl group may be present on the piperidyl group, as a substituent), morpholinyl lower alkyl group, pyrrolidinyl lower alkyl group, 1,3-dioxolanyl lower alkyl group, tetrahydrofuryl lower alkyl group, pyridyl lower alkyl group (a phenyl group may be present on the lower alkyl group as a substituent), imidazolyl lower alkyl group, furyl lower alkyl group, pyrrolidinyl carbonyl lower alkyl group, piperidyl group that may have a lower alkyl group as a substituent, pyridyl group (a substituent selected from the group consisting of a lower alkyl group, cyano group, and halogen substituted lower alkyl group may be present on the pyridyl group, as a substituent), thieno[2,3-c]pyridyl group aryl group (on which group selected from the group consisting of a halogen atom and a lower alkyl group may be present), aroyl group, furyl lower alkyl group, aryl lower alkoxycarbonyl group and oxo group, include a piperazinylcarbonyl group that may have 1 to 3 (preferably 1) substituents, on the piperazinyl group, which are selected from the group consisting of a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms);\n\na cyclo C3-C8 alkyl group as illustrated above;\n\na lower alkanoyl group as illustrated above ( a linear or branched alkanoyl group having 1 to 6 carbon atoms);\n\na hydroxy lower alkyl group as illustrated above (preferably a linear or branched alkyl group having 1 to 6 carbon atoms with 1 to 3 hydroxy groups);\n\na lower alkoxy lower alkyl group as illustrated above (preferably a linear or branched alkyl group having 1 to 6 carbon atoms and to 3 lower alkoxy groups as illustrated above (linear or branched alkoxy groups having 1 to 6 carbon atoms)) ;\n\na lower alkoxycarbonyl group as illustrated above ;\n\nan amino lower alkyl group whose lower alkyl moiety is one as illustrated above, preferably a linear or branched alkyl group having to 6 carbon atoms (1 to 2 lower alkyl groups as illustrated above ( linear or branched alkyl group having 1 to 6 carbon atoms) may be present on the amino group, as substituent(s));\n\na piperidyl lower alkyl group whose lower alkyl moiety is one as illustrated above, preferably a linear or branched alkyl group having 1 to 6 carbon atoms (1 to 3 lower alkyl groups as illustrated above ( linear or branched alkyl groups having 1 to 6 carbon atoms) may be present on the piperidyl group as a substituent(s));\n\na morpholinyl lower alkyl group whose alkyl moiety is one as illustrated above ( a linear or branched alkyl group having 1 to 6 carbon atoms);\n\na pyrrolidinyl lower alkyl group whose alkyl moiety is one as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms);\n\na 1,3 dioxolanyl lower alkyl group whose lower alkyl moiety is one as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms);\n\na tetrahydrofuryl lower alkyl group whose lower alkyl moiety is one as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms);\n\na pyridyl lower alkyl group whose lower alkyl moiety is one as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) (1 to 3 phenyl groups may be present on the alkyl group, as a substituent(s));\n\nan imidazolyl lower alkyl group, whose lower alkyl moiety is one as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms);\n\na furyl lower alkyl group, whose lower alkyl moiety is one as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms);\n\na pyrrolidinyl carbonyl lower alkyl group, whose lower alkyl moiety is one as illustrated above (a linear or branched alkyl group having to 6 carbon atoms):\n\na piperidyl group that may have 1 to 3 lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms) ;\n\na pyridyl group (1 to 3 groups (preferably 1) selected from the groups consisting of a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms), cyano group, and halogen substituted lower alkyl group as illustrated above (preferably a linear or branched alkyl group having 1 to 6 carbon atoms substituted with 1 to 7 halogen atoms) may be present on the pyridyl group); a tieno[2,3-c]pyridyl group; aryl group as illustrated above (which may have on the aryl group 1 to 3 (preferably 1) groups selected from the group consisting of a halogen atom and a lower alkyl group), aroyl group as illustrated above, furyl lower alkyl group having a lower alkyl moiety as illustrated above, aryl lower alkoxy carbonyl group having an aryl moiety and lower alkoxy carbonyl moiety as illustrated above and oxo group. Specific examples thereof include a (1-or 2-)piperazinylcarbonyl group, (2-, 3-, or 4-)methyl-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)methyl-2-piperazinylcarbonyl group, (2-, 3-, or 4-)ethyl-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)ethyl-2-piperazinylcarbonyl group, (2-, 3-, or 4-)n-propyl-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)n-propyl-2-piperazinylcarbonyl group, (2-, 3-, or 4-)n-butyl-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)n-butyl-2-piperazinylcarbonyl group, (2-, 3-, or 4-)[(1-ethyl-n-propyl)]-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)[(1-ethyl-n-propyl)]-2-piperazinylcarbonyl group, (2-, 3-, or 4-)isopropyl-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)isopropyl-2-piperazinylcarbonyl group, (2-, 3-, or 4-)tert-butyl-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)tert-butyl-2-piperazinylcarbonyl group, (2-, 3-, or 4-)n-hexyl-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)n-hexyl-2-piperazinylcarbonyl group, (2-, 3-, or 4-)cyclopentyl-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)cyclopentyl-2-piperazinylcarbonyl group, (2-, 3-, or 4-)cycloheptyl-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)cycloheptyl-2-piperazinylcarbonyl group, (2-, 3-, or 4-)acetyl-1-piperazinylcarbonyl group, (2-, 3-, or 4-)butyryl-1-piperazinyl carbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)acetyl-2-piperazinylcarbonyl group, (2-, 3-, or 4-)(2-hydroxyethyl)-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(2-hydroxyethyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-)(2-methoxyethyl)-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(2-methoxyethyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-)(3-methoxypropyl)-1-piperazinylcarbonyl group, (1-,·-2-, 3-, 4-, 5-, or 6-) (3-methoxypropyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-) (4-methoxybutyl)-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(4-methoxybutyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-)ethoxycarbonyl-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)ethoxycarbonyl-2-piperazinylcarbonyl group, (2-, 3-, or 4-)tert-butoxycarbonyl-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-) tert-butoxycarbonyl-2-piperazinylcarbonyl group, (2-, 3-, or 4-)methoxycarbonyl-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)methoxycarbonyl-2-piperazinylcarbonyl group, (2-, 3-, or 4-)[3-(N,N-dimethylamino)propyl]-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)[3-(N,N-dimethylamino)propyl]-2-piperazinylcarbonyl group, (2-, 3-, or 4-)[2-(N,N-dimethylamino)ethyl]-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(2-(N,N-dimethylamino)ethyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-)(2-(1-piperidyl)ethyl)-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(2-(1-piperidyl)ethyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-) [(1-methyl-3-piperidyl)methyl]-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-) [(1-methyl-3-piperidyl)methyl]-2-piperazinylcarbonyl group, (2-, 3-, or 9-) [(1-methyl-4-piperidyl)methyl]-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)[(1-methyl-4-piperidyl)methyl]-2-piperazinylcarbonyl group, (2-, 3-, or 4-)[2-(4-morpholinyl)ethyl]-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)[2-(4-morpholinyl)ethyl]-2-piperazinylcarbonyl group, (2-, 3-, or 4-)[2-(1-pyrrolidinyl)ethyl]-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)[2-(1-pyrrolidinyl)ethyl]-2-piperazinylcarbonyl group, (2-, 3-, or 4-)[2-(1,3-dioxolanyl)methyl]-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-) [2-(1,3-dioxolanyl)methyl]-2-piperazinylcarbonyl group, (2-, 3-, or 4-){2-[2-(1,3-dioxolanyl)]ethyl}-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-){2-[2-(1,3-dioxolanyl)]ethyl}-2-piperazinylcarbonyl group, (2-, 3-, or 4-)(2-tetrahydrofurylmethyl)-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(2-tetrahydrofurylmethyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-)(2-pyridylmethyl)-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(2-pyridylmethyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-)(3-pyridylmethyl)-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(3-pyridylmethyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-)(4-pyridylmethyl)-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(4-pyridylmethyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-)[2-(4-pyridyl)ethyl]-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)[2-(4-pyridyl)ethyl]-2-piperazinylcarbonyl group, (2-, 3-, or 4-)[2-(2-pyridyl)ethyl]-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)[2-(2-pyridyl)ethyl]-2-piperazinylcarbonyl group, (2-, 3-, or 4-)[2-phenyl-2-(4-pyridyl)ethyl]-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)[2-phenyl-2-(4-pyridyl)ethyl]-2-piperazinylcarbonyl group, (2-, 3-, or 4-)[2-(1-imidazolyl)ethyl]-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)[2-(1-imidazolyl)ethyl]-2-piperazinylcarbonyl group, (2-, 3-, or 4-)(3-furylmethyl)-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(3-furylmethyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-)(1-pyrrolidinylcarbonylmethyl)-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(1-pyrrolidinylcarbonylmethyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-)(1-methyl-4-piperidyl)-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(1-methyl-4-piperidyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)pyridyl]-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(2-, 3-, or 4-pyridyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-)(3-cyano-2-pyridyl)-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(3-cyano-2-pyridyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-){4-methyl-2-pyridyl}-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(4-methyl-2-pyridyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-)(3-methyl-2-pyridyl)-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)(3-methyl-2-pyridyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-)(3-trifluoromethyl-2-pyridyl)-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-) (3-trifluoromethyl-2-pyridyl)-2-piperazinylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, 4-, 5-, or 6-)hieno[2,3-c]pyridy)-1-piperazinylcarbonyl group, (1-, 2-, 3-, 4-, 5-, or 6-)[(2-, 3-, 4-, 5-, or 6-)thieno[2,3-c]pyridyl]-2-piperazinylcarbonyl group, (2-, 3-, or 4-)phenyl-1-piperazinylcarbonyl group, (2-, 3-, or 4-) [(2-, 3-, or 4-)chlorophenyl]-1-piperazinylcarbonyl group, (2-, 3-, or 4-)[(2-, 3-, or 4-)methylphenyl]-1-piperazinylcarbonyl group, 3-oxo-(2- or 4-)phenyl-1-piperazinylcarbonyl group, (2-, 3-, or 4-)benzolyl-1-piperazinylcarbonyl group, (2-, 3-, or 4-) [(2- or 3-)furylcarbonyl]-1-piperazinylcarbonyl group, and (2-, 3-, or 4-)benzyloxycarbonyl-1-piperazinylcarbonyl group.\n\n\n \n \n \n \nExample of a hexahydroazepinylcarbonyl group include a (1-, 2-, 3- or 4-)hexahydroazepinylcarbonyl group.\n\n\n \n \n \n \nExample of a hexahydro-1,4-diazepinylcarbonyl group that may have a substituent selected from the group consisting of a lower alkyl group and a pyridyl group include a hexahydro-1,4-diazepinylcarbonyl group that may have 1 to 3, preferably 1, substituents selected from the group consisting of a lower alkyl group as illustrated above ( a linear or branched alkyl group having 1 to 6 carbon atoms) and a pyridyl group. Specific examples thereof include a (hexahydro-1,4-diazepin-(1-,2-, 5- or 6-)yl) carbonyl group, (4-methyl-hexahydro-1,4-diazepin-1-yl) carbonyl group, and (4-(4-pyridyl)-methyl-hexahydro-1,4-diazepin-1-yl)carbonyl group.\n\n\n \n \n \n \nExample of a dihydropyrrolylcarbonyl group include a 2,3-dihydropyrrolylcarbonyl group and a 2, 5-dihydropyrrolylcarbonyl group.\n\n\n \n \n \n \nExamples of the dihydropyrrolylcarbonyl group that may have a lower alkyl group include a dihydropyrrolylcarbonyl group as illustrated above that may have 1 to 4, preferably 1 to 2 lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms) . Specific examples thereof include a (1-, 2- or 3-) (2,5-dihydropyrrolylcarbonyl) group, 2,5-dimethyl-1-(2,5-dihydropyrrolylcarbonyl) group, and 2,5-dimethyl-1-(2,3-dihydropyrrolylcarbonyl) group.\n\n\n \n \n \n \nExamples of the thiomorpholinylcarbonyl group include a (2-, 3- or 4-)thiomorpholinylcarbonyl group.\n\n\n \n \n \n \nExamples of the morpholinylcarbonyl group that may have a group selected from the group consisting of a lower alkyl group, and piperidyl lower alkyl group, and aryl group include a morpholinylcarbonyl group that may have 1 to 5 groups, more preferably 1 to 2 groups selected from the group consisting of a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) (on which 1 to 3 (preferably 1) piperidyl groups may be present as substituent (s)) an aryl group as described above. Specific examples thereof include a (2-, 3- or 4-)morpholinylcarbonyl group, 2,6-dimethyl-4-morpholinylcarbonyl group, 2-(1-piperidylmethyl)-4-morpholinylcarbonyl group, and 2-phenyl-4-morpholinylcarbonyl group.\n\n\n \n \n \n \nExamples of the thiazolidinylcarbonyl group include a (2-, 3-, 4- or 5-) thiazolidinylcarbonyl group.\n\n\n \n \n \n \nExamples of the thiazolidinylcarbonyl group that may have an aryl group that may have a group selected from the group consisting of a lower alkoxy group and a cyano group include a thiazolidinylcarbonyl group that may have 1 to 3 (preferably 1) aryl groups that may have 1 to 3 (preferably 1) groups selected from the group consisting of a lower alkoxy group and a cyano group as illustrated above. Specific examples thereof include a (2-, 3-, 4- or 5-)thiazolidinylcarbonyl group, (2-, 4- or 5-)[(2-, 3- or 4-)methoxyphenyl]-3-thiazolidinylcarbonyl group and (2-, 4- or 5-)[(2-, 3- or 4-)cyanophenyl]-3-thiazolidinylcarbonyl group.\n\n\n \n \n \n \nExamples of the azabicyclo[3.2.2]nonylcarbonyl group include a 1-azabicyclo[3.2.2]non-(2-, 3-, 5-, or 6-)ylcarbonyl group, 2-azabicyclo[3.2.2]non-(1-, 2-, 3-, 4-, 5-, 6- or 7-)ylcarbonyl group, 3-azabicyclo[3.2.2]non-(1-, 2-, 3-, or 6-)ylcarbonyl group, and 6-azabicyclo[3.2.2]non-(1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-)ylcarbonyl group.\n\n\n \n \n \n \nExamples of the azabicyclo[3.2.1]octylcarbonyl group that may have a halogen substituted or unsubstituted aryloxy group include an azabicyclo[3.2.1]octylcarbonyl group that may have 1 to 2 (preferably 1) halogen substituted aryl groups as illustrated above (preferably an aryl group that may be substituted with 1 to 3, preferably 1 halogen atom), or an azabicyclo[3.2.1]octylcarbonyl group that may have 1 to 2 (preferably 1) unsubstituted aryl groups as illustrated above. Specific examples thereof include a 1-azabicyclo[3.2.1]oct-(2-, 3-, 4-, 5-, 6-, 7-, or 8-)ylcarbonyl group, 2-azabicyclo[3.2.1]oct-(1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-)ylcarbonyl group, 3-azabicyclo[3.2.1]oct-(1-, 2-, 3-, 6-, or 8-)ylcarbonyl group, 6-azabicyclo[3.2.1]oct-(1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-)ylcarbonyl group, 8-azabicyclo[3.2.1]oct-(1-, 2-, 3-, 6-, or 8-) ylcarbonyl group, 3-(phenyloxy)-1-azabicyclo[3.2.1]oct-2-ylcarbonyl group, 3-(2-biphenyloxy)-1-azabicyclo[3.2.1]oct-3-ylcarbonyl group, 3-(1-naphthyloxy)-1-azabicyclo[3.2.1]oct-4-ylcarbonyl group, 3-(3-methylphenyloxy)-1-azabicyclo[3.2.1]oct-5-ylcarbonyl group, 3-(4-ethylphenyloxy)-1-azabicyclo[3.2.1]oct-6-ylcarbonyl group, 3-(2-n-propylphenyloxy)-1-azabicyclo[3.2.1]oct-7-ylcarbonyl group, 3-(3-n-butylphenyloxy)-1-azabicyclo[3.2.1]oct-8-ylcarbonyl group, 3-(4-n-pentylphenyloxy)-2-azabicyclo[3.2.1]oct-1-ylcarbonyl group, 3-(2-n-hexylphenyloxy)-2-azabicyclo [3.2.1]oct-2-ylcarbonyl group, 3-(3-isobutylphenyloxy)-2-axabicyclo[3.2.1]oct-3-ylcarbonyl group, 3-(4-tert-butylphenyloxy)-2-azabicyclo[3.2.1]oct-4-ylcarbonyl group, 3-(2-chlorophenyloxy)-2-azabicyclo[3.2.1]oct-5-ylcarbonyl group, 3-(3-fluorophenyloxy)-8-azabicclo [3.2.1]oct-8-ylcarbonyl group, 3-(3-bromophenyloxy)-2-azabicyclo[3.2.1joct-6-ylcarbonyl group, 3-(2-aminophenyloxy) -2-azabicyclo [3.2.1]oct-7-ylcarbonyl group, 3-(2, 3-dimethyphenyloxy)-2-azabicyclo[3.2.1]oct-8-ylcarbonyl group, 3-(3,4,5-trimethylpbenyloxy)-8-azabicyclo[3.2.1]oct-1-yl-carbonyl group, and 3-(2,3-diaminophenyloxy)-8-azabicyclo[3.2.1]oct-2-ylcarbonyl group.\n\n\n \n \n \n \nExamples of the indolinylcarbonyl group include a (1-, 2-, 3-, 4-, 5-, 6-, or 7-)indolinylcarbonyl group.\n\n\n \n \n \n \nExamples of the tetrahydropyrido[3.4-b]inndolylcarbonyl group include a (1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-)(2-, 3-, 4-, 5-tetrahydropyrido[3.4-b]indolylcarbonyl) group.\n\n\n \n \n \n \nExamples of the piperazinyl lower alkyl group that may have a lower alkyl group on the piperazinyl group include a piperazinyl lower alkyl group whose lower alkyl moiety is a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) and 1 to 7, preferably 1 to 5, more preferably 1, lower alkyl groups as illustrated above (linear or branched alkyl groups having 1 to 6 carbon atoms) may be present on the piperazinyl group. Specific examples thereof include a (1- or 2-)piperazinylmethyl group, 2-[(1- or 2-)piperazinyl]ethyl group, 1-[(1- or 2-)piperazinyl]ethyl group, 3-[(1- or 2-)piperazinyl]propyl group, 4-[(1- or 2-)piperazinyl]butyl group, 5-[(1- or 2-)piperazinyl]pentyl group, 6-[(1- or 2-)piperazinyl]hexyl group, 1,1-dimethyl-2-[(1-or 2-)piperazinyl]ethyl group, 2-methyl-3-[(1- or 2-)piperazinyl]propyl group, 4-methyl-1-piperazinylmethyl group, 2-(4-methyl-2-pipezazinyl)ethyl group, 3-(2-ethyl-1-piperazinyl)propyl group, 4-(3-n-propyl-1-piperazinyl)butyl group, 5-(4-n-butyl-1-piperazinyl)pentyl group, 6-(1-n-pentyl-2-piperazinyl)hexyl group, 2-n-hexyl-2-piperazinylmethyl group, 2-(3-isobutyl-2-piperezinyl)ethyl group, and 3-(4-tert-butyl-2-piperazinyl) propyl group.\n\n\n \n \n \n \nExamples of the morpholinylcarbonyl lower alkyl group include a morpholinylcarbonyl lower alkyl group whose lower alkyl moiety is a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms). Specific examples thereof include a 2-morpholinylcarbonylmethyl group, 3-morpholinylcarbonylmethyl group, 4-morpholinylcarbonylmethyl group, 2-(2-morpholinylcarbonyl)ethyl group, 2-(3-morpholinylcarbonyl)ethyl group, 2-(4-morpholinylcarbonyl)ethyl group, 1-(2-morpholinylcarbonyl)ethyl group, 1-(3-morpholinylcarbonyl)ethyl group, 1-(4-morpholinylcarbonyl)ethyl group, 3-(2-morpholinylcarbonyl)propyl group, 3-(3-morpholinylcarbonyl)propyl group, 3-(4-morpholinylcarbonyl)propyl group, 4-(2-morpholinylcarbonyl)butyl group, 4-(3-morpholinylcarbonyl)butyl group, 4-(4-morpholinylcarbonyl.)butyl group, 5-(2-morpholinylcarbonyl)pentyl group, 5-(3-morpholinylcarbonyl)pentyl group, 5-(4-morpholinylcarbonyl)pentyl group, 6-(2-morpholinylcarbonyl)hexyl group, 6-(3-morpholinylcarbonyl)hexyl group, 6-(4-morpholinylcarbonyl)hexyl group, 3-methyl-3-(2-morpholinylcarbonyl)propyl group, 3-methyl-3-(3-morpholinylcarbonyl)propyl group, 3-methyl-3-(4-morpholinylcarbonyl)propyl group, 1,1-dimethyl-2-(2-morpholinylcarbonyl)ethyl group, 1,1-dimethyl-2-(3-morpholinylcarbonyl)ethyl group, and 1,1-dimethyl-2-(4-morpholinylcarbonyl)ethyl group.\n\n\n \n \n \n \nExamples of the piperazinylcarbonyl lower alkyl group that may have a lower alkyl group on the piperazinyl group include a piperazinylcarbonyl lower alkyl group whose lower alkyl moiety is a lower alkyl group as illustrated above (a linear or branched alkyl group having 1 to 6 carbon atoms) and which may have 1 to 7, preferably 1 to 5, more preferably 1, lower alkyl groups as illustrated above (a linear or branched alkyl groups having 1 to 6 carbon atoms) on the piperazinyl group. Specific examples thereof include a (1- or 2-) piperarinyl carbonylmethyl group, 2-[(1- or 2-)piperazinylcarbonyl]ethyl group, 2-[(1- or 2-)piperazinylcarbonyl]ethyl group, 3-[(1- or 2-)piperazinylcarbonyl]propyl group, 4-[(1- or 2-)piperazinylcarbonyl]butyl group, 5- [(1- or 2-)piperazinylcarbonyl]penty group, 6-[(1- or 2-)piperazinylcarbonyl]hexyl group, 1,1-dimethyl-2-[1-or 2-)piperazinylcarbonyl]ethyl group, 2-methyl-3-[(1-or 2-)piperarinylcarbonyl]propyl group, 4-methyl-1-piperazinylcarbonylmethyl group, 2-(4-methyl-2-piperazinylcarbonyl)ethyl group, 2-(2-ethyl-1-piperazinylcarbonyl)propyl group, 4-(3-n-propyl-1-piperazinylcarbonyl)butyl group, 5-(4-n-butyl-1-piperazinylcarbonyl)penty group, 6-(1-n-pentyl-2-piperarinylcarbonyl)hexyl group, 2-n-hexyl-2-piperazinylcarbonylmethyl group, 2-(3-isobutyl-2-piperazinylcarbonyl)ethyl croup, and 3-(4-tert-butyl-2-piperazinylcarbonyl)propyl group.\n\n\n \n \n \n \nExamples of the amino lower alkoxy group (on the amino group, a lower alkyl group may be present) include a lower alkoxy group as illustrated above (a linear or branched alkoxy group having 1 to 6 carbon atoms) having 1 to 5 (preferably 1) amino groups that may have 1 to 2 lower alkyl groups as illustrated above. Specific examples thereof include an amino methoxy group, 2-amino ethoxy group, 1-aminoethoxy group, 3-aminopropoxy group, 4-aminobutoxy group, 5-aminopentoxy group, 6-aminohexyloxy group, 1,1-dimethyl-2-aminoethoxy group, N, N-dimethylaminomethoxy group, N-methyl-N-ethylaminomethoxy group, N-methylaminomethoxy group, 2-(N-methylamino)ethoxy group, 2-(N,N-dimethylamino)ethoxy group, 2-(N,N-diethylamino)ethoxy group, 2-(NnN-diisopropylamino)ethoxy group and 3-(N,N-dimethhylamino)propoxy group.\n\n\n \n \n \n \nExamples of the lower alkoxy lower alkoxy group include a lower alkoxy lower alkoxy group having a lower alkoxy moiety as illustrated above. Specific examples thereof include a methoxymethoxy group, 2-methoxyethoxy group, 1-ethoxyethoxy group, 2-ethoxyethoxy group, 2-isobutoxyethoxy group, 2,2-dimethtoxyethoxy group and 2-methoxy-1-methylethoxy group.\n\n\n \n \n \n \nExamples of the piperazinyl group that may have group selected from the group consisting of an oxo group, lower alkyl group, lower alkanoyl group and lower alkoxy carbonyl group include a piperazinyl group that may have a group 1 to 3 (1 two 2) groups selected from the group consisting of an oxo, group, lower alkyl group as illustrated above, lower alkanoyl group as illustrated above and lower alkoxy carbonyl group as illustrated above. Specific examples thereof include a (1- or 2-)piperazinyl group, (2-, 3- or 4-)methyl-1-piperazinyl group, (1-, 2-, 3-, 4-, 5- or 6-)methyl-2-piperazinyl group, (2-, 3- or 4-)ethyl-1-piperazinyl group, (1-, 2-, 3-, 4-, 5- or 6-)ethyl-2-piperazinyl group, (2-, 3- or 4-)n-propyl-1-piperazinyl group, (1-, 2-, 3-, 4-, 5- or 6-)n-propyl-2-piperazinyl group, (2-, 3- or 4-)formyl-1-piperazinyl group, (2-, 3- or 4-)acetyl-1-piperazinyl group, (2-, 3- or 4-)propionyl-1-piperazinyl group, (1-, 2-, 3-, 4-, 5- or 6-)propionyl-2-piperazinyl group, (2-, 3- or 4-)butyryl-1-piperazinyl group, (1-, 2-, 3-, 4-, 5- or 6-)butyryl-2-piperazinyl group, (2-, 3- or 4-)methoxycarbonyl-1-piperazinyl group, (2-, 3- or 4-)ethoxycarbonyl-1-piperazinyl group, (2-, 3- or 4-)tert-butoxycarbonyl-1-piperazinyl group, (2-'or 3-)oxo -1-piperazinyl group, 2-oxo-(3-, 4-,5- or 6-)acetyl-1-piperazinyl group, 2-oxo-(3-, 4-, 5- or 6-)butyryl-1-piperazinyl group, 2-oxo-(3-, 4-, 5- or 6-)methoxycarbonyl-1-piperazinyl group and 2-oxo-(3-, 4-, 5- or 6-)methoxycarbonyl-1-piperazinyl group.\n\n\n \n \n \n \nExamples of the 1,3,8-triazaspiro[4.5]decanylcarbonyl group that may have a group selected from the group consisting of an oxo group and an aryl group include a 1,3,8-triazaspiro[4.5]decanylcarbonyl group that may have 1 to 3 (1 to 2) groups selected from the group consisting of an oxo group and an aryl group as illustrated above. Specific examples thereof include a 1,3,8-triazaspiro[4.5]decanyl-(1, 2, 3, 4 or 8-)ylcarbonyl group, 1-phenyl-1,3,8-triazaspiro[4.5]decanyl-8-ylcarbonyl group and 1-phenyl-4-oxo-1,3,8-triazaspiro[4.5]decanyl-8-ylcarbonyl group.\n\n\n \n \n \n \nExamples of the tetrahydropyridyl group include a (1-, 2-, 3-, 4-, 5- or 6-)-1,2,3,4-tetrahydropyridyl group and (1-, 2-, 3-, 4-, 5- or 6-)-1,2,3,6-tetrahydropyridyl group.\n\n\n \n \n \n \nExamples of the tetrahydropyridylcarbonyl group that may have a pyridyl group include a tetrahydropyridylcarbonyl group as illustrated above that may have 1 to 3 (preferably 1) pyridyl groups. Specific examples thereof include a (2-, 3- or - 4)pyridyl-1,2,3,6-tetrahydropyridyl-1-ylcarbonyl group.\n\n\n \n \n \n \nExamples of the imidazolidinylcarbonyl group that may have a thioxo group include an imidazolidinylcarbonyl group that may have 1 to 2 (preferably 1) thioxo groups. Specific examples thereof include a 2-thioxo-1-imidazolidinylcarbonyl group.\n\n\n \n \n \n \nExamples of the tetrahydronaphthyl group include a (1- or 2-)-1,2,3,4-tetrahydronaphthyl group.\n\n\n \n \n \n \nExamples of the saturated or unsaturated heteromonocyclic group having 1 to 4 heteroatoms selected from the group consisting of a nitrogen atom, oxygen atom and sulfur atom include a heteromonocyclic groups represented by (1) to (9) below.\n\n \n \n \n(1) a saturated 3 to 8 (preferably 5 to 6) membered heteromonocyclic group having 1 to 4 (preferably 1 to 2) nitrogen atoms (for example, pyrrolidinyl group, imidazolidinyl group, piperidyl group, hexahydropyrimidinyl group, piperazinyl group, azepanyl group and azocanyl group);\n \n(2) an unsaturated 3 to 8 (preferably 5 to 6) membered heteromonocyclic group having 1 to 4 (preferably 1 to 3) nitrogen atoms, for example, a pyrrolyl group, dihydropyrrolyl group such as 1H-2,5-dihydropyrolyl group, imidazolyl group (such as 1H-imidazolyl group), dihydroimidazolyl group (such as 1H-2,3-dihydroimidazolyl group), triazolyl group (such as 4H-1,2,4-trizaolyl group, 1H-1,2,3-trizaolyl group, and 2H-1,2,3-trizaolyl group), dihydrotriazolyl group (such as 1H-4,5-dihydro-1,2,4-triazolyl group), pyrazolyl group , pyridyl group, dihydropyridyl group (such as 1,2-dihydropyridyl group), pyrimidinyl group, dihydropyrimidinyl group (such as 1,6-dihydropyrimidinyl group), pyrazinyl group, dihydropyrazinyl group (such as 1,2-dihydropyrazinyl), pyridazinyl group, and tetrazolyl group (such as 1H-tetrazolyl group and 2H-tetrazolyl group);\n \n(3) an unsaturated 3 to 8 (preferably 5 to 6) membered heteromonocyclic group having 1 to 2 (preferably 1) oxygen atoms and 1 to 3 (preferably 1 to 2) nitrogen atoms, for example, an oxazolyl group, isoxazolyl group, oxadiazolyl group (such as 1,2,4-oxadiazolyl group, 1,3,4-oxadiazolyl group and 1,2,5-oxadiazolyl group) and a saturated 3 to 8 (preferably 5 to 6) membered heteromonocyclic group having 1 to 2 (preferably 1) oxygen atoms and 1 to 3 (preferably 1 to 2) nitrogen atoms, for example an oxazolidinyl group, isoxazolidinyl group and morpholinyl group;\n \n(4) an unsaturated 3 to 8 (preferably 5) membered heteromonocyclic group having 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, a thiazolyl group, dihydrothiazolyl group (such as 2,3-dihydrothiazolyl group), isothiazolyl group, thiadiazolyl group (such as, 1,2,3-thiadiazolyl group, 1,2,4-thiadiazolyl group, 1,3,4-thiadiazolyl group, and 1,2,5-thiadiazolyl group) and dihydrothiazinyl group.\n \n(5) a saturated 3 to 8 (preferably 5 to 6) membered heteromonocyclic group having 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, a thiazolidinyl group;\n \n(6) a saturated 3 to 8 (preferably 5 to 6) membered heteromonocyclic group having 1 to 2 oxygen atom, for example, a tetrahydrofuryl group and a tetrahydropyranyl group;\n \n(7) an unsaturated 3 to 8 (preferably 5 to 6) membered heteromonocyclic group having 1 to 2 oxygen atoms, for example, a pyranyl group (such as 2H-pyranyl group);\n \n(8) a saturated 3 to 8 (preferably 5 to 6) membered heteromonocyclic group having 1 to 2 sulfur atoms, for example, a tetrahydrothiofuryl group and a tetrahydrothiopyranyl group; and\n \n(9) an unsaturated 3 to 8 (preferably 5 to 6) membered heteromonocyclic group having 1 to 2 sulfur atoms, for example, a thienyl group and a thiopyranyl group (such as 2H-thiopyranyl).\n \n\n\n \n \n \nOf them, mention may be preferably made of a saturated or unsaturated heteromonocyclic group having a 1 to 2 hetero atoms selected from a nitrogen atom, oxygen atom and sulfur atom and selected from the group consisting of a pyrrolidinyl group, piperidyl group, pyrazolyl group, pyridyl group, pyrimidinyl group, pyrazinyl group, isoxazolyl group, thiazolyl group, pyranyl group and thienyl group; and further preferably made of a saturated or unsaturated heteromonocyclic group having a 1 to 2 nitrogen atoms and selected from the group a pyrrolidinyl group, piperidyl group, pyrazolyl group, pyridyl group, pyrimidinyl group and thiazolyl group.\n\n\n \n \n \n \nExamples of the tetrahydroquinoxalinyl group include a (1-, 2-, 5- or 6-)-1,2,3,4-tetrahydroquinoxalinyl group and (1-, 2-, 5- or 6-)-5,6,7,8-tetrahydroquinoxalinyl group.\n\n\n \n \n \n \nExamples of the tetrahydroquinazolinyl group include a (1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-)-1,2,3,4-tetrahydroquinazolinyl group and (1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-)-5,6,7,8-tetrahydroquinazolinyl group.\n\n\n \n \n \n \nExamples of the dihydroquinazolinyl group include a (1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-)-3,4-dihydroquinazolinyl group and (1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-)-1,2-dihydroquinazolinyl group.\n\n\n \n \n \n \nExamples of the dihydrobenzimidazolyl group include a (1-, 2-, 4- or 5-)-2,3-dihydro-1H-benzimidazolyl group.\n\n\n \n \n \n \nExamples of the tetrahydrobenzazepinyl group include a (1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-)-2,3,4,5-tetrahydro-1H-benzo[b]azepinyl group and (1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-)-2,3,4,5-tetrahydro-1H-benzo[c]azepinyl group.\n\n\n \n \n \n \nExamples of the tetrahydrobenzodiazepinyl group include a (1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-)-2,3,4,5-tetrahydro-1H-benzo[b][1.4]diazepinyl group and (1-, 2-, 3-, 4- 5-, 6-, 7-, 8- or 9-)-2,3,4,5-tetrahydro-1H-benzo[e] [1.4]diazepinyl group.\n\n\n \n \n \n \nExamples of the hexahydrobenzazocinyl group include a (1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, or 10-)-1,2,3,4,5,6-tetrahydrobenzo[b]azocinyl group and (1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- or 10-)-1,2,3,4,5,6-hexahydrobenzo[c]azocinyl group.\n\n\n \n \n \n \nExamples of the dihydrobenzoxazinyl group include a (2-, 3-, 4-, 5-, 6-, 7- or 8-)-3,4-dihydro-2H-benzo[b][1.4]oxazinyl group and (1-, 2-, 4-, 5-, 6-, 7- or 8-)-2,4-dihydro-1H-benzo[d][1.3]oxazinyl group.\n\n\n \n \n \n \nExamples of the dihydrobenzoxazolyl group include a (2-, 3-, 4-, 5-, 6- or 7-)-2,3-dihydrobenzoxazolyl group.\n\n\n \n \n \n \nExamples of the benzisoxazolyl group include a (3-, 4-, 5-, 6- or 7-)-benzo[d]-isoxazolyl group and (3-, 4-, 5-, 6- or 7-)-benzo[c]-isoxazolyl group.\n\n\n \n \n \n \nExamples of the benzoxadiazolyl group include a (4- or 5-)-benzo[c][1.2.5]oxadiazolyl group.\n\n\n \n \n \n \nExamples of the tetrahydrobenzoxazepinyl group include a (2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-)-2,3,4,5-tetrahydrobenzo[b][1.4]oxazepinyl group, (1-, 3-, 4-, 5-, 6-, 7-, 8- or 9-)-1,3,4,5-tetrahydrobenzo[e][1.3]oxazepinyl group and (2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-)-2,3,4,5-tetrahydrobenzo[f][1.4]oxazepinyl group.\n\n\n \n \n \n \nExamples of the dihydrobenzothiazinyl group include a (2-, 3-, 4-, 5-, 6-, 7- or 8-)-3,4-dihydro-2H-benzo[b][1.4]thiazinyl group and (2-, 3-, 4-, 5-, 6-, 7- or 8-)-3,4-dihydro-2H-benzo[e][1.3]thiazinyl group.\n\n\n \n \n \n \nExamples of the benzoxathiolyl group include a (2-, 4-, 5-, 6- or 7-)-benzo[d][1.3]oxathiolyl group, (3-, 4-, 5-, 6- or 7-)-3H-benzo[c][1.2]oxathiolyl group and (3-, 4-, 5-, 6- or 7-)-3H-benzo[d][1.2]oxathiolyl group.\n\n\n \n \n \n \nExamples of the dihydrobenzofuryl group include a (2-, 3-, 4-, 5-, 6- or 7-)-2,3-dihydrobenzofuryl group.\n\n\n \n \n \n \nA heterocyclic compound (hereinafter referred to as a compound (1)) represented by the general formula (1) can be produced by various kinds of methods, for example, a method shown in the following reaction formula-1 or reaction formula 2.\n\n \n \n\nwherein R\n1\n, R\n2\n and A are the same as defined above; and X\n1\n is a halogen atom or a group mediating the same substitution reaction as in a halogen atom.\n\n\n \n \n \n \nExamples of the group mediating the same substitution reaction as in a halogen atom include a lower alkanesulfonyloxy group, arylsulfonyloxy group, and aralkylsulfonyloxy group.\n\n\n \n \n \n \nA halogen atom represented by X\n1\n in the general formula (2) is a fluorine atom, chlorine atom, bromine atom and iodine atom.\n\n\n \n \n \n \nSpecific examples of the lower alkanesulfonyloxy group represented by X\n1\n include a linear or branched alkanesulfonyloxy group having 1 to 6 carbon atoms such as a methanesulfonyloxy group ethanesulfonyloxy group, isopropanesulfonyloxy group, n-propanesulfonyloxy group, n-butanesulfonyloxy group, tert-butanesulfonyloxy group, n-pentanesulfonyloxy group, and n-hexanesulfonyloxy group.\n\n\n \n \n \n \nSpecific examples of the arylsulfonyloxy group represented by X\n1\n include a phenylsulfonyloxy group and naphthylsulfonyloxy group that may have 1 to 3 substituents selected from the group consisting of a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkoxy group having 1 to 6 carbon atoms, a nitro group, and a halogen atom, on the phenyl ring. Specific examples of the phenylsulfonyloxy group that may have a substituent include a phenylsulfonyloxy group, 4-methylphenylsulfonyloxy group, 2-methylphenylsulfonyloxy group, 4-nitrophenylsulfonyloxy group, 4-methoxyphenylsulfonyloxy group, 2-nitrophenylsulfonyloxy group, and 3-chlorophenylsulfonyloxy group. Specific examples of the naphthylsulfonyloxy group include α-naphthylsulfonyloxy group and β-naphthylsulfonyloxy group.\n\n\n \n \n \n \nExamples of the aralkylsulfonyloxy group represented by X\n1\n include a linear or branched alkylsulfonyloxy group having 1 to 6 carbon atoms and substituted with a phenyl group; and\n\na linear or branched alkylsulfonyloxy group having 1 to 6 carbon atoms and substituted with a naphthyl group; both of which may have 1 to 3 substituents selected from the group consisting of a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkoxy group having 1 to 6 carbon atoms, a nitro group and a halogen atom, on the phenyl ring.\n\nSpecific examples of the alkylsulfonyloxy group substituted with a phenyl group as mentioned above include a benzylsulfonyloxy group, 2-phenylethylsulfonyloxy group, 4-phenylbutylsulfonyloxy group, 2-methylbenzylsulfonyloxy group, 4-methoxybenzylsulfonyloxy group, 4-nitrobenzylsulfonyloxy group, and 3-chlorobenzylsulfonyloxy group. Specific examples of the alkylsulfonyloxy group substituted with a naphthyl group include an α-naphthylmethylsulfonyloxy group and β-naphthylmethylsulfonyloxy group.\n\n\n \n \n \n \nThe compound (1) can be produced by reacting a compound (hereinafter referred to as a compound (2)) represented by the general formula (2) and a compound (hereinafter referred to as a compound (3)) represented by the general formula (3).\n\n\n \n \n \n \nThis reaction is generally performed in a conventional solvent that may not negatively affect the reaction, such as water; an alcohol based solvent such as methanol, ethanol, isopropanol, n-butanol, trifluoroethanol, and ethylene glycol; a ketone based solvent such as acetone and methylethyl ketone; an ether based solvent such as tetrahydrofuran, dioxane, diethyl ether, and diglyme; an ester based solvent such as methyl acetate and ethyl acetate; a non-proton polar solvent such as acetonitrile, N,N-dimethylformamide, and dimethylsulfoxide; a halogenated hydrocarbon based solvent such as methylene chloride and ethylene chloride; or other organic solvents. Furthermore, the reaction can be performed in a solution mixture of these conventional solvents. The reaction is generally performed in the presence of an inorganic base such as an alkali metal (e.g., sodium and potassium), an alkaline metal hydrogen carbonate (e.g., lithium hydrogen carbonate, sodium hydrogen carbonate, and potassium hydrogen carbonate), alkali metal hydroxide (e.g., lithium hydroxide, sodium hydroxide, potassium hydroxide, and cesium hydroxide), alkali metal carbonate (e.g., lithium carbonate, sodium carbonate, potassium carbonate, and cesium carbonate), alkali metal lower alkoxide (e.g., sodium methoxide and sodium ethoxide), and a hydride (e.g., sodium hydride and potassium hydride); or in the presence of an organic base such as a trialkylamine (e.g., trimethylamine, triethylamine, N-ethyl diisopropylamine), pyridine, quinoline, piperidine, imidazole, picoline, dimethylaminopyridine, dimethylaniline, N-methylmorpholine, 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,4-diazabicyclo[2.2.2]octane (DABCO), and 1,8-diazabicyclo[5.4.0]undecene-7 (DBU). When these bases take liquid form, they can be used as solvents.\n\n\n \n \n \n \nThese basic compounds may be used alone or in a mixture of two types or more.\n\n\n \n \n \n \nA basic compound may be used in a molar amount, which is generally 0.5 to 10 times, preferably 0.5 to 6 times as large as that of the compound (2).\n\n\n \n \n \n \nThe reaction mentioned above may be performed, if necessary, with the addition of an alkaline metal iodide serving as an accelerator, such as potassium iodide and sodium iodide.\n\n\n \n \n \n \nThe ratio of a compound (2) to a compound (3) used in the reaction formula-1 may be at least about 0.5 times mole, preferably about 0.5-5 times by mole.\n\n\n \n \n \n \nThe reaction temperature is not particularly limited and may be generally performed under cool or heating conditions and preferably performed at a temperature from near room temperature to about 150°C for 1 to 30 hours.\n\n\n \n \n \n \nThe compound (2) serving as a starting material for a compound according to the present invention include a novel compound and can be produced by various methods, for example, a method represented by the following reaction formula-3.\n\n\n \n \n \n \nThe compound (3) serving as a starting material for a compound according to the present invention is a known compound or a compound that can be easily produced from a known compound.\n\n\n \n \n \n \nA salt of a compound (2) in place of the compound (2) and a salt of a compound (3) in place of the compound (3) may be used. The salts of compounds (2) and (3) include acid-addition salts. These acid addition salts may be prepared by reacting a pharmaceutically acceptable acid with a compound (2) or (3). Examples of the acid used herein include inorganic acids such as sulfuric acid, nitric acid, hydrochloric acid, phosphoric acid, and hydrobromic acid; sulfonic acids such as p-toluene sulfonic acid, methane sulfonic acid, and ethane sulfonic acid; and organic acids such as acetic acid, oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, succinic acid, and benzoic acid.\n\n\n \n \n \n \nOf the compounds (2), a compound having an acidic group can easily produce a salt by reacting with a pharmaceutically acceptable basic compound. Examples of such a basic compound include metal hydroxides such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and calcium hydroxide; alkali metal carbonates or bicarbonates such as sodium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate; and alkali metal alcoholates such as sodium methylate and potassium ethylate.\n\n \n \n\nwherein R\n1\n, R\n2\n and A are the same as defined above; and X\n2\n is a hydroxy group, halogen atom or a group mediating the same substitution reaction as in a halogen atom.\n\n\n \n \n \n \nExamples of the halogen atom represented by X\n2\n and the group mediating the same substitution reaction as in a halogen atom in connection with the general formula (4) are the same as mentioned above.\n\n\n \n \n \n \nThe compound (1) can be produced by reacting a compound (hereinafter referred to as a compound (4)) represented by the general formula (4) and a compound (hereinafter referred to as a \"compound (5)\") represented by the general formula (5).\n\n\n \n \n \n \nThe reaction can be performed under the similar conditions as in reaction formula-1.\n\n\n \n \n \n \nIn the case of a compound (4) in which X\n2\n is a hydroxy group, the reaction can be performed in an appropriate solvent in the presence of an appropriate condensing agent.\n\n\n \n \n \n \nThis reaction is generally performed in a conventional solvent that may not negatively affect the reaction, such as water; an alcohol based solvent such as methanol, ethanol, isopropanol, n-butanol, trifluoroethanol, and ethylene glycol; a ketone based solvent such as acetone and methylethyl ketone; an ether based solvent such as tetrahydrofuran, dioxane, diethyl ether, and diglyme; an ester based solvent such as methyl acetate and ethyl acetate; a non-proton polar solvent such as acetonitrile, N,N-dimethylformamide, and dimethylsulfoxide; a halogenated hydrocarbon based solvent such as methylene chloride and ethylene chloride; or other organic solvents. Furthermore, as a solvent to be used herein, a solution mixture of these conventional solvents may be mentioned.\n\n\n \n \n \n \nAs the condensing agent, a mixture of an azocarboxylate such as diethyl azodicarboxylate and a phosphine compound such as triphenylphosphine may be mentioned.\n\n\n \n \n \n \nThe amount of the condensing agent used herein is generally at least equimolar, preferably equimolar to twice as large as that of a compound (4).\n\n\n \n \n \n \nThe ratio of a compound (4) to a compound (5) used in the reaction formula-2 may be generally at least equimole preferably about 2 times by mole.\n\n\n \n \n \n \nThe reaction temperature is not particularly limited and may generally be performed under cool or heating conditions, and preferably performed at a temperature from 0°C to about 150°C for 1 to 10 hours.\n\n\n \n \n \n \nThe compound (4) serving as a starting material for a compound according to the present invention is a known compound or a compound that can be easily produced from a known compound.\n\n\n \n \n \n \nThe compound (5) serving as a starting material for a compound according to the present invention include a novel compound and a compound that can be produced by various methods, for example, a method represented by the following reaction formula-4 or -5.\n\n\n \n \n \n \nA salt of a compound (4) in place of the compound (4) and a salt of a compound (5) in place of the compound (5) may be used. As a preferable salt of a compound (4), the same salt as shown in a compound (2) may be mentioned. As a preferable salt of a compound (5), the same salt as shown in a compound (3) may be mentioned.\n\n \n \n\nwherein R\n1\n, X\n1\n and A are the same as defined above; and X\n3\n is a halogen atom or a group mediating the same substitution reaction as in a halogen atom.\n\n\n \n \n \n \nExamples of the halogen atom represented by X\n3\n and the group mediating the same substitution reaction as in a halogen atom in connection with the general formula (7) are the same as mentioned above.\n\n\n \n \n \n \nThe compound (2) can be produced by reacting a compound (hereinafter referred to as a compound (6)) represented by the general formula (6) and a compound (hereinafter referred to as a compound (7)) represented by the general formula (7).\n\n\n \n \n \n \nThe reaction can be performed under the similar conditions as in reaction formula-1.\n\n\n \n \n \n \nThe compounds (6) and (7) serving as starting materials for a compound according to the present invention are known compounds or compounds that can be easily produced from known compounds.\n\n\n \n \n \n \nIn place of a compound (6), a salt of the compound (6) may be used. As a preferable salt of a compound (6), the same salt as shown in a compound (2) may be mentioned.\n\n \n \n\nwherein R\n2\n and A are the same as defined above; and X\n4\n is a halogen atom or a group mediating the same substitution reaction as in a halogen atom.\n\n\n \n \n \n \nExamples of the halogen atom represented by X\n4\n and the group mediating the same substitution reaction as in a halogen atom in connection with the general formula (8) are the same as mentioned above.\n\n\n \n \n \n \nThe compound (5) can be produced by reacting a compound (3) and a compound (hereinafter referred to as a compound (8)) represented by the general formula (8).\n\n\n \n \n \n \nThe reaction can be performed under the similar conditions as in reaction formula-1.\n\n\n \n \n \n \nThe compound (8) serving as a starting material for a compound according to the present invention is a known compound or a compound that can be easily produced from a known compound.\n\n\n \n \n \n \nIn place of a compound (3), a salt of the compound (3) may be used. As a preferable salt of a compound (3), the same salts as above may be mentioned.\n\n \n \n\nwherein R\n2\n and A are the same as defined above; R\n4\n is a lower alkanoyl group; and X\n4\n is a halogen atom or a group mediating the same substitution reaction as in a halogen atom.\n\n\n \n \n \n \nExamples of the lower alkanoyl group represented by R\n4\n in the general formulas (9) and (10) are the same as mentioned above.\n\n\n \n \n \n \nFurthermore, examples of the halogen atom represented by X\n4\n and the group mediating the same substitution reaction as in a halogen atom in connection with the general formula (9) are the same as mentioned above.\n\n\n \n \n \n \nA compound (hereinafter referred to as a compound (10)) represented by the general formula (10) can be produced by reacting a compound (3) and a compound (9).\n\n\n \n \n \n \nThe reaction can be performed under the similar conditions as in reaction formula-1.\n\n\n \n \n \n \nThe compound (9) serving as a starting material for a compound according to the present invention is a known compound or a compound that can be easily produced from a known compound.\n\n\n \n \n \n \nIn place of a compound (3), a salt of the compound (3) may be used. As a preferable salt of a compound (3), the same salts as above may be mentioned.\n\n\n \n \n \n \nSubsequently, the compound (10) is subjected to a reaction for removing an acyl group to produce a compound (5).\n\n\n \n \n \n \nAs a preferable method of the reaction, a conventional reaction such as hydrolysis may be mentioned. The hydrolysis reaction may be preferably performed in the presence of a base or an acid including Lewis acid. Examples of the preferable base include inorganic salts such as an alkali metal (e.g., sodium and potassium), an alkaline metal hydrogen carbonate (e.g., lithium hydrogen carbonate, sodium hydrogen carbonate, and potassium hydrogen carbonate), an alkali metal hydroxide (e.g., lithium hydroxide, sodium hydroxide, potassium hydroxide, and cesium hydroxide), an alkali metal carbonate (e.g., lithium carbonate, sodium carbonate, potassium carbonate, and cesium carbonate), an alkali metal lower alkoxide (e.g., sodium methoxide and sodium ethoxide), and hydrides (e.g., sodium hydride and potassium hydride); and organic bases such as a trialkylamine (e.g., trimethylamine, triethylamine, and N-ethyl diisopropylamine), pyridine, quinoline, piperidine, imidazole, picoline, dimethylaminopyridine, dimethylaniline, N-methylmorpholine, DBN, DABCO, and DBU. As a preferable acid, mention can be made of organic acids (such as formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid) and inorganic acids (such as hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, and hydrogen bromide). The removal reaction using a Lewis acid such as a trihaloacetic acid (e.g., trichloroacetic acid and trifluoroacetic acid) may be preferably performed in the presence of a cation-trapping agent (e.g., anisole and phenol).\n\n\n \n \n \n \nThis reaction is generally performed in a conventional solvent that may not negatively affect the reaction, such as water; an alcohol based solvent such as methanol, ethanol, isopropanol, n-butanol, trifluoroethanol, and ethylene glycol; a ketone based solvent such as acetone and methylethyl ketone; an ether based solvent such as tetrahydrofuran, dioxane, diethyl ether, and diglyme; an ester based solvent such as methyl acetate and ethyl acetate; a non-proton polar solvent such as acetonitrile, N,N-dimethylformamide, and dimethylsulfoxide; a halogenated hydrocarbon based solvent such as methylene chloride and ethylene chloride; or other organic solvents. Furthermore, the reaction may be performed in a solution mixture of these conventional solvents. Of them, ethanol is preferable. The reaction temperature is not particularly limited and may generally be performed under cool or heating conditions, and preferably performed at near room temperature to near a boiling point of the solvent to be used for 0.5 to 75 hours.\n\n\n \n \n \n \nIn place of a compound (10), a salt of the compound (10) may be used. As a preferable salt of a compound (10), the same salt as shown in a compound (3) may be mentioned.\n\n\n \n \n \n \nFurthermore, a compound (hereinafter referred to as a compound (5a)) where A of the compound (5) represents -CH\n2\nA\"- where A\" represents a C1 to C5 alkylene group can be produced by a method represented by the following reaction formula-6.\n\n \n \n\nwherein R\n2\n is the same as defined above; and R\n3\n is a lower alkoxy group. A\" represents a C1 to C5 alkylene group. The lower alkoxy group represented by R\n3\n in the general formula (11) is the same as defined above.\n\n\n \n \n \n \nExamples of the C1 to C5 alkylene group represented by A\" in the general formulas (11) and (5a) include a linear or branched alkylene group having 1 to 5 carbon atoms such as methylene, ethylene, methyl methylene, trimethylene, tetramethylene, 1-methyl trimethylene, 2-methyl trimethylene, 3-methyl tetramethylene, pentamethylene, and 2,2-dimethyl trimethylene.\n\n\n \n \n \n \nThe compound (5a) can be produced by subjecting a compound (hereinafter referred to as a compound (11)) represented by the general formula (11) to a reducing reaction.\n\n\n \n \n \n \nThe reaction can be performed by the method shown in Reference Example 6 or a similar method thereof. The reaction also can be performed by a conventional method using a reducing agent.\n\n\n \n \n \n \nAs a preferable reducing agent, mention may be made of a hydride (such as lithium aluminum hydride, sodium borohydride, lithium borohydride, diborane, and sodium cyanoborohydride).\n\n\n \n \n \n \nThis reaction is generally performed in a conventional solvent that may not negatively affect the reaction, such as an alcohol based solvent such as methanol, ethanol, isopropanol, n-butanol, trifluoroethanol, and ethylene glycol; a ketone based solvent such as acetone and methylethyl ketone; an ether based solvent such as tetrahydrofuran, dioxane, diethyl ether, and diglyme; an ester based solvent such as methyl acetate and ethyl acetate; a non-proton polar solvent such as acetonitrile, N,N-dimethylformamide, and dimethylsulfoxide; a halogenated hydrocarbon based solvent such as methylene chloride and ethylene chloride; or other organic solvents. Furthermore, the reaction may be performed in a solution mixture of these conventional solvents. The reaction temperature is not particularly limited and may generally be performed under cool or heating conditions, and preferably performed at near room temperature to near a boiling point of the solvent to be used for 0.5 to 75 hours.\n\n\n \n \n \n \nThe compound (11) serving as a starting material for a compound according to the present invention is a known compound or a compound that can be easily produced from a known compound.\n\n\n \n \n \n \nIn place of a compound (11), a salt of the compound (11) may be used. As a preferable salt of a compound (11), the same salt as shown in a compound (2) may be mentioned.\n\n\n \n \n \n \nFurthermore, a compound (hereinafter referred to as a compound (11a)) where A\" of the compound (11) represents \"-(CH\n2\n)\n2\n-\" can be produced by a method represented by the following reaction formula-7.\n\n \n \n\nwhere R\n2\n and R\n3\n are the same as defined above.\n\n\n \n \n \n \nThe compound (11a) can be produced by reacting a compound (3) and a compound (hereinafter referred to as a compound (12)) represented by the general formula (12).\n\n\n \n \n \n \nThe reaction can be performed by the method shown in Reference Example 5 or a similar method thereof. This reaction is generally performed in a conventional solvent that may not negatively affect the reaction, such as water, an alcohol based solvent such as methanol, ethanol, isopropanol, n-butanol, trifluoroethanol, and ethylene glycol; a ketone based solvent such as acetone and methylethyl ketone; an ether based solvent such as tetrahydrofuran, dioxane, diethyl ether, and diglyme; an ester based solvent such as methyl acetate and ethyl acetate; a non-proton polar solvent such as acetonitrile, N,N-dimethylformamide, and dimethylsulfoxide; a halogenated hydrocarbon based solvent such as methylene chloride and ethylene chloride; or other organic solvents. Furthermore, the reaction may be performed in a solution mixture of these conventional solvents. The reaction temperature is not particularly limited and may generally be performed under cool or heating conditions, and preferably performed at near room temperature to near a boiling point of the solvent to be used for 0.5 to 75 hours.\n\n\n \n \n \n \nThe compound (12) serving as a starting material for a compound according to the present invention is a known compound or a compound that can be easily produced from a known compound.\n\n\n \n \n \n \nA salt of a compound (3) in place of the compound (3) and a salt of a compound (12) in place of the compound (12) may be used. As a preferable salt of a compound (3), the same salt as shown above may be mentioned. As a preferable salt of a compound (12), the same salt as shown in a compound (2) may be mentioned.\n\n\n \n \n \n \nThe object compound obtained by each of the above reaction formula may form a suitable salt. Such suitable salts include the preferable salts of compound (1) exemplified below.\n\n\n \n \n \n \nThe preferable salts of compound (1) are pharmacologically acceptable salts and examples include metal salts such as alkali metal salts (for example, sodium salt potassium salt, etc.), alkaline earth metal salts (for example, calcium salt, magnesium salt, etc.), salts of inorganic bases such as ammonium salt, alkaline metal carbonates (for example, lithium carbonate, potassium carbonate, sodium carbonate, cesium carbonate, etc.), alkaline metal hydrogen carbonates (for example, lithium hydrogen carbonate, sodium hydrogen carbonate, potassium bicarbonate, etc.), alkali metal hydroxides (for example, lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide, etc.); for example, salts of organic bases such as tri(lower)alkylamine (for example, trimethylamine, triethylamine, N-ethyldiisopropylamine), pyridine, quinoline, piperidine, imidazole, picoline, dimethylaminopyridine, dimethylaniline, N-(lower)alkyl-morpholine (for example, N-methylmorpholine), 1,5-diazabicyclo[4.3.0]nonene-5 (DBN), 1,8-diazabicyclo[5.4.0]undecene-7 (DBU), 1,4-diazabicyclo[2.2.2] octane (DABCO); salts of inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate; salts of organic acids such as formate, acetate, propionate, oxalate, malonate, succinate, fumarate, maleate, lactate, malate, citrate, tartrate, carbonate, picrate, methanesulfonate, ethanesulfonate, p-toluenesulfonate, glutamate.\n\n\n \n \n \n \nIn addition, compounds in the form in which solvate (for example, hydrate, ethanolate, etc.) was added to the starting compounds and object compound shown in each of the reaction formulae are included in each of the general formulas. As a preferable solvate, hydrate can be mentioned.\n\n\n \n \n \n \nEach of the object compounds obtained by each of the general formulas can be isolated and purified from the reaction mixture by, for example, subjecting the reaction mixture to isolation operation such as filtration, concentration and extraction after cooling to separate a crude reaction product followed by conventional purification operation such as column chromatography or recrystallization.\n\n\n \n \n \n \nThe compound represented by the general formula (1) of the present invention naturally encompasses isomers such as geometrical isomer, stereoisomer and enantiomer.\n\n\n \n \n \n \nA compound and a salt thereof represented by the general formula (1) may be used in the form of general pharmaceutical preparation. The preparation may be prepared by use of a diluent or an excipient such as a filler, extending agent, binder, humectant, disintegrator, surfactant, and lubricant. As a pharmaceutical preparation, various forms can be selected depending upon the therapeutic purpose. Typical forms thereof include a tablet, pill, powder, liquid, suspension, emulsion, granule, encapsulate, suppository, and injection (liquid, suspension).\n\n\n \n \n \n \nIn forming a tablet, a wide variety of types of carriers conventionally known in the art may be used. Examples of the carrier that may be used include an excipient such as lactose, saccharose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, and silicate; a binder such as water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatine solution, carboxymethylcellulose, shellac, methyl cellulose, potassium phosphate, and polyvinylpyrrolidine; a disintegrator such as dried starch, sodium alginate, powdered agar, powdered laminaran, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, stearic acid monoglyceride, starch, and lactose; a disintegration suppressant such as saccharose, stearin, cocoa butter, and hydrogenated oil; a sorbefacient such as quaternary ammonium base and sodium lauryl sulfate; a humectant such as glycerin and starch; an adsorbing agent such as starch, lactose, kaolin, bentonite, and colloidal silica; and a lubricant such as refined talc, stearate, powdered boric acid, and polyethylene glycol. Furthermore, if necessary, a tablet may be coated with a general film. Examples of such a coated tablet include a sugar-coated tablet, gelatine encapsulated tablet, enteric-coated tablet, film coated tablet or double-layer tablet, and multi-layer tablet.\n\n\n \n \n \n \nIn forming a pill, a wide variety of types of carriers conventionally known in the art may be used. Examples of the carrier that may be used include an excipient such as glucose, lactose, starch, cacao butter, hardened vegetable oil, kaolin and talc; a binder such as powdered gum Arabic, powdered tragacanth, gelatine and ethanol; and a disintegrator such as laminaran and agar.\n\n\n \n \n \n \nIn forming a suppository, a wide variety of types of carriers conventionally known in the art may be used. Examples of the carrier that may be used include polyethylene glycol, cacao butter, higher alcohol, esters of a higher alcohol, gelatine, and semisynthetic glyceride.\n\n\n \n \n \n \nA capsule is usually prepared by mixing an active ingredient compound with a carrier as illustrated above in accordance with a conventional method and filling the mixture in a hard gelatine capsule or a soft capsule.\n\n\n \n \n \n \nIn preparing an injection, a liquid agent, emulsion and suspension are preferably sterilized and isotonic with blood. When they are prepared into an injection, any diluent can be used as long as it is conventionally used as a diluent in the art. Examples of the diluent that may be used include water, ethyl alcohol, macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters.\n\n\n \n \n \n \nNote that, in this case, a pharmaceutical preparation may contain a salt, glucose or glycerin in a sufficient amount to prepare an isotonic solution. Alternatively, a general auxiliary solubilizer, buffer, soothing agent may be added. Furthermore, a pigment, preservative, aroma, flavor, sweetening agent and other medicinal substances may be added to a pharmaceutical preparation, if necessary.\n\n\n \n \n \n \nThe amount of a compound of the general formula (1) and a salt thereof to be contained in a pharmaceutical preparation according to the present invent is not particularly limited and appropriately selected from the wide range; however generally about 1 to 70 wt%, preferably about 1 to 30 wt% in a preparation composition.\n\n\n \n \n \n \nA method of administrating a pharmaceutical preparation according to the present invention is not limited and administered by a method in accordance with the form of a preparation, the age, gender and other conditions of a patient, and severity of a disease. For example, in the case of a tablet, pill, liquid agent, suspension, emulsion, granule and capsule, it is perorally administrated. In addition, in the case of an injection, it is intravenously administered by itself or by mixing with a general replenisher such as glucose and amino acids, and, if necessary, it is solely administered intramuscularly, intracutaneously, subcutaneously or intraperitoneally. In the case of a suppository, it is administered into the rectum.\n\n\n \n \n \n \nThe dose of a pharmaceutical preparation according to the present invention is appropriately selected depending upon the dosage regimen (direction for use), age, gender and other conditions of a patient, and severity of a disease, etc.; however, the dose of an active ingredient compound may be generally and preferably set at about 0.1 to 10 mg/weight (kg) per day. It is desirable that an active ingredient compound be contained in the range of about 1 to 200 mg per dosage unit of a preparation.\n\n\n \n[Advantages of the Invention]\n\n\n \n \n \nA compound according to the present invention has a D\n2\n receptor partial agonist effect, 5-HT\n2A\n receptor antagonist effect and serotonin uptake inhibitory effect.\n\n\n \n \n \n \nThe D\n2\n receptor partial agonist effect refers to an action which decelerates dopaminergic (DA) neurotransmission when it is enhanced, whereas accelerates dopaminergic (DA) neurotransmission when it is lowered. In this manner, the D\n2\n receptor partial agonist acts as a dopamine system stabilizer, which stabilizes DA neurotransmission into a normal state. By virtue of this effect, the compound of the present invention produces an excellent clinical improvement effect on symptoms caused by abnormal DA neurotransmission (acceleration or deceleration) without developing side effects. As the excellent clinical improvement effect, mention may be made of, effects of improving positive and negative symptoms, cognitive impairment and depressive symptom (see\n Michio Toru, Psychiatry, Vol. 46, page 855-864 (2004\n);\n Tetsuro Kikuchi and Hirose Takeshi, Brain Science, vol. 25, page 579-583 (2004\n); and \nHarrison, T. S. and Perry, C.M.: Drugs 64: 1715-1736, 2004\n).\n\n\n \n \n \n \n5-HT\n2A\n receptor antagonist effect refers to an action which reduces extrapyramidal side effects and develops a superior clinical response and more specifically effectively works for improving negative symptoms, cognitive impairment, depressive symptom, and insomnia (see Jun Ishigooka and Ken Inada: Japanese Journal of Clinical Psychopharmacology, vol. 4, page 1653-1664 (2001); Mitsukuni Murasaki: Japanese Journal of Clinical Psychopharmacology, vol. 1, page 5-22 (1998), and Meltzer, H. Y. et al.: Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27: 1159-1172, 2003).\n\n\n \n \n \n \nThe serotonin uptake inhibitory effect is, for example, effective in improving depressive symptoms (see Mitsukuni Murasaki: Japanese Journal of Clinical Psychopharmacology, vol. 1, page 5-22 (1998)).\n\n\n \n \n \n \nThe compound of the present invention is excellent in all these three effects or significantly excellent in one or two effects of them.\n\n\n \n \n \n \nIn addition, some of the compounds according to the present invention has an α\n1\n receptor antagonist effect in addition to the effects mentioned above. The α\n1\n receptor antagonist effect is effective in improving positive symptoms of schizophrenia (see Svensson, T. H.: Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27: 1145-1158, 2003)\n\n\n \n \n \n \nTherefore, a compound of the present invention has a wide treatment spectrum for schizophrenia and other central nervous system disorder and possesses a superior clinical response.\n\n\n \n \n \n \nAccordingly, a compound of the present invention is extremely effective for improving various kinds of disorders of the central nervous system such as schizophrenia; refractory, intractable or chronic schizophrenia; emotional disturbance; psychotic disorder; mood disorder; bipolar disorder (for example, bipolar Type-I disorder and bipolar Type-II disorder); depression, endogenous depression, major depression; melancholy and refractory depression; dysthymic disorder; cyclothymic disorder; anxiety disorder (for example, panic attack, panic disorder, agoraphobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, and acute stress disorder); somatoform disorder (for example, hysteria, somatization disorder, conversion disorder, pain disorder, and hypochondriasis), factitious disorder; dissociative disorder; sexual disorder (for example, sexual dysfunction, sexual desire disorder, sexual arousal disorder, and erectile dysfunction); eating disorder (for example, anorexia nervosa and bulimia nervosa); sleep disorder; adjustment disorder; substance-related disorder (for example, alcohol abuse; alcohol intoxication; drug addiction, stimulant intoxication, and narcotism); anhedonia (for example, iatrogenic anhedonia, anhedonia of a psychic or mental cause, anhedonia associated with depression, and anhedonia associated with schizophrenia); delirium; cognitive impairment; cognitive impairment associated with Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases; cognitive impairment caused by Alzheimer's disease; Parkinson's disease and associated neurodegenerative diseases; cognitive impairment of schizophrenia; cognitive impairment caused by refractory, intractable or chronic schizophrenia; vomiting; motion sickness; obesity; migraine; pain (ache); mental retardation; autism disorder (autism); Tourette's disorder; tic disorder; attention-deficit/hyperactivity disorder; conduct disorder; and Down's syndrome.\n\n\n \n \n \n \nFurthermore, a compound of the present invention has few side effects, and excellent in tolerability and safety.\n\n\n \n \n \n \nThe starting compounds used in each of the above reaction formula may be suitable salt, the object compound obtained by each of the reaction may form a suitable salt. Such suitable salts include the preferable salts of compound (1) exemplified below.\n\n\n \n \n \n \nThe preferable salts of compound (1) are pharmacologically acceptable salts and examples include metal salts such as alkali metal salts (for example, sodium salt potassium salt, etc.), alkaline earth metal salts (for example, calcium salt, magnesium salt, etc.), salts of inorganic bases such as ammonium salt, alkaline metal carbonates (for example, lithium carbonate, potassium carbonate, sodium carbonate, cesium carbonate, etc.), alkaline metal hydrogen carbonates (for example, lithium hydrogen carbonate, sodium hydrogen carbonate, potassium bicarbonate, etc.), alkali metal hydroxides (for example, lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide, etc.); for example, salts of organic bases such as tri(lower)alkylamine (for example, trimethylamine, triethylamine, N-ethyldiisopropylamine), pyridine, quinoline, piperidine, imidazole, picoline, dimethylaminopyridine, dimethylaniline, N-(lower)alkyl-morpholine (for example, N-methylmorpholine), 1,5-diazabicyclo[4.3.0]nonene-5 (DBN), 1,8-diazabicyclo[5.4.0]undecene-7 (DBU), 1,4-diazabicyclo[2.2.2] octane (DABCO); salts of inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate; salts of organic acids such as formate, acetate, propionate, oxalate, malonate, succinate, fumarate, maleate, lactate, malate, citrate, tartrate, carbonate, picrate, methanesulfonate, ethanesulfonate, p-toluenesulfonate, glutamate.\n\n\n \n \n \n \nIn addition, compounds in the form in which solvate (for example, hydrate, ethanolate, etc.) was added to the starting compounds and object compound shown in each of the reaction formulae are included in each of the general formulas. As a preferable solvate, hydrate can be mentioned.\n\n\n \n \n \n \nEach of the object compounds obtained by each of the general formulas can be isolated and purified from the reaction mixture by, for example, subjecting the reaction mixture to isolation operation such as filtration, concentration and extraction after cooling to separate a crude reaction product followed by conventional purification operation such as column chromatography or recrystallization.\n\n\n \n \n \n \nThe compound represented by the general formula (1) of the present invention naturally encompasses isomers such as geometrical isomer, stereoisomer and enantiomer.\n\n\n \n \n \n \nThe compound of the general formula (1) and a salt thereof can be used in a common form of pharmaceutical preparation. The pharmaceutical preparation is prepared by using usually used diluent or excipient such as filler, extending agent, binder, humectant, disintegrating agent, surfactant and lubricant. As for this pharmaceutical preparation, various forms can be selected depending on the purpose of treatment, and typical examples include a tablet, pill, powder, solution, suspension, emulsion, granule, capsule, suppository, and injection (solution, suspension).\n\n\n \n \n \n \nFor shaping in tablet form, various materials conventionally well known as carrier in the art can be widely used. As examples, excipient such as lactose, saccharose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicate; binder such as water, ethanol, propanol, simple syrup, glucose solution, starch liquid, gelatine solution, carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone; disintegrating agent such as dried starch, sodium alginate, agar powder, laminaran powder, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose; disintegration preventing agent such as saccharose, stearin, cacao butter, hydrogenated oil; sorbefacient such as quaternary ammonium base, sodium lauryl sulfate; moisturizing agent such as glycerine, starch; absorbing agent such as starch, lactose, kaolin, bentonite, colloidal silica; lubricant such as purified talc, stearate, borate powder, polyethylene glycol can be used, for example. Furthermore, the tablet may be a tablet provided with conventional coating as required, for example, sugar-coated tablet, gelatine encapsulated tablet, enteric coating tablet, film coated tablet or double tablet, multilayer tablet.\n\n\n \n \n \n \nFor shaping in pill form, various materials conventionally well known as carrier in the art can be widely used. As examples, excipient such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oil, kaolin, talc; binder such as powdered gum arabic, powdered tragacanth, gelatine, ethanol; disintegrating agent such as laminaran, agar can be used, for example.\n\n\n \n \n \n \nFor shaping in suppository form, various materials conventionally well known as carrier can be widely used. Examples thereof include polyethylene glycol, cacao butter, higher alcohol, esters of higher alcohol, gelatine, semisynthesized glyceride, for example.\n\n\n \n \n \n \nA capsule is usually prepared according to a conventional method by mixing active ingredient compounds with various carrier exemplified above and filling them into a hard gelatin capsule, a soft capsule or the like.\n\n\n \n \n \n \nWhen prepared as injection liquid, it is preferable that solution, emulsion and suspension are sterilized and isotonic to the blood and for forming in these modes, any of those conventionally used in the art as diluent can be used, and, for example, water, ethyl alcohol, macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid ester, etc. can be used.\n\n\n \n \n \n \nThe pharmaceutical preparation may contain common salt, glucose or glycerine in an amount sufficient to prepare an isotonic solution in this case, and conventional solubilizer, buffer, soothing agent may be also added. Pigment, preservative, aromatic, flavor, sweetening and other pharmaceuticals may be further contained as required.\n\n\n \n \n \n \nThe amount of a compound of the general formula (1) or a salt thereof to be contained in the pharmaceutical preparation of the present invention is not particularly limited but usually about 1 to 70% by weight in the preparation composition is suitable and preferably about 1 to 30% by weight.\n\n\n \n \n \n \nThere is not limitation in particular in the way of administration of the pharmaceutical preparation of the present invention and may be administered by a method in accordance with specific form of the preparation, age, sex and the other conditions of a patient, severity of disease, etc. For example, in the case of tablet, pill, solution, suspension, emulsion, granule and capsule, it is orally administered. In the case of injection, it is intravenously administered alone or in a mixture with conventional replacement fluid such as glucose and amino acids, and if necessary, and the preparation alone may be also administered intramuscularly, intracutaneously, subcutaneously or interperitoneally. It is administered in rectum in the case of suppository.\n\n\n \n \n \n \nApplied dose of the pharmaceutical preparation of the present invention is appropriately selected in accordance with dosage regimen, age, sex and the other conditions of a patient, severity of disease, etc., but it is suitable that the amount of the active ingredient compound is usually about 0.1 to 10 mg per 1 kg of body weight per day. In addition, it is desirable that the active ingredient compound is contained in the preparation of a dosage unit form in the range of about 1 to 200 mg.\n\n\n \n \n \n \nThe compound of the present invention has D\n2\n receptor partial agonist effect, 5-HT\n2A\n receptor antagonist effect and serotonin uptake inhibitory effect (or serotonin uptake inhibitory effect).\n\n\n \n \n \n \nThe D\n2\n receptor partial agonist effect suppresses dopaminergic (DA) neurotransmission when it is enhanced, and accelerates the DA neurotransmission when it is lowered and thus has a function to stabilize the DA neurotransmission to a normal state (dopamine system stabilizer). According to this function, excellent clinically improving effect on the conditions based on the DA abnormal neurotransmission (enhancement and lowering), for example, improving effect on positive and negative symptoms, improving effect on cognitive impairment, improving effect on depressive symptom, etc. are developed without developing side effects (See \nMichio Toru: Seishin-Igaku (Psychiatry), Vol. 46, pp. 855-864 (2004\n), \nTetsuro Kikuchi and Tsuyoshi Hirose: Nou-no-Kagaku (Brain Science), Vol. 25, pp. 579-583 (2003\n) and \nHarrison, T.S. and Perry, C.M.: Drugs 64: 1715-1736, 2004\n).\n\n\n \n \n \n \n5-HT\n2A\n receptor antagonist effect reduces extrapyramidal side effects, develops superior clinical effects, and is effective for improvement of negative symptoms, improvement of cognitive impairment, improvement of depression condition, improvement of insomnia, for example (See \nJun Ishigooka and Ken Inada: Rinsho-Seishin-Yakuri (Japanese Journal of Clinical Psychopharmacology), Vol. 4, pp. 1653-1664 (2001\n), \nMitsukuni Murasaki: Rinsho-Seishin-Yakuri (Japanese Journal of Clinical Psychopharmacology), Vol. 1, pp. 5-22 (1998\n), \nPuller, I.A. et al., Eur. J. Pharmacol., 407:39-46, 2000\n, and \nMeltzer, H.Y. et al, Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27: 1159-1172, 2003\n).\n\n\n \n \n \n \nSerotonin uptake inhibitory effect (or serotonin reuptake inhibitory effect) is effective for improving depressive symptoms, for example (See \nMitsukuni Murasaki: Rinsho-Seishin-Yakuri (Japanese Journal of Clinical Psychopharmacology), Vol. 1, pp. 5-22 (1998\n)).\n\n\n \n \n \n \nThe compounds of the present invention are excellent in all of these three effects, or remarkably excellent in one or two of these effects.\n\n\n \n \n \n \nIn addition, some of the compounds of the present invention have α\n1\n receptor antagonist effect in addition to the above-described effects. The α\n1\n receptor antagonist effect is effective for improving positive symptoms of schizophrenia (See \nSvensson, T.H.: Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27: 1145-1158, 2003\n).\n\n\n \n \n \n \nTherefore, the compounds of the present invention have a wide treatment spectrum for and excellent clinical effect on schizophrenia and other central nervous system disorders.\n\n\n \n \n \n \nAccordingly, the compounds of the present invention are extremely effective for the treatment or prevention of central nervous system disorders including the group consisting of schizophrenia; refractory, intractable or chronic schizophrenia; emotional disturbance; psychotic disorder; mood disorder; bipolar disorder (for example, bipolar I type disorder and bipolar II type disorder); depression; endogenous depression; major depression; melancholy and refractory depression; dysthymic disorder; cyclothymic disorder; anxiety disorder (for example, panic attack, panic disorder, agoraphobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, acute stress disorder, etc.); somatoform disorder (for example, hysteria, somatization disorder, conversion disorder, pain disorder, hypochondriasis, etc.); factitious disorder; dissociative disorder; sexual disorder (for example, sexual dysfunction, sexual desire disorder, sexual arousal disorder, erectile dysfunction, etc.); eating disorder (for example, anorexia nervosa, bulimia nervosa, etc.); sleep disorder; adjustment disorder; substance-related disorder (for example, alcohol abuse, alcohol intoxication, drug addiction, stimulant intoxication, narcotism, etc.); anhedonia (for example, iatrogenic anhedonia, anhedonia of a psychic or mental cause, anhedonia associated with depression, anhedonia associated with schizophrenia, etc.); delirium; cognitive impairment; cognitive impairment associated with Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases; cognitive impairment caused by Alzheimer's disease, Parkinson's disease and associated neurodegenerative diseases; cognitive impairment of schizophrenia; cognitive impairment caused by refractory, intractable or chronic schizophrenia; vomiting; motion sickness; obesity; migraine; pain (ache); mental retardation; autism disorder (autism); Tourette's disorder; tic disorder; attention-deficit/hyperactivity disorder; conduct disorder; and Down's syndrome.\n\n\n \n \n \n \nFurthermore, the compounds of the present invention have little or no side effects and they are excellent in safety and tolerability.\n\n\n \n \n \n \nA preferable example of a desired compound (1) is as follows:\n\n \n \n\nwhere R\n2\n represents a hydrogen atom or a lower alkyl group;\n\nA represents a lower alkylene group or a lower alkenylene group (preferably a lower alkylene group); and\n\nR\n1\n represents a heterocyclic group selected from\n\na saturated or unsaturated heteromonocyclic group having 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, oxygen atom and sulfur atom and selected from the group consisting of a pyrrolidinyl group, imidazolidinyl group, piperidyl group, hexahydropyrimidinyl group, piperazinyl group, azepanyl group, azocanyl group, pyrrolyl group, dihydropyrrolyl group, imidazolyl group, dihydroimidazolyl group, triazolyl group, dihydrotriazolyl group, pyrazolyl group, pyridyl, dihydropyridyl group, pyrimidinyl group, dihydropyrimidinyl group, pyrazinyl group, dihydropyrazinyl group, pyridazinyl group, tetrazolyl group, oxazolyl group, isoxazolyl group, oxadiazolyl group, oxazolidinyl group, isoxazolidinyl group, morpholinyl group, thiazolyl group, dihydrothiazolyl group, isothiazolyl group, thiadiazolyl group, dihydrothiazinyl group, thiazolidinyl group, tetrahydrofuryl group, tetrahydropyranyl group, pyranyl group, tetrahydrothiofuryl group, tetrahydrothiopyranyl group, thienyl group and thiopyranyl group (more preferably, a saturated or unsaturated heteromonocyclic group having 1 to 2 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom and selected from the group consisting of a pyrrolidinyl group, a piperidyl group, a pyrazolyl group, a pyridyl group, a pyrimidinyl group, a pyrazinyl group, an isoxazolyl group, a thiazolyl group, a pyranyl group and a thienyl group; and more preferably, a saturated or unsaturated heteromonocyclic group having 1 to 2 nitrogen atoms selected from the group consisting of a pyrrolidinyl group, a piperidyl group, a pyrazolyl group, a pyridyl group, a pyrimidinyl group and a thiazolyl group; and\n\nwherein, on the heterocyclic group represented by R\n1\n, 1 to 5 (more preferably 1 to 3) groups selected from the group consisting of the groups (1) to (66) below may be present as a substituent:\n\n \n \n \n(1) a lower alkyl group,\n \n(2) a lower alkenyl group,\n \n(3) a halogen substituted lower alkyl group,\n \n(4) a lower alkoxy group,\n \n(5) a phenoxy group,\n \n(6) a lower alkylthio group,\n \n(7) a halogen substituted lower alkoxy group,\n \n(8) a hydroxy group,\n \n(9) a phenyl lower alkoxy group,\n \n(10) a hydroxy lower alkyl group,\n \n(11) a lower alkoxy lower alkyl group,\n \n(12) a halogen atom,\n \n(13) a cyano group,\n \n(14) a phenyl aryl group,\n \n(15) a nitro group,\n \n(16) an amino group,\n \n(17) an amino group having 1 to 2 groups selected from the group consisting of a lower alkyl group; a lower alkanoyl group, a lower alkoxycarbonyl group, a lower alkylsulfonyl group, a carbamoyl group, a lower alkyl carbamoyl group, an amino lower alkanoyl group, a lower alkanoylamino lower alkanoyl group and a lower alkoxycarbonylamino lower alkanoyl group as a substituent(s) (more preferably an N-lower alkylamino group, N,N-di lower alkylamino group, N-lower alkanoylamino group, N-lower alkoxycarbonylamino group, N-lower alkylsulfonylamino group, N-lower alkyl-N-lower alkanoylamino group, N-lower alkyl-N-lower alkoxycarbonylamino group, N-[carbamoyl]amino group, N-[N-lower alkylcarbamoyl]amino group, N-[N,N-di lower alkylcarbamoyl]amino group, N-[amino lower alkanoyl]amino group, N-[[N-lower alkanoylamino] lower alkanoyl]amino group, or N-[[N-lower alkoxycarbonylamino] lower alkanoyl]amino group),\n \n(18) a lower alkanoyl group,\n \n(19) a phenyl sulfonyl group that may have a lower alkyl group on the phenyl group (more preferably a lower alkylphenylsulfonyl group),\n \n(20) a carboxy group,\n \n(21) a lower alkoxycarbonyl group,\n \n(22) a carboxy lower alkyl group,\n \n(23) a lower alkoxycarbonyl lower alkyl group,\n \n(24) a lower alkanoylamino lower alkanoyl group,\n \n(25) a carboxy lower alkenyl group,\n \n(26) a lower alkoxycarbonyl lower alkenyl group,\n \n(27) a carbamoyl lower alkenyl group that may have as a substituent(s) 1 to 2 groups selected from the group consisting of a lower alkyl group and a lower alkyl group substituted with 1 to 3 halogen atoms (more preferably a carbamoyl lower alkenyl group, an N-lower alkylcarbamoyl lower alkenyl group, an N,N-di lower alkylcarbamoyl lower alkenyl group or N-[a lower alkyl substituted with 1 to 3 halogen atoms] carbamoyl lower alkenyl),\n \n(28) a carbamoyl group that may have 1 to 2 groups selected from the group consisting of the groups (i) to (lxxviii) below as a substituent(s):\n\n \n(i) a lower alkyl group,\n \n(ii) a lower alkoxy group,\n \n(iii) a hydroxy lower alkyl group,\n \n(iv) a lower alkoxy lower alkyl group,\n \n(v) an phenyloxy lower alkyl group,\n \n(vi) a halogen substituted lower alkyl group,\n \n(vii) an amino lower alkyl group that may have 1 to 2 groups selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a benzoyl group and a carbamoyl group (more preferably an N,N-di lower alkylamino lower alkyl group, an N-lower alkanoylamino lower alkyl group, an N-lower alkyl-N-lower alkanoylamino lower alkyl group, an N-lower alkyl-N-benzoylamino lower alkyl group, or an N-carbamoylamino lower alkyl group)\n \n(viii) a cyclo C3-C8 alkyl group that may have 1 to 3 groups (preferably 1 to 2 groups, and more preferably 1 group) selected from the group consisting of a lower alkyl group, a hydroxy group, a lower alkoxycarbonyl group and a phenyl lower alkoxy group as a substituent,\n \n(ix) a cyclo C3-C8 alkyl substituted lower alkyl group,\n \n(x) a lower alkenyl group,\n \n(xi) a lower alkyl group having 1 to 2 carbamoyl groups which may have 1 to 2 groups (preferably 1 group) selected from the group consisting of a lower alkyl group, a phenyl group that may have a single lower alkyl group and a phenyl group that may have a single lower alkoxy group as a substituent(s) (more preferably a carbamoyl lower alkyl group, a dicarbamoyl lower alkyl group, an N-lower alkylcarbamoyl lower alkyl group, an N,N-di lower alkylcarbamoyl lower alkyl group, an N-[lower alkylphenyl]carbamoyl lower alkyl group, or an N-[lower alkoxyphenyl]carbamoyl lower alkyl group),\n \n(xii) a lower alkyl group having 1 to 2 lower alkoxycarbonyl groups,\n \n(xiii) a furyl lower alkyl group (that may have 1 to 2 lower alkyl groups as a substituent(s) on the furyl group),\n \n(xiv) a tetrahydrofuryl lower alkyl group,\n \n(xv) a 1,3-dioxolanyl lower alkyl group,\n \n(xvi) a tetrahydropyranyl lower alkyl group,\n \n(xvii) a pyrrolyl lower alkyl group (that may have 1 to 2 lower alkyl groups as a substituent(s) on the pyrrolyl group),\n \n(xviii) a dihydropyrazolyl lower alkyl group that may have a single oxo group,\n \n(xix) a pyrazolyl lower alkyl group (that may have 1 to 3 lower alkyl groups as a substituent(s) on the pyrazolyl group),\n \n(xx) an imidazolyl lower alkyl group,\n \n(xxi) a pyridyl lower alkyl group,\n \n(xxii) a pyrazinyl lower alkyl group (that may have 1 to 3 (preferably 1) lower alkyl groups as a substituent on the pyrazinyl group),\n \n(xxiii) a pyrrolidinyl lower alkyl group (that may have 1 to 2 groups selected from the group consisting of an oxo group and a lower alkyl group as a substituent(s) on the pyrrolidinyl group),\n \n(xxiv) a piperidyl lower alkyl group (that may have 1 to 3 groups (preferably 1 group) selected from the group consisting of a benzoyl group and a lower alkanoyl group as a substituent(s) on the piperidyl group),\n \n(xxv) a piperazinyl lower alkyl group (that may have 1 to 3 (preferably 1) lower alkyl groups as a substituent(s) on the piperazinyl group),\n \n(xxvi) a morpholinyl lower alkyl group,\n \n(xxvii) a thienyl lower alkyl group (that may have 1 to 3 (preferably 1) lower alkyl group as a substituent(s) on the thienyl group),\n \n(xxviii) a thiazolyl lower alkyl group,\n \n(xxix) a dihydrobenzofuryl lower alkyl group,\n \n(xxx) a benzopyranyl lower alkyl group (that may have a single oxo group as a substituent on the benzopyranyl group),\n \n(xxxi) a benzimidazolyl lower alkyl group,\n \n(xxxii) an indolyl lower alkyl group that may have 1 to 3 (preferably 1) lower alkoxycarbonyl groups on the lower alkyl group),\n \n(xxxiii) an imidazolyl lower alkyl group that has 1 to 3 substituents (preferably 1 substituent) selected from the group consisting of a carbamoyl group and a lower alkoxycarbonyl group on the lower alkyl group,\n \n(xxxiv) a pyridyl group that may have 1 to 3 groups (preferably 1 group) selected from the group consisting of a lower alkyl group, a lower alkoxy group and a lower alkylthio lower alkyl group as a substituent(s),\n \n(xxxv) a pyrrolidinyl group that may have 1 to 3 groups (preferably 1 group) selected from the group consisting of a lower alkyl group, a lower alkoxycarbonyl group, a lower alkanoyl group and a benzoyl group as a substituent,\n \n(xxxvi) a piperidyl group that may have 1 to 3 groups (preferably 1 group) selected from the group consisting of a lower alkyl group, a lower alkoxycarbonyl group, a lower alkanoyl group and a benzoyl group that may have 1 to 3 groups (preferably 1 group) selected from the group consisting of a lower alkyl group and a halogen atom on the phenyl group,\n \n(xxxvii) a tetrahydrofuryl group that may have a single oxo group,\n \n(xxxviii) a hexahydroazepinyl group that may have a single oxo group,\n \n(xxxix) a pyrazolyl group that may have 1 to 3 groups (preferably 1 group) selected from the group consisting of a lower alkyl group, a phenyl group and a furyl group as a substituent,\n \n(xl) a thiazolyl group,\n \n(xli) a thiadiazolyl group that may have 1 to 3 (preferably 1) lower alkyl groups,\n \n(xlii) an isoxazolyl group that may have 1 to 3 (preferably 1 to 2) lower alkyl groups,\n \n(xliii) an indazolyl group,\n \n(xliv) an indolyl group,\n \n(xlv) a tetrahydrobenzothiazolyl group,\n \n(xlvi) a tetrahydroquinolyl group that may have 1 to 3 (preferably 1 to 2) groups selected from the group consisting of a lower alkyl group, a lower alkoxy group, a halogen atom and an oxo group as a substituent,\n \n(xlvii) a quinolyl group that may have 1 to 3 (preferably 1) lower alkyl groups,\n \n(xlviii) a benzodioxolyl lower alkyl group, (xlix) a phenyl group or naphthyl group that may have 1 to 3 groups as a substituent(s), selected from the group consisting of\n\na halogen atom; a lower alkyl group; a lower alkoxy group; a halogen substituted lower alkyl group; a halogen substituted lower alkoxy group; a lower alkenyl group; an amino group that may have 1 to 2 groups selected from the group consisting of a lower alkanoyl group, a lower alkyl sulfonyl group, a lower alkyl group and an aryl group; a sulfamoyl group; a lower alkylthio group; a lower alkanoyl group; a lower alkoxycarbonyl group; a pyrrolyl group; a lower alkynyl group; a cyano group; a nitro group; a phenyloxy group; a phenyl lower alkoxy group; a hydroxy group; a hydroxy lower alkyl group; a carbamoyl group that may have a group selected from the group consisting of a lower alkyl group and a phenyl group; a pyrazolyl group; a pyrrolidinyl group that may have a single oxo group; an oxazolyl group; an imidazolyl group that may have 1 to 3 (preferably 1 to 2) lower alkyl groups; a dihydrofuryl group that may have a single oxo group; a thiazolidinyl lower alkyl group that may have two oxo groups; an imidazolyl lower alkanoyl group and a piperidinylcarbonyl group,\n \n(l) a cyano lower alkyl group,\n \n(li) a dihydroquinolyl group that may have 1 to 3 (more preferably 1 to 2) groups selected from the group consisting of a lower alkyl group and an oxo group,\n \n(lii) a halogen substituted lower alkylamino group,\n \n(liii) a lower alkylthio lower alkyl group,\n \n(liv) an amidino group that may have 1 to 2 lower alkyl groups,\n \n(lv) an amidino lower alkyl group,\n \n(lvi) a lower alkenyloxy lower alkyl group,\n \n(lvii) a phenyl amino group that may have 1 to 3 substituents (more preferably 1 substituent) selected from the group consisting of a lower alkyl group, a lower alkoxy group, a halogen substituted lower alkyl group and a halogen substituted lower alkoxy group on the phenyl group,\n \n(lviii) a phenyl lower alkenyl group,\n \n(lix) a pyridylamino group that may have 1 to 3 (more preferably 1 to 2) lower alkyl groups (more preferably N-lower alkyl-N-[lower alkylpyridyl]amino group),\n \n(lx) a phenyl lower alkyl group (that may have 1 to 3 groups (more preferably 1 to 2 groups) selected from the group consisting of a halogen atom, a lower alkyl group, a halogen substituted lower alkyl group, a halogen substituted lower alkoxy group, a lower alkoxy group, a carbamoyl group and a lower alkoxycarbonyl group as a substituent on the phenyl group and/or the lower alkyl group),\n \n(lxi) a lower alkynyl group,\n \n(lxii) a phenyloxy lower alkyl group (that may have as a substituent(s) on the phenyl group 1 to 3 groups (preferably 1 group) selected from the group consisting of a lower alkoxy group, an N-lower alkoxy-N-lower alkylcarbamoyl group and an oxopyrrolidinyl group),\n \n(lxiii) an isoxazolidinyl group that may have a single oxo group,\n \n(lxiv) a dihydroindenyl group,\n \n(lxv) a phenyl lower alkoxy lower alkyl group,\n \n(lxvi) a tetrahydropyranyl group,\n \n(lxvii) an azetidinyl group that may have 1 to 3 groups (more preferably 1 group) selected from the group consisting of a lower alkanoyl group and a benzoyl group,\n \n(lxviii) an azetidinyl lower alkyl group that may have 1 to 3 groups (more preferably 1 group) selected from the group consisting of a lower alkanoyl group and a benzoyl group,\n \n(lxix) a tetrazolyl group,\n \n(lxx) an indolinyl group that may have a single oxo group,\n \n(lxxi) a triazolyl group that may have 1 to 3 groups (more preferably 1 to 2 groups) selected from the group consisting of a lower alkyl group and a lower alkylthio group,\n \n(lxxii) an imidazolyl group that may have 1 to 3 (more preferably 1) carbamoyl groups,\n \n(lxxiii) an oxazolyl group that may have 1 to 3 (more preferably 1) lower alkyl groups,\n \n(lxxiv) an isothiazolyl group that may have 1 to 3 (more preferably 1) lower alkyl groups,\n \n(lxxv) a benzimidazolyl group,\n \n(lxxvi) a dihydrobenzothiazolyl group that may have a single oxo group,\n \n(lxxvii) a thienyl group that may have 1 to 3 (more preferably 1) lower alkoxycarbonyl groups, and\n \n(lxxviii) an oxazolyl lower alkyl group that may have 1 to 3 (more preferably 1 to 2) lower alkyl groups\n \n \n \n(29) an amino lower alkyl group that may have 1 to 2 groups selected from the group consisting of a lower alkyl group, a halogen substituted lower alkyl group, a lower alkoxycarbonyl group, a lower alkanoyl group, a phenyl group, a phenyl lower alkyl group, a benzoyl group and an amino substituted alkyl group (that may have 1 to 2 (more preferably 2) lower alkyl groups as a substituent(s) on the amino group) on the amino group,\n \n(30) a lower alkyl group substituted with a single carbamoyl group that may have 1 to 2 groups selected from the group consisting of a lower alkyl group and a halogen substituted lower alkyl group,\n \n(31) a thiocarbamoyl group that may have 1 to 2 (more preferably 1) lower alkyl group,\n \n(32) a sulfamoyl group,\n \n(33) an oxazolidinyl group that may have a single oxo group (more preferably an oxazolidinyl group substituted with a single oxo group),\n \n(34) an imidazolidinyl group that may have 1 to 2 substituents selected from the group consisting of an oxo group and a lower alkyl group,\n \n(35) a pyrrolidinyl group that may have a single oxo group,\n \n(36) an imidazolyl group,\n \n(37) a triazolyl group,\n \n(38) an isoxazolyl group,\n \n(39) a piperidyl group that may have 1 to 3 (more preferably 1 to 2, and still more preferably 1) substituents selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkylphenylsulfonyl group, an oxo group, a hydroxy group, and amino group that may have 1 to 2 groups selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkoxycarbonyl group and lower alkanoylamino lower alkanoyl group (more preferably a piperidyl group that may have 1 to 3 (more preferably 1 to 2, and still more preferably 1) substituents selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkylphenylsulfonyl group, an oxo group, a hydroxy group, an amino group, an N-lower alkylamino group, an N,N-di lower alkylamino group, an N-lower alkanoylamino group, an N-lower alkyl-N-lower alkoxycarbonylamino group, an N-lower alkyl-N-lower alkanoylamino group, and an N-lower alkanoylamino lower alkanoylamino group),\n \n(40) a piperidylcarbonyl group that may have 1 to 3 (more preferably 1 to 2) substituents selected from the group consisting of a lower alkyl group, a hydroxy group, a hydroxy lower alkyl group, a lower alkanoyl group, a carboxy lower alkyl group, a lower alkyl carbamoyl lower alkyl group, a carbamoyl group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, an amino group (on which 1 to 2 groups selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkoxycarbonyl group and a benzoyl group may be present), a piperidyl group (on which 1 to 3 groups (more preferably 1 group) selected from the group consisting of a lower alkanoyl group, a lower alkoxycarbonyl group and a benzoyl group may be present), a piperazinyl group (on which 1 to 3 (more preferably 1 to 2) lower alkyl groups may be present as a substituent), a 1,4-dioxa-8-azaspiro[4.5]decyl group, a morpholinyl group, a hexahydro-1,4-diazepinyl group (on which a single lower alkyl group may be present as a substituent), pyridyl group, pyridyloxy group, pyridyl lower alkoxy group, tetrahydroquinolyl group (on which a single oxo group may be present), benzodioxolyl group, phenyl lower alkoxy group (that may have 1 to 3 groups (more preferably 1 to 2 groups) selected from the group consisting of a halogen atom, a lower alkyl group, a lower alkoxy group and a halogen substituted lower alkoxy group on the phenyl group), phenyl group (on which 1 to 3 groups (preferably 1 to 2 groups) selected from the group consisting of a halogen atom, a lower alkoxy group and a hydroxy group may be present), a phenyloxy group (that may have on the phenyl group 1 to 3 groups (preferably 1 to 2 groups) selected from the group consisting of a cyano group, a halogen atom, a lower alkyl group, a lower alkoxy group and a halogen substituted lower alkyl group), a phenyl lower alkyl group (that may have on the phenyl group 1 to 3 groups (more preferably 1 to 2 groups) selected from the group consisting of a halogen atom, a lower alkyl group, a lower alkoxy group and a halogen substituted lower alkyl group), and a benzoyl group (that may have on the phenyl group 1 to 3 groups (more preferably 1 to 2 groups) selected from the group consisting of a halogen atom and a lower alkoxy group),\n \n(41) a pyrrolidinylcarbonyl group that may have 1 to 3 (more preferably 1) groups as a substituent, selected from the group consisting of a hydroxy lower alkyl group, a carbamoyl group, a hydroxy group, an amino group (that may have on the amino group 1 to 2 groups selected from the group consisting of a lower alkyl group, a lower alkanoyl group and a benzoyl group), morpholinyl lower alkyl group, a pyrrolidinyl lower alkyl group, a piperidyl lower alkyl group, a piperazinyl lower alkyl group (that may have a single lower alkyl group as a substituent on the piperazinyl group), an amino lower alkyl group (that may have 1 to 2 lower alkyl groups as a substituent on the amino group), phenyloxy group (that may have 1 to 3 (more preferably 1) halogen substituted lower alkoxy groups on the phenyl group), a phenyloxy lower alkyl group (that may have 1 to 3 (more preferably 1) halogen substituted lower alkoxy groups on the phenyl group) and a tetrahydroquinolyl group (on which an oxo group may be present),\n \n(42) a piperazinylcarbonyl group that may have 1 to 3 groups (more preferably 1 to 2 groups), as a substituent, selected from the group consisting of a lower alkyl group, a cyclo C3-C8 alkyl group, a lower alkanoyl group, a hydroxy lower alkyl group, a lower alkoxy lower alkyl group, a lower alkoxycarbonyl group, an amino lower alkyl group (that may have 1 to 2 lower alkyl groups as a substituent on the amino group), piperidyl lower alkyl group (that may have 1 to 2 (more preferably 1) lower alkyl groups as a substituent(s) on the piperidyl group), a morpholinyl lower alkyl group, a pyrrolidinyl lower alkyl group, a 1,3-dioxolanyl lower alkyl group, a tetrahydrofuryl lower alkyl group, a pyridyl lower alkyl group (that may have 1 to 2 (more preferably 1) phenyl groups as a substituent(s) on the lower alkyl group), an imidazolyl lower alkyl group, a furyl lower alkyl group, a pyrrolidinylcarbonyl lower alkyl group, a piperidyl group that may have 1 to 2 (more preferably 1) lower alkyl groups as a substituent(s), a pyridyl group (that may have on the pyridyl group 1 to 3 groups (more preferably 1 group) selected from the group consisting of a lower alkyl group, a cyano group and a halogen substituted lower alkyl group as a substituent), a thieno[2,3-b]pyridyl group, a phenyl group (on which 1 to 3 groups (more preferably 1 group) selected from the group consisting of a halogen atom and a lower alkyl group may be present), a benzoyl group, a furyl carbonyl group, a phenyl lower alkoxycarbonyl group and an oxo group,\n \n(43) a hexahydroazepinylcarbonyl group,\n \n(44) a hexahydro-1,4-diazepinylcarbonyl group that may have 1 to 3 substituents (more preferably 1 substituent) selected from the group consisting of a lower alkyl group and a pyridyl group,\n \n(45) a dihydropyrrolylcarbonyl group that may have 1 to 3 (more preferably 1 to 2) lower alkyl groups,\n \n(46) a thiomorpholinylcarbonyl group,\n \n(47) a morpholinylcarbonyl group that may have 1 to 3 groups (more preferably 1 group) selected from the group consisting of a lower alkyl group, a piperidyl lower alkyl group and a phenyl group,\n \n(48) a thiazolidinyl carbonyl group that may have 1 to 3 (more preferably 1) phenyl groups that may have 1 to 3 groups (more preferably 1 group) selected from the group consisting of a lower alkoxy group and a cyano group,\n \n(49) an azabicyclo[3.2.2]nonylcarbonyl group,\n \n(50) an 8-azabicyclo[3.2.1]octylcarbonyl group that may have 1 to 3 (more preferably 1) halogen substituted or unsubstituted phenyloxy groups,\n \n(51) an indolinylcarbonyl group,\n \n(52) a tetrahydroquinolylcarbonyl group,\n \n(53) a tetrahydropyrido[3.4-b]indolylcarbonyl group,\n \n(54) a morpholinyl lower alkyl group,\n \n(55) a piperazinyl lower alkyl group that may have 1 to 3 (more preferably 1) lower alkyl groups on the piperazinyl group,\n \n(56) a morpholinylcarbonyl lower alkyl group,\n \n(57) a piperazinylcarbonyl lower alkyl group that may have 1 to 3 (more preferably 1) lower alkyl groups on the piperazinyl group,\n \n(58) an oxo group,\n \n(59) an amino lower alkoxy group (that may have 1 to 2 (more preferably 2) lower alkyl groups on the amino group),\n \n(60) a lower alkoxy lower alkoxy group,\n \n(61) a piperazinyl group that may have 1 to 3 groups (more preferably 1 to 2 groups) selected from the group consisting of an oxo group, a lower alkyl group, a lower alkanoyl group and a lower alkoxycarbonyl group (more preferably, a piperazinyl group substituted with a single oxo group, a piperazinyl group substituted with a single lower alkyl group, a piperazinyl group substituted with a single lower alkanoyl group, a piperazinyl group substituted with a single oxo group and a single lower alkanoyl group, and a piperazinyl group substituted with a single oxo group and a single lower alkoxy carbonyl group),\n \n(62) a morpholinyl group,\n \n(63) a 1,3,8-triazaspiro[4.5]decanylcarbonyl group that may have 1 to 3 groups (more preferably 1 to 2 groups) selected from the group consisting of an oxo group and a phenyl group,\n \n(64) a tetrahydropyridylcarbonyl group that may have 1 to 3 (more preferably 1) pyridyl groups,\n \n(65) an imidazolidinylcarbonyl group that may have one thioxo group, and\n \n(66) a 1,4-dioxa-8-azaspiro[4.5]decanyl group.\n \n\n\n \n \n \nIn the general formula (1), R\n1\n is preferably a pyrrolidinyl group, piperidyl group, pyrazolyl group, pyridyl group, pyrimidinyl group, or thiazolyl group. The ring of each groups is preferably substituted with 1 to 3 groups selected from the group consisting of ;\n\n \n \n \n(1) a lower alkyl group,\n \n(4) a lower alkoxy group,\n \n(10) a hydroxy lower alkyl group,\n \n(17) an amino group having 1 to 2 groups selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkoxy carbonyl group, a lower alkyl sulfonyl group, a carbamoyl group, a lower alkyl carbamoyl group, an amino lower alkanoyl group, a lower alkanoylamino lower alkanoyl group and a lower alkoxycarbonylamino lower alkanoyl group as a substituent(s),\n \n(21) a lower alkoxycarbonyl group,\n \n(28) a carbamoyl group that may have 1 to 2 substituents selected from the group consisting of the groups (i), (ii), (iv), (xii) and (xxi) below:\n\n \n(i) a lower alkyl group,\n \n(ii) a lower alkoxy group,\n \n(iv) a lower alkoxy lower alkyl group,\n \n(xii) a lower alkyl group having 1 to 2 lower alkylcarbonyl groups,\n \n(xxi) a pyridyl lower alkyl group,\n \n \n \n(29) an amino lower alkyl group that may have 1 to 2 groups selected from the group consisting of a lower alkyl group, a halogen substituted lower alkyl group, a lower alkoxycarbonyl group, a lower alkanoyl group, a phenyl group, a phenyl lower alkyl group, a benzoyl group and an amino substituted alkyl group (that may have 1 to 2 lower alkyl groups as a substituent(s) on the amino group) on the amino group,\n \n(30) a lower alkyl group substituted with a single carbamoyl group that may have 1 to 2 groups selected from the group consisting of a lower alkyl group and a halogen substituted lower alkyl group,\n \n(33) an oxazolidinyl group that may have a single oxo group,\n \n(34) an imidazolidinyl group that may have 1 to 2 substituents selected from the group consisting of an oxo group and a lower alkyl group,\n \n(35) a pyrrolidinyl group that may have a single oxo group,\n \n(36) an imidazolyl group,\n \n(39) a piperidyl group that may have a single substituent selected from the group consisting of a lower alkyl group, a lower alkanoyl group, a lower alkyl phenylsulfonyl group, an oxo group, a hydroxy group, an amino group, an N-lower alkylamino group, an N-N di-lower alkyl amino group, an N-lower alkanoylamino group, an N-lower alkyl-N-lower alkoxycarbonylamino group, an N-lower alkyl-N-lower alkanoylamino group, and an N-lower alkanoylamino lower alkanoylamino group,\n \n(61) a piperazinyl group that may have 1 to 2 groups selected from the group consisting of an oxo group, a lower alkyl group, a lower alkanoyl group and a lower alkoxy carbonyl group, and\n \n(62) a morpholinyl group.\n \n\n\nEXAMPLE\n\n\n \n \n \nHereinbelow, the present invention.will be further made clear with reference to Reference Examples, Examples and Pharmacological Experimental Examples and Preparation Examples.\n\n\n \nReference Example 1\n\n\nSynthesis of 1-benzo[b]thiophen-4-yl-piperazine hydrochloride\n\n\n \n \n \nA mixture consisting of 14.4 g of 4-bromobenzo[b]thiophene, 29.8 g of piperazine anhydride, 9.3 g of sodium t-butoxide, 0.65 g of (R)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP), 0.63 g of tris (dibenzylideneacetone) dipalladium (0) and 250 ml of toluene was refluxed with heating for one hour under a nitrogen atmosphere. Water was poured to the reaction solution, which was then extracted with ethyl acetate, washed with water and dried over magnesium sulfate. The solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (dichloromethane: methanol: 25% ammonia water = 100:10:1), to obtain 9.5 g of 1-benzo[b]thiophen-4-yl-piperazine in the form of yellow oil.\n\n\n \n \n \n \nThen, 3.7 ml of concentrated hydrochloric acid was added to a methanol solution of 9.5 g of 1-benzo[b]thiophen-4-yl-piperazine, and the solvent was evaporated under reduced pressure. Ethyl acetate was added to the obtained residue and precipitated crystals were obtained by filtration. Recrystallization was performed from methanol to obtain 1-benzo[b]thiophen-4-yl-piperazine hydrochloride as colorless needle-like crystals.\n\nMelting point 276-280°C\n\n\n1\nH-NMR (DMSO-d\n6\n) δppm : 3.25-3.35 (8H, m), 6.94 (1H, d, J=7.6Hz), 7.30 (1H, dd, J=7.8Hz, J=7.8Hz), 7.51 (1H, d, J=5.5Hz), 7.68 (1H, d, J=8.1Hz), 7.73 (1H, d, J=5.5Hz), 9.35 (2H, brs).\n\n\n \nReference Example 2\n\n\nSynthesis of tert-butyl 4-benzo[b]thiophen-4-yl-3-methylpiperazin-1-carboxylate\n\n\n \n \n \nThe titled compound was obtained using tert-butyl 3-methylpiperazin-1-carboxylate and 4-bromobenzo[b]thiophene in the same manner as in Reference Example 1.\n\n\n1\nH -NMR (CDCl\n3\n) δppm: 1.85-1.95 (3H, m , 1.50 (9H, s , 2.8-2.9 (1H, m), 3.15-3.35 (2H, m), 3.4-3.5 (1H, m), 3.5-3.65 (1H, m), 3.65-3.7 (1H, m), 3.7-3.9 (1H, m), 6.98 (1H, d, J = 7.5Hz), 7.29 (1H, dd, J = 8Hz, J=8Hz), 7.38 (1H, d, J = 5.5Hz), 7.61 (1H, d, J = 8Hz).\n\n\n \nReference Example 3\n\n\nSynthesis of 1-benzo[b]thiophen-4-yl-2-methylpiperazine dihydrochloride\n\n\n \n \n \nTrifluoroacetic acid (6 ml) was added to a solution of 1.22 g (3.7 mmol) of tert-butyl 4-benzo[b]thiophen-4-yl-3-methylpiperazin-1-carboxylate in a dichloromethane solution (12 ml) and the mixture was stirred at room temperature for one hour. The reaction mixture was concentrated under reduced pressure, and a 5% aqueous potassium carbonate solution was added to the residue and the resulting mixture was extracted with dichloromethane. The extraction solution with dichloromethane was dried over magnesium sulfate and thereafter concentrated under reduced pressure. To the residue obtained, concentrated hydrochloric acid (0.6 ml) and methanol (10 ml) were added and the resulting mixture was concentrated under reduced pressure. The obtained residue was subjected to recrystallization from acetonitrile to obtain 1-benzo[b]thiophen-4-yl-2-methylpiperazine dihydrochloride (0.98 g) as light brown powder.\n\n\n1\nH -NMR (DMSQ-d\n6\n) δppm: 0.92 (3H, d, J = 6.5Hz), 2.8-3.6 (6H, m), 3.6-4.0 (1H, m), 5.3-6.8 (1H, m), 7.20 (1H, br), 7.38 (1H, dd, J = 8Hz; J=8Hz), 7.5-8.0 (3H, m), 9.4-10.1 (2H, m).\n\n\n \nReference Example 4\n\n\nSynthesis of 1-benzo[b]thiophen-4-yl-3-methylpiperazine dihydrochloride\n\n\n \n \n \nThe titled compound was obtained using 2-methylpiperazine and 4-bromobenzo[b]thiophene in the same manner as in Reference Example 1.\n\n\n1\nH-NMR (DMSO-d\n6\n) δppm: 1.34 (3H, d, J = 6.5Hz), 2.85-2.95 (1H, m), 3.05-3.15 (1H, m), 3.2-3.6 (6H, m), 6.97 (1H, d, J = 7.5Hz), 7.31 (1H, dd, J = 8Hz, J = 8Hz), 7.54 (1H, d, J = 5.5Hz), 7.69 (1H, d, J = 8Hz), 7.75 (1H, d, J = 5.5Hz), 9.2-9.3 (1H, m), 9.64 (1H, br).\n\n\n \nReference Example 5\n\n\nSynthesis of ethyl 3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propionate\n\n\n \n \n \n5.05 g (19.8 mmol) of 1-benzo[b]thiophen-4-yl-piperazine hydrochloride was added to an aqueous solution of sodium hydroxide, and the mixture was extracted with dichloromethane. The extraction solution was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was dissolved in 50 ml of ethanol and ethyl acrylate (2.44 ml, 21.8 mmol) was added thereto, and then the reaction mixture was refluxed with heating for 4 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. Diisopropyl ether was added to the residue and insoluble matter precipitated was obtained by filtration, washed with diisopropyl ether, and dried to obtain ethyl 3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propionate (5.26 g) as white powder.\n\n\n1\nH -NMR (CDCl\n3\n) δppm: 1.28 (3H, t, J=7.0Hz), 2.50-2.63 (2H, m), 2.67-2.87 (6H, m), 3.11-3.24 (4H, m), 4.17 (2H, q, J=7.0Hz), 6.89 (1H, d, J=7.8Hz), 7.27 (1H, t, J=7.8Hz), 7.37-7.42 (2H, m), 7.55 (1H, d, J=7.8Hz).\n\n\n \nReference Example 6\n\n\nSynthesis of 3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propan-1-ol\n\n\n \n \n \nLithium aluminum hydride (1.18 g, 24.8 mmol) was added to a solution of 5.26 g (16.5 mmol) of ethyl 3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propionate in a tetrahydrofuran (THF) solution (55 ml) under ice cooling, and the mixture was stirred at room temperature for 4 hours. To the reaction solution, water (1.2 ml), 15 % aqueous sodium hydroxide solution (1.2 ml), and water (3.6 ml) were added in this order and the mixture was stirred at room temperature. Insoluble matter was removed by filtration, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 3:2 → ethyl acetate) and concentrated to dryness under reduced pressure to obtain 3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propan-1-ol (0.23 g) as white powder.\n\n\n1\nH -NMR (CDCl\n3\n) δppm: 1.75-1.85 (2H, m), 2.74 (2H, t, J=5.8 Hz), 2.75-2.85 (4H, m), 3.15-3.25 (4H, m), 3.85 (2H, t, J=5.3 Hz), 5.19 (1H, brs), 6.88 (1H, d, J=7.6 Hz), 7.27 (1H, dd, J=7.9 Hz, J=7.8 Hz), 7.39 (2H, s), 7.56 (1H, d, J=8.0 Hz).\n\n\n \nReference Example 7\n\n\nSynthesis of 4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl acetate\n\n\n \n \n \n1.0 g (3.9 mmol) of 1-benzo[b]thiophen-4-yl-piperazine hydrochloride was suspended in 20 ml of dimethylformamide (DMF), and potassium carbonate (1.3 g, 9.4 mmol) and 4-bromobutyl acetate (0.7 ml, 4.8 mmol) were added thereto. The reaction mixture was stirred at 80°C for 6 hours, cooled to room temperature, and water was added thereto, and extracted with ethyl acetate. The organic phase was washed with water, dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (dichloromethane: methanol = 30:1), and concentrated to dryness under reduced pressure to obtain 4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl acetate (0.72 g) as light yellow oil.\n\n\n1\nH -NMR (CDCl\n3\n) δppm: 1.60-1.73 (4H, m), 2.07 (3H, s), 2.47 (2H, t, J=7.2Hz), 2.60-2.72 (4H, m), 3.17-3.22 (4H, m), 4.11 (2H, t, J=6.3Hz), 6.90 (1H, d, J=7.6Hz), 7.27 (1H, dd, J=7.6Hz, J=8.0Hz), 7.37-7.42 (2H, m), 7.55 (1H, d, J=8.0Hz).\n\n\n \nReference Example 8\n\n\nSynthesis of 4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butan-1-ol\n\n\n \n \n \nPotassium carbonate (3.87 g, 28 mmol) was added to a solution of 7.76 g (23.3 mmol) of 4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butyl acetate in 90% methanol solution (150 ml). The solution mixture was stirred at room temperature for 2 hours. Water was added to the reaction solution, which was then extracted with dichloromethane. The extraction solution was dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 2:1 → 1:1), and concentrated under reduced pressure to obtain 4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butan-1-ol (6.65 g) as colorless oil. \n1\nH -NMR (CDCl\n3\n) δppm : 1.60-1.74 (4H, m), 2.50-2.55 (2H, m), 2.70-2.80 (4H, m), 3.20-3.30 (4H, m), 3.60-3.63 (2H, m), 6.2 (1H, brs), 6.90 (1H, d, J=7.6Hz), 7.27 (1H, dd, J=7.6Hz, J=8.0Hz), 7.39 (1H, s), 7.56 (1H, d, J=8.0Hz).\n\n\n \nReference Example 9\n\n\nSynthesis of 1-benzo[b]thiophen-4-yl-4-(3-chloropropyl)piperazine\n\n\n \n \n \n3.56 g (12.9 mmol) of 3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propan-1-ol was suspended in 30 ml of dichloromethane, and carbon tetrachloride (30 ml) and triphenyl phosphine (4.06 g, 15.5 mmol) were added thereto. The mixture was refluxed with heating for 3 hours. The reaction solution was cooled to room temperature, then methanol and dichloromethane were added thereto to homogenize the mixture. Silica gel (30 g) was added to the solution, and the solvent was evaporated under reduced pressure. The obtained residue was loaded on silica gel column (300 g) and extracted with a solvent mixture of n-hexane : ethyl acetate = 2:1. The extraction solution was concentrated under reduced pressure to obtain 1-benzo[b]thiophen-4-yl-4-(3-chloropropyl)piperazine (2.36 g) as colorless oil.\n\n\n1\nH -NMR (CDCl\n3\n) δppm: 1.95-2.10 (2H, m), 2.60 (2H, t, J=7.2 Hz), 2.65-2.75 (4H, m), 3.15-3.25 (4H, m), 3.65 (2H, t, J=6.6 Hz), 6.89 (1H, dd, J=7.6 Hz, J=0.7 Hz), 7.27 (1H, dd, J=7.9 Hz, J=7.8 Hz), 7.38 (1H, d, J=5.6 Hz), 7.41 (1H, d, J=5.7 Hz), 7.55 (1H, d, J=8.0 Hz).\n\n\n \nReference Example 10\n\n\nSynthesis of methyl 4-hydroxythiophene-2-carboxylate\n\n\n \n \n \nThionyl chloride (1.6 ml) was added dropwise to a methanol solution (20 ml) of 4-hydroxythiophene-2-carboxylic acid (1.1 g, 7.6 mmol) under ice cooling. The solution mixture was refluxed with heating for 5 hours. The reaction solution was cooled to room temperature, poured into ice water and extracted with ethyl acetate. The extraction solution with ethyl acetate was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 4:1) and concentrated/dried under reduced pressure to obtain methyl 4-hydroxythiophene-2-carboxylate (0.7 g) as white powder. \n1\nH-NMR (CDCl\n3\n) δppm: 3.90 (3H, s), 5.50-6.60 (1H, br), 6.64 (1H, d, J=1.9 Hz), 7.43 (1H, d, J=1.8 Hz).\n\n\n \nReference Example 11\n\n\nSynthesis of ethyl 6-hydroxypyrimidine-4-carboxylate\n\n\n \n \n \nThe titled compound was obtained using 6-hydroxypyrimidine-4-carboxylic acid in the same manner as in Reference Example 10.\n\n\n1\nH-NMR (CDCl\n3\n) δppm: 1.29 (3H, t, J=7.0Hz), 4.29 (2H, q, J=7.0Hz), 6.87 (1H, d, J=1.0Hz), 8.27 (1H, d, J=1.0Hz), 10.54 (1H, br).\n\n\n \nReference Example 12\n\n\nSynthesis of methyl 5-hydroxy-1-methyl-1H-pyrazole-3-carboxylate\n\n\n \n \n \nA diethyl ether solution (35 ml) of dimethyl acetylenedicarboxylate (5.0 g, 35 mmol) was cooled with a freezing medium (salt & ice). To this solution, a diethyl ether solution (15 ml) of methyl hydrazine (0.63 ml, 35 mmol) was added dropwise while maintaining the temperature at 0°C or less. After completion of dropwise addition, the solution was stirred at 0°C for one hour. The insoluble matter precipitated was obtained by filtration and washed with diethyl ether. The filter cake was heated to 130°C for 30 minutes and cooled to room temperature. Methanol was added to the cake, which was concentrated under reduced pressure. Ethyl acetate was added to the obtained residue and the residue was concentrated under reduced pressure. Ethyl acetate was added to the residue and the insoluble matter precipitated was obtained by filtration, washed with ethyl acetate, and dried to obtain methyl 5-hydroxy-1-methyl-1H-pyrazole-3-carboxylate (3.26 g) as light yellow powder.\n\n\n1\nH-NMR (DMSO-d\n6\n) δppm: 3.58 (3H, s), 3.73 (3H, s), 5.77 (1H, s), 11.41 (1H, br).\n\n\n \nReference Example 13\n\n\nSynthesis of 6-chloro-N-(2,2,2-trifluoroethyl)nicotine amide\n\n\n \n \n \nTriethylamine (1.03 ml, 7.4 mmol) and isobutyl chloroformate (0.76 ml, 5.5 mmol) were added to an acetonitrile solution (12 ml) of 6-chloronicotinic acid (0.58 g, 3.6 mmol) under ice cooling and the mixture was stirred at 0°C for 30 minutes. To the solution mixture, 2,2,2-trifluoroethyl amine (0.88 ml, 11.2 mmol) was added and the mixture was stirred at room temperature for 10 minutes. Water was added to the reaction solution, which was then extracted with ethyl acetate. The extraction solution with ethyl acetate was dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 5:1 → 1:1). The purified product was concentrated under reduced pressure and diisopropyl ether and n-hexane were added. The insoluble matter precipitated was obtained by filtration and dried to obtain 6-chloro-N-(2,2,2-trifluoroethyl)nicotine amide (0.58 g) as light yellow powder.\n\n\n1\nH-NMR (CDCl\n3\n) δppm: 4.15 (2H, dq, J=6.5Hz, 9.0Hz), 6.35 (1H, br), 7.46 (1H, dd, J=0.7Hz, J=8.5Hz), 8.11 (1H, dd, J=2.5Hz, J=8.5Hz), 8.77 (1H, dd, J=0.7Hz, J=2.5Hz).\n\n\n \nReference Example 14\n\n\nSynthesis of N-(2,2,2-trifluoroethyl)-4-chloropyridine-2-carboxamide\n\n\n \n \n \n1-hydroxybenzotriazole (0.53 g, 3.5 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (WSC) (0.67 g, 3.5 mmol) and 2,2,2-trifluoroethyl amine (0.51 ml. 6.35 mmol) were added to a dichloromethane solution (5 ml) of 4-chloropyridine-2-carboxylic acid (0.5 g, 3.17 mmol) and the mixture was stirred at room temperature for one hour. Water was added to the reaction solution, which was then extracted with ethyl acetate. The extraction solution with ethyl acetate was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 11:1 → 5:1). The purified product was concentrated to dryness under reduced pressure to obtain N-(2,2,2-trifluoroethyl)-4-chloropyridine-2-carboxamide (435 mg) as white powder.\n\n\n1\nH-NMR (CDCl\n3\n) δppm: 4.13 (2H, dq, J=6.8Hz, 9.0Hz), 7.49 (1H, dd, J=2.1Hz, J=5.3Hz), 8.22 (1H, dd, J=0.4Hz, J=2.1Hz), 8.30 (1H, br), 8.49 (1H, dd, J=0.4Hz, J=5.3Hz).\n\n\n \nReference Example 15\n\n\nSynthesis of 2-chlorothiazole-4-carboxamide\n\n\n \n \n \n1-hydroxybenzotriazole (0.56 g, 3.7 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (WSC) (0.7 g, 3.7 mmol) and ammonia water (28%, 0.5 ml)) were added to a dichloromethane solution (10 ml) of 2-chlorothiazole-4-carboxylic acid (0.5 g, 3.06 mmol) and the mixture was stirred at room temperature for 46 hours. Water was added to the reaction solution, which was then extracted with ethyl acetate. The extraction solution with ethyl acetate was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 3:5 → ethyl acetate). The purified product was concentrated to dryness under reduced pressure to obtain 2-chlorothiazole-4-carboxamide (475 mg) as white powder.\n\n\n1\nH-NMR (CDCl\n3\n) δppm: 5.70 (1H, br), 7.01 (1H, br), 8.06 (1H, s).\n\n\n \nReference Example 16\n\n\nSynthesis of N-methyl-2-chlorothiazole-5-carboxamide\n\n\n \n \n \nThe titled compound was obtained using 2-chlorothiazole-5-carboxylic acid in the same manner as in Reference Example 13.\n\n\n1\nH-NMR (CDCl\n3\n) δppm: 3.00 (3H, d, J=4.9Hz), 5.92 (1H, br), 7.84(1H, br).\n\n\n \nReference Example 17\n\n\nSynthesis of 6-methoxy-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one\n\n\n \n \n \n5% palladium carbon (1.5 g) were added to an ethanol solution (250 ml) of ethyl 2-(4-methoxy-2-nitrophenoxy)-2-methylpropionate (14.6 g, 51.6 mmol) to perform catalytic reduction at room temperature. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure. Water was added to the obtained residue, which was then extracted with ethyl acetate. The extraction solution was dried over magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 9:1). The purified product was concentrated to dryness under reduced pressure to obtain 6-methoxy-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one (7.0 g) as white powder.\n\n\n1\nH-NMR (CDCl\n3\n) δppm : 1.53 (6H, s), 3.78 (3H, s), 6.40 (1H, d, J=2.8Hz), 6.52 (1H, dd, J=2.8Hz, J=8.8Hz), 6.88 (1H, d, J=8.7Hz), 8.66 (1H, brs).\n\n\n \nReference Example 18\n\n\nSynthesis of 6-hydroxy-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one\n\n\n \n \n \nA dichloromethane solution (36 ml) of 2M boron tribromide was added dropwise to a dichloromethane solution of 6-methoxy-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one (5.0 g, 26 mmol) under ice cooling and the mixture was stirred overnight. Water was added to the reaction solution to decompose the reagents excessively present. The reaction solution was washed with water, dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 2:1). The purified product was concentrated to dryness under reduced pressure to obtain 6-hydroxy-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one (4.02 g) as white powder.\n\n\n1\nH-NMR (DMSO-d\n6\n) δppm : 1.34 (6H, s), 6.25-6.40 (2H, m), 6.70 (1H, d, J=8.5 Hz), 9.09 (1H, s), 10.41 (1H, brs).\n\n\n \nReference Example 19\n\n\nSynthesis of 6-hydroxy-2-methyl-4H-benzo[1,4]oxazin-3-one\n\n\n \n \n \nThe titled compound was obtained using 6-methoxy-2-methyl-4H-benzo[1,4]oxazin-3-one in the same manner as in Reference Example 18.\n\nWhite powder\n\n\n1\nH-NMR (DMSO-d\n6\n) δppm: 1.34 (3H, d, J=6.8 Hz), 4.46 (1H, q, J=6.8 Hz), 6.23-6.27 (1H, m), 6.33 (1H, d, J=2.7 Hz), 6.70 (1H, d, J=8.6 Hz), 9.11 (1H, s), 10.44 (1H, brs).\n\n\n \nReference Example 20\n\n\nSynthesis of 4-(4-methoxyphenyl)-1-(toluene-4-sulfonyl)piperidine\n\n\n \n \n \np-Toluenesulfonyl chloride (4.39 g, 23 mmol) was added to a pyridine solution (30 ml) of 4-(4-methoxyphenyl)piperidine (4.0 g, 21 mmol) and the mixture was stirred at room temperature overnight. Water was added to the solution mixture, which was then extracted with ethyl acetate. The organic phase was washed with hydrochloric acid and water, dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 1:1). The purified product was concentrated to dryness under reduced pressure to obtain 4-(4-methoxyphenyl)-1-(toluene-4-sulfonyl)piperidine (4.8 g) as white powder. \n1\nH-NMR (CDCl\n3\n) δppm : 1.60-1.90 (4H, m), 2.30-2.40 (3H, m), 2.46 (3H, s), 3.78 (3H, s), 3.90-3.95 (2H, m), 6.84 (2H, dd, J=1.9, J=6.8 Hz), 7.07 (2H, dd, J=1.9, J=6.8 Hz), 7.35 (2H, d, J=8.2 Hz), 7.68 (2H, d, J=8.2 Hz).\n\n\n \nReference Example 21\n\n\nSynthesis of 4-(4-hydroxyphenyl)-1-(toluene-4-sulfonyl)piperidine\n\n\n \n \n \nThe titled compound was obtained using 4-(4-methoxyphenyl)-1-(toluene-4-sulfonyl)piperidine in the same manner as in Reference Example 18.\n\nBrown powder\n\n\n1\nH-NMR (CDCl\n3\n) δppm : 1.60-1.90 (4H, m), 2.30-2.50 (3H, m), 2.45 (3H, s), 3.90-3.95 (2H, m), 6.67 (1H, brs), 6.80 (2H, dd, J=1.9, J=6.8 Hz), 7.02 (2H, dd, J=1.8, J=6.9 Hz), 7.35 (2H, d, J=8.1 Hz), 7.68 (2H, d, J=8.1 Hz).\n\n\n \nReference Example 22\n\n\nSynthesis of 4-bromo-2-hydroxymethyl-6-methoxyphenol\n\n\n \n \n \nSodium borohydride (0.28 g, 6.9 mmol) was added to a THF solution (30 ml) of 5-bromo-2-hydroxy-3-methoxybenzaldehyde (3.2 g 13.8 mmol) under ice cooling and the mixture was stirred at 0°C for 2 hours. Acetic acid was added to the reaction solution to set pH at 3. 10% hydrochloric acid was added to the reaction mixture, which was then extracted with ethyl acetate. The extracted material was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 5:1 → 1:1) and concentrated to dryness under reduced pressure to obtain 4-bromo-2-hydroxymethyl-6-methoxyphenol (3.23 g) as light yellow oil.\n\n\n1\nH-NMR (CDCl\n3\n) δppm: 3.88 (3H, s), 4.71 (2H, s), 6.94 (1H, d, J=2.0Hz), 7.03 (1H, d, J=2.0Hz).\n\n\n \nReference Example 23\n\n\nSynthesis of 5-bromo-3-methoxy-2-methoxymethoxybenzaldehyde\n\n\n \n \n \nEthyldiisopropylamine (3.01 ml, 17.1 mmol) and methoxymethylchloride (1.5 ml, 15.7 mmol) were added to a dichloromethane solution (30 ml) of 5-bromo-2-hydroxy-3-methoxybenzaldehyde (3.3 g, 14.3 mmol) under ice cooling, and the mixture was stirred at room temperature for 2 hours. The reaction solution was washed with water, dried over magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 3:1 → 11:9). The purified product was concentrated to dryness under reduced pressure to obtain 5-bromo-3-methoxy-2-methoxymethoxybenzaldehyde (4.2 g) as light yellow solid.\n\n\n1\nH-NMR (CDCl\n3\n) δppm: 3.56 (3H, s), 3.89 (3H, s), 5.21 (2H, s), 7.23 (1H, d, J=2.5Hz), 7.56 (1H, d, J=2.5Hz), 10.39 (1H, s).\n\n\n \nReference Example 24\n\n\nSynthesis of 3-methoxy-2-methoxymethoxy-5-(2-oxooxazolidin-3-yl)benzaldehyde\n\n\n \n \n \n2-oxazolidinone (0.38 g, 4.36 mmol), dipalladium tris(dibenzylideneacetone) (0.17 g, 0.18 mmol), 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene (XANTPHOS)(0.32 g, 0.55 mmol) and cesium carbonate (1.66 g, 5.1 mmol) were added to a dioxane solution (20 ml) of 5-bromo-3-methoxy-2-methoxymethoxybenzaldehyde (1.0 g, 3.6 mmol) and the mixture was stirred at 100 °C for 24 hours under an argon atmosphere. The reaction solution was cooled to room temperature and ethyl acetate was added thereto. The mixture was filtrated by cerite. The filtrate was washed with water, dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 4:1 → 1:1). The purified product was concentrated under reduced pressure. Ethyl acetate and diisopropyl ether were added to the residue. The insoluble matter thus purified was obtained by filtration and dried to obtain 3-methoxy-2-methoxymethoxy-5-(2-oxo-oxazolidin-3-yl)benzaldehyde (0.5 g).as white powder.\n\n\n1\nH-NMR (CDCl\n3\n) δppm : 3.57 (3H, s), 3.93 (3H, s), 4.06-4.12 (2H, m), 4.48-4.54 (2H, m), 5.21 (2H, s), 6.96 (1H, d, J=2.5Hz), 8.18 (1H, d, J=2.5Hz), 10.45(1H, s).\n\n\n \nReference Example 25\n\n\nSynthesis of 3-(3-methoxy-4-methoxymethoxy-5-methylphenyl)oxazolidin-2-one\n\n\n \n \n \n3-Methoxy-2-methoxymethoxy-5-(2-oxooxazolidin-3-yl)benzaldehyde (0.5 g, 1.79 mmol) was dissolved in a solvent mixture of acetic acid (5 ml) and ethanol (5 ml) and 10% palladium carbon (0.05 g) was added thereto to perform catalytic reduction at 1 atm at 50°C for 4 hours. The reaction mixture was cooled to room temperature and filtrated by cerite. The filtrate was concentrated under reduced pressure. The residue was dissolved in acetic acid (10 ml) and 10% palladium carbon (0.05 g) was added thereto to perform catalytic reduction at 1 atm at 50°C for 6 hours. The solvent was removed under reduced pressure to obtain 3-(3-methoxy-4-methoxymethoxy-5-methylphenyl)oxazolidin-2-one as a crude product, which was subjected to the next reaction as it was.\n\n\n1\nH-NMR (CDCl\n3\n) δppm: 2.32 (3H, s), 3.56 (3H, s), 3.85 (3H, s), 3.98-4.06 (2H, m), 4.43-4.50 (2H, m), 5.05 (2H, s), 6.61 (1H, d, J=2.3Hz), 7.36 (1H, d, J=2.3Hz).\n\n\n \nReference Example 26\n\n\nSynthesis of 3-(4-hydroxy-3-methoxy-5-methylphenyl)oxazolidin-2-one\n\n\n \n \n \n10% hydrochloric acid (5 ml) was added to a methanol solution (5 ml) of 3-(3-methoxy-4-methoxymethoxy-5-methylphenyl)oxazolidin-2-one (0.48 g, 1.79 mmol) and the mixture was stirred at 50°C for 10 minutes. Water was added to the reaction solution, which was extracted with ethyl acetate. The extracted material was dried over magnesium sulfate, and thereafter concentrated to dryness under reduced pressure to obtain 3-(4-hydroxy-3-methoxy-5-methylphenyl)oxazolidin-2-one (434 mg) as a light yellow powder.\n\n\n1\nH-NMR (CDCl\n3\n) δppm: 2.26 (3H, s), 3.90 (3H, s), 4.02 (2H, dd, J=7.0Hz, J=8.5Hz), 4.46 (2H, dd, J=7.0Hz, J=8.5Hz), 5.55 (1H, br), 6.56 (1H, d, J=2.5Hz), 7.31 (1H, d, J=2.5Hz).\n\n\n \nReference Example 27\n\n\nSynthesis of 1-(8-methoxy-2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)pyrrolidin-2-one\n\n\n \n \n \nThe titled compound was obtained using 6-bromo-8-methoxy-2,2-dimethyl-4H-benzo[1,3]dioxin and 2-pyrrolidone in the same manner as in Reference Example 25.\n\n\n1\nH-NMR (CDCl\n3\n) δppm: 1.59 (6H, s), 2.09-2.21 (2H, m), 2.60 (2H, t, J=8.3Hz), 3.82 (2H, t, J=7.0Hz), 3.88 (3H, s), 4.83 (2H, s), 6.67 (1H, d, J=2.5Hz), 7.24 (1H, d, J=2.5Hz).\n\n\n \nReference Example 28\n\n\nSynthesis of 1-(4-hydroxy-3-hydroxymethyl-5-methoxyphenyl)pyrrolidin-2-one\n\n\n \n \n \n10% hydrochloric acid (4 ml) was added to a THF solution (7 ml) of 1-(8-methoxy-2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)pyrrolidin-2-one (0.36 g, 1.3 mmol) and the mixture was stirred at room temperature for 17 hours. Water was added to the reaction solution, which was then extracted with dichloromethane. The extracted material was dried over magnesium sulfate, concentrated under reduced pressure and purified by silica gel column chromatography (dichloromethane : methanol: = 300: 1 → 30:1). The purified product was concentrated to dryness under reduced pressure to obtain 1-(4-hydroxy-3-hydroxymethyl-5-methoxyphenyl)pyrrolidin-2-one (0.31 g) as light brown powder.\n\n\n1\nH-NMR (CDCl\n3\n) δppm: 2.05-2.28 (3H, m), 2.26 (2H, t, J=7.5Hz), 3.84 (2H, t, J=7.0Hz), 3.91 (3H, s), 4.74 (2H, s), 5.90 (1H, br), 6.78 (1H, d, J=2.5Hz), 7.52 (1H, d, J=2.5Hz).\n\n\n \nReference Example 29\n\n\nSynthesis of 3-methoxy-2-methoxymethoxy-5-(2-oxopyrrolidin-1-yl)benzaldehyde\n\n\n \n \n \nThe titled compound was obtained using 5-bromo-3-methoxy-2-methoxymethoxybenzaldehyde and 2-pyrrolidone in the same manner as Reference Example 25.\n\n\n1\nH-NMR (CDCl\n3\n) δppm: 2.11-2.24 (2H, m), 2.63 (2H, t, J=8.3Hz), 3.56 (3H, s), 3.89 (2H, t, J=7.0Hz), 3.92 (3H, s), 5.21 (2H, s), 7.08 (1H, d, J=2.5Hz), 8.28 (1H, d, J=2.5Hz), 10.46 (1H, s).\n\n\n \nReference Example 30\n\n\nSynthesis of 1-(4-hydroxy-3-methoxy-5-methylphenyl)pyrrolidin-2-one\n\n\n \n \n \n3-methoxy-2-methoxymethoxy-5-(2-oxopyrrolidin-1-yl)benzaldehyde (0.72 g, 2.56 mmol) was dissolved in a solvent mixture of acetic acid (5 ml) and ethanol (7 ml) and 10% palladium carbon (70 mg) was added thereto to perform catalytic reduction at 50°C for 10 hours. The reaction solution was cooled to room temperature and filtrated by cerite. The filtered cake was concentrated under reduced pressure. The residue thus obtained was dissolved in dichloromethane (15 ml) and trifluoroacetic acid (2.0 ml, 25.6 mmol) and triethylsilane (2.0 ml, 12.8 mmol) were added thereto under ice cooling. The mixture was stirred at room temperature for 16 hours. The mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 5:1 → ethyl acetate). The purified product was concentrated under reduced pressure to obtain 1-(4-hydroxy-3-methoxy-5-methylphenyl)pyrrolidin-2-one (0.41 g) as light yellow oil.\n\n\n1\nH-NMR (CDCl\n3\n) δppm : 2.17-2.25 (5H, m), 2.72 (2H, t, J=8.3Hz), 3.88 (2H, t, J=7.0Hz), 3.89 (3H, s), 6.66 (1H, d, J=2.5Hz), 7.15 (1H, d, J=2.5Hz).\n\n\n \nReference Example 31\n\n\nSynthesis of 3,4-diacetoxy-5-methylbenzaldehyde\n\n\n \n \n \nAcetic anhydride (1.2 ml, 12 mmol) was added to a pyridine solution (4 ml) of 3,4-dihydroxy-5-methylbenzaldehyde (0.72 g, 4.7 mmol) and the mixture was stirred at 0°C for one hour. 10% hydrochloric acid was added to the reaction solution, which was extracted with ethyl acetate. The organic phase was washed with an aqueous sodium hydrogen carbonate solution, dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 5:1 → 3:1). The purified product was concentrated under reduced pressure to obtain 3,4-diacetoxy-5-methylbenzaldehyde (0.98 g) as light yellow oil.\n\n\n1\nH-NMR (CDCl\n3\n) δppm: 2.29 (3H, s), 2.32 (3H, s), 2.35 (3H, s), 7.58 (1H, d, J=1.6Hz), 7.67 (1H, d, J=1.6Hz), 9.93 (1H, s).\n\n\n \nReference Example 32\n\n\nSynthesis of 7-hydroxy-1,4-dihydrobenzo[d][1,3]oxazin-2-one\n\n\n \n \n \nThe titled compound was obtained using 7-methoxymethoxy-1,4-dihydrobenzo[d][1,3]oxazin-2-one in the same manner as in Reference Example 26.\n\nWhite powder\n\n\n1\nH-NMR (DMSO-d\n6\n) δppm: 5.14 (2H, s), 6.35 (1H, d, J=2.2 Hz), 6.39 (1H, dd, J= 8.1, J=2.2 Hz), 6.97 (1H, d, J=8.1 Hz), 9.98 (1H, br-s).\n\n\n \nReference Example 33\n\n\nSynthesis of 7-methoxy-3,4-dihydro-1H-quinazolin-2-one\n\n\n \n \n \n2-aminomethyl-5-methoxyaniline (1.2 g. 7.9 mmol) and carbonyl diimidazole (1.53 g, 9.5 mmol) were added to THF (100 ml) and the mixture was stirred at room temperature overnight. The insoluble matter precipitated was obtained by filtration, washed with dichloromethane and water, dried to obtain 7-methoxy-3,4-dihydro-1H-quinazolin-2-one (1.11 g) as white powder.\n\n\n1\nH-NMR (DMSO-d\n6\n) δppm: 3.68 (3H, s), 4.23 (2H, s), 6.35 (1H, d, J=2.5Hz), 6.42 (1H, dd, J=8.3Hz, J=2.5Hz), 6.96 (1H, d, J=8.3Hz), 8.90 (1H, brs).\n\n\n \nReference Example 34\n\n\nSynthesis of 7-hydroxy-3,4-dihydro-1H-quinazolin-2-one\n\n\n \n \n \nThe titled compound was obtained using 7-methoxy-3,4-dihydro-1H-quinazolin-2-one in the same manner as in Reference Example 18.\n\nLight brown powder\n\n\n1\nH-NMR (DMSO-d\n6\n) δppm: 4.18 (2H, brs), 6.75-6.85 (1H, m), 7.01 (1H, dd, J = 2.0 Hz, J=9.0Hz), 8.07 (1H, d, J = 9.0Hz), 8.87 (1H, brs), 9.48 (1H, brs), 13.21 (1H, burs).\n\n\n \nReference Example 35\n\n\nSynthesis of methyl 5-(3-chloropropoxy)-1-methyl-1H-pyrazole-3-carboxylate\n\n\n \n \n \nCesium carbonate (2.08 g, 6.4 mmol) and 1-bromo-3-chloropropane (1.6 ml) were added to a DMF solution (5 ml) of methyl 5-hydroxy-1-methyl-1H-pyrazole-3-carboxylate (0.83 g, 5.3 mmol) and the mixture was stirred at room temperature for 21 hours. Water was added to the reaction solution, which was then extracted with ethyl acetate. The organic phase was washed with water and dried over magnesium sulfate. The reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 100:1 → 4:1). The purified product was concentrated to dryness under reduced pressure to obtain methyl 5-(3-chloropropoxy)-1-methyl-1H-pyrazole-3-carboxylate (1.17 g) as white solid.\n\n\n1\nH-NMR (CDCl\n3\n) δppm: 2.21-2.32(2H, m), 3.72(2H, t, J=6.3Hz), 3.72(2H, s), 3.91(3H, s), 4.24(2H, t, J=5.8Hz), 6.10(1H, s).\n\n\n \nReference Example 36\n\n\nSynthesis of 7-(3-chloropropoxy)-2H-1,4-benzoxazin-3(4H)-one\n\n\n \n \n \nThe titled compound was obtained using 7-hydroxy-2H-1,4-benzoxazin-3(4H)-one and 1-bromo-3-chloropropane in the same manner as in Reference Example 35.\n\nLight brown needle-like crystal (ethanol-n-hexane) Melting point: 119-120°C\n\n\n \n \n \n \nThe compounds listed in the following Tables 1 to 3 were produced using appropriate starting substances in the same manners as in Reference Examples 1 to 36.\n\n \n[Table 1]\n \n \nR1-O-(CH2)3-Cl\n \n \n \n \n \n \nReference Example\n \nR1\n \nNMR\n \n \n \n \n37\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δppm: 2.15230 (2H. m), 3.72 (2H, t, J=6.3 Hz), 3.87 (3H, s), 4.05-4.15 (2H, m), 6.55 (1H, d, J=1.8 Hz), 7.42 (1H, d. J=1.8 Hz).\n \n \n \n38\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δppm: 2.21-2.31(2H, m), 3.70(2H, t, J=6.3Hz), 3.95(3H, s), 4.46(2H, t, J=6.0Hz), 6.54(1H, s)\n \n \n \n39\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δppm: 221-232(2H, m), 3.72(2H, t, J=6.3Hz), 3.72(2H, s), 3.91(3H, s), 4.24(2H, t, J=5.8Hz), 6.10(1H, s)\n \n \n \n40\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δppm: 1.39(3H, t, J=7.0Hz), 1.39(3H, t, J=7.3Hz), 2.22-2.32(2H, m), 3.71(2H, t, J=6.3Hz), 4.10(2H, q, J=7.3Hz), 4.24(2H, t, J=5.8Hz), 4.39(2H, q, J=7.0Hz), 6.08(1H, s)\n \n \n \n41\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δppm: 220-229(2H, m). 246(3H, s), 3.72(2H, t, J=6.3Hz). 4.12(2H, t, J=5.8Hz), 6.84(1H, dd,J=2.5Hz, 8.8Hz), 7.13(1H, d, J=8.8Hz), 8.07(1H, d, J=2.5Hz)\n \n \n \n42\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δppm: 2.13(3H, s), 221-231(2H, m), 3.76(2H, t, J=6.3Hz), 4.18(2H, t, J=5.8Hz), 5.17(2H, s). 7.19-7.32(2H, m), 8.30(1H. d, J=25Hz)\n \n \n \n43\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δppm: 2.27-2.36(2H, m), 3.77(2H, t, J=6.0Hz), 4.28(2H. t, J=5.8Hz). 7.33(1H, dd,J=25Hz, 8.5Hz), 7.97(1H, dd, J=2.5Hz, 8.5Hz), 8.44(1H, d, J=2.5Hz). 10.00(1H, s)\n \n \n \n44\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δppm: 1.26(3H, t, J=7.3Hz), 2.24.2.34(2H, m), 3.55(2H, dq, J=6.0Hz, 7.3Hz), 3.77(2H, t, J=6.3Hz), 4.22(2H, t, J=5.8Hz), 7.29(1H, dd, J=2.3Hz, 8.8Hz), 7.83(1H, br). 8.18(1H, d. J=8.8Hz), 8.20(1H, d, J=2.3Hz)\n \n \n \n45\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δppm: 2.25-2.34(2H, m), 3.77(2H, t,. J=6.3Hz). 4.23(2H. t, J=5.8Hz), 5.48(1H, br), 7.31(1H, dd, J=2.3Hz, 8.8Hz), 7.68(1H, br), 8.16(1H, d, J=8.8Hz), 8.23(1H, d, J=2.3Hz)\n \n \n \n46\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δppm: 2.24-2.34(2H, m), 3.73(2H, t,. J=6.3Hz), 4.00(3H, s). 4.58(2H, t, J=6.0Hz), 8.28(1H, d, J=1.3Hz), 8.87(1H, d, J=1.3Hz)\n \n \n \n \n\n\n \n[Table 2]\n \n \nR1-O-(CH2)3-Cl\n \n \n \n \n \n \nReference Example\n \nR1\n \nNMR\n \n \n \n \n47\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δppm: 1.44(3H, t, J=7.0Hz), 2.22-2.31(2H, m), 3.72(2H, t, J=6.3Hz), 4.48(2H, q, J=7.0Hz), 4.59(2H, t, J=6.0Hz), 7.44(1H, d, J=1.0Hz), 8.90(1H, o, J=1.0Hz)\n \n \n \n \n\n\n \n[Table 3]\n \n \nR1-O-(CH2)4-Cl\n \n \n \n \n \n \nReference Example\n \nR1\n \nNMR\n \n \n \n \n48\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δppm: 1.85-205 (4H, m), 3.62 (2H, t, J=6.3 Hz), 4.33 (2H, t, J=6.3 Hz), 6.72 (1H, d. J=8.3 Hz), 6.85 (1H, dt. J=0.8, 5.1 Hz), 7.56 (1H, dt, J=2.0, 8.4 Hz), 8.14 (1H, dd, J=5.1, 1.4 Hz).\n \n \n \n49\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δppm: 1.95-2.05 (4H, m), 3.62 (2H, t, J=6.2 Hz). 4.05 (2H, t, J=5.8 Hz), 6.80 (2H, dd, J=4.8, 1.6 Hz), 8.43 (2H, dd, J=4.9, 1.5 Hz).\n \n \n \n \n \n\n\n \nExample 1\n\n\nSynthesis of methyl 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazole-3-carboxylate\n\n\n \n \n \nMethyl 5-(3-chloropropoxy)-1-methyl-1H-pyrazole-3-carboxylate (1-17g, 5.0 mmol), 1-benzo[b]thiophen-4-yl piperazine hydrochloride (1.35 g, 5.3 mmol), potassium carbonate (1.74, 12.6 mmol) and sodium iodide (0.75 g, 5.0 mmol) were added to DMF (12 ml), and the mixture was stirred at 80°C for 3 hours. The reaction solution was cooled to room temperature and water was added thereto, and then, extracted with ethyl acetate. The organic phase was washed with water and dried over magnesium sulfate. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 7:3 → dichloromethane : methanol =100:3). The purified product was concentrated under reduced pressure to obtain a light yellow oily substance (1.97 g). The oily substance was allowed to stand still at room temperature to obtain a solid substance, which was washed with diisopropyl ether and dried to obtain methyl 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazole-3-carboxylate (1.49 g).\n\nMelting point: 109.0-110.5°C\n\nMS 414 (M\n+\n)\n\n\n \nExample 2\n\n\nSynthesis of 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazole-3-carboxylic acid\n\n\n \n \n \nA 6N aqueous sodium hydroxide solution (2 ml) was added to an ethanol solution (10 ml) of methyl 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazole-3-carboxylate (1.62 g, 3.9 mmol) and the mixture was stirred at room temperature for 4 days. Then, 6N hydrochloric acid (2 ml) was added to the reaction solution under ice cooling and the solution mixture was stirred. Dichloromethane was added to the reaction solution and the precipitate was obtained by filtration. The filtrate was separated and the organic phase was concentrated under reduced pressure. The filter cake and the residue were combined, washed with water and dried to obtain 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazole-3-carboxylic acid (1.53 g) as white powder.\n\nMelting point: 114.5-118.0°C\n\n\n \nExample 3\n\n\nSynthesis of N-methyl-5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)]propoxy]-1-methyl-1H-pyrazole-3-carboxamide hydrochloride\n\n\n \n \n \nA DMF solution of 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazole-3-carboxylic acid (0.3 g, 0.75 mmol) was cooled on ice and triethylamine (0.73 ml, 5.2 mmol), methylamine hydrochloride (0.3 g, 4.5 mmol) and diethylphosphorocyanidate (DEPC)(0.25 ml, 1.4 mmol) were added thereto, and then, the mixture was stirred at room temperature for 24 hours. To the reaction solution, triethylamine (0.73 ml, 5.2 mmol), methylamine hydrochloride (0.3 g, 4.5 mmol) and DEPC (0.25 ml, 1.4 mmol) were added and the mixture was stirred at room temperature for 4 days. Water was added to the reaction solution, which was then extracted with ethyl acetate. The extracted material was washed with water and dried over magnesium sulfate. The solution was concentrated under reduced pressure and the residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 5:1 → ethyl acetate). The purified product was concentrated under reduced pressure and the residue was dissolved in ethyl acetate and a solution of 4N-hydrochloric acid/ethyl acetate was added thereto. The insoluble matter precipitated was obtained by filtration and dried to obtain N-methyl-5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazole-3-carboxamide hydrochloride (0.24 g) as white powder.\n\nMelting point: 228.0-232.5°C (dec)\n\n\n \nExample 4\n\n\nSynthesis of 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazole-3-carboxamide\n\n\n \n \n \nThe titled compound was obtained using 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazole-3-carboxylic acid and ammonium chloride in the same manner as in Example 3.\n\nWhite powder (ethyl acetate-diisopropyl ether)\n\nMelting point: 186.5-188.5°C\n\n\n \nExample 5 (Reference)\n\n\nSynthesis of 4-[3-4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5,N-dimethylbenzamide\n\n\n \n \n \nThe titled compound was obtained using 4-(3-chloropropoxy)-3-methoxy-5,N-dimethylbenzamide and 1-benzo[b]thiophen-4-yl-piperazine hydrochloride in the same manner as in Example 1.\n\nWhite powder (ethyl acetate-methanol)\n\nMelting point: 141.5-142.5°C\n\n\n \nExample 6\n\n\nSynthesis of N-methyl-2-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]thiazole-4-carboxamide hydrochloride\n\n\n \n \n \nSodium hydride (55%, oily, 90 mg, 2.2 mmol) was added to a DMF solution (2 ml) of 3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propanol (0.2 g, 0.7 mmol) and N-methyl-2-chlorothiazole-4-carboxamide (0.26 g, 1.45 mmol) under ice cooling and the solution was stirred at 80°C for 1.5 hours. After the reaction solution was cooled to room temperature and water was added thereto, it was extracted with ethyl acetate. The extraction solution with ethyl acetate was washed with water, dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (dichloromethane: ethyl acetate = 5:1 → ethyl acetate). After the purified product was concentrated under reduced pressure, the residue was dissolved in ethyl acetate. A solution of 4N-hydrochloric acid/ethyl acetate was added to the solution and the insoluble matter precipitated was obtained by filtration and dried to obtain N-methyl-2-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]thiazole-4-carboxamide hydrochloride (0.24 g) as light yellow powder.\n\nMelting point: 199.5-202.5°C\n\n\n \nExample 7\n\n\nSynthesis of 2-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]thiazole-4-carboxamide\n\n\n \n \n \nThe titled compound was obtained using 3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propanol (0.2 g, 0.7 mmol) and 2-chlorothiazole-4-carboxamide in the same manner as in Example 6.\n\nWhite powder (ethyl acetate-diisopropyl ether)\n\nMelting point: 139.5-140.5°C\n\n\n \nExample 8 (Reference)\n\n\nSynthesis of 4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methylaniline\n\n\n \n \n \n6N-hydrochloric acid (3 ml) was added to a methanol solution (10 ml) of {4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methylphenyl}carbamic acid tert-butyl ester (2.18 g, 4.3 mmol) and the mixture was stirred at room temperature overnight. After stirred at 60°C for 15 minutes, the mixture was cooled to room temperature and a 6N aqueous sodium hydroxide solution was added thereto to neutralize it. Dichloromethane was added to the reaction mixture, and the substance extracted with dichloromethane was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (n-hexane : ethyl acetate = 3:2 → ethyl acetate). The purified product was concentrated to dryness under reduced pressure to obtain 4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methylaniline (1.26 g) as light yellow solid\n\nMelting point: 155.0-158.0°C\n\n\n\nMS 411 (M\n+\n)\n\n\n \nExample 9 (Reference)\n\n\nSynthesis of N-{4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methylphenyl}formamide hydrochloride\n\n\n \n \n \n4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methylaniline (0.9 g, 2.2 mmol) was added to ethyl formate (10 ml) and refluxed with heating for 33 hours. After the reaction solution was cooled to room temperature, it was concentrated under reduced pressure. The obtained residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 5:1 → ethyl acetate). The purified product was concentrated under reduced pressure and a solution of 4N-hydrochloric acid/ethyl acetate was added to an ethyl acetate solution of the residue. The insoluble matter precipitated was obtained by filtration to obtain N-{4-[3-(4-benzo[b]-thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methylphenyl)formamide hydrochloride (0.3 g) as white powder.\n\nMelting point: 247.5-253.0°C (dec)\n\n\n \nExample 10 (Reference)\n\n\nSynthesis of N-methyl-4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methylaniline hydrochloride\n\n\n \n \n \nA 6N aqueous sodium hydrochloride solution was added to N-{4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methylphenyl formamide hydrochloride (0.23 g, 0.48 mmol) and the solution mixture was extracted with dichloromethane. The extraction solution with dichloromethane was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was dissolved in a tetrahydrofuran (THF) solution (5 ml) and lithium aluminum hydride (30 mg, 0.71 mmol) was added thereto under ice cooling and refluxed with heating for 15 minutes. The reaction solution was cooled on ice, and water (0.03 ml), 15 % aqueous sodium hydroxide solution (0.03 ml), and water (0.09 ml) were added to the reaction mixture in this order and stirred. Insoluble matter was removed by filtration, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 5:1 → 3:1) and concentrated under reduced pressure. A solution of 4N-hydrochloric acid/ethyl acetate was added to an ethyl acetate solution of the residue, and the insoluble matter precipitated was obtained by filtration to obtain N-methyl-4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxyl-3-methoxy-5-methylaniline hydrochloride (63 mg) as white powder.\n\nMelting point: 239.5-244.0°C (dec)\n\n\n \nExample 12 (Reference)\n\n\nSynthesis of N-{4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methylphenyl}-N-methylacetamide hydrochloride\n\n\n \n \n \nSodium hydride (55%, oily, 0.06 g, 1.3 mmol) was added to a DMF solution (5 ml) of N-(4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methylphenyl)acetamide (0.45 g, 0.99 mmol) under ice cooling and the mixture was stirred at 0°C for 15 minutes. Methyl iodide (0.07 ml, 1.1 mmol) was added to the reaction solution and the solution was stirred at 0°C for one hour. Further, sodium hydride (55% oily, 0.06 g, 1.3 mmol) and methyl iodide (0.07 ml, 1.1 mmol) were added to the reaction solution and the solution mixture was stirred at 0°C for 2 hours. Water was added to the reaction solution and extraction was performed with ethyl acetate. The extracted material was washed with water, and dried over magnesium sulfate. The reaction solution was concentrated under reduced pressure and the residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 5:1 → ethyl acetate). After the purified product was concentrated under reduced pressure, a solution of 4N-hydrochloric acid/ethyl acetate was added to an ethyl acetate solution of the residue. The insoluble matter precipitated was obtained by filtration to obtain N-{4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methylphenyl}-N-methylacetamide hydrochloride (325 mg).\n\nMelting point: 230.0-234.0°C (dec)\n\n\n \nExample 13 (Reference)\n\n\nSynthesis of 4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-N,N-dimethyl-3-methoxy-5-methylaniline hydrochloride.\n\n\n \n \n \nFormalin (37%, 0.29 ml, 3.9 mmol) and sodium cyanoborohydride (0.21 g, 3.1 mmol) were added to a methanol solution (6 ml) of 4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methylaniline (0.32 g, 0.78 mmol) under ice cooling and the mixture was stirred at 0°C for 15 minutes. To the reaction solution, acetic acid (0.18 ml, 3.1 mmol) was added and the mixture was stirred at room temperature for one hour. An aqueous potassium carbonate solution was added to the reaction solution under ice cooling, and extraction was performed with ethyl acetate. The extracted material was dried over magnesium sulfate. The reaction solution was concentrated under reduced pressure, and the residue was purified by basic silica gel column chromatography (n-hexane :ethyl acetate = 11:1 → 3:1). The purified product was concentrated under reduced pressure. A solution of 4N-hydrochloric acid and ethyl acetate was added to an ethyl acetate solution of the residue and the insoluble matter precipitated was obtained by filtration to obtain 4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-N,N-dimethyl-3-methoxy-5-methylaniline hydrochloride (137 mg) as white powder.\n\nMelting point: 234.5-240.5°C (dec)\n\n\n \nExample 14 (Reference)\n\n\nSynthesis of 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-benzo[1,4]oxazine hydrochloride\n\n\n \n \n \nLithium aluminum hydride (86 mg, 2.3 mmol) was suspended in THF (20 ml). To this solution, a THF solution (10 ml) of 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-benzo[1,4]oxazin-3-one (0.8 g, 1.9 mmol) was added dropwise under an argon atmosphere. After completion of dropwise addition, the solution mixture was refluxed with heating for one hour. Water (0.1 ml), 15 % aqueous sodium hydroxide solution (0.1 ml), and water (0.3 ml) were added to the reaction mixture under ice cooling and stirred. Insoluble matter was removed by cerite filtration, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (dichloromethane : methanol = 1:0 → 20:1) and concentrated under reduced pressure. The residue was dissolved in ethyl acetate (10 ml) and a solution (0.34 ml) of 1N-hydrochloric acid/ethanol was added thereto and the mixture was stirred at room temperature for 15 minutes. The insoluble matter precipitated was obtained by filtration, washed with ethyl acetate, and dried to obtain 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-benzo[1,4]oxazine hydrochloride (0.11 g) as white solid.\n\nMelting point 207.9-208.8°C\n\n\n \nExample 15 (Reference)\n\n\nSynthesis of 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine hydrochloride\n\n\n \n \n \nFormalin (37%, 0.22 ml, 2.7 mmol) and MF-cyanoborohydride (2.41 mmol/g, 1.12 g, 2.7 mmol) were added to a methanol solution (15 ml) of 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,4-dihydro-2H-benzo[1,4]oxazine (0.30 g, 0.67 mmol) and the mixture was stirred at room temperature overnight. The insoluble matter was removed by filtration and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (dichloromethane : methanol = 1:0 → 50:1). The purified product was concentrated under reduced pressure and the residue was dissolved in ethyl acetate (15 ml) and a solution (0.64 ml) of 1N-hydrochloric acid/ethanol was added thereto. The mixture was stirred at room temperature for 15 minutes. The insoluble matter precipitated was obtained by filtration, washed with ethyl acetate, and dried to obtain 7-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine hydrochloride (0.23 g) as light brown solid.\n\nMelting point; 248.1-249.6°C\n\n\n \nExample 16 (Reference)\n\n\nSynthesis of 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methyl-1,2,3,4-tetrahydroquinazolin-4-ol hydrochloride and 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methyl-1,2,3,4-tetrahydroquinazoline hydrochloride\n\n\n \n \n \nA THF solution (20 ml) of 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methylquinazoline (0.25 g, 0.58 mmol) was cooled on ice. To this solution, a THF solution (5 ml) of lithium aluminum hydride (26 mg, 0.69 mmol) was added dropwise under an argon atmosphere. After completion of dropwise addition, the solution was stirred at room temperature for 20 minutes and refluxed with heating for one hour. Water (0.03 ml), 15 % aqueous sodium hydroxide solution (0.03 ml), and water (0.1 ml) were added to the reaction solution under ice cooling and stirred. Insoluble matter was removed by cerite filtration, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (dichloromethane : methanol = 1:0 → 25:1). The purified product was concentrated under reduced pressure and the residue was dissolved in ethyl acetate (5 ml). To this, a solution (0.189 ml) of 1N-hydrochloric acid/ethanol was added and the mixture was stirred at room temperature for 15 minutes. The insoluble matter precipitated was obtained by filtration, washed with ethyl acetate, and dried to obtain 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methyl-1,2,3,4-tetrahydroquinazolin-4-ol hydrochloride (87 mg) as white solid.\n\nMS: 438 (M\n+\n).\n\n\n \n \n \n \nAn eluting solution of dichloromethane/methanol (10:1) was passed through the column of the silica gel column chromatography. The obtained eluate was concentrated under reduced pressure and then the residue was dissolved in ethyl acetate (5 ml). To this, a solution (0.226 ml) of 1N-hydrochloric acid/ethanol was added and the mixture was stirred at room temperature for 15 minutes. The insoluble matter precipitated was obtained by filtration, washed with ethyl acetate, and dried to obtain 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methyl-1,2,3,4-tetrahydroquinazoline hydrochloride (49 mg) as white solid.\n\nMelting point: 203.1-204.4°C\n\n\n \nExample 17 (Reference)\n\n\nSynthesis of 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2,3-dihydro-1H-indole hydrochloride\n\n\n \n \n \nTriethylsilane (1.14 ml, 7.14 mmol) was added to a trifluoroacetic acid solution (5 ml) of 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1H-indole (228 mg, 0.71 mmol) and the mixture was stirred at 50°C for 2 hours. The mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane, neutralized by a saturated aqueous solution of sodium hydrogen carbonate and separated. The organic phase was washed with a saturated aqueous solution of sodium hydrogen carbonate, water and a saturated saline solution in this order and concentrated under reduced pressure. The obtained residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 5:1 → 1:1). The purified product was concentrated under reduced pressure and the residue was added to ethyl acetate (5 ml) and a solution of 1N-hydrochloric acid/ethanol (0.10 ml) was added thereto and the mixture was stirred at room temperature for 15 minutes. The insoluble matter precipitated was obtained by filtration, washed with ethyl acetate, and dried to obtain 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-2,3-dihydro-1H-indole hydrochloride (32 mg) as white solid.\n\nMelting point: 222.4-223.9°C\n\n\n \n \n \n \nCompounds listed in the following Tables 4 to 164 were produced using appropriate starting substances in the same manners as in Reference Examples 1 to 36 or Examples 1 to 17 and 1751 to 1767.\n\n\n \n \n \n \nIn the following Tables, compounds with the physical properties, such as crystalline form, m.p. (melting point), salt, \n1\nH-NMR and MS (mass spectrum), were prepared actually.\n\n \n[Table 4]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystalization solvent)\n \nMelting point (°C)\n \nSalt\n \n \n \n \n18\n \n \n \n \n \n \nWhite solid (Ethanol)\n \n225-228\n \nTrihydrochloride\n \n \n \n19\n \n \n \n \n \n \nWhite needle-form crystal (Ethanol/ethyl acetate)\n \n165.0-167.0\n \nHydrochloride\n \n \n \n20\n \n \n \n \n \n \nWhite solid (Ethanol)\n \n204-206\n \nHydrochloride\n \n \n \n21\n \n \n \n \n \n \nhite powder (Ethyl acetate)\n \n201.5-207.5\n \nHydrochloride\n \n \n \n22\n \n \n \n \n \n \nrite powder (Ethyl acetate/ isopropyl ether)\n \n132.5-133.5\n \n-\n \n \n \n23\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n205.5-208.0\n \nHydrochloride\n \n \n \n24\n \n \n \n \n \n \nWnite powder (2-propanol)\n \n206.5-208.0\n \n-\n \n \n \n25\n \n \n \n \n \n \nLight yellow powder (Ethyl acetate)\n \n201.5-204.0\n \nHydrochloride\n \n \n \n26\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n155.5-162.0\n \nHydrochloride\n \n \n \n27\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n140.0-141.5\n \nHydrochloride\n \n \n \n28\n \n \n \n \n \n \nLight yellow powder (Ethyl acetate)\n \n192-194\n \ndihydrochloride\n \n \n \n \n\n\n \n[Table 5]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystallization solvent)\n \nMelting Point (°C)\n \nSalt\n \n \n \n \n29\n \n \n \n \n \n \nLight yellow powder (Ethanol)\n \n201-203\n \nDihydrochloride\n \n \n \n30\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n201-203\n \nHydrochloride\n \n \n \n31\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n214.0-215.0\n \nHydrochloride\n \n \n \n32\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n131.5-132.0\n \n-\n \n \n \n33\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n193.0-194.0\n \n-\n \n \n \n34\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n128.0-129.5\n \n-\n \n \n \n35\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n234.0-236.0\n \nHydrochloride\n \n \n \n36\n \n \n \n \n \n \nLight yellow powder (Ethyl acetate)\n \n224.0-226.0\n \nDihydrochloride\n \n \n \n37\n \n \n \n \n \n \nWhite powder (water)\n \n230.0 (dec)\n \nHydrochloride\n \n \n \n38\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n171.0-174.5\n \n-\n \n \n \n \n\n\n \n[Table 6]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystallization solvent)\n \nMelting point (°C)\n \nSalt\n \n \n \n \n39\n \n \n \n \n \n \nLight yellow powder (Ethyl acetate)\n \n166.0 (dec)\n \nDihydrochloride\n \n \n \n40\n \n \n \n \n \n \nLight yellow powder (Ethyl acetate)\n \n198.5-204.0\n \nDihydrochloride\n \n \n \n41\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n211.5-214.5\n \nDihydrochloride\n \n \n \n42\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n241.0-243.0\n \nHydrochloride\n \n \n \n43\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n150.0-150.5\n \n-\n \n \n \n44\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n199.0-200.5\n \nDihydrochloride\n \n \n \n45\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n206.0-208.5\n \nHydrochloride\n \n \n \n46\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n208.0-213.0\n \nHydrochloride\n \n \n \n47\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n157-159\n \nHydrochloride\n \n \n \n48\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n197.0-199.0\n \nDihydrochloride\n \n \n \n \n\n\n \n[Table 7]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystallization solvent)\n \nMelting point (°C)\n \nSalt\n \n \n \n \n49\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n205-207\n \nHydrochloride\n \n \n \n50\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n178.0-182.5\n \nHydrochloride\n \n \n \n51\n \n \n \n \n \n \nLight yellow power (ethyl acetate)\n \n191.5-195.5\n \nHydrochloride\n \n \n \n52\n \n \n \n \n \n \nLight yellow powder (Ethyl acetate/ isopropyl ether)\n \n112.0-115.5\n \n-\n \n \n \n53\n \n \n \n \n \n \nWhite powder (Methanol)\n \n205.0-209.5\n \nHydrochloride\n \n \n \n54\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n149.5-151.0\n \n-\n \n \n \n55\n \n \n \n \n \n \nLight yellow powder (Ethyl acetate/ isopropyl ether)\n \n114.5-115.5\n \n-\n \n \n \n56\n \n \n \n \n \n \nWhite powder (Methanol)\n \n116.5-118.0\n \n-\n \n \n \n57\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n210.5-214.5\n \nHydrochloride\n \n \n \n58\n \n \n \n \n \n \nLight yellow powder (Ethyl acetate/ isopropyl ether)\n \n109.0-110.0\n \n-\n \n \n \n \n\n\n \n[Table 8]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystallization solvent)\n \nMelting point (°C)\n \nSalt\n \n \n \n \n59\n \n \n \n \n \n \nWhite powder (Ethanol/water)\n \n129.0-131.0\n \n-\n \n \n \n60\n \n \n \n \n \n \nWnite powder (Ethyl acetate)\n \n247.5 (dec)\n \nHydrochloride\n \n \n \n61\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n231.0-234.0\n \nHydrochloride\n \n \n \n62\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n245.5 (dec)\n \nHydrochloride\n \n \n \n63\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n199.5-201.5\n \nHydrochloride\n \n \n \n64\n \n \n \n \n \n \nWhite powder (Ethanol/water)\n \n252.5-255.0 (dec)\n \n-\n \n \n \n65\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n131.5-132.5\n \n-\n \n \n \n66\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n167.5-169.0\n \n-\n \n \n \n67\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n219.5-222.5 (dec)\n \nHydrochloride\n \n \n \n68\n \n \n \n \n \n \nLight yellow powder (Ethyl acetate)\n \n151.0-153.5\n \nHydrochloride\n \n \n \n69\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n138.5-140.0\n \n-\n \n \n \n \n\n\n \n[Table 9]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nNMR\n \nSalt\n \n \n \n \n70\n \n \n \n \n \n \n \n1\nH-NMR (DMSO-d\n6\n) δ ppm: 2.10 -2.30 (2H, m), 2.80-3.90 (16H, m), 4.09 (2H, t, J=5.9 Hz), 6.88 (1H, d, J=1.5 Hz), 6.96 (1H, d, J=7.6 Hz). 7.17 (1H, d. J=1.4 Hz), 7.31 (1H, dd, J=7.8, 7.8 Hz), 7.48 (1H, d, J=5.6 Hz). 7.70 (1H, d, J=8.1 Hz), 7.76 (1H, d, J=5.6 Hz), 10.68 (1H, brs).\n \nHydrochloride\n \n \n \n71\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) 6 ppm: 1.95-2.10 (2H, m), 2.62 (2H, t, J=7.0 Hz), 2.65-2.80 (4H, m), 2.98 (3H, d, J=4.9 Hz), 3.15-325 (4H, m), 4.05 (2H, t, J=6.3 Hz), 5.94 (1H, brs), 6.43 (1H, d, J=1.8 Hz), 6.90 (1H, dd, J=1.4, 7.6 Hz), 7.15 (1H, d, J=1.7 Hz), 7.20-7.35 (1H, m), 7.35-7.45 (2H. m), 7. 55 (1H, d, J=8.1 Hz).\n \n-\n \n \n \n72\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm 1.23 (3H, t, J=7.3 Hz), 1.95-2.05 (2H, m), 2.61 (2H, t, J=7.3 Hz), 2.65-2.80 (4H, m). 3.10-3.30 (4H, m), 3.40-3.55 (2H, m), 4.04 (2H, t, J=6.3 Hz), 6.01 (1H, brs), 6.43 (1H, d. J=1.6 Hz), 6.90 (1H, d, J=7.6 Hz), 7.16 (1H, d. J=1.7 Hz), 7.27 (1H, dd, J=7.8, 7.8 Hz), 7.35-7.45 (2H, m), 7.55 (1H, d, J=8.1 Hz).\n \n-\n \n \n \n73\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 1.95-2.10 (2H, m). 2.63 (2H, t, J=7.3 Hz), 2.70-2.80 (4H, m), 3.15-3.25 (4H, m), 4.06 (2H, t J=6.3 Hz), 5.74 (2H, brs), 6.51 (1H, d J=1.7 Hz), 6.90 (1H, dd, J=0.5. 7.6 Hz), 7.19 (1H, d, J=1.7 Hz), 7.28 (1H, dd, J=7.8, 7.8 Hz), 7. 35-7.45 (2H, m), 7.56 (1H, d, J=8.0 Hz).\n \n-\n \n \n \n \n\n\n \n[Table 10]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystallization solvent)\n \nMelting point (°C)\n \nSalt\n \n \n \n \n74\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ether)\n \n183-186\n \nHydrochloride\n \n \n \n \n\n\n \n[Table 11]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystallization solvent)\n \nMelting point (°C)\n \nSalt\n \n \n \n \n75\n \n \n \n \n \n \nWhite powder (Ethanol/ethyl acetate)\n \n183.0-185.0\n \nDihydrochloride\n \n \n \n76\n \n \n \n \n \n \nWhite powder (Ethanol/ethylacetate)\n \n205.0-207.0\n \nHydrochloride\n \n \n \n77\n \n \n \n \n \n \nWhite powder\n \n197.0-199.0\n \nHydrochloride\n \n \n \n78\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n166.5-168.0\n \nHydrochloride\n \n \n \n79\n \n \n \n \n \n \n(Ethyl acetate)\n \n196.0-201.0\n \nHydrochloride\n \n \n \n80\n \n \n \n \n \n \nWhite powder\n \n175.0-176.0\n \nHydrochloride\n \n \n \n81\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n150.0-154.5\n \n-\n \n \n \n82\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n172.0-175.0\n \nHydrochloride\n \n \n \n83\n \n \n \n \n \n \nWhite Powder (Ethyl acetate/either)\n \n201-205\n \nHydrochloride\n \n \n \n \n\n\n \n[Table 12]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystalization solvent)\n \nMelting point (°C)\n \nSalt\n \n \n \n \n84\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n195-197\n \nHydrochloride\n \n \n \n85\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n190-192\n \nHydrochloride\n \n \n \n \n\n\n \n[Table 13]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nNMR\n \nSalt\n \n \n \n \n86\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 2.00-2.10 (2H, m), 2.63 (2H, t, J=7.3 Hz), 2.70-2.80 (4H, m), 3.15-3.25 (4H, m), 3.89 (3H, s), 4.00-4.10 (2H, m), 8.57 (1H, d, J=1.9 Hz), 6.91 (1H, d, J=7.0 Hz), 7.20-7.35 (2H, m), 7.35-7.50 (3H, m), 7.50 (1H, d,J=8.0 Hz).\n \n-\n \n \n \n87\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 1.44(3H, t, 7.0Hz), 2.01-2.12(2H, m), 2.03(2H, t, J=7.5Hz), 2.67-2.81(4H, m), 3.12-3.29(4H, m), 4.44-4.55(1H, m), 6.90(1H, d, J=7.5Hz). 7.27(1H, dd, J=5.5Hz, 7.5Hz), 7.40(2H, dd, J=5.5Hz, 8.0Hz). 7.44(1H, d, J=1.0Hz), 7.55(1H, d, J=8.0Hz), 8.90(1H, d, J=1.0Hz)\n \n-\n \n \n \n88\n \n \n \n \n \n \n1H-NMR (DMSO-d\n6\n) δ ppm : 1.83-2.00 (2H, m), 2.59-2.70 (4H, m),3.00-3.15(4H, m). 3.17(1H, d,J=4.5Hz), 3.31(1H, d, J=4.5Hz), 4.15 (2H, t, J=6.0 Hz), 4.77(2H, q, J=8.8Hz), 0.90 (1H, d, J=7.3Hz), 7.27 (1H, t, J=7.8Hz), 7.40(1H, d. J=5.5Hz), 7.01(1H, d. J=8.0Hz), 7.09(1H, d,J=5.5Hz).\n \n-\n \n \n \n \n\n\n \n[Table 14]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS (M+1)\n \n \n \n \n89\n \n-3-PYRIDYL\n \n354\n \n \n \n90\n \n \n \n \n \n \n368\n \n \n \n91\n \n \n \n \n \n \n385\n \n \n \n \n\n\n \n[Table 15]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystalization solvent)\n \nMelting point\n \nSalt\n \n \n \n \n92\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n138.5-140.5\n \n-\n \n \n \n93\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n233.5 (dec)\n \nHydrochloride\n \n \n \n94\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n147.0-148.5\n \n-\n \n \n \n95\n \n \n \n \n \n \nWhite powder (water)\n \n115.0-121.0\n \n-\n \n \n \n96\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n129.0-130.5\n \n-\n \n \n \n97\n \n \n \n \n \n \n(Ethylacetate/ isopropyl ether)\n \n139.0-140.5\n \n-\n \n \n \n \n\n\n \n[Table 16]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystalization solvent)\n \nMelting point (°C)\n \nSalt\n \n \n \n \n98\n \n \n \n \n \n \nWhite powder (Ethyl acetate isopropyl ether)\n \n128.5-131.5\n \n-\n \n \n \n99\n \n \n \n \n \n \nWhite powder (Isopropyl alcohol/ ethyl acetate)\n \n227.0 (dec)\n \nHydrochloride\n \n \n \n100\n \n \n \n \n \n \nWhite powder (Ethanol/ ethyl acetate)\n \n211.0-213.5\n \nHydrochloride\n \n \n \n101\n \n \n \n \n \n \nWhite powder (Ethanol/water)\n \n245.0 (dec)\n \nHydrochloride\n \n \n \n102\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n112.0-113.0\n \n-\n \n \n \n103\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n123.5-126.0 0\n \n-\n \n \n \n104\n \n \n \n \n \n \nLight yellow powder (Ethyl acetate)\n \n174.0-176.5\n \nHydrochloride\n \n \n \n105\n \n \n \n \n \n \nWhite powder (Ethylacetate/ isopropyl ether)\n \n137.0-139.0\n \n-\n \n \n \n \n\n\n \n[Table 17]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal from (Recrystalization solvent)\n \npoint Melting point (°C)\n \nSalt\n \n \n \n \n106\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n194.0-196.0\n \nHydrochloride\n \n \n \n107\n \n \n \n \n \n \n(Ethyl acetate)\n \n173.0-177.0\n \nDihydrochloride\n \n \n \n108\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n162.5-165.0\n \n-\n \n \n \n109\n \n \n \n \n \n \nWhite powder (Methanol)\n \n202-205\n \nHydrochloride\n \n \n \n110\n \n \n \n \n \n \nWhite powder (Methanol)\n \n208-210\n \nHydrochloride\n \n \n \n111\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n255.0-257.0\n \nHydrochloride\n \n \n \n112\n \n \n \n \n \n \nWhite powder (methanol)\n \n178-182\n \nHydrochloride\n \n \n \n \n\n\n \n[Table 18]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMelting point (°C)\n \nSalt\n \n \n \n \n113\n \n \n \n \n \n \n \n1\nH-NMR (DMSO-d\n6\n) δ ppm: : 1.80-2.10 (4H, m), 2.74 (6H, s), 3.10-3.70 (16H, m), 4.00-4.10(1H, m), 6.97 (1H, d, J=7.5 Hz), 7. 32 (1H, t, J=7.9 Hz), 7.49 (1H, d, J=5.6 Hz), 7.71 (1H, d, J=8.0 Hz), 7.77 (1H, d, J=5.5 Hz), 10.91 (1H, brs).\n \nHydrochloride\n \n \n \n114\n \n \n \n \n \n \n \n1\nH-NMR(DMSO-d\n6\n)δ ppm: 1.00-2.10 (4H, m), 1.93 (3H, s), 3.10-3.60 (16H, m), 3.90-4.10 (1H, m), 6.95 (1H, d. J=7.5 Hz), 7.30 (1H, t, J=7.9 Hz), 7.47 (1H, d, J=5.5 Hz), 7.68 (1H, d, J=8.0Hz), 7.75 (1H, d, J=5.5 Hz), 11.30 (1H, brs).\n \nHydrochloride\n \n \n \n115\n \n \n \n \n \n \n \n1\nH-NMR (DMSO-d\n6\n) δ ppm: 2.20-2.40 (2H, m), 2.70-3.70 (10H, m), 4.55 (2H, t, J=5.9 Hz), 6.98 (1H, d, J=7.5 Hz), 7.32 (1H, t, J=7.9Hz), 7.50 (1H, d, J=5.5 Hz), 7.71 (1H, d, J=8.0 Hz), 7.77 (1H, d, J=5.5 Hz), 7.89 (1H, s), 10.97 (1H, brs), 12.93 (1H, brs).\n \nHydrochloride\n \n \n \n116\n \n \n \n \n \n \n \n1\nH-NMR (DMSO-d\n6\n) δ ppm: 2.25-2.35 (2H, m), 3.20-4.00 (10H, m), 4.30 (2H, t, J=5.8 Hz), 6.97 (1H, d, J=7.5 Hz), 7.24 (1H, dd, J=5.5, 2.8 Hz), 7.31 (1H, t, J=7.8 Hz), 7.49 (1H, d, J=5.4 Hz). 7.59 (1H, d, J=2.5 Hz), 7.70 (1H, d, J=8.1 Hz), 7.76 (1H, d. J=5.5 Hz), 8.53 (1H, d, J=5.7 Hz), 10.99 (1H, brs).\n \nHydrochloride\n \n \n \n \n\n\n \n[Table 19]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystalization solvent)\n \nMelting point (°C)\n \nSalt\n \n \n \n \n117\n \n \n \n \n \n \nLight brown powder (Ethanol/ethyl acetate)\n \n103.5 -106.0\n \n-\n \n \n \n118\n \n \n \n \n \n \nLight brown powder (Dichloromethane/water)\n \n140.5-144.0\n \n-\n \n \n \n119\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n143.0-144.5\n \n-\n \n \n \n120\n \n \n \n \n \n \nWhite powder (Ethanol/ethyl acetate)\n \n211.0-213.5\n \nHydrochloride\n \n \n \n121\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n207.5-209.5\n \nHydrochloride\n \n \n \n122\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n167.0-168.5\n \nHydrochloride\n \n \n \n123\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n156.5-158.5\n \nHydrochloride\n \n \n \n124\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n157.5-161.5\n \n-\n \n \n \n \n\n\n \n[Table 20]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystalization solvent)\n \nMelting point (°C)\n \nSalt\n \n \n \n \n125\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n203.5-206.0\n \nHydrochloride\n \n \n \n126\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n186.0-187.5\n \nHydrochloride\n \n \n \n127\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n203.0-207.0\n \nHydrochloride\n \n \n \n128\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n146.5-148.0\n \n-\n \n \n \n \n\n\n \n[Table 21]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystalization solvent)\n \nMelting point. (°C)\n \nSalt\n \n \n \n \n129\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n200.5-201.5\n \nHydrochloride\n \n \n \n130\n \n \n \n \n \n \nWhite powder (Ethanol/ethyl acetate)\n \n225.0-230.0\n \nHydrochloride\n \n \n \n131\n \n \n \n \n \n \nWhite powder (Dichloromethane/water)\n \n156.0-158.5\n \n-\n \n \n \n132\n \n \n \n \n \n \nWhite powder (Ethanol/ethyl acetate)\n \n169.0- 171.5\n \n-\n \n \n \n \n\n\n \n[Table 22]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nNMR\n \n \n \n \n133\n \n \n \n \n \n \n \n1\nH-NMR (DMSO-d\n6\n) δ ppm: 1. 85-1. 95 (2H, m), 2. 57 (2H, t, J=7.1 Hz), 2.60-2.75 (4H, m), 3.05-3.15 (4H, m), 4.03 (2H, t, J=6. 3 Hz), 6.85-6.95 (2H, m), 7.20-7.31 (2H, m), 7. 35-7.41 (1H, m), 7. 60 (1H, d, J=8.1 Hz), 7.68 (1H, d, J=5.5 Hz).\n \n \n \n134\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 1.39 (3H, t. J= 7.0Hz), 2.00-2.11 (2H, m) , 2. 60 (2H, t, J=7.0 Hz), 2.63-2.80 (4H, m), 3.09-3.25 (4H, m), 4. 24 (2H, t, J=6.3Hz), 4. 40 (2H, q, J=7. 0 Hz) , 4. 64 (2H, q, J=8.3Hz), 6.12 (1H, s), 6.90 (1H, dd, J=0.5Hz, 7.5Hz), 7.25-7.31 (1H, m). 7.36-7.43 (2H, m), 7.56 (1H, d, J=8.1Hz) .\n \n \n \n135\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 1.39 (3H, t, J= 7.0Hz), 2.00-2.06 (2H, m), 2.60 (2H, t, J=7.5Hz), 2.67-2.83 (4H, m), 3.13-3.28 (4H, m),4.18 (2H, t. J=6.3Hz), 4.39 (2H, q, J=7.0 Hz), 4. 61 (2H,m), 5.08-5.23 (2H, m), 5.87-6.09 (1H, m), 6.11 (1H, s), 6. 75 (1H, dd, J=0.6Hz, 7.5Hz), 7.25-7.37 (1H, m), 7.40-7.43 (2H, m), 7.65 (1H, d, J=8.0 Hz),\n \n \n \n136\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 0.91 (3H, t, J=7. 5Hz), 1. 38 (3H, t, J= 7.0Hz), 1. 72-1. 93 (2H, m), 1.98-2.13 (2H, m), 2.61 (2H, t, J=7.3Hz), 2.67-2.83 (4H, m), 3.09-3.28 (4H, m), 4.01 (2H, t, J=7.0Hz), 4.18 (2H, t, J=6.3Hz), 4.39 (2H, q, J=7.0 Hz), 6.08 (1H, s), 6.90 (1H, dd, J=0.7Hz, 7.5Hz), 7.25-7.30 (1H, m), 7.37-7.43 (2H, m), 7. 56 (1H, d, J=8.0 Hz).\n \n \n \n \n\n\n \n[Table 23]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nNMR\n \n \n \n \n137\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 1.51 (9H, s), 1. 97-2. 12 (2H, m) , 2.52-2.57 (2H, m), 2.67-2.80 (4H, m), 3.07-3.29 (4H, m) , 4.38 (2H, t, J=6.3Hz), 6.52 (1H, br), 6.90 (1H, d, J=7.6Hz), 7.03 (1H, br), 7.21-7.33 (1N, m), 7.40 (2H, dd, J=5.6Hz, 7.3Hz), 7.55(1H, d, J=8.0Hz).\n \n \n \n138\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 0.10 (6H, s), 0.92 (9H, s), 1.93-2.13 (2H, m), 2.62 (2H. t, J=7.5Hz), 2.70-2.83 (4H, m), 3.09-3.28 (4H, m), 3.59 (3H, s), 4.13 (2H, t, J=6.3Hz), 4.60 (2H, s), 5.54 (1H, s), 6.90 (1H, dd, J=0.7Hz, 7.5Hz), 7.20-7.33 (1H, m), 7.35-7.48 (2H, m), 7.55 (1H, d. J=8.0 Hz).\n \n \n \n139\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 1.50 (9H, s), 1.94-2.12 (2H, m), 2. 60 (2H. t. J=7.0Hz), 2.66-2. 80 (4H, m), 3.10-3.27 (4H, m), 3.52 (3H, s), 4.15 (2H, t, J=6.4Hz), 5.85 (1H, s), 6.81-6.97 (2H, m), 7.20-7.33 (1H, m), 7.35-7.45 (2H, m), 7.55 (1H, d, J=8.0 Hz).\n \n \n \n \n\n\n \n[Table 24]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nNMR\n \n \n \n \n140\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 1.46 (9H, s), 1.45-1.60 (2H, m), 1.75-1.90 (4H, m), 2.50-2.60 (2H, m), 2.65-2.80 (4H, m), 3.05-3.25 (6H, m), 3.40-3.50 (1H, m). 3.53 (2H, t, J=6.4 Hz), 3.70-3.80 (2H, m), 6.89 (1H, dd, J=7.6, 0.7 Hz), 7.20-7.30 (1H, m), 7.35-7.45 (2H, m), 7.54 (1H, d, J=8.0 Hz), 8.02 (1H, s).\n \n \n \n141\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 1.30-1.60 (2H, m), 1.75-2.00 (4H, m), 2. 50-2. 75 (4H, m), 3.05-3.25 (6H, m), 3.30-3.40 (1H, m), 3. 55 (2H, t, J=6.5Hz), 6.9C (1H, d, J=7.6 Hz). 7.20-7.30 (1H, m), 7.35-7.45 (2H, m), 7.55 (1H, d, J=8.1 Hz).\n \n \n \n142\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 1.38 (3H, t, J=7.1 Hz), 2.00-2.10 (2H, m), 2. 60 (2H, t, J=7.1 Hz), 2.65-2.75 (4H, m). 3.15-3.25 (4H, m), 3. 72 (3H, s), 4.17 (2H, t, J=6.4 Hz), 4. 38 (2H, q, J=7.1 Hz), 6.08 (1H, s), 6.89 (1H, d, J=7.6 Hz), 7.20-7.30 (1H, m), 7.35-7.45 (2H, m), 7. 54 (1H, d, J=8.1 Hz).\n \n \n \n143\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 1.94-2.10 (2H, m), 2. 60 (2H, t, J=7.1Hz). 2.65-2.78 (4H, m), 3.10-3.25 (4H, m), 3.57 (3H, s), 4. 15 (2H, t, J=6.3Hz), 5. 93 (1H, s), 6.89 (1H, d, J=7.5Hz), 7.12-7.32 (3H, m), 7.33-7.45 (4H, m), 7.55 (1H, d, J=8.0 Hz). 7.93 (1H, br).\n \n \n \n \n\n\n \n[Table 25]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nNMR\n \n \n \n \n144\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 1.75-2.00 (4H, m), 2.50-2.60 (2H, m), 2.70-2.75 (4H, m), 3.15-3.25 (4H, m). 3. 35-3. 80 (6H, m), 4. 00-4.05 (1H, m), 6. 91 (1H, dd, J=7.6, 0.5 Hz), 7.25-7.35 (1H, m), 7.35-7.45 (2H, m), 7.56 (1H, d, J=8.0 Hz).\n \n \n \n145\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 1.75-1.95 (4H, m), 2. 51 (2H, t. J=7.1 Hz), 2.50-2.75 (8H, m), 3.10-3.20 (4H, m), 3.46 (2H, t, J=6.3 Hz), 4.00-4.10 (1H. m), 6.88 (1H, d, J=7.1 Hz), 7.20-7.30 (1H, m), 7.30-7.45 (2H, m), 7.53 (1H, d, J=8.0 Hz).\n \n \n \n \n\n\n \n[Table 26]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nNMR\n \n \n \n \n146\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: : 1.50 (9H, s), 1.59-1.77 (2H, m), 1.77-1.93 (2H, m), 2. 50 (2H, t, J=7.3Hz), 2.61-2.80 (4H, m), 3.11-3.27 (4H, m). 3.54 (3H, s). 4.09 (2H, t, J=6.3Hz), 5.85 (1H, s), 6.90 (1H, d, J=7.5Hz), 7.23-7.32 (1H, m), 7.36-7.45 (2H, m), 7.55 (1H, d, J=8.0 Hz), 7.80 (1H, br).\n \n \n \n147\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: : 1.64-1.93 (4H, m), 2.51 (2H, t, J=7.3Hz), 2.61-2.79 (4H, m), 3.11-3.29 (4H. m), 3.46 (3H, s), 3.49 (2H, br), 4.02 (2H, t, J=6.2Hz), 4. 94 (1H, s), 6.90 (1H, dd, J=0.7hz, 7. 6Hz), 7.22-7.33 (1H, m), 7.35-7.46 (2H, m), 7.55 (1H, d, J=8.0 Hz).\n \n \n \n148\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: : 1.64-1.78 (2H, m), 1.78-1.94 (2H, m), 2.50 (2H, t, J=7.3Hz), 2.61-2.81 (4H, m), 3.10-3.28 (4H, m), 3.57 (3H, s). 4.09 (2H, t, J=6.3Hz), 5.92 (1H, s). 6.77-6.98 (4H, m), 7.11-7.32 (2H, m), 7.32-7.47 (4H, m), 7.55 (1H, d, J=8.0 Hz), 8.47 (1H, br).\n \n \n \n \n\n\n \n[Table 27]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n149\n \n-CO\n2\nCH\n2\nC\n2\nH\n5\n \n \n603\n \n \n \n150\n \n-CO\n2\nC\n2\nH\n5\n \n \n541\n \n \n \n151\n \n-COCH\n3\n \n \n511\n \n \n \n152\n \n-CO\n2\nC(CH\n3\n)\n3\n \n \n569\n \n \n \n153\n \n-COC\n6\nH\n5\n \n \n573\n \n \n \n154\n \n-COC\n2\nH\n7\n \n \n539\n \n \n \n155\n \n \n \n \n \n \n563\n \n \n \n \n\n\n \n[Table 28]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n156\n \n-CO\n2\nCH\n2\nC\n6\nH\n5\n \n \n617\n \n \n \n157\n \n-CO\n2\nC\n2\nH\n5\n \n \n555\n \n \n \n158\n \n-COCH\n3\n \n \n525\n \n \n \n159\n \n-CO\n2\nC(CH\n3\n)\n3\n \n \n583\n \n \n \n160\n \n-COC\n6\nH\n5\n \n \n587\n \n \n \n161\n \n-COC\n3\nH\n7\n \n \n553\n \n \n \n162\n \n \n \n \n \n \n577\n \n \n \n \n\n\n \n[Table 29]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nR3\n \nR4\n \nR5\n \nMS(M+1)\n \n \n \n \n163\n \n-H\n \n-H\n \n-H\n \n-Cl\n \n-H\n \n608\n \n \n \n164\n \n-H\n \n-H\n \n-H\n \n-H\n \n-F\n \n592\n \n \n \n165\n \n-H\n \n-H\n \n-H\n \n-H\n \n-Cl\n \n608\n \n \n \n166\n \n-H\n \n-H\n \n-Cl\n \n-Cl\n \n-H\n \n642\n \n \n \n167\n \n-H\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n604\n \n \n \n168\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-OCH\n3\n \n \n-H\n \n634\n \n \n \n169\n \n-H\n \n-H\n \n-OH\n3\n \n \n-H\n \n-H\n \n588\n \n \n \n170\n \n-H\n \n-H\n \n-H\n \n-CH\n3\n \n \n-H\n \n588\n \n \n \n171\n \n-H\n \n-H\n \n-H\n \n-H\n \n-CH\n3\n \n \n588\n \n \n \n172\n \n-H\n \n-H\n \n-F\n \n-H\n \n-H\n \n592\n \n \n \n173\n \n-H\n \n-H\n \n-H\n \n-F\n \n-H\n \n592\n \n \n \n174\n \n-H\n \n-H\n \n-OCF\n3\n \n \n-H\n \n-H\n \n658\n \n \n \n175\n \n-H\n \n-H\n \n-H\n \n-OCF\n3\n \n \n-H\n \n658\n \n \n \n176\n \n-H\n \n-H\n \n-H\n \n-H\n \n-OCF\n3\n \n \n658\n \n \n \n177\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-Cl\n \n-H\n \n638\n \n \n \n178\n \n-H\n \n-H\n \n-H\n \n-Br\n \n-H\n \n652\n \n \n \n179\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n604\n \n \n \n180\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n574\n \n \n \n \n\n\n \n[Table 30]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nR3\n \nR4\n \nR5\n \nMS(M+1)\n \n \n \n \n181\n \n-H\n \n-H\n \n-H\n \n-Cl\n \n-H\n \n622\n \n \n \n182\n \n-H\n \n-H\n \n-H\n \n-H\n \n-F\n \n606\n \n \n \n183\n \n-H\n \n-H\n \n-H\n \n-H\n \n-Cl\n \n622\n \n \n \n184\n \n-H\n \n-H\n \n-Cl\n \n-Cl\n \n-H\n \n656\n \n \n \n185\n \n-H\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n618\n \n \n \n186\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-OCH\n3\n \n \n-H\n \n648\n \n \n \n187\n \n-H\n \n-H\n \n-CH\n3\n \n \n-H\n \n-H\n \n602\n \n \n \n188\n \n-H\n \n-H\n \n-H\n \n-CH\n3\n \n \n-H\n \n602\n \n \n \n189\n \n-H\n \n-H\n \n-H\n \n-H\n \n-CH\n3\n \n \n602\n \n \n \n190\n \n-H\n \n-H\n \n-F\n \n-H\n \n-H\n \n606\n \n \n \n191\n \n-H\n \n-H\n \n-H\n \n-F\n \n-H\n \n606\n \n \n \n192\n \n-H\n \n-H\n \n-OCF\n3\n \n \n-H\n \n-H\n \n672\n \n \n \n193\n \n-H\n \n-H\n \n-H\n \n-OCF\n3\n \n \n-H\n \n672\n \n \n \n194\n \n-H\n \n-H\n \n-H\n \n-H\n \n-OCF\n3\n \n \n672\n \n \n \n195\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-Cl\n \n-H\n \n652\n \n \n \n196\n \n-H\n \n-H\n \n-H\n \n-Br\n \n-H\n \n666\n \n \n \n197\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n618\n \n \n \n198\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n588\n \n \n \n \n\n\n \n[Table 31]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nR3\n \nR4\n \nR5\n \nMS(M+1)\n \n \n \n \n199\n \n-H\n \n-H\n \n-CN\n \n-H\n \n-H\n \n585\n \n \n \n200\n \n-H\n \n-H\n \n-H\n \n-H\n \n-OCH\n3\n \n \n590\n \n \n \n201\n \n-H\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n590\n \n \n \n202\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n590\n \n \n \n203\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n560\n \n \n \n204\n \n-H\n \n-H\n \n-H\n \n-H\n \n-Cl\n \n594\n \n \n \n205\n \n-H\n \n-H\n \n-H\n \n-Cl\n \n-H\n \n594\n \n \n \n206\n \n-H\n \n-H\n \n-Cl\n \n-H\n \n-H\n \n594\n \n \n \n207\n \n-H\n \n-H\n \n-H\n \n-H\n \n-CH\n3\n \n \n574\n \n \n \n208\n \n-H\n \n-H\n \n-CH\n3\n \n \n-H\n \n-H\n \n574\n \n \n \n209\n \n-H\n \n-H\n \n-F\n \n-H\n \n-H\n \n578\n \n \n \n210\n \n-H\n \n-H\n \n-CF\n3\n \n \n-H\n \n-H\n \n628\n \n \n \n \n\n\n \n[Table 32]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nR3\n \nR4\n \nR5\n \nMS(M+1)\n \n \n \n \n211\n \n-H\n \n-H\n \n-CN\n \n-H\n \n-H\n \n599\n \n \n \n212\n \n-H\n \n-H\n \n-H\n \n-H\n \n-OCH\n3\n \n \n604\n \n \n \n213\n \n-H\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n604\n \n \n \n214\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n604\n \n \n \n215\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n574\n \n \n \n216\n \n-H\n \n-H\n \n-H\n \n-H\n \n-Cl\n \n608\n \n \n \n217\n \n-H\n \n-H\n \n-H\n \n-Cl\n \n-H\n \n608\n \n \n \n218\n \n-H\n \n-H\n \n-Cl\n \n-H\n \n-H\n \n608\n \n \n \n219\n \n-H\n \n-H\n \n-H\n \n-H\n \n-CH\n3\n \n \n588\n \n \n \n220\n \n-H\n \n-H\n \n-CH\n3\n \n \n-H\n \n-H\n \n588\n \n \n \n221\n \n-H\n \n-H\n \n-F\n \n-H\n \n-H\n \n592\n \n \n \n222\n \n-H\n \n-H\n \n-CF\n3\n \n \n-H\n \n-H\n \n642\n \n \n \n \n\n\n \n[Table 33]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n223\n \n-OCH\n3\n \n \n498\n \n \n \n224\n \n-CH\n2\nCONHC\n2\nH\n5\n \n \n553\n \n \n \n225\n \n-OH\n \n484\n \n \n \n226\n \n-CO\n2\nC\n2\nH\n5\n \n \n540\n \n \n \n227\n \n-CONH\n2\n \n \n511\n \n \n \n228\n \n-CH\n2\nOH\n \n498\n \n \n \n229\n \n-N(CH\n3\n)CO\n2\nC(CH\n3\n)\n3\n \n \n597\n \n \n \n230\n \n-NHCO\n2\nC(CH\n3\n)\n3\n \n \n583\n \n \n \n231\n \n-CO\n2\nC(CH\n3\n)\n3\n \n \n568\n \n \n \n232\n \n-NHCOCH\n3\n \n \n525\n \n \n \n233\n \n-N(CH\n3\n)COCH\n3\n \n \n539\n \n \n \n234\n \n-COOH\n \n512\n \n \n \n235\n \n-N(CH\n3\n)CO(CH\n2\n)\n2\nCH\n3\n \n \n567\n \n \n \n236\n \n-NHCO(CH\n2\n)\n2\nCH\n3\n \n \n553\n \n \n \n \n\n\n \n[Table 34]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n237\n \n \n \n \n \n \n578\n \n \n \n238\n \n \n \n \n \n \n574\n \n \n \n239\n \n \n \n \n \n \n560\n \n \n \n240\n \n \n \n \n \n \n592\n \n \n \n241\n \n \n \n \n \n \n572\n \n \n \n242\n \n \n \n \n \n \n558\n \n \n \n243\n \n \n \n \n \n \n602\n \n \n \n244\n \n \n \n \n \n \n588\n \n \n \n245\n \n \n \n \n \n \n642\n \n \n \n246\n \n \n \n \n \n \n606\n \n \n \n247\n \n \n \n \n \n \n602\n \n \n \n \n\n\n \n[Table 35]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n248\n \n \n \n \n \n \n590\n \n \n \n249\n \n \n \n \n \n \n572\n \n \n \n250\n \n \n \n \n \n \n545\n \n \n \n251\n \n \n \n \n \n \n561\n \n \n \n252\n \n \n \n \n \n \n561\n \n \n \n253\n \n \n \n \n \n \n575\n \n \n \n254\n \n \n \n \n \n \n575\n \n \n \n255\n \n \n \n \n \n \n587\n \n \n \n256\n \n \n \n \n \n \n601\n \n \n \n \n\n\n \n[Table 36]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n257\n \n \n \n \n \n \n651\n \n \n \n258\n \n \n \n \n \n \n655\n \n \n \n259\n \n \n \n \n \n \n593\n \n \n \n260\n \n \n \n \n \n \n621\n \n \n \n \n\n\n \n[Table 37]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n261\n \n \n \n \n \n \n592\n \n \n \n262\n \n \n \n \n \n \n588\n \n \n \n263\n \n \n \n \n \n \n574\n \n \n \n264\n \n \n \n \n \n \n606\n \n \n \n265\n \n \n \n \n \n \n586\n \n \n \n266\n \n \n \n \n \n \n572\n \n \n \n267\n \n \n \n \n \n \n616\n \n \n \n268\n \n \n \n \n \n \n602\n \n \n \n269\n \n \n \n \n \n \n656\n \n \n \n270\n \n \n \n \n \n \n620\n \n \n \n271\n \n \n \n \n \n \n616\n \n \n \n \n\n\n \n[Table 38]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n272\n \n-OCH\n3\n \n \n512\n \n \n \n273\n \n-CH\n2\nCONHC\n2\nH\n5\n \n \n567\n \n \n \n274\n \n-OH\n \n498\n \n \n \n275\n \n-CO\n2\nC\n2\nH\n5\n \n \n554\n \n \n \n276\n \n-CONH\n2\n \n \n525\n \n \n \n277\n \n-CH\n2\nOH\n \n512\n \n \n \n278\n \n-N(CH\n3\n)CO\n2\nC(CH\n3\n)\n3\n \n \n611\n \n \n \n279\n \n-NHCO\n2\nC(CH\n3\n)\n3\n \n \n597\n \n \n \n280\n \n-CO\n2\nC(CH\n3\n)\n3\n \n \n582\n \n \n \n281\n \n-NHCOCH\n3\n \n \n539\n \n \n \n282\n \n-N(CH\n3\n)COCH\n3\n \n \n553\n \n \n \n283\n \n-N(CH\n3\n)CO(CH\n2\n)\n2\nCH\n3\n \n \n581\n \n \n \n284\n \n-NHCO(CH\n2\n)\n2\nCH\n3\n \n \n567\n \n \n \n285\n \n-COOH\n \n526\n \n \n \n \n\n\n \n[Table 39]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n286\n \n \n \n \n \n \n604\n \n \n \n287\n \n \n \n \n \n \n586\n \n \n \n288\n \n \n \n \n \n \n559\n \n \n \n289\n \n \n \n \n \n \n575\n \n \n \n290\n \n \n \n \n \n \n575\n \n \n \n291\n \n \n \n \n \n \n589\n \n \n \n292\n \n \n \n \n \n \n589\n \n \n \n293\n \n \n \n \n \n \n601\n \n \n \n294\n \n \n \n \n \n \n615\n \n \n \n \n\n\n \n[Table 40]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n295\n \n \n \n \n \n \n665\n \n \n \n296\n \n \n \n \n \n \n669\n \n \n \n297\n \n \n \n \n \n \n607\n \n \n \n298\n \n \n \n \n \n \n635\n \n \n \n \n\n\n \n[Table 41]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n299\n \n \n \n \n \n \n644\n \n \n \n300\n \n \n \n \n \n \n630\n \n \n \n301\n \n \n \n \n \n \n497\n \n \n \n302\n \n \n \n \n \n \n599\n \n \n \n303\n \n \n \n \n \n \n511\n \n \n \n304\n \n \n \n \n \n \n587\n \n \n \n305\n \n \n \n \n \n \n573\n \n \n \n306\n \n \n \n \n \n \n525\n \n \n \n307\n \n \n \n \n \n \n553\n \n \n \n308\n \n \n \n \n \n \n539\n \n \n \n \n\n\n \n[Table 42]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n309\n \n \n \n \n \n \n480\n \n \n \n310\n \n \n \n \n \n \n472\n \n \n \n311\n \n \n \n \n \n \n578\n \n \n \n312\n \n \n \n \n \n \n573\n \n \n \n313\n \n \n \n \n \n \n496\n \n \n \n314\n \n \n \n \n \n \n544\n \n \n \n315\n \n \n \n \n \n \n560\n \n \n \n316\n \n \n \n \n \n \n594\n \n \n \n \n\n\n \n[Table 43]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n317\n \n \n \n \n \n \n540\n \n \n \n318\n \n \n \n \n \n \n600\n \n \n \n319\n \n \n \n \n \n \n627\n \n \n \n320\n \n \n \n \n \n \n484\n \n \n \n321\n \n \n \n \n \n \n540\n \n \n \n322\n \n \n \n \n \n \n512\n \n \n \n323\n \n \n \n \n \n \n574\n \n \n \n324\n \n \n \n \n \n \n526\n \n \n \n325\n \n \n \n \n \n \n614\n \n \n \n \n\n\n \n[Table 44]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n326\n \n \n \n \n \n \n543\n \n \n \n327\n \n \n \n \n \n \n486\n \n \n \n328\n \n \n \n \n \n \n470\n \n \n \n329\n \n \n \n \n \n \n498\n \n \n \n330\n \n \n \n \n \n \n546\n \n \n \n331\n \n \n \n \n \n \n559\n \n \n \n332\n \n \n \n \n \n \n539\n \n \n \n333\n \n \n \n \n \n \n483\n \n \n \n334\n \n \n \n \n \n \n593\n \n \n \n335\n \n \n \n \n \n \n573\n \n \n \n \n\n\n \n[Table 45]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n336\n \n \n \n \n \n \n468\n \n \n \n337\n \n \n \n \n \n \n658\n \n \n \n338\n \n \n \n \n \n \n644\n \n \n \n339\n \n \n \n \n \n \n511\n \n \n \n340\n \n \n \n \n \n \n613\n \n \n \n341\n \n \n \n \n \n \n484\n \n \n \n342\n \n \n \n \n \n \n525\n \n \n \n343\n \n \n \n \n \n \n601\n \n \n \n344\n \n \n \n \n \n \n587\n \n \n \n345\n \n \n \n \n \n \n539\n \n \n \n346\n \n \n \n \n \n \n567\n \n \n \n347\n \n \n \n \n \n \n553\n \n \n \n \n\n\n \n[Table 46]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n348\n \n \n \n \n \n \n494\n \n \n \n349\n \n \n \n \n \n \n486\n \n \n \n350\n \n \n \n \n \n \n592\n \n \n \n351\n \n \n \n \n \n \n587\n \n \n \n352\n \n \n \n \n \n \n499\n \n \n \n353\n \n \n \n \n \n \n510\n \n \n \n354\n \n \n \n \n \n \n558\n \n \n \n355\n \n \n \n \n \n \n574\n \n \n \n356\n \n \n \n \n \n \n608\n \n \n \n \n\n\n \n[Table 47]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n357\n \n \n \n \n \n \n554\n \n \n \n358\n \n \n \n \n \n \n614\n \n \n \n359\n \n \n \n \n \n \n641\n \n \n \n360\n \n \n \n \n \n \n498\n \n \n \n361\n \n \n \n \n \n \n554\n \n \n \n362\n \n \n \n \n \n \n526\n \n \n \n363\n \n \n \n \n \n \n588\n \n \n \n364\n \n \n \n \n \n \n540\n \n \n \n365\n \n \n \n \n \n \n628\n \n \n \n \n\n\n \n[Table 48]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n366\n \n \n \n \n \n \n557\n \n \n \n367\n \n \n \n \n \n \n500\n \n \n \n368\n \n \n \n \n \n \n484\n \n \n \n369\n \n \n \n \n \n \n512\n \n \n \n370\n \n \n \n \n \n \n560\n \n \n \n371\n \n \n \n \n \n \n573\n \n \n \n372\n \n \n \n \n \n \n553\n \n \n \n373\n \n \n \n \n \n \n497\n \n \n \n374\n \n \n \n \n \n \n607\n \n \n \n375\n \n \n \n \n \n \n587\n \n \n \n \n\n\n \n[Table 49]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nR3\n \nR4\n \nR5\n \nMS(M+1)\n \n \n \n \n376\n \n-H\n \n-H\n \n-OCF\n3\n \n \n-H\n \n-H\n \n560\n \n \n \n377\n \n-H\n \n-H\n \n-H\n \n-H\n \n-SO\n2\nNH\n2\n \n \n555\n \n \n \n378\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n506\n \n \n \n379\n \n-H\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n506\n \n \n \n380\n \n-H\n \n-H\n \n-COCH\n3\n \n \n-H\n \n-H\n \n518\n \n \n \n381\n \n-H\n \n-H\n \n-H\n \n-H\n \n-CO\n2\nCH\n3\n \n \n534\n \n \n \n382\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-OCH\n5\n \n \n536\n \n \n \n383\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n536\n \n \n \n384\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-OCH\n3\n \n \n-H\n \n536\n \n \n \n385\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-NHCOCH\n3\n \n \n-H\n \n563\n \n \n \n386\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-OCH\n3\n \n \n-H\n \n536\n \n \n \n387\n \n-H\n \n-H\n \n-N(CH\n3\n)\n2\n \n \n-H\n \n-H\n \n519\n \n \n \n388\n \n-H\n \n-H\n \n-H\n \n-COCH\n3\n \n \n-H\n \n518\n \n \n \n389\n \n-H\n \n-H\n \n-H\n \n-NHCOCH\n3\n \n \n-H\n \n533\n \n \n \n390\n \n-H\n \n-H\n \n-NHCOCH\n3\n \n \n-H\n \n-H\n \n533\n \n \n \n391\n \n-H\n \n-CN\n \n-H\n \n-H\n \n-H\n \n501\n \n \n \n392\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-CO\n2\nCH\n3\n \n \n-H\n \n564\n \n \n \n393\n \n-H\n \n-H\n \n-OC\n6\nH\n5\n \n \n-H\n \n-H\n \n568\n \n \n \n394\n \n-H\n \n-CO\n2\nCH\n3\n \n \n-H\n \n-CO\n2\nCH\n3\n \n \n-H\n \n592\n \n \n \n395\n \n-H\n \n-H\n \n-OH\n \n-Cl\n \n-H\n \n526\n \n \n \n396\n \n-Cl\n \n-H\n \n-H\n \n-NHCOCH\n3\n \n \n-H\n \n567\n \n \n \n397\n \n-H\n \n-CN\n \n-H\n \n-H\n \n-Cl\n \n535\n \n \n \n398\n \n-Cl\n \n-H\n \n-H\n \n-CONH\n2\n \n \n-H\n \n553\n \n \n \n399\n \n-H\n \n-H\n \n-NO\n2\n \n \n-H\n \n-H\n \n521\n \n \n \n400\n \n-H\n \n-H\n \n-CN\n \n-H\n \n-H\n \n501\n \n \n \n \n\n\n \n[Table 50]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nR3\n \nR4\n \nR5\n \nMS(M+1)\n \n \n \n \n401\n \n-H\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n558\n \n \n \n402\n \n-H\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n584\n \n \n \n403\n \n-H\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n561\n \n \n \n404\n \n-H\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n605\n \n \n \n405\n \n-H\n \n-H\n \n-H\n \n \n \n \n \n \n-H\n \n587\n \n \n \n406\n \n-H\n \n-H\n \n-H\n \n \n \n \n \n \n-H\n \n542\n \n \n \n \n\n\n \n[Table 51]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nR3\n \nR4\n \nR5\n \nMS(M+1)\n \n \n \n \n407\n \n-H\n \n-H\n \n-OCF\n3\n \n \n-H\n \n-H\n \n574\n \n \n \n408\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n520\n \n \n \n409\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n520\n \n \n \n410\n \n-H\n \n-H\n \n-COCH\n3\n \n \n-H\n \n-H\n \n532\n \n \n \n411\n \n-CO\n2\nCH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n548\n \n \n \n412\n \n-OCH\n3\n \n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n550\n \n \n \n413\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-OCH\n3\n \n \n550\n \n \n \n414\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-OCH\n3\n \n \n-H\n \n550\n \n \n \n415\n \n-H\n \n-NHCOCH\n3\n \n \n-H\n \n-H\n \n-OCH\n3\n \n \n577\n \n \n \n416\n \n-H\n \n-OCH\n3\n \n \n-OCH\n3\n \n \n-H\n \n-H\n \n550\n \n \n \n417\n \n-H\n \n-H\n \n-N(CH\n3\n)\n2\n \n \n-H\n \n-H\n \n533\n \n \n \n418\n \n-H\n \n-COCH\n3\n \n \n-H\n \n-H\n \n-H\n \n532\n \n \n \n419\n \n-H\n \n-NHCOCH\n3\n \n \n-H\n \n-H\n \n-H\n \n547\n \n \n \n420\n \n-H\n \n-H\n \n-NHCOCH\n3\n \n \n-H\n \n-H\n \n547\n \n \n \n421\n \n-H\n \n-CO\n2\nCH\n3\n \n \n-H\n \n-H\n \n-OCH\n3\n \n \n578\n \n \n \n422\n \n-H\n \n-H\n \n-OC\n6\nH\n5\n \n \n-H\n \n-H\n \n582\n \n \n \n423\n \n-H\n \n-CO\n2\nCH\n3\n \n \n-H\n \n-CO\n2\nCH\n3\n \n \n-H\n \n606\n \n \n \n424\n \n-OCH\n3\n \n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n550\n \n \n \n425\n \n-H\n \n-Cl\n \n-OH\n \n-H\n \n-H\n \n540\n \n \n \n426\n \n-H\n \n-OCH\n2\nC\n6\nH\n5\n \n \n-H\n \n-H\n \n-H\n \n596\n \n \n \n427\n \n-H\n \n-H\n \n-NHSO\n2\nCH\n3\n \n \n-H\n \n-H\n \n583\n \n \n \n428\n \n-H\n \n-H\n \n-CONHC\n6\nH\n5\n \n \n-H\n \n-H\n \n609\n \n \n \n429\n \n-H\n \n-H\n \n-CONHCH\n3\n \n \n-H\n \n-H\n \n547\n \n \n \n430\n \n-H\n \n-H\n \n-NHC\n6\nH\n5\n \n \n-H\n \n-H\n \n581\n \n \n \n431\n \n-H\n \n-H\n \n-CH\n2\nCH\n2\nOH\n \n-H\n \n-H\n \n534\n \n \n \n432\n \n-H\n \n-H\n \n-CCH\n \n-H\n \n-H\n \n514\n \n \n \n433\n \n-H\n \n-H\n \n-COC\n3\nH\n7\n \n \n-H\n \n-H\n \n560\n \n \n \n434\n \n-NHCOCH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n547\n \n \n \n435\n \n-H\n \n-CONHCH\n3\n \n \n-H\n \n-H\n \n-H\n \n547\n \n \n \n \n\n\n \n[Table 52]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nR3\n \nR4\n \nR5\n \nMS(M+1)\n \n \n \n \n436\n \n-H\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n573\n \n \n \n437\n \n-H\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n672\n \n \n \n438\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n-H\n \n601\n \n \n \n439\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n-H\n \n556\n \n \n \n440\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n-H\n \n557\n \n \n \n \n\n\n \n[Table 53]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nR3\n \nR4\n \nR5\n \nR6\n \nMS(M+1)\n \n \n \n \n441\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n490\n \n \n \n442\n \n-Cl\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n524\n \n \n \n443\n \n-H\n \n-Cl\n \n-H\n \n-H\n \n-H\n \n-H\n \n524\n \n \n \n444\n \n-H\n \n-H\n \n-Cl\n \n-H\n \n-H\n \n-H\n \n524\n \n \n \n445\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n-CH\n2\nCONHCH\n3\n \n \n561\n \n \n \n446\n \n-H\n \n-H\n \n-OC\n2\nH\n5\n \n \n-H\n \n-H\n \n-CH\n3\n \n \n548\n \n \n \n447\n \n-H\n \n-OCH\n3\n \n \n-OCH\n3\n \n \n-H\n \n-H\n \n-CH\n3\n \n \n564\n \n \n \n448\n \n-H\n \n-H\n \n-OC\n2\nH\n5\n \n \n-H\n \n-H\n \n-C\n2\nH\n5\n \n \n562\n \n \n \n449\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n520\n \n \n \n450\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n520\n \n \n \n451\n \n-H\n \n-H\n \n-OCF\n3\n \n \n-H\n \n-H\n \n-CH\n3\n \n \n588\n \n \n \n452\n \n-H\n \n-H\n \n-OCF\n3\n \n \n-H\n \n-H\n \n-H\n \n574\n \n \n \n453\n \n-H\n \n-OCH\n3\n \n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n550\n \n \n \n454\n \n-H\n \n-OCH\n3\n \n \n-OCH\n3\n \n \n-H\n \n-H\n \n-C\n3\nH\n5\n \n \n578\n \n \n \n455\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n520\n \n \n \n456\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n550\n \n \n \n457\n \n-H\n \n-OC\n4\nH\n9\n \n \n-H\n \n-OC\n4\nH\n9\n \n \n-H\n \n-H\n \n634\n \n \n \n458\n \n-OC\n2\nH\n5\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n534\n \n \n \n459\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n-(CH\n2\n)\n2\nOH\n \n548\n \n \n \n460\n \n-H\n \n-Cl\n \n-OCHF\n2\n \n \n-H\n \n-H\n \n-H\n \n590\n \n \n \n461\n \n-H\n \n-OCF\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n574\n \n \n \n462\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-CH\n3\n \n \n534\n \n \n \n \n\n\n \n[Table 54]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nR3\n \nR4\n \nR5\n \nR6\n \nMS(M+1)\n \n \n \n \n463\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n504\n \n \n \n464\n \n-Cl\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n538\n \n \n \n465\n \n-H\n \n-Cl\n \n-H\n \n-H\n \n-H\n \n-H\n \n538\n \n \n \n466\n \n-H\n \n-H\n \n-Cl\n \n-H\n \n-H\n \n-H\n \n538\n \n \n \n467\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n-CH\n2\nCONHCH\n3\n \n \n575\n \n \n \n468\n \n-H\n \n-H\n \n-OC\n2\nH\n5\n \n \n-H\n \n-H\n \n-CH\n3\n \n \n562\n \n \n \n469\n \n-H\n \n-OCH\n3\n \n \n-OCH\n3\n \n \n-H\n \n-H\n \n-CH\n3\n \n \n578\n \n \n \n470\n \n-H\n \n-H\n \n-OC\n2\nH\n5\n \n \n-H\n \n-H\n \n-C\n2\nH\n5\n \n \n576\n \n \n \n471\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n534\n \n \n \n472\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n534\n \n \n \n473\n \n-H\n \n-H\n \n-OCF\n3\n \n \n-H\n \n-H\n \n-CH\n3\n \n \n602\n \n \n \n474\n \n-H\n \n-H\n \n-OCF\n3\n \n \n-H\n \n-H\n \n-H\n \n588\n \n \n \n475\n \n-H\n \n-OCH\n3\n \n \n-OCH\n2\n \n \n-H\n \n-H\n \n-H\n \n564\n \n \n \n476\n \n-H\n \n-OCH\n3\n \n \n-OCH\n3\n \n \n-H\n \n-H\n \n-C\n2\nH\n5\n \n \n592\n \n \n \n477\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n534\n \n \n \n478\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n564\n \n \n \n479\n \n-H\n \n-OC\n4\nH\n9\n \n \n-H\n \n-OC\n4\nH\n9\n \n \n-H\n \n-H\n \n648\n \n \n \n480\n \n-OC\n2\nH\n5\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n548\n \n \n \n481\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n-(CH\n2\n)\n2\nOH\n \n562\n \n \n \n482\n \n-H\n \n-Cl\n \n-OCHF\n2\n \n \n-H\n \n-H\n \n-H\n \n604\n \n \n \n483\n \n-H\n \n-OCF\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n588\n \n \n \n484\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-CH\n3\n \n \n548\n \n \n \n \n\n\n \n[Table 55]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n485\n \n-cyclo-C\n6\nH\n11\n \n \n-CH\n3\n \n \n496\n \n \n \n486\n \n-cyclo-C\n6\nH\n11\n \n \n-H\n \n482\n \n \n \n487\n \n-CH\n2\nCH(CH\n3\n)\n2\n \n \n-CH\n2\nCH(CH\n3\n)\n2\n \n \n512\n \n \n \n488\n \n-CH\n2\nCH\n2\nOH\n \n-CH\n2\nCH\n2\nOH\n \n488\n \n \n \n489\n \n-CH\n2\nCH\n2\nOH\n \n-C\n2\nH\n5\n \n \n472\n \n \n \n490\n \n-cyclo-C\n6\nH\n11\n \n \n-CH\n2\nCH\n2\nOH\n \n526\n \n \n \n491\n \n-CH\n2\nCH\n2\nOCH\n3\n \n \n-CH\n2\nCH\n2\nOCH\n3\n \n \n516\n \n \n \n492\n \n-C\n2\nH\n5\n \n \n-C\n2\nH\n5\n \n \n456\n \n \n \n493\n \n-C\n4\nH\n9\n \n \n-H\n \n456\n \n \n \n494\n \n-C(CH\n3\n)\n2\n \n \n-H\n \n456\n \n \n \n495\n \n-cyclo-C\n2\nH\n5\n \n \n-H\n \n440\n \n \n \n496\n \n-CH\n3\n \n \n-H\n \n414\n \n \n \n497\n \n-C\n2\nH\n5\n \n \n-H\n \n428\n \n \n \n498\n \n-CH\n2\nCH(CH\n3\n)\n2\n \n \n-H\n \n456\n \n \n \n499\n \n-CH\n2\nCH\n2\nOCH\n2\n \n \n-H\n \n458\n \n \n \n500\n \n-CH\n2\nCH\n2\nOC\n2\nH\n5\n \n \n-H\n \n472\n \n \n \n501\n \n-(CH\n2\n)\n2\nOC\n2\nH\n5\n \n \n-H\n \n486\n \n \n \n502\n \n-(CH\n2\n)\n2\nOC\n6\nH\n5\n \n \n-H\n \n520\n \n \n \n503\n \n-CH\n2\n-cyclo-C\n2\nH\n5\n \n \n-H\n \n454\n \n \n \n504\n \n-(CH\n2\n)\n2\nNHCOCH\n3\n \n \n-H\n \n485\n \n \n \n505\n \n-(CH\n2\n)\n5\nOH\n \n-H\n \n486\n \n \n \n506\n \n-(CH\n2\n)\n2\nC\n6\nH\n5\n \n \n-H\n \n504\n \n \n \n507\n \n-CH\n2\nCO\n2\nCH\n3\n \n \n-H\n \n472\n \n \n \n508\n \n-CH\n2\nCONH\n2\n \n \n-H\n \n457\n \n \n \n509\n \n-CH(CO\n2\nC\n2\nH\n5\n)\n2\n \n \n-H\n \n558\n \n \n \n510\n \n-CH(CH\n3\n)CO\n2\nC\n2\nH\n5\n \n \n-H\n \n500\n \n \n \n511\n \n-CH\n2\nCO\n2\nCH\n3\n \n \n-CH\n3\n \n \n486\n \n \n \n512\n \n-CH\n2\nCCH\n \n-H\n \n438\n \n \n \n513\n \n-(CH\n2\n)\n2\nCH(CH\n3\n)\n2\n \n \n-H\n \n470\n \n \n \n514\n \n-(CH\n2\n)\n3\nCO\n2\nC\n2\nH\n5\n \n \n-CH\n3\n \n \n528\n \n \n \n515\n \n-(CH\n2\n)\n2\nCO\n2\nC\n2\nH\n5\n \n \n-H\n \n528\n \n \n \n516\n \n-CH(CONH\n2\n)\n2\n \n \n-H\n \n500\n \n \n \n517\n \n-CH\n2\nCF\n3\n \n \n-H\n \n482\n \n \n \n518\n \n-NHCH\n2\nCF\n3\n \n \n-H\n \n497\n \n \n \n519\n \n-CH\n3\n \n \n-CH\n3\n \n \n426\n \n \n \n520\n \n-(CH\n2\n)\n2\nOCH(CH\n3\n)\n2\n \n \n-H\n \n500\n \n \n \n \n\n\n \n[Table 56]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n521\n \n-CH\n2\nCN\n \n-H\n \n439\n \n \n \n522\n \n-(CH\n2\n)\n2\nOCH(CH\n3\n)\n2\n \n \n-H\n \n486\n \n \n \n523\n \n-CH(C\n2\nH\n5\n)CH\n2\nOCH\n3\n \n \n-H\n \n486\n \n \n \n524\n \n-CH(CH\n3\n)CH\n2\nOCH\n2\n \n \n-H\n \n472\n \n \n \n525\n \n-CH\n2\nCH\n2\nF\n \n-H\n \n446\n \n \n \n526\n \n-CH\n3\nCH(OH)CH\n2\nOH\n \n-H\n \n474\n \n \n \n527\n \n-CH\n2\nCONHCH\n3\n \n \n-H\n \n471\n \n \n \n528\n \n-(CH\n2\n)\n2\nSCH\n3\n \n \n-H\n \n474\n \n \n \n529\n \n-CH\n2\nCH\n2\nOH\n \n-H\n \n444\n \n \n \n530\n \n-C\n5\nH\n13\n \n \n-H\n \n484\n \n \n \n531\n \n-CH\n2\nCON(CH\n3\n)\n2\n \n \n-CH\n3\n \n \n499\n \n \n \n532\n \n-(CH\n2\n)\n2\nN(CH\n3\n)COCH\n3\n \n \n-H\n \n499\n \n \n \n533\n \n-(CH\n2\n)\n2\nN(CH\n2\n)CO(CH\n2\n)\n2\nCH\n3\n \n \n-H\n \n527\n \n \n \n \n\n\n \n[Table 57]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n534\n \n \n \n \n \n \n-CH\n3\n \n \n519\n \n \n \n535\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n526\n \n \n \n536\n \n \n \n \n \n \n-H\n \n518\n \n \n \n537\n \n \n \n \n \n \n-H\n \n491\n \n \n \n538\n \n \n \n \n \n \n-H\n \n491\n \n \n \n539\n \n \n \n \n \n \n-H\n \n491\n \n \n \n540\n \n \n \n \n \n \n-H\n \n480\n \n \n \n541\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n533\n \n \n \n542\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n572\n \n \n \n543\n \n \n \n \n \n \n-CH\n3\n \n \n534\n \n \n \n544\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n531\n \n \n \n545\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n633\n \n \n \n \n\n\n \n[Table 58]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n546\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n631\n \n \n \n547\n \n \n \n \n \n \n-CH\n2\n \n \n601\n \n \n \n548\n \n \n \n \n \n \n-CH\n3\n \n \n539\n \n \n \n549\n \n \n \n \n \n \n-CH\n9\n \n \n548\n \n \n \n550\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n562\n \n \n \n551\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n592\n \n \n \n552\n \n \n \n \n \n \n-H\n \n454\n \n \n \n553\n \n \n \n \n \n \n-H\n \n534\n \n \n \n554\n \n \n \n \n \n \n-H\n \n534\n \n \n \n555\n \n \n \n \n \n \n-H\n \n538\n \n \n \n556\n \n \n \n \n \n \n-H\n \n534\n \n \n \n557\n \n \n \n \n \n \n-H\n \n498\n \n \n \n558\n \n \n \n \n \n \n-H\n \n508\n \n \n \n \n\n\n \n[Table 59]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n559\n \n \n \n \n \n \n-H\n \n562\n \n \n \n560\n \n \n \n \n \n \n-H\n \n548\n \n \n \n561\n \n \n \n \n \n \n-H\n \n578\n \n \n \n562\n \n \n \n \n \n \n-H\n \n514\n \n \n \n563\n \n \n \n \n \n \n-H\n \n528\n \n \n \n564\n \n \n \n \n \n \n-H\n \n537\n \n \n \n565\n \n \n \n \n \n \n-H\n \n499\n \n \n \n566\n \n \n \n \n \n \n-H\n \n547\n \n \n \n567\n \n \n \n \n \n \n-H\n \n601\n \n \n \n568\n \n \n \n \n \n \n-H\n \n552\n \n \n \n569\n \n \n \n \n \n \n-H\n \n484\n \n \n \n \n\n\n \n[Table 60]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n570\n \n \n \n \n \n \n-H\n \n471\n \n \n \n571\n \n \n \n \n \n \n-H\n \n485\n \n \n \n572\n \n \n \n \n \n \n-CH\n3\n \n \n577\n \n \n \n573\n \n \n \n \n \n \n-CH\n3\n \n \n561\n \n \n \n574\n \n \n \n \n \n \n-H\n \n534\n \n \n \n575\n \n \n \n \n \n \n-H\n \n518\n \n \n \n576\n \n \n \n \n \n \n-H\n \n518\n \n \n \n577\n \n \n \n \n \n \n-H\n \n545\n \n \n \n578\n \n \n \n \n \n \n-H\n \n559\n \n \n \n579\n \n \n \n \n \n \n-H\n \n505\n \n \n \n580\n \n \n \n \n \n \n-CH(CH\n3\n)\n2\n \n \n547\n \n \n \n581\n \n \n \n \n \n \n-CH\n3\n \n \n619\n \n \n \n \n\n\n \n[Table 61]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n582\n \n \n \n \n \n \n-CH\n3\n \n \n615\n \n \n \n583\n \n \n \n \n \n \n-CH\n3\n \n \n615\n \n \n \n584\n \n \n \n \n \n \n-CH\n3\n \n \n615\n \n \n \n585\n \n \n \n \n \n \n-CH,\n \n635\n \n \n \n586\n \n \n \n \n \n \n-CH\n3\n \n \n635\n \n \n \n587\n \n \n \n \n \n \n-C\n4\nH\n9\n \n \n657\n \n \n \n588\n \n \n \n \n \n \n-CH(CH\n3\n)\n2\n \n \n643\n \n \n \n589\n \n \n \n \n \n \n-H\n \n583\n \n \n \n590\n \n \n \n \n \n \n-H\n \n569\n \n \n \n591\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n573\n \n \n \n592\n \n \n \n \n \n \n-H\n \n540\n \n \n \n \n\n\n \n[Table 62]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \nMW\n \n \n \n \n593\n \n \n \n \n \n \n-H\n \n558\n \n557.72\n \n \n \n594\n \n \n \n \n \n \n-H\n \n558\n \n557.68\n \n \n \n595\n \n \n \n \n \n \n-H\n \n572\n \n571.70\n \n \n \n596\n \n \n \n \n \n \n-H\n \n543\n \n542.71\n \n \n \n597\n \n \n \n \n \n \n-H\n \n530\n \n529.67\n \n \n \n598\n \n \n \n \n \n \n-H\n \n559\n \n558.63\n \n \n \n599\n \n \n \n \n \n \n-H\n \n525\n \n524.69\n \n \n \n600\n \n \n \n \n \n \n-H\n \n484\n \n483.64\n \n \n \n601\n \n \n \n \n \n \n-H\n \n506\n \n505.65\n \n \n \n602\n \n \n \n \n \n \n-H\n \n486\n \n485.61\n \n \n \n603\n \n \n \n \n \n \n-H\n \n505\n \n504.66\n \n \n \n604\n \n \n \n \n \n \n-H\n \n505\n \n504.66\n \n \n \n \n\n\n \n[Table 63]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n605\n \n \n \n \n \n \n-H\n \n494\n \n \n \n606\n \n \n \n \n \n \n-H\n \n494\n \n \n \n607\n \n \n \n \n \n \n-H\n \n493\n \n \n \n608\n \n \n \n \n \n \n-H\n \n522\n \n \n \n609\n \n \n \n \n \n \n-H\n \n508\n \n \n \n610\n \n \n \n \n \n \n-H\n \n508\n \n \n \n611\n \n \n \n \n \n \n-H\n \n480\n \n \n \n612\n \n \n \n \n \n \n-H\n \n497\n \n \n \n613\n \n \n \n \n \n \n-H\n \n510\n \n \n \n614\n \n \n \n \n \n \n-H\n \n532\n \n \n \n615\n \n \n \n \n \n \n-H\n \n454\n \n \n \n616\n \n \n \n \n \n \n-H\n \n524\n \n \n \n \n\n\n \n[Table 64]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n617\n \n \n \n \n \n \n-H\n \n498\n \n \n \n618\n \n \n \n \n \n \n-H\n \n588\n \n \n \n619\n \n \n \n \n \n \n-CH\n3\n \n \n580\n \n \n \n620\n \n \n \n \n \n \n-H\n \n516\n \n \n \n621\n \n \n \n \n \n \n-H\n \n494\n \n \n \n622\n \n \n \n \n \n \n-H\n \n505\n \n \n \n623\n \n \n \n \n \n \n-H\n \n562\n \n \n \n624\n \n \n \n \n \n \n-H\n \n543\n \n \n \n625\n \n \n \n \n \n \n-H\n \n574\n \n \n \n626\n \n \n \n \n \n \n-H\n \n574\n \n \n \n \n\n\n \n[Table 65]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n627\n \n \n \n \n \n \n-H\n \n484\n \n \n \n628\n \n \n \n \n \n \n-H\n \n587\n \n \n \n629\n \n \n \n \n \n \n-H\n \n573\n \n \n \n630\n \n \n \n \n \n \n-H\n \n561\n \n \n \n631\n \n \n \n \n \n \n-H\n \n615\n \n \n \n632\n \n \n \n \n \n \n-H\n \n559\n \n \n \n633\n \n \n \n \n \n \n-H\n \n573\n \n \n \n634\n \n \n \n \n \n \n-H\n \n587\n \n \n \n635\n \n \n \n \n \n \n-H\n \n525\n \n \n \n636\n \n \n \n \n \n \n-H\n \n511\n \n \n \n \n\n\n \n[Table 66]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n637\n \n \n \n \n \n \n-H\n \n553\n \n \n \n638\n \n \n \n \n \n \n-H\n \n497\n \n \n \n639\n \n \n \n \n \n \n-H\n \n511\n \n \n \n640\n \n \n \n \n \n \n-H\n \n525\n \n \n \n641\n \n \n \n \n \n \n-H\n \n553\n \n \n \n642\n \n \n \n \n \n \n-H\n \n539\n \n \n \n643\n \n \n \n \n \n \n-H\n \n581\n \n \n \n644\n \n \n \n \n \n \n-H\n \n525\n \n \n \n645\n \n \n \n \n \n \n-H\n \n539\n \n \n \n646\n \n \n \n \n \n \n-H\n \n553\n \n \n \n647\n \n \n \n \n \n \n-H\n \n477\n \n \n \n \n\n\n \n[Table 67]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n648\n \n \n \n \n \n \n-H\n \n516\n \n \n \n649\n \n \n \n \n \n \n-H\n \n477\n \n \n \n650\n \n \n \n \n \n \n-H\n \n507\n \n \n \n651\n \n \n \n \n \n \n-H\n \n575\n \n \n \n652\n \n \n \n \n \n \n-H\n \n515\n \n \n \n653\n \n \n \n \n \n \n-H\n \n483\n \n \n \n654\n \n \n \n \n \n \n-H\n \n540\n \n \n \n655\n \n \n \n \n \n \n-H\n \n467\n \n \n \n656\n \n \n \n \n \n \n-H\n \n443\n \n \n \n657\n \n \n \n \n \n \n-H\n \n481\n \n \n \n658\n \n \n \n \n \n \n-H\n \n557\n \n \n \n \n\n\n \n[Table 68]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n659\n \n \n \n \n \n \n-H\n \n531\n \n \n \n660\n \n \n \n \n \n \n-H\n \n340\n \n \n \n661\n \n \n \n \n \n \n-H\n \n527\n \n \n \n662\n \n \n \n \n \n \n-H\n \n498\n \n \n \n663\n \n \n \n \n \n \n-H\n \n509\n \n \n \n664\n \n \n \n \n \n \n-H\n \n532\n \n \n \n665\n \n \n \n \n \n \n-H\n \n481\n \n \n \n666\n \n \n \n \n \n \n-H\n \n480\n \n \n \n667\n \n \n \n \n \n \n-H\n \n497\n \n \n \n668\n \n \n \n \n \n \n-H\n \n467\n \n \n \n \n\n\n \n[Table 69]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n669\n \n-CH\n3\n \n \n-cycle-C\n6\nH\n11\n \n \n510\n \n \n \n670\n \n-H\n \n-cyclo-C\n6\nH\n11\n \n \n496\n \n \n \n671\n \n-H\n \n-CH(CH\n3\n)\n2\n \n \n456\n \n \n \n672\n \n-CH\n2\nCH(CH\n3\n)\n2\n \n \n-CH\n2\nCH(CH\n3\n)\n2\n \n \n526\n \n \n \n673\n \n-CH\n2\nCH\n2\nOH\n \n-CH\n2\nCH\n2\nOH\n \n502\n \n \n \n674\n \n-C\n2\nH\n6\n \n \n-CH\n2\nCH\n2\nO\nH\n \n \n486\n \n \n \n675\n \n-CH\n2\nCH\n2\nOH\n \n-cyclo-C\n6\nH\n11\n \n \n540\n \n \n \n676\n \n-CH\n2\nCH\n2\nOCH\n3\n \n \n-CH\n2\nCH\n2\nOCH\n3\n \n \n530\n \n \n \n677\n \n-C\n2\nH\n5\n \n \n-C\n2\nH\n5\n \n \n470\n \n \n \n678\n \n-H\n \n-C\n4\nH\n8\n \n \n470\n \n \n \n679\n \n-H\n \n-C(CH\n3\n)\n3\n \n \n470\n \n \n \n680\n \n-H\n \n-cyclo-C\n3\nH\n5\n \n \n454\n \n \n \n681\n \n-H\n \n-CH\n2\n \n \n428\n \n \n \n682\n \n-H\n \n-C\n2\nH\n5\n \n \n442\n \n \n \n683\n \n-H\n \n-C\n3\nH\n1\n \n \n456\n \n \n \n684\n \n-H\n \n-CH\n2\nCH(CH\n3\n)\n2\n \n \n470\n \n \n \n685\n \n-H\n \n-CH\n2\nCH\n2\nOCH\n3\n \n \n472\n \n \n \n686\n \n-H\n \n-CH\n2\nCH\n2\nOC\n2\nH\n5\n \n \n486\n \n \n \n687\n \n-H\n \n-(CH\n2\n)\n3\nOC\n2\nH\n5\n \n \n500\n \n \n \n688\n \n-H\n \n-(CH\n2\n)\n2\nOC\n1\nH\n5\n \n \n534\n \n \n \n689\n \n-H\n \n-CH\n2\n-cyclo-C\n3\nH\n5\n \n \n468\n \n \n \n690\n \n-H\n \n-(CH\n2\n)\n2\nNHCOCH\n3\n \n \n499\n \n \n \n691\n \n-H\n \n-(CH\n2\n)\n5\nOH\n \n500\n \n \n \n692\n \n-H\n \n-(CH\n2\n)\n2\nC\n6\nH\n5\n \n \n518\n \n \n \n693\n \n-H\n \n-CH\n2\nCO\n2\nCH\n3\n \n \n486\n \n \n \n694\n \n-H\n \n-CH\n2\nCONH\n2\n \n \n471\n \n \n \n695\n \n-H\n \n-CH(CO\n2\nC\n2\nH\n5\n)\n2\n \n \n572\n \n \n \n696\n \n-H\n \n-CH(CH\n3\n)CO\n2\nC\n2\nH\n5\n \n \n514\n \n \n \n697\n \n-CH\n3\n \n \n-CH\n2\nCO\n2\nCH\n3\n \n \n500\n \n \n \n698\n \n-H\n \n-CH\n2\nCCH\n \n452\n \n \n \n699\n \n-H\n \n-(CH\n2\n)\n2\nCH(CH\n3\n)\n2\n \n \n484\n \n \n \n700\n \n-CH\n3\n \n \n-(CH\n2\n)\n2\nCO\n2\nC\n2\nH\n5\n \n \n542\n \n \n \n701\n \n-H\n \n-(CH\n2\n)\n4\nCO\n2\nC\n2\nH\n5\n \n \n542\n \n \n \n702\n \n-H\n \n-CH(CONH\n2\n)\n2\n \n \n514\n \n \n \n703\n \n-H\n \n-CH\n2\nCF\n3\n \n \n486\n \n \n \n704\n \n-H\n \n-NHCH\n2\nCF\n3\n \n \n511\n \n \n \n \n\n\n \n[Table 70]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n705\n \n-CH\n3\n \n \n-CH\n3\n \n \n442\n \n \n \n706\n \n-H\n \n-CH\n2\nCH(OCH\n3\n)\n2\n \n \n502\n \n \n \n707\n \n-H\n \n-(CH\n2\n)\n3\nOCH(CH\n3\n)\n2\n \n \n514\n \n \n \n708\n \n-H\n \n-CH\n2\nCN\n \n453\n \n \n \n709\n \n-H\n \n-(CH\n2\n)\n3\nOCH\n3\n \n \n486\n \n \n \n710\n \n-H\n \n-(CH\n2\n)\n2\nOCH(CH\n3\n)\n2\n \n \n500\n \n \n \n711\n \n-H\n \n-CH(C\n2\nH\n5\nCH\n2\nOCH\n3\n \n \n500\n \n \n \n712\n \n-H\n \n-CH(CH\n3\n)CH\n2\nOCH\n3\n \n \n486\n \n \n \n713\n \n-H\n \n-CH\n2\nCH\n2\nF\n \n460\n \n \n \n714\n \n-H\n \n-CH\n2\nCH(OH)CH\n2\nOH\n \n488\n \n \n \n715\n \n-H\n \n-CH\n2\nCONHCH\n3\n \n \n485\n \n \n \n716\n \n-H\n \n-(CH\n2\n)\n2\nSCH\n3\n \n \n488\n \n \n \n717\n \n-H\n \n-CH\n2\nCH\n2\nOH\n \n458\n \n \n \n718\n \n-H\n \n-C\n1\nH\n13\n \n \n498\n \n \n \n719\n \n-CH\n3\n \n \n-CH\n3\nCON(CH\n3\n)\n2\n \n \n513\n \n \n \n720\n \n-H\n \n-(CH\n2\n)\n2\nN(CH\n3\n)COCH\n3\n \n \n513\n \n \n \n721\n \n-H\n \n-(CH\n2\n)\n2\nN(CH\n3\n)CO(CH\n2\n)-CH\n3\n \n \n541\n \n \n \n \n\n\n \n[Table 71]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n722\n \n \n \n \n \n \n-CH\n3\n \n \n533\n \n \n \n723\n \n \n \n \n \n \n-C\n2\nF\n5\n \n \n540\n \n \n \n724\n \n \n \n \n \n \n-H\n \n532\n \n \n \n725\n \n \n \n \n \n \n-H\n \n505\n \n \n \n726\n \n \n \n \n \n \n-H\n \n505\n \n \n \n727\n \n \n \n \n \n \n-H\n \n505\n \n \n \n728\n \n \n \n \n \n \n-H\n \n494\n \n \n \n729\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n547\n \n \n \n730\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n592\n \n \n \n731\n \n \n \n \n \n \n-CH\n3\n \n \n548\n \n \n \n732\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n605\n \n \n \n733\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n647\n \n \n \n \n\n\n \n[Table 72]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n734\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n645\n \n \n \n735\n \n \n \n \n \n \n-CH\n3\n \n \n615\n \n \n \n736\n \n \n \n \n \n \n-CH\n3\n \n \n553\n \n \n \n737\n \n \n \n \n \n \n-CH\n3\n \n \n562\n \n \n \n738\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n576\n \n \n \n739\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n606\n \n \n \n740\n \n \n \n \n \n \n-H\n \n468\n \n \n \n741\n \n \n \n \n \n \n-H\n \n548\n \n \n \n742\n \n \n \n \n \n \n-H\n \n548\n \n \n \n743\n \n \n \n \n \n \n-H\n \n552\n \n \n \n744\n \n \n \n \n \n \n-H\n \n548\n \n \n \n745\n \n \n \n \n \n \n-H\n \n512\n \n \n \n746\n \n \n \n \n \n \n-H\n \n522\n \n \n \n \n\n\n \n[Table 73]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n747\n \n \n \n \n \n \n-H\n \n576\n \n \n \n748\n \n \n \n \n \n \n-H\n \n562\n \n \n \n749\n \n \n \n \n \n \n-H\n \n592\n \n \n \n750\n \n \n \n \n \n \n-H\n \n528\n \n \n \n751\n \n \n \n \n \n \n-H\n \n542\n \n \n \n752\n \n \n \n \n \n \n-H\n \n551\n \n \n \n753\n \n \n \n \n \n \n-H\n \n513\n \n \n \n754\n \n \n \n \n \n \n-H\n \n561\n \n \n \n755\n \n \n \n \n \n \n-H\n \n615\n \n \n \n756\n \n \n \n \n \n \n-H\n \n566\n \n \n \n757\n \n \n \n \n \n \n-H\n \n498\n \n \n \n \n\n\n \n[Table 74]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n758\n \n \n \n \n \n \n-H\n \n485\n \n \n \n759\n \n \n \n \n \n \n-H\n \n499\n \n \n \n760\n \n \n \n \n \n \n-CH\n3\n \n \n591\n \n \n \n761\n \n \n \n \n \n \n-CH\n3\n \n \n575\n \n \n \n762\n \n \n \n \n \n \n-H\n \n548\n \n \n \n763\n \n \n \n \n \n \n-H\n \n532\n \n \n \n764\n \n \n \n \n \n \n-H\n \n532\n \n \n \n765\n \n \n \n \n \n \n-H\n \n559\n \n \n \n766\n \n \n \n \n \n \n-H\n \n573\n \n \n \n767\n \n \n \n \n \n \n-H\n \n519\n \n \n \n768\n \n \n \n \n \n \n-CH(CH\n3\n)\n2\n \n \n561\n \n \n \n769\n \n \n \n \n \n \n-H\n \n470\n \n \n \n \n\n\n \n[Table 75]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n770\n \n \n \n \n \n \n-CH\n3\n \n \n633\n \n \n \n771\n \n \n \n \n \n \n-CH\n3\n \n \n629\n \n \n \n772\n \n \n \n \n \n \n-CH\n3\n \n \n629\n \n \n \n773\n \n \n \n \n \n \n-CH\n3\n \n \n629\n \n \n \n774\n \n \n \n \n \n \n-CH\n3\n \n \n649\n \n \n \n775\n \n \n \n \n \n \n-C\n4\nH\n8\n \n \n649\n \n \n \n776\n \n \n \n \n \n \n-C\n4\nH\n8\n \n \n671\n \n \n \n777\n \n \n \n \n \n \n-CH(CH\n3\n)\n2\n \n \n657\n \n \n \n778\n \n \n \n \n \n \n-H\n \n597\n \n \n \n779\n \n \n \n \n \n \n-H\n \n583\n \n \n \n780\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n587\n \n \n \n \n\n\n \n[Table 76]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n781\n \n \n \n \n \n \n-H\n \n554\n \n \n \n782\n \n \n \n \n \n \n-H\n \n572\n \n \n \n783\n \n \n \n \n \n \n-H\n \n572\n \n \n \n784\n \n \n \n \n \n \n-H\n \n586\n \n \n \n785\n \n \n \n \n \n \n-H\n \n557\n \n \n \n786\n \n \n \n \n \n \n-H\n \n544\n \n \n \n787\n \n \n \n \n \n \n-H\n \n573\n \n \n \n788\n \n \n \n \n \n \n-H\n \n539\n \n \n \n789\n \n \n \n \n \n \n-H\n \n498\n \n \n \n790\n \n \n \n \n \n \n-H\n \n520\n \n \n \n791\n \n \n \n \n \n \n-H\n \n500\n \n \n \n \n\n\n \n[Table 77]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n792\n \n \n \n \n \n \n-H\n \n519\n \n \n \n793\n \n \n \n \n \n \n-H\n \n519\n \n \n \n794\n \n \n \n \n \n \n-H\n \n508\n \n \n \n795\n \n \n \n \n \n \n-H\n \n508\n \n \n \n796\n \n \n \n \n \n \n-H\n \n507\n \n \n \n797\n \n \n \n \n \n \n-H\n \n536\n \n \n \n798\n \n \n \n \n \n \n-H\n \n522\n \n \n \n799\n \n \n \n \n \n \n-H\n \n522\n \n \n \n800\n \n \n \n \n \n \n-H\n \n494\n \n \n \n801\n \n \n \n \n \n \n-H\n \n511\n \n \n \n802\n \n \n \n \n \n \n-H\n \n524\n \n \n \n803\n \n \n \n \n \n \n-H\n \n546\n \n \n \n804\n \n \n \n \n \n \n-H\n \n538\n \n \n \n \n\n\n \n[Table 78]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n805\n \n \n \n \n \n \n-H\n \n512\n \n \n \n806\n \n \n \n \n \n \n-H\n \n602\n \n \n \n807\n \n \n \n \n \n \n-CH\n3\n \n \n594\n \n \n \n808\n \n \n \n \n \n \n-H\n \n530\n \n \n \n809\n \n \n \n \n \n \n-H\n \n508\n \n \n \n810\n \n \n \n \n \n \n-H\n \n519\n \n \n \n811\n \n \n \n \n \n \n-H\n \n576\n \n \n \n812\n \n \n \n \n \n \n-H\n \n557\n \n \n \n813\n \n \n \n \n \n \n-H\n \n588\n \n \n \n814\n \n \n \n \n \n \n-H\n \n588\n \n \n \n815\n \n \n \n \n \n \n-H\n \n498\n \n \n \n \n\n\n \n[Table 79]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n816\n \n \n \n \n \n \n-H\n \n601\n \n \n \n817\n \n \n \n \n \n \n-H\n \n587\n \n \n \n818\n \n \n \n \n \n \n-H\n \n575\n \n \n \n819\n \n \n \n \n \n \n-H\n \n629\n \n \n \n820\n \n \n \n \n \n \n-H\n \n573\n \n \n \n821\n \n \n \n \n \n \n-H\n \n587\n \n \n \n822\n \n \n \n \n \n \n-H\n \n601\n \n \n \n823\n \n \n \n \n \n \n-H\n \n539\n \n \n \n824\n \n \n \n \n \n \n-H\n \n525\n \n \n \n825\n \n \n \n \n \n \n-H\n \n567\n \n \n \n \n\n\n \n[Table 80]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n826\n \n \n \n \n \n \n-H\n \n511\n \n \n \n827\n \n \n \n \n \n \n-H\n \n525\n \n \n \n828\n \n \n \n \n \n \n-H\n \n539\n \n \n \n829\n \n \n \n \n \n \n-H\n \n567\n \n \n \n830\n \n \n \n \n \n \n-H\n \n553\n \n \n \n831\n \n \n \n \n \n \n-H\n \n595\n \n \n \n832\n \n \n \n \n \n \n-H\n \n539\n \n \n \n833\n \n \n \n \n \n \n-H\n \n553\n \n \n \n834\n \n \n \n \n \n \n-H\n \n567\n \n \n \n835\n \n \n \n \n \n \n-H\n \n491\n \n \n \n836\n \n \n \n \n \n \n-H\n \n530\n \n \n \n \n\n\n \n[Table 81]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n837\n \n \n \n \n \n \n-H\n \n541\n \n \n \n838\n \n \n \n \n \n \n-H\n \n505\n \n \n \n839\n \n \n \n \n \n \n-CH\n3\n \n \n520\n \n \n \n840\n \n \n \n \n \n \n-CH\n3\n \n \n612\n \n \n \n841\n \n \n \n \n \n \n-H\n \n521\n \n \n \n842\n \n \n \n \n \n \n-H\n \n589\n \n \n \n843\n \n \n \n \n \n \n-H\n \n529\n \n \n \n844\n \n \n \n \n \n \n-H\n \n577\n \n \n \n845\n \n \n \n \n \n \n-H\n \n505\n \n \n \n846\n \n \n \n \n \n \n-H\n \n497\n \n \n \n847\n \n \n \n \n \n \n-H\n \n541\n \n \n \n \n\n\n \n[Table 82]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n848\n \n \n \n \n \n \n-H\n \n456\n \n \n \n849\n \n \n \n \n \n \n-H\n \n545\n \n \n \n850\n \n \n \n \n \n \n-H\n \n508\n \n \n \n851\n \n \n \n \n \n \n-H\n \n546\n \n \n \n852\n \n \n \n \n \n \n-H\n \n494\n \n \n \n853\n \n \n \n \n \n \n-H\n \n555\n \n \n \n \n\n\n \n[Table 83]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n854\n \n \n \n \n \n \n523\n \n \n \n855\n \n \n \n \n \n \n483\n \n \n \n856\n \n \n \n \n \n \n477\n \n \n \n857\n \n \n \n \n \n \n469\n \n \n \n858\n \n \n \n \n \n \n467\n \n \n \n859\n \n \n \n \n \n \n495\n \n \n \n860\n \n \n \n \n \n \n556\n \n \n \n861\n \n \n \n \n \n \n513\n \n \n \n862\n \n \n \n \n \n \n552\n \n \n \n863\n \n \n \n \n \n \n494\n \n \n \n \n\n\n \n[Table 84]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n864\n \n \n \n \n \n \n557\n \n \n \n865\n \n \n \n \n \n \n591\n \n \n \n866\n \n \n \n \n \n \n591\n \n \n \n867\n \n \n \n \n \n \n571\n \n \n \n868\n \n \n \n \n \n \n571\n \n \n \n869\n \n \n \n \n \n \n575\n \n \n \n870\n \n \n \n \n \n \n510\n \n \n \n871\n \n \n \n \n \n \n508\n \n \n \n872\n \n \n \n \n \n \n479\n \n \n \n873\n \n \n \n \n \n \n479\n \n \n \n \n\n\n \n[Table 85]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n874\n \n \n \n \n \n \n481\n \n \n \n875\n \n \n \n \n \n \n508\n \n \n \n876\n \n \n \n \n \n \n495\n \n \n \n877\n \n \n \n \n \n \n509\n \n \n \n878\n \n \n \n \n \n \n495\n \n \n \n879\n \n \n \n \n \n \n557\n \n \n \n880\n \n \n \n \n \n \n508\n \n \n \n881\n \n \n \n \n \n \n495\n \n \n \n882\n \n \n \n \n \n \n540\n \n \n \n \n\n\n \n[Table 86]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n883\n \n \n \n \n \n \n564\n \n \n \n884\n \n \n \n \n \n \n550\n \n \n \n885\n \n \n \n \n \n \n481\n \n \n \n886\n \n \n \n \n \n \n494\n \n \n \n887\n \n \n \n \n \n \n499\n \n \n \n888\n \n \n \n \n \n \n527\n \n \n \n889\n \n \n \n \n \n \n550\n \n \n \n890\n \n \n \n \n \n \n545\n \n \n \n891\n \n \n \n \n \n \n575\n \n \n \n \n\n\n \n[Table 87]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n892\n \n \n \n \n \n \n570\n \n \n \n893\n \n \n \n \n \n \n563\n \n \n \n894\n \n \n \n \n \n \n493\n \n \n \n895\n \n \n \n \n \n \n522\n \n \n \n896\n \n \n \n \n \n \n523\n \n \n \n897\n \n \n \n \n \n \n480\n \n \n \n898\n \n \n \n \n \n \n557\n \n \n \n899\n \n \n \n \n \n \n520\n \n \n \n900\n \n \n \n \n \n \n533\n \n \n \n \n\n\n \n[Table 88]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n901\n \n \n \n \n \n \n560\n \n \n \n902\n \n \n \n \n \n \n481\n \n \n \n903\n \n \n \n \n \n \n543\n \n \n \n904\n \n \n \n \n \n \n542\n \n \n \n905\n \n \n \n \n \n \n542\n \n \n \n \n\n\n \n[Table 89]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n906\n \n-CH\n3\n \n \n-cyclo-C\n6\nH\n11\n \n \n493\n \n \n \n907\n \n-H\n \n-cyclo-C\n6\nH\n11\n \n \n479\n \n \n \n908\n \n-CH\n2\nCH\n2\nOH\n \n-CH\n2\nCH\n2\nOH\n \n485\n \n \n \n909\n \n-CH\n3\n \n \n-CH\n2\nCH\n2\nN(CH\n3\n)\n2\n \n \n482\n \n \n \n910\n \n-H\n \n-C\n4\nH\n9\n \n \n453\n \n \n \n911\n \n-H\n \n-cyclo-C\n3\nH\n5\n \n \n437\n \n \n \n912\n \n-H\n \n-CH\n2\nC\n6\nH\n5\n \n \n487\n \n \n \n913\n \n-CH\n3\n \n \n-CH\n2\nC\n6\nH\n5\n \n \n501\n \n \n \n914\n \n-C\n2\nH\n5\n \n \n-CH(CH\n3\n)\n2\n \n \n467\n \n \n \n915\n \n-H\n \n-CH\n3\n \n \n411\n \n \n \n916\n \n-H\n \n-C\n2\nH\n5\n \n \n425\n \n \n \n917\n \n-H\n \n-C\n2\nH\n7\n \n \n439\n \n \n \n918\n \n-H\n \n-CH\n2\nCH(CH\n3\n)\n2\n \n \n453\n \n \n \n919\n \n-H\n \n-CH\n2\nCH\n2\nOCH\n3\n \n \n455\n \n \n \n920\n \n-H\n \n-CH\n2\nCH\n2\nC\n2\nH\n5\n \n \n469\n \n \n \n921\n \n-H\n \n-(CH\n2\n)\n2\nOC\n6\nH\n5\n \n \n517\n \n \n \n922\n \n-H\n \n-cyclo-C\n5\nH\n8\n \n \n465\n \n \n \n923\n \n-H\n \n-CH\n2\n-cyclo-C\n6\nH\n11\n \n \n493\n \n \n \n924\n \n-H\n \n-CH(CH\n3\n)C\n6\nH\n5\n \n \n501\n \n \n \n925\n \n-H\n \n-CH\n2\nCONH\n2\n \n \n454\n \n \n \n \n\n\n \n[Table 90]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n926\n \n-H\n \n-CH(CH\n3\n)\n2\n \n \n439\n \n \n \n927\n \n-C\n2\nH\n5\n \n \n-C\n2\nH\n5\n \n \n453\n \n \n \n928\n \n-H\n \n-(CH\n2\n)\n5\nOH\n \n483\n \n \n \n929\n \n-H\n \n-CH\n2\nCCH\n \n435\n \n \n \n930\n \n-CH\n2\n \n \n-CH(CH\n3\n)\n2\n \n \n453\n \n \n \n931\n \n-H\n \n-CH\n2\nC(CH\n3\n)\n3\n \n \n467\n \n \n \n932\n \n-H\n \n-CH\n2\nCH\n2\nN(CH\n3\n)\n2\n \n \n468\n \n \n \n933\n \n-H\n \n-CH(CONH\n2\n)\n2\n \n \n497\n \n \n \n934\n \n-CH\n3\n \n \n-CH\n2\n-cyclo-C\n3\nH\n5\n \n \n465\n \n \n \n935\n \n-CH\n3\n \n \n-(CH\n2\n)\n2\nN(C\n2\nH\n5\n)\n2\n \n \n510\n \n \n \n936\n \n-H\n \n-CH\n2\nCF\n3\n \n \n479\n \n \n \n937\n \n-H\n \n-NHCH\n2\nCF\n3\n \n \n494\n \n \n \n938\n \n-CH\n3\n \n \n-CH\n2\n \n \n425\n \n \n \n939\n \n-H\n \n-CH\n2\nCH(OCH\n3\n)\n2\n \n \n485\n \n \n \n940\n \n-H\n \n-(CH\n2\n)\n3\nOCH(CH\n3\n)\n2\n \n \n497\n \n \n \n941\n \n-H\n \n-CH(C\n2\nH\n5\n)\n2\n \n \n467\n \n \n \n942\n \n-H\n \n-CH\n2\nCN\n \n436\n \n \n \n943\n \n-H\n \n-(CH\n2\n)\n2\nOCH(CH\n3\n)\n2\n \n \n483\n \n \n \n944\n \n-H\n \n-CH(C\n2\nH\n5\n)CH\n2\nOCH\n3\n \n \n483\n \n \n \n945\n \n-H\n \n-CH\n2\nCH\n2\nF\n \n443\n \n \n \n946\n \n-H\n \n-CH\n2\nCONHCH\n3\n \n \n468\n \n \n \n947\n \n-H\n \n-(CH\n2\n)\n2\nSCH\n3\n \n \n471\n \n \n \n948\n \n-H\n \n-CH\n2\nCHF\n2\n \n \n461\n \n \n \n949\n \n-CH\n3\n \n \n-(CH\n2\n)\n2\nO(CH\n2\n)\n2\nNHCH\n3\n \n \n512\n \n \n \n \n\n\n \n[Table 91]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n950\n \n-CH\n3\n \n \n \n \n \n \n \n508\n \n \n \n951\n \n-H\n \n \n \n \n \n \n515\n \n \n \n952\n \n-H\n \n \n \n \n \n \n521\n \n \n \n953\n \n-H\n \n \n \n \n \n \n521\n \n \n \n954\n \n-H\n \n \n \n \n \n \n521\n \n \n \n955\n \n-H\n \n \n \n \n \n \n488\n \n \n \n956\n \n-H\n \n \n \n \n \n \n488\n \n \n \n957\n \n-H\n \n \n \n \n \n \n488\n \n \n \n958\n \n-H\n \n \n \n \n \n \n477\n \n \n \n959\n \n-CH\n3\n \n \n \n \n \n \n \n536\n \n \n \n \n\n\n \n[Table 92]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n960\n \n-CH\n3\n \n \n \n \n \n \n \n531\n \n \n \n961\n \n-H\n \n \n \n \n \n \n451\n \n \n \n962\n \n-H\n \n \n \n \n \n \n517\n \n \n \n963\n \n-H\n \n \n \n \n \n \n517\n \n \n \n964\n \n-H\n \n \n \n \n \n \n555\n \n \n \n965\n \n-H\n \n \n \n \n \n \n571\n \n \n \n966\n \n-H\n \n \n \n \n \n \n531\n \n \n \n967\n \n-H\n \n \n \n \n \n \n552\n \n \n \n968\n \n-H\n \n \n \n \n \n \n495\n \n \n \n969\n \n-H\n \n \n \n \n \n \n505\n \n \n \n \n\n\n \n[Table 93]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n970\n \n-H\n \n \n \n \n \n \n547\n \n \n \n971\n \n-H\n \n \n \n \n \n \n501\n \n \n \n972\n \n-H\n \n \n \n \n \n \n505\n \n \n \n973\n \n-H\n \n \n \n \n \n \n496\n \n \n \n974\n \n-H\n \n \n \n \n \n \n544\n \n \n \n975\n \n-H\n \n \n \n \n \n \n481\n \n \n \n976\n \n-H\n \n \n \n \n \n \n468\n \n \n \n977\n \n-H\n \n \n \n \n \n \n517\n \n \n \n978\n \n-H\n \n \n \n \n \n \n508\n \n \n \n \n\n\n \n[Table 94]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n979\n \n-H\n \n \n \n \n \n \n508\n \n \n \n980\n \n-H\n \n \n \n \n \n \n494\n \n \n \n981\n \n-H\n \n \n \n \n \n \n510\n \n \n \n982\n \n-H\n \n \n \n \n \n \n453\n \n \n \n983\n \n-H\n \n \n \n \n \n \n467\n \n \n \n984\n \n-H\n \n \n \n \n \n \n555\n \n \n \n985\n \n-H\n \n \n \n \n \n \n537\n \n \n \n986\n \n-H\n \n \n \n \n \n \n527\n \n \n \n987\n \n-H\n \n \n \n \n \n \n527\n \n \n \n988\n \n-H\n \n \n \n \n \n \n493\n \n \n \n \n\n\n \n[Table 95]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n989\n \n-H\n \n \n \n \n \n \n556\n \n \n \n990\n \n-H\n \n \n \n \n \n \n555\n \n \n \n991\n \n-H\n \n \n \n \n \n \n555\n \n \n \n992\n \n-C\n2\nH\n5\n \n \n \n \n \n \n \n479\n \n \n \n993\n \n-H\n \n \n \n \n \n \n522\n \n \n \n994\n \n-H\n \n \n \n \n \n \n481\n \n \n \n995\n \n-H\n \n \n \n \n \n \n503\n \n \n \n996\n \n-H\n \n \n \n \n \n \n483\n \n \n \n997\n \n-H\n \n \n \n \n \n \n497\n \n \n \n \n\n\n \n[Table 96]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n998\n \n-H\n \n \n \n \n \n \n491\n \n \n \n999\n \n-H\n \n \n \n \n \n \n491\n \n \n \n1000\n \n-H\n \n \n \n \n \n \n490\n \n \n \n1001\n \n-H\n \n \n \n \n \n \n519\n \n \n \n1002\n \n-H\n \n \n \n \n \n \n505\n \n \n \n1003\n \n-H\n \n \n \n \n \n \n505\n \n \n \n1004\n \n-H\n \n \n \n \n \n \n507\n \n \n \n1005\n \n-H\n \n \n \n \n \n \n493\n \n \n \n \n\n\n \n[Table 97]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1006\n \n-H\n \n \n \n \n \n \n477\n \n \n \n1007\n \n-H\n \n \n \n \n \n \n494\n \n \n \n1008\n \n-H\n \n \n \n \n \n \n529\n \n \n \n1009\n \n-H\n \n \n \n \n \n \n451\n \n \n \n1010\n \n-H\n \n \n \n \n \n \n495\n \n \n \n1011\n \n-H\n \n \n \n \n \n \n505\n \n \n \n1012\n \n-H\n \n \n \n \n \n \n519\n \n \n \n1013\n \n-H\n \n \n \n \n \n \n519\n \n \n \n1014\n \n-H\n \n \n \n \n \n \n515\n \n \n \n \n\n\n \n[Table 98]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1015\n \n-H\n \n \n \n \n \n \n537\n \n \n \n1016\n \n-H\n \n \n \n \n \n \n543\n \n \n \n1017\n \n-H\n \n \n \n \n \n \n513\n \n \n \n1018\n \n-H\n \n \n \n \n \n \n513\n \n \n \n1019\n \n-H\n \n \n \n \n \n \n502\n \n \n \n1020\n \n-H\n \n \n \n \n \n \n506\n \n \n \n \n\n\n \n[Table 99]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1021\n \n-2-PYRIDYL\n \n549\n \n \n \n1022\n \n-C\n4\nH\n9\n \n \n528\n \n \n \n1023\n \n-CH(CH\n3\n)\n2\n \n \n514\n \n \n \n1024\n \n-CH\n2\nCH\n2\nN(CH\n9\n)\n2\n \n \n543\n \n \n \n1025\n \n-4-PYRIDYL\n \n549\n \n \n \n1026\n \n-C\n6\nH\n5\n \n \n548\n \n \n \n1027\n \n-C\n3\nH\n7\n \n \n514\n \n \n \n1028\n \n-CH\n3\n \n \n486\n \n \n \n1029\n \n-3-PYRIDYL\n \n549\n \n \n \n1030\n \n-C\n8\nH\n13\n \n \n556\n \n \n \n1031\n \n-C\n2\nH\n5\n \n \n500\n \n \n \n1032\n \n-CH\n2\nCH\n2\nOH\n \n516\n \n \n \n1033\n \n-COCH\n3\n \n \n514\n \n \n \n1034\n \n-cyclo-C\n6\nH\n11\n \n \n554\n \n \n \n1035\n \n-SO\n2\nC\n2\nH\n5\n \n \n564\n \n \n \n \n\n\n \n[Table 100]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1036\n \n \n \n \n \n \n563\n \n \n \n1037\n \n \n \n \n \n \n563\n \n \n \n1038\n \n \n \n \n \n \n563\n \n \n \n1039\n \n \n \n \n \n \n550\n \n \n \n1040\n \n \n \n \n \n \n569\n \n \n \n1041\n \n \n \n \n \n \n634\n \n \n \n1042\n \n \n \n \n \n \n550\n \n \n \n1043\n \n \n \n \n \n \n566\n \n \n \n1044\n \n \n \n \n \n \n577\n \n \n \n \n\n\n \n[Table 101]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1045\n \n \n \n \n \n \n577\n \n \n \n1046\n \n \n \n \n \n \n583\n \n \n \n1047\n \n \n \n \n \n \n555\n \n \n \n1048\n \n \n \n \n \n \n540\n \n \n \n \n\n\n \n[Table 102]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1049\n \n-OCH\n3\n \n \n501\n \n \n \n1050\n \n-cyclo-C\n6\nH\n11\n \n \n553\n \n \n \n1051\n \n-C\n6\nH\n5\n \n \n547\n \n \n \n1052\n \n-OCH\n2\nC\n6\nH\n5\n \n \n577\n \n \n \n1053\n \n-OC\n6\nH\n5\n \n \n553\n \n \n \n1054\n \n-OH\n \n487\n \n \n \n1055\n \n-CONH\n2\n \n \n514\n \n \n \n1056\n \n-CH\n2\nOH\n \n501\n \n \n \n1057\n \n-C\n2\nH\n5\n \n \n499\n \n \n \n1058\n \n-NHCOCH\n3\n \n \n528\n \n \n \n1059\n \n-COC\n6\nH\n5\n \n \n575\n \n \n \n1060\n \n-2-PYRIDYL\n \n548\n \n \n \n \n\n\n \n[Table 103]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nRi\n \nMS(M+1)\n \n \n \n \n1061\n \n \n \n \n \n \n554\n \n \n \n1062\n \n \n \n \n \n \n578\n \n \n \n1063\n \n \n \n \n \n \n578\n \n \n \n1064\n \n \n \n \n \n \n556\n \n \n \n1065\n \n \n \n \n \n \n564\n \n \n \n1066\n \n \n \n \n \n \n564\n \n \n \n \n\n\n \n[Table 104]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1067\n \n \n \n \n \n \n485\n \n \n \n1068\n \n \n \n \n \n \n502\n \n \n \n1069\n \n \n \n \n \n \n525\n \n \n \n1070\n \n \n \n \n \n \n489\n \n \n \n1071\n \n \n \n \n \n \n475\n \n \n \n1072\n \n \n \n \n \n \n511\n \n \n \n1073\n \n \n \n \n \n \n539\n \n \n \n1074\n \n \n \n \n \n \n547\n \n \n \n1075\n \n \n \n \n \n \n576\n \n \n \n \n\n\n \n[Table 105]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1076\n \n \n \n \n \n \n519\n \n \n \n1077\n \n \n \n \n \n \n563\n \n \n \n1078\n \n \n \n \n \n \n558\n \n \n \n1079\n \n \n \n \n \n \n519\n \n \n \n1080\n \n \n \n \n \n \n505\n \n \n \n1081\n \n \n \n \n \n \n500\n \n \n \n1082\n \n \n \n \n \n \n548\n \n \n \n1083\n \n \n \n \n \n \n563\n \n \n \n1084\n \n \n \n \n \n \n487\n \n \n \n \n\n\n \n[Table 106]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1085\n \n \n \n \n \n \n515\n \n \n \n1086\n \n \n \n \n \n \n577\n \n \n \n1087\n \n \n \n \n \n \n473\n \n \n \n1088\n \n \n \n \n \n \n546\n \n \n \n1089\n \n \n \n \n \n \n570\n \n \n \n1090\n \n \n \n \n \n \n505\n \n \n \n1091\n \n \n \n \n \n \n533\n \n \n \n1092\n \n \n \n \n \n \n486\n \n \n \n1093\n \n \n \n \n \n \n545\n \n \n \n \n\n\n \n[Table 107]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1094\n \n \n \n \n \n \n542\n \n \n \n1095\n \n \n \n \n \n \n526\n \n \n \n1096\n \n \n \n \n \n \n568\n \n \n \n1097\n \n \n \n \n \n \n539\n \n \n \n1098\n \n \n \n \n \n \n576\n \n \n \n1099\n \n \n \n \n \n \n487\n \n \n \n1100\n \n \n \n \n \n \n585\n \n \n \n1101\n \n \n \n \n \n \n549\n \n \n \n1102\n \n \n \n \n \n \n554\n \n \n \n \n\n\n \n[Table 108]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1103\n \n \n \n \n \n \n548\n \n \n \n1104\n \n \n \n \n \n \n546\n \n \n \n1105\n \n \n \n \n \n \n553\n \n \n \n1106\n \n \n \n \n \n \n561\n \n \n \n1107\n \n \n \n \n \n \n526\n \n \n \n1108\n \n \n \n \n \n \n443\n \n \n \n \n\n\n \n[Table 109]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1109\n \n-cyclo-C\n6\nH\n11\n \n \n-OH\n3\n \n \n499\n \n \n \n1110\n \n-H\n \n-cyclo-C\n6\nH\n11\n \n \n485\n \n \n \n1111\n \n-H\n \n-CH(CH\n3\n)\n2\n \n \n445\n \n \n \n1112\n \n-C\n4\nH\n6\n \n \n-C\n4\nH\n9\n \n \n515\n \n \n \n1113\n \n-GH\n2\nOH(CH\n3\n)\n2\n \n \n-CH\n2\nCH(OH\n3\n)\n2\n \n \n515\n \n \n \n1114\n \n-OH\n2\nCH\n2\nOK\n \n-CH\n2\nOH\n2\nOH\n \n491\n \n \n \n1115\n \n-OH\n2\nOH\n2\nOH\n \n-O\n2\nH\n5\n \n \n475\n \n \n \n1116\n \n-C\n6\nH\n13\n \n \n-C\n6\nH\n13\n \n \n571\n \n \n \n1117\n \n-CH\n2\nCH\n2\nN(CH\n3\n)\n2\n \n \n-CH\n3\n \n \n488\n \n \n \n1118\n \n-cyclo-C\n6\nH\n11\n \n \n-CH\n2\nCH\n2\nOH\n \n529\n \n \n \n1119\n \n-OH\n2\nCH\n2\nOCH\n3\n \n \n-CH\n2\nCH\n2\nOCH\n3\n \n \n519\n \n \n \n1120\n \n-(CH\n2\n)\n2\nN(CH\n3\n),\n \n-(CH\n2\n)\n3\nN(CH\n3\n)\n2\n \n \n573\n \n \n \n1121\n \n-(CH\n2\n)\n3\nN(C\n2\nH\n3\n)\n2\n \n \n-OH\n3\n \n \n530\n \n \n \n1122\n \n-OH\n2\nOH=OH\n2\n \n \ncyclo-C\n5\nH\n9\n \n \n511\n \n \n \n1123\n \n-C\n2\nH\n5\n \n \n-C\n2\nH\n5\n \n \n459\n \n \n \n1124\n \n-H\n \n-C(OH\n3\n)\n3\n \n \n459\n \n \n \n1125\n \n-H\n \n-cyclo-C\n3\nH\n5\n \n \n443\n \n \n \n1126\n \n-H\n \n-cyclo-C\n7\nH\n13\n \n \n499\n \n \n \n1127\n \n-H\n \n-OH\n2\nC\n6\nH\n5\n \n \n493\n \n \n \n1128\n \n-C\n3\nH\n7\n \n \n-(CH\n2\n)\n3\nC\n6\nH\n5\n \n \n563\n \n \n \n1129\n \n-CH\n2\nCONHCH\n3\n \n \n-CH\n2\nC\n6\nH\n5\n \n \n564\n \n \n \n1130\n \n-CH\n2\nC\n6\nH\n5\n \n \n-cyclo-C\n6\nH\n11\n \n \n575\n \n \n \n1131\n \n-(CH\n2\n)\n2\nC\n6\nH\n5\n \n \n-CH\n3\n \n \n521\n \n \n \n1132\n \n-CH\n2\nC\n6\nH\n5\n \n \n-CH\n3\n \n \n507\n \n \n \n1133\n \n-CH\n2\nCH\n2\nN(CH\n3\n)\n2\n \n \n-CH\n2\nC\n6\nH\n5\n \n \n534\n \n \n \n1134\n \n-CH\n2\nC\n6\nH\n5\n \n \n-C\n5\nH\n11\n \n \n563\n \n \n \n \n\n\n \n[Table 110]\n \n \n \n \n \n \n \n \n \n \n \n \nExamples\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1135\n \n-CH\n2\nC\n6\nH\n5\n \n \n-CH\n2\nC\n6\nH\n5\n \n \n583\n \n \n \n1136\n \n-CH\n2\nC\n6\nH\n5\n \n \n-C\n2\nH\n5\n \n \n521\n \n \n \n1137\n \n-CH\n2\nC\n6\nH\n5\n \n \n-CH(CH\n3\n)\n2\n \n \n535\n \n \n \n1138\n \n-CH\n2\nCH\n2\nCN\n \n-CH\n2\nC\n6\nH\n5\n \n \n546\n \n \n \n1139\n \n-(CH\n2\n)\n2\nOC\n6\nH\n5\n \n \n-CH\n2\n \n \n537\n \n \n \n1140\n \n-cyclo-C\n6\nH\n11\n \n \n-C\n2\nH\n5\n \n \n513\n \n \n \n1141\n \n-CH(CH\n3\n)\n2\n \n \n-C\n2\nH\n5\n \n \n473\n \n \n \n1142\n \n-H\n \n-C\n2\nH\n5\n \n \n431\n \n \n \n1143\n \n-H\n \n-CH\n2\nCH(CH\n3\n)\n2\n \n \n459\n \n \n \n1144\n \n-H\n \n-CH\n2\nCH\n2\nOCH\n3\n \n \n461\n \n \n \n1145\n \n-C\n2\nH\n6\n \n \n-C\n4\nH\n8\n \n \n487\n \n \n \n1146\n \n-H\n \n-CH\n2\nCH\n2\nOC\n2\nH\n5\n \n \n475\n \n \n \n1147\n \n-H\n \n-(CH\n2\n)\n3\nOC\n2\nH\n5\n \n \n489\n \n \n \n1148\n \n-CH\n2\nC\n6\nH\n5\n \n \n-C\n6\nH\n5\n \n \n569\n \n \n \n1149\n \n-C\n6\nH\n5\n \n \n-C\n2\nH\n5\n \n \n507\n \n \n \n1150\n \n-C\n6\nH\n5\n \n \n-cyclo-C\n6\nH\n11\n \n \n561\n \n \n \n1151\n \n-CH\n2\nCH\n2\nCN\n \n-C\n6\nH\n5\n \n \n532\n \n \n \n1152\n \n-2-PYRIDYL\n \n-C\n2\nH\n3\n \n \n508\n \n \n \n1153\n \n-H\n \n-C\n6\nH\n5\n \n \n479\n \n \n \n1154\n \n-H\n \n-3-PYRIDYL\n \n480\n \n \n \n1155\n \n-H\n \n-2-PYRIDYL\n \n480\n \n \n \n1156\n \n-H\n \n-4-PYRIDYL\n \n480\n \n \n \n1157\n \n-C\n6\nH\n6\n \n \n-CH\n3\n \n \n493\n \n \n \n1158\n \n-H\n \n-CH\n2\n-cyclo-C\n6\nH\n11\n \n \n499\n \n \n \n1159\n \n-H\n \n-(CH\n2\n)\n3\nC\n6\nH\n5\n \n \n521\n \n \n \n1160\n \n-H\n \n-(CH\n2\n)\n2\nNHCOCH\n3\n \n \n488\n \n \n \n1161\n \n-H\n \n-(CH\n2\n)\n5\nOH\n \n489\n \n \n \n \n\n\n \n[Table 111]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1162\n \n-H\n \n-(CH\n2\n)\n2\nC\n6\nH\n5\n \n \n507\n \n \n \n1163\n \n-H\n \n-CH\n2\nCONH\n2\n \n \n460\n \n \n \n1164\n \n-H\n \n-CH\n2\nCCH\n \n441\n \n \n \n1165\n \n-C\n5\nH\n11\n \n \n-CH\n3\n \n \n487\n \n \n \n1166\n \n-H\n \n-(CH\n2\n)\n2\nCH(CH\n3\n)\n2\n \n \n473\n \n \n \n1167\n \n-H\n \n-CH\n2\nC(CH\n3\n)\n3\n \n \n473\n \n \n \n1168\n \n-H\n \n-CH\n2\nCH\n2\nN(CH\n3\n)\n2\n \n \n474\n \n \n \n1169\n \n-CH\n2\nC\n6\nH\n5\n \n \n-(CH\n2\n)\n3\nOH\n \n551\n \n \n \n1170\n \n-CH\n3\n \n \n-CH\n2\n-cyclo-C\n3\nH\n5\n \n \n471\n \n \n \n1171\n \n-H\n \n-CH\n2\nCF\n3\n \n \n485\n \n \n \n1172\n \n-H\n \n-NHCH\n2\nCF\n3\n \n \n500\n \n \n \n1173\n \n-CH\n3\n \n \n-CH\n3\n \n \n434\n \n \n \n1174\n \n-H\n \n-(CH\n2\n)\n3\nOCH(CH\n3\n)\n2\n \n \n503\n \n \n \n1175\n \n-H\n \n-CH\n2\nCH\n2\nC(CH\n3\n)\n3\n \n \n487\n \n \n \n1176\n \n-H\n \n-CH\n2\nCN\n \n442\n \n \n \n1177\n \n-H\n \n-(CH\n2\n)\n2\nOCH\n3\n \n \n475\n \n \n \n1178\n \n-H\n \n-(CH\n2\n)\n2\nOCH(CH\n3\n)\n2\n \n \n489\n \n \n \n1179\n \n-H\n \n-CH\n2\nCH\n2\nCN\n \n456\n \n \n \n1180\n \n-H\n \n-CH\n2\nCONHCH\n3\n \n \n474\n \n \n \n1181\n \n-H\n \n-(CH\n2\n)SCH\n3\n \n \n477\n \n \n \n1182\n \n-H\n \n-CH\n2\nCHF\n2\n \n \n467\n \n \n \n1183\n \n-H\n \n-CH\n2\nCH\n2\nOH\n \n447\n \n \n \n1184\n \n-H\n \n-C\n6\nH\n13\n \n \n487\n \n \n \n1185\n \n-CH\n2\nCON(CH\n3\n)\n2\n \n \n-CH\n3\n \n \n502\n \n \n \n1186\n \n-CH\n2\nC\n8\nH\n5\n \n \n-CH\n2\nCH\n2\nOCH\n3\n \n \n551\n \n \n \n1187\n \n-H\n \n-(CH\n2\n)\n2\nNHCONH\n2\n \n \n489\n \n \n \n \n\n\n \n[Table 112]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1188\n \n \n \n \n \n \n-CH\n3\n \n \n522\n \n \n \n1189\n \n \n \n \n \n \n-CH\n3\n \n \n514\n \n \n \n1190\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n529\n \n \n \n1191\n \n \n \n \n \n \n-H\n \n494\n \n \n \n1192\n \n \n \n \n \n \n-H\n \n494\n \n \n \n1193\n \n \n \n \n \n \n-H\n \n494\n \n \n \n1194\n \n \n \n \n \n \n-H\n \n483\n \n \n \n1195\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n536\n \n \n \n1196\n \n \n \n \n \n \n-CH\n3\n \n \n542\n \n \n \n1197\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n547\n \n \n \n \n\n\n \n[Table 113]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1198\n \n \n \n \n \n \n-CH\n3\n \n \n564\n \n \n \n1199\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n522\n \n \n \n1200\n \n \n \n \n \n \n-H\n \n457\n \n \n \n1201\n \n \n \n \n \n \n-H\n \n485\n \n \n \n1202\n \n \n \n \n \n \n-CH\n3\n \n \n507\n \n \n \n1203\n \n \n \n \n \n \n-H\n \n509\n \n \n \n1204\n \n \n \n \n \n \n-H\n \n521\n \n \n \n1205\n \n \n \n \n \n \n-H\n \n529\n \n \n \n1206\n \n \n \n \n \n \n-H\n \n544\n \n \n \n1207\n \n \n \n \n \n \n-H\n \n519\n \n \n \n \n\n\n \n[Table 114]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1208\n \n \n \n \n \n \n-H\n \n530\n \n \n \n1209\n \n \n \n \n \n \n-H\n \n530\n \n \n \n1210\n \n \n \n \n \n \n-H\n \n571\n \n \n \n1211\n \n \n \n \n \n \n-H\n \n518\n \n \n \n1212\n \n \n \n \n \n \n-H\n \n558\n \n \n \n1213\n \n \n \n \n \n \n-H\n \n486\n \n \n \n1214\n \n \n \n \n \n \n-H\n \n552\n \n \n \n1215\n \n \n \n \n \n \n-H\n \n471\n \n \n \n1216\n \n \n \n \n \n \n-H\n \n562\n \n \n \n \n\n\n \n[Table 115]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1217\n \n \n \n \n \n \n-H\n \n572\n \n \n \n1218\n \n \n \n \n \n \n-H\n \n536\n \n \n \n1219\n \n \n \n \n \n \n-H\n \n523\n \n \n \n1220\n \n \n \n \n \n \n-H\n \n534\n \n \n \n1221\n \n \n \n \n \n \n-H\n \n570\n \n \n \n1222\n \n \n \n \n \n \n-H\n \n540\n \n \n \n1223\n \n \n \n \n \n \n-H\n \n533\n \n \n \n1224\n \n \n \n \n \n \n-H\n \n519\n \n \n \n1225\n \n \n \n \n \n \n-H\n \n487\n \n \n \n \n\n\n \n[Table 116]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1226\n \n \n \n \n \n \n-H\n \n497\n \n \n \n1227\n \n \n \n \n \n \n-H\n \n501\n \n \n \n1228\n \n \n \n \n \n \n-H\n \n545\n \n \n \n1229\n \n \n \n \n \n \n-H\n \n535\n \n \n \n1230\n \n \n \n \n \n \n-H\n \n545\n \n \n \n1231\n \n \n \n \n \n \n-H\n \n546\n \n \n \n1232\n \n \n \n \n \n \n-H\n \n530\n \n \n \n1233\n \n \n \n \n \n \n-H\n \n483\n \n \n \n \n\n\n \n[Table 117]\n \n \n \n \n \n \n \n \n \n \n \n \nExamples\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1234\n \n \n \n \n \n \n-H\n \n562\n \n \n \n1235\n \n \n \n \n \n \n-H\n \n532\n \n \n \n1236\n \n \n \n \n \n \n-H\n \n545\n \n \n \n1237\n \n \n \n \n \n \n-H\n \n560\n \n \n \n1238\n \n \n \n \n \n \n-H\n \n559\n \n \n \n1239\n \n \n \n \n \n \n-H\n \n559\n \n \n \n1240\n \n \n \n \n \n \n-H\n \n546\n \n \n \n1241\n \n \n \n \n \n \n-H\n \n511\n \n \n \n1242\n \n \n \n \n \n \n-H\n \n530\n \n \n \n \n\n\n \n[Table 118]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1243\n \n \n \n \n \n \n-H\n \n508\n \n \n \n1244\n \n \n \n \n \n \n-H\n \n514\n \n \n \n1245\n \n \n \n \n \n \n-H\n \n514\n \n \n \n1246\n \n \n \n \n \n \n-H\n \n500\n \n \n \n1247\n \n \n \n \n \n \n-H\n \n514\n \n \n \n1248\n \n \n \n \n \n \n-H\n \n516\n \n \n \n1249\n \n \n \n \n \n \n-H\n \n530\n \n \n \n1250\n \n \n \n \n \n \n-H\n \n551\n \n \n \n1251\n \n \n \n \n \n \n-H\n \n543\n \n \n \n1252\n \n \n \n \n \n \n-H\n \n546\n \n \n \n \n\n\n \n[Table 119]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1253\n \n \n \n \n \n \n-H\n \n533\n \n \n \n1254\n \n \n \n \n \n \n-H\n \n499\n \n \n \n1255\n \n \n \n \n \n \n-H\n \n528\n \n \n \n1256\n \n \n \n \n \n \n-H\n \n487\n \n \n \n1257\n \n \n \n \n \n \n-H\n \n509\n \n \n \n1258\n \n \n \n \n \n \n-H\n \n508\n \n \n \n1259\n \n \n \n \n \n \n-H\n \n508\n \n \n \n1260\n \n \n \n \n \n \n-H\n \n497\n \n \n \n1261\n \n \n \n \n \n \n-H\n \n497\n \n \n \n1262\n \n \n \n \n \n \n-H\n \n496\n \n \n \n \n\n\n \n[Table 120]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1263\n \n \n \n \n \n \n-H\n \n525\n \n \n \n1264\n \n \n \n \n \n \n-H\n \n511\n \n \n \n1265\n \n \n \n \n \n \n-H\n \n511\n \n \n \n1266\n \n \n \n \n \n \n-H\n \n513\n \n \n \n1267\n \n \n \n \n \n \n-H\n \n499\n \n \n \n1268\n \n \n \n \n \n \n-H\n \n483\n \n \n \n1269\n \n \n \n \n \n \n-H\n \n500\n \n \n \n1270\n \n \n \n \n \n \n-H\n \n513\n \n \n \n1271\n \n \n \n \n \n \n-H\n \n535\n \n \n \n1272\n \n \n \n \n \n \n-H\n \n457\n \n \n \n \n\n\n \n[Table 121]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1273\n \n \n \n \n \n \n-H\n \n527\n \n \n \n1274\n \n \n \n \n \n \n-H\n \n554\n \n \n \n1275\n \n \n \n \n \n \n-H\n \n549\n \n \n \n1276\n \n \n \n \n \n \n-H\n \n519\n \n \n \n1277\n \n \n \n \n \n \n-H\n \n519\n \n \n \n1278\n \n \n \n \n \n \n-H\n \n497\n \n \n \n1279\n \n \n \n \n \n \n-H\n \n546\n \n \n \n1280\n \n \n \n \n \n \n-H\n \n497\n \n \n \n1281\n \n \n \n \n \n \n-H\n \n528\n \n \n \n1282\n \n \n \n \n \n \n-H\n \n487\n \n \n \n \n\n\n \n[Table 122]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1283\n \n \n \n \n \n \n-H\n \n575\n \n \n \n1284\n \n \n \n \n \n \n-CH\n3\n \n \n511\n \n \n \n1285\n \n \n \n \n \n \n-CH\n3\n \n \n525\n \n \n \n1286\n \n \n \n \n \n \n-CH\n3\n \n \n557\n \n \n \n1287\n \n \n \n \n \n \n-CH\n3\n \n \n528\n \n \n \n1288\n \n \n \n \n \n \n-CH\n3\n \n \n544\n \n \n \n1289\n \n \n \n \n \n \n-H\n \n547\n \n \n \n1290\n \n \n \n \n \n \n-CH\n3\n \n \n526\n \n \n \n1291\n \n \n \n \n \n \n-CH\n3\n \n \n564\n \n \n \n \n\n\n \n[Table 123]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1292\n \n \n \n \n \n \n-CH\n3\n \n \n574\n \n \n \n1293\n \n \n \n \n \n \n-CH\n3\n \n \n547\n \n \n \n1294\n \n \n \n \n \n \n-H\n \n511\n \n \n \n1295\n \n \n \n \n \n \n-CH\n3\n \n \n561\n \n \n \n1296\n \n \n \n \n \n \n-CH\n3\n \n \n564\n \n \n \n1297\n \n \n \n \n \n \n-H\n \n512\n \n \n \n1298\n \n \n \n \n \n \n-H\n \n515\n \n \n \n1299\n \n \n \n \n \n \n-CH\n3\n \n \n560\n \n \n \n1300\n \n \n \n \n \n \n-H\n \n566\n \n \n \n \n\n\n \n[Table 124]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1301\n \n \n \n \n \n \n-H\n \n573\n \n \n \n1302\n \n \n \n \n \n \n-CH\n3\n \n \n571\n \n \n \n1303\n \n \n \n \n \n \n-CH\n3\n \n \n584\n \n \n \n1304\n \n \n \n \n \n \n-CH\n2\n \n \n587\n \n \n \n1305\n \n \n \n \n \n \n-H\n \n560\n \n \n \n1306\n \n \n \n \n \n \n-H\n \n547\n \n \n \n1307\n \n \n \n \n \n \n-H\n \n549\n \n \n \n \n\n\n \n[Table 125]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1308\n \n-2-PYRIDYL\n \n544\n \n \n \n1309\n \n-C\n4\nH\n5\n \n \n523\n \n \n \n1310\n \n-CH(CH\n3\n)\n2\n \n \n509\n \n \n \n1311\n \n-CH\n2\nCH\n2\nN(CH\n3\n)\n2\n \n \n538\n \n \n \n1312\n \n-4-PYRIDYL\n \n544\n \n \n \n1313\n \n-C\n6\nH\n5\n \n \n543\n \n \n \n1314\n \n-C\n2\nH\n7\n \n \n509\n \n \n \n1315\n \n-CH\n2\nCH\n2\nOCH\n3\n \n \n525\n \n \n \n1316\n \n-CH\n3\n \n \n481\n \n \n \n1317\n \n-3-PYRIDYL\n \n544\n \n \n \n1318\n \n-C\n2\nH\n13\n \n \n551\n \n \n \n1319\n \n-C\n2\nH\n5\n \n \n495\n \n \n \n1320\n \n-CH\n2\nCH\n2\nOH\n \n511\n \n \n \n1321\n \n-COCH\n3\n \n \n509\n \n \n \n1322\n \n-cyclo-C\n6\nH\n11\n \n \n549\n \n \n \n1323\n \n-SO\n2\nC\n2\nH\n5\n \n \n559\n \n \n \n \n\n\n \n[Table 126]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1324\n \n \n \n \n \n \n558\n \n \n \n1325\n \n \n \n \n \n \n558\n \n \n \n1326\n \n \n \n \n \n \n558\n \n \n \n1327\n \n \n \n \n \n \n545\n \n \n \n1328\n \n \n \n \n \n \n564\n \n \n \n1329\n \n \n \n \n \n \n629\n \n \n \n1330\n \n \n \n \n \n \n545\n \n \n \n1331\n \n \n \n \n \n \n551\n \n \n \n1332\n \n \n \n \n \n \n561\n \n \n \n \n\n\n \n[Table 127]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1333\n \n \n \n \n \n \n572\n \n \n \n1334\n \n \n \n \n \n \n572\n \n \n \n1335\n \n \n \n \n \n \n578\n \n \n \n1336\n \n \n \n \n \n \n550\n \n \n \n1337\n \n \n \n \n \n \n535\n \n \n \n \n\n\n \n[Table 128]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1338\n \n-OCH\n3\n \n \n496\n \n \n \n1339\n \n-cyclo-C\n6\nH\n11\n \n \n548\n \n \n \n1340\n \n-C\n6\nH\n5\n \n \n542\n \n \n \n1341\n \n-OCH\n2\nC\n8\nH\n5\n \n \n572\n \n \n \n1342\n \n-OC\n8\nH\n5\n \n \n558\n \n \n \n1343\n \n-OH\n \n482\n \n \n \n1344\n \n-CONH\n2\n \n \n509\n \n \n \n1345\n \n-C\n2\nH\n5\n \n \n494\n \n \n \n1346\n \n-NHCOCH\n3\n \n \n523\n \n \n \n1347\n \n-COC\n6\nH\n5\n \n \n570\n \n \n \n1348\n \n-2-PYRIDYL\n \n543\n \n \n \n \n\n\n \n[Table 129]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1349\n \n \n \n \n \n \n549\n \n \n \n1350\n \n \n \n \n \n \n573\n \n \n \n1351\n \n \n \n \n \n \n573\n \n \n \n1352\n \n \n \n \n \n \n551\n \n \n \n1353\n \n \n \n \n \n \n559\n \n \n \n1354\n \n \n \n \n \n \n559\n \n \n \n \n\n\n \n[Table 130]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1355\n \n \n \n \n \n \n480\n \n \n \n1356\n \n \n \n \n \n \n520\n \n \n \n1357\n \n \n \n \n \n \n484\n \n \n \n1358\n \n \n \n \n \n \n470\n \n \n \n1359\n \n \n \n \n \n \n506\n \n \n \n1360\n \n \n \n \n \n \n534\n \n \n \n1361\n \n \n \n \n \n \n542\n \n \n \n1362\n \n \n \n \n \n \n571\n \n \n \n1363\n \n \n \n \n \n \n514\n \n \n \n1364\n \n \n \n \n \n \n558\n \n \n \n \n\n\n \n[Table 131]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1365\n \n \n \n \n \n \n553\n \n \n \n1366\n \n \n \n \n \n \n514\n \n \n \n1367\n \n \n \n \n \n \n500\n \n \n \n1368\n \n \n \n \n \n \n495\n \n \n \n1369\n \n \n \n \n \n \n543\n \n \n \n1370\n \n \n \n \n \n \n558\n \n \n \n1371\n \n \n \n \n \n \n510\n \n \n \n1372\n \n \n \n \n \n \n572\n \n \n \n1373\n \n \n \n \n \n \n468\n \n \n \n \n\n\n \n[Table 132]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1374\n \n \n \n \n \n \n541\n \n \n \n1375\n \n \n \n \n \n \n565\n \n \n \n1376\n \n \n \n \n \n \n500\n \n \n \n1377\n \n \n \n \n \n \n528\n \n \n \n1378\n \n \n \n \n \n \n481\n \n \n \n1379\n \n \n \n \n \n \n540\n \n \n \n1380\n \n \n \n \n \n \n537\n \n \n \n1381\n \n \n \n \n \n \n521\n \n \n \n1382\n \n \n \n \n \n \n563\n \n \n \n1383\n \n \n \n \n \n \n534\n \n \n \n \n\n\n \n[Table 133]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1384\n \n \n \n \n \n \n573\n \n \n \n1385\n \n \n \n \n \n \n482\n \n \n \n1386\n \n \n \n \n \n \n578\n \n \n \n1387\n \n \n \n \n \n \n544\n \n \n \n1388\n \n \n \n \n \n \n549\n \n \n \n1389\n \n \n \n \n \n \n543\n \n \n \n1390\n \n \n \n \n \n \n541\n \n \n \n1391\n \n \n \n \n \n \n548\n \n \n \n \n\n\n \n[Table 134]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \n \n \n \n1392\n \n \n \n \n \n \n556\n \n \n \n1393\n \n \n \n \n \n \n521\n \n \n \n1394\n \n \n \n \n \n \n438\n \n \n \n \n\n\n \n[Table 135]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1395\n \n-cyclo-C\n6\nH\n11\n \n \n-CH\n3\n \n \n494\n \n \n \n1396\n \n-H\n \n-CH(CH\n3\n)\n2\n \n \n440\n \n \n \n1397\n \n-C\n4\nH\n9\n \n \n-C\n4\nH\n9\n \n \n510\n \n \n \n1398\n \n-CH\n2\nCH(CH\n3\n)\n2\n \n \n-CH\n2\nCH(CH\n3\n)\n2\n \n \n510\n \n \n \n1399\n \n-CH\n2\nCH\n2\nOH\n \n-CH\n2\nCH\n2\nOH\n \n486\n \n \n \n1400\n \n-C\n6\nH\n13\n \n \n-C\n6\nH\n13\n \n \n566\n \n \n \n1401\n \n-CH\n2\nCH\n2\nN(CH\n3\n)\n2\n \n \n-CH\n3\n \n \n483\n \n \n \n1402\n \n-CH\n2\nCH\n2\nOCH\n3\n \n \n-CH\n2\nCH\n2\nOCH\n3\n \n \n514\n \n \n \n1403\n \n-CH\n2\nCH(CH\n3\n)\n2\n \n \n-CH\n2\nCH(CH\n3\n)\n2\n \n \n568\n \n \n \n1404\n \n-(CH\n2\n)\n2\nN(C\n2\nH\n5\n)\n2\n \n \n-CH\n2\n \n \n525\n \n \n \n1405\n \n-CH\n2\nCH=CH\n2\n \n \n-cylo-C\n5\nH\n9\n \n \n506\n \n \n \n1406\n \n-H\n \n-C\n4\nH\n9\n \n \n454\n \n \n \n1407\n \n-H\n \n-cyclo-C\n3\nH\n5\n \n \n438\n \n \n \n1408\n \n-H\n \n-cyclo-C\n7\nH\n13\n \n \n494\n \n \n \n1409\n \n-H\n \n-CH\n2\nC\n6\nH\n5\n \n \n488\n \n \n \n1410\n \n-C\n2\nH\n7\n \n \n-(CH\n2\n)\n3\nC\n6\nH\n5\n \n \n558\n \n \n \n1411\n \n-CH\n2\nCONHCH\n3\n \n \n-CH\n2\nC\n6\nH\n5\n \n \n559\n \n \n \n1412\n \n-CH\n2\nC\n8\nH\n5\n \n \n-cyclo-C\n6\nH\n11\n \n \n570\n \n \n \n1413\n \n-(CH\n2\n)\n2\nC\n6\nH\n5\n \n \n-CH\n3\n \n \n516\n \n \n \n1414\n \n-CH\n2\nC\n6\nH\n5\n \n \n-CH\n3\n \n \n502\n \n \n \n1415\n \n-CH\n2\nCH\n2\nN(CH\n3\n)\n2\n \n \n-CH\n2\nC\n6\nH\n5\n \n \n559\n \n \n \n1416\n \n-CH\n2\nC\n6\nH\n5\n \n \n-C\n5\nH\n11\n \n \n558\n \n \n \n1417\n \n-CH\n2\nC\n6\nH\n5\n \n \n-CH\n2\nC\n6\nH\n5\n \n \n578\n \n \n \n1418\n \n-CH\n2\nC\n6\nH\n5\n \n \n-C\n2\nH\n5\n \n \n516\n \n \n \n1419\n \n-CH\n2\nC\n6\nH\n5\n \n \n-CH(CH\n3\n)\n2\n \n \n530\n \n \n \n1420\n \n-CH\n2\nCH\n2\nCN\n \n-CH\n2\nC\n5\nH\n5\n \n \n541\n \n \n \n1421\n \n-(CH\n2\n)\n2\nOC\n5\nH\n5\n \n \n-CH\n3\n \n \n532\n \n \n \n1422\n \n-cyclo-C\n6\nH\n11\n \n \n-C\n2\nH\n5\n \n \n508\n \n \n \n \n\n\n \n[Table 136]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1423\n \n-CH(CH\n3\n)\n2\n \n \n-C\n2\nH\n5\n \n \n468\n \n \n \n1424\n \n-H\n \n-C\n2\nH\n5\n \n \n426\n \n \n \n1425\n \n-H\n \n-C\n3\nH\n7\n \n \n440\n \n \n \n1426\n \n-H\n \n-CH\n2\nCH\n2\nOCH\n3\n \n \n456\n \n \n \n1427\n \n-CH\n3\n-cyclo-C\n6\nH\n11\n \n \n-C\n2\nH\n5\n \n \n522\n \n \n \n1428\n \n-C\n2\nH\n5\n \n \n-C\n4\nH\n2\n \n \n482\n \n \n \n1429\n \n-H\n \n-1-CH\n2\n-CYCLOHEXYL\n \n494\n \n \n \n1430\n \n-H\n \n-(CH\n2\n)\n2\nOC\n6\nH\n5\n \n \n518\n \n \n \n1431\n \n-CH\n2\nC\n6\nH\n5\n \n \n-C\n6\nH\n5\n \n \n564\n \n \n \n1432\n \n-C\n6\nH\n5\n \n \n-CH\n2\nCH\n2\nOH\n \n518\n \n \n \n1433\n \n-C\n6\nH\n5\n \n \n-C\n2\nH\n5\n \n \n502\n \n \n \n1434\n \n-CH\n2\nCH\n2\nCN\n \n-C\n6\nH\n5\n \n \n527\n \n \n \n1435\n \n-2-PYRIDYL\n \n-C\n2\nH\n5\n \n \n503\n \n \n \n1436\n \n-H\n \n-C\n6\nH\n5\n \n \n474\n \n \n \n1437\n \n-H\n \n-3-PYRIDYL\n \n475\n \n \n \n1438\n \n-H\n \n-2-PYRIDYL\n \n475\n \n \n \n1439\n \n-H\n \n-4-PYRIDYL\n \n475\n \n \n \n1440\n \n-C\n6\nH\n5\n \n \n-CH,\n \n488\n \n \n \n1441\n \n-H\n \n-CH\n2\n-cyclo-C\n8\nH\n11\n \n \n494\n \n \n \n1442\n \n-H\n \n-(CH\n2\n)\n3\nC\n6\nH\n5\n \n \n516\n \n \n \n1443\n \n-H\n \n-(CH\n2\n)\n2\nC\n6\nH\n5\n \n \n502\n \n \n \n1444\n \n-H\n \n-CH\n2\nCONH\n2\n \n \n455\n \n \n \n1445\n \n-H\n \n-CH\n2\nCCH\n \n436\n \n \n \n1446\n \n-C\n5\nH\n11\n \n \n-CH\n3\n \n \n482\n \n \n \n1447\n \n-CH(CH\n3\n)\n2\n \n \n-CH\n3\n \n \n454\n \n \n \n1448\n \n-H\n \n-(CH\n2\n)\n2\nCH(CH\n3\n)\n2\n \n \n468\n \n \n \n1449\n \n-H\n \n-CH\n2\nC(CH\n3\n)\n3\n \n \n468\n \n \n \n1450\n \n-H\n \n-CH\n2\nCH\n2\nN(CH\n3\n)\n2\n \n \n469\n \n \n \n \n\n\n \n[Table 137]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1451\n \n-CH\n2\nC\n6\nH\n5\n \n \n-(CH\n2\n)\n3\nOH\n \n546\n \n \n \n1452\n \n-CH\n3\n \n \n-CH\n2\n-cyclo-C\n3\nH\n5\n \n \n466\n \n \n \n1453\n \n-H\n \n-CH\n2\nCF\n3\n \n \n480\n \n \n \n1454\n \n-H\n \n-NHCH\n2\nCF\n3\n \n \n495\n \n \n \n1455\n \n-CH\n3\n \n \n-CH\n3\n \n \n426\n \n \n \n1456\n \n-H\n \n-(CH\n2\n)\n2\nOCH(CH\n3\n)\n2\n \n \n498\n \n \n \n1457\n \n-H\n \n-CH\n2\nCH\n2\nC(CH\n3\n)\n3\n \n \n482\n \n \n \n1458\n \n-H\n \n-CH\n2\nCN\n \n437\n \n \n \n1459\n \n-H\n \n-(CH\n2\n)\n2\nOCH\n3\n \n \n470\n \n \n \n1460\n \n-H\n \n-(CH\n2\n)\n2\nOCH(CH\n3\n)\n2\n \n \n484\n \n \n \n1461\n \n-H\n \n-CH\n2\nCH\n2\nCN\n \n451\n \n \n \n1462\n \n-H\n \n-CH\n2\nCONHCH\n3\n \n \n469\n \n \n \n1463\n \n-H\n \n-(CH\n2\n)SCH\n3\n \n \n472\n \n \n \n1464\n \n-H\n \n-CH\n2\nCHF\n2\n \n \n462\n \n \n \n1465\n \n-H\n \n-C\n6\nH\n13\n \n \n482\n \n \n \n1466\n \n-CH\n2\nCON(CH\n3\n)\n2\n \n \n-CH\n3\n \n \n497\n \n \n \n1467\n \n-CH\n2\nC\n6\nH\n5\n \n \n-CH\n2\nCH\n2\nOCH\n3\n \n \n546\n \n \n \n1468\n \n-H\n \n-(CH\n2\n)\n2\nNHCONH\n2\n \n \n484\n \n \n \n \n\n\n \n[Table 138]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1469\n \n \n \n \n \n \n-CH\n3\n \n \n517\n \n \n \n1470\n \n \n \n \n \n \n-CH\n3\n \n \n509\n \n \n \n1471\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n524\n \n \n \n1472\n \n \n \n \n \n \n-H\n \n489\n \n \n \n1473\n \n \n \n \n \n \n-H\n \n489\n \n \n \n1474\n \n \n \n \n \n \n-H\n \n489\n \n \n \n1475\n \n \n \n \n \n \n-H\n \n478\n \n \n \n1476\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n531\n \n \n \n1477\n \n \n \n \n \n \n-CH\n3\n \n \n537\n \n \n \n1478\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n542\n \n \n \n \n\n\n \n[Table 139]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1479\n \n \n \n \n \n \n-CH\n3\n \n \n559\n \n \n \n1480\n \n \n \n \n \n \n-C\n2\nH\n5\n \n \n517\n \n \n \n1481\n \n \n \n \n \n \n-H\n \n452\n \n \n \n1482\n \n \n \n \n \n \n-H\n \n480\n \n \n \n1483\n \n \n \n \n \n \n-CH\n3\n \n \n536\n \n \n \n1484\n \n \n \n \n \n \n-CH\n2\n \n \n502\n \n \n \n1485\n \n \n \n \n \n \n-H\n \n508\n \n \n \n1486\n \n \n \n \n \n \n-H\n \n504\n \n \n \n1487\n \n \n \n \n \n \n-H\n \n516\n \n \n \n1488\n \n \n \n \n \n \n-H\n \n524\n \n \n \n1489\n \n \n \n \n \n \n-H\n \n539\n \n \n \n \n\n\n \n[Table 140]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1490\n \n \n \n \n \n \n-H\n \n514\n \n \n \n1491\n \n \n \n \n \n \n-H\n \n525\n \n \n \n1492\n \n \n \n \n \n \n-H\n \n525\n \n \n \n1493\n \n \n \n \n \n \n-H\n \n566\n \n \n \n1494\n \n \n \n \n \n \n-H\n \n513\n \n \n \n1495\n \n \n \n \n \n \n-H\n \n553\n \n \n \n1496\n \n \n \n \n \n \n-H\n \n481\n \n \n \n1497\n \n \n \n \n \n \n-H\n \n476\n \n \n \n1498\n \n \n \n \n \n \n-H\n \n519\n \n \n \n1499\n \n \n \n \n \n \n-H\n \n547\n \n \n \n \n\n\n \n[Table 141]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1500\n \n \n \n \n \n \n-H\n \n465\n \n \n \n1501\n \n \n \n \n \n \n-H\n \n466\n \n \n \n1502\n \n \n \n \n \n \n-H\n \n479\n \n \n \n1503\n \n \n \n \n \n \n-H\n \n557\n \n \n \n1504\n \n \n \n \n \n \n-H\n \n567\n \n \n \n1505\n \n \n \n \n \n \n-H\n \n531\n \n \n \n1506\n \n \n \n \n \n \n-H\n \n518\n \n \n \n1507\n \n \n \n \n \n \n-H\n \n529\n \n \n \n1508\n \n \n \n \n \n \n-H\n \n565\n \n \n \n \n\n\n \n[Table 142]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1509\n \n \n \n \n \n \n-H\n \n535\n \n \n \n1510\n \n \n \n \n \n \n-H\n \n514\n \n \n \n1511\n \n \n \n \n \n \n-H\n \n492\n \n \n \n1512\n \n \n \n \n \n \n-H\n \n525\n \n \n \n1513\n \n \n \n \n \n \n-H\n \n496\n \n \n \n1514\n \n \n \n \n \n \n-H\n \n493\n \n \n \n1515\n \n \n \n \n \n \n-H\n \n540\n \n \n \n1516\n \n \n \n \n \n \n-H\n \n530\n \n \n \n1517\n \n \n \n \n \n \n-H\n \n540\n \n \n \n \n\n\n \n[Table 143]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1518\n \n \n \n \n \n \n-H\n \n541\n \n \n \n1519\n \n \n \n \n \n \n-H\n \n525\n \n \n \n1520\n \n \n \n \n \n \n-H\n \n478\n \n \n \n1521\n \n \n \n \n \n \n-H\n \n476\n \n \n \n1522\n \n \n \n \n \n \n-H\n \n495\n \n \n \n1523\n \n \n \n \n \n \n-H\n \n465\n \n \n \n1524\n \n \n \n \n \n \n-H\n \n557\n \n \n \n1525\n \n \n \n \n \n \n-H\n \n527\n \n \n \n1526\n \n \n \n \n \n \n-H\n \n540\n \n \n \n \n\n\n \n[Table 144]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1527\n \n \n \n \n \n \n-H\n \n555\n \n \n \n1528\n \n \n \n \n \n \n-H\n \n554\n \n \n \n1529\n \n \n \n \n \n \n-H\n \n554\n \n \n \n1530\n \n \n \n \n \n \n-H\n \n541\n \n \n \n1531\n \n \n \n \n \n \n-H\n \n506\n \n \n \n1532\n \n \n \n \n \n \n-H\n \n525\n \n \n \n1533\n \n \n \n \n \n \n-H\n \n503\n \n \n \n1534\n \n \n \n \n \n \n-H\n \n509\n \n \n \n1535\n \n \n \n \n \n \n-H\n \n509\n \n \n \n1536\n \n \n \n \n \n \n-H\n \n495\n \n \n \n \n\n\n \n[Table 145]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1537\n \n \n \n \n \n \n-H\n \n509\n \n \n \n1538\n \n \n \n \n \n \n-H\n \n511\n \n \n \n1539\n \n \n \n \n \n \n-H\n \n525\n \n \n \n1540\n \n \n \n \n \n \n-H\n \n556\n \n \n \n1541\n \n \n \n \n \n \n-H\n \n538\n \n \n \n1542\n \n \n \n \n \n \n-H\n \n541\n \n \n \n1543\n \n \n \n \n \n \n-H\n \n528\n \n \n \n1544\n \n \n \n \n \n \n-H\n \n494\n \n \n \n1545\n \n \n \n \n \n \n-H\n \n523\n \n \n \n1546\n \n \n \n \n \n \n-H\n \n482\n \n \n \n \n\n\n \n[Table 146]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1547\n \n \n \n \n \n \n-H\n \n504\n \n \n \n1548\n \n \n \n \n \n \n-H\n \n503\n \n \n \n1549\n \n \n \n \n \n \n-H\n \n503\n \n \n \n1550\n \n \n \n \n \n \n-H\n \n492\n \n \n \n1551\n \n \n \n \n \n \n-H\n \n492\n \n \n \n1552\n \n \n \n \n \n \n-H\n \n491\n \n \n \n1553\n \n \n \n \n \n \n-H\n \n520\n \n \n \n1554\n \n \n \n \n \n \n-H\n \n506\n \n \n \n1555\n \n \n \n \n \n \n-H\n \n506\n \n \n \n1556\n \n \n \n \n \n \n-H\n \n508\n \n \n \n \n\n\n \n[Table 147]\n \n \n \n \n \n \n \n \n \n \n \n \nExamples\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1557\n \n \n \n \n \n \n-H\n \n494\n \n \n \n1558\n \n \n \n \n \n \n-H\n \n478\n \n \n \n1559\n \n \n \n \n \n \n-H\n \n495\n \n \n \n1560\n \n \n \n \n \n \n-H\n \n508\n \n \n \n1561\n \n \n \n \n \n \n-H\n \n530\n \n \n \n1562\n \n \n \n \n \n \n-H\n \n452\n \n \n \n1563\n \n \n \n \n \n \n-H\n \n522\n \n \n \n1564\n \n \n \n \n \n \n-H\n \n495\n \n \n \n1565\n \n \n \n \n \n \n-H\n \n549\n \n \n \n1566\n \n \n \n \n \n \n-H\n \n544\n \n \n \n1567\n \n \n \n \n \n \n-H\n \n514\n \n \n \n \n\n\n \n[Table 148]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1568\n \n \n \n \n \n \n-H\n \n514\n \n \n \n1569\n \n \n \n \n \n \n-H\n \n492\n \n \n \n1570\n \n \n \n \n \n \n-H\n \n541\n \n \n \n1571\n \n \n \n \n \n \n-H\n \n492\n \n \n \n1572\n \n \n \n \n \n \n-H\n \n482\n \n \n \n1573\n \n \n \n \n \n \n-H\n \n570\n \n \n \n1574\n \n \n \n \n \n \n-CH\n3\n \n \n506\n \n \n \n1575\n \n \n \n \n \n \n-CH\n3\n \n \n520\n \n \n \n1576\n \n \n \n \n \n \n-CH\n3\n \n \n552\n \n \n \n1577\n \n \n \n \n \n \n-CH\n3\n \n \n523\n \n \n \n1578\n \n \n \n \n \n \n-CH\n3\n \n \n539\n \n \n \n \n\n\n \n[Table 149]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1579\n \n \n \n \n \n \n-H\n \n542\n \n \n \n1580\n \n \n \n \n \n \n-CH\n3\n \n \n521\n \n \n \n1581\n \n \n \n \n \n \n-CH\n3\n \n \n559\n \n \n \n1582\n \n \n \n \n \n \n-CH\n3\n \n \n569\n \n \n \n1583\n \n \n \n \n \n \n-CH\n3\n \n \n542\n \n \n \n1584\n \n \n \n \n \n \n-H\n \n506\n \n \n \n1585\n \n \n \n \n \n \n-CH\n3\n \n \n556\n \n \n \n1586\n \n \n \n \n \n \n-CH\n3\n \n \n559\n \n \n \n1587\n \n \n \n \n \n \n-H\n \n507\n \n \n \n \n\n\n \n[Table 150]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1588\n \n \n \n \n \n \n-H\n \n510\n \n \n \n1589\n \n \n \n \n \n \n-CH\n3\n \n \n555\n \n \n \n1590\n \n \n \n \n \n \n-H\n \n561\n \n \n \n1591\n \n \n \n \n \n \n-H\n \n568\n \n \n \n1592\n \n \n \n \n \n \n-CH\n3\n \n \n566\n \n \n \n1593\n \n \n \n \n \n \n-CH\n3\n \n \n579\n \n \n \n1594\n \n \n \n \n \n \n-CH\n3\n \n \n582\n \n \n \n1595\n \n \n \n \n \n \n-H\n \n544\n \n \n \n \n\n\n \n[Table 151]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystalization solvent)\n \nMelting Point (°C)\n \nSalt\n \n \n \n \n1596\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ methanol)\n \n214-217\n \nHydrochloride\n \n \n \n1597\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ methanol)\n \n218-222\n \n1/2 fumarate\n \n \n \n1598\n \n \n \n \n \n \nColorless needle-form crystal (Ethanol)\n \n195-196\n \n-\n \n \n \n1599\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n145-146\n \n-\n \n \n \n1600\n \n \n \n \n \n \nWhite powder (Ethanol/ ethyl acetate)\n \n219-221\n \nDihydrochloride\n \n \n \n1601\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n162-164\n \n-\n \n \n \n1602\n \n \n \n \n \n \nWhite powder (Ethanol/ether)\n \n208.5-209.5\n \nDihydrochloride\n \n \n \n1603\n \n \n \n \n \n \nWhite powder (n-hexane/ ethyl acetate)\n \n137-139\n \n-\n \n \n \n1604\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n137-139\n \n-\n \n \n \n1605\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n163-165\n \n-\n \n \n \n1606\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n196-199\n \n-\n \n \n \n \n\n\n \n[Table 152]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystalization solvent)\n \nMelting Point (°C)\n \nSalt\n \n \n \n \n1607\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n197-199\n \n-\n \n \n \n1608\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n232-233\n \nDihydrochloride\n \n \n \n1609\n \n \n \n \n \n \nWhite powder (Ethanol/ether)\n \n255-257\n \nHydrochloride\n \n \n \n1610\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n169.5-172.5\n \n-\n \n \n \n1611\n \n \n \n \n \n \nWhite powder (Ethanol)\n \n195.0-196.5\n \n-\n \n \n \n1612\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n151.5-153.5\n \n-\n \n \n \n1613\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n235.0 (dec)\n \nHydrochloride\n \n \n \n1614\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n1615\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n224.0-227.5\n \nHydrochloride\n \n \n \n1616\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n175.0-178.5\n \n-\n \n \n \n \n\n\n \n[Table 153]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystalization solvent)\n \nMelting Point (°C)\n \nSalt\n \n \n \n \n1617\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n169.0-173.0\n \n-Trihydrochloride\n \n \n \n1618\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n1619\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n210.0-217.0\n \nDihydrochloride\n \n \n \n1620\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n181.0-188.0\n \nDihydrochloride\n \n \n \n1621\n \n \n \n \n \n \nWhite powder (Ethanol/ethyl acetate)\n \n163.5-167.0\n \nHydrochloride\n \n \n \n1622\n \n \n \n \n \n \nWhite powder (methyl acetate/ether)\n \n172.5-176.5\n \nHydrochloride\n \n \n \n1623\n \n \n \n \n \n \nWhite powder (Ethyl aaetate/ether)\n \n145.0-151.0\n \nDihydrochloride\n \n \n \n1624\n \n \n \n \n \n \nWhite powder (Ethanol/ethyl acetate)\n \n144.0-150.0\n \nDihydrochloride\n \n \n \n \n\n\n \n[Table 154]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystalization solvent)\n \nMelting Point (°C)\n \nSalt\n \n \n \n \n1625\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ether)\n \n177-182\n \nDihydrochloride\n \n \n \n1626\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ether)\n \n198-201\n \nHydrochloride\n \n \n \n1627\n \n \n \n \n \n \nWhite powder (Ethyl acetate/other)\n \n195-200\n \nHydrochloride\n \n \n \n1628\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ether)\n \n215-218\n \nHydrochloride\n \n \n \n1629\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ether)\n \n152-157\n \nHydrochloride\n \n \n \n1630\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ether)\n \n158-161\n \nHydrochloride\n \n \n \n1631\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ether)\n \n168-172\n \nHydrochloride\n \n \n \n1632\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n178.5-181.5\n \n-\n \n \n \n1633\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n228.0 (dec)\n \nHydrochloride\n \n \n \n \n\n\n \n[Table 155]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nNMR Salt\n \n \n \n \n1634\n \n \n \n \n \n \n \n1\nH-NMR (DMSO-d6) δ ppm: 1.95-210 (2H, m), 2.85-2.95 (2H, m), 3.00-3.15 (4H, m), 3.15-3.30 (4H, m), 4.41 (2H, t, J=5.8Hz), 6.89 (1H, d, J=5.0 Hz), 7.15 (1H, s), 7.26 (1H, t, J=7.9Hz), 7.43 (1H, d, J=5.5 Hz), 7.63 (1H, d, J=8.0 Hz), 7.71 (1H, d, J=5.5 Hz), 8.73 (1H, s),\n \n \n \n1635\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n ) δ ppm: 1.72-1.98 (4H, m). 2.30-246(1H, m), 246-2.58(2H, m), 262-2-77 (5H. m). 280(3H, d, J=5.1Hz), 3.04-3.29 (5H, m), 3.38-3.55 (2H, m), 3.83-4.04 (2H, m), 6.90 (1H, dd, J=0.5Hz, 7.6Hz ), 7.22-7.34 (1H, m), 7.34-7.47 (2H, m), 7.55 (1H, d, J=8.0 Hz), 7.63(1H, br).\n \n \n \n1636\n \n \n \n \n \n \n \n1\nH-NMR (CDCl\n3\n) δ ppm: 1.46 (9H, s), 1.70-1.89 (2H. m), 1.90-2.17(1H, m), 2.44-260(2H, m), 2.62-2.75 (4H, m), 2.81(3H, d, J=4.7Hz), 3.09-3.26 (4H, m), 3.39-3.57 (4H, m), 3.93-4.21 (1H, m), 4.21-4.46(1H, m), 6.65-6.95(1H, br), 6.90 (1H, d, J=7.0 Hz), 7.20-7.34 (1H. m), 7.35-7.45 (2H, m), 7.55 (1H, d, J=8.0 Hz).\n \n \n \n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nMS(M+1)\n \nSalt\n \n \n \n \n1637\n \n \n \n \n \n \n440\n \nHydrochloride\n \n \n \n1638\n \n \n \n \n \n \n360\n \nMaleate\n \n \n \n \n\n\n \n[Table 156]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nCrystal form (Recrystalization solvent)\n \nMelting Point (°C)\n \nSalt\n \n \n \n \n1639\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ether\n \n215.5-216.5\n \nHydrochloride\n \n \n \n1640\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n1641\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n132.5-135.0\n \n-\n \n \n \n1642\n \n \n \n \n \n \nWhite powder (2-proparol water)\n \n180.0-182.0\n \n-\n \n \n \n1643\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n216.0-220.2\n \nHydrochloride\n \n \n \n1644\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n203.0-207.0\n \nHydrochloride\n \n \n \n1645\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl other)\n \n146.5-148.0\n \n-\n \n \n \n1646\n \n \n \n \n \n \nWhite powder (Ethyl acetate)\n \n197.0-201.0\n \nHydrochloride\n \n \n \n1647\n \n \n \n \n \n \nWhite powder (Ethyl acetate/ isopropyl ether)\n \n133.0-134.5\n \n-\n \n \n \n \n\n\n \n[Table 157]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nR3\n \nR4\n \nR5\n \nR6\n \nMS(M+1)\n \n \n \n \n1648\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n-CH\n3\n \n \n517\n \n \n \n1649\n \n-H\n \n-H\n \n-CH\n3\n \n \n-H\n \n-H\n \n-CH\n3\n \n \n501\n \n \n \n1650\n \n-H\n \n-H\n \n-Cl\n \n-H\n \n-H\n \n-CH\n3\n \n \n521\n \n \n \n1651\n \n-H\n \n-SCH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n519\n \n \n \n1652\n \n-SCH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n519\n \n \n \n1653\n \n-H\n \n-Cl\n \n-Cl\n \n-H\n \n-H\n \n-H\n \n541\n \n \n \n1654\n \n-H\n \n-H\n \n-OCF\n3\n \n \n-H\n \n-H\n \n-H\n \n557\n \n \n \n1655\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n473\n \n \n \n1656\n \n-H\n \n-H\n \n-Cl\n \n-H\n \n-H\n \n-H\n \n507\n \n \n \n1657\n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n503\n \n \n \n1658\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n503\n \n \n \n1659\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n503\n \n \n \n1660\n \n-Cl\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n507\n \n \n \n1661\n \n-H\n \n-Cl\n \n-H\n \n-H\n \n-H\n \n-H\n \n507\n \n \n \n1662\n \n-H\n \n-H\n \n-CH\n2\n \n \n-H\n \n-H\n \n-H\n \n487\n \n \n \n1663\n \n-OCH\n2\n \n \n-H\n \n-OCH\n2\n \n \n-H\n \n-H\n \n-H\n \n533\n \n \n \n1664\n \n-N(CH\n3\n)\n2\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n516\n \n \n \n1665\n \n-1-PYRRYL\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n538\n \n \n \n1666\n \n-H\n \n-Cl\n \n-H\n \n-H\n \n-DCH\n3\n \n \n-H\n \n537\n \n \n \n1667\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-OCH\n3\n \n \n-H\n \n533\n \n \n \n1668\n \n-H\n \n-OCH\n3\n \n \n-H\n \n-OCH\n3\n \n \n-H\n \n-H\n \n533\n \n \n \n1669\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-CH\n3\n \n \n-H\n \n-H\n \n517\n \n \n \n1670\n \n-H\n \n-OCH\n3\n \n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n533\n \n \n \n1671\n \n-C(CH\n3\n)=CH\n2\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n513\n \n \n \n1672\n \n-H\n \n-OCF\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n557\n \n \n \n1673\n \n-CH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n487\n \n \n \n1674\n \n-H\n \n-CH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n487\n \n \n \n1675\n \n-F\n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n491\n \n \n \n \n\n\n \n[Table 158]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nR3\n \nR4\n \nR5\n \nR6\n \nMS(M+1)\n \n \n \n \n1676\n \n-H\n \n-H\n \n-F\n \n-H\n \n-H\n \n-H\n \n491\n \n \n \n1677\n \n-H\n \n-N(CH\n3\n)\n2\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n516\n \n \n \n1678\n \n-H\n \n-H\n \n-N(CH\n3\n)\n2\n \n \n-H\n \n-H\n \n-H\n \n516\n \n \n \n1679\n \n-CF\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n-H\n \n541\n \n \n \n1680\n \n-H\n \n-CF\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n541\n \n \n \n1681\n \n-H\n \n-NHCOCH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n530\n \n \n \n1682\n \n-H\n \n-H\n \n-NHCOCH\n3\n \n \n-H\n \n-H\n \n-H\n \n530\n \n \n \n1683\n \n-H\n \n-H\n \n-H\n \n-H\n \n-CN\n \n-H\n \n498\n \n \n \n1684\n \n-H\n \n-H\n \n-H\n \n-CN\n \n-H\n \n-H\n \n498\n \n \n \n1685\n \n-CH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n-CH\n3\n \n \n501\n \n \n \n1686\n \n-H\n \n-CH\n3\n \n \n-H\n \n-H\n \n-H\n \n-CH\n3\n \n \n501\n \n \n \n1687\n \n-H\n \n-Cl\n \n-H\n \n-H\n \n-H\n \n-CH\n3\n \n \n521\n \n \n \n1688\n \n-H\n \n-H\n \n-OH\n \n-H\n \n-H\n \n-CH\n3\n \n \n503\n \n \n \n1689\n \n-CH\n3\n \n \n-CH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n501\n \n \n \n1690\n \n-CH\n3\n \n \n-H\n \n-CH\n3\n \n \n-H\n \n-H\n \n-H\n \n501\n \n \n \n1691\n \n-CH\n3\n \n \n-H\n \n-H\n \n-H\n \n-CH\n3\n \n \n-H\n \n501\n \n \n \n1692\n \n-H\n \n-CH\n3\n \n \n-CH\n3\n \n \n-H\n \n-H\n \n-H\n \n501\n \n \n \n1693\n \n-H\n \n-CH\n3\n \n \n-H\n \n-CH\n3\n \n \n-H\n \n-H\n \n501\n \n \n \n1694\n \n-F\n \n-F\n \n-H\n \n-H\n \n-H\n \n-H\n \n509\n \n \n \n1695\n \n-H\n \n-F\n \n-F\n \n-H\n \n-H\n \n-H\n \n509\n \n \n \n1696\n \n-H\n \n-F\n \n-H\n \n-F\n \n-H\n \n-H\n \n509\n \n \n \n1697\n \n-H\n \n-F\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n521\n \n \n \n1698\n \n-H\n \n-OCH\n3\n \n \n-CH\n3\n \n \n-H\n \n-H\n \n-H\n \n517\n \n \n \n1699\n \n-H\n \n-Cl\n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n537\n \n \n \n1700\n \n-H\n \n-Cl\n \n-CH\n3\n \n \n-H\n \n-H\n \n-H\n \n521\n \n \n \n1701\n \n-OCH\n3\n \n \n-OCH\n3\n \n \n-H\n \n-H\n \n-H\n \n-H\n \n533\n \n \n \n1702\n \n-H\n \n-Cl\n \n-OH\n \n-H\n \n-H\n \n-H\n \n523\n \n \n \n1703\n \n-Cl\n \n-H\n \n-H\n \n-CH\n3\n \n \n-H\n \n-H\n \n521\n \n \n \n \n\n\n \n[Table 159]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nR3\n \nR4\n \nR5\n \nR6\n \nMS(M+1)\n \n \n \n \n1704\n \n-H\n \n-CONH\n2\n \n \n-H\n \n-H\n \n-Cl\n \n-H\n \n550\n \n \n \n1705\n \n-CH\n3\n \n \n-H\n \n-Br\n \n-H\n \n-CH\n3\n \n \n-H\n \n579\n \n \n \n1706\n \n-H\n \n-H\n \n-CN\n \n-H\n \n-H\n \n-H\n \n498\n \n \n \n1707\n \n-H\n \n-H\n \n-SCH\n3\n \n \n-H\n \n-H\n \n-H\n \n519\n \n \n \n1708\n \n-H\n \n-H\n \n-CH(CH\n3\n)\n2\n \n \n-H\n \n-H\n \n-H\n \n515\n \n \n \n1709\n \n-H\n \n-H\n \n-2-FURYL\n \n-H\n \n-H\n \n-H\n \n539\n \n \n \n \n\n\n \n[Table 160]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nR3\n \nR4\n \nR5\n \nR6\n \nMS(M+1)\n \n \n \n \n1710\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n-H\n \n-H\n \n539\n \n \n \n1711\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n-H\n \n-H\n \n540\n \n \n \n1712\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n-H\n \n-H\n \n542\n \n \n \n1713\n \n-H\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n-H\n \n554\n \n \n \n1714\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n-H\n \n-H\n \n553\n \n \n \n1715\n \n-H\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n-H\n \n553\n \n \n \n1716\n \n-H\n \n \n \n \n \n \n-H\n \n-H\n \n-H\n \n-H\n \n540\n \n \n \n \n\n\n \n[Table 161]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1717\n \n \n \n \n \n \n-H\n \n474\n \n \n \n1718\n \n \n \n \n \n \n-H\n \n523\n \n \n \n1719\n \n \n \n \n \n \n-H\n \n513\n \n \n \n1720\n \n \n \n \n \n \n-H\n \n474\n \n \n \n1721\n \n \n \n \n \n \n-H\n \n474\n \n \n \n1722\n \n \n \n \n \n \n-H\n \n524\n \n \n \n1723\n \n \n \n \n \n \n-H\n \n504\n \n \n \n1724\n \n \n \n \n \n \n-H\n \n512\n \n \n \n1725\n \n \n \n \n \n \n-H\n \n560\n \n \n \n \n\n\n \n[Table 162]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1726\n \n \n \n \n \n \n-H\n \n556\n \n \n \n1727\n \n \n \n \n \n \n-H\n \n556\n \n \n \n1728\n \n \n \n \n \n \n-H\n \n572\n \n \n \n1729\n \n \n \n \n \n \n-H\n \n488\n \n \n \n1730\n \n \n \n \n \n \n-H\n \n480\n \n \n \n1731\n \n \n \n \n \n \n-H\n \n524\n \n \n \n1732\n \n \n \n \n \n \n-H\n \n546\n \n \n \n1733\n \n \n \n \n \n \n-H\n \n478\n \n \n \n \n\n\n \n[Table 163]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1734\n \n \n \n \n \n \n-H\n \n556\n \n \n \n1735\n \n \n \n \n \n \n-H\n \n528\n \n \n \n1736\n \n \n \n \n \n \n-H\n \n564\n \n \n \n1737\n \n \n \n \n \n \n-H\n \n534\n \n \n \n1738\n \n \n \n \n \n \n-H\n \n513\n \n \n \n1739\n \n \n \n \n \n \n-H\n \n491\n \n \n \n1740\n \n \n \n \n \n \n-H\n \n506\n \n \n \n1741\n \n \n \n \n \n \n-H\n \n492\n \n \n \n1742\n \n \n \n \n \n \n-H\n \n529\n \n \n \n \n\n\n \n[Table 164]\n \n \n \n \n \n \n \n \n \n \n \n \nExample\n \nR1\n \nR2\n \nMS(M+1)\n \n \n \n \n1743\n \n \n \n \n \n \n-H\n \n480\n \n \n \n1744\n \n \n \n \n \n \n-H\n \n477\n \n \n \n1745\n \n \n \n \n \n \n-H\n \n494\n \n \n \n1746\n \n \n \n \n \n \n-H\n \n464\n \n \n \n1747\n \n \n \n \n \n \n-H\n \n478\n \n \n \n1748\n \n \n \n \n \n \n-H\n \n566\n \n \n \n1749\n \n \n \n \n \n \n-H\n \n556\n \n \n \n1750\n \n \n \n \n \n \n-H\n \n526\n \n \n \n \n \n\n\n \nExample 1751 (Reference)\n\n\nSynthesis of 3-amino-4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-N-ethylbenzamide\n\n\n \n \n \n5% palladium carbon (0.8 g) was added to an ethanol solution (30 ml) of 4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-N-ethyl-3-nitrobenzamide (1.0 g, 2.1 mmol) and the mixture was subjected to catalytic reduction at room temperature under normal pressure. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure. Water was added to the residue and the solution was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and thereafter concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane : methanol = 30:1 → 20:1). The purified product was concentrated under reduced pressure to obtain 3-amino-4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-N-ethyl-benzamide (0.78 g, 83% yield) as yellow amorphous solid.\n\n\n1\nH-NMR (CDCl\n3\n ) δppm: 1.23 (3H, t, J=7.4 Hz), 2.00-2.15 (2H, m), 2.67 (2H, t, J=7.3 Hz), 2.75 (4H, brs), 3.21 (4H, brs), 3.40-3.50 (2H, m), 3.50-4.30 (2H, br), 4.13 (2H, t, J=6.5 Hz), 5.99 (1H, brs), 6.80 (1H, d, J=8.4 Hz), 6.90 (1H, d, J=7.6 Hz), 7.08 (1H, dd, J=2.1, 8.3 Hz), 7.19 (1H, d, J=2.1 Hz), 7.25-7.30 (1H, m), 7.35-7.45 (2H, m), 7.55 (1H. d, J=8.0 Hz).\n\n\n \nExample 1752\n\n\nSynthesis of 1-benzo[b]thiophen-4-yl-4-[3-(1-acetylpiperidin-4-yloxy)propyl]piperazine hydrochloride\n\n\n \n \n \nTriethylamine (0.28 ml, 2.0 mmol) was added to a dichloromethane solution (15 ml) of 1-benzo[b]thiophen-4-yl-4-[3-(piperidin-4-yloxy)-propyl]-piperazine (0.45 g, 1.25 mmol) and the mixture was cooled in an ice bath. To this, acetyl chloride (0.1 ml, 1.4 mmol) was added and the mixture was stirred at room temperature overnight. Water was added to the reaction solution, which was then extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate and thereafter concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane : methanol = 30:1). The purified product was concentrated under reduced pressure. To the residue, 0.5 N hydrochloride-methanol solution (3 ml) was added. The crystal produced was obtained by filtration and dried to obtain 1-benzo[b]thiopher-4-yl-4-[3-(1-acetylpiperidin-4-yloxy)propyl]piperazine hydrochloride as white powder (0.36 g, 66% yield).\n\nMelting point: 208-210°C\n\n\n \nExample 1753\n\n\nSynthesis of 1-[3-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]pyrrolidine-2,5-dione hydrochloride\n\n\n \n \n \nPS-triphenylphosphine (3 mmol/g, 1.80 g), ditert-butylazodicarboxylate (1.27 g, 5.4 mmol) and N-hydroxysuccinimide (510 mg, 4.3 mmol) were added to a THF solution (50 ml) of 3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propanol (1.00 g, 3.6 mmol) and the mixture was stirred at room temperature for 4 hours. The resin was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 1:2). The purified product was concentrated under reduced pressure to obtain white amorphous solid (7.62 mg, 47% yield) . 157 mg of the white amorphous solid was dissolved in ethanol. To the solution, 1N hydrochloric acid-ethanol solution (0.42 ml) was added and further ether was added. The solution was stand still in a refrigerator. The crystal produced was filtrated and dried to obtain 1-[3-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-pyrrolidine-2,5-dione hydrochloride (158 mg) as a white powder.\n\nMelting point: 255.0-257.0°C\n\n\n \nExample 1754 (Reference)\n\n\nSynthesis of 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]naphthalene-1-carboxylic acid amide\n\n\n \n \n \nTriethylamine (0.24 ml, 1.7 mmol) and isobutyl chloroformate (0.19 ml, 1.4 mmol) were added to an acetonitrile solution (10 ml) of 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-propoxy]naphthalene-1-carboxylic acid (0.52 g, 1.2 mmol) under ice cooling and the mixture was stirred for 20 minutes. To the reaction solution, 28 % ammonia water (0.5 ml) was added and the mixture was stirred at room temperature for 20 minutes. To the reaction solution, ethyl acetate was added and the solution was washed with water. The organic layer was dried over anhydrous magnesium sulfate and thereafter concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 2:1 → 0:1). The purified product was concentrated under reduced pressure and the residue was recrystallized from a solvent mixture of ethyl acetate-diisopropylether to obtain 6-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-naphthalene-1-carboxylic acid amide (0.27 g, 53% yield) as white powder.\n\nMelting point 167.0-169.0°C\n\n\n \nExample 1755\n\n\nSynthesis of 1-allyl-5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1H-pyrazole-3-carboxylic acid methylamine\n\n\n \n \n \n40% methylamine methanol solution (5 ml) was added to a methanol solution (5 ml) of 1-allyl-5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1H-pyrazole-3-carboxylic acid ethyl ester (0.5 g, 1.1 mmol) and the mixture was stirred at room temperature for 3 days. The solution was concentrated under reduced pressure and the residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 5:1 → 0:1). The purified product was concentrated under reduced pressure and the residue was recrystallized from a solvent mixture of ethyl acetate-diisopropylether to obtain 1-allyl-5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1H-pyrazole-3-carboxylic acid methylamide (0.32 g, 67% yield) as white powder.\n\nMelting point 138.5-140.5°C\n\n\n \nExample 1756 (Reference)\n\n\nSynthesis of 4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-cyclohexanecarboxylic acid amide\n\n\n \n \n \nAmmonia water (23%, 0.5 ml), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (WSC)(0.35 g, 1.9 mmol) and 4-dimethylaminopyridine (DMAP) (0.05 g, 0.4 mmol) were added to a dichloromethane solution (10 ml) of 4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-cyclohexanecarboxylic acid (0.5 g, 1.2 mmol) and the mixture was stirred at room temperature for 19 hours. To the reaction solution, dichloromethane was added and the mixture was washed with water. The organic layer was dried over anhydrous magnesium sulfate and thereafter concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 3:1 → 0:1). The purified product was concentrated under reduced pressure and the residue was recrystallized from a solvent mixture of ethyl acetate-diisopropylether to obtain 4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-propoxy]-cyclohexanecarboxylic acid amide (0.1 g, 22% yield), as white powder.\n\nMelting point 107.5-108.5°C\n\n\n \nExample 1757 (Reference)\n\n\nSynthesis of ethanesulfonic acid {4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methyl-phenyl}amide hydrochloride\n\n\n \n \n \nA dichloromethane solution (4 ml) of 4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methylphenylamine (0.2 g, 0.49 mmol) was cooled on ice. To this, N-ethyldiisopropylamine (0.15 ml, 0. 67 mmol) and ethane sulfonylchloride (0.07 ml, 0.73 mmol) were added and the mixture was stirred at room temperature for one hour. Further, N-ethyldiisopropylamine (0.15 ml, 0,87 mmol) and ethane sulfonylchloride (0.07 ml, 0.73 mmol) were added and the mixture was stirred at room temperature for 19 hours. To this, an aqueous 6N-sodium hydroxide solution (0.5 ml) and ethanol (2 ml) were added and the mixture was stirred at room temperature overnight. Dichloromethane was added to the reaction solution, which was then washed with water. The organic layer was dried over anhydrous magnesium sulfate and thereafter concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 2:1 → 4 0:1). The purified product was concentrated under reduced pressure. 4N-hydrochloride/ethyl acetate solution was added to the residue. The crystal generated was filtrated and dried to obtain ethanesulfonic acid {4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methyl-phenyl)amide hydrochloride (222 mg, 85% yield) as white powder.\n\nMelting point: 235.5-237.5°C\n\n\n \nExample 1758\n\n\nSynthesis or 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazol-3-yl}-carbamic acid methyl ester\n\n\n \n \n \nA dichloromethane solution (2 ml) of 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazol-3-yl-amine (0.17 g, 0.47 mmol) was cooled on ice. To this, pyridine (0.08 ml, 0.94 mmol) and methyl chloroformate (0.04 ml, 0.52 mmol) were added and the mixture was stirred at room temperature for 17 hours. To the reaction solution, ethyl acetate was added and the reaction mixture was washed with water. The water layer was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous magnesium sulfate, and thereafter, concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 2:1 → 1:1). The purified product was concentrated under reduced pressure and the residue was recrystallized from a solvent mixture of ethyl acetate-diisopropylether to obtain 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazol-3 yl}carbamic acid methyl ester (0.10 g, 51% yield) as white powder.\n\nMelting point: 162.5-165.0°C.\n\n\n \nExample 1759\n\n\nSynthesis of 3-{5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazol-3-yl}-1,1-dimethyl-urea hydrochloride\n\n\n \n \n \nA dichloromethane solution (5 ml) of 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazol-3-yl-amine (0.27 g, 0.73 mmol) was cooled on ice. To this, triethylamine (0.36 ml, 2.5 mmol), dimethylcarbamoyl chloride (0.20 ml, 2.1 mmol) and pyridine (0.06 ml, 0.73 mmol) were added and the mixture was stirred at room temperature overnight. To the reaction solution, water was added and the reaction solution was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and thereafter concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 3:1 → 0:1). The purified product was concentrated under reduced pressure and the residue was dissolved in ethyl acetate and a 4N-hydrochloride/ethyl acetate solution was added thereto. The crystal produced was filtrated and dried to obtain 3-{5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazol-3-yl}-1,1-dimethyl-urea hydrochloride (0.10 g, 30% yield), as light yellow powder.\n\nMelting point : 174.0-176.5°C\n\n\n \nExample 1760\n\n\nSynthesis of 3-{5-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1-methyl-1H-pyrazol-3-yl} - 1,1-dimethyl-urea hydrochloride\n\n\n \n \n \nAn aqueous dimethylamine solution (50%, 0.16 ml , 1.6 mmol) was added to a DMF solution (3 ml) of 5-[4-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1-methyl-1H-pyrazol-3-yl carbamic acid phenyl ester (0.26 g, 0.52 mmol) and the mixture was stirred at room temperature for 16 hours. Water was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and thereafter concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 7:3 → 0:1). The purified product was concentrated under reduced pressure and the residue was dissolved in ethyl acetate. A 1N-hydrochloric acid/ethanol solution was added and the crystal produced was filtrated and dried to obtain 3-{5-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1-methyl-1H-pyrazol-3-yl}-1,1-dimethyl-urea hydrochloride (95 mg, 37% yield) as white powder.\n\nMelting point: 186.0-187.5°C\n\n\n \nExample 1761\n\n\nSynthesis of N-{5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazol-3-yl}-acetamide\n\n\n \n \n \nAcetic anhydride (1 ml) and triethylamine (0. 09 ml, 0.65 mmol) were added to a dichloromethane solution (4 ml) of 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazol-3-yl-amine (0.20 g, 0.54 mmol) and the mixture was stirred at room temperature for 6 hours. An aqueous potassium carbonate solution was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and thereafter concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (n-hexane : ethyl acetate = 2:1 → 0:1). The purified product was concentrated under reduced pressure and the residue was recrystallized from a solvent mixture of ethyl acetate-diisopropylether to obtain N-{S-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazol-3-yl}acetamide (0.19 g, 89% yield) as white powder. Melting point: 137.0-139.0°C\n\n\n \nExample 1762\n\n\nSynthesis of 3-{4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-hydroxymethyl-5-methoxyphenyl}oxazolidin-2-one hydrochloride\n\n\n \n \n \nFirst, 2-[3-(4-benzo[b] thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-(2-oxo-oxazolidin-3-yl)benzaldehyde hydrochloride (1.28 g. 2.4 mmol)) was added to an aqueous potassium hydrochloride solution. The mixture was extracted with dichloromethane. The extracted solution was concentrated under reduced pressure and the residue was dissolved in THF (15 ml). To the solution, sodium borohydride (0.05 g, 1.2 mmol) was added under ice cooling and the mixture was stirred at room temperature for 3 hours. Then, 10% hydrochloric acid was added to the mixture under ice cooling to decompose the reagent excessively present. After an aqueous 6N sodium hydroxide solution was added to the solution to make it an alkaline solution, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and thereafter concentrate under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane : ethyl acetate = 3:7 → dichloromethane : methanol = 100:3). The purifies product was concentrated under reduced pressure and the residue was dissolved in ethanol. A 1N hydrochloric acid/ethanol solution was added to this. The crystal produced was recrystallized from ethanol to obtain 3-{4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-propoxy]-3-hydroxymethyl-5-methoxy-phenyl}oxazolidin-2-one hydrochloride (0.52 g, 41% yield) as white powder.\n\nMelting point: 224.0-226.5°C (decomposed)\n\n\n \nExample 1763 (Reference)\n\n\nSynthesis of 1-acetyl-4-{4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methylphenyl}piperazin hydrochloride\n\n\n \n \n \n1-benzo[b]thiophen-4-yl-4-[3-(4-bromo-2-methoxy-6-methylphenoxy)propyl]piperazine hydrochloride (0.5 g, 0.98 mmol)), 1-acetyl piperazine (0.15 g, 1.2 mmol), palladium acetate (11 mg, 0.048 mmol), 2,2'-bis(diphenylphosphino)-1,1-binaphtyl (BINAP) (63 mg, 0.098 mmol) and sodium t-butoxide (0.23 g, 2.3 mmol) were added to toluene (10 ml) and the mixture was stirred under an argon atmosphere at 90°C for 22 hours. The reaction mixture was cooled to room temperature and filtrated by cerite. The filter cake was washed with ethyl acetate. The filtrate and wash liquid were combined and thereafter concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (n-hexane: ethyl acetate = 11:1 → 1:1). The purified product was concentrated under reduced pressure and the residue was dissolved in ethyl acetate. A 1N hydrochloric acid/ethanol solution was added to this and the crystal produced was filtrated and dried to obtain 1-acetyl-4-{4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-methoxy-5-methylphenyl}-piperazin hydrochloride (75 mg, 14% yield) as white powder.\n\nMelting point: 257.0-261.0 °C (decomposed)\n\n\n \nExample 1764 (Reference)\n\n\nSynthesis of 1-benzo[b]thiophen-4-yl-4-[3-(4-imidazol-1-yl-2-methoxy-6-methyl-phenoxy)-propyl]-piperazine dihydrochloride\n\n\n \n \n \n1-benzo[b]thiophen-4-yl-4-[3-(4-iodo-2-methoxy-6-methyl-phenoxy)-propyl]-piperazine (0.6 g, 0.69 mmol), imidazole (0.07 g, 1.03 mmol), copper iodide (I) (15 mg, 0.069 mmol) , trans-N,N'-dimethyl-1,2-cyclohexanedimaine (0.02 ml, 0.14 mmol) and cesium carbonate (0.47 g, 1.38 mmol) were added to 1,4-dioxane (6 ml) and the mixture was refluxed with heating under an argon atmosphere for 50 hours. After the resultant reaction mixture was cooled to room temperature, water was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and thereafter concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (n-hexane: ethyl acetate = 5:1 → 1:1). The purified product was concentrated under reduced pressure and the residue was dissolved in ethyl acetate. A 1N-hydrochloric acid/ethanol solution was added to this and the crystal produced was filtrated and dried to obtain 1-benzo[b]thiophen-4-yl-4-[3-(4-imidazol-1-yl-2-methoxy-6-methylphenoxy)propyl]-piperazine dihydrochloride (60 mg, 17% yield) as light yellow powder.\n\nMelting point: 234.0-240.0°C (decomposed).\n\n\n \nExample 1765 (Reference)\n\n\nSynthesis of 4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,N-dimethyl-5-(2,2,2-trifluoroethoxy)benzamide hydrochloride\n\n\n \n \n \nCesium carbonate (0.34 g, 0.99 mmol) and 1,1,1-trifluoro-2-iodoethane (0.05 ml, 0.47 mmol) were added to a DMF solution (2 m) of 4-[3-(4-Benzo[b] thiophen-4-yl-piperazin-1-yl)propoxy]-3-hydroxy-5,N-dimethylbenzamide (188 mg, 0.39 mmol), and the mixture was stirred at 40°C for 2 hours. Then, 1,1,1-trifluoro-2-iodoethane (0.1 ml, 0.94 mmol) was further added and the mixture was stirred at 40°C for 5 hours. After the reaction mixture was cooled to room temperature, water was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and thereafter concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (n-hexane: ethyl acetate = 3:1 → 0:1). The purified product was concentrated under reduced pressure and the residue was dissolved in isopropyl alcohol. A 1N-hydrochloric acid/ethanol solution was added to this and thereafter concentrated under reduced pressure. The residue was recrystallized from a solvent mixture of isopropyl alcohol/ethyl acetate to obtain 4-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3,N-dimethyl-5-(2,2,2-trifluoro-ethoxy)benzamide hydrochloride (88 mg, 40% yield) as light yellow powder.\n\nMelting point: 156.0-157.5°C\n\n\n \nExample 1766\n\n\nSynthesis of 1-{5-13-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazol-3-yl}-ethanone hydrochloride\n\n\n \n \n \n5-[3-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)-propoxy]-1-methyl-1H-pyrazol-3-carboxylic acid methoxy methylamide hydrochloride (0.61 g, 1.3 mmol) was added to an aqueous sodium hydroxide solution and the solution mixture was extracted with dichloromethane. The extracted solution was concentrated under reduced pressure and the residue was dissolved in THF (12 ml). The solution was cooled to - 78°C and 1N-methyllithium ether solution (1.2 ml) was added thereto and the mixture was stirred at the same temperature for 2 hours. To the reaction solution, an aqueous ammonium chloride solution was added and the solution was heated to room temperature. Potassium chloride was added to the solution, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and thereafter concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane: ethyl acetate = 3:1 → 0:1). The purified product was concentrated under reduced pressure and the residue was dissolved in ethanol. A 1N hydrochloric acid/ethanol solution was added to this and the crystal produced was recrystallized from water-containing ethanol to obtain 1-[5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-1-methyl-1H-pyrazol-3-yl}ethanone hydrochloride (0.22 g, 40% yield) as white powder.\n\nMelting point: 245.0°C (decomposed)\n\n\n \nExample 1767\n\n\nSynthesis of 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-hydroxymethyl-1-methyl-1H pyrazole\n\n\n \n \n \nA THF solution (8 ml) of 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)propoxy]-3-(tert-butyl-dimethylsilanyloxymethyl)-1-methyl-1H-pyrazole (0.75 g, 1.5 mmol) was cooled on ice and a 1M THF solution of tetrabutyl ammonium fluoride (1.7 ml) was added thereto. The mixture was stirred at room temperature for 16 hours. Ethyl acetate was added to the reaction solution, which was washed with water. The organic layer was dried over anhydrous magnesium sulfate and thereafter concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 1:0 → 30:1 →15:1). The purified product was concentrated under reduced pressure and the residue was recrystallized from a solvent mixture of ethyl acetate and diisopropyl ether to obtain 5-[3-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-propoxy]-3-hydroxymethyl-3-methyl-1H-pyrazole (0.46 g, 79% yield) as white powder.\n\nMelting temperature: 123.5-126.0°C\n\n\n \nPharmacological Test 1\n\n\n1) Dopamine D\n2\n receptor binding assay\n\n\n \n \n \nThe assay was performed according to the method by Kohler et al. (\nKohler C, Hall H, Ogren SO and Gawell L, Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem. Pharmacol., 1985; 34: 2251-2259\n).\n\n\n \n \n \n \nWistar male rats were decapitated, the brain was retrieved immediately and corpus striatum was taken out. It was homogenized in 50 mM tris(hydroxymethyl)aminomethane (Tris)-hydrochloric acid buffer (pH 7.4) of a volume 50 times of the weight of the tissue using a homogenizer with a high-speed rotating blade, and centrifuged at 4°C, 48,000 x g for 10 minutes. The obtained precipitate was suspended again in the above-described buffer of a volume 50 times of the weight of the tissue and after incubated at 37°C for 10 minutes, centrifuged in the above-described condition. The obtained precipitate was suspended in 50 mM (Tris)-hydrochloric acid buffer (containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl\n2\n, 1 mM MgCl\n2\n, pH 7.4) of a volume 25 times of the weight of the tissue and preserved by freezing at -85°C till it was used for binding assay as a membrane specimen.\n\n\n \n \n \n \nThe binding assay was performed using 40 µl of the membrane specimen, 20 µl of [\n3\nH]-raclopride (final concentration 1 to 2 nM), 20 µl of a test drug and 50 mM Tris-hydrochloric acid buffer (containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl\n2\n, 1 mM MgCl\n2\n, pH 7.4) so that the total amount was 200 µl (final dimethylsulfoxide concentration 1%). The reaction was performed at room temperature for 1 hour and terminated by conducting suction filtration with a cell harvester on a glass fiber filter plate. The filter plate made of class fiber as washed with 50 mM Tris-hydrochloric acid buffer (ph 7,4), and after dried, a microplate liquid scintillation cocktail was added and the radioactivity was measured with a microplats scintillation counter. Radioactivity in the presence of 10 µM (÷) -butaclamol hydrochloride was assumed as nonspecific binding.\n\n\n \n \n \n \nIC\n50\n value was calculated from concentration-dependent reaction using a non-linear analysis program. Ki value was calculated from IC\n50\n value using cheng-Prussoff formula. The results are shown in the following Table 165.\n\n \n[Table 165]\n \n \n \nDopamine D2 receptor binding test\n \n \n \nTest compound\n \nKi (nM)\n \n \n \n \nCompound of Example 3\n \n1.5\n \n \n \nCompound of Example 4\n \n1.9\n \n \n \nCompound of Example 6\n \n0.7\n \n \n \nCompound of Example 7\n \n0.8\n \n \n \nCompound of Example 21\n \n2.6\n \n \n \nCompound of Example 22\n \n1.5\n \n \n \nCompound of Example 27\n \n2.5\n \n \n \nCompound of Example 35\n \n3.1\n \n \n \nCompound of Example 43\n \n2.3\n \n \n \nCompound of Example 53\n \n2.0\n \n \n \nCompound of Example 56\n \n5.0\n \n \n \nCompound of Example 57\n \n1.6\n \n \n \nCompound of Example 67\n \n3.4\n \n \n \nCompound of Example 68\n \n1.3\n \n \n \nCompound of Example 71\n \n2.5\n \n \n \nCompound of Example 75\n \n1.6\n \n \n \nCompound of Example 105\n \n1.0\n \n \n \nCompound of Example 109\n \n1.2\n \n \n \nCompound of Example 112\n \n0.7\n \n \n \nCompound of Example 123\n \n1.4\n \n \n \n \n \n\n\n \n2) Serotonin 5-HT\n2A\n receptor binding assay\n\n\n \n \n \nThe assay was performed according to the method by Leysen JE et al. (\nLeysen JE, Niemegeers CJE, Van Nueten JM and Laduron PM. [3H] Ketanserin (R 41 468), a selective 3H-ligand for serotonin 2 receptor binding sites. Mol. Pharmacol., 1982, 21: 301-314\n).\n\n\n \n \n \n \nWistar male rats were decapitated, the brain was retrieved immediately and frontal cortex was taken out. It was homogenized in 0.25 M sucrose of a volume 10 times of the weight of the tissue using a Teflon glass homogenizer, and centrifuged at 4°C, 1,000 x g for 10 minutes. The obtained supernatant was transferred to another centrifuge tube and suspended in 0.25 M sucrose of a volume 5 times of the weight of the tissue and the precipitate was centrifuged in the above-described condition. The obtained supernatant was combined with the supernatant obtained above and adjusted to a volume 40 times of the weight of the tissue with 50 mM Tris-hydrochloric acid buffer (pH 7.4), and centrifuged at 4°C, 35,000 × g for 10 minutes. The obtained precipitate was suspended again in the above-described buffer of a volume 40 times of the weight of the tissue and centrifuged in the above-described condition. The obtained precipitate was suspended in the above-described buffer of a volume 20 times of the weight of the tissue and preserved by freezing at -85°C till it was used for binding assay as a membrane specimen.\n\n\n \n \n \n \nThe binding assay was performed using 40 µl of the membrane specimen, 20 µl of [\n3\nH]-Ketanserin (final concentration 1 to 3 nM), 20 µl of a test drug and 50 mM Tris-hydrochloric acid buffer (pH 7.4) so that the total amount was 200 µl (final dimethylsulfoxide concentration 1%) . The reaction was performed at 37°C for 20 minutes and terminated by conducting suction filtration with a cell harvester on a glass fiber filter plate.\n\n\n \n \n \n \nThe filter plate made of glass fiber was washed with 50 mM Tris-hydrochloric acid buffer (pH 7.4), and after dried, a microplate liquid scintillation cocktail was added and the radioactivity was measured with a microplate scintillation counter. Radioactivity in the presence of 10 uM spiperone was assumed as nonspecific binding.\n\n\n \n \n \n \nIC\n50\n value was calculated from concentration-dependent reaction using a non-linear analysis program. Ki value was calculated from IC\n50\n value using Cheng-Prussoff formula. The results are shown in the following Table 166\n\n \n[Table 166]\n \n \n \nSerotonion 5-HT\n2A\n receptor binding test\n \n \n \nTest compound\n \nKi (nM)\n \n \n \n \nCompound of Example 3\n \n6.0\n \n \n \nCompound of Example 4\n \n7.7\n \n \n \nCompound of Example 6\n \n3.3\n \n \n \nCompound of Example 7\n \n2.9\n \n \n \nCompound of Example 21\n \n0.8\n \n \n \nCompound of Example 22\n \n1.0\n \n \n \nCompound of Example 27\n \n1.4\n \n \n \nCompound of Example 35\n \n0.6\n \n \n \nCompound of Example 43\n \n3.8\n \n \n \nCompound of Example 53\n \n4.9\n \n \n \nCompound of Example 56\n \n4.9\n \n \n \nCompound of Example 57\n \n4.7\n \n \n \nCompound of Example 67\n \n3.4\n \n \n \nCompound of Example 68\n \n5.6\n \n \n \nCompound of Example 71\n \n1.7\n \n \n \nCompound of Example 75\n \n3.3\n \n \n \nCompound of Example 105\n \n7.1\n \n \n \nCompound of Example 109\n \n4.9\n \n \n \nCompound of Example 112\n \n5.0\n \n \n \nCompound of Example 123\n \n19.7\n \n \n \n \n \n\n\n \n3) Adrenalin α1 receptor binding assay\n\n\n \n \n \nThe assay was performed according to the method by Groβ G et al. (\nGroβ G, Hanft G and Kolassa N. Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and for α1-adrenoceptor binding sites. Naunyn-Schmiedeberg's Arch Pharmacol., 1987, 336: 597-601\n).\n\n\n \n \n \n \nWistar male rats were decapitated, the brain was retrieved immediately and cerebral cortex was taken out. It was homogenized in 50 mM Tris-hydrochloric acid buffer (100 mM NaCl, containing 2 mM dihydrogen disodium ethylene diamine tetraacetate, pH 7.4) of a volume 20 times of the weight of the tissue using a homogenizer with a high-speed rotating blade, and centrifuged at 4°C, 80,000 x g for 20 minutes. The obtained precipitate was suspended in the above-described buffer of a volume 20 times of the weight of the tissue and after incubated at 37°C for 10 minutes, centrifuged in the above-described condition. The obtained precipitate was suspended again in the above-described buffer of a volume 20 times of the weight of the tissue and centrifuged in the above-described condition. The obtained precipitate was suspended in 50 mM (Tris)-hydrochloric acid buffer (containing 1 mM dihydrogen disodium ethylene diamine tetraacetate, pH 7.4) of a volume 20 times of the weight of the tissue and preserved by freezing at -85°C till it was used for binding assay as a membrane specimen.\n\n\n \n \n \n \nThe binding assay was performed using 40 µl of the membrane specimen, 20 µl of [\n3\nH]-prazosin (final concentration 0.2 to 0.5 nM), 20 µl of a test drug and 50 mM Tris-hydrochloric acid buffer (containing 1 mM EDTA, pH 7.4) so that the total amount was 200 µl (final dimethylsulfoxide concentration 1%). The reaction was performed at 30°C for 45 minutes and terminated by conducting suction filtration with a cell harvester on a glass fiber filter plate.\n\n\n \n \n \n \nThe filter plate made of glass fiber was washed with 50 mM Tris-hydrochloric acid buffer (pH 7.4), and after dried, a microplate liquid scintillation cocktail was added and the radioactivity was measured with a microplate scintillation counter. Radioactivity in the presence of 10 µM phentolamine hydrochloride was assumed as nonspecific binding.\n\n\n \n \n \n \nIC\n50\n value was calculated from concentration-dependent reaction using a non-linear analysis program. Ki value was calculated from IC\n50\n value using Cheng-Prussoff formula.\n\n\n \nPharmacological Test 2\n\n\nPartial agonistic activity on dopamine D\n2\n receptor using D\n2\n receptor expression cells\n\n\n \n \n \nPartial agonistic activity on dopamine D\n2\n receptor was evaluated by quantitatively determining cyclic AMP production inhibitory effect of a test compound in dopamine D\n2\n receptor expression cells in which adenosine 3',5'-cyclic monophosphate (cyclic AMP) production was induced by forskolin stimulation.\n\n\n \n \n \n \nHuman recombinant dopamine D\n2\n receptor expressing Chinese hamster ovary/DHFR(-) cells were cultured in a culture medium (Iscove's Modified Dulbecco's Medium (IMDM culture medium), 10% fetal bovine serum, 50 I.U./ml penicillin, 50 µg/ml streptomycin, 200 µg/ml geneticin, 0.1 mM sodium hypoxanthine, 16 µM thymidine) at 37°C and 5% carbon dioxide condition. Cells were seeded at 10\n4\n cells/well on a 96-well microtiter plate coated with poly-L-lysine and grown under the same condition for 2 days. Each well was washed with 100 µl of a culture medium (IMDM culture medium, 0.1 mM sodium hypoxanthine, 16 µM thymidine). The culture medium was replaced with 50 µl of culture medium (IMDM culture medium, 0.1% sodium ascorbate, 0.1 mM sodium hypoxanthine, 16 µM thymidine) having dissolved therein 3 µM of a test compound. After allowed to incubate at 37°C, 5% carbon dioxide condition for 20 minutes, the culture medium was replaced with 100 µl of forskolin stimulative culture medium (IMDM culture medium, 0.1% sodium ascorbate, 0.1 mM sodium hypoxanthine, 16 µM thymidine, 10 µM forskolin, 500 µM 3-isobutyl-1-methylxanthine) having 3 µM of the test compound dissolved therein and allowed to incubate at 37°C, 5% carbon dioxide condition for 10 minutes. After the culture medium was removed, 200 µl of Lysis 1B aqueous solution (Amersham Bioscience, reagent attached to cyclic AMP biotrack enzyme immunoassay system) was dispensed and shaken for 10 minutes. The aqueous solution of each well was used as a sample for measurement. Samples for measurement quadruply diluted were subjected to measurement of the quantity of cyclic AMP using the above-described enzyme immunoassay system. Inhibition ratio of the respective test compound was calculated assuming that the quantity of cyclic AMP of the well to which no test compound was added was 100%. In this empiric test system, dopamine which was used as a control drug suppressed the quantity of cyclic AMP to about 10% as the maximum activity.\n\n\n \n \n \n \nIt was confirmed that test compounds had partial agonistic activity for dopamine D\n2\n receptor in the above-described test.\n\n\n \n \n \n \nSince the test compounds has partial agonistic activity for dopamine D\n2\n receptor, they can stabilize dopamine neurotransmission to a normal condition in a schizophrenia patient and as a result, exhibit, for example, positive and negative condition improving effect, cognitive impairment improving effect and the other symptom improving effects without causing side effects.\n\n\n \nPharmacological Test 3\n\n\nInhibitory effect on apomorphine-induced stereotyped behavior in rats\n\n\n \n \n \nWistar rats (male, six-seven weeks old, Japan SLC, Inc.) were used as test animals. A test compound was suspended in 5% gum arabic/(physiological saline or water) using an agate mortar and was diluted with the same solvent if necessary.\n\n\n \n \n \n \nTest animals were fasted overnight from the day before. Apomorphine (0.7 mg/kg) was subcutaneously administered (1 ml/kg) 1 hour after each test compound was orally administered (5 ml/kg). Stereotyped behavior was observed for 1 minute respectively 20, 30 and 40 minutes after apomorphine injection.\n\n\n \n \n \n \nThe stereotyped behavior of each animal was quantified according to the following condition and score made at three points were summed up and the anti-apomorphine effect was evaluated. Six test animals were used for each group.\n\n \n \n \n0: The appearance of the animals is the same as saline treated rats;\n \n1: Discontinuous sniffing, constant exploratory activity;\n \n2: Continuous sniffing, periodic exploratory activity;\n \n3: Continuous sniffing, discontinuous biting, gnawing or licking. Very brief periods of locomotor activity;\n \n4: Continuous biting, gnawing or licking; no exploratory activity.\n \n\n\n \n \n \nNon-clinical statistical analysis system was used for all statistical processing. When the significance probability value was lower than 0.05, it was judged that a significant difference existed. The difference of the score between the solvent administration group and each test compound administration group was analyzed using Wilcoxon ranksum test or Steel test. In addition, linear regression analysis was used for calculating 50% effective dose (95 % confidence interval).\n\n\n \n \n \n \nSince the test compounds showed inhibitory effect for apomorphine-induced stereotyped behavior, it was confirmed that the test compounds have D\n2\n receptor antagonistic effect.\n\n\n \nPharmacological Test 4\n\n\n \n \n \nInhibitory effect on (±)D-2,5-dimethoxy-4-iodoamphetamine (DOI) induced head twitch in rats\n\n\n \n \n \n \nWistar rats (male, six-seven weeks old, Japan SLC, Inc.) were used as test animals. A test compound was suspended in 5% gum arabic/(physiological saline or water) using an agate mortar and was diluted with the same solvent if necessary.\n\n\n \n \n \n \nTest animals were fasted overnight from the day before. DOI (5.0 mg/kg) was subcutaneously administered (1 ml/kg) 1 hour after each test compound was orally administered (5 ml/kg). The number of head twitches was counted for 10 minutes immediately after DOI injection. Six test animals were used for each group.\n\n\n \n \n \n \nNon-clinical statistical analysis was used for all statistical processing. When the significance probability value was lower than 0.05, it was judged that a significant difference existed. The difference of the number of head twitches between the solvent administration group and each test compound administration group was analyzed using t-test or Dunnett's test. In addition, linear regression analysis was used for calculating 50% effective dose (95 % confidence interval).\n\n\n \n \n \n \nSince the test compounds showed inhibitory effect for DOI-induced head twitch, it was confirmed that the test compounds have serotonin 5HT\n2A\n receptor antagonistic effect.\n\n\n \nPharmacological Test 5\n\n\nCatalepsy inducing effect in rats\n\n\n \n \n \nWistar rats (male, six-seven weeks old, Japan SLC, Inc.) were used as test animals. A test compound was suspended in 5% gum arabic/(physiological saline or water) using an agate mortar and was diluted with the same solvent if necessary.\n\n\n \n \n \n \nTest animals were fasted overnight from the day before observation on catalepsy and ptosis was performed 1, 2, 4, 6 and 8 hours after each test compound was orally administered (5 ml/kg). Six test animals were used for each group.\n\n\n \n \n \n \nOne forepaw of a rat was placed on an edge of a steel small box (width: 6.5 cm, depth: 4.0 cm, height: 7.2 cm) (an unnatural pose) and when the rat maintained the pose for more than 30 seconds, it was judged that the case was catalepsy positive. This observation was performed three times at each point, and if there was at least one positive case, it was judged that catalepsy occurred in the individual.\n\n\n \n \n \n \nAs a result, catalepsy induction effect of a test compound was dissociated from inhibitory effect on apomorphine-induced stereotyped behavior, therefore it was suggested that apprehension for extrapyramidal side effect in clinic would be low.\n\n\n \nPharmacological Test 6\n\n\n \n \n \nMeasurement of serotonin (5-HT) uptake inhibitory activity of a test compound by rat brain synaptosome\n\n\n \n \n \n \nWistar male rats were decapitated, the brain was retrieved and frontal cortex was dissected out, and it was homogenized in 0.32 M sucrose solution of a weight 20 times of the weight of the tissue using a Potter type homogenizer. The homogenate was centrifuged at 4°C, 1,000 x g for 10 minutes, the obtained supernatant was further centrifuged at 4°C, 20,000 x g for 20 minutes, and the pellet was suspended in an incubation buffer (20 mM Hepes buffer (pH 7.4) containing 10 mM glucose, 145 mM sodium chloride, 4.5 mM potassium chloride, 1.2 mM magnesium chloride, 1.5 mM calcium chloride), which was used as crude synaptosome fraction.\n\n\n \n \n \n \n5-HT uptake reaction was performed in a volume of 200 µl using a 96-well round bottom plate and pargyline (final concentration 10 µM) and sodium ascorbate (final concentration 0.2 mg/ml) were contained in the incubation buffer upon reaction and used.\n\n\n \n \n \n \nIncubation buffer (total counting), non-labeled 5-HT(final concentration 10µM, non-specific counting) and the diluted test compound (final concentration 300nM) were added to each well. One-tenth quantity of the final volume of the synaptosome fraction was added and after preincubated at 37°C for 10 minutes, tritium labeled 5-HT solution (final concentration 8 nM) was added and uptake reaction was started at 37°C. The uptake time was 10 minutes and the reaction was terminated by vacuum filtration through a 96-well fiber glass filter paper plate, and after the filter paper was washed with cold normal saline, it was dried enough and Microscint0 (Perkin-Elmer) was added to the filter and remaining radioactivity on the filter was measured.\n\n\n \n \n \n \nSerotonin uptake inhibitory activity (%) was calculated from the radioactivity of total counting as 100%, of non-specific counting as 0%, and of counting obtained with test compound. \n \n \n%\n \n \n \nof inhibition of\n \n \n \n5\n \n-\n \nHT\n \n \n%\n \n \n=\n \n100\n \n-\n \n \n \nCount obtained with test compound\n \n-\n \nNonspecific count\n \n \n \n \n0\n \n%\n \n \n \nUptake\n \n \n \n/\n \n \nTotal count\n \n \n100\n \n%\n \n \n \nUptake\n \n \n-\n \nNonspecific count\n \n \n0\n \n%\n \n \n \nUptake\n \n \n \n \n×\n \n100\n \n \n \n \n\n\n \n \n \n \nThe results are shown in the next Table 167.\n\n \n[Table 167]\n \n \n \nTest compound\n \nSerotonin uptake inhibitory ratio (%) (300 nM)\n \n \n \n \nCompound of Example 105\n \n69.9\n \n \n \nCompound of Example 123\n \n67.2\n \n \n \nCompound of Example 109\n \n38.5\n \n \n \nCompound of Example 112\n \n59.3\n \n \n \n \n \n\n\n \nPreparation Examples\n\n\n \n \n \n100 g of a compound of the present invention, 40 g of Avicel (trade name, product of Asahi Chemical Industry Co., Ltd.), 30 g of corn starch and 2 g of magnesium stearate was mixed and polished and tableted with a pestle for glycocalyx R10 mm.\n\n\n \n \n \n \nThe obtained tablet was coated with a film using a film coating agent made up of 10 g of TC-5 (trade name, product of Shin-Etsu Chemical Co., Ltd., hydroxypropyl methylcellulose), 3 g of polyethylene glycol 6000, 40 g of castor oil and an appropriate amount of ethanol to produce a film coated tablet of the above composition."
  },
  {
    "id": "EP2448940A2",
    "text": "Novel 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof AbstractThe invention relates to the novel materials of formula (I), where: R1is an optionally substituted L-aryl or L-heteroaryl, such that L is a single bond, alkyl, CO, or CO-alk, or L-X, with L being an alkyl and X being O or S; R2is H or alkyl; R3is an alkyl optionally substituted by Hal; and R4is Hou Hal, wherein said materials are in any isomeric form and the salts thereof, to be used as drugs. Claims\n\n\n\n\n\n\n\n\n \n REVENDICATIONS\n    \n \n \n\n\n\n\n \n 1 ) Produits de formule (I): \n 1) Products of formula (I):\n\n\n\n\n\n\n \n \n\n dans laquelle : \n \n in which :\n\n\n\n\n\n\n \nR1 représente un radical -L-aryle ou -L-hétéroaryle, tel que L représente : soit une simple liaison, \nR1 represents a -L-aryl or -L-heteroaryl radical, such that L represents: either a single bond,\n\n\n\n\n\n\n \nsoit un radical alkyle linéaire ou ramifié renfermant de 1 à 6 atomes de carbone et éventuellement substitué par un radical hydroxyle, \nis a linear or branched alkyl radical containing from 1 to 6 carbon atoms and optionally substituted with a hydroxyl radical,\n\n\n\n\n\n\n \nsoit un groupe CO ou -CO-AIk- , \neither a CO group or -CO-AIk-,\n\n\n\n\n\n\n \nsoit un groupe L'-X où L' représente un radical alkyle linéaire ou ramifié renfermant de 1 à 6 atomes de carbone et X un atome d'oxygène ou de soufre ; \nor a group L'-X where L 'represents a linear or branched alkyl radical containing from 1 to 6 carbon atoms and X an oxygen or sulfur atom;\n\n\n\n\n\n\n \nles radicaux aryle et hétéroaryle étant éventuellement substitués par un ou plusieurs radicaux identiques ou différents choisis parmi les atomes d'halogène et les radicaux hydroxyle, CN, nitro, -COOH, -COOaIk, -NRxRy, - CONRxRy, -NRxCORy, -NRxCO2Rz, -CORy, alcoxy, phénoxy, alkylthio, alkyle, cycloalkyle et hétérocycloalkyle ; \nthe aryl and heteroaryl radicals being optionally substituted by one or more identical or different radicals chosen from halogen atoms and hydroxyl, CN, nitro, -COOH, -COOaIk, -NRxRy, -CONRxRy, -NRxCORy, -NRxCO2Rz radicals, -COR y, alkoxy, phenoxy, alkylthio, alkyl, cycloalkyl and heterocycloalkyl;\n\n\n\n\n\n\n \nces derniers radicaux alcoxy, phénoxy, alkylthio, alkyle et hétérocycloalkyle, étant eux-mêmes éventuellement substitués par un ou plusieurs radicaux identiques ou différents choisis parmi les atomes d'halogène et NRvRw ; \nthese latter alkoxy, phenoxy, alkylthio, alkyl and heterocycloalkyl radicals, themselves being optionally substituted with one or more identical or different radicals chosen from halogen atoms and NRvRw;\n\n\n\n\n\n\n \nles radicaux hétérocycloalkyle et hétéroaryle pouvant de plus renfermer un radical oxo ; \nheterocycloalkyl and heteroaryl radicals additionally capable of containing an oxo radical;\n\n\n\n\n\n\n \n R2 représente un atome d'hydrogène ou un radical alkyle ; \n\n R3 représente un radical alkyle éventuellement substitué par un ou plusieurs atomes d'halogène ; \nR2 represents a hydrogen atom or an alkyl radical;  R3 represents an alkyl radical optionally substituted with one or more halogen atoms;\n\n\n\n\n\n\n \n R4 représente un atome d'hydrogène ou un atome d'halogène ; \n R4 represents a hydrogen atom or a halogen atom;\n\n\n\n\n\n\n \n NRxRy étant tel que Rx représente un atome d'hydrogène ou un radical alkyle et Ry représente un atome d'hydrogène, un radical cycloalkyle ou un radical alkyle éventuellement substitué par un ou plusieurs radicaux identiques ou différents choisis parmi les radicaux hydroxyle, alcoxy, NRvRw et hétérocycloalkyle ; soit Rx et Ry forment avec l'atome d'azote auquel ils sont liés un radical cyclique renfermant de 3 à 10 chaînons et éventuellement un ou plusieurs autres hétéroatomes choisi(s) parmi O, S, NH et N-alkyle, ce radical cyclique étant éventuellement substitué; \n NRxRy being such that Rx represents a hydrogen atom or an alkyl radical and Ry represents a hydrogen atom, a cycloalkyl radical or an alkyl radical optionally substituted with one or more identical or different radicals chosen from hydroxyl, alkoxy and NRvRw radicals; and heterocycloalkyl; either Rx and Ry form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 10 members and optionally one or more other heteroatoms chosen from O, S, NH and N-alkyl, this cyclic radical being optionally substituted;\n\n\n\n\n\n\n \n NRvRw étant tel que Rv représente un atome d'hydrogène ou un radical alkyle et Rw représente un atome d'hydrogène, un radical cycloalkyle ou un radical alkyle éventuellement substitué par un ou plusieurs radicaux identiques ou différents choisis parmi les radicaux hydroxyle, alcoxy, hétérocycloalkyle ; soit Rv et Rw forment avec l'atome d'azote auquel ils sont liés un radical cyclique renfermant de 3 à 10 chaînons et éventuellement un ou plusieurs autres hétéroatomes choisi(s) parmi O, S, NH et N-alkyle, ce radical cyclique étant éventuellement substitué; \n NRvRw being such that Rv represents a hydrogen atom or an alkyl radical and Rw represents a hydrogen atom, a cycloalkyl radical or an alkyl radical optionally substituted with one or more identical or different radicals chosen from hydroxyl, alkoxy and heterocycloalkyl radicals; ; either Rv and Rw form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 10 ring members and optionally one or more other heteroatoms chosen from O, S, NH and N-alkyl, this cyclic radical being optionally substituted;\n\n\n\n\n\n\n \nles radicaux cycliques que peuvent former Rx et Ry ou Rv et Rw respectivement avec l'atome d'azote auquel ils sont liés, étant éventuellement substitués par un ou plusieurs radicaux identiques ou différents choisis parmi les atomes d'halogène, les radicaux alkyle, hydroxyle, oxo, alcoxy, NH2; NHaIk et N(alk)2 ; \nthe cyclic radicals that can be formed by Rx and Ry or Rv and Rw respectively with the nitrogen atom to which they are attached, being optionally substituted by one or more identical or different radicals chosen from halogen atoms, alkyl radicals, hydroxyl radicals, oxo, alkoxy, NH2; NHaIk and N (alk) 2;\n\n\n\n\n\n\n \nRz représente les valeurs de Ry à l'exception de hydrogène ; \nRz represents the values of Ry with the exception of hydrogen;\n\n\n\n\n\n\n \n Rx, Ry et Rz dans les radicaux -NRxCORy, -CORy et NRxCO2Rz étant choisis parmi les significations indiquées ci-dessus pour Rx, Ry, et Rz ; \n Rx, Ry and Rz in the radicals -NRxCORy, -CORy and NRxCO2Rz being selected from the meanings indicated above for Rx, Ry, and Rz;\n\n\n\n\n\n\n \ntous les radicaux alkyle (alk), alcoxy et alkylthio ci-dessus étant linéaires ou ramifiés et renfermant de 1 à 6 atomes de carbone, \n\n lesdits produits de formule (I) étant sous toutes les formes isomères possibles racémiques, énantiomères et diastéréoisomères, ainsi que les sels d'addition avec les acides minéraux et organiques ou avec les bases minérales et organiques desdits produits de formule (I). \nall the above alkyl (alk), alkoxy and alkylthio radicals being linear or branched and containing from 1 to 6 carbon atoms,  said products of formula (I) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as the addition salts with mineral and organic acids or with the inorganic and organic bases of said products of formula (I).\n\n\n\n\n\n\n \n2) Produits de formule (I) tels que définis à la revendication 1 dans laquelle : R1 représente un radical -L-phényle ou -L-hétéroaryle, tel que L représente : soit une simple liaison, \n2) Products of formula (I) as defined in claim 1 in which: R1 represents a -L-phenyl or -L-heteroaryl radical, such that L represents: either a single bond,\n\n\n\n\n\n\n \nsoit un radical alkyle linéaire ou ramifié renfermant de 1 à 6 atomes de carbone et éventuellement substitué par un radical hydroxyle, \nis a linear or branched alkyl radical containing from 1 to 6 carbon atoms and optionally substituted with a hydroxyl radical,\n\n\n\n\n\n\n \nsoit un groupe CO ou -CO-AIk- ,, \neither a CO or -CO-Alk- group,\n\n\n\n\n\n\n \nsoit un groupe L'-X où L' représente un radical alkyle linéaire ou ramifié renfermant de 1 à 6 atomes de carbone et X un atome d'oxygène ou de soufre ; \nor a group L'-X where L 'represents a linear or branched alkyl radical containing from 1 to 6 carbon atoms and X an oxygen or sulfur atom;\n\n\n\n\n\n\n \nles radicaux phényle et hétéroaryle étant éventuellement substitués par un ou plusieurs radicaux identiques ou différents choisis parmi les atomes d'halogène et les radicaux -NRxRy, alcoxy et alkyle ; \nthe phenyl and heteroaryl radicals being optionally substituted by one or more identical or different radicals chosen from halogen atoms and -NRxRy, alkoxy and alkyl radicals;\n\n\n\n\n\n\n \nces derniers radicaux alcoxy et alkyle étant eux-mêmes éventuellement substitués par un ou plusieurs radicaux choisis parmi les atomes d'halogène ; R2 représente un radical alkyle ; \nthese latter alkoxy and alkyl radicals themselves being optionally substituted by one or more radicals chosen from halogen atoms; R2 represents an alkyl radical;\n\n\n\n\n\n\n \n R3 représente un radical alkyle éventuellement substitué par un ou plusieurs atomes d'halogène ; \n R3 represents an alkyl radical optionally substituted with one or more halogen atoms;\n\n\n\n\n\n\n \n R4 représente un atome d'hydrogène ou un atome de fluor ; \n R4 represents a hydrogen atom or a fluorine atom;\n\n\n\n\n\n\n \n NRxRy étant tel que Rx représente un atome d'hydrogène ou un radical alkyle et Ry représente un atome d'hydrogène ou un radical alkyle; soit Rx et Ry forment avec l'atome d'azote auquel ils sont liés un radical morpholino ; \n\n tous les radicaux alkyle (alk) ou alcoxy ci-dessus étant linéaires ou ramifiés et renfermant de 1 à 6 atomes de carbone, \nNRxRy being such that Rx represents a hydrogen atom or an alkyl radical and Ry represents a hydrogen atom or an alkyl radical; either Rx and Ry form with the nitrogen atom to which they are bonded a morpholino radical;  all the above alkyl (alk) or alkoxy radicals being linear or branched and containing from 1 to 6 carbon atoms,\n\n\n\n\n\n\n \nlesdits produits de formule (I) étant sous toutes les formes isomères possibles racémiques, énantiomères et diastéréoisomères, ainsi que les sels d'addition avec les acides minéraux et organiques ou avec les bases minérales et organiques desdits produits de formule (I). \nsaid products of formula (I) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as the addition salts with mineral and organic acids or with the inorganic and organic bases of said products of formula (I).\n\n\n\n\n\n\n \n3) Produits de formule (I) tels que définis à l'une quelconque des \n3) Products of formula (I) as defined in any one of\n\n\n\n\n\n\n \nrevendications 1 ou 2, répondant aux formules suivantes : \nclaims 1 or 2, corresponding to the following formulas:\n\n\n\n\n\n\n \n - (8S)-9-[2-(4-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one \n (8S) -9- [2- (4-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1, 2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n - 9-[2-(4-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one \n 9- [2- (4-Methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n (8S)-2-(morpholin-4-yl)-9-(2-phényléthyl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one \n (8S) -2- (Morpholin-4-yl) -9- (2-phenylethyl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin 4-one\n\n\n\n\n\n\n \n - (8S)-9-benzyl-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H- pyrimido[1 ,2-a]pyhmidin-4-one \n (8S) -9-Benzyl-2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(2S)-2-hydroxy-2-phényléthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one \n - (8S) -9 - [(2S) -2-hydroxy-2-phenylethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1, 2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(2R)-2-hydroxy-2-phényléthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one \n - (8S) -9 - [(2R) -2-Hydroxy-2-phenylethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1, 2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n (8S)-9-[(2S)-2-hydroxy-2-(4-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one \n (8S) -9 - [(2S) -2-hydroxy-2- (4-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro -4H-pyhmido [1, 2-a] pyhmidin-4-one\n\n\n\n\n\n\n \n (8S)-2-(morpholin-4-yl)-9-[(1 R)-1 -phényléthyl]-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one \n (8S) -2- (Morpholin-4-yl) -9 - [(1R) -1-phenylethyl] -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2] -a] pyrimidin-4-one\n\n\n\n\n\n\n \n (8S)-9-[1 -(4-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one \n\n - (8S)-9-[(1 S)-1 -(4-bromophényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n(8S) -9- [1- (4-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2] -a] pyrimidin-4-one  - (8S) -9 - [(1S) -1- (4-bromophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H -pyrinnido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(1 R)-1 -(4-bromophényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(1R) -1- (4-bromophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H -pyrinnido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n- (8S)-2-(morpholin-4-yl)-9-phényl-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H- pyrimido[1 ,2-a]pyrinnidin-4-one \n- (8S) -2- (Morpholin-4-yl) -9-phenyl-8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrinidin-4-one\n\n\n\n\n\n\n \n (8S)-9-(4-fluorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n (8S) -9- (4-fluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin 4-one\n\n\n\n\n\n\n \n (8S)-9-(3-fluorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyrinnidin-4-one \n (8S) -9- (3-fluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyridinoline. 4-one\n\n\n\n\n\n\n \n (8S)-9-(2-fluorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n (8S) -9- (2-fluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin 4-one\n\n\n\n\n\n\n \n - (8S)-9-[(1 R)-1 -(3-fluorophényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(1R) -1- (3-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H -pyrinnido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-(4-fluorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n - (8S) -9- (4-fluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidine -4-one\n\n\n\n\n\n\n \n (8S)-2-(morpholin-4-yl)-9-(phénylcarbonyl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n (8S) -2- (Morpholin-4-yl) -9- (phenylcarbonyl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinnido [1,2-a] pyridin-4- one\n\n\n\n\n\n\n \n (8S)-2-(morpholin-4-yl)-9-(pyridin-3-yl)-8-(tπfluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyrinnidin-4-one \n (8S) -2- (Morpholin-4-yl) -9- (pyridin-3-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinnido [1,2-a] pyrinnidin-4-one\n\n\n\n\n\n\n \n - (8S)-2-(morpholin-4-yl)-9-(pyridin-4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro- 4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -2- (Morpholin-4-yl) -9- (pyridin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinnido [1,2-a] ] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-(4-méthylphényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9- (4-methylphenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyridin -4-one\n\n\n\n\n\n\n \n- (8S)-9-(2-chlorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n- (8S) -9- (2-chlorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinnido [1,2-a] pyridin -4-one\n\n\n\n\n\n\n \n - (8S)-9-(3-fluorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n\n - (8S)-9-[2-(2-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n- (8S) -9- (3-fluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyridin -4-one  (8S) -9- [2- (2-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrrolidone [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[2-(3-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n (8S) -9- [2- (3-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrrolidido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n- (8S)-9-(3-méthoxybenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n(8S) -9- (3-Methoxybenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidine -4-one\n\n\n\n\n\n\n \n - (8S)-9-(4-méthoxyphényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n - (8S) -9- (4-methoxyphenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidine -4-one\n\n\n\n\n\n\n \n - (8S)-9-[(2-fluorophényl)carbonyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyrinnidin-4-one \n - (8S) -9 - [(2-Fluorophenyl) carbonyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrrolidone [1, 2- a] pyrinnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-(3,5-difluorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n - (8S) -9- (3,5-difluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] ] pyrimidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-(2,4-difluorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9- (2,4-Difluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] ] pyπnnidin-4-one\n\n\n\n\n\n\n \n- (8S)-2-(morpholin-4-yl)-9-(2,3,4-trifluorobenzyl)-8-(tπfluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n- (8S) -2- (Morpholin-4-yl) -9- (2,3,4-trifluorobenzyl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2] -a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(5-chloro-1 -benzothiophén-3-yl)méthyl]-2-(morpholin-4-yl)-8- (trifluoronnéthyl)-6,7,8,9-tétrahydro-4H-pyπnnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(5-Chloro-1-benzothiophen-3-yl) methyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro- 4H-pyπnnido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(1 R ou 1 S)-1 -(4-fluorophényl)éthyl]-2-(morpholin-4-yl)-8- (trifluoronnéthyl)-6,7,8,9-tétrahydro-4H-pyπnnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(1R or 1S) -1- (4-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9- tetrahydro-4H-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -(8S)-9-[(1 R ou 1 S)-1 -(4-fluorophényl)éthyl]-2-(morpholin-4-yl)-8-\n - (8S) -9 - [(1R or 1S) -1- (4-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8-\n\n\n\n\n\n\n \n(trifluoronnéthyl)-6,7,8,9-tétrahydro-4H-pyπnnido[1 ,2-a]pyπnnidin-4-one \n(trifluoronnethyl) -6,7,8,9-tetrahydro-4H-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -(8S)-9-(3-méthylphényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9- (3-methylphenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyπnnidine -4-one\n\n\n\n\n\n\n \n- (8S)-9-(4-chlorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n- (8S) -9- (4-chlorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyridin -4-one\n\n\n\n\n\n\n \n - (8S)-2-(morpholin-4-yl)-8-(trifluorométhyl)-9-[4-(trifluorométhyl)phényl]- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n\n - (8S)-9-[(1 R ou 1 S)-1 -(2-fluorophényl)éthyl]-2-(morpholin-4-yl)-8- (tπfluorométhyl)-6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n- (8S) -2- (Morpholin-4-yl) -8- (trifluoromethyl) -9- [4- (trifluoromethyl) phenyl] -6,7,8,9-tetrahydro-4H-pyrrolidone [1,2-tetrahydro-4H-pyrrolidone] a] pyπnnidin-4-one  - (8S) -9 - [(1R or 1S) -1- (2-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (t-fluoromethyl) -6,7,8,9- tetrahydro-4H-pyrinnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(1 R ou 1 S)-1 -(2-fluorophényl)éthyl]-2-(morpholin-4-yl)-8- (trifluoronnéthyl)-6,7,8,9-tétrahydro-4H-pyπnnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(1R or 1S) -1- (2-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9- tetrahydro-4H-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n-(8S)-9-[2-(3-fluorophényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n(8S) -9- [2- (3-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1, 2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n -(8S)-9-benzyl-3-fluoro-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n - (8S) -9-benzyl-3-fluoro-2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidine -4-one\n\n\n\n\n\n\n \n -(8S)-9-(3,5-difluorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyrimidin-4-one \n - (8S) -9- (3,5-difluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinnido [1,2-a] ] pyrimidin-4-one\n\n\n\n\n\n\n \n -(8S)-9-[(2,6-difluorophényl)carbonyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(2,6-difluorophenyl) carbonyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrrolidido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -(8S)-9-[(2,4-difluorophényl)carbonyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(2,4-difluorophenyl) carbonyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimidido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n-(8S)-2-(morpholin-4-yl)-9-(phénylacétyl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n- (8S) -2- (Morpholin-4-yl) -9- (phenylacetyl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinnido [1,2-a] pyridin-4 -one\n\n\n\n\n\n\n \n -(8S)-9-[2-(3-chlorophényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n (8S) -9- [2- (3-chlorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrrolidido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -9-((R)-2-Benzo[b]thiophen-2-yl-2-hydroxy-ethyl)-2-morpholin-4-yl-8-(S)- trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n (-) - ((R) -2-Benzo [b] thiophen-2-yl-2-hydroxy-ethyl) -2-morpholin-4-yl-8- (S) -trifluoroethyl-6,7,8,9 tetrahydro-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -9-[(S)-2-Hydroxy-2-(3-hydroxy-phenyl)-ethyl]-2-morpholin-4-yl-8-(S)- trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n -9 - [(S) -2-Hydroxy-2- (3-hydroxy-phenyl) -ethyl] -2-morpholin-4-yl-8- (S) -trifluoroethyl-6,7,8,9-tetrahydro -pyπnnido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -2-Dimethylamino-N-{3-[(S)-1 -hydroxy-2-((S)-8-morpholin-4-yl-6-oxo-2- trifluoronnethyl-3,4-dihydro-2H,6H-pyπnnido[1 ,2-a]pyπnnidin-1-yl)-ethyl]- phenyl}-acetamide \n 2-Dimethylamino-N- {3 - [(S) -1-hydroxy-2 - ((S) -8-morpholin-4-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H, 6H-pyπnnido [1,2-a] pyrimidin-1-yl) -ethyl] -phenyl} -acetamide\n\n\n\n\n\n\n \n -9-[(S)-2-Hydroxy-2-(2-methoxy-phenyl)-ethyl]-2-morpholin-4-yl-8-(S)- trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n\n -9-[(S)-2-(4-Fluoro-2-methoxy-phenyl)-2-hydroxy-ethyl]-2-nnorpholin-4-yl-8- (S)-trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n-9 - [(S) -2-Hydroxy-2- (2-methoxy-phenyl) -ethyl] -2-morpholin-4-yl-8- (S) -trifluoroethyl-6,7,8,9-tetrahydro -pyπnnido [1, 2-a] pyπnnidin-4-one  -9 - [(S) -2- (4-Fluoro-2-methoxy-phenyl) -2-hydroxy-ethyl] -2-nnorpholin-4-yl-8- (S) -trifluoroethyl-6,7,8 9-tetrahydro-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -9-[(S)-2-(4-Chloro-2-methoxy-phenyl)-2-hydroxy-ethyl]-2-morpholin-4-yl-8- (S)-trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n -9 - [(S) -2- (4-Chloro-2-methoxy-phenyl) -2-hydroxy-ethyl] -2-morpholin-4-yl-8- (S) -trifluoroethyl-6,7,8 9-tetrahydro-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n-9-[(S)-2-(2-Chloro-4-methoxy-phenyl)-2-hydroxy-ethyl]-2-morpholin-4-yl-8- (S)-trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n-9 - [(S) -2- (2-Chloro-4-methoxy-phenyl) -2-hydroxy-ethyl] -2-morpholin-4-yl-8- (S) -trifluoroethyl-6,7,8 9-tetrahydro-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - 9-(2-Hydroxy-3-phenyl-propyl)-2-morpholin-4-yl-8-(S)-trifluoromethyl-6,7,8,9- tetrahydro-pyrimido[1 ,2-a]pyrinnidin-4-on \n 9- (2-Hydroxy-3-phenylpropyl) -2-morpholin-4-yl-8- (S) -trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyridinidine -4-one\n\n\n\n\n\n\n \n 9-[2-(4-Hydroxy-phenyl)-ethyl]-2-morpholin-4-yl-8-(S)-trifluoromethyl-6,7,8,9- tetrahydro-pyrinnido[1 ,2-a]pyrinnidin-4-one \n 9- [2- (4-Hydroxy-phenyl) -ethyl] -2-morpholin-4-yl-8- (S) -trifluoromethyl-6,7,8,9-tetrahydro-pyrinido [1,2-a] pyrinnidin-4-one\n\n\n\n\n\n\n \nainsi que les sels d'addition avec les acides minéraux et organiques ou avec les bases minérales et organiques desdits produits de formule (I). \nas well as the addition salts with the mineral and organic acids or with the inorganic and organic bases of said products of formula (I).\n\n\n\n\n\n\n \n4) Procédé de préparation des produits de formule (I) tels que définis à l'une quelconque des revendications 1 à 3 selon le schéma 1 tel que défini ci- après. \n4) Process for the preparation of the products of formula (I) as defined in any one of claims 1 to 3 according to scheme 1 as defined below.\n\n\n\n\n\n\n \n Schéma 1 : \n\n\nFigure 1: \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n C \n VS\n\n\n\n\n\n\n \n Morphohne \n\n\n\nMorphohne \n \n\n\n\n\n\n\n \ndans lequel les substituants R1 , R2, R3 et R4 ont les significations indiquées à l'une quelconque des revendications 1 ou 2 et dans lequel R représente alkyle. X représente un atome de Chlore, brome ou iode ou un groupe sulfonyloxy tel que trifluorométhylsulfonyloxy. \nwherein the substituents R1, R2, R3 and R4 have the meanings given in any one of claims 1 or 2 and wherein R represents alkyl. X represents a chlorine, bromine or iodine atom or a sulfonyloxy group such as trifluoromethylsulfonyloxy.\n\n\n\n\n\n\n \n5) Procédé de préparation des produits de formule (I) tels que définis à l'une quelconque des revendications 1 à 3 selon le schéma 2 tel que défini ci- après. \n5) Process for preparing the products of formula (I) as defined in any one of claims 1 to 3 according to scheme 2 as defined below.\n\n\n\n\n\n\n \n Schéma 2 : \n Figure 2:\n\n\n\n\n\n\n \n \n\n dans lequel les substituants R1 , R2, R3 et R4 ont les significations indiquées à l'une quelconque des revendications 1 ou 2. X représente un atome de Chlore, brome ou iode ou un groupe sulfonyloxy tel que trifluorométhylsulfonyloxy. \n \n wherein the substituents R1, R2, R3 and R4 have the meanings given in any one of claims 1 or 2. X represents a chlorine, bromine or iodine atom or a sulfonyloxy group such as trifluoromethylsulfonyloxy.\n\n\n\n\n\n\n \n6) A titre de médicaments, les produits de formule (I) telle que définie à l'une quelconque des revendications 1 à 3, ainsi que les sels d'addition avec les acides minéraux et organiques ou avec les bases minérales et organiques pharmaceutiquement acceptables desdits produits de formule (I). \n6) As medicaments, the products of formula (I) as defined in any one of claims 1 to 3, and the addition salts with inorganic and organic acids or with inorganic and organic bases pharmaceutically acceptable. said products of formula (I).\n\n\n\n\n\n\n \n7) A titre de médicaments, les produits de formule (I) telle que définie à la revendication 3, ainsi que les sels d'addition avec les acides minéraux et organiques ou avec les bases minérales et organiques pharmaceutiquement acceptables desdits produits de formule (I). \n7) As medicaments, the products of formula (I) as defined in claim 3, as well as the addition salts with inorganic and organic acids or with the pharmaceutically acceptable inorganic and organic bases of said products of formula (I ).\n\n\n\n\n\n\n \n 8) Compositions pharmaceutiques contenant à titre de principe actif l'un au moins des produits de formule (I) tel que défini à l'une quelconque des revendications 1 à 3, ou un sel pharmaceutiquement acceptable de ce produit ou un prodrug de ce produit et un support pharmaceutiquement acceptable. \n 8) Pharmaceutical compositions containing as active ingredient at least one of the products of formula (I) as defined in any one of claims 1 to 3, or a pharmaceutically acceptable salt of this product or a prodrug of this product and a pharmaceutically acceptable carrier.\n\n\n\n\n\n\n \n 9) Utilisation d'un produit de formule (I) tel que défini à l'une quelconque des revendications 1 à 3 pour la préparation d'un médicament destiné au traitement de cancers. \n 9) Use of a product of formula (I) as defined in any one of claims 1 to 3 for the preparation of a medicament for the treatment of cancers.\n\n\n\n\n\n\n \n 10) Utilisation selon la revendication 9 destinée au traitement de tumeurs solides ou liquides. \n 10) Use according to claim 9 for the treatment of solid or liquid tumors.\n\n\n\n\n\n\n \n 11 ) Utilisation selon la revendication 9 et 10 destinée au traitement de cancers résistant à des agents cytotoxiques. \n 11) Use according to claim 9 and 10 for the treatment of cancers resistant to cytotoxic agents.\n\n\n\n\n\n\n \n 12) Utilisation selon l'une ou plusieurs des revendications 9 à 11 destinée au traitement de tumeurs primaires et/ou de métastases en particulier dans les cancers gastriques, hépatiques, rénaux, ovariens, du colon, de la prostate, de l'endomètre, du poumon (NSCLC et SCLC), les glioblastomes, les cancers de \n\n la thyroïde, de la vessie, du sein, dans le mélanome, dans les tumeurs hématopoietiques lymphoïdes ou myéloïdes, dans les sarcomes, dans les cancers du cerveau, du larynx, du système lymphatique, cancers des os et du pancréas, dans les hamartomes. \n12) Use according to one or more of claims 9 to 11 for the treatment of primary tumors and / or metastases especially in gastric, hepatic, renal, ovarian, colon, prostate, endometrial cancers, lung cancer (NSCLC and SCLC), glioblastomas,  thyroid, bladder, breast, melanoma, lymphoid or myeloid hematopoietic tumors, sarcomas, cancers of the brain, larynx, lymphatic system, bone and pancreatic cancers, in hamartomas.\n\n\n\n\n\n\n \n13) Utilisation des produits de formule (I) telle que définie aux revendications 1 à 3, pour la préparation de médicaments destinés à la chimiothérapie de cancers. \n13) Use of the products of formula (I) as defined in claims 1 to 3, for the preparation of medicaments for the chemotherapy of cancers.\n\n\n\n\n\n\n \n 14) Utilisation des produits de formule (I) telle que définie aux revendications 1 à 3, pour la préparation de médicaments destinés à la chimiothérapie de cancers seul ou en en association. \n 14) Use of the products of formula (I) as defined in claims 1 to 3, for the preparation of medicaments for cancer chemotherapy alone or in combination.\n\n\n\n\n\n\n \n 15) Produits de formule (I) tels que définis à l'une quelconque des revendications 1 à 3 comme inhibiteurs de phosphorylation de AKT(PKB)\n 15) Products of formula (I) as defined in any one of claims 1 to 3 as inhibitors of phosphorylation of AKT (PKB)\n\n\n\n\n\n\n \n16) A titre de produits industriels nouveaux, les intermédiaires de synthèse de formules C, D, E et J tels que définis aux revendications 4 et 5 ci-dessus et rappelés ci-après : \n16) As new industrial products, synthetic intermediates of formulas C, D, E and J as defined in claims 4 and 5 above and recalled below:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n D E J \n D E J\n\n\n\n\n\n\n \ndans lesquels R1 , R2, R3 et R4 ont les définitions indiquées à l'une quelconque des revendications 1 à 2. 17) Produits de formule (I) tels que définis à l'une quelconque des revendications 1 à 3 pour leur utilisation pour le traitement de cancers. \nin which R1, R2, R3 and R4 have the meanings given in any one of claims 1 to 2. 17) Products of formula (I) as defined in any one of claims 1 to 3 for their use for the cancer treatment.\n\n\n\n\n\n\n \n 18) Produits de formule (I) tels que définis à l'une quelconque des revendications 1 à 3 pour leur utilisation pour le traitement de tumeurs solides ou liquides. \n\n 19) Produits de formule (I) tels que définis à l'une quelconque des revendications 1 à 3 pour leur utilisation pour le traitement de cancers résistant à des agents cytotoxiques. \n18) Products of formula (I) as defined in any one of claims 1 to 3 for their use for the treatment of solid or liquid tumors.  19) Products of formula (I) as defined in any one of claims 1 to 3 for their use for the treatment of cancers resistant to cytotoxic agents.\n\n\n\n\n\n\n \n 20) Produits de formule (I) tels que définis à l'une quelconque des revendications 1 à 3 pour leur utilisation pour le traitement de tumeurs primaires et/ou de métastases en particulier dans les cancers gastriques, hépatiques, rénaux, ovariens, du colon, de la prostate, de l'endomètre, du poumon (NSCLC et SCLC), les glioblastomes, les cancers de la thyroïde, de la vessie, du sein, dans le mélanome, dans les tumeurs hématopoietiques lymphoïdes ou myéloïdes, dans les sarcomes, dans les cancers du cerveau, du larynx, du système lymphatique, cancers des os et du pancréas, dans les hamartomes. \n 20) Products of formula (I) as defined in any one of claims 1 to 3 for their use for the treatment of primary tumors and / or metastases, particularly in gastric, hepatic, renal, ovarian, colon cancers. , prostate, endometrium, lung (NSCLC and SCLC), glioblastomas, thyroid, bladder, breast, melanoma, lymphoid or myeloid hematopoietic tumors, sarcomas, in cancers of the brain, larynx, lymphatic system, cancers of the bones and pancreas, in hamartomas.\n\n\n\n\n\n\n \n 21 ) Produits de formule (I) tels que définis à l'une quelconque des revendications 1 à 3 pour leur utilisation pour la chimiothérapie de cancers. 22) Produits de formule (I) tels que définis à l'une quelconque des revendications 1 à 3 pour leur utilisation pour la chimiothérapie de cancers, seuls ou en en association. \n 21) Products of formula (I) as defined in any one of claims 1 to 3 for their use for the chemotherapy of cancers. 22) Products of formula (I) as defined in any one of claims 1 to 3 for their use for cancer chemotherapy, alone or in combination.\n\n\n\n\n\n\n \n 23). Produits de formule (I) tels que définis à l'une quelconque des revendications 1 à 3 pour la prévention ou le traitement de maladies lysosomales telles que la glycogénose de type II ou maladie de Pompe. \n 23). Products of formula (I) as defined in any one of claims 1 to 3 for the prevention or treatment of lysosomal diseases such as glycogenosis type II or Pompe disease.\n\n\n\n\n\n\n \n 24) Utilisation des produits de formule (I) tel que défini à l'une quelconque des revendications 1 à 3 pour la préparation d'un médicament destiné à la prévention ou au traitement de maladies lysosomales telles que la glycogénose de type II ou maladie de Pompe. \n 24) Use of the products of formula (I) as defined in any one of claims 1 to 3 for the preparation of a medicament for the prevention or treatment of lysosomal diseases such as glycogenosis type II or disease of Pump.\n\n\n\n\n\n\n \n25) Utilisation telle que définie à la revendication 23 ou 24 dans lesquelles lesdits produits de formule (I) sont seuls ou en association. \n25) Use as defined in claim 23 or 24 wherein said products of formula (I) are alone or in combination.\n\n\n\n\n\n\n \n 26) Produits de formule (I) tels que définis à l'une quelconque des revendications 1 à 3 pour le traitement de maladies parasitaires telles que la malaria, la maladie du sommeil, la maladie de Chagas, les leishmanioses. \n\n 27) Utilisation des produits de formule (I) tels que définis à l'une quelconque des revendications 1 à 3 pour la préparation d'un médicament pour le traitement de maladies parasitaires telles que la malaria, la maladie du sommeil, la maladie de Chagas, les leishmanioses. \n\n26) Products of formula (I) as defined in any one of claims 1 to 3 for the treatment of parasitic diseases such as malaria, sleeping sickness, Chagas disease, leishmaniasis.  27) Use of the products of formula (I) as defined in any one of claims 1 to 3 for the preparation of a medicament for the treatment of parasitic diseases such as malaria, sleeping sickness, Chagas disease , leishmaniasis. Description\n\n\n\n\n\n\n \n NOUVEAUX DERIVES DE 1 ,2,3,4-TETRAHYDRO-PYRIMIDO(I ,2- a}PYRIMIDIN-6-ONE, LEUR PREPARATION ET LEUR UTILISATION \n NOVEL DERIVATIVES OF 1,2,3,4-TETRAHYDRO-PYRIMIDO (I, 2- a) PYRIMIDIN-6-ONE, THEIR PREPARATION AND USE\n\n\n\n\n\n\n \n PHARMACEUTIQUE \n PHARMACEUTICAL\n\n\n\n\n\n\n \n La présente invention concerne de nouveaux composés chimiques (1 ,2,3,4-tetrahydro-pyhmido{1 ,2-a}pyhmidin-6-one), dérivés de pyrimidinones, leur procédé de préparation, les nouveaux intermédiaires obtenus, leur application à titre de médicaments, les compositions pharmaceutiques les renfermant et la nouvelle utilisation de tels dérivés. \n The present invention relates to novel chemical compounds (1, 2,3,4-tetrahydro-pyhmido {1,2-a} pyhmidin-6-one), derivatives of pyrimidinones, their process of preparation, the new intermediates obtained, their application as medicaments, the pharmaceutical compositions containing them and the novel use of such derivatives.\n\n\n\n\n\n\n \nLa présente invention concerne ainsi également l'utilisation desdits dérivés pour la préparation d'un médicament destiné au traitement de l'homme. \nThe present invention thus also relates to the use of said derivatives for the preparation of a medicament for the treatment of humans.\n\n\n\n\n\n\n \n Plus particulièrement, l'invention concerne, de nouveaux dérivés de pyrimidinones et leur utilisation pharmaceutique pour la prévention et le traitement d'affections capables d'être modulées par l'inhibition de la voie PI3K/AKT/mTOR. AKT est un acteur clé dans cette voie de signalisation. Un niveau élevé de phosphorylation d'AKT est le marqueur de l'activation de la voie qui est retrouvée dans de nombreux cancers humains. \n More particularly, the invention relates to novel pyrimidinone derivatives and their pharmaceutical use for the prevention and treatment of conditions capable of being modulated by inhibition of the PI3K / AKT / mTOR pathway. AKT is a key player in this signaling path. A high level of AKT phosphorylation is the marker of pathway activation that is found in many human cancers.\n\n\n\n\n\n\n \nLes produits de la présente invention peuvent ainsi notamment être utilisés pour la prévention ou le traitement d'affections capables d'être modulées par l'inhibition de la phosphorylation d'AKT (P-AKT). L'inhibition de P-AKT peut être notamment obtenue par l'inhibition de la voie PI3K/AKT/mTOR, et en particulier par l'inhibition de kinases appartenant à cette voie comme les récepteurs à activité tyrosine kinase tels EGFR, IGFR, ErbB2, la 3'- phosphoinositide-dependent protein kinase-1 (PDK1 ), la phosphoinositide kinase PI3K, la serine-threonine kinase AKT, la kinase mTOR. L'inhibition et la régulation de la voie PI3K/AKT/mTOR constitue notamment un nouveau et puissant mécanisme d'action pour le traitement d'un grand nombre de maladies cancéreuses incluant des tumeurs solides et liquides. \n\n De telles affections que peuvent traiter les produits de la présente demande sont les tumeurs humaines solides ou liquides. \nThe products of the present invention can thus be used in particular for the prevention or treatment of conditions capable of being modulated by the inhibition of AKT phosphorylation (P-AKT). The inhibition of P-AKT can be obtained in particular by the inhibition of the PI3K / AKT / mTOR pathway, and in particular by the inhibition of kinases belonging to this pathway such as receptors with tyrosine kinase activity such as EGFR, IGFR, ErbB2 , 3'-phosphoinositide-dependent protein kinase-1 (PDK1), phosphoinositide kinase PI3K, serine threonine kinase AKT, mTOR kinase. The inhibition and regulation of the PI3K / AKT / mTOR pathway is a novel and powerful mechanism of action for the treatment of a large number of cancerous diseases including solid and fluid tumors.  Such conditions which can be treated by the products of the present application are solid or liquid human tumors.\n\n\n\n\n\n\n \n Cette invention concerne également, de nouveaux dérivés de pyrimidinones et leur utilisation pharmaceutique pour la prévention et le traitement d'affections impactées par la modulation de l'autophagie. L'inhibition et la régulation de l'autophagie constitue un nouveau mécanisme d'action pour le traitement d'un grand nombre de maladies cancéreuses incluant des tumeurs solides et liquides. \n This invention also relates to novel pyrimidinone derivatives and their pharmaceutical use for the prevention and treatment of conditions impacted by modulation of autophagy. The inhibition and regulation of autophagy is a novel mechanism of action for the treatment of a large number of cancerous diseases including solid and fluid tumors.\n\n\n\n\n\n\n \n Cette invention concerne également, de nouveaux dérivés de pyrimidinones et leur utilisation pharmaceutique pour le traitement de maladies parasitaires telles que la malaria, la maladie du sommeil, la maladie de Chagas, les leishmanioses. \n This invention also relates to novel pyrimidinone derivatives and their pharmaceutical use for the treatment of parasitic diseases such as malaria, sleeping sickness, Chagas disease, leishmaniasis.\n\n\n\n\n\n\n \nRôle de la voie PI3K/AKT/mTOR \nRole of the PI3K / AKT / mTOR pathway\n\n\n\n\n\n\n \n La voie de signalisation PI3K/AKT/mTOR est un réseau complexe qui régule de multiples fonctions cellulaires, comme la croissance, la survie, la prolifération et la motilité cellulaire, qui sont des processus clés de la tumorigénèse. \n The PI3K / AKT / mTOR signaling pathway is a complex network that regulates multiple cellular functions, such as growth, survival, proliferation, and cell motility, which are key processes in tumorigenesis.\n\n\n\n\n\n\n \n Cette voie de signalisation est une cible importante dans le traitement du cancer car la plupart de ses effecteurs sont altérés dans les tumeurs humaines. Les principaux effecteurs contribuant à l'activation de la voie sont i) les oncogènes tels que ErbB1 (EGFR), ErbB2 (HER2), PIK3CA et AKT activés par mutation, amplification ou surexpression ; ii) la déficience des gènes suppresseurs de tumeurs tels que PTEN, TSC1/2, LKB et PML qui sont inactivés suite à des mutations ou à des délétions (Jiang L-Z & Liu L-Z, Biochim Biophys Acta, 2008, 1784 :150 ; Vivanco I & Sawyers CL, 2002, Nat Rev Cancer, 2 :489 ; CuIIy M et al., Nature Rev. Cancer, 2006, 6 :184). \n This signaling pathway is an important target in the treatment of cancer because most of its effectors are altered in human tumors. The main effectors contributing to the activation of the pathway are: i) oncogenes such as ErbB1 (EGFR), ErbB2 (HER2), PIK3CA and AKT activated by mutation, amplification or overexpression; ii) the deficiency of tumor suppressor genes such as PTEN, TSC1 / 2, LKB and PML that are inactivated by mutations or deletions (Jiang LZ & Liu LZ, Biochim Biophys Acta, 2008, 1784: 150; & Sawyers CL, 2002, Nat Rev Cancer, 2: 489, CuIIy M et al., Nature Rev. Cancer, 2006, 6: 184).\n\n\n\n\n\n\n \n L'activation des oncogènes de cette voie de signalisation est retrouvée dans de nombreuses maladies cancéreuses humaines. \n Activation of oncogenes of this signaling pathway is found in many human cancer diseases.\n\n\n\n\n\n\n \n- les mutations activatrices de PIK3CA sont présentes dans 15-30% des cancers du colon, du sein, de l'endomètre, du foie, de l'ovaire et \n\n de la prostate (TL Yuan and LC Cantley, Oncogene, 2008, 27:5497; Y. Samuels et al. Science, 2004, 304:554; KE. Bachman et al. Cancer Biol Ther, 2004, 3:772; DA Levine et al. Clin Cane Res. 2005, 11 :2875; C. Hartmann et al. Acta Neuropathol. 2005, 109:639). - les amplifications, mutations activatrices et surexpressions des RTKs tels qu'EGFR et HER2 dans les cancers du cerveau, du sein et du poumon (NSCLC) \nPIK3CA activating mutations are present in 15-30% of cancers of the colon, breast, endometrium, liver, ovary and  prostate (TL Yuan and LC Cantley, Oncogene, 2008, 27: 5497, Y. Samuels et al., Science, 2004, 304: 554, KE Bachman et al., Cancer Biol Ther, 2004, 3: 772; DA Levine et al., Clin Cane Res 2005, 11: 2875, C. Hartmann et al., Acta Neuropathol 2005, 109: 639). - the amplifications, activating mutations and over-expression of RTKs such as EGFR and HER2 in brain, breast and lung cancers (NSCLC)\n\n\n\n\n\n\n \n l'amplification et la surexpression activatrice d'AKT dans les cancers du cerveau, du poumon (NSCLC), du sein, du rein, de l'ovaire et du pancréas (Testa JR. and Bellacosa A., Proct. Natl. Acad. Sci. USA\n the amplification and activating overexpression of AKT in cancers of the brain, lung (NSCLC), breast, kidney, ovary and pancreas (Testa JR and Bellacosa A., Proct Natl Acad. Sci USA\n\n\n\n\n\n\n \n2001 , 98:10983 ; Cheng et al., Proct. Natl. Acad. Sci. USA 1992, 89: 9267 ; Bellacosa et al., Int. J. Cancer, 1995, 64:280 ; Cheng et al., Proct. Natl. Acad. Sci. USA 1996, 93 :3636 ; Yuan et al., Oncogene, 2000, 19 :2324). \n2001, 98: 10983; Cheng et al., Proct. Natl. Acad. Sci. USA 1992, 89: 9267; Bellacosa et al., Int. J. Cancer, 1995, 64: 280; Cheng et al., Proct. Natl. Acad. Sci. USA 1996, 93: 3636; Yuan et al., Oncogene, 2000, 19: 2324).\n\n\n\n\n\n\n \nLa déficience des gènes suppresseurs de tumeurs de cette voie de signalisation est également retouvée dans de nombreuses maladies cancéreuses humaines: \nThe deficiency of the tumor suppressor genes of this signaling pathway is also found in many human cancer diseases:\n\n\n\n\n\n\n \n o la délétion de PTEN dans 50% des cancers du poumon (NSCLC), du foie, du rein, de la prostate, du sein, du cerveau, du pancréas, de l'endomètre et du colon (Maxwell GL et al. Cane. Res. 1998, 58 :2500 ;\n o the deletion of PTEN in 50% of lung cancers (NSCLC), liver, kidney, prostate, breast, brain, pancreas, endometrium and colon (Maxwell GL et al. Res 1998, 58: 2500;\n\n\n\n\n\n\n \nZhou X-P et al. Amer. J. Pathol., 2002, 161 :439 ; Endersby R & Baker SJ, Oncogene, 2008, 27 :5416 ; Li et al. Science, 1997, 275:1943; Steack PA et al., Nat. Genêt., 1997, 15 :356) \nZhou X-P et al. Bitter. J. Pathol., 2002, 161: 439; Endersby R & Baker SJ, Oncogene, 2008, 27: 5416; Li et al. Science, 1997, 275: 1943; Steack PA et al., Nat. Genet., 1997, 15: 356)\n\n\n\n\n\n\n \n o les mutations de TSC1/2 dans plus de 50% des scléroses tubéreuses o les mutations ou délétions de LKB1 (or STK11) qui prédisposent aux cancers du tractus gastro-intestinal et au cancer du pancréas et qui sont retouvées en particulier dans 10-38% des adenocarcinomes du poumon (Shah U. et al. Cancer Res. 2008, 68 :3562) \n o mutations of TSC1 / 2 in more than 50% of tuberous sclerosis o mutations or deletions of LKB1 (or STK11) which predispose to cancers of the gastrointestinal tract and pancreatic cancer and which are detected in particular in 10-38 % of lung adenocarcinomas (Shah U. et al., Cancer Res., 2008, 68: 3562)\n\n\n\n\n\n\n \n o les modification de PML notament par translocation dans les tumeurs humaines (Gurheri C et al, J. NAtI Cancer Inst. 2004, 96 :269). \n\n De plus cette voie de signalisation est un facteur majeur de résistance à la chimiothérapie, la radiothérapie et à des thérapies ciblées tels que les inhibiteurs d'EGFR et HER2 par exemple (C. Sawyers et al. Nat Rev 2002). RoIe d'AKT \no PML modification by translocation in human tumors (Gurheri C et al, J. NAtI Cancer Institute 2004, 96: 269).  In addition, this signaling pathway is a major factor of resistance to chemotherapy, radiotherapy and targeted therapies such as EGFR and HER2 inhibitors for example (C. Sawyers et al., Nat Rev 2002). RoIe of AKT\n\n\n\n\n\n\n \nAKT (protéine kinase B ; PKB) est une sérine-thréonine kinase qui occupe une place centrale dans une des voies majeures de signalisation cellulaire, la voie PI3K/AKT. AKT est notamment impliquée dans la croissance, la prolifération et la survie des cellules tumorales. L'activation d'AKT se fait en deux étapes (i) par phosphorylation de la thréonine 308 (P-T308) par PDK1 et (2) par phosphorylation de la serine 473 (P-S473) par mTORC2 (ou complexe mTOR-Rictor), résultant en une activation totale. AKT à son tour régule un grand nombre de protéines dont mTOR (mammalian target of Rapamycin), BAD, GSK3, p21 , p27, FOXO ou FKHRL1 (Manning BD & Cantley LC, CeII, 2007 129 :1261 ). L'activation d'AKT promeut l'internalisation des nutriments, ce qui déclenche un processus de métabolisation anabolisante soutenant la croissance et la prolifération cellulaire. En particulier, AKT contrôle l'initiation de la synthèse protéique à travers une cascade d'interactions qui procède par l'intermédiaire de TSC1/2 (complexe de sclérose tubéreuse), Rheb, et TOR pour aboutir à deux cibles critiques de la voie de signalisation, p70S6K et 4EBP. AKT induit également une phosphorylation inhibitrice du facteur de transcription Forkhead et l'inactivation de GSK3β qui conduisent à l'inhibition de l'apoptose et à la progression du cycle cellulaire (Franke TF, Oncogene, 2008, 27 :6473). AKT est donc une cible pour la thérapie anti-cancéreuse et l'inhibition de l'activation d'AKT par l'inhibition de sa phosphorylation peut induire l'apoptose des cellules malignes et par la même, présenter un traitement pour le cancer. \nAKT (protein kinase B, PKB) is a serine-threonine kinase that occupies a central position in one of the major cell signaling pathways, the PI3K / AKT pathway. AKT is particularly involved in the growth, proliferation and survival of tumor cells. The activation of AKT is done in two steps (i) by phosphorylation of threonine 308 (P-T308) by PDK1 and (2) by phosphorylation of serine 473 (P-S473) by mTORC2 (or mTOR-Rictor complex ), resulting in total activation. AKT in turn regulates a large number of proteins including mTOR (mammalian target of Rapamycin), BAD, GSK3, p21, p27, FOXO or FKHRL1 (BD Manning & Cantley LC, CeII, 2007 129: 1261). Activation of AKT promotes the internalization of nutrients, which triggers anabolic metabolism process supporting cell growth and proliferation. In particular, AKT controls the initiation of protein synthesis through a cascade of interactions that proceeds via TSC1 / 2 (tuberous sclerosis complex), Rheb, and TOR to achieve two critical targets of the pathway. signaling, p70S6K and 4EBP. AKT also induces inhibitory phosphorylation of the Forkhead transcription factor and inactivation of GSK3β that lead to inhibition of apoptosis and cell cycle progression (Franke TF, Oncogene, 2008, 27: 6473). AKT is therefore a target for anti-cancer therapy and inhibition of AKT activation by inhibition of its phosphorylation can induce apoptosis of malignant cells and thus, present a treatment for cancer.\n\n\n\n\n\n\n \n Les récepteurs à activité tyrosyne kinase comme IGF1 R \n Receptors with tyrosyne kinase activity as IGF1 R\n\n\n\n\n\n\n \nDes niveaux anormalement élevés d'activité protéine kinase ont été impliqués dans de nombreuses maladies résultant de fonctions cellulaires anormales. Ceci peut provenir soit directement soit indirectement, d'un disfonctionnement dans les mécanismes de contrôle de l'activité kinase, lié par exemple à une \n\n mutation, une sur-expression ou une activation inappropriée de l'enzyme, ou par une sur- ou sous-production de cytokines ou des facteurs de croissance, également impliqués dans la transduction des signaux en amont ou en aval des kinases. Dans tous ces cas, une inhibition sélective de l'action des kinases laisse espérer un effet bénéfique. \nAbnormally high levels of protein kinase activity have been implicated in many diseases resulting from abnormal cell functions. This can come either directly or indirectly, from a dysfunction in the mechanisms of kinase activity control, linked for example to a  mutation, over-expression or inappropriate activation of the enzyme, or over-or under-production of cytokines or growth factors, also involved in signal transduction upstream or downstream of kinases. In all these cases, a selective inhibition of the kinase action suggests a beneficial effect.\n\n\n\n\n\n\n \nLe récepteur de type 1 pour l'insulin-like growth factor (IGF-I-R) est un récepteur transmembranaire à activité tyrosine kinase qui se lie en premier lieu à NGFI mais aussi à NGFII et à l'insuline avec une plus faible affinité. La liaison de NGF1 à son récepteur entraîne une oligomérisation du récepteur, l'activation de la tyrosine kinase, l'autophosphorylation intermoléculaire et la phosphorylation de substrats cellulaires (principaux substrats : IRS1 et Shc). Le récepteur activé par son ligand induit une activité mitogènique dans les cellules normales. Cependant IGF-I-R joue un rôle important dans la croissance dite anormale. Plusieurs rapports cliniques soulignent le rôle important de la voie IGF-I dans le développement des cancers humains : \nThe type 1 receptor for insulin-like growth factor (IGF-I-R) is a transmembrane receptor with tyrosine kinase activity that binds primarily to NGFI but also to NGFII and insulin with lower affinity. The binding of NGF1 to its receptor results in oligomerization of the receptor, tyrosine kinase activation, intermolecular autophosphorylation and phosphorylation of cellular substrates (major substrates: IRS1 and Shc). The ligand-activated receptor induces mitogenic activity in normal cells. However, IGF-I-R plays an important role in so-called abnormal growth. Several clinical reports highlight the important role of the IGF-I pathway in the development of human cancers:\n\n\n\n\n\n\n \nIGF-I-R est souvent trouvé sur-exprimé dans de nombreux types tumoraux (sein, colon, poumon, sarcome, prostate, myelome multiple) et sa présence est souvent associée à un phénotype plus agressif. De fortes concentrations d'IGFI circulant sont fortement corrélées à un risque de cancer de la prostate, poumon et sein. \nIGF-I-R is often found over-expressed in many tumor types (breast, colon, lung, sarcoma, prostate, multiple myeloma) and its presence is often associated with a more aggressive phenotype. High concentrations of circulating IGFI are strongly correlated with a risk of prostate cancer, lung cancer and breast cancer.\n\n\n\n\n\n\n \nDe plus, il a été largement documenté que IGF-I-R est nécessaire à \nIn addition, it has been widely documented that IGF-I-R is necessary for\n\n\n\n\n\n\n \nl'établissement et au maintient du phénotype transformé in vitro comme in vivo [Baserga R, Exp. CeII. Res., 1999, 253, pages 1 -6]. L'activité kinase d'IGF-l-R est essentielle à l'activité de transformation de plusieurs \nestablishment and maintenance of the phenotype transformed in vitro as in vivo [Baserga R, Exp. IECI. Res., 1999, 253, pp. 1-6]. The kinase activity of IGF-1-R is essential for the transformation activity of several\n\n\n\n\n\n\n \noncogènes: EGFR, PDGFR, l'antigène grand T du virus SV40, Ras activé, Raf, et v-Src. L'expression d'IGF-l-R dans des fibroblastes normaux induit un \n\n phénotype néoplasique, qui peut ensuite entraîner la formation de tumeur in vivo. L'expression d'IGF-l-R joue un rôle important dans la croissance indépendante du substrat. IGF-I-R a également été montré comme un protecteur dans l'apoptose induite par chimiothérapie, radiation, et l'apoptose induite par des cytokines. De plus, l'inhibition d'IGF-l-R endogène par un dominant négatif, la formation de triple hélice ou l'expression d'un antisens provoque une suppression de l'activité transformante in vitro et la diminution de la croissance de tumeurs dans les modèles animaux. \noncogenes: EGFR, PDGFR, SV40 virus large T antigen, activated Ras, Raf, and v-Src. The expression of IGF-1R in normal fibroblasts induces a  neoplastic phenotype, which can then lead to tumor formation in vivo. The expression of IGF-1R plays an important role in the independent growth of the substrate. IGF-IR has also been shown to be a protector in apoptosis-induced chemotherapy, radiation, and cytokine-induced apoptosis. In addition, inhibition of endogenous IGF-1R by a dominant negative, triple helix formation or expression of antisense causes suppression of the transforming activity in vitro and decreased tumor growth in the cells. animal models.\n\n\n\n\n\n\n \nPDK1 \nPDK1\n\n\n\n\n\n\n \n La 3'-phosphoinositide-dependent protein kinase-1 (PDK1 ) est une des composantes essentielles de la voie de signalisation PI3K-AKT. C'est une sérine-thréonine (Ser/Thr) kinase dont le rôle est de phosphoryler et d'activer d'autres Ser/Thr kinases de la famille des AGC impliquées dans le contrôle de la croissance, la prolifération, la survie cellulaire et dans la régulation du métabolisme. Ces kinases incluent la protéine kinase B (PKB ou AKT), SGK (ou sérum and glucocorticoïd regulated kinase), RSK (ou p90 ribosomal S6 kinase), p70S6K (ou p70 ribosomal S6 kinase) ainsi que diverses isoformes de la protéine kinase C (PKC) (Vanhaesebroeck B. & Alessi DR., Biochem J, 2000, 346:561 ). Un des rôles clés de PDK1 est donc l'activation d'AKT : en présence de PIP3, le second messager généré par PI3K, PDK-1 est recruté à la membrane plasmique via son domaine PH (plekstrin homology) et phosphoryle AKT sur la thréonine 308 situé dans la boucle d'activation, une modification essentielle de l'activation d'AKT. PDK1 est exprimée de façon ubiquitaire et est une kinase constitutivement active. PDK1 est un élément clé dans la voie de signalisation PI3K/AKT pour la régulation de processus clés dans la tumorigénèse comme la prolifération et la survie cellulaire. Cette voie étant activée dans plus de 50% des cancers humains, PDK1 représente une cible pour la thérapie anticancéreuse. L'inhibition de PDK1 devrait résulter en une inhibition effective de la prolifération et de la survie des cellules cancéreuses et donc apporter un bénéfice thérapeutique pour les cancers \n\n humains (Bayascas JR, CeII cycle, 2008, 7 :2978 ; Peifer C. & Alessi DR,\n3'-Phosphoinositide-dependent protein kinase-1 (PDK1) is one of the essential components of the PI3K-AKT signaling pathway. It is a serine-threonine (Ser / Thr) kinase whose role is to phosphorylate and activate other Ser / Thr kinases of the AGC family involved in the control of growth, proliferation, cell survival and in the regulation of metabolism. These kinases include protein kinase B (PKB or AKT), SGK (or serum and glucocorticoid regulated kinase), RSK (or p90 ribosomal S6 kinase), p70S6K (or p70 ribosomal S6 kinase), and various isoforms of protein kinase C ( PKC) (Vanhaesebroeck B. & Alessi DR., Biochem J, 2000, 346: 561). One of the key roles of PDK1 is the activation of AKT: in the presence of PIP3, the second PI3K-generated messenger, PDK-1 is recruited to the plasma membrane via its PH domain (plekstrin homology) and phosphorylates AKT on threonine. 308 located in the activation loop, an essential modification of AKT activation. PDK1 is ubiquitously expressed and is a constitutively active kinase. PDK1 is a key element in the PI3K / AKT signaling pathway for the regulation of key processes in tumorigenesis such as cell proliferation and survival. Since this pathway is activated in more than 50% of human cancers, PDK1 represents a target for cancer therapy. Inhibition of PDK1 should result in an effective inhibition of the proliferation and survival of cancer cells and thus provide a therapeutic benefit for cancers  Humans (Bayascas JR, CeII cycle, 2008, 7: 2978, Peifer C. & Alessi DR,\n\n\n\n\n\n\n \nChemMedChem, 2008, 3 :1810). \nChemMedChem, 2008, 3: 1810).\n\n\n\n\n\n\n \n Les phosphoinositides-3 kinases (PI3Ks) \n Phosphoinositide-3 kinases (PI3Ks)\n\n\n\n\n\n\n \n La lipide kinase PI3K est une cible importante dans cette voie de signalisation pour l'oncologie. Les PI3Ks de la classe I sont réparties en classe Ia (PI3Kα,β,δ) activée par les récepteurs à activité tyrosine kinase (RTKs), les récepteurs couplés aux protéines G (GPCRs), les GTPases de la famille Rho, p21 -Ras et en classe Ib (PI3Kγ) activé par les GPCRs et par p21 -Ras. Les PI3Ks de la classe Ia sont des hétérodimères qui consistent en une sous unité catalytique p110α, β ou δ et une sous unité régulatrice p85 ou p55. La classe Ib (p110γ) est monomérique. Les PI3Ks de la classe I sont des lipides/protéines kinases qui sont activées par les RTKs, les GPCRs ou Ras après recrutement à la membrane. Ces PI3Ks de la classe I phosphorylent le phosphatidylinositol 4,5 diphosphate (PIP2) sur la position 3 de l'inositol pour donner le phosphatidylinositol 3,4,5 triphosphate (PIP3), messager secondaire clé de cette voie de signalisation. A son tour, PIP3 recrute AKT et PDK1 à la membrane où ils se fixent par leur domaine homologue à la pleckstrine (domaine PH), conduisant à l'activation d'AKT par phosphorylation de PDK1 sur la thréonine 308. AKT phosphoryle de nombreux substrats, jouant ainsi un rôle clé dans de nombreux processus aboutissant à la transformation cellulaire comme la prolifération, la croissance et la survie cellulaire ainsi que l'angiogénèse. \n PI3K lipid kinase is an important target in this signaling pathway for oncology. PI3Ks of class I are divided into class Ia (PI3Kα, β, δ) activated by tyrosine kinase receptors (RTKs), G-protein coupled receptors (GPCRs), Rho GTPases, p21 -Ras and in class Ib (PI3Kγ) activated by the GPCRs and by p21 -Ras. PI3Ks of class Ia are heterodimers which consist of a catalytic subunit p110α, β or δ and a p85 or p55 regulatory subunit. Class Ib (p110γ) is monomeric. PI3Ks of class I are lipids / protein kinases that are activated by RTKs, GPCRs or Ras after membrane recruitment. These PI3Ks of class I phosphorylate phosphatidylinositol 4,5 diphosphate (PIP2) at position 3 of inositol to give phosphatidylinositol 3,4,5 triphosphate (PIP3), the key secondary messenger of this signaling pathway. In turn, PIP3 recruits AKT and PDK1 to the membrane where they bind to their domain homologous to the pleckstrin (PH domain), leading to the activation of AKT by phosphorylation of PDK1 on threonine 308. AKT phosphorylates many substrates , thus playing a key role in many processes leading to cellular transformation such as proliferation, growth and cell survival as well as angiogenesis.\n\n\n\n\n\n\n \n Les PI3Ks de classe I sont impliquées dans les cancers humains : des mutations somatiques du gène PIK3CA qui code pour PI3K se retrouvent dans 15-35% des tumeurs humaines avec notamment deux mutations oncogéniques principales H1047R (dans le domaine kinase) et E545K/E542K (dans le domaine hélical) (Y. Samuels et al. Science, 2004, 304:554; TL Yuan and LC Cantley, Oncogene, 2008, 27:5497). Des inhibiteurs de PI3K sont attendus efficaces pour le traitement de nombreux cancers humains présentant des altérations génétiques aboutissant à l'activation de la voie \n\n PI3K/AKT/mTOR (Vogt P. et al., Virology, 2006, 344 :131 ; Zhao L & Vogt PK, Oncogene, 2008, 27 :5486). \nClass I PI3Ks are involved in human cancers: somatic mutations of the PIK3CA gene encoding PI3K are found in 15-35% of human tumors including two main oncogenic mutations H1047R (in the kinase domain) and E545K / E542K ( in the helical domain) (Y. Samuels et al., Science, 2004, 304: 554, TL Yuan and LC Cantley, Oncogene, 2008, 27: 5497). PI3K inhibitors are expected to be effective for the treatment of many human cancers with genetic alterations leading to activation of the pathway  PI3K / AKT / mTOR (Vogt P. et al., Virology, 2006, 344: 131, Zhao L & Vogt PK, Oncogene, 2008, 27: 5486).\n\n\n\n\n\n\n \n mTOR \n mTOR\n\n\n\n\n\n\n \n mTOR (mammalian target of rapamycin) est une serine-threonine kinase apparentée aux lipide kinases de la famille PI3K. mTOR a été impliquée dans divers processus biologiques incluant la croissance, la prolifération, la motilité et la survie cellulaires. mTOR est une kinase multifonctionnelle intégrant à la fois les signaux venant des facteurs de croissance et ceux venant des nutriments pour réguler la traduction des protéines, la capture des nutriments, l'autophagie et la fonction mitochondriale. mTOR existe sous la forme de deux complexes différent appelés mTORCI et mTORC2. mTORCI contient la sous-unité raptor et mTORC2, la sous-unité rictor. Ces deux complexes sont régulés de façon différente : mTORCI phosphoryle la kinase S6 (S6K) et 4EBP1 , stimulant ainsi la traduction et la biogenèse des ribosomes pour faciliter la croissance des cellules et la progression dans le cycle cellulaire. S6K agit aussi dans une voie de rétro-contrôle pour atténuer l'activation d'AKT. mTORCI est sensible à la rapamycine alors que mTORC2 est généralement insensible à la rapamycine. mTORC2 modulerait la signalisation des facteurs de croissance en phosphorylant AKT sur le résidu serine 473. mTOR a été impliquée dans diverses pathologies incluant notamment le cancer, le diabète, l'obésité, les maladies cardio-vasculaires et les désordres neurologiques. mTOR module de nombreux processus biologiques incluant la traduction, l'autophagie, et la biogenèse des ribosomes en intégrant des signaux intra et extra-cellulaires comme les signaux transportés par les facteurs de croissance, les nutriments, les niveau d'énergie et le stress cellulaire (Guertin D.A. and Sabatini D., Cancer CeII, 2007, 12 :9 ; Menon S. and Manning B.D., Oncogene, 2009, 27 :S43). \n\n Rôle de l'autophaqie \nmTOR (mammalian target of rapamycin) is a serine threonine kinase related to PI3K family lipid kinases. mTOR has been implicated in a variety of biological processes including cell growth, proliferation, motility and survival. mTOR is a multifunctional kinase that integrates both growth factor and nutrient signals to regulate protein translation, nutrient uptake, autophagy, and mitochondrial function. mTOR exists as two different complexes called mTORCI and mTORC2. mTORCI contains the raptor subunit and mTORC2, the rictor subunit. These two complexes are regulated in different ways: mTORCI phosphorylates the S6 (S6K) and 4EBP1 kinase, thus stimulating the translation and biogenesis of ribosomes to facilitate cell growth and cell cycle progression. S6K also acts in a back-control channel to mitigate the activation of AKT. mTORCI is sensitive to rapamycin whereas mTORC2 is generally insensitive to rapamycin. mTORC2 modulates growth factor signaling by phosphorylating AKT on the serine 473 residue. mTOR has been implicated in various pathologies including cancer, diabetes, obesity, cardiovascular diseases and neurological disorders. mTOR modulates many biological processes including translation, autophagy, and ribosome biogenesis by integrating intra and extracellular signals such as signals carried by growth factors, nutrients, energy levels and cellular stress (Guertin DA and Sabatini D., CeII Cancer, 2007, 12: 9, Menon S. and Manning BD, Oncogene, 2009, 27: S43).  Role of the autophaqie\n\n\n\n\n\n\n \n L'autophagie est un mécanisme de dégradation intracellulaire (organelles, protéines de longues vies...) dépendant des lysosomes. Le processus autophagie implique la formation de vésicules particulières appelées autophagosomes. La lipide kinase PI3K de classe III (Vps34) est impliquée dans la formation des autophagosomes. Cette PI3K de la classe III phosphoryle le phosphatidylinositol (Pl) sur la position 3 de l'inositol pour donner le phosphatidylinositol 3 triphosphate (PI3P). Le PI3P est un messager secondaire clé dans la formation des autophagosomes via le recrutement de protéines telles que WIPI, DFCP1 et Alfy. L'autophagie est un mécanisme de survie cellulaire permettant à la cellule de survivre en situation de stress, comme par exemple face à un stress métabolique. Dans le cas du cancer, l'autophagie est impliquée dans la résistance des cellules tumorales face aux stress envirronnementaux tels que : l'hypoxie, les stress oxydatifs, la carence en nutriments, mais aussi face aux stress thérapeutiques : traitements par agents anticancéreux, radiations ionisantes. \n Autophagy is a mechanism of intracellular degradation (organelles, long life proteins ...) dependent on lysosomes. The autophagy process involves the formation of particular vesicles called autophagosomes. Class III PI3K lipid kinase (Vps34) is involved in the formation of autophagosomes. This class III PI3K phosphorylates phosphatidylinositol (P1) at position 3 of inositol to give phosphatidylinositol 3 triphosphate (PI3P). PI3P is a key secondary messenger in the formation of autophagosomes via the recruitment of proteins such as WIPI, DFCP1 and Alfy. Autophagy is a cell survival mechanism that allows the cell to survive under stress, such as metabolic stress. In the case of cancer, autophagy is involved in the resistance of tumor cells to environmental stresses such as: hypoxia, oxidative stress, nutrient deficiency, but also to therapeutic stresses: anticancer treatments, radiation ionizing.\n\n\n\n\n\n\n \nApplication en chimiothérapie anti-paludique \nApplication in anti-malarial chemotherapy\n\n\n\n\n\n\n \n Le paludisme est l'une des premières causes infectieuses de mortalité au monde et touche chaque année 100 à 200 millions de personnes. La forte recrudescence de la maladie observée depuis quelques années est due à plusieurs facteurs, dont: \n Malaria is one of the leading infectious causes of death in the world and affects every year 100 to 200 million people. The strong upsurge of the disease observed in recent years is due to several factors, including:\n\n\n\n\n\n\n \n -les vecteurs, à savoir les anophèles, qui deviennent résistants aux insecticides classiques et bon marché, \n the vectors, namely anopheles, which become resistant to conventional and cheap insecticides,\n\n\n\n\n\n\n \n- l'augmentation de la population dans les zones à risque et, principalement, - la résistance de nombreuses souches de Plasmodium falciparum, parasite responsable des formes mortelles de la maladie, aux médicaments classiquement utilisés, tels que la chloroquine et la méfloquine. \n- the increase of the population in the areas at risk and, mainly, - the resistance of numerous strains of Plasmodium falciparum, parasite responsible for the deadly forms of the disease, to the classically used drugs, such as chloroquine and mefloquine.\n\n\n\n\n\n\n \nLa propagation de la résistance parmi les souches de Plasmodium, en particulier P. falciparum, contre la plupart des médicaments anti-paludéens démontre le besoin urgent de développer de nouveaux composés possédant un nouveau mode d'action et permettant ainsi une diminution du risque de \n\n résistance croisée. Les kinases humaines sont des cibles validées dans le traitement de nombreuses pathologies et le kinome de P. falciparum a été proposé comme un réservoir de nouvelles cibles pour le développement de nouveaux médicaments, non encore explorées dans le traitement du paludisme. \nThe spread of resistance among Plasmodium strains, particularly P. falciparum, against most anti-malarial drugs demonstrates the urgent need to develop new compounds with a new mode of action and thereby reduce the risk of  cross resistance. Human kinases are validated targets in the treatment of many pathologies and the kinome of P. falciparum has been proposed as a reservoir of new targets for the development of new drugs, not yet explored in the treatment of malaria.\n\n\n\n\n\n\n \n Le kinome de Plasmodium falciparum est composé de 64 kinases, dont certaines sont orthologues de kinases humaines. Des inhibiteurs des voies de signalisation kinases ont été testés pour leur capacité à inhiber in vitro et in vivo la croissance de P. falciparum et d'autres espècess pathogènes à l'origine du paludisme. \n The Plasmodium falciparum kinome is composed of 64 kinases, some of which are orthologous to human kinases. Inhibitors of signaling kinase pathways have been tested for their ability to inhibit in vitro and in vivo growth of P. falciparum and other pathogenic species causing malaria.\n\n\n\n\n\n\n \n Les molécules de l'invention inhibent la croissance de P. falciparum (hautement résistant à la chloroquine souche Fcm29-Cameroun) à 1 uM et 0,1 uM dans un test in vitro utilisant des érythrocytes humains infectés, comme indiqué dans le tableau 2. \n The molecules of the invention inhibit the growth of P. falciparum (highly resistant to chloroquine strain Fcm29-Cameroon) at 1 μM and 0.1 μM in an in vitro test using infected human erythrocytes, as shown in Table 2.\n\n\n\n\n\n\n \nDes kinomes similaires sont présents dans toutes les espèces de Plasmodium, tels que P. falciparum, P. vivax, P. malariae, P. ovale et P. knowlesi. Les composés de l'invention peuvent donc être utiles dans le traitement du paludisme induit par tous les parasites mentionnés ci-dessus. En outre, les kinases se trouvent dans d'autres parasites, tels que Trypanosoma (par exemple T. brucei, T. cruzei) et Leishmania (par exemple L. major, L. donovani). Les composés de l'invention peuvent donc être utilisés dans le traitement de la maladie du sommeil, la maladie de Chagas, les différentes formes de leishmaniose et d'autres infections parasitaires. Des dérivés Morpholino pyrimidinones inhibiteurs de kinases sont connus de l'homme de l'art. \nSimilar kinomas are present in all Plasmodium species, such as P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. The compounds of the invention may therefore be useful in the treatment of malaria induced by all the parasites mentioned above. In addition, kinases are found in other parasites, such as Trypanosoma (for example T. brucei, T. cruzei) and Leishmania (for example L. major, L. donovani). The compounds of the invention can therefore be used in the treatment of sleeping sickness, Chagas disease, various forms of leishmaniasis and other parasitic infections. Morpholino pyrimidinone derivatives which are kinase inhibitors are known to those skilled in the art.\n\n\n\n\n\n\n \n L'application WO2008/148074 décrit des produits qui possèdent une activité inhibitrice de mTOR. Ces produits sont des pyπdo[1 ,2-a]pyhmidin-4- ones qui diffèrent des produits de la présente invention en raison de leur caractère entièrement aromatique et de leurs substitutions. \n\n L'application WO2008/064244 décrit l'application des produits TGX- 221 et TGX-155 inhibiteurs de PI3Kβ utiles dans le traitement du cancer et notamment dans le cancer du sein. Ces produits sont des pyrido[1 ,2- a]pyπmidin-4-ones précédemment décrits dans les applications WO2004/016607 et WO2001 /053266 qui diffèrent des produits de la présente invention en raison de leur caractère entièrement aromatique et de leurs substitutions. \nThe WO2008 / 148074 application describes products that have mTOR inhibitory activity. These products are pyπdo [1,2-a] pyhmidin-4-ones which differ from the products of the present invention because of their wholly aromatic character and their substitutions.  The application WO2008 / 064244 describes the application of the products TGX-221 and TGX-155 inhibitors of PI3Kβ useful in the treatment of cancer and in particular in breast cancer. These products are pyrido [1,2-a] pyrimidin-4-ones previously described in the applications WO2004 / 016607 and WO2001 / 053266 which differ from the products of the present invention because of their wholly aromatic character and their substitutions.\n\n\n\n\n\n\n \n Les applications WO2006/109081 , WO2006/109084 et\n The applications WO2006 / 109081, WO2006 / 109084 and\n\n\n\n\n\n\n \nWO2006/126010 décrivent des produits inhibiteurs de DNA-PK utiles pour le traitement des cancers ATM déficients. Ces produits sont des pyrido[1 ,2- a]pyπmidin-4-ones qui diffèrent des produits de la présente invention en raison de leur caractère entièrement aromatique et de leurs substitutions \nWO2006 / 126010 disclose DNA-PK inhibitory products useful for the treatment of deficient ATM cancers. These products are pyrido [1,2-a] pyrimidin-4-ones which differ from the products of the present invention because of their wholly aromatic character and their substitutions.\n\n\n\n\n\n\n \n L'application WO2003/024949 décrit des produits inhibiteurs de DNA-\n The application WO2003 / 024949 describes DNA-inhibiting products.\n\n\n\n\n\n\n \nPK utiles pour le traitement des cancers ATM déficients. Ces produits sont des pyhdo[1 ,2-a]pyrimidin-4-ones qui diffèrent des produits de la présente invention en raison de leur caractère entièrement aromatique et de leurs substitutions \nPK useful for the treatment of deficient ATM cancers. These products are pyhdo [1,2-a] pyrimidin-4-ones which differ from the products of the present invention because of their wholly aromatic character and their substitutions.\n\n\n\n\n\n\n \n La présente invention a pour objet les produits de formule (I): \n The subject of the present invention is the products of formula (I):\n\n\n\n\n\n\n \n \n\n dans laquelle : \n \n in which :\n\n\n\n\n\n\n \n R1 représente un radical -L-aryle ou -L-hétéroaryle, tel que L représente : soit une simple liaison, \n R1 represents a -L-aryl or -L-heteroaryl radical, such that L represents: either a single bond,\n\n\n\n\n\n\n \nsoit un radical alkyle linéaire ou ramifié renfermant de 1 à 6 atomes de carbone et éventuellement substitué par un radical hydroxyle, \n\n soit un groupe CO ou -CO-AIk- ; \nis a linear or branched alkyl radical containing from 1 to 6 carbon atoms and optionally substituted with a hydroxyl radical,  either a CO or -CO-Alk- group;\n\n\n\n\n\n\n \nsoit un groupe L'-X où L' représente un radical alkyle linéaire ou ramifié renfermant de 1 à 6 atomes de carbone et X un atome d'oxygène ou de soufre ; \nor a group L'-X where L 'represents a linear or branched alkyl radical containing from 1 to 6 carbon atoms and X an oxygen or sulfur atom;\n\n\n\n\n\n\n \nles radicaux aryle et hétéroaryle étant éventuellement substitués par un ou plusieurs radicaux identiques ou différents choisis parmi les atomes d'halogène et les radicaux hydroxyle, CN, nitro, -COOH, -COOaIk, -NRxRy, - CONRxRy, -NRxCORy, -NRxCO2Rz, -CORy, alcoxy, phénoxy, alkylthio, alkyle, cycloalkyle et hétérocycloalkyle ; \nthe aryl and heteroaryl radicals being optionally substituted by one or more identical or different radicals chosen from halogen atoms and hydroxyl, CN, nitro, -COOH, -COOaIk, -NRxRy, -CONRxRy, -NRxCORy, -NRxCO2Rz radicals, -COR y, alkoxy, phenoxy, alkylthio, alkyl, cycloalkyl and heterocycloalkyl;\n\n\n\n\n\n\n \nces derniers radicaux alcoxy, phénoxy, alkylthio, alkyle et hétérocycloalkyle, étant eux-mêmes éventuellement substitués par un ou plusieurs radicaux identiques ou différents choisis parmi les atomes d'halogène et NRvRw ; \nthese latter alkoxy, phenoxy, alkylthio, alkyl and heterocycloalkyl radicals, themselves being optionally substituted with one or more identical or different radicals chosen from halogen atoms and NRvRw;\n\n\n\n\n\n\n \nles radicaux hétérocycloalkyle et hétéroaryle pouvant de plus renfermer un radical oxo ; \nheterocycloalkyl and heteroaryl radicals additionally capable of containing an oxo radical;\n\n\n\n\n\n\n \nR2 représente un atome d'hydrogène ou un radical alkyle ; \nR2 represents a hydrogen atom or an alkyl radical;\n\n\n\n\n\n\n \n R3 représente un radical alkyle éventuellement substitué par un ou plusieurs atomes d'halogène ; \n R3 represents an alkyl radical optionally substituted with one or more halogen atoms;\n\n\n\n\n\n\n \n R4 représente un atome d'hydrogène ou un atome d'halogène ; \n R4 represents a hydrogen atom or a halogen atom;\n\n\n\n\n\n\n \n NRxRy étant tel que Rx représente un atome d'hydrogène ou un radical alkyle et Ry représente un atome d'hydrogène, un radical cycloalkyle ou un radical alkyle éventuellement substitué par un ou plusieurs radicaux identiques ou différents choisis parmi les radicaux hydroxyle, alcoxy, NRvRw et hétérocycloalkyle ; soit Rx et Ry forment avec l'atome d'azote auquel ils sont liés un radical cyclique renfermant de 3 à 10 chaînons et éventuellement un ou plusieurs autres hétéroatomes choisi(s) parmi O, S, NH et N-alkyle, ce radical cyclique étant éventuellement substitué; \n NRxRy being such that Rx represents a hydrogen atom or an alkyl radical and Ry represents a hydrogen atom, a cycloalkyl radical or an alkyl radical optionally substituted with one or more identical or different radicals chosen from hydroxyl, alkoxy and NRvRw radicals; and heterocycloalkyl; either Rx and Ry form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 10 members and optionally one or more other heteroatoms chosen from O, S, NH and N-alkyl, this cyclic radical being optionally substituted;\n\n\n\n\n\n\n \n NRvRw étant tel que Rv représente un atome d'hydrogène ou un radical alkyle et Rw représente un atome d'hydrogène, un radical cycloalkyle ou un radical alkyle éventuellement substitué par un ou plusieurs radicaux \n\n identiques ou différents choisis parmi les radicaux hydroxyle, alcoxy, hétérocycloalkyle ; soit Rv et Rw forment avec l'atome d'azote auquel ils sont liés un radical cyclique renfermant de 3 à 10 chaînons et éventuellement un ou plusieurs autres hétéroatomes choisi(s) parmi O, S, NH et N-alkyle, ce radical cyclique étant éventuellement substitué; \nNRvRw being such that Rv represents a hydrogen atom or an alkyl radical and Rw represents a hydrogen atom, a cycloalkyl radical or an alkyl radical optionally substituted with one or more radicals;  identical or different selected from hydroxyl, alkoxy, heterocycloalkyl radicals; either Rv and Rw form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 10 ring members and optionally one or more other heteroatoms chosen from O, S, NH and N-alkyl, this cyclic radical being optionally substituted;\n\n\n\n\n\n\n \nles radicaux cycliques que peuvent former Rx et Ry ou Rv et Rw respectivement avec l'atome d'azote auquel ils sont liés, étant éventuellement substitués par un ou plusieurs radicaux identiques ou différents choisis parmi les atomes d'halogène, les radicaux alkyle, hydroxyle, oxo, alcoxy, NH2; NHaIk et N(alk)2 ; \nthe cyclic radicals that can be formed by Rx and Ry or Rv and Rw respectively with the nitrogen atom to which they are attached, being optionally substituted by one or more identical or different radicals chosen from halogen atoms, alkyl radicals, hydroxyl radicals, oxo, alkoxy, NH2; NHaIk and N (alk) 2;\n\n\n\n\n\n\n \n Rz représente les valeurs de Ry à l'exception de hydrogène ; \n Rz represents the values of Ry with the exception of hydrogen;\n\n\n\n\n\n\n \n Rx, Ry et Rz dans les radicaux -NRxCORy, -CORy et NRxCO\n2\nRz étant choisis parmi les significations indiquées ci-dessus pour Rx, Ry, et Rz ; \nRx, Ry and Rz in the radicals -NRxCORy, -CORy and NRxCO \n2\n Rz being selected from the meanings indicated above for Rx, Ry, and Rz;\n\n\n\n\n\n\n \nlesdits produits de formule (I) étant sous toutes les formes isomères possibles racémiques, énantiomères et diastéréoisomères, ainsi que les sels d'addition avec les acides minéraux et organiques ou avec les bases minérales et organiques desdits produits de formule (I). \nsaid products of formula (I) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as the addition salts with mineral and organic acids or with the inorganic and organic bases of said products of formula (I).\n\n\n\n\n\n\n \n La présente invention a ainsi pour objet les produits de formule (I) tels que définis ci-dessus dans laquelle : \n The subject of the present invention is thus the products of formula (I) as defined above in which:\n\n\n\n\n\n\n \nR1 représente un radical -L-aryle ou -L-hétéroaryle, tel que L représente : soit une simple liaison, \nR1 represents a -L-aryl or -L-heteroaryl radical, such that L represents: either a single bond,\n\n\n\n\n\n\n \nsoit un radical alkyle linéaire ou ramifié renfermant de 1 à 6 atomes de carbone et éventuellement substitué par un radical hydroxyle, \nis a linear or branched alkyl radical containing from 1 to 6 carbon atoms and optionally substituted with a hydroxyl radical,\n\n\n\n\n\n\n \nsoit un groupe CO \na CO group\n\n\n\n\n\n\n \nsoit un groupe L'-X où L' représente un radical alkyle linéaire ou ramifié renfermant de 1 à 6 atomes de carbone et X un atome d'oxygène ou de soufre ; \n\n les radicaux aryle et hétéroaryle étant éventuellement substitués par un ou plusieurs radicaux identiques ou différents choisis parmi les atomes d'halogène et les radicaux hydroxyle, CN, nitro, -COOH, -COOaIk, -NRxRy, - CONRxRy, -NRxCORy, -NRxCO2Rz, -CORy, alcoxy, phénoxy, alkylthio, alkyle, cycloalkyle et hétérocycloalkyle ; \nor a group L'-X where L 'represents a linear or branched alkyl radical containing from 1 to 6 carbon atoms and X an oxygen or sulfur atom;  the aryl and heteroaryl radicals being optionally substituted by one or more identical or different radicals chosen from halogen atoms and hydroxyl, CN, nitro, -COOH, -COOaIk, -NRxRy, -CONRxRy, -NRxCORy, -NRxCO2Rz radicals, -COR y, alkoxy, phenoxy, alkylthio, alkyl, cycloalkyl and heterocycloalkyl;\n\n\n\n\n\n\n \nces derniers radicaux alcoxy, phénoxy, alkylthio, alkyle et hétérocycloalkyle, étant eux-mêmes éventuellement substitués par un ou plusieurs radicaux identiques ou différents choisis parmi les atomes d'halogène et NRvRw ; \nthese latter alkoxy, phenoxy, alkylthio, alkyl and heterocycloalkyl radicals, themselves being optionally substituted with one or more identical or different radicals chosen from halogen atoms and NRvRw;\n\n\n\n\n\n\n \nles radicaux hétérocycloalkyle et hétéroaryle pouvant de plus renfermer un radical oxo ; \nheterocycloalkyl and heteroaryl radicals additionally capable of containing an oxo radical;\n\n\n\n\n\n\n \n R2 représente un atome d'hydrogène ou un radical alkyle ; \n R2 represents a hydrogen atom or an alkyl radical;\n\n\n\n\n\n\n \n R3 représente un radical alkyle éventuellement substitué par un ou plusieurs atomes d'halogène ; \n R3 represents an alkyl radical optionally substituted with one or more halogen atoms;\n\n\n\n\n\n\n \n R4 représente un atome d'hydrogène ou un atome d'halogène ; \n R4 represents a hydrogen atom or a halogen atom;\n\n\n\n\n\n\n \nNRxRy étant tel que Rx représente un atome d'hydrogène ou un radical alkyle et Ry représente un atome d'hydrogène, un radical cycloalkyle ou un radical alkyle éventuellement substitué par un ou plusieurs radicaux identiques ou différents choisis parmi les radicaux hydroxyle, alcoxy, NRvRw et hétérocycloalkyle ; soit Rx et Ry forment avec l'atome d'azote auquel ils sont liés un radical cyclique renfermant de 3 à 10 chaînons et éventuellement un ou plusieurs autres hétéroatomes choisi(s) parmi O, S, NH et N-alkyle, ce radical cyclique étant éventuellement substitué; \nNRxRy being such that Rx represents a hydrogen atom or an alkyl radical and Ry represents a hydrogen atom, a cycloalkyl radical or an alkyl radical optionally substituted with one or more identical or different radicals chosen from hydroxyl, alkoxy and NRvRw radicals; and heterocycloalkyl; either Rx and Ry form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 10 members and optionally one or more other heteroatoms chosen from O, S, NH and N-alkyl, this cyclic radical being optionally substituted;\n\n\n\n\n\n\n \n NRvRw étant tel que Rv représente un atome d'hydrogène ou un radical alkyle et Rw représente un atome d'hydrogène, un radical cycloalkyle ou un radical alkyle éventuellement substitué par un ou plusieurs radicaux identiques ou différents choisis parmi les radicaux hydroxyle, alcoxy, hétérocycloalkyle ; soit Rv et Rw forment avec l'atome d'azote auquel ils sont liés un radical cyclique renfermant de 3 à 10 chaînons et éventuellement un \n\n ou plusieurs autres hétéroatomes choisi(s) parmi O, S, NH et N-alkyle, ce radical cyclique étant éventuellement substitué; \nNRvRw being such that Rv represents a hydrogen atom or an alkyl radical and Rw represents a hydrogen atom, a cycloalkyl radical or an alkyl radical optionally substituted with one or more identical or different radicals chosen from hydroxyl, alkoxy and heterocycloalkyl radicals; ; either Rv and Rw form with the nitrogen atom to which they are bonded a cyclic radical containing from 3 to 10 members and optionally a  or a plurality of other heteroatoms selected from O, S, NH and N-alkyl, said cyclic radical being optionally substituted;\n\n\n\n\n\n\n \nles radicaux cycliques que peuvent former Rx et Ry ou Rv et Rw respectivement avec l'atome d'azote auquel ils sont liés, étant éventuellement substitués par un ou plusieurs radicaux identiques ou différents choisis parmi les atomes d'halogène, les radicaux alkyle, hydroxyle, oxo, alcoxy, NH2; NHaIk et N(alk)2 ; \nthe cyclic radicals that can be formed by Rx and Ry or Rv and Rw respectively with the nitrogen atom to which they are attached, being optionally substituted by one or more identical or different radicals chosen from halogen atoms, alkyl radicals, hydroxyl radicals, oxo, alkoxy, NH2; NHaIk and N (alk) 2;\n\n\n\n\n\n\n \n Rz représente les valeurs de Ry à l'exception de hydrogène ; \n Rz represents the values of Ry with the exception of hydrogen;\n\n\n\n\n\n\n \n Rx, Ry et Rz dans les radicaux -NRxCORy, -CORy et NRxCO\n2\nRz étant choisis parmi les significations indiquées ci-dessus pour Rx, Ry, et Rz ; \nRx, Ry and Rz in the radicals -NRxCORy, -CORy and NRxCO \n2\n Rz being selected from the meanings indicated above for Rx, Ry, and Rz;\n\n\n\n\n\n\n \nlesdits produits de formule (I) étant sous toutes les formes isomères possibles racémiques, énantiomères et diastéréoisomères, ainsi que les sels d'addition avec les acides minéraux et organiques ou avec les bases minérales et organiques desdits produits de formule (I). \nsaid products of formula (I) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as the addition salts with mineral and organic acids or with the inorganic and organic bases of said products of formula (I).\n\n\n\n\n\n\n \nDans les produits de formule (I) : \nIn the products of formula (I):\n\n\n\n\n\n\n \n - le terme radical alkyle (ou alk) désigne les radicaux, linéaires et le cas échéant ramifiés, méthyle, éthyle, propyle, isopropyle, butyle, isobutyle, sec- butyle, tert-butyle, pentyle, isopentyle, hexyle, isohexyle et également heptyle, octyle, nonyle et décyle ainsi que leurs isomères de position linéaires ou ramifiés : on préfère les radicaux alkyles renfermant de 1 à 6 atomes de carbone et plus particulièrement les radicaux alkyle renfermant de 1 à 4 atomes de carbone de la liste ci-dessus ; \n the term \"alkyl (or alk) radical\" denotes the radicals, linear and, if appropriate, branched, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl and also heptyl; , octyl, nonyl and decyl and their linear or branched positional isomers: alkyl radicals containing from 1 to 6 carbon atoms and more particularly alkyl radicals containing from 1 to 4 carbon atoms of the above list are preferred;\n\n\n\n\n\n\n \n - le terme radical alcoxy désigne les radicaux linéaires et le cas échéant ramifiés, méthoxy, éthoxy, propoxy, isopropoxy, butoxy linéaire, secondaire ou tertiaire, pentoxy ou hexoxy ainsi que leurs isomères de position linéaires ou ramifiés : on préfère les radicaux alkoxy renfermant de 1 à 4 atomes de carbone de la liste ci-dessus ; \n the term \"alkoxy radical\" denotes the linear and, if appropriate, branched, methoxy, ethoxy, propoxy, isopropoxy, linear butoxy, secondary or tertiary, pentoxy or hexoxy radicals, as well as their linear or branched positional isomers: the alkoxy radicals containing 1 to 4 carbon atoms from the above list;\n\n\n\n\n\n\n \n - le terme radical alkylthio désigne les radicaux linéaires et le cas échéant ramifiés, méthylthio, éthylthio, propylthio , isopropylthio, butylthio linéaire, \n\n secondaire ou tertiaire, pentylthio ou hexylthio ainsi que leurs isomères de position linéaires ou ramifiés : on préfère les radicaux alkylthio renfermant de 1 à 4 atomes de carbone de la liste ci-dessus ; \nthe term alkylthio radical denotes the linear and, if appropriate, branched radicals, methylthio, ethylthio, propylthio, isopropylthio, linear butylthio,  secondary or tertiary pentylthio or hexylthio and their linear or branched positional isomers: alkylthio radicals containing from 1 to 4 carbon atoms of the above list are preferred;\n\n\n\n\n\n\n \n - le terme atome d'halogène désigne les atomes de chlore, de brome, d'iode ou de fluor et de préférence l'atome de chlore, de brome ou de fluor. \n the term \"halogen atom\" denotes the chlorine, bromine, iodine or fluorine atoms and preferably the chlorine, bromine or fluorine atom.\n\n\n\n\n\n\n \n- le terme radical cycloalkyle désigne un radical carbocyclique saturé renfermant 3 à 10 atomes de carbone et désigne ainsi notamment les radicaux cyclopropylee, cyclobutyle, cyclopentyle et cyclohexyle et tout particulièrement les radicaux cyclopropyle, cyclopentyle et cyclohexyle ; - dans le radical -O-cycloalkyle, cycloalkyle est tel que défini ci-dessus ; \nthe term \"cycloalkyl radical\" denotes a saturated carbocyclic radical containing 3 to 10 carbon atoms and thus particularly denotes the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals, and especially the cyclopropyl, cyclopentyl and cyclohexyl radicals; in the -O-cycloalkyl radical, cycloalkyl is as defined above;\n\n\n\n\n\n\n \n- le terme radical hétérocycloalkyle désigne ainsi un radical carbocyclique monocyclique ou bicyclique, renfermant de 3 à 10 chaînons interrompu par un ou plusieurs hétéroatomes, identiques ou différents, choisis parmi les atomes d'oxygène, d'azote ou de soufre : on peut citer par exemple les radicaux morpholinyle, thiomorpholinyle, homomorpholinyle, aziridyle, azétidyle, pipérazinyle, pipéridyle, homopipérazinyle, pyrrolidinyle, imidazolidinyle, pyrazolidinyle, tétrahydrofuryle, tétrahydrothiényle, tétrahydropyranne, oxodihydropyridazinyle, ou encore oxétanyle tous ces radicaux étant éventuellement substitués ; on peut citer notamment les radicaux morpholinyle, thiomorpholinyle, homomorpholinyle, pipérazinyle, pipéridyle, homopipérazinyle ou encore pyrrolidinyle, \nthe term \"heterocycloalkyl radical\" thus denotes a monocyclic or bicyclic carbocyclic radical containing from 3 to 10 members interrupted by one or more heteroatoms, which may be identical or different, chosen from oxygen, nitrogen or sulfur atoms; for example morpholinyl, thiomorpholinyl, homomorpholinyl, aziridyl, azetidyl, piperazinyl, piperidyl, homopiperazinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuryl, tetrahydrothienyl, tetrahydropyran, oxodihydropyridazinyl or oxetanyl radicals being optionally substituted; mention may in particular be made of morpholinyl, thiomorpholinyl, homomorpholinyl, piperazinyl, piperidyl, homopiperazinyl or pyrrolidinyl radicals,\n\n\n\n\n\n\n \n- les termes aryle et hétéroaryle désignent des radicaux insaturés ou partiellement insaturés, respectivement carbocycliques et hétérocycliques, monocycliques ou bicycliques, renfermant au plus 12 chaînons, pouvant éventuellement contenir un chaînon -C(O), les radicaux hétérocycliques contenant un ou plusieurs hétéroatomes identiques ou différents choisis parmi O, N, ou S avec N, le cas échéant, éventuellement substitué ; \n\n - le terme radical aryle désigne ainsi des radicaux monocycliques ou bicycliques renfermant 6 à 12 chaînons tels que par exemple les radicaux phényle, naphtyle, biphényle, indényle, fluorényle et anthracényle, plus particulièrement les radicaux phényle et naphtyle et encore plus particulièrement le radical phényle. On peut noter qu'un radical carbocyclique contenant un chaînon -C(O) est par exemple le radical tétralone ; \nthe terms aryl and heteroaryl denote unsaturated or partially unsaturated, respectively carbocyclic and heterocyclic, monocyclic or bicyclic radicals, containing at most 12 members, which may optionally contain a -C (O) - chain, heterocyclic radicals containing one or more identical heteroatoms or different selected from O, N, or S with N, if appropriate, optionally substituted;  the term \"aryl radical\" thus denotes monocyclic or bicyclic radicals containing 6 to 12 members, such as, for example, the phenyl, naphthyl, biphenyl, indenyl, fluorenyl and anthracenyl radicals, more particularly the phenyl and naphthyl radicals and even more particularly the phenyl radical. It may be noted that a carbocyclic radical containing a -C (O) - linkage is, for example, the tetralone radical;\n\n\n\n\n\n\n \n- le terme radical hétéroaryle désigne ainsi des radicaux monocycliques ou bicycliques renfermant 5 à 12 chaînons : des radicaux hétéroaryles \nthe term \"heteroaryl radical\" thus denotes monocyclic or bicyclic radicals containing 5 to 12 ring members: heteroaryl radicals\n\n\n\n\n\n\n \nmonocycliques tels que par exemple les radicaux thiényle tel que 2-thiényle et 3-thiényle, furyle tel que 2-furyle, 3-furyle, pyrannyle, pyrrolyle, pyrrolinyle, pyrazolinyle, imidazolyle, pyrazolyle, pyridyle tel que 2-pyridyle, 3-pyhdyle et 4-pyhdyle, pyrazinyle, pyrimidinyle, pyridazinyle, oxazolyle, thiazolyle, isothiazolyle, diazolyle, thiadiazolyle, thiathazolyle, oxadiazolyle, isoxazolyle tel que 3- ou 4-isoxazolyle, furazannyle, tétrazolyle libre ou salifié, tous ces radicaux étant éventuellement substitués parmi lesquels plus \nmonocyclic such as, for example, thienyl radicals such as 2-thienyl and 3-thienyl, furyl such as 2-furyl, 3-furyl, pyranyl, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, pyridyl such as 2-pyridyl, 3- pyhdyl and 4-pyhdyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, isothiazolyl, diazolyl, thiadiazolyl, thiathazolyl, oxadiazolyl, isoxazolyl such as 3- or 4-isoxazolyl, furazannyl, free or salt tetrazolyl, all of these radicals being optionally substituted from which ones more\n\n\n\n\n\n\n \nparticulièrement les radicaux thiényle tel que 2-thiényle et 3-thiényle, furyle tel que 2-furyle, pyrrolyle, pyrrolinyle, pyrazolinyle, imidazolyle, pyrazolyle, oxazolyle, isoxazolyle, pyridyle, pyridazinyle, ces radicaux étant \nespecially thienyl radicals such as 2-thienyl and 3-thienyl, furyl such as 2-furyl, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyridyl, pyridazinyl, these radicals being\n\n\n\n\n\n\n \néventuellement substitués ; des radicaux hétéroaryles bicycliques tels que par exemple les radicaux benzothiényle tel que 3-benzothiényle, \noptionally substituted; bicyclic heteroaryl radicals such as, for example, benzothienyl radicals such as 3-benzothienyl,\n\n\n\n\n\n\n \nbenzothiazolyle, quinolyle, isoquinolyle, dihydroquinolyle, quinolone, tétralone, adamentyl, benzofuryle, isobenzofuryle, dihydrobenzofuranne, éthylènedioxyphényle, thianthrényle, benzopyrrolyle, benzimidazolyle, benzoxazolyle, thionaphtyle, indolyle, azaindolyle, indazolyle, purinyle, thiénopyrazolyle, tétrahydroindazolyle, tétrahydrocyclopentapyrazolyle, dihydrofuropyrazolyle, tétrahydropyrrolopyrazolyle, \nbenzothiazolyl, quinolyl, isoquinolyl, dihydroquinolyl, quinolone, tetralone, adamentyl, benzofuryl, isobenzofuryl, dihydrobenzofuran, ethylenedioxyphenyl, thianthrenyl, benzopyrrolyl, benzimidazolyl, benzoxazolyl, thionaphthyl, indolyl, azaindolyl, indazolyl, purinyl, thiénopyrazolyle, tétrahydroindazolyle, tétrahydrocyclopentapyrazolyle, dihydrofuropyrazolyle, tétrahydropyrrolopyrazolyle,\n\n\n\n\n\n\n \noxotétrahydropyrrolopyrazolyle, tétrahydropyranopyrazolyle, \noxotetrahydropyrrolopyrazolyl, tetrahydropyranopyrazolyl,\n\n\n\n\n\n\n \ntétrahydropyridinopyrazolyle ou oxodihydropyhdino-pyrazolyle, tous ces radicaux étant éventuellement substitués ; \n\n Comme exemples de radicaux hétéroaryles ou bicycliques, on peut citer plus particulièrement les radicaux pyrimidinyle, pyridyle, pyrrolyle, azaindolyle, indazolyle ou pyrazolyle, benzothiazolyle ou benzimidazolyle éventuellement substitués par un ou plusieurs substituants identiques ou différents comme indiqué ci-dessus. \ntetrahydropyridinopyrazolyl or oxodihydropyhdino-pyrazolyl, all of these radicals being optionally substituted;  As examples of heteroaryl or bicyclic radicals, there may be mentioned more particularly the pyrimidinyl, pyridyl, pyrrolyl, azaindolyl, indazolyl or pyrazolyl, benzothiazolyl or benzimidazolyl radicals optionally substituted by one or more identical or different substituents as indicated above.\n\n\n\n\n\n\n \n Le ou les radicaux carboxy des produits de formule (I) peuvent être salifiés ou estérifiés par les groupements divers connus de l'homme du métier parmi lesquels on peut citer, par exemple : \n The carboxyl group (s) of the products of formula (I) may be salified or esterified with the various groups known to those skilled in the art, among which may be mentioned, for example:\n\n\n\n\n\n\n \n - parmi les composés de salification, des bases minérales telles que, par exemple, un équivalent de sodium, de potassium, de lithium, de calcium, de magnésium ou d'ammonium ou des bases organiques telles que, par exemple, la méthylamine, la propylamine, la triméthylamine, la diéthylamine, la théthylamine, la N,N-diméthyléthanolamine, le tris (hydroxyméthyl) amino méthane, l'éthanolamine, la pyridine, la picoline, la dicyclohexylamine, la morpholine, la benzylamine, la procaïne, la lysine, l'arginine, l'histidine, la N-méthylglucamine, \n among the salification compounds, mineral bases such as, for example, one equivalent of sodium, potassium, lithium, calcium, magnesium or ammonium or organic bases such as, for example, methylamine, propylamine, trimethylamine, diethylamine, theylamine, N, N-dimethylethanolamine, tris (hydroxymethyl) amino methane, ethanolamine, pyridine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine , arginine, histidine, N-methylglucamine,\n\n\n\n\n\n\n \n - parmi les composés d'estérification, les radicaux alkyle pour former des groupes alcoxy carbonyle tel que, par exemple, méthoxycarbonyle, éthoxycarbonyle, tert-butoxycarbonyle ou benzyloxycarbonyle, ces radicaux alkyles pouvant être substitués par des radicaux choisis par exemple parmi les atomes d'halogène, les radicaux hydroxyle, alcoxy, acyle, acyloxy, alkylthio, amino ou aryle comme, par exemple, dans les groupements chlorométhyle, hydroxypropyle, méthoxyméthyle, propionyloxyméthyle, méthylthiométhyle, diméthylaminoéthyle, benzyle ou phénéthyle. \n from the esterification compounds, the alkyl radicals to form alkoxycarbonyl groups such as, for example, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl or benzyloxycarbonyl, these alkyl radicals being able to be substituted by radicals chosen for example from the atoms of halogen, hydroxyl, alkoxy, acyl, acyloxy, alkylthio, amino or aryl radicals such as, for example, in chloromethyl, hydroxypropyl, methoxymethyl, propionyloxymethyl, methylthiomethyl, dimethylaminoethyl, benzyl or phenethyl groups.\n\n\n\n\n\n\n \n Les sels d'addition avec les acides minéraux ou organiques des produits de formule (I) peuvent être, par exemple, les sels formés avec les acides chlorhydrique, bromhydrique, iodhydrique, nitrique, sulfurique, phosphorique, propionique, acétique, trifluoroacétique, formique, benzoïque, maléique, fumarique, succinique, tartrique, citrique, oxalique, glyoxylique, aspartique, ascorbique, les acides alcoylmonosulfoniques tels que par \n\n exemple l'acide méthanesulfonique, l'acide éthanesulfonique, l'acide propanesulfonique, les acides alcoyldisulfoniques tels que par exemple l'acide méthanedisulfonique, l'acide alpha, bêta-éthanedisulfonique, les acides arylmonosulfoniques tels que l'acide benzènesulfonique et les acides aryldisulfoniques. \nThe addition salts with the inorganic or organic acids of the products of formula (I) can be, for example, the salts formed with hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, propionic, acetic, trifluoroacetic, formic acids, benzoic, maleic, fumaric, succinic, tartaric, citric, oxalic, glyoxylic, aspartic, ascorbic, alkylmonosulfonic acids such as  methanesulfonic acid, ethanesulphonic acid, propanesulphonic acid, alkylsulphonic acids, for example methanedisulphonic acid, alpha, beta-ethanedisulphonic acid, arylmonosulphonic acids such as benzenesulphonic acid and aryldisulphonic acids; .\n\n\n\n\n\n\n \n On peut rappeler que la stéréoisomérie peut être définie dans son sens large comme l'isomérie de composés ayant mêmes formules \n It may be recalled that stereoisomerism can be defined in its broad sense as the isomerism of compounds having the same formulas\n\n\n\n\n\n\n \ndéveloppées, mais dont les différents groupes sont disposés différemment dans l'espace, tels que notamment dans des cyclohexanes monosubstitués dont le substituant peut être en position axiale ou équatohale, et les différentes conformations rotationnelles possibles des dérivés de l'éthane. Cependant, il existe un autre type de stéréoisomérie, dû aux arrangements spatiaux différents de substituants fixés, soit sur des doubles liaisons, soit sur des cycles, que l'on appelle souvent isomérie géométrique ou isomérie cis- trans. Le terme stéréoisomères est utilisé dans la présente demande dans son sens le plus large et concerne donc l'ensemble des composés indiqués ci-dessus. \ndeveloped, but whose different groups are arranged differently in space, such as in particular in monosubstituted cyclohexanes whose substituent may be in the axial or equatohal position, and the different possible rotational conformations of the ethane derivatives. However, there is another type of stereoisomerism, due to the different spatial arrangements of fixed substituents, either on double bonds or on rings, often called geometric isomerism or cis-trans isomerism. The term stereoisomers is used in the present application in its broadest sense and therefore relates to all of the compounds indicated above.\n\n\n\n\n\n\n \n La présente invention a pour objet les produits de formule (I) tels que définis ci-dessus dans laquelle : \n The subject of the present invention is the products of formula (I) as defined above in which:\n\n\n\n\n\n\n \nR1 représente un radical -L-phényle ou -L-hétéroaryle, tel que L représente : soit une simple liaison, \nR 1 represents a -L-phenyl or -L-heteroaryl radical, such that L represents: either a single bond,\n\n\n\n\n\n\n \nsoit un radical alkyle linéaire ou ramifié renfermant de 1 à 6 atomes de carbone et éventuellement substitué par un radical hydroxyle, \nis a linear or branched alkyl radical containing from 1 to 6 carbon atoms and optionally substituted with a hydroxyl radical,\n\n\n\n\n\n\n \nsoit un groupe CO ou -CO-AIk- ; \neither a CO or -CO-Alk- group;\n\n\n\n\n\n\n \nsoit un groupe L'-X où L' représente un radical alkyle linéaire ou ramifié renfermant de 1 à 6 atomes de carbone et X un atome d'oxygène ou de soufre ; \n\n les radicaux phényle et hétéroaryle étant éventuellement substitués par un ou plusieurs radicaux identiques ou différents choisis parmi les atomes d'halogène et les radicaux -NRxRy, alcoxy et alkyle ; \nor a group L'-X where L 'represents a linear or branched alkyl radical containing from 1 to 6 carbon atoms and X an oxygen or sulfur atom;  the phenyl and heteroaryl radicals being optionally substituted by one or more identical or different radicals chosen from halogen atoms and -NRxRy, alkoxy and alkyl radicals;\n\n\n\n\n\n\n \nces derniers radicaux alcoxy et alkyle étant eux-mêmes éventuellement substitués par un ou plusieurs radicaux choisis parmi les atomes d'halogène ;\nthese latter alkoxy and alkyl radicals themselves being optionally substituted by one or more radicals chosen from halogen atoms;\n\n\n\n\n\n\n \nR2 représente un radical alkyle ; \nR2 represents an alkyl radical;\n\n\n\n\n\n\n \n R3 représente un radical alkyle éventuellement substitué par un ou plusieurs atomes d'halogène ; \n R3 represents an alkyl radical optionally substituted with one or more halogen atoms;\n\n\n\n\n\n\n \n R4 représente un atome d'hydrogène ou un atome de fluor ; \n R4 represents a hydrogen atom or a fluorine atom;\n\n\n\n\n\n\n \nNRxRy étant tel que Rx représente un atome d'hydrogène ou un radical alkyle et Ry représente un atome d'hydrogène ou un radical alkyle; soit Rx et Ry forment avec l'atome d'azote auquel ils sont liés un radical morpholino ; tous les radicaux alkyle (alk) ou alcoxy ci-dessus étant linéaires ou ramifiés et renfermant de 1 à 6 atomes de carbone, \nNRxRy being such that Rx represents a hydrogen atom or an alkyl radical and Ry represents a hydrogen atom or an alkyl radical; either Rx and Ry form with the nitrogen atom to which they are bonded a morpholino radical; all the above alkyl (alk) or alkoxy radicals being linear or branched and containing from 1 to 6 carbon atoms,\n\n\n\n\n\n\n \nlesdits produits de formule (I) étant sous toutes les formes isomères possibles racémiques, énantiomères et diastéréoisomères, ainsi que les sels d'addition avec les acides minéraux et organiques ou avec les bases minérales et organiques desdits produits de formule (I). \nsaid products of formula (I) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as the addition salts with mineral and organic acids or with the inorganic and organic bases of said products of formula (I).\n\n\n\n\n\n\n \n Notamment, lorsque NRxRy ou NRvRw forme un cycle comme défini ci- dessus, un tel cycle aminé peut être choisi notamment parmi les radicaux pyrrolidinyle, pyrazolidinyle, pyrazolinyle, pipéridyle, azépinyle, morpholinyle, homomorpholinyle, pipérazinyle ou homopipérazinyle, ces radicaux étant eux- mêmes éventuellement substitués comme indiqué ci-dessus ou ci-après.\n In particular, when NRxRy or NRvRw forms a ring as defined above, such an amine ring may be chosen in particular from pyrrolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, azepinyl, morpholinyl, homomorpholinyl, piperazinyl or homopiperazinyl radicals, these radicals being themselves optionally substituted as indicated above or hereinafter.\n\n\n\n\n\n\n \nLe cycle NRxRy ou NRvRw peut plus particulièrement être choisi parmi les radicaux pyrrolidinyle, morpholinyle éventuellement substitué par un ou deux radicaux alkyle ou pipérazinyle éventuellement substitué sur le second atome d'azote par un radical alkyle, phényle, ou et CH2-phényle, eux-mêmes éventuellement substitués par un ou plusieurs radicaux identiques ou \n\n différents choisis parmi les atomes d'halogène et les radicaux alkyle, hydroxyle et alcoxy. \nThe NRxRy or NRvRw ring may more particularly be chosen from pyrrolidinyl, morpholinyl radicals optionally substituted by one or two alkyl or piperazinyl radicals optionally substituted on the second nitrogen atom by an alkyl, phenyl or CH 2 -phenyl radical, themselves same optionally substituted with one or more identical radicals or  various selected from halogen atoms and alkyl, hydroxyl and alkoxy radicals.\n\n\n\n\n\n\n \n La présente invention a tout particulièrement pour objet les produits de formule (I) tels que définis ci-dessus répondant aux formules suivantes : \n The subject of the present invention is particularly the products of formula (I) as defined above, corresponding to the following formulas:\n\n\n\n\n\n\n \n - (8S)-9-[2-(4-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one \n (8S) -9- [2- (4-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1, 2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n - 9-[2-(4-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one \n 9- [2- (4-Methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n (8S)-2-(morpholin-4-yl)-9-(2-phényléthyl)-8-(thfluorométhyl)-6,7,8,9- tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one \n (8S) -2- (Morpholin-4-yl) -9- (2-phenylethyl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyhmidin 4-one\n\n\n\n\n\n\n \n - (8S)-9-benzyl-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H- pyrimido[1 ,2-a]pyhmidin-4-one \n (8S) -9-Benzyl-2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(2S)-2-hydroxy-2-phényléthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one \n - (8S) -9 - [(2S) -2-hydroxy-2-phenylethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1, 2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(2R)-2-hydroxy-2-phényléthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one \n - (8S) -9 - [(2R) -2-Hydroxy-2-phenylethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1, 2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n (8S)-9-[(2S)-2-hydroxy-2-(4-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one \n (8S) -9 - [(2S) -2-hydroxy-2- (4-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro -4H-pyhmido [1, 2-a] pyhmidin-4-one\n\n\n\n\n\n\n \n (8S)-2-(morpholin-4-yl)-9-[(1 R)-1 -phényléthyl]-8-(thfluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one \n (8S) -2- (Morpholin-4-yl) -9 - [(1R) -1-phenylethyl] -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2] -a] pyrimidin-4-one\n\n\n\n\n\n\n \n (8S)-9-[1 -(4-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one \n (8S) -9- [1- (4-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2] -a] pyrimidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(1 S)-1 -(4-bromophényl)éthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one \n - (8S) -9 - [(1S) -1- (4-bromophenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H -pyhmido [1, 2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(1 R)-1 -(4-bromophényl)éthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one \n - (8S) -9 - [(1 R) -1- (4-bromophenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H -pyhmido [1, 2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n - (8S)-2-(morpholin-4-yl)-9-phényl-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H- pyrimido[1 ,2-a]pyhmidin-4-one \n\n (8S)-9-(4-fluorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n- (8S) -2- (Morpholin-4-yl) -9-phenyl-8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one  (8S) -9- (4-fluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin 4-one\n\n\n\n\n\n\n \n (8S)-9-(3-fluorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n (8S) -9- (3-fluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin 4-one\n\n\n\n\n\n\n \n - (8S)-9-(2-fluorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n - (8S) -9- (2-fluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidine -4-one\n\n\n\n\n\n\n \n - (8S)-9-[(1 R)-1 -(3-fluorophényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(1R) -1- (3-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H -pyrinnido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n (8S)-9-(4-fluorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyrimidin-4-one \n (8S) -9- (4-fluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyrimidine; 4-one\n\n\n\n\n\n\n \n (8S)-2-(morpholin-4-yl)-9-(phénylcarbonyl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n (8S) -2- (Morpholin-4-yl) -9- (phenylcarbonyl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinnido [1,2-a] pyridin-4- one\n\n\n\n\n\n\n \n (8S)-2-(morpholin-4-yl)-9-(pyridin-3-yl)-8-(tπfluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n (8S) -2- (Morpholin-4-yl) -9- (pyridin-3-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-2-(morpholin-4-yl)-9-(pyridin-4-yl)-8-(tπfluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -2- (Morpholin-4-yl) -9- (pyridin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] ] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-(4-méthylphényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrinnidin-4-one \n - (8S) -9- (4-methylphenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyridinidine -4-one\n\n\n\n\n\n\n \n - (8S)-9-(2-chlorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyrinnidin-4-one \n - (8S) -9- (2-chlorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyridinidine -4-one\n\n\n\n\n\n\n \n - (8S)-9-(3-fluorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9- (3-fluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyridin -4-one\n\n\n\n\n\n\n \n - (8S)-9-[2-(2-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n (8S) -9- [2- (2-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrrolidone [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n- (8S)-9-[2-(3-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n(8S) -9- [2- (3-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrrolidido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-(3-méthoxybenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n\n - (8S)-9-(4-méthoxyphényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n- (8S) -9- (3-Methoxybenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyπnnidine -4-one  - (8S) -9- (4-methoxyphenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidine -4-one\n\n\n\n\n\n\n \n -(8S)-9-[(2-fluorophényl)carbonyl]-2-(morpholin-4-yl)-8-(tπfluoronnéthyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(2-fluorophenyl) carbonyl] -2- (morpholin-4-yl) -8- (tfluoronethyl) -6,7,8,9-tetrahydro-4H-pyrrolidone [1,2-tetrahydro-4H-pyrrolidone] a] pyπnnidin-4-one\n\n\n\n\n\n\n \n- (8S)-9-(3,5-difluorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n- (8S) -9- (3,5-difluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] ] pyrimidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-(2,4-difluorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n (8S) -9- (2,4-Difluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] ] pyrimidin-4-one\n\n\n\n\n\n\n \n - (8S)-2-(morpholin-4-yl)-9-(2,3,4-trifluorobenzyl)-8-(tπfluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyrinnidin-4-one \n - (8S) -2- (Morpholin-4-yl) -9- (2,3,4-trifluorobenzyl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2] a] pyrinnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(5-chloro-1-benzothiophén-3-yl)méthyl]-2-(morpholin-4-yl)-8- (trifluoronnéthyl)-6,7,8,9-tétrahydro-4H-pyπnnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(5-Chloro-1-benzothiophen-3-yl) methyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro- 4H-pyπnnido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(1 R ou 1 S)-1 -(4-fluorophényl)éthyl]-2-(morpholin-4-yl)-8- (trifluoronnéthyl)-6,7,8,9-tétrahydro-4H-pyπnnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(1R or 1S) -1- (4-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9- tetrahydro-4H-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n- (8S)-9-[(1 R ou 1 S)-1-(4-fluorophényl)éthyl]-2-(morpholin-4-yl)-8-\n- (8S) -9 - [(1R or 1S) -1- (4-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8-\n\n\n\n\n\n\n \n(trifluoronnéthyl)-6,7,8,9-tétrahydro-4H-pyπnnido[1 ,2-a]pyπnnidin-4-one \n(trifluoronnethyl) -6,7,8,9-tetrahydro-4H-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n (8S)-9-(3-méthylphényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n (8S) -9- (3-methylphenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyrimidin 4-one\n\n\n\n\n\n\n \n - (8S)-9-(4-chlorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyrinnidin-4-one \n - (8S) -9- (4-chlorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyrrolidin -4-one\n\n\n\n\n\n\n \n - (8S)-2-(morpholin-4-yl)-8-(trifluorométhyl)-9-[4-(tπfluorométhyl)phényl]- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n (8S) -2- (Morpholin-4-yl) -8- (trifluoromethyl) -9- [4- (trifluoromethyl) phenyl] -6,7,8,9-tetrahydro-4H-pyrrolidone [1,2-tetrahydro-4H-pyrrolidone] a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(1 R ou 1 S)-1 -(2-fluorophényl)éthyl]-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n - (8S) -9 - [(1R or 1S) -1- (2-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9- tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n- (8S)-9-[(1 R ou 1 S)-1 -(2-fluorophényl)éthyl]-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n- (8S) -9 - [(1R or 1S) -1- (2-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9- tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n -(8S)-9-[2-(3-fluorophényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n\n -(8S)-9-benzyl-3-fluoro-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n(8S) -9- [2- (3-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1, 2-a] pyrimidin-4-one  - (8S) -9-benzyl-3-fluoro-2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidine -4-one\n\n\n\n\n\n\n \n -(8S)-9-(3,5-difluorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n (8S) -9- (3,5-difluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] ] pyrimidin-4-one\n\n\n\n\n\n\n \n-(8S)-9-[(2,6-difluorophényl)carbonyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n(8S) -9 - [(2,6-difluorophenyl) carbonyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1, 2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n -(8S)-9-[(2,4-difluorophényl)carbonyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(2,4-difluorophenyl) carbonyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimidido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -(8S)-2-(morpholin-4-yl)-9-(phénylacétyl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyrinnidin-4-one \n - (8S) -2- (Morpholin-4-yl) -9- (phenylacetyl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyrinidin-4 -one\n\n\n\n\n\n\n \n -(8S)-9-[2-(3-chlorophényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n (8S) -9- [2- (3-chlorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrrolidido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -9-((R)-2-Benzo[b]thiophen-2-yl-2-hydroxy-ethyl)-2-morpholin-4-yl-8-(S)- trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n (-) - ((R) -2-Benzo [b] thiophen-2-yl-2-hydroxy-ethyl) -2-morpholin-4-yl-8- (S) -trifluoroethyl-6,7,8,9 tetrahydro-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n-9-[(S)-2-Hydroxy-2-(3-hydroxy-phenyl)-ethyl]-2-morpholin-4-yl-8-(S)- trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n-9 - [(S) -2-Hydroxy-2- (3-hydroxy-phenyl) -ethyl] -2-morpholin-4-yl-8- (S) -trifluoroethyl-6,7,8,9-tetrahydro -pyπnnido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -2-Dimethylamino-N-{3-[(S)-1 -hydroxy-2-((S)-8-morpholin-4-yl-6-oxo-2- trifluoronnethyl-3,4-dihydro-2H,6H-pyπnnido[1 ,2-a]pyπnnidin-1-yl)-ethyl]- phenyl}-acetamide \n 2-Dimethylamino-N- {3 - [(S) -1-hydroxy-2 - ((S) -8-morpholin-4-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H, 6H-pyπnnido [1,2-a] pyrimidin-1-yl) -ethyl] -phenyl} -acetamide\n\n\n\n\n\n\n \n-9-[(S)-2-Hydroxy-2-(2-methoxy-phenyl)-ethyl]-2-morpholin-4-yl-8-(S)- trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n-9 - [(S) -2-Hydroxy-2- (2-methoxy-phenyl) -ethyl] -2-morpholin-4-yl-8- (S) -trifluoroethyl-6,7,8,9-tetrahydro -pyπnnido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -9-[(S)-2-(4-Fluoro-2-methoxy-phenyl)-2-hydroxy-ethyl]-2-nnorpholin-4-yl-8- (S)-trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n -9 - [(S) -2- (4-Fluoro-2-methoxy-phenyl) -2-hydroxy-ethyl] -2-nnorpholin-4-yl-8- (S) -trifluoroethyl-6,7,8 9-tetrahydro-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -9-[(S)-2-(4-Chloro-2-methoxy-phenyl)-2-hydroxy-ethyl]-2-morpholin-4-yl-8- (S)-trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n -9 - [(S) -2- (4-Chloro-2-methoxy-phenyl) -2-hydroxy-ethyl] -2-morpholin-4-yl-8- (S) -trifluoroethyl-6,7,8 9-tetrahydro-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -9-[(S)-2-(2-Chloro-4-methoxy-phenyl)-2-hydroxy-ethyl]-2-morpholin-4-yl-8- (S)-trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n\n - 9-(2-Hydroxy-3-phenyl-propyl)-2-morpholin-4-yl-8-(S)-trifluoromethyl-6,7,8,9- tetrahydro-pyrimido[1 ,2-a]pyrimidin-4-on \n-9 - [(S) -2- (2-Chloro-4-methoxy-phenyl) -2-hydroxy-ethyl] -2-morpholin-4-yl-8- (S) -trifluoroethyl-6,7,8 9-tetrahydro-pyπnnido [1,2-a] pyπnnidin-4-one  9- (2-Hydroxy-3-phenylpropyl) -2-morpholin-4-yl-8- (S) -trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyrimidine -4-one\n\n\n\n\n\n\n \n 9-[2-(4-Hydroxy-phenyl)-ethyl]-2-morpholin-4-yl-8-(S)-trifluoromethyl-6,7,8,9- tetrahydro-pyrimido[1 ,2-a]pyrinnidin-4-one \n 9- [2- (4-Hydroxy-phenyl) -ethyl] -2-morpholin-4-yl-8- (S) -trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyrinnidin-4-one\n\n\n\n\n\n\n \nainsi que les sels d'addition avec les acides minéraux et organiques ou avec les bases minérales et organiques desdits produits de formule (I). \nas well as the addition salts with the mineral and organic acids or with the inorganic and organic bases of said products of formula (I).\n\n\n\n\n\n\n \n La présente invention a encore pour objet tout procédé de préparation des produits de formule (I) tels que définis ci-dessus. \n The present invention also relates to any process for preparing the products of formula (I) as defined above.\n\n\n\n\n\n\n \n Les produits selon l'invention peuvent être préparés à partir de méthodes conventionnelles de chimie organique. \n The products according to the invention can be prepared from conventional methods of organic chemistry.\n\n\n\n\n\n\n \n Préparation de composés de formule (I) \n Preparation of compounds of formula (I)\n\n\n\n\n\n\n \n Les schémas généraux 1 et 2 ci-dessous sont illustratifs des méthodes utilisées pour la préparation des produits de formule (I). A ce titre, elles ne sauraient constituer une limitation de la portée de l'invention, en ce qui concerne les méthodes de préparation des composés revendiqués. \n General schemes 1 and 2 below are illustrative of the methods used for the preparation of the products of formula (I). As such, they can not constitute a limitation of the scope of the invention, as regards the methods of preparation of the claimed compounds.\n\n\n\n\n\n\n \n Les produits de formule (I) tels que définis ci-dessus selon la présente invention peuvent ainsi notamment être préparés selon les procédés décrits dans les schémas 1 et 2. \n The products of formula (I) as defined above according to the present invention can thus be prepared in particular according to the processes described in Schemes 1 and 2.\n\n\n\n\n\n\n \n La présente invention a ainsi également pour objet le procédé de préparation de produits de formule (I) selon le schéma 1 tel que défini ci- après. \n The present invention thus also relates to the process for preparing products of formula (I) according to Scheme 1 as defined below.\n\n\n\n\n\n\n \n La présente invention a ainsi également pour objet le procédé de préparation de produits de formule (I) selon le schéma général 2 tel que défini ci-après. \n The present invention thus also relates to the process for preparing products of formula (I) according to general scheme 2 as defined below.\n\n\n\n\n\n\n \n Schéma Général 1 : \n\n \n\n\n\nGeneral Diagram 1: \n \n\n\n\n\n\n\n \n C \n VS\n\n\n\n\n\n\n \n Morphohne \n\n\n\nMorphohne \n \n\n\n\n\n\n\n \n Dans le schéma général 1 : \n In the general diagram 1:\n\n\n\n\n\n\n \n Les guanidines A sont soit commerciales soit préparées selon les procédés décrits dans Lochead, A.W. et coll. (EP1460076 2002), Lochead, A.W. et coll. (EP1340761 2003), Lochead, A.W. et coll. (EP1454909 2004) et Lochead, A.W. et coll. (WO2005058908 2005). \n Guanidines A are either commercial or prepared according to the methods described in Lochead, A.W. et al. (EP1460076 2002), Lochead, A.W. et al. (EP1340761 2003), Lochead, A.W. et al. (EP1454909 2004) and Lochead, A.W. et al. (WO2005058908 2005).\n\n\n\n\n\n\n \n Les composés C peuvent être obtenus par condensation d'une guanidine A avec un malonate de dialkyle (de préférence de diéthyl) B, en présence d'une base telle que le méthylate de sodium, à une température comprise entre 60\n0\nC et 100\n0\nC, selon les conditions décrites par exemple par\nThe compounds C can be obtained by condensation of a guanidine A with a dialkyl (preferably diethyl) malonate B, in the presence of a base such as sodium methoxide, at a temperature of between 60 \n°\n C. and 100 \n°\n C. C, according to the conditions described for example by\n\n\n\n\n\n\n \nBadawey E.-S.A.M. et coll. (Eur J Med Chem, 1998, 33(5), 349-361. \nBadawey E.-S.A.M. et al. (Eur J Med Chem, 1998, 33 (5), 349-361.\n\n\n\n\n\n\n \n Les composés D peuvent être obtenus à partir d'un composé C par traitement avec un agent de chloration tel que l'oxychlorure de phosphore, en l'absence de solvant, à une température comprise entre 20°C et 120\n0\nC, ou en présence d'un solvant tel que le dichloroéthane, à une température \n\n comprise entre 20\n0\nC et la température d'ébullition du solvant, comme par exemple dans les conditions décrites par Yamashita, A. et coll.(Syn. Commun. (2004), 34(5), 795-803). \nThe compounds D can be obtained from a compound C by treatment with a chlorinating agent such as phosphorus oxychloride, in the absence of a solvent, at a temperature of between 20 ° C. and 120 \n°\n C., or presence of a solvent such as dichloroethane, at a temperature  between 20 \n°\n C. and the boiling point of the solvent, such as, for example, under the conditions described by Yamashita, A. et al (Syn.Commun (2004), 34 (5), 795-803).\n\n\n\n\n\n\n \n Les composés E peuvent être obtenus à partir d'un composé D par réaction avec la morpholine, en l'absence de solvant, à une température comprise entre 20\n0\nC et 120°C, ou en présence d'un solvant tel que l'acétonitrile, à une température comprise entre 20\n0\nC et la température de reflux du solvant, comme décrit par exemple par Aliabiev S. B. (Lett. Org. Chem. (2007), 4(4), 273-280. \nThe compounds E can be obtained from a compound D by reaction with morpholine, in the absence of a solvent, at a temperature of between 20 \n°\n C. and 120 ° C., or in the presence of a solvent such as acetonitrile, at a temperature of between 20 \n°\n C. and the reflux temperature of the solvent, as described, for example, by Aliabiev SB (Lett Org Chem (2007), 4 (4), 273-280).\n\n\n\n\n\n\n \n Les composés (l)-1 peuvent être obtenus par une réaction d'alkylation ou d'acylation, par addition d'un composé F (R1 -X avec R1 = L-Aryl ou Hétéroaryl tel que défini ci-dessus et X = Cl, Br, I ou OTf dans le cas d'une alkylation et X = Cl dans le cas d'une acylation) sur un mélange d'un composé E et d'une base telle que l'hydrure de sodium ou le carbonate de césium en excès, dans un solvant tel que le tétrahydrofuranne, la N, N- diméthylformamide ou l'acétonitrile, à une température comprise entre 0°C et 80°C, tel que décrit par exemple par Ting P.C. et coll. (J. Med. Chem. (1990), 33(10), 2697-2706) dans le cas de la réaction d'alkylation. \n The compounds (I) -1 can be obtained by an alkylation or acylation reaction, by addition of a compound F (R 1 -X with R 1 = L-Aryl or heteroaryl as defined above and X = Cl , Br, I or OTf in the case of an alkylation and X = Cl in the case of an acylation) on a mixture of a compound E and a base such as sodium hydride or cesium carbonate in excess, in a solvent such as tetrahydrofuran, N, N-dimethylformamide or acetonitrile, at a temperature between 0 ° C and 80 ° C, as described for example by Ting PC et al. (J. Med Chem (1990), 33 (10), 2697-2706) in the case of the alkylation reaction.\n\n\n\n\n\n\n \n En suivant la procédure décrite par E. P. Seest et al. dans Tet. Assymetry 17 (2006) 2154-2182, les composés F correspondants à des 1 - aryl-2-chloroéthanols ou 1-hétéroaryl-2-chloroéthanols chiraux on été synthétisés à partir des dérivés chlorocétone correspondants qui sont eux- mêmes issues de la chloration dans des conditions standards des dérivés acétyles disponibles commercialement. \n Following the procedure described by E. P. Seest et al. in Tet. Assymetry 17 (2006) 2154-2182, compounds F corresponding to chiral 1-aryl-2-chloroethanols or 1-heteroaryl-2-chloroethanols were synthesized from the corresponding chloroketone derivatives which are themselves derived from chlorination in standard conditions of acetyl derivatives commercially available.\n\n\n\n\n\n\n \n Les composés (l)-2 peuvent être obtenus par réaction d'un composé E avec un halogénure (X = Cl, Br ou I) ou triflate d'aryle ou d'hétéroaryle G, en présence d'un agent de couplage tel que l'iodure de cuivre, en présence ou non d'un ligand du cuivre tel le (+/-)-trans-1 ,2-diaminocyclohexane ou la 4,7- diméthoxy-1 ,10-phénantroline, en présence d'une base telle que le phosphate de potassium, dans un solvant tel que la N-méthyl pyrrolidone ou \n\n la N,N-diméthylfornnannide, sous irradiation micro-ondes, à une température comprise entre 100\n0\nC et 200\n0\nC, tel que décrit par exemple par Lianbo Z. et coll. (J. Org. Chem. (2009), 74(5), 2200-2202). \nThe compounds (I) -2 can be obtained by reaction of a compound E with a halide (X = Cl, Br or I) or aryl or heteroaryl triflate G, in the presence of a coupling agent such as copper iodide, in the presence or absence of a copper ligand such as (+/-) - trans-1, 2-diaminocyclohexane or 4,7-dimethoxy-1, 10-phenanthroline, in the presence of a such as potassium phosphate, in a solvent such as N-methyl pyrrolidone or  N, N-dimethylfornnannide, under microwave irradiation, at a temperature between 100 \n0\n C and 200 \n0\n C, as described for example by Lianbo Z. et al. (J. Org Chem (2009), 74 (5), 2200-2202).\n\n\n\n\n\n\n \n Alternativement, les composés (l)-1 peuvent être obtenus selon le schéma général 2. \n Alternatively, the compounds (I) -1 can be obtained according to the general scheme 2.\n\n\n\n\n\n\n \n Schéma Général 2 : \n General Diagram 2:\n\n\n\n\n\n\n \n R3\n R3\n\n\n\n\n\n\n \n^\n3\nR\n2\n ^ p n- \nR2\n \n^ \n3\n R \n2\n ^ p n- \nR2\n \n\n\n\n\n\n\n \nO\nV\nN NH Alkylat\ni\non f T\n~R2\n Moroholine ^\"V^\n1\n \n R4\n i ^\n1\n b \nR\na's-e\nX\n ou\nF\n «-V \nQ|\n Λ I J \nO N NH \nV\n is Alkylate \ni\n f T \n~ R2\n Moroholine ^ \"V ^ i ^ \n1\n \n1\n \nR4\n \nR\n b a's-e \nX\n or \nF\"\n -V \nQ | Λ\n IJ\n\n\n\n\n\n\n \n D R\n1\n-OH H \nj\n ° \nDR \n1\n -OH H \nj\n °\n\n\n\n\n\n\n \n DEAD/PPh\n3\n 0-1 \nDEAD / PPh \n3\n 0-1\n\n\n\n\n\n\n \nLes composés (l)-1 peuvent être obtenus à partir d'un composé J par réaction avec la morpholine, en l'absence de solvant à une température comprise entre 20°C et 120\n0\nC, ou en présence d'un solvant tel que l'acétonitrile, à une température comprise entre 20°C et la température de reflux du solvant, comme décrit par exemple par Aliabiev S. B. (Lett. Org. Chem. (2007), 4(4), 273-280. \nThe compounds (I) -1 can be obtained from a compound J by reaction with morpholine, in the absence of a solvent at a temperature of between 20 ° C. and 120 \n°\n C., or in the presence of a solvent such as acetonitrile, at a temperature between 20 ° C and the reflux temperature of the solvent, as described for example by Aliabiev SB (Lett Org Chem (2007), 4 (4), 273-280.\n\n\n\n\n\n\n \n Les composés J peuvent être obtenus par une réaction d'alkylation ou d'acylation, par addition d'un composé F (R1 -X avec R1 = L-Aryl ou\n The compounds J can be obtained by an alkylation or acylation reaction, by addition of a compound F (R 1 -X with R 1 = L-Aryl or\n\n\n\n\n\n\n \nHétéroaryl tel que défini ci-dessus et X = Cl, Br, I ou OTf dans le cas d'une alkylation et X = Cl dans le cas d'une acylation) sur un mélange d'un composé E et d'une base telle que l'hydrure de sodium ou le carbonate de césium en excès, dans un solvant tel que le tétrahydrofuranne, la N\n1\nN- diméthylformamide ou l'acétonitrile, à une température comprise entre 0°C et\nHeteroaryl as defined above and X = Cl, Br, I or OTf in the case of an alkylation and X = Cl in the case of an acylation) on a mixture of a compound E and a base such as that sodium hydride or cesium carbonate in excess, in a solvent such as tetrahydrofuran, N \n1\n N-dimethylformamide or acetonitrile, at a temperature between 0 ° C and\n\n\n\n\n\n\n \n80\n0\nC, tel que décrit par exemple par Ting P.C. et coll. (J. Med. Chem. (1990),\n80 \n0\n C, as described for example by Ting PC et al. (J. Med Chem (1990),\n\n\n\n\n\n\n \n33(10), 2697-2706) dans le cas de la réaction d'alkylation. \n33 (10), 2697-2706) in the case of the alkylation reaction.\n\n\n\n\n\n\n \n Alternativement, les composés J peuvent être obtenus par réaction de\n Alternatively, the compounds J can be obtained by reaction of\n\n\n\n\n\n\n \nMitsunobu entre un composé D et un alcool H, en présence d'azo- dicarboxylate de diéthyle et de triphénylphosphine (éventuellement supportée \n\n sur résine), dans un solvant tel que le tétrahydrofuranne, à une température comprise entre 0\n0\nC et 65°C, tel que décrit par exemple par Mitsunobu O. et coll. (Synthesis (1981 ), 1 -28). \nMitsunobu between a compound D and an alcohol H, in the presence of diethyl azodicarboxylate and triphenylphosphine (optionally supported  on a resin), in a solvent such as tetrahydrofuran, at a temperature of between 0 \n°\n C. and 65 ° C., as described for example by Mitsunobu O. et al. (Synthesis (1981), 1-28).\n\n\n\n\n\n\n \n Dans les cas où R2 est différent de R3 et si la synthèse n'est pas stéréosélective, les énantiomères ou les éventuels diastéréoisomères des intermédiaires de synthèse ou des composés (H) peuvent être séparés par chromatographie sur support chiral. \n In cases where R2 is different from R3 and if the synthesis is not stereoselective, the enantiomers or the possible diastereoisomers of the synthesis intermediates or the compounds (H) can be separated by chromatography on chiral support.\n\n\n\n\n\n\n \n Les exemples suivants de produits de formule (I) illustrent l'invention sans toutefois la limiter. \n The following examples of products of formula (I) illustrate the invention without however limiting it.\n\n\n\n\n\n\n \n Parmi les produits de départs de formule A ou B certains sont connus et peuvent être obtenus soit commercialement, soit selon les méthodes usuelles connues de l'homme du métier, par exemple à partir de produits commerciaux. \n Some of the starter products of formula A or B are known and can be obtained either commercially or according to the usual methods known to those skilled in the art, for example from commercial products.\n\n\n\n\n\n\n \n Il est entendu pour l'homme du métier que, pour la mise en œuvre des procédés selon l'invention décrits précédemment, il peut être nécessaire d'introduire des groupements protecteurs des fonctions amino, carboxyle et alcool afin d'éviter des réactions secondaires. \n It is understood by those skilled in the art that, for the implementation of the methods according to the invention described above, it may be necessary to introduce protective groups of the amino, carboxyl and alcohol functions in order to avoid side reactions.\n\n\n\n\n\n\n \n La liste suivante, non exhaustive, d'exemples de protection de fonctions réactives peut être citée : \n The following non-exhaustive list of examples of protection of reactive functions can be cited:\n\n\n\n\n\n\n \n - les groupements hydroxyle peuvent être protégés par exemple par les radicaux alkyle tels que tert-butyle, triméthylsilyle, tert-butyldiméthylsilyle, méthoxyméthyle, tétrahydropyrannyle, benzyle ou acétyle, \n the hydroxyl groups may be protected, for example, by alkyl radicals such as tert-butyl, trimethylsilyl, tert-butyldimethylsilyl, methoxymethyl, tetrahydropyranyl, benzyl or acetyl,\n\n\n\n\n\n\n \n - les groupements amino peuvent être protégés par exemple par les radicaux acétyles, trityle, benzyle, tert-butoxycarbonyle, BOC, benzyloxycarbonyle, phtalimido ou d'autres radicaux connus dans la chimie des peptides, \n the amino groups may be protected for example by the acetyl, trityl, benzyl, tert-butoxycarbonyl, BOC, benzyloxycarbonyl, phthalimido or other radicals known in peptide chemistry,\n\n\n\n\n\n\n \n Les fonctions acide peuvent être protégées par exemple sous forme d'esters formés avec les esters facilement clivables tels que les esters \n\n benzyliques ou ter butyliques ou des esters connus dans la chimie des peptides. \nThe acid functions can be protected for example in the form of esters formed with easily cleavable esters such as esters  benzyl or tert-butyl or esters known in peptide chemistry.\n\n\n\n\n\n\n \n On trouvera une liste de différents groupements protecteurs utilisables dans les manuels connus de l'homme du métier et par exemple dans le brevet BF 2 499 995. \n A list of different protective groups used in the manuals known to those skilled in the art and for example in the patent FR 2,499,995.\n\n\n\n\n\n\n \n On peut noter que l'on peut soumettre, si désiré et si nécessaire, des produits intermédiaires ou des produits de formule (I) ainsi obtenus par les procédés indiqués ci-dessus, pour obtenir d'autres intermédiaires ou d'autres produits de formule (I), à une ou plusieurs réactions de transformations connues de l'homme du métier telles que par exemple : \n It may be noted that intermediate products or products of formula (I) thus obtained can be subjected, if desired and if necessary, to the processes described above, to obtain other intermediates or other products of formula (I), to one or more reactions of transformations known to those skilled in the art such as, for example:\n\n\n\n\n\n\n \n a) une réaction d'estérification de fonction acide, \n a) an esterification reaction of an acid function,\n\n\n\n\n\n\n \n b) une réaction de saponification de fonction ester en fonction acide, c) une réaction de réduction de la fonction carboxy libre ou estérifié en fonction alcool, \n b) a saponification reaction of ester function in acid function, c) a reduction reaction of the carboxy function free or esterified alcohol function,\n\n\n\n\n\n\n \n d) une réaction de transformation de fonction alcoxy en fonction hydroxyle, ou encore de fonction hydroxyle en fonction alcoxy, \n d) an alkoxy function conversion reaction in the hydroxyl function, or an alkoxy-functional hydroxyl function,\n\n\n\n\n\n\n \n e) une réaction d'élimination des groupements protecteurs que peuvent porter les fonctions réactives protégées, \n e) an elimination reaction of the protective groups that the protected reactive functions can carry,\n\n\n\n\n\n\n \n f) une réaction de salification par un acide minéral ou organique ou par une base pour obtenir le sel correspondant, \n f) a salification reaction with a mineral or organic acid or with a base to obtain the corresponding salt,\n\n\n\n\n\n\n \n g) une réaction de dédoublement des formes racémiques en produits dédoublés, \n (g) a split reaction of the racemic forms into split products,\n\n\n\n\n\n\n \n lesdits produits de formule (I) ainsi obtenus étant sous toutes les formes isomères possibles racémiques, énantiomères et diastéréoisomères. Les réactions a) à g) peuvent être réalisées dans les conditions usuelles connues de l'homme du métier telles que, par exemple, celles indiquées ci- après. \n\n a) Les produits décrits ci-dessus peuvent, si désiré, faire l'objet, sur les éventuelles fonctions carboxy, de réactions d'estérification qui peuvent être réalisées selon les méthodes usuelles connues de l'homme du métier. b) Les éventuelles transformations de fonctions ester en fonction acide des produits décrits ci-dessus peuvent être, si désiré, réalisées dans les conditions usuelles connues de l'homme du métier notamment par hydrolyse acide ou alcaline par exemple par de la soude ou de la potasse en milieu alcoolique tel que, par exemple, dans du méthanol ou encore par de l'acide chlorhydrique ou sulfurique. La réaction de saponification peut être réalisée selon les méthodes usuelles connues de l'homme du métier, telles que par exemple dans un solvant tel que le méthanol ou l'éthanol, le dioxanne ou le diméthoxyéthane, en présence de soude ou de potasse. c) Les éventuelles fonctions carboxy libre ou estérifié des produits décrits ci- dessus peuvent être, si désiré, réduites en fonction alcool par les méthodes connues de l'homme de métier : les éventuelles fonctions carboxy estérifié peuvent être, si désiré, réduites en fonction alcool par les méthodes connues de l'homme du métier et notamment par de l'hydrure de lithium et d'aluminium dans un solvant tel que par exemple le tétrahydrofuranne ou encore le dioxanne ou l'éther éthylique. \nsaid products of formula (I) thus obtained being in all possible isomeric forms racemic, enantiomers and diastereoisomers. The reactions a) to g) can be carried out under the usual conditions known to those skilled in the art such as, for example, those indicated below.  a) The products described above may, if desired, be subjected, on the possible carboxy functions, to esterification reactions which may be carried out according to the usual methods known to those skilled in the art. b) The possible acid-functional ester function transformations of the products described above may, if desired, be carried out under the usual conditions known to those skilled in the art, in particular by acid or alkaline hydrolysis, for example with sodium hydroxide or sodium hydroxide. potash in an alcoholic medium such as, for example, in methanol or in hydrochloric or sulfuric acid. The saponification reaction may be carried out according to the usual methods known to those skilled in the art, such as, for example, in a solvent such as methanol or ethanol, dioxane or dimethoxyethane, in the presence of sodium hydroxide or potassium hydroxide. c) The optional free or esterified carboxy functions of the products described above may, if desired, be reduced in alcohol function by the methods known to those skilled in the art: the optional esterified carboxy functions may, if desired, be reduced depending on the alcohol by the methods known to those skilled in the art and in particular by lithium hydride and aluminum in a solvent such as for example tetrahydrofuran or dioxane or ethyl ether.\n\n\n\n\n\n\n \nLes éventuelles fonctions carboxy libre des produits décrits ci-dessus peuvent être, si désiré, réduites en fonction alcool notamment par de l'hydrure de bore. d) Les éventuelles fonctions alcoxy telles que notamment méthoxy des produits décrits ci-dessus peuvent être, si désiré, transformées en fonction hydroxyle dans les conditions usuelles connues de l'homme du métier par exemple par du tribromure de bore dans un solvant tel que par exemple le chlorure de méthylène, par du bromhydrate ou chlorhydrate de pyridine ou \n\n encore par de l'acide bromhydrique ou chlorhydrique dans de l'eau ou de l'acide trifluoro acétique au reflux. e) L'élimination de groupements protecteurs tels que par exemple ceux indiqués ci-dessus peut être effectuée dans les conditions usuelles connues de l'homme de métier notamment par une hydrolyse acide effectuée avec un acide tel que l'acide chlorhydrique, benzène sulfonique ou para-toluène sulfonique, formique ou trifluoroacétique ou encore par une hydrogénation catalytique. \nThe optional free carboxy functions of the products described above may, if desired, be reduced in particular alcohol function by boron hydride. d) The optional alkoxy functions, such as in particular methoxy, of the products described above may, if desired, be converted into hydroxyl function under the usual conditions known to those skilled in the art, for example by boron tribromide in a solvent such as methylene chloride, for example by hydrobromide or pyridine hydrochloride or  again with hydrobromic or hydrochloric acid in water or refluxing trifluoroacetic acid. e) The elimination of protective groups such as for example those indicated above can be carried out under the usual conditions known to those skilled in the art, in particular by acid hydrolysis carried out with an acid such as hydrochloric acid, benzene sulfonic acid or para-toluenesulphonic, formic or trifluoroacetic or catalytic hydrogenation.\n\n\n\n\n\n\n \nLe groupement phtalimido peut être éliminé par l'hydrazine. f) Les produits décrits ci-dessus peuvent, si désiré, faire l'objet de réactions de salification par exemple par un acide minéral ou organique ou par une base minérale ou organique selon les méthodes usuelles connues de l'homme du métier : une telle réaction de salification peut être réalisée par exemple en présence d'acide chlorhydrique par exemple ou encore d'acide tartrique, citrique ou méthane sulfonique, dans un alcool tel que par exemple l'éthanol ou le méthanol . g) Les éventuelles formes optiquement actives des produits décrits ci-dessus peuvent être préparées par dédoublement des racémiques selon les méthodes usuelles connues de l'homme du métier. \nThe phthalimido group can be removed by hydrazine. f) The products described above may, if desired, be the subject of salification reactions, for example by a mineral or organic acid or by a mineral or organic base according to the usual methods known to those skilled in the art: such salification reaction can be carried out for example in the presence of hydrochloric acid for example or tartaric acid, citric or methanesulfonic acid in an alcohol such as for example ethanol or methanol. g) The optional optically active forms of the products described above may be prepared by resolution of the racemates according to the usual methods known to those skilled in the art.\n\n\n\n\n\n\n \nLes produits de formule (I) tels que définis ci-dessus ainsi que leurs sels d'addition avec les acides présentent d'intéressantes propriétés \nThe products of formula (I) as defined above and their addition salts with acids have interesting properties.\n\n\n\n\n\n\n \npharmacologiques notamment en raison de leurs propriétés inhibitrices de kinases ainsi qu'il est indiqué ci-dessus. \nparticularly because of their kinase inhibitory properties as indicated above.\n\n\n\n\n\n\n \n Les produits de la présente invention sont notamment utiles pour la thérapie de tumeurs. \n The products of the present invention are especially useful for tumor therapy.\n\n\n\n\n\n\n \n Les produits de l'invention peuvent également ainsi augmenter les effets thérapeutiques d'agents anti-tumoraux couramment utilisés. \n\n Ces propriétés justifient leur application en thérapeutique et l'invention a particulièrement pour objet à titre de médicaments, les produits de formule (I) telle que définie ci-dessus, lesdits produits de formule (I) étant sous toutes les formes isomères possibles racémiques, énantiomères et diastéréoisomères, ainsi que les sels d'addition avec les acides minéraux et organiques ou avec les bases minérales et organiques pharmaceutiquement acceptables desdits produits de formule (I). \nThe products of the invention can also increase the therapeutic effects of commonly used anti-tumor agents.  These properties justify their application in therapeutics and the subject of the invention is particularly useful as medicaments, the products of formula (I) as defined above, said products of formula (I) being in all possible racemic isomeric forms, enantiomers and diastereoisomers, as well as addition salts with inorganic and organic acids or with the pharmaceutically acceptable inorganic and organic bases of said products of formula (I).\n\n\n\n\n\n\n \n L'invention a tout particulièrement pour objet, à titre de médicaments, les produits répondant aux formules suivantes : \n The subject of the invention is, as medicaments, the products corresponding to the following formulas:\n\n\n\n\n\n\n \n - (8S)-9-[2-(4-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one \n (8S) -9- [2- (4-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1, 2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n - 9-[2-(4-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one \n 9- [2- (4-Methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n (8S)-2-(morpholin-4-yl)-9-(2-phényléthyl)-8-(thfluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one \n (8S) -2- (Morpholin-4-yl) -9- (2-phenylethyl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin 4-one\n\n\n\n\n\n\n \n - (8S)-9-benzyl-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H- pyrimido[1 ,2-a]pyhmidin-4-one \n (8S) -9-Benzyl-2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(2S)-2-hydroxy-2-phényléthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one \n - (8S) -9 - [(2S) -2-hydroxy-2-phenylethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1, 2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(2R)-2-hydroxy-2-phényléthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one \n - (8S) -9 - [(2R) -2-Hydroxy-2-phenylethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1, 2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n (8S)-9-[(2S)-2-hydroxy-2-(4-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one \n (8S) -9 - [(2S) -2-hydroxy-2- (4-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro -4H-pyhmido [1, 2-a] pyhmidin-4-one\n\n\n\n\n\n\n \n (8S)-2-(morpholin-4-yl)-9-[(1 R)-1 -phényléthyl]-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one \n (8S) -2- (Morpholin-4-yl) -9 - [(1R) -1-phenylethyl] -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2] -a] pyrimidin-4-one\n\n\n\n\n\n\n \n (8S)-9-[1 -(4-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one \n\n - (8S)-9-[(1 S)-1 -(4-bromophényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n(8S) -9- [1- (4-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2] -a] pyrimidin-4-one  - (8S) -9 - [(1S) -1- (4-bromophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H -pyrinnido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(1 R)-1 -(4-bromophényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(1R) -1- (4-bromophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H -pyrinnido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n- (8S)-2-(morpholin-4-yl)-9-phényl-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H- pyrimido[1 ,2-a]pyrinnidin-4-one \n- (8S) -2- (Morpholin-4-yl) -9-phenyl-8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrinidin-4-one\n\n\n\n\n\n\n \n (8S)-9-(4-fluorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n (8S) -9- (4-fluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin 4-one\n\n\n\n\n\n\n \n (8S)-9-(3-fluorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyrinnidin-4-one \n (8S) -9- (3-fluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyridinoline. 4-one\n\n\n\n\n\n\n \n (8S)-9-(2-fluorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n (8S) -9- (2-fluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin 4-one\n\n\n\n\n\n\n \n - (8S)-9-[(1 R)-1 -(3-fluorophényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(1R) -1- (3-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H -pyrinnido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-(4-fluorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n - (8S) -9- (4-fluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidine -4-one\n\n\n\n\n\n\n \n (8S)-2-(morpholin-4-yl)-9-(phénylcarbonyl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n (8S) -2- (Morpholin-4-yl) -9- (phenylcarbonyl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinnido [1,2-a] pyridin-4- one\n\n\n\n\n\n\n \n (8S)-2-(morpholin-4-yl)-9-(pyridin-3-yl)-8-(tπfluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyrinnidin-4-one \n (8S) -2- (Morpholin-4-yl) -9- (pyridin-3-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinnido [1,2-a] pyrinnidin-4-one\n\n\n\n\n\n\n \n (8S)-2-(morpholin-4-yl)-9-(pyridin-4-yl)-8-(tπfluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n (8S) -2- (Morpholin-4-yl) -9- (pyridin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-(4-méthylphényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9- (4-methylphenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyridin -4-one\n\n\n\n\n\n\n \n- (8S)-9-(2-chlorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n- (8S) -9- (2-chlorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidine -4-one\n\n\n\n\n\n\n \n - (8S)-9-(3-fluorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n\n - (8S)-9-[2-(2-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n- (8S) -9- (3-fluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyridin -4-one  (8S) -9- [2- (2-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrrolidone [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[2-(3-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n (8S) -9- [2- (3-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrrolidido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n- (8S)-9-(3-méthoxybenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n(8S) -9- (3-Methoxybenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidine -4-one\n\n\n\n\n\n\n \n - (8S)-9-(4-méthoxyphényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n - (8S) -9- (4-methoxyphenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidine -4-one\n\n\n\n\n\n\n \n - (8S)-9-[(2-fluorophényl)carbonyl]-2-(morpholin-4-yl)-8-(tπfluoronnéthyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyrimidin-4-one \n - (8S) -9 - [(2-fluorophenyl) carbonyl] -2- (morpholin-4-yl) -8- (tfluoronethyl) -6,7,8,9-tetrahydro-4H-pyrrolidone [1,2-tetrahydro-4H-pyrrolidone] a] pyrimidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-(3,5-difluorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n - (8S) -9- (3,5-difluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] ] pyrimidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-(2,4-difluorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n (8S) -9- (2,4-Difluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] ] pyrimidin-4-one\n\n\n\n\n\n\n \n- (8S)-2-(morpholin-4-yl)-9-(2,3,4-trifluorobenzyl)-8-(tπfluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n- (8S) -2- (Morpholin-4-yl) -9- (2,3,4-trifluorobenzyl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2] -a] pyrimidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(5-chloro-1-benzothiophén-3-yl)méthyl]-2-(morpholin-4-yl)-8- (trifluoronnéthyl)-6,7,8,9-tétrahydro-4H-pyπnnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(5-Chloro-1-benzothiophen-3-yl) methyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro- 4H-pyπnnido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(1 R ou 1 S)-1 -(4-fluorophényl)éthyl]-2-(morpholin-4-yl)-8- (trifluoronnéthyl)-6,7,8,9-tétrahydro-4H-pyπnnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(1R or 1S) -1- (4-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9- tetrahydro-4H-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n (8S)-9-[(1 R ou 1 S)-1-(4-fluorophényl)éthyl]-2-(morpholin-4-yl)-8- (trifluoronnéthyl)-6,7,8,9-tétrahydro-4H-pyπnnido[1 ,2-a]pyπnnidin-4-one \n (8S) -9 - [(1R or 1S) -1- (4-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro 4H-pyπnnido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n (8S)-9-(3-méthylphényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n (8S) -9- (3-methylphenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyrimidin 4-one\n\n\n\n\n\n\n \n- (8S)-9-(4-chlorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n- (8S) -9- (4-chlorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinido [1,2-a] pyridin -4-one\n\n\n\n\n\n\n \n - (8S)-2-(morpholin-4-yl)-8-(trifluorométhyl)-9-[4-(trifluorométhyl)phényl]- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n\n - (8S)-9-[(1 R ou 1 S)-1 -(2-fluorophényl)éthyl]-2-(morpholin-4-yl)-8- (tπfluorométhyl)-6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n- (8S) -2- (Morpholin-4-yl) -8- (trifluoromethyl) -9- [4- (trifluoromethyl) phenyl] -6,7,8,9-tetrahydro-4H-pyrrolidone [1,2-tetrahydro-4H-pyrrolidone] a] pyπnnidin-4-one  - (8S) -9 - [(1R or 1S) -1- (2-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (t-fluoromethyl) -6,7,8,9- tetrahydro-4H-pyrinnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - (8S)-9-[(1 R ou 1 S)-1 -(2-fluorophényl)éthyl]-2-(morpholin-4-yl)-8- (trifluoronnéthyl)-6,7,8,9-tétrahydro-4H-pyπnnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(1R or 1S) -1- (2-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9- tetrahydro-4H-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n-(8S)-9-[2-(3-fluorophényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n(8S) -9- [2- (3-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1, 2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n -(8S)-9-benzyl-3-fluoro-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \n - (8S) -9-benzyl-3-fluoro-2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidine -4-one\n\n\n\n\n\n\n \n -(8S)-9-(3,5-difluorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyrimidin-4-one \n - (8S) -9- (3,5-difluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinnido [1,2-a] ] pyrimidin-4-one\n\n\n\n\n\n\n \n -(8S)-9-[(2,6-difluorophényl)carbonyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(2,6-difluorophenyl) carbonyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrrolidido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -(8S)-9-[(2,4-difluorophényl)carbonyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n - (8S) -9 - [(2,4-difluorophenyl) carbonyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimidido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n-(8S)-2-(morpholin-4-yl)-9-(phénylacétyl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n- (8S) -2- (Morpholin-4-yl) -9- (phenylacetyl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrinnido [1,2-a] pyridin-4 -one\n\n\n\n\n\n\n \n -(8S)-9-[2-(3-chlorophényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrinnido[1 ,2-a]pyπnnidin-4-one \n (8S) -9- [2- (3-chlorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrrolidido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -9-((R)-2-Benzo[b]thiophen-2-yl-2-hydroxy-ethyl)-2-morpholin-4-yl-8-(S)- trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n (-) - ((R) -2-Benzo [b] thiophen-2-yl-2-hydroxy-ethyl) -2-morpholin-4-yl-8- (S) -trifluoroethyl-6,7,8,9 tetrahydro-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -9-[(S)-2-Hydroxy-2-(3-hydroxy-phenyl)-ethyl]-2-morpholin-4-yl-8-(S)- trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n -9 - [(S) -2-Hydroxy-2- (3-hydroxy-phenyl) -ethyl] -2-morpholin-4-yl-8- (S) -trifluoroethyl-6,7,8,9-tetrahydro -pyπnnido [1, 2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -2-Dimethylamino-N-{3-[(S)-1 -hydroxy-2-((S)-8-morpholin-4-yl-6-oxo-2- trifluoronnethyl-3,4-dihydro-2H,6H-pyπnnido[1 ,2-a]pyπnnidin-1-yl)-ethyl]- phenyl}-acetamide \n 2-Dimethylamino-N- {3 - [(S) -1-hydroxy-2 - ((S) -8-morpholin-4-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H, 6H-pyπnnido [1,2-a] pyrimidin-1-yl) -ethyl] -phenyl} -acetamide\n\n\n\n\n\n\n \n -9-[(S)-2-Hydroxy-2-(2-methoxy-phenyl)-ethyl]-2-morpholin-4-yl-8-(S)- trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n\n -9-[(S)-2-(4-Fluoro-2-methoxy-phenyl)-2-hydroxy-ethyl]-2-nnorpholin-4-yl-8- (S)-trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n-9 - [(S) -2-Hydroxy-2- (2-methoxy-phenyl) -ethyl] -2-morpholin-4-yl-8- (S) -trifluoroethyl-6,7,8,9-tetrahydro -pyπnnido [1, 2-a] pyπnnidin-4-one  -9 - [(S) -2- (4-Fluoro-2-methoxy-phenyl) -2-hydroxy-ethyl] -2-nnorpholin-4-yl-8- (S) -trifluoroethyl-6,7,8 9-tetrahydro-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n -9-[(S)-2-(4-Chloro-2-methoxy-phenyl)-2-hydroxy-ethyl]-2-morpholin-4-yl-8- (S)-trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n -9 - [(S) -2- (4-Chloro-2-methoxy-phenyl) -2-hydroxy-ethyl] -2-morpholin-4-yl-8- (S) -trifluoroethyl-6,7,8 9-tetrahydro-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n-9-[(S)-2-(2-Chloro-4-methoxy-phenyl)-2-hydroxy-ethyl]-2-morpholin-4-yl-8- (S)-trifluoronnethyl-6,7,8,9-tetrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one \n-9 - [(S) -2- (2-Chloro-4-methoxy-phenyl) -2-hydroxy-ethyl] -2-morpholin-4-yl-8- (S) -trifluoroethyl-6,7,8 9-tetrahydro-pyπnnido [1,2-a] pyπnnidin-4-one\n\n\n\n\n\n\n \n - 9-(2-Hydroxy-3-phenyl-propyl)-2-morpholin-4-yl-8-(S)-trifluoromethyl-6,7,8,9- tetrahydro-pyrimido[1 ,2-a]pyrinnidin-4-on \n 9- (2-Hydroxy-3-phenylpropyl) -2-morpholin-4-yl-8- (S) -trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyridinidine -4-one\n\n\n\n\n\n\n \n 9-[2-(4-Hydroxy-phenyl)-ethyl]-2-morpholin-4-yl-8-(S)-trifluoromethyl-6,7,8,9- tetrahydro-pyrinnido[1 ,2-a]pyrinnidin-4-one \n 9- [2- (4-Hydroxy-phenyl) -ethyl] -2-morpholin-4-yl-8- (S) -trifluoromethyl-6,7,8,9-tetrahydro-pyrinido [1,2-a] pyrinnidin-4-one\n\n\n\n\n\n\n \nainsi que les sels d'addition avec les acides minéraux et organiques ou avec les bases minérales et organiques pharmaceutiquement acceptables desdits produits de formule (I). \nas well as the addition salts with inorganic and organic acids or with the pharmaceutically acceptable inorganic and organic bases of said products of formula (I).\n\n\n\n\n\n\n \n L'invention concerne aussi des compositions pharmaceutiques contenant à titre de principe actif l'un au moins des produits de formule (I) tels que définis ci-dessus ou un sel pharmaceutiquement acceptable de ce produit ou un prodrug de ce produit et, le cas échéant, un support pharmaceutiquement acceptable. \n The invention also relates to pharmaceutical compositions containing as active principle at least one of the products of formula (I) as defined above or a pharmaceutically acceptable salt of this product or a prodrug of this product and, where appropriate, optionally, a pharmaceutically acceptable carrier.\n\n\n\n\n\n\n \n L'invention s'étend ainsi aux compositions pharmaceutiques contenant à titre de principe actif l'un au moins des médicaments tels que définis ci- dessus. \n The invention thus extends to pharmaceutical compositions containing, as active principle, at least one of the medicaments as defined above.\n\n\n\n\n\n\n \n De telles compositions pharmaceutiques de la présente invention peuvent également, le cas échéant, renfermer des principes actifs d'autres médicaments antimitotiques tels que notamment ceux à base de taxol, cis- platine, les agents intercalants de l'ADN et autres. \n Such pharmaceutical compositions of the present invention may also, if appropriate, contain active principles of other antimitotic drugs such as in particular those based on taxol, cisplatin, intercalating agents of DNA and others.\n\n\n\n\n\n\n \n Ces compositions pharmaceutiques peuvent être administrées par voie buccale, par voie parentérale ou par voie locale en application topique sur la peau et les muqueuses ou par injection par voie intraveineuse ou intramusculaire. \n\n Ces compositions peuvent être solides ou liquides et se présenter sous toutes les formes pharmaceutiques couramment utilisées en médecine humaine comme, par exemple, les comprimés simples ou dragéifiés, les pilules, les tablettes, les gélules, les gouttes, les granulés, les préparations injectables, les pommades, les crèmes ou les gels ; elles sont préparées selon les méthodes usuelles. Le principe actif peut y être incorporé à des excipients habituellement employés dans ces compositions pharmaceutiques, tels que le talc, la gomme arabique, le lactose, l'amidon, le stéarate de magnésium, le beurre de cacao, les véhicules aqueux ou non, les corps gras d'origine animale ou végétale, les dérivés paraffiniques, les glycols, les divers agents mouillants, dispersants ou émulsifiants, les conservateurs. \nThese pharmaceutical compositions may be administered orally, parenterally or locally by topical application to the skin and mucous membranes or by intravenous or intramuscular injection.  These compositions may be solid or liquid and may be in any of the pharmaceutical forms commonly used in human medicine, such as, for example, simple or coated tablets, pills, lozenges, capsules, drops, granules, injectable preparations, ointments, creams or gels; they are prepared according to the usual methods. The active ingredient can be incorporated into the excipients usually employed in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous vehicles or not, the fatty substances of animal or vegetable origin, paraffinic derivatives, glycols, various wetting agents, dispersing or emulsifying agents, preservatives.\n\n\n\n\n\n\n \n La posologie usuelle, variable selon le produit utilisé, le sujet traité et l'affection en cause, peut être, par exemple, de 0,05 à 5 g par jour chez l'adulte, ou de préférence de 0,1 à 2 g par jour. \n The usual dosage, variable according to the product used, the subject treated and the condition in question, may be, for example, from 0.05 to 5 g per day in the adult, or preferably from 0.1 to 2 g. per day.\n\n\n\n\n\n\n \n La présente invention a également pour objet l'utilisation de produits de formule (I) tels que définis ci-dessus pour la préparation d'un médicament destiné au traitement ou à la prévention d'une maladie caractérisée par le dérèglement de l'activité d'une protéine ou d'une lipide kinase. \n The subject of the present invention is also the use of products of formula (I) as defined above for the preparation of a medicament intended for the treatment or prevention of a disease characterized by the dysregulation of a protein or a lipid kinase.\n\n\n\n\n\n\n \n Un tel médicament peut notamment être destiné au traitement ou à la prévention d'une maladie chez un mammifère. \n Such a medicament may especially be intended for the treatment or prevention of a disease in a mammal.\n\n\n\n\n\n\n \n La présente invention a notamment pour objet l'utilisation d'un produit de formule (I) tel que défini ci-dessus pour la préparation d'un médicament destiné à la prévention ou au traitement de différentes maladies comme les maladies cardiovasculaires incluant notamment la thrombose. \n The subject of the present invention is in particular the use of a product of formula (I) as defined above for the preparation of a medicament intended for the prevention or treatment of various diseases such as cardiovascular diseases, in particular including thrombosis. .\n\n\n\n\n\n\n \n La présente invention a notamment pour objet l'utilisation d'un produit de formule (I) tel que défini ci-dessus pour la préparation d'un médicament destiné à la prévention ou au traitement de maladies liées à une prolifération non contrôlée. \n The present invention particularly relates to the use of a product of formula (I) as defined above for the preparation of a medicament for the prevention or treatment of diseases related to uncontrolled proliferation.\n\n\n\n\n\n\n \n La présente invention a ainsi tout particulièrement pour objet l'utilisation d'un produit de formule (I) tel que défini ci-dessus pour la \n\n préparation d'un médicament destiné au traitement ou à la prévention de maladies en oncologie et notamment destiné au traitement de cancers. \nThe subject of the present invention is therefore particularly the use of a product of formula (I) as defined above for the  preparation of a medicament for the treatment or prevention of diseases in oncology and in particular for the treatment of cancers.\n\n\n\n\n\n\n \n Parmi ces cancers, on s'intéresse au traitement de tumeurs solides ou liquides, au traitement de cancers résistant à des agents cytotoxiques \n Among these cancers, one is interested in the treatment of solid or liquid tumors, in the treatment of cancers resistant to cytotoxic agents.\n\n\n\n\n\n\n \n Les produits de la présente invention cités peuvent notamment être utilisés pour le traitement de tumeurs primaires et/ou de métastases en particulier dans les cancers gastriques, hépatiques, rénaux, ovariens, du colon, de la prostate, de l'endomètre, du poumon (NSCLC et SCLC), les glioblastomes, les cancers de la thyroïde, de la vessie, du sein, dans le mélanome, dans les tumeurs hématopoietiques lymphoïdes ou myéloïdes, dans les sarcomes, dans les cancers du cerveau, du larynx, du système lymphatique, cancers des os et du pancréas, dans les hamartomes. Sont concernées notamment les maladies présentant des anomalies génétiques aboutissant à l'activation de la voie PI3K/AKT/mTOR et/ou à l'activation de la voie MAP Kinase. \n The products of the present invention cited can in particular be used for the treatment of primary tumors and / or metastases, in particular in gastric, hepatic, renal, ovarian, colon, prostate, endometrial, lung cancers ( NSCLC and SCLC), glioblastomas, thyroid, bladder, breast, melanoma, lymphoid or myeloid hematopoietic tumors, sarcomas, brain, larynx, lymphatic system cancers, cancers of the bones and pancreas, in hamartomas. These include diseases with genetic abnormalities resulting in activation of the PI3K / AKT / mTOR pathway and / or activation of the MAP Kinase pathway.\n\n\n\n\n\n\n \n La présente invention a aussi pour objet l'utilisation des produits de formule (I) telle que définie ci-dessus pour la préparation de médicaments destinés à la chimiothérapie de cancers. \n The subject of the present invention is also the use of the products of formula (I) as defined above for the preparation of medicaments intended for the chemotherapy of cancers.\n\n\n\n\n\n\n \n La présente invention a ainsi pour objet les produits de formule (I) tels que définis ci-dessus pour leur utilisation pour le traitement de cancers. \n The subject of the present invention is thus the products of formula (I) as defined above for their use for the treatment of cancers.\n\n\n\n\n\n\n \n La présente invention a pour objet les produits de formule (I) tels que définis ci-dessus pour leur utilisation pour le traitement de tumeurs solides ou liquides. \n The subject of the present invention is the products of formula (I) as defined above for their use for the treatment of solid or liquid tumors.\n\n\n\n\n\n\n \n La présente invention a donc pour objet les produits de formule (I) tels que définis ci-dessus pour leur utilisation pour le traitement de cancers résistant à des agents cytotoxiques. \n The subject of the present invention is therefore the products of formula (I) as defined above for their use for the treatment of cancers resistant to cytotoxic agents.\n\n\n\n\n\n\n \n La présente invention a donc pour objet les produits de formule (I) tels que définis ci-dessus pour leur utilisation pour le traitement de tumeurs primaires et/ou de métastases en particulier dans les cancers gastriques, hépatiques, \n\n rénaux, ovariens, du colon, de la prostate, de l'endomètre, du poumon (NSCLC et SCLC), les glioblastomes, les cancers de la thyroïde, de la vessie, du sein, dans le mélanome, dans les tumeurs hématopoietiques lymphoïdes ou myéloïdes, dans les sarcomes, dans les cancers du cerveau, du larynx, du système lymphatique, cancers des os et du pancréas, dans les hamartomes.\nThe subject of the present invention is therefore the products of formula (I) as defined above for their use for the treatment of primary tumors and / or metastases, in particular in gastric, hepatic,  renal, ovarian, colon, prostate, endometrial, lung (NSCLC and SCLC), glioblastomas, thyroid, bladder, breast, melanoma, lymphoid, or myeloid, in sarcomas, in cancers of the brain, larynx, lymphatic system, cancers of the bones and pancreas, in hamartomas.\n\n\n\n\n\n\n \nLa présente invention a donc pour objet les produits de formule (I) tels que définis ci-dessus pour leur utilisation pour la chimiothérapie de cancers. \nThe subject of the present invention is therefore the products of formula (I) as defined above for their use for the chemotherapy of cancers.\n\n\n\n\n\n\n \n La présente invention a donc pour objet les produits de formule (I) tels que définis ci-dessus pour leur utilisation pour la chimiothérapie de cancers, seuls ou en en association. \n The subject of the present invention is therefore the products of formula (I) as defined above for their use for the chemotherapy of cancers, alone or in combination.\n\n\n\n\n\n\n \n De tels médicaments destinés à la chimiothérapie de cancers peuvent être utilisés seuls ou en en association. \n Such drugs for cancer chemotherapy may be used alone or in combination.\n\n\n\n\n\n\n \n Les produits de la présente demande peuvent notamment être administrés seuls ou en association avec de la chimiothérapie ou de la radiothérapie ou encore en association par exemple avec d'autres agents thérapeutiques.\n The products of the present application can in particular be administered alone or in combination with chemotherapy or radiotherapy or in combination with other therapeutic agents, for example.\n\n\n\n\n\n\n \nDe tels agents thérapeutiques peuvent être des agents anti-tumoraux couramment utilisés. \nSuch therapeutic agents may be commonly used anti-tumor agents.\n\n\n\n\n\n\n \n On peut notamment attendre un bénéfice thérapeutique en administrant les produits de la présente demande en combinaisons avec des thérapies ciblées variées. Ces thérapies ciblées sont notamment les suivantes : i) les thérapies inhibant la voie de signalisation MAP Kinase comme les thérapies inhibant RAS, RAF, MEK ou ERK ; ii) les thérapies ciblées inhibant les kinases ou pseudo-kinases de la voie PI3K/AKT/mTOR comme EGFR, HER2, HER3, ALK, MET, PI3K, PDK1 , AKT, mTOR et S6K. \n In particular, one can expect a therapeutic benefit by administering the products of the present application in combination with various targeted therapies. These targeted therapies include: i) therapies inhibiting the MAP Kinase signaling pathway such as RAS, RAF, MEK or ERK inhibitory therapies; ii) targeted therapies inhibiting PI3K / AKT / mTOR kinases or pseudokinesis such as EGFR, HER2, HER3, ALK, MET, PI3K, PDK1, AKT, mTOR and S6K.\n\n\n\n\n\n\n \nLa présente invention a notamment pour objet l'utilisation d'un produit de formule (I) tel que défini ci-dessus pour la préparation d'un médicament destiné à la prévention ou au traitement de maladies lysosomales telles que la glycogénose de type II ou maladie de Pompe. De tels médicaments \n\n destinés au traitement des maladies lysosomales peuvent être utilisés seuls ou en en association par exemple avec d'autres agents thérapeutiques. \nThe present invention particularly relates to the use of a product of formula (I) as defined above for the preparation of a medicament for the prevention or treatment of lysosomal diseases such as glycogenosis type II or Pompe disease. Such drugs  for the treatment of lysosomal diseases may be used alone or in combination with other therapeutic agents, for example.\n\n\n\n\n\n\n \n La présente invention a ainsi pour objet les produits de formule (I) tels que définis ci-dessus pour la prévention ou le traitement de maladies lysosomales telles que la glycogénose de type II ou maladie de Pompe. \n The subject of the present invention is thus the products of formula (I) as defined above for the prevention or the treatment of lysosomal diseases such as glycogenosis type II or Pompe disease.\n\n\n\n\n\n\n \n La présente invention a ainsi pour objet l'utilisation des produits de formule (I) tel que défini ci-dessus pour la préparation d'un médicament destiné à la prévention ou au traitement de maladies lysosomales telles que la glycogénose de type II ou maladie de Pompe. \n The subject of the present invention is therefore the use of the products of formula (I) as defined above for the preparation of a medicament intended for the prevention or treatment of lysosomal diseases such as glycogenosis type II or Pump.\n\n\n\n\n\n\n \nLa présente invention a ainsi pour objet l'utilisation telle que définie ci-dessus dans laquelle lesdits produits de formule (I) sont seuls ou en association.\nThe present invention thus relates to the use as defined above wherein said products of formula (I) are alone or in combination.\n\n\n\n\n\n\n \nLa présente invention a également pour objet l'utilisation d'un produit de formule (I) tel que défini ci-dessus pour la préparation d'un médicament destiné au traitement de maladies parasitaires telles que la malaria, la maladie du sommeil, la maladie de Chagas, les leishmanioses. De tels médicaments destinés au traitement des infections parasitaires peuvent être utilisés seuls ou en en association par exemple avec d'autres agents thérapeutiques. \nThe present invention also relates to the use of a product of formula (I) as defined above for the preparation of a medicament for the treatment of parasitic diseases such as malaria, sleeping sickness, the disease of Chagas, leishmaniasis. Such medicaments for the treatment of parasitic infections may be used alone or in combination with, for example, other therapeutic agents.\n\n\n\n\n\n\n \n La présente invention a ainsi pour objet les produits de formule (I) tels que définis ci-dessus pour le traitement de maladies parasitaires telles que la malaria, la maladie du sommeil, la maladie de Chagas, les leishmanioses.\n The present invention thus relates to the products of formula (I) as defined above for the treatment of parasitic diseases such as malaria, sleeping sickness, Chagas disease, leishmaniasis.\n\n\n\n\n\n\n \nLa présente invention a ainsi pour objet l'utilisation des produits de formule (I) tels que définis ci-dessus pour la préparation d'un médicament pour le traitement de maladies parasitaires telles que la malaria, la maladie du sommeil, la maladie de Chagas, les leishmanioses. \nThe subject of the present invention is therefore the use of the products of formula (I) as defined above for the preparation of a medicament for the treatment of parasitic diseases such as malaria, sleeping sickness, Chagas' disease. , leishmaniasis.\n\n\n\n\n\n\n \n La présente invention a encore pour objet à titre de produits industriels nouveaux, les intermédiaires de synthèse de formules C, D, E et J tels que définis ci-dessus et rappelés ci-après : \n\n \n\n\n\nThe subject of the present invention is also, as new industrial products, the synthetic intermediates of formulas C, D, E and J as defined above and recalled hereinafter: \n \n\n\n\n\n\n\n \n D E J \n D E J\n\n\n\n\n\n\n \ndans lesquels R1 , R2, R3 et R4 ont les définitions indiquées à l'une quelconque des revendications 1 à 2. \nwherein R1, R2, R3 and R4 are as defined in any one of claims 1 to 2.\n\n\n\n\n\n\n \n Les exemples suivants qui sont des produits de formule (I) illustrent l'invention sans toutefois la limiter. \n The following examples which are products of formula (I) illustrate the invention without however limiting it.\n\n\n\n\n\n\n \n Partie expérimentale \n Experimental part\n\n\n\n\n\n\n \n La nomenclature des composés de cette présente invention a été effectuée avec le logiciel ACDLABS version 10.0. \n The nomenclature of the compounds of this invention was carried out with ACDLABS software version 10.0.\n\n\n\n\n\n\n \n Le four à microondes utilisé est un appareil Biotage, Initiator™ 2.0, 400W max, 2450 MHz. \n The microwave oven used is a Biotage device, Initiator ™ 2.0, 400W max, 2450 MHz.\n\n\n\n\n\n\n \n Les spectres de RMN \n1\nH à 400 MHz et \n1\nH à 500 MHz ont été effectués sur spectromètre BRUKER AVANCE DRX-400 ou BRUKER AVANCE DPX-\nThe \n1\n H NMR spectra at 400 MHz and \n1\n H at 500 MHz were carried out on the BRUKER AVANCE DRX-400 or BRUKER AVANCE DPX spectrometer.\n\n\n\n\n\n\n \n500 avec les déplacements chimiques (δ en ppm) dans le solvant diméthylsulfoxide-dβ (DMSO-dβ) référencé à 2,5 ppm à la température de 303K. \n500 with the chemical shifts (δ in ppm) in the solvent dimethylsulfoxide-dβ (DMSO-dβ) referenced at 2.5 ppm at the temperature of 303K.\n\n\n\n\n\n\n \n Les spectres de masse (SM) ont été obtenus soit par la méthode A, soit par la méthode B, soit par la méthode E : \n Mass spectra (MS) were obtained by method A, method B or method E:\n\n\n\n\n\n\n \n Méthode A : \n Method A:\n\n\n\n\n\n\n \n Appareil WATERS UPLC-SQD ; Ionisation : électrospray en mode positif et/ou négatif (ES+/-) ; Conditions chromatographiques : Colonne :\n WATERS UPLC-SQD apparatus; Ionisation: electrospray in positive and / or negative mode (ES +/-); Chromatographic conditions: Column:\n\n\n\n\n\n\n \nACQUITY BEH C18 1 ,7 μm - 2,1 x 50 mm ; Solvants : A : H\n2\nO (0,1 % acide formique) B : CH\n3\nCN (0,1 % acide formique) ; Température de colonne : 50\nACQUITY BEH C18 1, 7 μm - 2.1 x 50 mm; Solvents: A: H \n2\n O (0.1% formic acid) B: CH \n3\n CN (0.1% formic acid); Column temperature: 50\n\n\n\n\n\n\n \n \n0\nC ; Débit : 1 ml/min ; Gradient (2 min) : de 5 à 50 % de B en 0,8 min ; 1 ,2 min : 100 % de B ; 1 ,85 min : 100 % de B ; 1 ,95 : 5 % de B ; Temps de rétention = Tr (min). \n\n Méthode B : \n \n0\n C; Flow rate: 1 ml / min; Gradient (2 min): 5 to 50% B in 0.8 min; 1, 2 min: 100% B; 1.85 min: 100% B; 1, 95: 5% B; Retention time = Tr (min).  Method B:\n\n\n\n\n\n\n \n Appareil WATERS ZQ ; Ionisation : électrospray en mode positif et/ou négatif (ES+/-) ; Conditions chromatographiques : Colonne : XBridge Ci\n8\n2,5 μm - 3 x 50 mm ; Solvants : A : H\n2\nO (0,1 % acide formique) B : CH\n3\nCN (0,1 % acide formique) ; Température de colonne : 70\n0\nC ; Débit : 0,9 ml/min ; Gradient (7 min) : de 5 à 100 % de B en 5,3 min ; 5,5 min : 100 % de B ; 6,3 min : 5 % de B ; Temps de rétention = Tr (min). \nWATERS ZQ apparatus; Ionisation: electrospray in positive and / or negative mode (ES +/-); Chromatographic conditions: Column: XBridge Ci \n8\n 2.5 μm - 3 x 50 mm; Solvents: A: H \n2\n O (0.1% formic acid) B: CH \n3\n CN (0.1% formic acid); Column temperature: 70 \n0\n C; Flow rate: 0.9 ml / min; Gradient (7 min): from 5 to 100% of B in 5.3 min; 5.5 min: 100% B; 6.3 min: 5% B; Retention time = Tr (min).\n\n\n\n\n\n\n \n Méthode E : \n Method E:\n\n\n\n\n\n\n \n Appareil WATERS UPLC-SQD ; Ionisation : électrospray en mode positif et/ou négatif (ES+/-) ; Conditions chromatographiques : Colonne :\n WATERS UPLC-SQD apparatus; Ionisation: electrospray in positive and / or negative mode (ES +/-); Chromatographic conditions: Column:\n\n\n\n\n\n\n \nAscentis express C18 2,7 μm - 2,1 x 50 mm ; Solvants : A : H2O (0,02 % acide trifluorocétique) B : CH3CN (0,014 % acide trifluoroacétique) ;\nAscentis express C18 2.7 μm - 2.1 x 50 mm; Solvents: A: H2O (0.02% trifluorocetic acid) B: CH3CN (0.014% trifluoroacetic acid);\n\n\n\n\n\n\n \nTempérature de colonne : 55 \n0\nC ; Débit : 1 ml/min ; Gradient: TOmin 2%B,\nColumn temperature: 55 \n°\n C .; Flow rate: 1 ml / min; Gradient: TOmin 2% B,\n\n\n\n\n\n\n \nT1 min 98%B, T1.3min 98%B, T1.33min 2%B, T1.5 min autre injection; Temps de rétention = Tr (min). \nT1 min 98% B, T1.3min 98% B, T1.33min 2% B, T1.5 min other injection; Retention time = Tr (min).\n\n\n\n\n\n\n \n Les pouvoirs rotatoires (PR) ont été mesurés sur un polahmètre modèle 341 de chez Perkin Elmer. Longueur d'onde: raie α du sodium (589 nanomètres). \n The rotational powers (PR) were measured on a Polahmeter Model 341 from Perkin Elmer. Wavelength: sodium α line (589 nanometers).\n\n\n\n\n\n\n \n Purifications par HPLC / MS préparative : \n Purifications by preparative HPLC / MS:\n\n\n\n\n\n\n \n - Méthode C \n - Method C\n\n\n\n\n\n\n \n Colonne de phase inverse C18 SunFire (Waters) 30 x 100, 5 μ. \n SunFire C18 reverse phase column (Waters) 30 x 100, 5 μ.\n\n\n\n\n\n\n \n Gradient d'acétonitrile (+ 0.07 % TFA) dans l'eau (+ 0.07 % TFA)\n Gradient of acetonitrile (+ 0.07% TFA) in water (+ 0.07% TFA)\n\n\n\n\n\n\n \nTO : 20 % acétonitrile (+ 0.07 % TFA) \nTO: 20% acetonitrile (+ 0.07% TFA)\n\n\n\n\n\n\n \n T1 : 20 % acétonitrile (+ 0.07 % TFA) \n T1: 20% acetonitrile (+ 0.07% TFA)\n\n\n\n\n\n\n \n T11.5 : 95 % acétonitrile (+ 0.07 % TFA) \n T11.5: 95% acetonitrile (+ 0.07% TFA)\n\n\n\n\n\n\n \n T15 : 95 % acétonitrile (+ 0.07 % TFA) \n T15: 95% acetonitrile (+ 0.07% TFA)\n\n\n\n\n\n\n \n T15.5: 20% acétonitrile (+ 0.07 % TFA) \n T15.5: 20% acetonitrile (+ 0.07% TFA)\n\n\n\n\n\n\n \n Débit : 30 ml/min \n Flow rate: 30 ml / min\n\n\n\n\n\n\n \n Masse : 130_800 UMA= ; ESP+, ESP \n\n • Méthode D \nMass: 130-800 AMU =; ESP +, ESP  • Method D\n\n\n\n\n\n\n \n Colonne de phase inverse C18 SunFire (Waters) 30 x 100, 5 μ. \n SunFire C18 reverse phase column (Waters) 30 x 100, 5 μ.\n\n\n\n\n\n\n \n Gradient d'acétonitrile (+ 0.07 % TFA) dans l'eau (+ 0.07 % TFA)\n Gradient of acetonitrile (+ 0.07% TFA) in water (+ 0.07% TFA)\n\n\n\n\n\n\n \nTO : 40 % acétonitrile (+ 0.07 % TFA) \nTO: 40% acetonitrile (+ 0.07% TFA)\n\n\n\n\n\n\n \n T1 : 40 % acétonitrile (+ 0.07 % TFA) \n T1: 40% acetonitrile (+ 0.07% TFA)\n\n\n\n\n\n\n \n T11 : 95 % acétonitrile (+ 0.07 % TFA) \n T11: 95% acetonitrile (+ 0.07% TFA)\n\n\n\n\n\n\n \n T14.5 : 95 % acétonitrile (+ 0.07 % TFA) \n T14.5: 95% acetonitrile (+ 0.07% TFA)\n\n\n\n\n\n\n \n T15 : 10% acétonitrile (+ 0.07 % TFA) \n T15: 10% acetonitrile (+ 0.07% TFA)\n\n\n\n\n\n\n \n Débit : 30 ml/min \n Flow rate: 30 ml / min\n\n\n\n\n\n\n \n Masse : 130_800 UMA= ; ESP+, ESP \n Mass: 130-800 AMU =; ESP +, ESP\n\n\n\n\n\n\n \nExemple 1 : (S)-9-[2-(4-méthoxy-phényl)-éthyl]-2-morpholin-4-yl-8- trifluorométhyl-6,7,8,9-tétrahydro-pyrimido[1,2-a]pyrimidin-4-one \nExample 1: (S) -9- [2- (4-methoxy-phenyl) -ethyl] -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2 -a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nStade f : (S)-9-[2-(4-méthoxy-phényl)-éthyl]-2-morpholin-4-yl-8- trifluorométhyl-6,7,8,9-tétrahydro-pyrimido[1,2-a]pyrimidin-4-one \nStep f: (S) -9- [2- (4-methoxy-phenyl) -ethyl] -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2 -a] pyrimidin-4-one\n\n\n\n\n\n\n \n A une solution de 150 mg de la (S)-2-morpholin-4-yl-8-trifluorométhyl- 6,7,8,9-tétrahydro-pyrimido[1 ,2-a]pyhmidin-4-one dans 5 ml_ de diméthylformamide anhydre sont ajoutés, à température ambiante et sous atmosphère d'argon, 0.5 g de carbonate de césium, 0.23 g du bromure de 4- méthoxyphénéthyle et 5 mg du chlorure de benzyl théthylammonium (BTEAC). Le mélange réactionnel est chauffé à 80\n0\nC pendant 18 heures. \n\n Après refroidissement, on ajoute au mélange obtenu 10 ml_ d'eau froide et 50 ml_ d'acétate d'éthyle. La phase organique est séparée puis séchée sur sulfate de magnésium, filtrée et concentrée sous pression réduite. Le résidu obtenu est purifié par chromatographie sur silice (gradient de 0% à 20% de l'éluant CH2CI2/MeOH/NH4OH 28% 38/17/2 dans le dichlorométhane), pour donner 160 mg de la (S)-9-[2-(4-méthoxy-phényl)- éthyl]-2-morpholin-4-yl-8-thfluorométhyl-6,7,8,9-tétrahydro-pyhmido[1 ,2- a]pyπmidin-4-one dont les caractéristiques sont les suivantes : \nTo a solution of 150 mg of (S) -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyhmidin-4-one in 5 ml. anhydrous dimethylformamide are added, at room temperature and under argon, 0.5 g of cesium carbonate, 0.23 g of 4-methoxyphenethyl bromide and 5 mg of benzylthylammonium chloride (BTEAC). The reaction mixture is heated at 80 \n°\n C. for 18 hours.  After cooling, 10 ml of cold water and 50 ml of ethyl acetate are added to the resulting mixture. The organic phase is separated and then dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue obtained is purified by chromatography on silica (gradient from 0% to 20% of the eluent CH 2 Cl 2 / MeOH / NH 4 OH 28% 38/17/2 in dichloromethane), to give 160 mg of the (S) -9- [2- (4-Methoxy-phenyl) -ethyl] -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyrimidin-4-one with the characteristics are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H: \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 1 ,82 à 2,05 (m, 1 H) ; 2,25 à 2,39 (m, 1 H) ; 2,73 à 2,83 (m, 1 H ); 2,88 à 2,99 (m, 1 H) ; 3,10 à 3,21 (m, 1 H) ; 3,34 à 3,41 (m, 1 H) ; 3,43 à 3,46 (m, 4 H) ; 3,65 (m, 4 H) ; 3,72 (s, 3 H) ; 4,03 à 4,23 (m, 2 H) ; 4,47 à 4,60 (m, 1 H) ; 4,99 (s, 1 H) ; 6,87 (d, J=8,6 Hz, 2 H) ; 7,12 (d, J=8,6 Hz, 2 H) \n 1.82 to 2.05 (m, 1H); 2.25 to 2.39 (m, 1H); 2.73 to 2.83 (m, 1H); 2.88 to 2.99 (m, 1H); 3.10 to 3.21 (m, 1H); 3.34 to 3.41 (m, 1H); 3.43 to 3.46 (m, 4H); 3.65 (m, 4H); 3.72 (s, 3H); 4.03 to 4.23 (m, 2H); 4.47 at 4.60 (m, 1H); 4.99 (s, 1H); 6.87 (d, J = 8.6 Hz, 2H); 7.12 (d, J = 8.6 Hz, 2H)\n\n\n\n\n\n\n \n Spectrométhe de Masse : Méthode A \n Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,93 \n Retention time Tr (min) = 0.93\n\n\n\n\n\n\n \n [M+H]+ : m/z 439 \n [M + H] +: m / z 439\n\n\n\n\n\n\n \n Pouvoir rotatoire : PR= +91 ; C=2.426mg/0.5ML MeOH. \n Rotatory power: PR = +91; C = 2.426mg / 0.5ML MeOH.\n\n\n\n\n\n\n \nStade e : (S)-2-morpholin-4-yl-8-trifluorométhyl-6,7,8,9-tétrahydro- pyrimido[1 ,2-a]pyrimidin-4-one \nStep e: (S) -2-Morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Un mélange de 1 g de la (S)-2-chloro-8-trifluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one et de 15 mL de morpholine est chauffé à 80\n0\nC. Après une heure et demie de chauffage et après contrôle par LC/MS, la réaction est terminée. Après refroidissement, le mélange réactionnel est concentré sous pression réduite. Sur le résidu obtenu, on \n\n ajoute 10 ml_ d'eau froide et 100 ml_ d'acétate d'éthyle. La phase organique résultante est séparée puis séchée sur sulfate de magnésium, filtrée et concentrée sous pression réduite pour donner 1.2 g de la (S)-2-morpholin-4- yl-8-thfluorométhyl-6,7,8,9-tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one dont les caractéristiques sont les suivantes : \nA mixture of 1 g of (S) -2-chloro-8-trifluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one and 15 ml of morpholine is heated. at 80 \n°\n C. After one and a half hours of heating and after control by LC / MS, the reaction is complete. After cooling, the reaction mixture is concentrated under reduced pressure. On the residue obtained,  10 ml of cold water and 100 ml of ethyl acetate are added. The resulting organic phase is separated and then dried over magnesium sulfate, filtered and concentrated under reduced pressure to give 1.2 g of (S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro -pyhmido [1,2-a] pyhmidin-4-one whose characteristics are as follows:\n\n\n\n\n\n\n \n Spectrométhe de Masse : Méthode A \n Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,49 \n Retention time Tr (min) = 0.49\n\n\n\n\n\n\n \n [M+H]+ : m/z 305 ; [M-H]- : m/z 303 \n [M + H] +: m / z 305; [M-H] -: m / z 303\n\n\n\n\n\n\n \n Pouvoir rotatoire : PR= +14.2+/-0.6; C=2.25mg/0.5ML MeOH. \n Rotatory power: PR = +14.2 +/- 0.6; C = 2.25mg / 0.5ML MeOH.\n\n\n\n\n\n\n \nStade d : (S)- 2-chloro-8-trifluorométhyl-6,7,8,9-tétrahydro-pyrimido[1,2- a]pyrimidin-4-one \n\n\n\nStep d: (S) - 2-chloro-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyrimidin-4-one \n \n\n\n\n\n\n\n \n La séparation des deux énantiomères de la (R,S)-2-chloro-8- trifluorométhyl-6,7,8,9-tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (17 g) est réalisée par chromatographie chirale : phase stationnaire : Chiralpak AD; phase mobile: EtOH (20%) / Heptane (80%). \n The separation of the two enantiomers of (R, S) -2-chloro-8-trifluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one (17 g) is carried out by chiral chromatography: stationary phase: Chiralpak AD; mobile phase: EtOH (20%) / heptane (80%).\n\n\n\n\n\n\n \n L'énantiomère levogyre est concentré pour donner 8.52 g de la (R)-2- chloro-8-thfluorométhyl-6,7,8,9-tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one, sous forme d'une poudre blanche. \n The levogyre enantiomer is concentrated to give 8.52 g of (R) -2-chloro-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one, in the form of a white powder.\n\n\n\n\n\n\n \n L'énantiomère dextrogyre est concentré pour obtenir 8.21 g de la (S)- 2-chloro-8-thfluorométhyl-6,7,8,9-tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one, sous forme d'une poudre blanche, dont les caractéristiques sont les suivantes: \n The dextrorotatory enantiomer is concentrated to obtain 8.21 g of (S) -2-chloro-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one, in the form of a white powder, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectrométhe de Masse : Méthode A \n Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,51 \n\n [M+H]+ : m/z 254 ; [M-H]- : m/z 252 \nRetention time Tr (min) = 0.51  [M + H] +: m / z 254; [MH] -: m / z 252\n\n\n\n\n\n\n \n Pouvoir rotatoire : PR= +21.3+/-0.5. MeOH. \n Rotatory power: PR = +21.3 +/- 0.5. MeOH.\n\n\n\n\n\n\n \nStade c : (R,S)-2-chloro-8-trifluorométhyl-6,7,8,9-tétrahydro- pyrimido[1,2-a]pyrimidin-4-one \n\n\n\nStep c: (R, S) -2-chloro-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one \n \n\n\n\n\n\n\n \n A une suspension de 34 g de la (R,S)-2-hydroxy-8-trifluoronnéthyl- 6,7,8,9-tétrahydro-pyrimido[1 ,2-a]pyhnnidin-4-one dans 500 ml_ de 1 ,2- dichloroéthane, sont ajoutés, à température ambiante et sous atmosphère d'argon, 60 ml_ d'oxychlorure de phosphore. Le mélange obtenu est alors chauffé à 65°C. Après trois heures d'agitation à 65°C, la réaction est terminée d'après le contrôle par LC/MS. Après refroidissement, le mélange réactionnel est évaporé à sec sous pression réduite. Le résidu obtenu est repris par 100 mL d'eau froide et 400 mL d'acétate d'éthyle. Sur le mélange obtenu, on additionne de la soude 32% jusqu'à pH = 6. La phase organique résultante est séparée puis séchée sur sulfate de magnésium, filtrée et concentrée sous pression réduite pour donner un résidu orange. Ce résidu est purifié par chromatographie sur silice (éluent : CH2CI2/MeOH : 97/03) pour donner 20 g de la (R,S)-2-chloro-8-thfluorométhyl-6,7,8,9-tétrahydro-pyhmido[1 ,2- a]pyπmidin-4-one, sous forme d'un solide blanc, dont les caractéristiques sont les suivantes : \n To a suspension of 34 g of (R, S) -2-hydroxy-8-trifluoronnethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyhnnidin-4-one in 500 ml of 1 2 ml of phosphorus oxychloride are added at room temperature under an argon atmosphere. The resulting mixture is then heated to 65 ° C. After stirring for 3 hours at 65 ° C, the reaction is complete by LC / MS control. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up in 100 ml of cold water and 400 ml of ethyl acetate. 32% sodium hydroxide solution is added to the pH of 6 on the mixture obtained. The resulting organic phase is separated and then dried over magnesium sulfate, filtered and concentrated under reduced pressure to give an orange residue. This residue is purified by chromatography on silica (eluent: CH 2 Cl 2 / MeOH: 97/03) to give 20 g of (R, S) -2-chloro-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido [1, 2- a] pyrimidin-4-one, in the form of a white solid, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectrométrie de Masse : Méthode A \n Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,51 \n Retention time Tr (min) = 0.51\n\n\n\n\n\n\n \n [M+H]+ : m/z 254 ; [M-H]- : m/z 252 \n [M + H] +: m / z 254; [M-H] -: m / z 252\n\n\n\n\n\n\n \nStade b : (R,S)-2-hydroxy-8-trifluorométhyl-6,7,8,9-tétrahydro- pyrimido[1 ,2-a]pyrimidin-4-one \n\n \n\n\n\nStep b: (R, S) -2-hydroxy-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one \n \n\n\n\n\n\n\n \n Sur un mélange de 50 ml_ de malonate de diéthyle sont ajoutés 10 g de chlorhydrate de 6-thfluorométhyl-1 ,4,5,6-tétrahydropyhnnidin-2-ylannine et 10 g de méthylate de sodium. Le mélange obtenu est porté à 100\n0\nC pendant 75 minutes. Le mélange hétérogène s'épaissit et devient jaune avec un léger dégagement gazeux. Après refroidissement, le mélange réactionnel est évaporé à sec sous pression réduite. Le résidu obtenu est trituré avec de l'éther éthylique. Le solide formé est filtré sur fritte puis est repris par 20 mL d'eau froide. Sur la suspension épaisse obtenue, on additionne de l'acide chlorhydrique 12N jusqu'à pH=5-6. La suspension obtenue est filtrée sur verre fritte et l'insoluble est rincé avec de l'éther éthylique pour donner 11.5 g de la (R,S)-2-hydroxy-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido[1 ,2- a]pyhmidin-4-one, sous forme d'un solide blanc, dont les caractéristiques sont les suivantes : \nOn a mixture of 50 ml of diethyl malonate are added 10 g of 6-thfluoromethyl-1, 4,5,6-tetrahydropynynidin-2-ylannine hydrochloride and 10 g of sodium methylate. The mixture obtained is heated at 100 \n°\n C. for 75 minutes. The heterogeneous mixture thickens and turns yellow with a slight gassing. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is triturated with ethyl ether. The solid formed is filtered on a frit then is taken up in 20 ml of cold water. On the slurry obtained, 12N hydrochloric acid is added until pH = 5-6. The suspension obtained is filtered on sintered glass and the insoluble material is rinsed with ethyl ether to give 11.5 g of (R, S) -2-hydroxy-8-thfluoromethyl-6,7,8,9-tetrahydro- pyhmido [1, 2- a] pyhmidin-4-one, in the form of a white solid, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectrométhe de Masse : Méthode A \n Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,26 \n Retention time Tr (min) = 0.26\n\n\n\n\n\n\n \n [M+H]+ : m/z 236 ; [M-H]- : m/z 234 \n [M + H] +: m / z 236; [M-H] -: m / z 234\n\n\n\n\n\n\n \nStade a : chlorhydrate de la (R,S)-6-trifluorométhyl-1, 4,5,6- tétrahydropyrimidin-2-ylamine \nStep a: (R, S) -6-trifluoromethyl-1, 4,5,6-tetrahydropyrimidin-2-ylamine hydrochloride\n\n\n\n\n\n\n \nNH\n2\n \nNH \n2\n \n\n\n\n\n\n\n \n I HCI HN\"^N \n I HCI HN \"^ N\n\n\n\n\n\n\n \nDans un autoclave, on hydrogène, sous 3 bars, à 22 \n0\nC, pendant 24 heures, un mélange de 1.1 g de Pd/C à 10%, de 22 g de 2-amino-4-\nIn an autoclave, a mixture of 1.1 g of 10% Pd / C, 22 g of 2-amino-4- is hydrogenated under 3 bar at 22 \n°\n C. for 24 hours.\n\n\n\n\n\n\n \n(thfluorométhyl)pyrimidine dissous dans 200 ml d'eau, 50 mL de méthanol et 50 ml d'HCI 12N.. Le mélange résultant est alors filtré et le filtrat est \n\n concentré sous pression réduite. Le résidu obtenu est séché en étuve, en présence de P2O5, pour donner 27 g du chlorhydrate de la (R,S)-6- trifluorométhyl-1 ,4,5,6-tétrahydropyhnnidin-2-ylannine, sous forme d'un solide gris, dont les caractéristiques sont les suivantes : \n(thfluoromethyl) pyrimidine dissolved in 200 ml of water, 50 ml of methanol and 50 ml of 12N HCl. The resulting mixture is then filtered and the filtrate is  concentrated under reduced pressure. The residue obtained is dried in an oven, in the presence of P2O5, to give 27 g of (R, S) -6-trifluoromethyl-1, 4,5,6-tetrahydropynynidin-2-ylanine hydrochloride, in the form of a solid gray, whose characteristics are as follows:\n\n\n\n\n\n\n \n Spectrométhe de Masse : Méthode A \n Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,17 \n Retention time Tr (min) = 0.17\n\n\n\n\n\n\n \n [M+H]+ : m/z 168 \n [M + H] +: m / z 168\n\n\n\n\n\n\n \nExemple 2 : (R,S)-9-[2-(4-méthoxy-phényl)-éthyl]-2-morpholin-4-yl-8- trifluorométhyl-6,7,8,9-tétrahydro-pyrimido[1,2-a]pyrimidin-4-one \nExample 2: (R, S) -9- [2- (4-methoxy-phenyl) -ethyl] -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1] , 2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Stade b : (R,S)-9-[2-(4-méthoxy-phényl)-éthyl]-2-morpholin-4-yl-8- trifluorométhyl-6,7,8,9-tétrahydro-pyrimido[1,2-a]pyrimidin-4-one \n Step b: (R, S) -9- [2- (4-methoxy-phenyl) -ethyl] -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1 , 2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n A une solution de 120 mg de la (R,S)-2-morpholin-4-yl-8- trifluorométhyl-6,7,8,9-tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one dans 5 mL de diméthylformamide anhydre sont ajoutés, à température ambiante et sous atmosphère d'argon, 0.5 g de carbonate de césium, 0.23 g du bromure de 4- methoxyphénéthyle et 10 mg du chlorure du benzyl triéthylammonium (BTEAC). Le mélange résultant est chauffé à 80\n0\nC pendant 18 heures. \nTo a solution of 120 mg of (R, S) -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one in 5 ml of anhydrous dimethylformamide are added, at room temperature and under argon, 0.5 g of cesium carbonate, 0.23 g of 4-methoxyphenethyl bromide and 10 mg of benzyl triethylammonium chloride (BTEAC). The resulting mixture is heated at 80 \n°\n C. for 18 hours.\n\n\n\n\n\n\n \n Après refroidissement, le mélange réactionnel est concentré sous pression réduite. Le résidu obtenu est repris par 50 mL d'acétate d'éthyle et la solution obtenue est lavée par 3 mL d'eau. La phase organique est séparée puis séchée sur sulfate de magnésium, filtrée et évaporée sous pression réduite. Après purification par chromatographie sur silice (gradient de 0% à 20% de l'éluant CH2CI2/MeOH/NH4OH 28% 38/17/2 dans le \n\n dichlorométhane), on obtient 80 mg de la (R,S)-(9-[2-(4-méthoxy-phényl)- éthyl]-2-morpholin-4-yl-8-thfluoronnéthyl-6,7,8,9-tétrahydro-pyhnnido[1 ,2- a]pyrimidin-4-one dont les caractéristiques sont les suivantes : \nAfter cooling, the reaction mixture is concentrated under reduced pressure. The residue obtained is taken up in 50 mL of ethyl acetate and the resulting solution is washed with 3 mL of water. The organic phase is separated and then dried over magnesium sulfate, filtered and evaporated under reduced pressure. After purification by chromatography on silica (gradient from 0% to 20% of the eluent CH 2 Cl 2 / MeOH / NH 4 OH 28% 38/17/2 in the  dichloromethane), 80 mg of (R, S) - (9- [2- (4-methoxy-phenyl) ethyl] -2-morpholin-4-yl-8-thfluoronethyl-6,7,8 are obtained, 9-tetrahydro-pyhnnido [1,2-a] pyrimidin-4-one, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H: \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 1 ,85 à 2,02 (m, 1 H) ; 2,27 à 2,35 (m, 1 H) ; 2,72 à 2,84 (m, 1 H) ; 2,88 à 2,98 (m, 1 H) ; 3,09 à 3,20 (m, 1 H) ; 3,37 à 3,42 (m, 1 H) ; 3,45 (m, 4 H) ; 3,63 à 3,67 (m, 4 H) ; 3,72 (s, 3 H) ; 4,08 (m, 1 H) ; 4,14 à 4,21 (m, 1 H) ; 4,51 à 4,63 (m, 1 H) ; 5,00 (s, 1 H) ; 6,88 (d, J=8,6 Hz, 2 H) ; 7,13 (d, J=8,6 Hz, 2 H) \n 1.85 to 2.02 (m, 1H); 2.27 to 2.35 (m, 1H); 2.72 to 2.84 (m, 1H); 2.88 to 2.98 (m, 1H); 3.09 to 3.20 (m, 1H); 3.37 at 3.42 (m, 1H); 3.45 (m, 4H); 3.63 to 3.67 (m, 4H); 3.72 (s, 3H); 4.08 (m, 1H); 4.14 to 4.21 (m, 1H); 4.51 to 4.63 (m, 1H); 5.00 (s, 1H); 6.88 (d, J = 8.6 Hz, 2H); 7.13 (d, J = 8.6 Hz, 2H)\n\n\n\n\n\n\n \n Spectrométhe de Masse : Méthode A \n Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,93 \n Retention time Tr (min) = 0.93\n\n\n\n\n\n\n \n [M+H]+ : m/z 439 \n [M + H] +: m / z 439\n\n\n\n\n\n\n \nStade a : (R,S)-2-morpholin-4-yl-8-trifluorométhyl-6,7,8,9-tétrahydro- pyrimido[1 ,2-a]pyrimidin-4-one \nStep a: (R, S) -2-Morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Un mélange de 220 mg de la (R,S)-2-chloro-4-yl-8-trifluorométhyl- 6,7,8,9-tétrahydro-pyrimido[1 ,2-a]pyhmidin-4-one dans 5 ml_ de morpholine est chauffé à 80\n0\nC. Après une heure et demie de chauffage, la réaction est terminée d'après le contrôle par LC/MS. Après refroidissement, le mélange réactionnel est concentré sous pression réduite. Le résidu obtenu est purifié par chromatographie sur silice (gradient de 5% à 20% de l'éluant CH2CI2/MeOH/NH4OH 28% 38/17/2 dans le dichlorométhane) pour donner 270 mg de la (R,S)-2-morpholin-4-yl-8-trifluorométhyl-6,7,8,9-tétrahydro- pyrimido[1 ,2-a]pyhmidin-4-one dont les caractéristiques sont les suivantes : \nA mixture of 220 mg of (R, S) -2-chloro-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyhmidin-4-one in 5 ml of morpholine is heated at 80 \n°\n C. After one hour and a half of heating, the reaction is terminated according to LC / MS control. After cooling, the reaction mixture is concentrated under reduced pressure. The residue obtained is purified by chromatography on silica (gradient from 5% to 20% of the eluent CH 2 Cl 2 / MeOH / NH 4 OH 28% 38/17/2 in dichloromethane) to give 270 mg of the (R, S) -2 -morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido [1,2-a] pyhmidin-4-one having the following characteristics:\n\n\n\n\n\n\n \n Spectrométhe de Masse : Méthode B \n\n Temps de rétention Tr (min) = 2,53 \nSpectrometry of Mass: Method B  Retention time Tr (min) = 2.53\n\n\n\n\n\n\n \n [M+H]+ : m/z 305 ; [M-H]- : m/z 303 \n [M + H] +: m / z 305; [M-H] -: m / z 303\n\n\n\n\n\n\n \nExemple 3 : (S)-2-morpholin-4-yl-9-phénéthyl-8-trifluorométhyl-6,7,8,9- tétrahydro-pyrimido[1 ,2-a]pyrimidin-4-one \nExample 3: (S) -2-Morpholin-4-yl-9-phenethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nStade a : \nStage a:\n\n\n\n\n\n\n \n La (R,S)-2-morpholin-4-yl-9-phénéthyl-8-thfluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one est préparée en suivant le mode opératoire décrit à l'exemple 2 à partir de 80 mg de la (R,S)-2-morpholin-4-yl-\n (R, S) -2-Morpholin-4-yl-9-phenethyl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one is prepared by following the procedure described in Example 2 from 80 mg of (R, S) -2-morpholin-4-yl-\n\n\n\n\n\n\n \n8-thfluorométhyl-6,7,8,9-tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one et de 240 mg de (2-bromoéthyl)benzène. Après purification par chromatographie sur silice (éluant : un gradient de 5% à 20% de l'éluant CH2CI2/MeOH/NH4OH 28% 38/17/2 dans le dichlorométhane), on obtient 75 mg de la (R,S)-2-morpholin-4-yl-9-phénéthyl-8-thfluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one dont les caractéristiques sont les suivantes : \n8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one and 240 mg of (2-bromoethyl) benzene. After purification by chromatography on silica (eluent: a gradient of 5% to 20% of the eluent CH 2 Cl 2 / MeOH / 28% NH 4 OH 38/17/2 in dichloromethane), 75 mg of the (R, S) - 2-morpholin-4-yl-9-phenethyl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one having the following characteristics:\n\n\n\n\n\n\n \n Spectre RMN 1 H: \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 1 ,85 à 2,01 (m, 1 H) ; 2,27 à 2,35 (m, 1 H) ; 2,86 (m, 1 H) ; 2,95 à 3,05\n 1.85 to 2.01 (m, 1H); 2.27 to 2.35 (m, 1H); 2.86 (m, 1H); 2.95 to 3.05\n\n\n\n\n\n\n \n(m, 1 H) ; 3,11 à 3,21 (m, 1 H) ; 3,39 à 3,49 (m, 5 H) ; 3,63 à 3,68 (m, 4 H) ; 4,08 à 4,23 (m, 2 H) ; 4,53 à 4,62 (m, 1 H) ; 5,00 (s, 1 H) ; 7,18 à 7,25 (m, 3 H) ; 7,29 à 7,34 (m, 2 H) \n(m, 1H); 3.11 to 3.21 (m, 1H); 3.39 to 3.49 (m, 5H); 3.63 to 3.68 (m, 4H); 4.08 to 4.23 (m, 2H); 4.53 to 4.62 (m, 1H); 5.00 (s, 1H); 7.18 to 7.25 (m, 3H); 7.29 to 7.34 (m, 2H)\n\n\n\n\n\n\n \n Spectrométhe de Masse : Méthode A \n Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,95 \n\n [M+H]+ : m/z 409 \nRetention time Tr (min) = 0.95  [M + H] +: m / z 409\n\n\n\n\n\n\n \nStade b : \nStage b:\n\n\n\n\n\n\n \n La séparation des deux énantiomères de la (R,S)-2-morpholin-4-yl-9- phénéthyl-8-tπfluorométhyl-6,7,8,9-tétrahydro-pyπmido[1 ,2-a]pyπmidin-4-one est réalisée par chromatographie chirale : colonne Chiralpak IC 20 μm; élution 75 % Heptane 20% EtOH 5 % MeOH. \n The separation of the two enantiomers of (R, S) -2-morpholin-4-yl-9-phenethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4 -one is carried out by chiral chromatography: Chiralpak IC 20 μm column; Elution 75% Heptane 20% EtOH 5% MeOH\n\n\n\n\n\n\n \n L'énantiomère dextrogyre est concentré pour obtenir 27 mg de la (S)- 2-morpholin-4-yl-9-phénéthyl-8-thfluorométhyl-6,7,8,9-tétrahydro- pyrimido[1 ,2-a]pyhmidin-4-one dont les caractéristiques sont les suivantes : \n The dextrorotatory enantiomer is concentrated to obtain 27 mg of (S) -2-morpholin-4-yl-9-phenethyl-8-thfluoromethyl-6,7,8,9-tetrahydropyrimido [1,2-a] pyhmidin-4-one whose characteristics are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H: \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 1 ,94 (m, 1 H) ; 2,23 à 2,35 (m, 1 H) ; 2,83 à 2,91 (m, 1 H) ; 2,96 à 3,04 (m, 1 H) ; 3,16 (m, 1 H) ; 3,40 à 3,52 (m, 5 H) ; 3,65 (m, 4 H) ; 4,07 à 4,21 (m, 2 H) ; 4,50 à 4,62 (m, 1 H) ; 5,00 (s, 1 H) ; 7,18 à 7,25 (m, 3 H) ; 7,29 à 7,35 (m, 2 H) \n 1.94 (m, 1H); 2.23 - 2.35 (m, 1H); 2.83 to 2.91 (m, 1H); 2.96 to 3.04 (m, 1H); 3.16 (m, 1H); 3.40 to 3.52 (m, 5H); 3.65 (m, 4H); 4.07 to 4.21 (m, 2H); 4.50 to 4.62 (m, 1H); 5.00 (s, 1H); 7.18 to 7.25 (m, 3H); 7.29 to 7.35 (m, 2H)\n\n\n\n\n\n\n \n Spectrométhe de Masse : Méthode A \n Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,95 \n Retention time Tr (min) = 0.95\n\n\n\n\n\n\n \n [M+H]+ : m/z 409 \n [M + H] +: m / z 409\n\n\n\n\n\n\n \n Pouvoir rotatoire : PR = signe positif (+40); C=1.093mg/0.5ML DMSO. La purification chromatographique conduit aussi à 30 mg de l'énantiomère lévogyre, la (R)-2-morpholin-4-yl-9-phénéthyl-8-thfluorométhyl- 6,7,8,9-tétrahydro-pyrimido[1 ,2-a]pyhmidin-4-one. \n Rotatory power: PR = positive sign (+40); C = 1.093mg / 0.5ML DMSO. Chromatographic purification also leads to 30 mg of the laevorotatory enantiomer, (R) -2-morpholin-4-yl-9-phenethyl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2] -a] pyrimidin-4-one.\n\n\n\n\n\n\n \nExemple 4 : (S)-9-benzyl-2-morpholin-4-yl-8-trifluorométhyl-6, 7,8,9- tétrahydro-pyrimido[1 ,2-a]pyrimidin-4-one \nExample 4: (S) -9-Benzyl-2-morpholin-4-yl-8-trifluoromethyl-6,8,8,9-tetrahydro-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n \n\n Stade b : \n \n Stage b:\n\n\n\n\n\n\n \n La séparation des deux énantiomères du (R,S)-9-benzyl-2-morpholin- 4-yl-8-trifluoronnéthyl-6,7,8,9-tétrahydro-pyπnnido[1 ,2-a]pyπnnidin-4-one est réalisée par chromatographie chirale : colonne 6x35cm; phase mobile : EtOH 60% Heptane 40%. \n The separation of the two enantiomers of (R, S) -9-benzyl-2-morpholin-4-yl-8-trifluoronethyl-6,7,8,9-tetrahydro-pyπnnido [1,2-a] pyπnnidin-4- one is performed by chiral chromatography: column 6x35cm; mobile phase: EtOH 60% Heptane 40%.\n\n\n\n\n\n\n \n L'énantiomère dextrogyre est concentré pour donner 36 mg de la (S)- 9-benzyl-2-morpholin-4-yl-8-trifluorométhyl-6,7,8,9-tétrahydro-pyrinnido[1 ,2- a]pyrimidin-4-one dont les caractéristiques sont les suivantes : \n The dextrorotatory enantiomer is concentrated to give 36 mg of (S) -9-benzyl-2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrinnido [1,2-a] pyrimidin-4-one whose characteristics are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H: \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,10 à 2,25 (m, 1 H) ; 2,35 à 2,43 (m, 1 H) ; 3,19 à 3,27 (m, 5 H) ; 3,39 à 3,53 (m, 4 H) ; 4,16 à 4,27 (m, 1 H) ; 4,51 (d, J=15,9 Hz, 1 H) ; 4,57 à 4,72 (m, 1 H) ; 4,96 (s, 1 H) ; 5,23 (d, J=15,9 Hz, 1 H) ; 7,20 à 7,27 (m, 3 H) ; 7,28 à 7,34 (m, 2 H) \n 2.10-2.25 (m, 1H); 2.35 to 2.43 (m, 1H); 3.19 to 3.27 (m, 5H); 3.39-3.53 (m, 4H); 4.16 to 4.27 (m, 1H); 4.51 (d, J = 15.9 Hz, 1H); 4.57 to 4.72 (m, 1H); 4.96 (s, 1H); 5.23 (d, J = 15.9 Hz, 1H); 7.20 to 7.27 (m, 3H); 7.28 to 7.34 (m, 2H)\n\n\n\n\n\n\n \n Spectrométhe de Masse : Méthode A \n Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,88 \n Retention time Tr (min) = 0.88\n\n\n\n\n\n\n \n [M+H]+ : m/z 395 \n [M + H] +: m / z 395\n\n\n\n\n\n\n \n Pouvoir rotatoire : PR= +16.3+/-0.7. C=1.960mg/0.5ML DMSO. \n Rotatory power: PR = +16.3 +/- 0.7. C = 1.960mg / 0.5ML DMSO.\n\n\n\n\n\n\n \n La purification chromatographique ci-dessus conduit aussi à 38 mg de l'énantiomère lévogyre, la ((R)-9-benzyl-2-morpholin-4-yl-8-trifluorométhyl- 6,7,8,9-tétrahydro-pyrimido[1 ,2-a]pyhmidin-4-one. \n The above chromatographic purification also leads to 38 mg of the levorotatory enantiomer, ((R) -9-benzyl-2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyhmidin-4-one.\n\n\n\n\n\n\n \nStade a : (R,S)-9-benzyl-2-morpholin-4-yl-8-trifluorométhyl-6,7,8,9- tétrahydro-pyrimido[1,2-a]pyrimidin-4-one \nStep a: (R, S) -9-Benzyl-2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n \n\n Le produit est préparé en suivant le mode opératoire décrit à l'exemple 2, à partir de 140 mg de la (R,S)-2-morpholin-4-yl-8-thfluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one et de 0.270 ml_ de bromure de benzyle. Après purification par chromatographie sur silice (gradient de 5% à 20% de l'éluant CH2CI2/MeOH/NH4OH 28% 38/17/2 dans le dichlorométhane), on obtient 32 mg du (R,S)-9-benzyl-2-morpholin-4-yl-8- trifluorométhyl-6,7,8,9-tétrahydro-pyhmido[1 ,2-a]pyπmidin-4-one dont les caractéristiques sont les suivantes : \n \n The product is prepared following the procedure described in Example 2, starting from 140 mg of (R, S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro -pyhmido [1,2-a] pyhmidin-4-one and 0.270 ml of benzyl bromide. After purification by chromatography on silica (gradient from 5% to 20% of the eluent CH 2 Cl 2 / MeOH / 28% NH 4 OH 38/17/2 in dichloromethane), 32 mg of (R, S) -9-benzyl- 2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyrimidin-4-one, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H: \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,11 à 2,25 (m, 1 H) ; 2,35 à 2,44 (m, 1 H) ; 3,17 à 3,27 (m, 5 H) ; 3,40 à 3,53 (m, 4 H) ; 4,18 à 4,29 (m, 1 H) ; 4,51 (d, J=15,9 Hz, 1 H ); 4,58 à 4,72 (m, 1 H) ; 4,96 (s, 1 H) ; 5,22 (d, J=15,9 Hz, 1 H) ; 7,20 à 7,27 (m, 3 H) ; 7,28 à 7,36 (m, 2 H) \n 2.11 to 2.25 (m, 1H); 2.35 to 2.44 (m, 1H); 3.17 to 3.27 (m, 5H); 3.40 to 3.53 (m, 4H); 4.18 to 4.29 (m, 1H); 4.51 (d, J = 15.9 Hz, 1H); 4.58 to 4.72 (m, 1H); 4.96 (s, 1H); 5.22 (d, J = 15.9 Hz, 1H); 7.20 to 7.27 (m, 3H); 7.28 to 7.36 (m, 2H)\n\n\n\n\n\n\n \n Spectrométhe de Masse : Méthode A \n Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,88 \n Retention time Tr (min) = 0.88\n\n\n\n\n\n\n \n [M+H]+ : m/z 395 \n [M + H] +: m / z 395\n\n\n\n\n\n\n \nExemple 5 : 9-((S)-2-hydroxy-2-phényl-éthyl)-2-morpholin-4-yl-8-(S)- trifluorométhyl-6,7,8,9-tétrahydro-pyrimido[1,2-a]pyrimidin-4-one \nExample 5: 9 - ((S) -2-Hydroxy-2-phenyl-ethyl) -2-morpholin-4-yl-8- (S) -trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1] , 2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Le produit est préparé en suivant le mode opératoire décrit à l'exemple\n The product is prepared following the procedure described in the example\n\n\n\n\n\n\n \n2 à partir de 135 mg de la (R,S)-2-morpholin-4-yl-8-thfluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one et de 342 mg de (S)-2-chloro-1 - phényl-éthanol. Après purification par chromatographie sur silice (gradient de 5% à 20% de l'éluant CH2CI2/MeOH/NH4OH 28% 38/17/2 dans le \n\n dichlorométhane), on obtient 26 mg de la 9-((S)-2-hydroxy-2-phényl-éthyl)-2- morpholin-4-yl-8-(R)-trifluorométhyl-6,7,8,9-tétrahydro-pyrimido[1 ,2- a]pyrimidin-4-one et 18 mg de (S)-9-((S)-2-hydroxy-2-phényl-éthyl)-2- morpholin-4-yl-8-thfluoronnéthyl-6,7,8,9-tétrahydro-pyhnnido[1 ,2-a]pyhnnidin-4- one dont les caractéristiques sont les suivantes : \n2 from 135 mg of (R, S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one and 342 mg of (S) -2-chloro-1-phenylethanol. After purification by chromatography on silica (gradient from 5% to 20% of the eluent CH 2 Cl 2 / MeOH / NH 4 OH 28% 38/17/2 in the  dichloromethane) gives 26 mg of 9 - ((S) -2-hydroxy-2-phenyl-ethyl) -2-morpholin-4-yl-8- (R) -trifluoromethyl-6,7,8,9 tetrahydro-pyrimido [1,2-a] pyrimidin-4-one and 18 mg of (S) -9 - ((S) -2-hydroxy-2-phenyl-ethyl) -2-morpholin-4-yl; 8-thfluoronethyl-6,7,8,9-tetrahydro-pyhnnido [1,2-a] pyhnnidin-4-one, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H \n 1 H NMR Spectrum\n\n\n\n\n\n\n \n 2,24 (m, 1 H) ; 2,36 à 2,46 (m, 1 H) ; 3,08 (dd, J=I O\n1\nO et 14,2 Hz, 1 H) ; 3,17 à 3,27 (m, 1 H) ; 3,40 à 3,48 (m, 4 H) ; 3,63 à 3,69 (m, 4 H) ; 4,17 à 4,32 (m, 2 H) ; 4,74 à 4,85 (m, 1 H) ; 4,99 (m 1 H) ; 5,02 (s, 1 H) ; 5,67 (d, J=5,1 Hz, 1 H) ; 7,22 à 7,44 (m, 5 H) \n2.24 (m, 1H); 2.36 to 2.46 (m, 1H); 3.08 (dd, J = IO \n1\n O and 14.2 Hz, 1H); 3.17 to 3.27 (m, 1H); 3.40 to 3.48 (m, 4H); 3.63 to 3.69 (m, 4H); 4.17 to 4.32 (m, 2H); 4.74 to 4.85 (m, 1H); 4.99 (m H); 5.02 (s, 1H); 5.67 (d, J = 5.1Hz, 1H); 7.22 to 7.44 (m, 5H)\n\n\n\n\n\n\n \n Spectrométhe de Masse : Méthode A \n Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,85 \n Retention time Tr (min) = 0.85\n\n\n\n\n\n\n \n [M+H]+ : m/z 425; [M-H+HCO2H]- : m/z 469 \n [M + H] +: m / z 425; [M-H + HCO 2 H] -: m / z 469\n\n\n\n\n\n\n \n Pouvoir rotatoire : PR= +7.4+/-0.6; C=1.959mg/0.5ML CH3OH. \n Rotatory power: PR = +7.4 +/- 0.6; C = 1.959mg / 0.5ML CH3OH.\n\n\n\n\n\n\n \nExemple 6 : 9-((R)-2-hydroxy-2-phényl-éthyl)-2-morpholin-4-yl-8-(S)- trifluorométhyl-6,7,8,9-tétrahydro-pyrimido[1,2-a]pyrimidin-4-one \nExample 6: 9 - ((R) -2-Hydroxy-2-phenyl-ethyl) -2-morpholin-4-yl-8- (S) -trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1] , 2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Le produit est préparé en suivant le mode opératoire décrit à l'exemple 2 à partir de 135 mg de la (R,S)-2-morpholin-4-yl-8-thfluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one et de 342 mg (R)-2-chloro-1 - phényl-éthanol. Après purification par chromatographie sur silice (gradient de 5% à 20% de l'éluant CH2CI2/MeOH/NH4OH 28% 38/17/2 dans le dichlorométhane), on obtient 25mg du 9-((R)-2-hydroxy-2-phényl-éthyl)-2- \n\n morpholin-4-yl-8-(S)-tπfluoronnéthyl-6,7,8,9-tétrahydro-pyπnnido[1 ,2- a]pyrimidin-4-one dont les caractéristiques sont les suivantes : \nThe product is prepared following the procedure described in Example 2 starting from 135 mg of (R, S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro- pyhmido [1,2-a] pyhmidin-4-one and 342 mg (R) -2-chloro-1-phenylethanol. After purification by chromatography on silica (gradient from 5% to 20% of the eluent CH 2 Cl 2 / MeOH / NH 4 OH 28% 38/17/2 in dichloromethane), 25 mg of 9 - ((R) -2-hydroxy- 2-phenyl-ethyl) -2-  morpholin-4-yl-8- (S) -tfluoronethyl-6,7,8,9-tetrahydro-pyπnnido [1,2-a] pyrimidin-4-one having the following characteristics:\n\n\n\n\n\n\n \n Spectre RMN 1 H \n 1 H NMR Spectrum\n\n\n\n\n\n\n \n 1 ,40 à 1 ,56 (m, 1 H) ; 2,05 à 2,17 (m, 1 H) ; 3,05 à 3,20 (m, 2 H) ; 3,36 à 3,47 (m, 4 H) ; 3,62 à 3,67 (m, 4 H) ; 3,84 à 3,94 (m, 1 H) ; 3,96 à 4,03 (m, 1 H) ; 4,54 (dd, J=6,0 et 13,8 Hz, 1 H) ; 4,96 (s, 1 H) ; 4,99 à 5,04 (m, 1 H) ; 5,56 (s large, 1 H) ; 7,18 à 7,37 (m, 5 H) \n 1.40-1.56 (m, 1H); 2.05 to 2.17 (m, 1H); 3.05 to 3.20 (m, 2H); 3.36 at 3.47 (m, 4H); 3.62 to 3.67 (m, 4H); 3.84-3.94 (m, 1H); 3.96 to 4.03 (m, 1H); 4.54 (dd, J = 6.0 and 13.8 Hz, 1H); 4.96 (s, 1H); 4.99 to 5.04 (m, 1H); 5.56 (bs, 1H); 7.18 to 7.37 (m, 5H)\n\n\n\n\n\n\n \n Spectrométhe de Masse : Méthode A \n Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,73 \n Retention time Tr (min) = 0.73\n\n\n\n\n\n\n \n [M+H]+ : m/z 425 ; [M-H+HCO2H]- : m/z 469 \n [M + H] +: m / z 425; [M-H + HCO 2 H] -: m / z 469\n\n\n\n\n\n\n \n Pouvoir rotatoire : PR=+63.3 +/- 1.4 dans le MeOH \n Rotatory power: PR = + 63.3 +/- 1.4 in MeOH\n\n\n\n\n\n\n \n Dans la purification ci-dessus, on obtient également 20 mg de 9-((R)-2- hydroxy-2-phényl-éthyl)-2-morpholin-4-yl-8-(R)-thfluorométhyl-6, 7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one. \n In the above purification, there is also obtained 20 mg of 9 - ((R) -2-hydroxy-2-phenyl-ethyl) -2-morpholin-4-yl-8- (R) -thfluoromethyl-6,7 8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one.\n\n\n\n\n\n\n \nExemple 7 : (8S)-9-[(2S)-2-hydroxy-2-(4-méthoxyphényl)éthyl]-2-\nExample 7: (8S) -9 - [(2S) -2-hydroxy-2- (4-methoxyphenyl) ethyl] -2-\n\n\n\n\n\n\n \n(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2- a]pyrimidin-4-one \n(Morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Le produit est préparé en suivant le mode opératoire décrit à l'exemple\n The product is prepared following the procedure described in the example\n\n\n\n\n\n\n \n2 à partir de 135 mg de la (R,S)-2-morpholin-4-yl-8-thfluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one et de 760 mg de (S)-2-chloro-1 -(4- méthoxy-phényl)-éthanol. Après purification par chromatographie sur silice \n\n (gradient de 5% à 20% de l'éluant CH2CI2/MeOH/NH4OH 28% 38/17/2 dans le dichlorométhane), on obtient 66 mg de la (8S)-9-[(2S)-2-hydroxy-2-(4- méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)-6,7,8,9-tétrahydro- 4H-pyrimido[1 ,2-a]pyhnnidin-4-one dont les caractéristiques sont les suivantes: \n2 from 135 mg of (R, S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one and 760 mg of (S) -2-chloro-1- (4-methoxy-phenyl) -ethanol. After purification by chromatography on silica  (Gradient from 5% to 20% of the eluent CH 2 Cl 2 / MeOH / NH 4 OH 28% 38/17/2 in dichloromethane), 66 mg of (8S) -9 - [(2S) -2-hydroxy- 2- (4-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhnnidine-4- one whose characteristics are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,14 à 2,29 (m, 1 H) ; 2,35 à 2,44 (m, 1 H) ; 3,06 (dd, J=9,8 et 13,9\n 2.14 to 2.29 (m, 1H); 2.35 to 2.44 (m, 1H); 3.06 (dd, J = 9.8 and 13.9\n\n\n\n\n\n\n \nHz, 1 H) ; 3,14 à 3,27 (m, 1 H) ; 3,37 à 3,50 (m, 4 H) ; 3,62 à 3,69 (m, 4 H) ;\nHz, 1H); 3.14 to 3.27 (m, 1H); 3.37 at 3.50 (m, 4H); 3.62 to 3.69 (m, 4H);\n\n\n\n\n\n\n \n3,74 (s, 3 H) ; 4,14 à 4,28 (m, 2 H) ; 4,79 (m, 1 H); 4,90 à 4,98 (m, 1 H) ; 5,01 (s, 1 H) ; 5,57 (d, J=4,9 Hz, 1 H) ; 6,93 (d, J=8,6 Hz, 2 H) ; 7,25 (d, J=8,6 Hz,\n3.74 (s, 3H); 4.14 to 4.28 (m, 2H); 4.79 (m, 1H); 4.90 to 4.98 (m, 1H); 5.01 (s, 1H); 5.57 (d, J = 4.9 Hz, 1H); 6.93 (d, J = 8.6 Hz, 2H); 7.25 (d, J = 8.6 Hz,\n\n\n\n\n\n\n \n2 H). \n2H).\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,84 \n Retention time Tr (min) = 0.84\n\n\n\n\n\n\n \n [M+H]+ : m/z 499 \n [M + H] +: m / z 499\n\n\n\n\n\n\n \n Pouvoir rotatoire : PR= +4; C=1.397mg/0.5ml dans CH3OH. \n Rotatory power: PR = +4; C = 1.397mg / 0.5ml in CH3OH.\n\n\n\n\n\n\n \n On obtient également 36 mg de la (8R)-9-[(2S)-2-hydroxy-2-(4- méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)-6,7,8,9-tétrahydro- 4H-pyπmido[1 ,2-a]pyhmidin-4-one. Exemple 8 : (8S)-2-(morpholin-4-yl)-9-[(1 R ou 1S)-1-phényléthyl]-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n 36 mg of (8R) -9 - [(2S) -2-hydroxy-2- (4-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6 are also obtained, 7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one. Example 8: (8S) -2- (morpholin-4-yl) -9 - [(1R or 1S) -1-phenylethyl] -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H- pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Le produit est préparé en suivant le mode opératoire décrit à l'exemple\n The product is prepared following the procedure described in the example\n\n\n\n\n\n\n \n1f, à partir de 135 mg de la (S)-2-morpholin-4-yl-8-thfluorométhyl-6, 7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1d) dans 5 ml_ \n\n d'acétonitrile et de 520 mg (i -bromoéthyl)benzène. Après purification par chromatographie sur silice (gradient de 5% à 20% de l'éluant CH2CI2/MeOH/NH4OH 28% 38/17/2 dans le dichlorométhane), on obtient 23 mg du (8S)-2-(morpholin-4-yl)-9-[1 -phényléthyl]-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one, sous forme d'un seul diastéréoisomère de configuration indéterminée sur la chaîne phénéthyl dont les caractéristiques sont les suivantes : \n1f, from 135 mg of (S) -2-morpholin-4-yl-8-thfluoromethyl-6,8,8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one (Example 1d) in 5 ml_  acetonitrile and 520 mg (1-bromoethyl) benzene. After purification by chromatography on silica (gradient from 5% to 20% of the eluent CH 2 Cl 2 / MeOH / NH 4 OH 28% 38/17/2 in dichloromethane), 23 mg of (8S) -2- (morpholin-4) are obtained. N -yl) -9- [1-phenylethyl] -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one in the form of a single diastereoisomer of indeterminate configuration on the phenethyl chain, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 1 ,65 (d, J=7,0 Hz, 3 H) ; 1 ,72 à 1 ,84 (m, 1 H) ; 2,29 à 2,38 (m, 1 H) ; 3,15 à 3,26 (m, 5 H) ; 3,43 à 3,55 (m, 4 H) ; 4,08 (m, 1 H) ; 4,31 à 4,44 (m, 1 H) ; 4,96 (s, 1 H) ; 5,67 (q, J=7,0 Hz, 1 H) ; 7,23 à 7,40 (m, 5 H). \n 1.65 (d, J = 7.0 Hz, 3H); 1.72 to 1.84 (m, 1H); 2.29 to 2.38 (m, 1H); 3.15 to 3.26 (m, 5H); 3.43 to 3.55 (m, 4H); 4.08 (m, 1H); 4.31 to 4.44 (m, 1H); 4.96 (s, 1H); 5.67 (q, J = 7.0 Hz, 1H); 7.23 to 7.40 (m, 5H).\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 4,07 \n Retention time Tr (min) = 4.07\n\n\n\n\n\n\n \n [M+H]+ : m/z 409 \n [M + H] +: m / z 409\n\n\n\n\n\n\n \n Pouvoir rotatoire : PR= +54.5+/-0.6; C=1.594mg/0.5ML CH3OH. \n Rotatory power: PR = +54.5 +/- 0.6; C = 1.594mg / 0.5ML CH3OH.\n\n\n\n\n\n\n \nExemple 9 : (8S)-9-[(1 R et 1S)-1-(4-méthoxyphényl)éthyl]-2-(morpholin-4- yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4- one \nExample 9: (8S) -9 - [(1R and 1S) -1- (4-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9 4-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n On introduit dans un ballon 130 mg de la (S)-2-chloro-8-thfluorométhyl-\n 130 mg of (S) -2-chloro-8-thfluoromethyl are introduced into a flask.\n\n\n\n\n\n\n \n6,7,8,9-tétrahydro-pyrimido[1 ,2-a]pyhmidin-4-one (exemple 1d) dans 3 ml_ de tétrahydrofuranne, 250 mg de triphénylphosphine supportée sur résine (3 mmol/g) et 116 mg 1 -(4-méthoxyphényl)éthanol. On ajoute alors, goutte à goutte, 0.12 ml_ d'azo-dicarboxylate de diéthyle. Après addition, le mélange \n\n réactionnel est agité pendant 18 heures à température ambiante. 250 mg de triphénylphosphine supportée sur résine (3 mmol/g) sont alors ajoutées au mélange réactionnel. Après 18 heures supplémentaires d'agitation à température ambiante, le mélange résultant est filtré sur Millex et le filtrat obtenu est ensuite concentré sous pression réduite. \n6,7,8,9-tetrahydro-pyrimido [1,2-a] pyhmidin-4-one (Example 1d) in 3 ml of tetrahydrofuran, 250 mg of resin-supported triphenylphosphine (3 mmol / g) and 116 mg 1 - (4-methoxy-phenyl) ethanol. 0.12 ml of diethyl azodicarboxylate are then added dropwise. After addition, the mixture  The reaction mixture is stirred for 18 hours at room temperature. 250 mg of resin-supported triphenylphosphine (3 mmol / g) are then added to the reaction mixture. After stirring for another 18 hours at room temperature, the resulting mixture is filtered through Millex and the filtrate obtained is then concentrated under reduced pressure.\n\n\n\n\n\n\n \n Le résidu est dissout dans 5 ml_ de morpholine et le mélange résultant est chauffé à 80 \n0\nC pendant 2 heures. Le mélange réactionnel est concentré sous pression réduite. Après purification par chromatographie sur silice (gradient de 0% à 20% de l'éluant CH2CI2/MeOH/NH4OH 28% 38/17/2 dans le dichlorométhane), on obtient 40 mg de la (8S)-9-[1-(4- méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)-6,7,8,9-tétrahydro- 4H-pyrimido[1 ,2-a]pyhmidin-4-one, sous forme d'un mélange 60/40 des deux diastéréoisomères, dont les caractéristiques sont les suivantes: \nThe residue is dissolved in 5 ml of morpholine and the resulting mixture is heated at 80 \n°\n C. for 2 hours. The reaction mixture is concentrated under reduced pressure. After purification by chromatography on silica (gradient from 0% to 20% of the eluent CH 2 Cl 2 / MeOH / NH 4 OH 28% 38/17/2 in dichloromethane), 40 mg of (8S) -9- [1- (4-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one, in the form of a 60/40 mixture of the two diastereoisomers, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 1 ,61 (d, J=7,1 Hz, 1 ,8 H) ; 1 ,68 (d, J=7,1 Hz, 1 ,2 H) ; 2,09 à 2,47 (m, 2\n 1.61 (d, J = 7.1Hz, 1.8H); 1.68 (d, J = 7.1 Hz, 1, 2H); 2.09 to 2.47 (m, 2\n\n\n\n\n\n\n \nH) ; 3,10 à 3,65 (m partiellement masqué, 9 H) ; 3,72 (s, 1 ,2 H) ; 3,74 (s, 1 ,8 H) ; 3,85 à 4,34 (m, 1 ,6 H) ; 4,68 à 4,87 (m, 0,4 H) ; 4,93 (s, 0,4 H) ; 4,98 (s, 0,6 H) ; 5,47 (q, J=7,1 Hz, 0,4 H) ; 5,79 (q, J=7,1 Hz, 0,6 H) ; 6,86 (d, J=8,6 Hz, 0,8 H) ; 6,92 (d, J=8,6 Hz, 1.2 H) ; 7,26 (d, J=8,6 Hz, 2 H) \nH); 3.10-3.65 (partially masked m, 9H); 3.72 (s, 1, 2H); 3.74 (s, 1, 8H); 3.85 to 4.34 (m, 1, 6H); 4.68 to 4.87 (m, 0.4 H); 4.93 (s, 0.4H); 4.98 (s, 0.6 H); 5.47 (q, J = 7.1Hz, 0.4H); 5.79 (q, J = 7.1Hz, 0.6H); 6.86 (d, J = 8.6 Hz, 0.8H); 6.92 (d, J = 8.6 Hz, 1.2H); 7.26 (d, J = 8.6 Hz, 2H)\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,94 et 0,89 (mélange 60/40 des deux diastéréoisomères) \n Retention time Tr (min) = 0.94 and 0.89 (60/40 mixture of the two diastereoisomers)\n\n\n\n\n\n\n \n [M+H]+ : m/z 439 Exemple 10: (8S)-9-[(1 R ou 1S)-1-(4-bromophényl)éthyl]-2-(morpholin-4- yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4- one \n\n\n[M + H] +: m / z 439 Example 10: (8S) -9 - [(1R or 1S) -1- (4-bromophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Le produit est préparé en suivant le mode opératoire décrit à l'exemple 9 à partir de 300 mg de la (S)-2-chloro-8-thfluorométhyl-6,7,8,9-tétrahydro- pyπmido[1 ,2-a]pyhmidin-4-one dans 6 ml_ de tétrahydrofuranne, de 600 mg de triphénylphosphine supportée sur résine (3 mmol/g) et de 354 mg 1 -(4- bromophényl)éthanol. On ajoute alors, goutte à goutte, 0.28 ml_ d'azo- dicarboxylate de diéthyle. Après addition, le mélange réactionnel est agité pendant 18 heures à température ambiante. 600 mg de triphénylphosphine supportée sur résine (3 mmol/g) sont alors ajoutées au mélange réactionnel. Après 18 heures supplémentaires d'agitation à température ambiante, le mélange résultant est filtré sur Millex et le filtrat obtenu est ensuite concentré sous pression réduite. \n The product is prepared following the procedure described in Example 9 starting from 300 mg of (S) -2-chloro-8-thfluoromethyl-6,7,8,9-tetrahydropyrimido [1,2- a] pyhmidin-4-one in 6 ml of tetrahydrofuran, 600 mg of resin-supported triphenylphosphine (3 mmol / g) and 354 mg 1- (4-bromophenyl) ethanol. 0.28 ml of diethyl azodicarboxylate are then added dropwise. After addition, the reaction mixture is stirred for 18 hours at room temperature. 600 mg of resin-supported triphenylphosphine (3 mmol / g) are then added to the reaction mixture. After stirring for another 18 hours at room temperature, the resulting mixture is filtered through Millex and the filtrate obtained is then concentrated under reduced pressure.\n\n\n\n\n\n\n \n Le résidu d'évaporation est dissout dans 5 mL de morpholine et le mélange obtenu est agité à température ambiante pendant 4 jours. Le mélange réactionnel est alors concentré sous pression réduite. Après purification par chromatographie sur silice (gradient de 0 à 20 % de l'éluant CH2CI2/MeOH/NH4OH 28% 38/17/2 dans le dichlorométhane) on obtient 15 mg de l'un des diastéréoisomères de la (8S)-9-[1-(4-bromophényl)éthyl]-2- (morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2- a]pyπmidin-4-one (configuration indéterminée sur la chaîne phénéthyl) dont les caractéristiques sont les suivantes : \n The evaporation residue is dissolved in 5 ml of morpholine and the resulting mixture is stirred at room temperature for 4 days. The reaction mixture is then concentrated under reduced pressure. After purification by chromatography on silica (gradient from 0 to 20% of the eluent CH 2 Cl 2 / MeOH / NH 4 OH 28% 38/17/2 in dichloromethane), 15 mg of one of the diastereoisomers of (8S) -9 are obtained. - [1- (4-Bromophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyrimidine 4-one (indeterminate configuration on the phenethyl chain) whose characteristics are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 1 ,73 (d, J=7,1 Hz, 3 H) ; 2,16 à 2,31 (m, 1 H) ; 2,39 à 2,47 (m, 1 H) ; 3,12 à 3,25 (m, 5 H) ; 3,35 à 3,51 (m, 4 H) ; 4,15 (m, 1 H); 4,82 à 4,90 (m, 1 H) ; 4,92 (s, 1 H) ; 5,33 (q, J=7,1 Hz, 1 H) ; 7,27 (d, J=8,6 Hz, 2 H) ; 7,49 (d, J=8,6 Hz, 2 H). \n\n Spectrométrie de Masse : méthode B \n1.73 (d, J = 7.1 Hz, 3H); 2.16 to 2.31 (m, 1H); 2.39 to 2.47 (m, 1H); 3.12 to 3.25 (m, 5H); 3.35-3.51 (m, 4H); 4.15 (m, 1H); 4.82 to 4.90 (m, 1H); 4.92 (s, 1H); 5.33 (q, J = 7.1Hz, 1H); 7.27 (d, J = 8.6 Hz, 2H); 7.49 (d, J = 8.6 Hz, 2H).  Mass Spectrometry: Method B\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 4,26 \n Retention time Tr (min) = 4.26\n\n\n\n\n\n\n \n [M+H]+ : m/z 487 Exemple 11 : (8S)-9-[(1S ou 1 R)-1-(4-bromophényl)éthyl]-2-(morpholin-4- yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4- one \n [M + H] +: m / z 487 Example 11: (8S) -9 - [(1S or 1R) -1- (4-bromophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n On obtient également à la suite de la purification précédente 60 mg du second diastéréoisomère de la (8S)-9-[1 -(4-bromophényl)éthyl]-2-(morpholin- 4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one (configuration indéterminée sur la chaîne phénéthyl) dont les caractéristiques sont les suivantes : \n 60 mg of the second diastereoisomer of (8S) -9- [1- (4-bromophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) - are also obtained after the preceding purification. 6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one (indeterminate configuration on the phenethyl chain), the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 1 ,64 (d, J=7,1 Hz, 3 H) ; 1 ,78 à 1 ,94 (m, 1 H) ; 2,30 à 2,40 (m, 1 H) ;\n 1.64 (d, J = 7.1 Hz, 3H); 1.78-1.44 (m, 1H); 2.30 to 2.40 (m, 1H);\n\n\n\n\n\n\n \n3,08 à 3,26 (m, 5 H) ; 3,39 à 3,52 (m, 4 H) ; 4,11 (m, 1 H) ; 4,52 (m, 1 H) ; 4,95 (s, 1 H) ; 5,50 (q, =7,1 Hz, 1 H ); 7,25 (d, J=8,6 Hz, 2 H) ; 7,53 (d, J=8,6 Hz, 2 H) \n3.08 to 3.26 (m, 5H); 3.39 to 3.52 (m, 4H); 4.11 (m, 1H); 4.52 (m, 1H); 4.95 (s, 1H); 5.50 (q, = 7.1 Hz, 1H); 7.25 (d, J = 8.6 Hz, 2H); 7.53 (d, J = 8.6 Hz, 2H)\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode B \n Mass Spectrometry: Method B\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 4,37 \n Retention time Tr (min) = 4.37\n\n\n\n\n\n\n \n [M+H]+ : m/z 487 \n [M + H] +: m / z 487\n\n\n\n\n\n\n \nExemple 12 : (8S)-2-(morpholin-4-yl)-9-phényl-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n\n\nExample 12: (8S) -2- (Morpholin-4-yl) -9-phenyl-8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4 -one \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Dans un tube micro-ondes, on introduit 425 mg de la (S)-2-morpholin- 4-yl-8-thfluorométhyl-6,7,8,9-tétrahydro-pyrinnido[1 ,2-a]pyhnnidin-4-one \n In a microwave tube, 425 mg of (S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyrinnido [1,2-a] pyhnnidin-4 are introduced. -one\n\n\n\n\n\n\n \n(exemple 1 e) dans 1 ml_ de diméthylformamide, 422 mg de phosphate de tripotassium, 380 mg d'iodure de cuivre et 2 ml_ d'iodo benzène. Le mélange obtenu est chauffé dans un four micro-ondes, pendant 30 minutes à 150\n0\nC. On centrifuge ensuite le mélange réactionnel. Le surnageant séparé est ensuite rincé à l'acétate d'éthyle puis évaporé à sec. Le résidu est repris par de l'acétate d'éthyle et la solution obtenue est lavée avec de l'eau. La phase organique est séparée puis séchée sur sulfate de magnésium, filtrée et concentrée sous vide. Après purification par chromatographie sur silice (gradient de 5 à 15 % de l'éluant CH2CI2/MeOH/NH4OH 28% 38/17/2 dans le dichlorométhane), on obtient 150 mg de la (8S)-2-(morpholin-4-yl)-9- phényl-8-(thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4- one dont les caractéristiques sont les suivantes : \n(Example 1 e) in 1 ml of dimethylformamide, 422 mg of tripotassium phosphate, 380 mg of copper iodide and 2 ml of iodo benzene. The mixture obtained is heated in a microwave oven for 30 minutes at 150 \n°\n C. The reaction mixture is then centrifuged. The separated supernatant is then rinsed with ethyl acetate and then evaporated to dryness. The residue is taken up in ethyl acetate and the resulting solution is washed with water. The organic phase is separated and then dried over magnesium sulfate, filtered and concentrated in vacuo. After purification by chromatography on silica (gradient of 5 to 15% of eluent CH 2 Cl 2 / MeOH / NH 4 OH 28% 38/17/2 in dichloromethane), 150 mg of (8S) -2- (morpholin-4) are obtained. -yl) -phenyl-8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one having the following characteristics:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,40 à 2,48 (m, 2 H) ; 3,00 à 3,13 (m, 4 H) ; 3,31 à 3,37 (m, 1 H) ; 3,38 à 3,48 (m, 4 H) ; 4,33 à 4,40 (m, 1 H) ; 4,93 (m, 1 H) ; 4,99 (s, 1 H) ; 7,28 à 7,37 (m, 3 H) ; 7,43 (t, J=7,7 Hz, 2 H). \n 2.40 to 2.48 (m, 2H); 3.00 to 3.13 (m, 4H); 3.31 to 3.37 (m, 1H); 3.38 at 3.48 (m, 4H); 4.33 to 4.40 (m, 1H); 4.93 (m, 1H); 4.99 (s, 1H); 7.28-7.37 (m, 3H); 7.43 (t, J = 7.7 Hz, 2H).\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,83 \n Retention time Tr (min) = 0.83\n\n\n\n\n\n\n \n [M+H]+ : m/z 381 \n [M + H] +: m / z 381\n\n\n\n\n\n\n \nExemple 13 : (8S)-9-(4-fluorophényl)-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n\n\nExample 13: (8S) -9- (4-fluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] ] pyrimidin-4-one \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Le produit est préparé en suivant le mode opératoire décrit à l'exemple 12, à partir de 140 mg de la (S)-2-morpholin-4-yl-8-thfluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1 e) et de 0.66 mL de 1 - fluoro-4-iodobenzène. Après purification par chromatographie sur silice (gradient de 5% à 15% de l'éluant CH2CI2/MeOH/NH4OH 28% 38/17/2 dans le dichlorométhane), on obtient 125 mg de la (8S)-9-(4-fluorophényl)-2- (morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2- a]pyπmidin-4-one dont les caractéristiques sont les suivantes : \n The product is prepared following the procedure described in Example 12, starting from 140 mg of (S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido [1, 2-a] pyhmidin-4-one (Example 1 e) and 0.66 ml of 1-fluoro-4-iodobenzene. After purification by chromatography on silica (gradient of 5% to 15% of the eluent CH 2 Cl 2 / MeOH / NH 4 OH 28% 38/17/2 in dichloromethane), 125 mg of (8S) -9- (4- fluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyrimidin-4-one having the following characteristics: :\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,41 à 2,48 (m, 2 H) ; 3,01 à 3,15 (m, 4 H) ; 3,33 à 3,37 (m, 1 H) ; 3,40 à 3,50 (m, 4 H) ; 4,35 (m, 1 H) ; 4,82 à 4,94 (m, 1 H) ; 5,00 (s, 1 H) ; 7,25 (t, J=8,8 Hz, 2 H) ; 7,40 (dd, J=5,6 et 8,8 Hz, 2 H). \n 2.41 to 2.48 (m, 2H); 3.01 to 3.15 (m, 4H); 3.33 to 3.37 (m, 1H); 3.40 to 3.50 (m, 4H); 4.35 (m, 1H); 4.82 to 4.94 (m, 1H); 5.00 (s, 1H); 7.25 (t, J = 8.8 Hz, 2H); 7.40 (dd, J = 5.6 and 8.8 Hz, 2H).\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,86 \n Retention time Tr (min) = 0.86\n\n\n\n\n\n\n \n [M+H]+ : m/z 399 \n [M + H] +: m / z 399\n\n\n\n\n\n\n \nExemple 14 : (8S)-9-(3-fluorophényl)-2-(morpholin-4-yl)-8-\nExample 14: (8S) -9- (3-fluorophenyl) -2- (morpholin-4-yl) -8-\n\n\n\n\n\n\n \n(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n(Trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n \n\n Le produit est préparé en suivant le mode opératoire décrit à l'exemple 12 à partir de 140 mg de la (S)-2-morpholin-4-yl-8-thfluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1 e) et de 0.66 mL de 1 - fluoro-3-iodobenzène. Après purification par chromatographie sur silice (gradient de 5% à 15%de l'éluant CH2CI2/MeOH/NH4OH 28% 38/17/2 dans le dichlorométhane), on obtient 60 mg de la (8S)-9-(3-fluorophényl)-2- (morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2- a]pyπmidin-4-one dont les caractéristiques sont les suivantes : \n \n The product is prepared following the procedure described in Example 12 starting from 140 mg of (S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido [ 1, 2-a] pyhmidin-4-one (Example 1 e) and 0.66 ml of 1-fluoro-3-iodobenzene. After purification by chromatography on silica (gradient from 5% to 15% of the eluent CH 2 Cl 2 / MeOH / NH 4 OH 28% 38/17/2 in dichloromethane), 60 mg of (8S) -9- (3- fluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyrimidin-4-one having the following characteristics: :\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,41 à 2,48 (m, 2 H) ; 3,03 à 3,15 (m, 4 H) ; 3,25 à 3,27 (m, 1 H) ; 3,42 à 3,49 (m, 4 H) ; 4,32 à 4,41 (m, 1 H) ; 4,93 à 5,00 (m, 1 H) ; 5,02 (s, 1 H) ; 7,14 à 7,24 (m, 2 H) ; 7,30 (td, J=2,2 et 10,5 Hz, 1 H) ; 7,46 (dt, J=6,7 et 8,1 Hz, 1 H). \n 2.41 to 2.48 (m, 2H); 3.03 to 3.15 (m, 4H); 3.25 to 3.27 (m, 1H); 3.42 to 3.49 (m, 4H); 4.32 to 4.41 (m, 1H); 4.93 to 5.00 (m, 1H); 5.02 (s, 1H); 7.14 to 7.24 (m, 2H); 7.30 (td, J = 2.2 and 10.5 Hz, 1H); 7.46 (dt, J = 6.7 and 8.1 Hz, 1H).\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,86 \n Retention time Tr (min) = 0.86\n\n\n\n\n\n\n \n [M+H]+ : m/z 399 \n [M + H] +: m / z 399\n\n\n\n\n\n\n \nExemple 15 : (8S)-9-(2-fluorophényl)-2-(morpholin-4-yl)-8-\nExample 15: (8S) -9- (2-fluorophenyl) -2- (morpholin-4-yl) -8-\n\n\n\n\n\n\n \n(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n(Trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Le produit est préparé en suivant le mode opératoire décrit à l'exemple\n The product is prepared following the procedure described in the example\n\n\n\n\n\n\n \n12, à partir de 140 mg de la (S)-2-morpholin-4-yl-8-thfluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1 e) et de 0.66 mL de 1 - fluoro-2-iodobenzène. Après purification par chromatographie sur silice (gradient de 5% à 15% de l'éluant CH2CI2/MeOH/NH4OH 28% 38/17/2 dans le dichlorométhane), on obtient 12 mg de la (8S)-9-(2-fluorophényl)-2- \n\n (morpholin-4-yl)-8-(tπfluoronnéthyl)-6,7,8,9-tétrahydro-4H-pyπnnido[1 ,2- a]pyrimidin-4-one dont les caractéristiques sont les suivantes : \n12, from 140 mg of (S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one (Example 1 e) and 0.66 mL of 1-fluoro-2-iodobenzene. After purification by chromatography on silica (gradient of 5% to 15% of the eluent CH 2 Cl 2 / MeOH / NH 4 OH 28% 38/17/2 in dichloromethane), 12 mg of (8S) -9- (2- fluorophenyl) -2-  (Morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyπnnido [1,2-a] pyrimidin-4-one having the following characteristics:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,37 à 2,47 (m, 2 H) ; 3,05 à 3,09 (m, 5 H) ; 3,41 à 3,47 (m, 4 H) ; 4,35 à 4,44 (m, 1 H) ; 4,89 (m, 1 H) ; 5,02 (s, 1 H) ; 7,24 à 7,33 (m, 2 H) ; 7,36 à 7,45 (m, 1 H) ; 7,51 (m, 1 H). \n 2.37 to 2.47 (m, 2H); 3.05 to 3.09 (m, 5H); 3.41 to 3.47 (m, 4H); 4.35 to 4.44 (m, 1H); 4.89 (m, 1H); 5.02 (s, 1H); 7.24-7.33 (m, 2H); 7.36-7.45 (m, 1H); 7.51 (m, 1H).\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,83 \n Retention time Tr (min) = 0.83\n\n\n\n\n\n\n \n [M+H]+ : m/z 399 \n [M + H] +: m / z 399\n\n\n\n\n\n\n \nExemple 16 : (8S)-9-[(1 R ou 1S)-1-(3-fluorophényl)éthyl]-2-(morpholin-4- yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4- one \nExample 16: (8S) -9 - [(1R or 1S) -1- (3-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9 4-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nStade b : \nStage b:\n\n\n\n\n\n\n \n Dans un ballon, on chauffe à 80\n0\nC pendant 30 minutes un mélange de 300 mg de la (S)-2-chloro-1-[1 -(3-fluoro-phényl)-éthyl]-8-thfluorométhyl- 1 ,6,7,8-tétrahydro-pyrimido[1 ,2-a]pyhmidin-4-one et de 3 ml_ de morpholine. Après refroidissement, le mélange réactionnel est concentré sous pression réduite. Le résidu est repris par de l'acétate d'éthyle et de l'eau. La phase organique est séparée puis séchée sur sulfate de magnésium, filtrée et concentrée sous pression réduite. Après purification par chromatographie sur silice (éluant : CH2CI2/MeOH 97.5/2.5), on obtient 152 mg de la (8S)-9-[(1 -(3- fluorophényl)éthyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro- 4H-pyπmido[1 ,2-a]pyhmidin-4-one, sous forme d'un seul diastéréoisomère \n\n (configuration indéterminée au niveau de la chaîne phénéthyl) dont les caractéristiques sont les suivantes : \nIn a flask, a mixture of 300 mg of (S) -2-chloro-1- [1- (3-fluoro-phenyl) -ethyl] -8-thfluoromethyl-1, is heated at 80 \n°\n C. for 30 minutes. 6,7,8-tetrahydro-pyrimido [1,2-a] pyhmidin-4-one and 3 ml of morpholine. After cooling, the reaction mixture is concentrated under reduced pressure. The residue is taken up in ethyl acetate and water. The organic phase is separated and then dried over magnesium sulfate, filtered and concentrated under reduced pressure. After purification by chromatography on silica (eluent: CH 2 Cl 2 / MeOH 97.5 / 2.5), 152 mg of (8S) -9 - [(1 - (3-fluorophenyl) ethyl] -2- (morpholin-4-yl) are obtained 8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyπmido [1,2-a] pyhmidin-4-one as a single diastereoisomer  (indeterminate configuration at the level of the phenethyl chain) whose characteristics are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 1 ,66 (d, J=7,0 Hz, 3 H) ; 1 ,80 à 1 ,95 (m, 1 H) ; 2,33 à 2,41 (m, 1 H) ; 3,09 à 3,28 (m, 5 H) ; 3,40 à 3,52 (m, 4 H) ; 4,06 à 4,16 (m, 1 H) ; 4,56 (m, 1 H) ; 4,95 (s, 1 H) ; 5,51 (q, J=7,0 Hz, 1 H) ; 7,00 à 7,17 (m, 3 H) ; 7,33 à 7,42 (m, 1 H). \n 1.66 (d, J = 7.0 Hz, 3H); 1.80 to 1.95 (m, 1H); 2.33 to 2.41 (m, 1H); 3.09 to 3.28 (m, 5H); 3.40 to 3.52 (m, 4H); 4.06 to 4.16 (m, 1H); 4.56 (m, 1H); 4.95 (s, 1H); 5.51 (q, J = 7.0Hz, 1H); 7.00 to 7.17 (m, 3H); 7.33 to 7.42 (m, 1H).\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,94 \n Retention time Tr (min) = 0.94\n\n\n\n\n\n\n \n [M+H]+ : m/z 427 \n [M + H] +: m / z 427\n\n\n\n\n\n\n \nStade a : \nStage a:\n\n\n\n\n\n\n \n Dans un ballon, on introduit 400 mg de la (S)-2-chloro-8- trifluorométhyl-6,7,8,9-tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1d) dans 20 ml_ de tétrahydrofuranne, 1.6 g de triphénylphosphine supportée sur résine (3 mmol/g) et 663 mg 1 -(3-fluorophényl)éthanol. Le mélange réactionnel est alors agité à température ambiante pendant 5 minutes avant ajout de 0.790 ml_ de l'azodicarboxylate de diéthyle. Après 1 heure d'agitation à température ambiante, le mélange réactionnel est filtré et le filtrat concentré sous pression réduite. \n 400 mg of (S) -2-chloro-8-trifluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one (Example 1d) are introduced into a flask in 20 ml of tetrahydrofuran, 1.6 g of resin-supported triphenylphosphine (3 mmol / g) and 663 mg of 1- (3-fluorophenyl) ethanol. The reaction mixture is then stirred at room temperature for 5 minutes before addition of 0.790 ml of diethyl azodicarboxylate. After stirring for 1 hour at ambient temperature, the reaction mixture is filtered and the filtrate concentrated under reduced pressure.\n\n\n\n\n\n\n \n Le résidu est repris par de l'acétate d'éthyle et de l'eau. La phase organique est séparée puis séchée sur sulfate de magnésium, filtrée et concentrée sous pression réduite. Après purification par chromatographie sur silice (éluant CH2CI2/AcOEt 96/04), on obtient 150 mg de la (S)-2-chloro-1 - [1 -(3-fl uoro-phényl )-éthyl]-8-trifl uorométhyl - 1 ,6,7,8-tétrahydro-pyhmido[1 ,2- a]pyπmidin-4-one, sous forme d'un seul diastéréoisomère (configuration indéterminée au niveau de la chaîne phénéthyl) dont les caractéristiques sont les suivantes: \n The residue is taken up in ethyl acetate and water. The organic phase is separated and then dried over magnesium sulfate, filtered and concentrated under reduced pressure. After purification by chromatography on silica (eluent CH 2 Cl 2 / AcOEt 96/04), 150 mg of (S) -2-chloro-1- [1- (3-fluoro-phenyl) -ethyl] -8-trifl are obtained. uoromethyl-1, 6,7,8-tetrahydro-pyhmido [1,2-a] pyrimidin-4-one, in the form of a single diastereoisomer (indeterminate configuration at the phenethyl chain), the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n\n Temps de rétention Tr (min) = 1 ,11 \nMass spectrometry: method A  Retention time Tr (min) = 1, 11\n\n\n\n\n\n\n \n [M+H]+ : m/z 376 ; [M-H]- : m/z 253 (pic de base) \n [M + H] +: m / z 376; [M-H] -: m / z 253 (base peak)\n\n\n\n\n\n\n \nExemple 17 : (8S)-9-(4-fluorobenzyle)-2-(morpholin-4-yl)-8-\nExample 17: (8S) -9- (4-fluorobenzyl) -2- (morpholin-4-yl) -8-\n\n\n\n\n\n\n \n(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n(Trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n A une solution de 300 mg de la 2(S)-2-morpholin-4-yl-8-thfluorométhyl- 6,7,8,9-tétrahydro-pyrimido[1 ,2-a]pyrimidin-4-one (exemple 1e) dans 3 ml_ d'acétonitrile, sont ajoutés, sous atmosphère d'argon, 0.536 g de carbonate de césium et 0.44 ml_ de 1 -(bromométhyl)-4-fluorobenzène. Le mélange résultant est alors chauffé à 80\n0\nC durant deux heures. Le mélange réactionnel est alors évaporé sous pression réduite et le résidu obtenu est ensuite purifié par chromatographie sur silice (éluant : CH2CI2/MeOH 98/02) pour donner 61 mg de la (8S)-9-(4-fluorobenzyl)-2-(morpholin-4-yl)-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one, sous forme d'un solide blanc, dont les caractéristiques sont les suivantes : \nTo a solution of 300 mg of 2 (S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyrimidin-4-one (example 1e) in 3 ml of acetonitrile are added, under argon atmosphere, 0.536 g of cesium carbonate and 0.44 ml of 1- (bromomethyl) -4-fluorobenzene. The resulting mixture is then heated at 80 \n°\n C. for two hours. The reaction mixture is then evaporated off under reduced pressure and the residue obtained is then purified by chromatography on silica (eluent: CH 2 Cl 2 / MeOH 98/2) to give 61 mg of (8S) -9- (4-fluorobenzyl) -2- (Morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyhmidin-4-one, as a white solid, characteristics are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,09 à 2,25 (m, 1 H) ; 2,34 à 2,44 (m, 1 H) ; 3,18 à 3,32 (m, 5 H) ; 3,41 à 3,53 (m, 4 H) ; 4,21 (m, 1 H) ; 4,51 (d, J=15,2 Hz, 1 H) ; 4,60 à 4,72 (m, 1 H) ; 4,96 (s, 1 H) ; 5,17 (d, J=15,2 Hz, 1 H) ; 7,13 (t, J=8,7 Hz, 2 H) ; 7,30 (dd, J=5,4 et 8,7 Hz, 2 H) \n 2.09 to 2.25 (m, 1H); 2.34 to 2.44 (m, 1H); 3.18 to 3.32 (m, 5H); 3.41 to 3.53 (m, 4H); 4.21 (m, 1H); 4.51 (d, J = 15.2 Hz, 1H); 4.60 to 4.72 (m, 1H); 4.96 (s, 1H); 5.17 (d, J = 15.2 Hz, 1H); 7.13 (t, J = 8.7 Hz, 2H); 7.30 (dd, J = 5.4 and 8.7 Hz, 2H)\n\n\n\n\n\n\n \n Spectrométhe de Masse : Méthode A \n Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,89 \n Retention time Tr (min) = 0.89\n\n\n\n\n\n\n \n [M+H]+ : m/z 413 \n\n Exemple 18 : (S)-9-Benzoyl-2-morpholin-4-yl-8-trifluorométhyl-6,7,8,9- tétrahydro-pyrimido[1,2-a]pyrimidin-4-one \n[M + H] +: m / z 413  Example 18: (S) -9-Benzoyl-2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n A une solution de 300 mg de la 2(S)-2-morpholin-4-yl-8-trifluorométhyl- 6,7,8,9-tétrahydro-pyrinnido[1 ,2-a]pyhnnidin-4-one (exemple 1 e) dans 3 ml_ de tétrahydrofuranne, sont ajoutés, sous atmosphère d'argon, 35.7 mg d'hydrure de sodium puis, après 10 minutes d'agitation, 0.135 ml_ de chlorure de benzoyle. Après six heures d'agitation à température ambiante, on ajoute au mélange réactionnel une solution saturée en bicarbonate de sodium et de l'acétate d'éthyle. La phase organique est séparée puis successivement lavée avec une solution saturée en chlorure de sodium, séchée sur sulfate de magnésium, filtrée et concentrée sous pression réduite. Le résidu obtenu est purifié par chromatographie sur silice (éluant : CH2CI2) pour donner 74 mg de la (S)-9-benzoyl-2-morpholin-4-yl-8-trifluorométhyl-6,7,8,9-tétrahydro- pyπmido[1 ,2-a]pyhmidin-4-one, sous forme de solide blanc, dont les caractéristiques sont les suivantes : \n To a solution of 300 mg of 2 (S) -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrinnido [1,2-a] pyhnnidin-4-one (Example 1 e) in 3 ml of tetrahydrofuran, 35.7 mg of sodium hydride are added under an argon atmosphere and then, after stirring for 10 minutes, 0.135 ml of benzoyl chloride. After stirring for six hours at room temperature, a saturated solution of sodium bicarbonate and ethyl acetate is added to the reaction mixture. The organic phase is separated then successively washed with a saturated solution of sodium chloride, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue obtained is purified by chromatography on silica (eluent: CH 2 Cl 2) to give 74 mg of (S) -9-benzoyl-2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro- pyπmido [1, 2-a] pyhmidin-4-one, in the form of a white solid, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,20 à 2,31 (m, 1 H) ; 2,68 à 2,82 (m, 3 H) ; 2,86 à 2,96 (m, 2 H) ; 3,15 à 3,44 (m partiellement masqué, 4 H) ; 3,75 à 3,87 (m, 1 H) ; 4,17 à 4,30 (m, 1 H) ; 5,15 (s, 1 H) ; 5,38 à 5,53 (m, 1 H) ; 7,37 à 7,43 (m, 2 H) ; 7,45 à 7,53 (m, 3 H). \n 2.20 to 2.31 (m, 1H); 2.68 to 2.82 (m, 3H); 2.86 to 2.96 (m, 2H); 3.15 to 3.44 (partially masked m, 4H); 3.75 to 3.87 (m, 1H); 4.17 to 4.30 (m, 1H); 5.15 (s, 1H); 5.38 to 5.53 (m, 1H); 7.37 to 7.43 (m, 2H); 7.45 to 7.53 (m, 3H).\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode B \n Mass Spectrometry: Method B\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 3,59 \n Retention time Tr (min) = 3.59\n\n\n\n\n\n\n \n [M+H]+ : m/z 409 \n [M + H] +: m / z 409\n\n\n\n\n\n\n \n Pouvoir rotatoire : PR= -15.8+/-0.8; C= 1.650mg/0.5ML DMSO. \n\n Exemple 19 : (S)-2-morpholin-4-yl-9-pyridin-3-yl-8-trifluorométhyl- 6,7,8,9-tétrahydro-pyrimido[1,2-a]pyrimidin-4-one \nRotatory power: PR = -15.8 +/- 0.8; C = 1.650mg / 0.5ML DMSO.  Example 19: (S) -2-Morpholin-4-yl-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit est préparé en suivant le mode opératoire décrit à l'exemple 12, à partir de 200 mg de la (S)-2-morpholin-4-yl-8-trifluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1e) et de 380 mg de 3- iodopyridine. Après purification par chromatographie sur silice (gradient d'élution de CH2CI2 à CH2CI2/MeOH 96/04), on obtient 48 mg de la (S)-2- morpholin-4-yl-9-pyhdin-3-yl-8-thfluorométhyl-6,7,8,9-tétrahydro-pyrimido[1 ,2- a]pyπmidin-4-one, sous forme de solide jaune, dont les caractéristiques sont les suivantes : \nThe product is prepared following the procedure described in Example 12, starting from 200 mg of (S) -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyhmido [1, 2-a] pyhmidin-4-one (Example 1e) and 380 mg of 3-iodopyridine. After purification by chromatography on silica (elution gradient from CH 2 Cl 2 to CH 2 Cl 2 / MeOH 96/04), 48 mg of (S) -2-morpholin-4-yl-9-pyhdin-3-yl-8 are obtained. thfluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyrimidin-4-one, in the form of a yellow solid, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,44 à 2,48 (m, 2 H) ; 3,00 à 3,13 (m, 4 H) ; 3,31 à 3,37 (m, 1 H) ; 3,41 à 3,47 (m, 4 H) ; 4,37 (d, J=16,1 Hz, 1 H) ; 4,97 à 5,09 (m, 2 H) ; 7,48 (dd, J=4,9 et 8,3 Hz, 1 H) ; 7,80 à 7,85 (m, 1 H) ; 8,50 (dd, J=1 ,4 et 4,9 Hz, 1 H) ; 8,57 (d, J=2,2 Hz, 1 H). \n 2.44 to 2.48 (m, 2H); 3.00 to 3.13 (m, 4H); 3.31 to 3.37 (m, 1H); 3.41 to 3.47 (m, 4H); 4.37 (d, J = 16.1 Hz, 1H); 4.97 to 5.09 (m, 2H); 7.48 (dd, J = 4.9 and 8.3 Hz, 1H); 7.80 to 7.85 (m, 1H); 8.50 (dd, J = 1, 4 and 4.9 Hz, 1H); 8.57 (d, J = 2.2 Hz, 1H).\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,55 \n Retention time Tr (min) = 0.55\n\n\n\n\n\n\n \n [M+H]+ : m/z 382 \n [M + H] +: m / z 382\n\n\n\n\n\n\n \n Pouvoir rotatoire : PR=-40 +/-1.6, C=0.2% dans le DMSO. \n Rotatory power: PR = -40 +/- 1.6, C = 0.2% in the DMSO.\n\n\n\n\n\n\n \nExemple 20 : (S)-2-morpholin-4-yl-9-pyridin-4-yl-8-trifluorométhyl-\nExample 20: (S) -2-Morpholin-4-yl-9-pyridin-4-yl-8-trifluoromethyl\n\n\n\n\n\n\n \n6,7,8,9-tétrahydro-pyrimido[1,2-a]pyrimidin-4-one \n6,7,8,9-tetrahydro-pyrimido [1,2- a] pyrimidin-4-one\n\n\n\n\n\n\n \n SAR236152 \n\n \n\n\n\nSAR236152 \n \n\n\n\n\n\n\n \n Le produit est préparé en suivant le mode opératoire décrit à l'exemple 12, à partir de 200 mg de la (S)-2-morpholin-4-yl-8-trifluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1e) et de 380 mg de A- iodopyridine. Après purification par chromatographie sur silice (gradient d'élution de CH2CI2 à CH2CI2/MeOH 96/04), on obtient 26 mg de la (S)-2- morpholin-4-yl-9-pyhdin-4-yl-8-trifluorométhyl-6,7,8,9-tétrahydro-pyrimido[1 ,2- a]pyπmidin-4-one, sous forme de solide jaune, dont les caractéristiques sont les suivantes : \n The product is prepared following the procedure described in Example 12, starting from 200 mg of (S) -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyhmido [1, 2-a] pyhmidin-4-one (Example 1e) and 380 mg of A-iodopyridine. After purification by chromatography on silica (elution gradient from CH 2 Cl 2 to CH 2 Cl 2 / MeOH 96/04), 26 mg of (S) -2-morpholin-4-yl-9-pyhdin-4-yl-8 are obtained. trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1,2-a] pyrimidin-4-one, in the form of a yellow solid, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,43 à 2,48 (m, 2 H) ; 3,07 à 3,19 (m, 4 H) ; 3,33 à 3,39 (m, 1 H) ; 3,45 à 3,50 (m, 4 H) ; 4,30 à 4,38 (m, 1 H) ; 5,06 (s, 1 H) ; 5,09 à 5,17 (m, 1 H) ; 7,45 (d, J=6,1 Hz, 2 H) ; 8,62 (d, J=6,1 Hz, 2 H). \n 2.43 to 2.48 (m, 2H); 3.07 to 3.19 (m, 4H); 3.33 to 3.39 (m, 1H); 3.45 to 3.50 (m, 4H); 4.30 to 4.38 (m, 1H); 5.06 (s, 1H); 5.09 to 5.17 (m, 1H); 7.45 (d, J = 6.1 Hz, 2H); 8.62 (d, J = 6.1 Hz, 2H).\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n [M+H]+ : m/z 382 ; [M-H]- : m/z 380 \n [M + H] +: m / z 382; [M-H] -: m / z 380\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,42 \n Retention time Tr (min) = 0.42\n\n\n\n\n\n\n \n Pouvoir rotatoire : PR=-31 +/- 1.3, C=0.2% dans le DMSO. \n Rotatory power: PR = -31 +/- 1.3, C = 0.2% in the DMSO.\n\n\n\n\n\n\n \nExemple 21 : (8S)-9-(4-méthylphényl)-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n\n\nExample 21: (8S) -9- (4-methylphenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] ] pyrimidin-4-one \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit est préparé en suivant le mode opératoire décrit à l'exemple 12, à partir de 100 mg de la (8S)-2-morpholin-4-yl-8-thfluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1e) et de 100 mg de 1 - iodo-4-méthylbenzène. Après purification par chromatographie sur silice (éluant: CH2CI2/MeOH 98/02), on obtient 23 mg de la (8S)-9-(4- méthylphényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H- pyπmido[1 ,2-a]pyhmidin-4-one, sous forme de solide crème, dont les caractéristiques sont les suivantes : \nThe product is prepared following the procedure described in Example 12, starting from 100 mg of (8S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido. [1, 2-a] pyhmidin-4-one (Example 1e) and 100 mg of 1-iodo-4-methylbenzene. After purification by chromatography on silica (eluent: CH 2 Cl 2 / MeOH 98/2), 23 mg of (8S) -9- (4-methylphenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) are obtained. 6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one, in the form of a cream solid, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,32 (s, 3 H) ; 2,44 (m, 2 H) ; 2,97 à 3,15 (m, 4 H) ; 3,33 à 3,50 (m partiellement masqué, 5 H) ; 4,34 (m, 1 H) ; 4,86 (m, 1 H) ; 4,98 (s, 1 H) ; 7,22 (s, 4 H). \n 2.32 (s, 3H); 2.44 (m, 2H); 2.97 to 3.15 (m, 4H); 3.33 - 3.50 (partially masked m, 5H); 4.34 (m, 1H); 4.86 (m, 1H); 4.98 (s, 1H); 7.22 (s, 4H).\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,90 \n Retention time Tr (min) = 0.90\n\n\n\n\n\n\n \n [M+H]+ : m/z 395 \n [M + H] +: m / z 395\n\n\n\n\n\n\n \nExemple 22 : (8S)-9-(2-chlorobenzyl)-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n\n\nExample 22: (8S) -9- (2-chlorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] ] pyrimidin-4-one \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 100 mg de la (8S)-2-(morpholin-4-yl)-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhnnido[1 ,2-a]pyhnnidin-4-one \nTo a solution of 100 mg of (8S) -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhnnido [1,2-a] pyhnnidine 4-one\n\n\n\n\n\n\n \n(exemple 1 e) dans 2 ml_ de diméthylfornnannide sont ajoutés 214 mg de carbonate de césium et 74 mg de 1 -(bromométhyl)-2-chlorobenzène. Après 16 heures à une température voisine de 20\n0\nC, le milieu réactionnel est versé dans de l'eau. La phase organique est séparée et la phase aqueuse est extraite par de l'acétate d'éthyle. Les phases organiques rassemblées sont concentrées à sec sous pression réduite. Le résidu est purifié par HPLC/MS préparative (Méthode C). Après évaporation de l'acétonitrile et lyophilisation, on obtient 94 mg de (8S)-9-(2-chlorobenzyl)-2-(morpholin-4-yl)-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one, sous forme d'une huile dont les caractéristiques, sont les suivantes : \n(Example 1 e) in 2 ml of dimethylfornnannide are added 214 mg of cesium carbonate and 74 mg of 1- (bromomethyl) -2-chlorobenzene. After 16 hours at a temperature in the region of 20 \n°\n C., the reaction medium is poured into water. The organic phase is separated and the aqueous phase is extracted with ethyl acetate. The combined organic phases are concentrated to dryness under reduced pressure. The residue is purified by preparative HPLC / MS (Method C). After evaporation of the acetonitrile and lyophilization, 94 mg of (8S) -9- (2-chlorobenzyl) -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9- tetrahydro-4H-pyhmido [1,2-a] pyhmidin-4-one, in the form of an oil, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,29 à 2,66 (m, 2 H) ; 3,09 à 3,18 (m, 4 H) ; 3,23 à3,50 (m partiellement masqué, 5 H) ; 4,27 (m, 1 H) ; 4,68 (d, J=16,6 Hz, 1 H) ; 4,74 (m, 1 H) ; 4,96 (s, 1 H); 5,12 (d, J=16,6 Hz, 1 H) ; 7,16 à 7,22 (m, 1 H) ; 7,24 à 7,32 (m, 2 H) ; 7,41 à 7,48 (m, 1 H). \n 2.29 to 2.66 (m, 2H); 3.09 to 3.18 (m, 4H); 3.23 to 3.50 (partially masked m, 5H); 4.27 (m, 1H); 4.68 (d, J = 16.6 Hz, 1H); 4.74 (m, 1H); 4.96 (s, 1H); 5.12 (d, J = 16.6 Hz, 1H); 7.16 to 7.22 (m, 1H); 7.24-7.32 (m, 2H); 7.41 to 7.48 (m, 1H).\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,96 \n Retention time Tr (min) = 0.96\n\n\n\n\n\n\n \n [M+H]+ : m/z 429 \n\n Exemple 23 : (8S)-9-(3-fluorobenzyl)-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n[M + H] +: m / z 429  Example 23: (8S) -9- (3-fluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] ] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit est préparé en suivant le mode opératoire décrit à l'exemple 22, à partir de 100 mg de la (8S)-2-(morpholin-4-yl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one, de 214 mg de carbonate de césium et de 68 mg de 1 -(bromométhyl)-3-fluorobenzène. \nThe product is prepared following the procedure described in Example 22, starting from 100 mg of (8S) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9 4-tetrahydro-4H-pyhmido [1,2-a] pyrimidin-4-one, 214 mg of cesium carbonate and 68 mg of 1- (bromomethyl) -3-fluorobenzene.\n\n\n\n\n\n\n \nAprès purification par HPLC/MS préparative (Méthode C), on obtient 102 mg de là (8S)-9-(3-fluorobenzyl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one, sous la forme d'une huile, dont les caractéristiques sont les suivantes : \nAfter purification by preparative HPLC / MS (Method C), 102 mg of (8S) -9- (3-fluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6.7 is obtained, 8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one, in the form of an oil, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,17 à 2,45 (m, 2 H) ; 3,15 à 3,31 (m, 5 H) ; 3,39 à 3,49 (m, 4 H) ; 4,23 (m, 1 H) ; 4,58 (d, J=16,1 Hz, 1 H) ; 4,66 à 4,78 (m, 1 H) ; 4,97 (s, 1 H) ; 5,13 (d, J=16,1 Hz, 1 H) ; 6,98 à 7,15 (m, 3 H ); 7,35 (dt, J=6,0 et 8,1 Hz, 1 H)\n 2.17 to 2.45 (m, 2H); 3.15 to 3.31 (m, 5H); 3.39 to 3.49 (m, 4H); 4.23 (m, 1H); 4.58 (d, J = 16.1 Hz, 1H); 4.66 to 4.78 (m, 1H); 4.97 (s, 1H); 5.13 (d, J = 16.1 Hz, 1H); 6.98 to 7.15 (m, 3H); 7.35 (dt, J = 6.0 and 8.1 Hz, 1H)\n\n\n\n\n\n\n \nSpectrométrie de Masse : méthode A \nMass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,89 \n Retention time Tr (min) = 0.89\n\n\n\n\n\n\n \n [M+H]+ : m/z 413 \n [M + H] +: m / z 413\n\n\n\n\n\n\n \nExemple 24 : (8S)-9-[2-(2-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n\n\nExample 24: (8S) -9- [2- (2-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [ 1,2-a] pyrimidin-4-one \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 100 mg de la (8S)-2-(morpholin-4-yl)-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhnnido[1 ,2-a]pyhnnidin-4-one \nTo a solution of 100 mg of (8S) -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhnnido [1,2-a] pyhnnidine 4-one\n\n\n\n\n\n\n \n(exemple 1 e) dans 2 ml_ de diméthylformannide sont ajoutés 214 mg de carbonate de césium et 78 mg de 1 -(2-bromoéthyl)-3-méthoxybenzène . Après 18 heures à température de 60\n0\nC, on rajoute 78 mg de 1 -(2- bromoéthyl)-3-fluorobenzène. Après 2 jours à une température de 60\n0\nC, le mélange réactionnel obtenu est versé dans de l'eau. La phase organique est séparée et la phase aqueuse est extraite par de l'acétate d'éthyle. Les phases organiques rassemblées sont concentrées à sec sous pression réduite. Le résidu est purifié par HPLC/MS préparative (Méthode C). Après évaporation de l'acétonitrile et lyophilisation, on obtient 25 mg de la (8S)-9-[2- (2-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one, sous forme d'une huile, dont les caractéristiques sont les suivantes : \n(Example 1 e) in 2 ml of dimethylformanide are added 214 mg of cesium carbonate and 78 mg of 1- (2-bromoethyl) -3-methoxybenzene. After 18 hours at a temperature of 60 \n°\n C., 78 mg of 1- (2-bromoethyl) -3-fluorobenzene are added. After 2 days at a temperature of 60 \n°\n C., the reaction mixture obtained is poured into water. The organic phase is separated and the aqueous phase is extracted with ethyl acetate. The combined organic phases are concentrated to dryness under reduced pressure. The residue is purified by preparative HPLC / MS (Method C). After evaporation of the acetonitrile and lyophilization, 25 mg of (8S) -9- [2- (2-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6 are obtained, 7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one, in the form of an oil, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 1 ,84 à 2,00 (m, 1 H) ; 2,25 à 2,35 (m, 1 H) ; 2,83 à 3,03 (m, 2 H) ; 3,06 à 3,30\n 1.84 at 2.00 (m, 1H); 2.25 to 2.35 (m, 1H); 2.83 to 3.03 (m, 2H); 3.06 to 3.30\n\n\n\n\n\n\n \n(m, 2 H) ; 3,44 (m, 4 H) ; 3,61 à 3,67 (m, 4 H) ; 3,76 (s, 3 H) ; 4,08 à 4,24 (m,\n(m, 2H); 3.44 (m, 4H); 3.61 to 3.67 (m, 4H); 3.76 (s, 3H); 4.08 to 4.24 (m,\n\n\n\n\n\n\n \n2H) ; 4,37 à 4,52 (m, 1 H) ; 4,99 (s, 1 H) ; 6,88 (dt, J=0,9 et 7,6 Hz, 1 H) ; 6,96 (d large, J=7,9 Hz, 1 H) ; 7,14 (dd, J=1 ,5 et 7,6 Hz, 1 H) ; 7,18 à 7,26 (m, 1 H)\n2H); 4.37 to 4.52 (m, 1H); 4.99 (s, 1H); 6.88 (dt, J = 0.9 and 7.6 Hz, 1H); 6.96 (broad d, J = 7.9 Hz, 1H); 7.14 (dd, J = 1.5 and 7.6 Hz, 1H); 7.18 to 7.26 (m, 1H)\n\n\n\n\n\n\n \nSpectrométhe de Masse : méthode A \nMass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,98 \n Retention time Tr (min) = 0.98\n\n\n\n\n\n\n \n [M+H]+ : m/z 439 \n\n Exemple 25 :(8S)-9-[2-(3-méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n[M + H] +: m / z 439  Example 25: (8S) -9- [2- (3-methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [ 1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n \n\n Le produit est préparé en suivant le mode opératoire décrit à l'exemple\n \n The product is prepared following the procedure described in the example\n\n\n\n\n\n\n \n24, mais à partir de 100 mg de la (8S)-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one, de 78 mg de 1 -(2- bromoéthyl)-3-méthoxybenzène et de 214 mg de carbonate de césium dans 2 ml_ de diméthylformamide. Après 3 jours de réaction à une température de 60\n0\nC, traitement comme décrit à l'exemple 24 et purification par HPLC/MS préparative (Méthode C), on obtient 20 mg de la (8S)-9-[2-(3- méthoxyphényl)éthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)-6,7,8,9-tétrahydro- 4H-pyrimido[1 ,2-a]pyhmidin-4-one, sous la forme d'une huile, dont les caractéristiques sont les suivantes : \n24, but starting from 100 mg of (8S) -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyrimidin-4-one, 78 mg of 1- (2-bromoethyl) -3-methoxybenzene and 214 mg of cesium carbonate in 2 ml of dimethylformamide. After 3 days of reaction at a temperature of 60 \n°\n C., treatment as described in Example 24 and purification by preparative HPLC / MS (Method C), 20 mg of (8S) -9- [2- (3) methoxyphenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one, form of an oil, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 1 ,88 à 2,01 (m, 1 H) ; 2,32 (m, 1 H) ; 2,74 à 2,90 (m, 1 H) ; 2,96 (m, 1 H) ; 3,10 à 3,22 (m, 1 H) ; 3,26 à 3,39 (m partiellement masqué, 1 H) ; 3,43 à 3,48 (m, 4 H) ; 3,62 à 3,68 (m, 4 H) ; 3,73 (s, 3 H) ; 4,02 à 4,23 (m, 2 H) ; 4,49 à 4,65 (m, 1 H) ; 5,00 (s, 1 H) ; 6,70 à 6,88 (m, 3 H) ; 7,14 à 7,26 (m, 1 H) Spectrométrie de Masse : méthode A \n 1.88 to 2.01 (m, 1H); 2.32 (m, 1H); 2.74 to 2.90 (m, 1H); 2.96 (m, 1H); 3.10 to 3.22 (m, 1H); 3.26 to 3.39 (partially masked m, 1H); 3.43 to 3.48 (m, 4H); 3.62 to 3.68 (m, 4H); 3.73 (s, 3H); 4.02 to 4.23 (m, 2H); 4.49 to 4.65 (m, 1H); 5.00 (s, 1H); 6.70 to 6.88 (m, 3H); 7.14 to 7.26 (m, 1H) Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,94 \n Retention time Tr (min) = 0.94\n\n\n\n\n\n\n \n [M+H]+ : m/z 439 \n\n Exemple 26 : (8S)-9-(3-méthoxybenzyl)-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n[M + H] +: m / z 439  Example 26: (8S) -9- (3-Methoxybenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] ] pyrimidin-4-one\n\n\n\n\n\n\n \n \n\n Le produit est préparé en suivant le mode opératoire décrit à l'exemple\n \n The product is prepared following the procedure described in the example\n\n\n\n\n\n\n \n22, mais à partir de 100 mg de la (8S)-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one, de 57 mg de 1 - (chlorométhyl)-3-méthoxybenzène et de 214 mg de carbonate de césium dans 2 ml_ de diméthylformamide. Après traitement, le résidu est agité dans de l'acétonitrile. Le solide est essoré, rincé par de l'oxyde de diéthyle puis séché sous cloche à vide. On obtient ainsi 111 mg de (8S)-9-(3- méthoxybenzyl)-2-(morpholin-4-yl)-8-(thfluorométhyl)-6,7,8,9-tétrahydro-4H- pyπmido[1 ,2-a]pyhmidin-4-one, sous forme d'un solide blanc, dont les caractéristiques sont les suivantes : \n22, but starting from 100 mg of (8S) -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyrimidin-4-one, 57 mg of 1- (chloromethyl) -3-methoxybenzene and 214 mg of cesium carbonate in 2 ml of dimethylformamide. After treatment, the residue is stirred in acetonitrile. The solid is drained, rinsed with diethyl ether and then dried under vacuum. 111 mg of (8S) -9- (3-methoxybenzyl) -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyπmido [1 are thereby obtained. 2-a] pyhmidin-4-one, in the form of a white solid, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,07 à 2,23 (m, 1 H) ; 2,35 à 2,44 (m, 1 H) ; 3,19 à 3,28 (m, 5 H) ; 3,40 à 3,55 (m, 4 H) ; 3,72 (s, 3 H) ; 4,22 (m, 1 H) ; 4,45 (d, J=15,9 Hz, 1 H) ; 4,56 à 4,70 (m, 1 H) ; 4,96 (s, 1 H) ; 5,21 (d, J=15,9 Hz, 1 H) ; 6,75 à 6,88 (m, 3 H) ; 7,19 à 7,27 (m, 1 H) \n 2.07 to 2.23 (m, 1H); 2.35 to 2.44 (m, 1H); 3.19 to 3.28 (m, 5H); 3.40 to 3.55 (m, 4H); 3.72 (s, 3H); 4.22 (m, 1H); 4.45 (d, J = 15.9 Hz, 1H); 4.56 to 4.70 (m, 1H); 4.96 (s, 1H); 5.21 (d, J = 15.9 Hz, 1H); 6.75 to 6.88 (m, 3H); 7.19 to 7.27 (m, 1H)\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,88 \n Retention time Tr (min) = 0.88\n\n\n\n\n\n\n \n [M+H]+ : m/z 425 \n\n Exemple 27 : (8S)-9-(4-méthoxyphényl)-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n[M + H] +: m / z 425  Example 27: (8S) -9- (4-Methoxyphenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] ] pyrimidin-4-one\n\n\n\n\n\n\n \nChiral \nchiral\n\n\n\n\n\n\n \n \n\n Le produit est préparé en suivant le mode opératoire décrit à l'exemple\n \n The product is prepared following the procedure described in the example\n\n\n\n\n\n\n \n12, à partir de 100 mg de la (8S)-2-morpholin-4-yl-8-thfluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1 e), de 108 mg de 1- iodo-4-méthoxybenzène et de 79 mg de 4,7-diméthoxy-1 ,10-phénanthroline. Après purification par chromatographie sur silice (éluant : CH2CI2/MeOH 98/02), on obtient 31 mg de (8S)-9-(4-méthoxyphényl)-2-(morpholin-4-yl)-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one, sous forme d'une meringue crème, dont les caractéristiques sont les suivantes : \n12, starting from 100 mg of (8S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one (example 1 e), 108 mg of 1-iodo-4-methoxybenzene and 79 mg of 4,7-dimethoxy-1,10-phenanthroline. After purification by chromatography on silica (eluent: CH 2 Cl 2 / MeOH 98/2), 31 mg of (8S) -9- (4-methoxyphenyl) -2- (morpholin-4-yl) -8- (thfluoromethyl) are obtained. 6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyhmidin-4-one, in the form of a cream meringue, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,38 à 2,46 (m, 2 H) ; 3,04 à 3,15 (m, 4 H) ; 3,20 à 3,35 (m partiellement masqué, 1 H) ; 3,45 (m, 4 H) ; 3,77 (s, 3 H) ; 4,34 (m, 1 H) ; 4,83 (m, 1 H) ; 4,98 (s, 1 H) ; 6,95 (d, J=8,8 Hz, 2 H) ; 7,25 (d, J=8,8 Hz, 2 H) \n 2.38 to 2.46 (m, 2H); 3.04 to 3.15 (m, 4H); 3.20 to 3.35 (partially masked m, 1H); 3.45 (m, 4H); 3.77 (s, 3H); 4.34 (m, 1H); 4.83 (m, 1H); 4.98 (s, 1H); 6.95 (d, J = 8.8 Hz, 2H); 7.25 (d, J = 8.8 Hz, 2H)\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,83 \n Retention time Tr (min) = 0.83\n\n\n\n\n\n\n \n [M+H]+ : m/z 411 \n\n Exemple 28 : (8S)-9-[(2-fluorophényl)carbonyl]-2-(morpholin-4-yl)-\n[M + H] +: m / z 411  Example 28: (8S) -9 - [(2-fluorophenyl) carbonyl] -2- (morpholin-4-yl) -\n\n\n\n\n\n\n \n8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n \nChiral \nchiral\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit est préparé en suivant le mode opératoire décrit à l'exemple 18, à partir de 300 mg de la (8S)-2-morpholin-4-yl-8-trifluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1 e), de 47 mg d'hydrure de sodium et de 156 mg de chlorure de 2-fluorobenzoyle dans 5 ml_ de tétrahydrofuranne. Après purification par chromatographie sur silice (éluant :\nThe product is prepared following the procedure described in Example 18, starting from 300 mg of (8S) -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyhmido [1, 2-a] pyhmidin-4-one (Example 1 e), 47 mg of sodium hydride and 156 mg of 2-fluorobenzoyl chloride in 5 ml of tetrahydrofuran. After purification by chromatography on silica (eluent:\n\n\n\n\n\n\n \nCH2CI2/MeOH 98/02), on obtient 35mg de la (8S)-9-[(2- fluorophényl)carbonyl]-2-(morpholin-4-yl)-8-(trifluorométhyl)-6, 7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one, sous forme d'une meringue blanche, dont les caractéristiques sont les suivantes : \nCH 2 Cl 2 / MeOH 98/02), 35 mg of (8S) -9 - [(2-fluorophenyl) carbonyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6.7,8 are obtained, 9-Tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one, in the form of a white meringue, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,13 à 2,26 (m, 1 H) ; 2,65 à 2,85 (m, 3 H) ; 2,94 à 3,02 (m, 2 H) ; 3,20 à 3,40 (m partiellement masqué, 4 H) ; 3,43 à 3,55 (m, 1 H) ; 4,42 (m, 1 H) ; 5,19 (s, 1 H) ; 5,55 à 5,69 (m, 1 H) ; 7,18 à 7,31 (m, 2 H) ; 7,49 à 7,64 (m, 2 H) \n 2.13 to 2.26 (m, 1H); 2.65 to 2.85 (m, 3H); 2.94 to 3.02 (m, 2H); 3.20 to 3.40 (partially masked m, 4H); 3.43 to 3.55 (m, 1H); 4.42 (m, 1H); 5.19 (s, 1H); 5.55 to 5.69 (m, 1H); 7.18 to 7.31 (m, 2H); 7.49 to 7.64 (m, 2H)\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,79 \n Retention time Tr (min) = 0.79\n\n\n\n\n\n\n \n [M+H]+ : m/z 427 \n [M + H] +: m / z 427\n\n\n\n\n\n\n \nExemple 29 : (8S)-9-(3,5-difluorobenzyl)-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n\n\nExample 29: (8S) -9- (3,5-difluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2 -a] pyrimidin-4-one \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit est préparé en suivant le mode opératoire décrit à l'exemple 22, à partir de 100 mg de la (8S)-2-morpholin-4-yl-8-thfluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1 e), de 214 mg de carbonate de césium et de 75 mg de 1 -(bromométhyl)-3,5-difluorobenzène dans 2 ml_ de diméthylformamide. Après purification par HPLC/MS \nThe product is prepared following the procedure described in Example 22, starting from 100 mg of (8S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido. [1, 2-a] pyhmidin-4-one (Example 1 e), 214 mg of cesium carbonate and 75 mg of 1- (bromomethyl) -3,5-difluorobenzene in 2 ml of dimethylformamide. After purification by HPLC / MS\n\n\n\n\n\n\n \npréparative (Méthode C), on obtient 85 mg de la (8S)-9-(3,5-difluorobenzyl)-2- (morpholin-4-yl)-8-(thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2- a]pyπmidin-4-one, sous forme d'une huile, dont les caractéristiques sont les suivantes : \nPreparative procedure (Method C) gives 85 mg of (8S) -9- (3,5-difluorobenzyl) -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9- tetrahydro-4H-pyhmido [1,2-a] pyrimidin-4-one, in the form of an oil, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,21 à 2,44 (m, 2 H) ; 3,14 à 3,33 (m, 5 H) ; 3,36 à 3,52 (m, 4 H) ; 4,23 (m, 1 H) ; 4,61 (d, J=16,4 Hz, 1 H) ; 4,68 à 4,81 (m, 1 H) ; 4,98 (s, 1 H) ; 5,07 (d, J=16,4 Hz, 1 H) ; 6,90 à 7,02 (m, 2 H) ; 7,07 (tt, J=2,3 et 9,3 Hz, 1 H) \n 2.21 to 2.44 (m, 2H); 3.14 to 3.33 (m, 5H); 3.36-3.52 (m, 4H); 4.23 (m, 1H); 4.61 (d, J = 16.4 Hz, 1H); 4.68 to 4.81 (m, 1H); 4.98 (s, 1H); 5.07 (d, J = 16.4 Hz, 1H); 6.90 to 7.02 (m, 2H); 7.07 (tt, J = 2.3 and 9.3 Hz, 1H)\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode B \n Mass Spectrometry: Method B\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 3,93 \n Retention time Tr (min) = 3.93\n\n\n\n\n\n\n \n [M+H]+ : m/z 431 \n [M + H] +: m / z 431\n\n\n\n\n\n\n \nExemple 30 : (8S)-9-(2,4-difluorobenzyl)-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n\n\nExample 30: (8S) -9- (2,4-difluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2 -a] pyrimidin-4-one \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit est préparé en suivant le mode opératoire décrit à l'exemple 22, à partir de 100 mg de la (8S)-2-morpholin-4-yl-8-thfluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1e), de 214 mg de carbonate de césium et de 75 mg de 1 -(bromométhyl)-2,4-difluorobenzène dans 2 ml_ de diméthylformamide. Après purification par HPLC/MS \nThe product is prepared following the procedure described in Example 22, starting from 100 mg of (8S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido. [1, 2-a] pyhmidin-4-one (Example 1e), 214 mg of cesium carbonate and 75 mg of 1- (bromomethyl) -2,4-difluorobenzene in 2 ml of dimethylformamide. After purification by HPLC / MS\n\n\n\n\n\n\n \npréparative (Méthode C), on obtient 86 mg de la (8S)-9-(2,4-difluorobenzyl)-2- (morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2- a]pyπmidin-4-one, sous forme d'une huile, dont les caractéristiques sont les suivantes : \nPreparative method (Method C) gives 86 mg of (8S) -9- (2,4-difluorobenzyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9- tetrahydro-4H-pyhmido [1,2-a] pyrimidin-4-one, in the form of an oil, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,16 à 2,30 (m, 1 H) ; 2,35 à 2,45 (m, 1 H) ; 3,17 à 3,32 (m, 5 H) ; 3,41 à 3,49 (m, 4 H) ; 4,22 (dd, J=5,9 et 14,2 Hz, 1 H) ; 4,60 (d, J=16,1 Hz, 1 H) ;\n 2.16 to 2.30 (m, 1H); 2.35 to 2.45 (m, 1H); 3.17 to 3.32 (m, 5H); 3.41 to 3.49 (m, 4H); 4.22 (dd, J = 5.9 and 14.2 Hz, 1H); 4.60 (d, J = 16.1 Hz, 1H);\n\n\n\n\n\n\n \n4,66 à 4,76 (m, 1 H) ; 4,97 (s, 1 H) ; 5,11 (d, J=16,1 Hz, 1 H) ; 7,03 (ddt, J=1 ,1 - 2,6 et 9,0 Hz,1 H) ; 7,22 (ddd, J=2,6 - 9,0 et 10,9 Hz,1 H) ; 7,30 (dt,\n4.66 to 4.76 (m, 1H); 4.97 (s, 1H); 5.11 (d, J = 16.1 Hz, 1H); 7.03 (ddt, J = 1.1, 2.6 and 9.0 Hz, 1H); 7.22 (ddd, J = 2.6 - 9.0 and 10.9 Hz, 1H); 7.30 (dt,\n\n\n\n\n\n\n \nJ=6,7 et 9,0 Hz, 1 H) \nJ = 6.7 and 9.0 Hz, 1H)\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode B \n Mass Spectrometry: Method B\n\n\n\n\n\n\n \n Temps de rétention Tr (min)= 3,96 \n Retention time Tr (min) = 3.96\n\n\n\n\n\n\n \n [M+H]+ : m/z 431 \n [M + H] +: m / z 431\n\n\n\n\n\n\n \nExemple 31 : (8S)-2-(morpholin-4-yl)-9-(2,3,4-trifluorobenzyl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n\n\nExample 31: (8S) -2- (Morpholin-4-yl) -9- (2,3,4-trifluorobenzyl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1 , 2-a] pyrimidin-4-one \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit est préparé en suivant le mode opératoire décrit à l'exemple 22, à partir de 100 mg de la (8S)-2-morpholin-4-yl-8-thfluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1e), de 214 mg de carbonate de césium et de 82 mg de 1 -(bromométhyl)-2,3,4-trifluorobenzène dans 2 ml_ de diméthylformamide. Après purification par HPLC/MS \nThe product is prepared following the procedure described in Example 22, starting from 100 mg of (8S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido. [1, 2-a] pyhmidin-4-one (Example 1e), 214 mg of cesium carbonate and 82 mg of 1- (bromomethyl) -2,3,4-trifluorobenzene in 2 ml of dimethylformamide. After purification by HPLC / MS\n\n\n\n\n\n\n \npréparative (Méthode C), on obtient 76 mg de la (8S)-2-(morpholin-4-yl)-9- (2,3,4-trifluorobenzyl)-8-(thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2- a]pyπmidin-4-one, sous forme d'une huile, dont les caractéristiques sont les suivantes : \nPreparative method (Method C) gives 76 mg of (8S) -2- (morpholin-4-yl) -9- (2,3,4-trifluorobenzyl) -8- (thfluoromethyl) -6,7,8, 9-tetrahydro-4H-pyhmido [1,2-a] pyrimidin-4-one, in the form of an oil, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,15 à 2,31 (m, 1 H) ; 2,35 à 2,44 (m, 1 H) ; 3,18 à 3,32 (m, 5 H) ; 3,42 à 3,54 (m, 4 H) ; 4,22 (dd, J=5,5 et 14,3 Hz, 1 H) ; 4,65 (d, J=16,1 Hz, 1 H) ; 4,73 (m, 1 H) ; 4,98 (s, 1 H) ; 5,16 (d, J=16,1 Hz, 1 H) ; 7,05 à 7,17 (m, 1 H) ; 7,20 à 7,32 (m, 1 H) \n 2.15 to 2.31 (m, 1H); 2.35 to 2.44 (m, 1H); 3.18 to 3.32 (m, 5H); 3.42 to 3.54 (m, 4H); 4.22 (dd, J = 5.5 and 14.3 Hz, 1H); 4.65 (d, J = 16.1 Hz, 1H); 4.73 (m, 1H); 4.98 (s, 1H); 5.16 (d, J = 16.1 Hz, 1H); 7.05 to 7.17 (m, 1H); 7.20 to 7.32 (m, 1H)\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode B \n Mass Spectrometry: Method B\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 4,08 \n Retention time Tr (min) = 4.08\n\n\n\n\n\n\n \n [M+H]+ : m/z 449 \n [M + H] +: m / z 449\n\n\n\n\n\n\n \nExemple 32 : (8S)-9-[(5-chloro-1-benzothiophén-3-yl)méthyl]-2-\nExample 32: (8S) -9 - [(5-chloro-1-benzothiophen-3-yl) methyl] -2-\n\n\n\n\n\n\n \n(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2- a]pyrimidin-4-one \n\n\n(Morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit est préparé en suivant le mode opératoire décrit à l'exemple 22, à partir de 100 mg de la (8S)-2-morpholin-4-yl-8-thfluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1e), de 214 mg de carbonate de césium et de 95 mg de 3-(bromométhyl)-5-chloro-1 - benzothiophène dans 2 ml_ de diméthylformamide. Après purification par HPLC/MS préparative (Méthode C), on obtient 72 mg de la (8S)-9-[(5-chloro- 1 -benzothiophén-3-yl)méthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one, sous forme d'une huile, dont les caractéristiques sont les suivantes : \nThe product is prepared following the procedure described in Example 22, starting from 100 mg of (8S) -2-morpholin-4-yl-8-thfluoromethyl-6,7,8,9-tetrahydro-pyhmido. [1, 2-a] pyhmidin-4-one (Example 1e), 214 mg of cesium carbonate and 95 mg of 3- (bromomethyl) -5-chloro-1-benzothiophene in 2 ml of dimethylformamide. After purification by preparative HPLC / MS (Method C), 72 mg of (8S) -9 - [(5-chloro-1-benzothiophen-3-yl) methyl] -2- (morpholin-4-yl) is obtained (6-thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one, in the form of an oil, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,13 à 2,25 (m, 1 H) ; 2,34 à 2,43 (m, 1 H) ; 3,16 à 3,32 (m, 5 H) ; 3,35 à 3,48 (m, 4 H) ; 4,21 (dd, J=6,0 et 14,3 Hz, 1 H) ; 4,62 à 4,74 (m, 2 H) ; 5,00 (s, 1 H) ; 5,52 (d, J=16,1 Hz, 1 H) ; 7,42 (dd, J=2,0 et 8,6 Hz, 1 H); 7,67 (s, 1 H) ; 8,01 (d, J=2,0 Hz, 1 H); 8,03 (d, J=8,6 Hz, 1 H) \n 2.13 to 2.25 (m, 1H); 2.34 to 2.43 (m, 1H); 3.16 to 3.32 (m, 5H); 3.35 at 3.48 (m, 4H); 4.21 (dd, J = 6.0 and 14.3 Hz, 1H); 4.62 to 4.74 (m, 2H); 5.00 (s, 1H); 5.52 (d, J = 16.1Hz, 1H); 7.42 (dd, J = 2.0 and 8.6 Hz, 1H); 7.67 (s, 1H); 8.01 (d, J = 2.0 Hz, 1H); 8.03 (d, J = 8.6 Hz, 1H)\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode B \n Mass Spectrometry: Method B\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 4,42 \n Retention time Tr (min) = 4.42\n\n\n\n\n\n\n \n [M+H]+ : m/z 485 \n\n Exemple 33 : (8S)-9-[(1 R ou 1S)-1-(4-fluorophényl)éthyl]-2-(morpholin-4- yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4- one \n[M + H] +: m / z 485  Example 33: (8S) -9 - [(1R or 1S) -1- (4-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9 4-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n \n \n\n Stade a : \n \n Stage a:\n\n\n\n\n\n\n \n La séparation des deux diastéréoisomères de la (8S)-9-[(1 R et 1 S)-1 -\n The separation of the two diastereoisomers of (8S) -9 - [(1 R and 1 S) -1 -\n\n\n\n\n\n\n \n(4-fluorophényl)éthyl]-2-(morpholin-4-yl)-8-(tπfluorométhyl)-6,7,8,9-tétrahydro-\n(4-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (tπfluorométhyl) -6,7,8,9-tetrahydro-\n\n\n\n\n\n\n \n4H-pyrimido[1 ,2-a]pyrimidin-4-one est réalisée par chromatographie chirale :\n4H-pyrimido [1,2-a] pyrimidin-4-one is produced by chiral chromatography:\n\n\n\n\n\n\n \nColonne Chiralpak IC 20 μm; Elution 70 % Heptane 30% EtOH, à partir de 130 mg d'un mélange 70/30 des deux diastéréoisomères. \nChiralpak column IC 20 μm; Elution 70% Heptane 30% EtOH, from 130 mg of a 70/30 mixture of the two diastereoisomers.\n\n\n\n\n\n\n \n Le premier diastéréoisomère est concentré pour obtenir 42 mg de la (8S)-9-[(1 R ou 1 S)-1 -(4-fluorophényl)éthyl]-2-(morpholin-4-yl)-8-\n The first diastereoisomer is concentrated to obtain 42 mg of (8S) -9 - [(1R or 1S) -1- (4-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8-\n\n\n\n\n\n\n \n(thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one, sous forme d'un solide incolore, dont les caractéristiques sont les suivantes : \n(thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyhmidin-4-one, in the form of a colorless solid, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H (400MHz): \n 1H NMR Spectrum (400MHz):\n\n\n\n\n\n\n \n 1 ,72 (d, J=6,8 Hz, 3 H) ; 2,22 (m, 1 H) ; 2,43 (m, 1 H) ; 3,14 à 3,27 (m, 5 H) ; 3,39 à 3,54 (m, 4 H) ; 4,13 (dd, J=5,6 et 14,4 Hz, 1 H) ; 4,80 à 4,88 (m, 1 H) ; 4,93 (s, 1 H) ; 5,43 (q, J=6,8 Hz, 1 H) ; 7,12 (t, J=8,8 Hz, 2 H) ; 7,36 (dd, J=5,6 et 8,8 Hz, 2 H) \n 1.72 (d, J = 6.8 Hz, 3H); 2.22 (m, 1H); 2.43 (m, 1H); 3.14 to 3.27 (m, 5H); 3.39-3.54 (m, 4H); 4.13 (dd, J = 5.6 and 14.4 Hz, 1H); 4.80 to 4.88 (m, 1H); 4.93 (s, 1H); 5.43 (q, J = 6.8 Hz, 1H); 7.12 (t, J = 8.8 Hz, 2H); 7.36 (dd, J = 5.6 and 8.8 Hz, 2H)\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,95 \n Retention time Tr (min) = 0.95\n\n\n\n\n\n\n \n [M+H]+ : m/z 427 \n\n Stade b : (8S)-9-[(1 R et 1S)-1-(4-fluorophényl)éthyl]-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n[M + H] +: m / z 427  Step b: (8S) -9 - [(1R and 1S) -1- (4-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9 tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Le mélange de (8S)-9-[(1 R et 1 S)-1 -(4-fluorophényl)éthyl]-2- (morpholin-4-yl)-8-(tπfluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1 ,2- a]pyrimidin-4-one est préparée en suivant le mode opératoire décrit à l'exemple 24 à partir de 500 mg de la (8S)-2-(morpholin-4-yl)-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one, de 1 g de carbonate de césium et de 391 mg de 1 -(1-chloroéthyl)-4-fluorobenzène dans 20 ml_ d'acétonitrile. Après purification par chromatographie sur silice (éluant : CH2CI2/MeOH 97/3), on obtient 130 mg de la (8S)-9-[(1 R et 1 S)-1 - (4-fluorophényl)éthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)-6,7,8,9-tétrahydro- 4H-pyrimido[1 ,2-a]pyhmidin-4-one, sous forme d'un mélange 70/30 de deux diastéréoisomères, dont les caractéristiques sont les suivantes : \n The mixture of (8S) -9 - [(1R and 1S) -1- (4-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8, 9-Tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one is prepared by following the procedure described in Example 24 starting from 500 mg of (8S) -2- (morpholin-4- (1H) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyhmidin-4-one, 1 g of cesium carbonate and 391 mg of 1 - ( 1-chloroethyl) -4-fluorobenzene in 20 ml of acetonitrile. After purification by chromatography on silica (eluent: CH 2 Cl 2 / MeOH 97/3), 130 mg of (8S) -9 - [(1R and 1S) -1- (4-fluorophenyl) ethyl] -2- are obtained. (Morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one, as a 70/30 mixture of two diastereoisomers, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n II s'agit d'un mélange 70-30 de deux isomères avec : 1 ,65 (d, J=7,0 Hz, 2,1 H) ; 1 ,72 (d, J=7,0 Hz, 0,9 H) ; 1 ,75 à 1 ,86 (m, 0,7 H) ; 2,25 à 2,48 (m, 1 ,3 H) ; 3,12 à 3,27 (m, 5 H) ; 3,40 à 3,56 (m, 4 H) ; 4,00 à 4,22 (m, 1 H) ; 4,42 (m, 0,7 H) ; 4,80 à 4,87 (m, 0,3 H) ; 4,93 (s, 0,3 H) ; 4,96 (s, 0,7 H) ; 5,44 (q, J=7,0 Hz, 0,3 H) ; 5,65 (q, J=7,0 Hz, 0,7 H) ; 7,06 à 7,21 (m, 2 H) ; 7,32 à 7,40 (m, 2 H) \n\n Exemple 34 : (8S)-9-[(1 R ou 1S)-1-(4-fluorophényl)éthyl]-2-(morpholin-4- yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4- one \nIt is a 70-30 mixture of two isomers with: 1.65 (d, J = 7.0 Hz, 2.1 H); 1.72 (d, J = 7.0 Hz, 0.9 H); 1.75 to 1.86 (m, 0.7 H); 2.25 to 2.48 (m, 1.3H); 3.12 to 3.27 (m, 5H); 3.40 to 3.56 (m, 4H); 4.00 to 4.22 (m, 1H); 4.42 (m, 0.7 H); 4.80 to 4.87 (m, 0.3 H); 4.93 (s, 0.3H); 4.96 (s, 0.7H); 5.44 (q, J = 7.0Hz, 0.3H); 5.65 (q, J = 7.0Hz, 0.7H); 7.06 to 7.21 (m, 2H); 7.32 to 7.40 (m, 2 H)  Example 34: (8S) -9 - [(1R or 1S) -1- (4-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9 4-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n \nLa purification précédente (exemple 33, stade a) conduit aussi à 85 mg de la (8S)-9-[(1 R ou 1 S)-1-(4-fluorophényl)éthyl]-2-(morpholin-4-yl)-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhnnido[1 ,2-a]pyhnnidin-4-one, sous forme d'un solide incolore, dont les caractéristiques sont les suivantes : \nThe preceding purification (Example 33, Step a) also leads to 85 mg of (8S) -9 - [(1R or 1S) -1- (4-fluorophenyl) ethyl] -2- (morpholin-4-yl) 8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhnnido [1,2-a] pyhnnidin-4-one, as a colorless solid, which has the following characteristics:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 1 ,65 (d, J=7,0 Hz, 3 H) ; 1 ,69 à 1 ,86 (m, 1 H) ; 2,29 à 2,37 (m, 1 H) ;\n 1.65 (d, J = 7.0 Hz, 3H); 1.69 to 1.86 (m, 1H); 2.29 to 2.37 (m, 1H);\n\n\n\n\n\n\n \n3,14 à 3,28 (m, 5 H) ; 3,44 à 3,58 (m, 4 H) ; 4,08 (dd, J=5,9 et 14,7 Hz, 1 H) ; 4,42 (m, 1 H) ; 4,96 (s, 1 H) ; 5,64 (q, J=7,0 Hz, 1 H) ; 7,17 (t, J=8,8 Hz, 2 H) ; 7,35 (dd, J=5,6 et 8,8 Hz, 2 H) \n3.14 to 3.28 (m, 5H); 3.44 to 3.58 (m, 4H); 4.08 (dd, J = 5.9 and 14.7 Hz, 1H); 4.42 (m, 1H); 4.96 (s, 1H); 5.64 (q, J = 7.0Hz, 1H); 7.17 (t, J = 8.8 Hz, 2H); 7.35 (dd, J = 5.6 and 8.8 Hz, 2H)\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,95 \n Retention time Tr (min) = 0.95\n\n\n\n\n\n\n \n [M+H]+ : m/z 427 \n [M + H] +: m / z 427\n\n\n\n\n\n\n \nExemple 35 : (8S)-9-(3-méthylphényl)-2-(morpholin-4-yl)-8-\nExample 35: (8S) -9- (3-methylphenyl) -2- (morpholin-4-yl) -8-\n\n\n\n\n\n\n \n(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n(Trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n \nChiral \nchiral\n\n\n\n\n\n\n \n \n\n Le produit est préparé en suivant le mode opératoire décrit dans l'exemple 12, mais à partir de 250 mg de la (8S)-2-morpholin-4-yl-8- trifluorométhyl-6,7,8,9-tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1 e) dans 4 ml_ de diméthylformamide, de 251 mg de 1 -iodo-3-méthylbenzène, de 349 mg de phosphate de tripotassium, de 156 mg d'iodure de cuivre et de 93 mg de (1 S,2S)-cyclohexane-1 ,2-diamine. Après 1 heure à 150\n0\nC sous irradiation micro-ondes et purification sur colonne de silice du mélange réactionnel résultant (gradient d'élution de CH2CI2 à CH2CI2/MeOH 98/02), on obtient 195 mg de la (8S)-9-(3-méthylphényl)-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one, sous forme d'un solide vert, dont les caractéristiques sont les suivantes : \n \n The product is prepared following the procedure described in Example 12, but starting with 250 mg of (8S) -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro- pyhmido [1, 2-a] pyhmidin-4-one (Example 1 e) in 4 ml of dimethylformamide, 251 mg of 1-iodo-3-methylbenzene, 349 mg of tripotassium phosphate, 156 mg of iodide of copper and 93 mg of (1S, 2S) -cyclohexane-1,2-diamine. After 1 hour at 150 \n°\n C. under microwave irradiation and purification on a silica column of the resulting reaction mixture (elution gradient from CH 2 Cl 2 to CH 2 Cl 2 / MeOH 98/2), 195 mg of (8S) -9- (3-Methylphenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyhmidin-4-one, in the form a green solid, whose characteristics are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,31 (s, 3 H) ; 2,37 à 2,47 (m, 2 H) ; 3,02 à 3,16 (m, 4 H) ; 3,19 à 3,39 (m partiellement masqué, 1 H) ; 3,40 à 3,53 (m, 4 H) ; 4,28 à 4,40 (m, 1 H) ; 4,93 (m, 1 H) ; 4,99 (s, 1 H) ; 7,13 (m, 2 H) ; 7,19 (s large, 1 H) ; 7,29 (t, J=7,5 Hz, 1 H) \n 2.31 (s, 3H); 2.37 to 2.47 (m, 2H); 3.02 to 3.16 (m, 4H); 3.19 to 3.39 (partially masked m, 1H); 3.40 to 3.53 (m, 4H); 4.28 to 4.40 (m, 1H); 4.93 (m, 1H); 4.99 (s, 1H); 7.13 (m, 2H); 7.19 (brs, 1H); 7.29 (t, J = 7.5 Hz, 1H)\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,90 \n Retention time Tr (min) = 0.90\n\n\n\n\n\n\n \n [M+H]+ : m/z 395 \n [M + H] +: m / z 395\n\n\n\n\n\n\n \nExemple 36 : (8S)-9-(4-chlorophényl)-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n\n\nExample 36: (8S) -9- (4-chlorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] ] pyrimidin-4-one \n\n\n\n\n\n\n \nChiral \nchiral\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit est préparé en suivant le mode opératoire décrit dans l'exemple 12, mais à partir de 250 mg de la (8S)-2-morpholin-4-yl-8- trifluorométhyl-6,7,8,9-tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1 e), de 274 mg de 1 -chloro-4-iodobenzène, de 349 mg de phosphate de tripotassium, de 156 mg d'iodure de cuivre et de 93 mg de (1 S,2S)- cyclohexane-1 ,2-diamine. Après 1 heure à 150\n0\nC sous irradiation microondes et purification du mélange réactionnel résultant sur colonne de silice (gradient d'élution de CH2CI2 à CH2CI2/MeOH 98/02), on obtient 145 mg de la (8S)-9-(4-chlorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one, sous forme d'une meringue verte, dont les caractéristiques sont les suivantes : \nThe product is prepared following the procedure described in Example 12, but starting with 250 mg of (8S) -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro- pyhmido [1, 2-a] pyhmidin-4-one (example 1 e), 274 mg of 1-chloro-4-iodobenzene, 349 mg of tripotassium phosphate, 156 mg of copper iodide and mg of (1S, 2S) -cyclohexane-1,2-diamine. After 1 hour at 150 \n°\n C. under microwave irradiation and purification of the resulting reaction mixture on a silica column (elution gradient from CH 2 Cl 2 to CH 2 Cl 2 / MeOH 98/2), 145 mg of (8S) -9- (4H) are obtained. 2-chlorophenyl) (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one in the form of a green meringue whose characteristics are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H : \n 1 H NMR spectrum:\n\n\n\n\n\n\n \n 2,41 à 2,47 (m, 2 H) ; 3,07 à 3,12 (m, 4 H) ; 3,20 à 3,43 (m partiellement masqué, 1 H) ; 3,46 (m, 4 H) ; 4,35 (m, 1 H) ; 4,94 (m, 1 H) ; 5,01 (s, 1 H) ; 7,39 (d, J=8,8 Hz, 2 H) ; 7,49 (d, J=8,8 Hz, 2 H) \n 2.41 to 2.47 (m, 2H); 3.07 to 3.12 (m, 4H); 3.20 to 3.43 (partially masked m, 1H); 3.46 (m, 4H); 4.35 (m, 1H); 4.94 (m, 1H); 5.01 (s, 1H); 7.39 (d, J = 8.8 Hz, 2H); 7.49 (d, J = 8.8 Hz, 2H)\n\n\n\n\n\n\n \n Spectrométrie de Masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,94 ; \n Retention time Tr (min) = 0.94;\n\n\n\n\n\n\n \n [M+H]+ : m/z 415 \n\n Exemple 37 : (8S)-2-(morpholin-4-yl)-8-(trifluorométhyl)-9-[4-\n[M + H] +: m / z 415  Example 37: (8S) -2- (morpholin-4-yl) -8- (trifluoromethyl) -9- [4-\n\n\n\n\n\n\n \n(trifluorométhyl)phényl]-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-\n(Trifluoromethyl) phenyl] -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin\n\n\n\n\n\n\n \n4-one \n4-one\n\n\n\n\n\n\n \n \n\n Le produit est préparé en suivant le mode opératoire décrit dans l'exemple 12 mais à partir de 250 mg de la (8S)-2-morpholin-4-yl-8- trifluorométhyl-6,7,8,9-tétrahydro-pyrimido[1 ,2-a]pyhmidin-4-one (exemple 1 e), de 313 mg de 1 -iodo-4-(trifluorométhyl)benzène, de 349 mg de phosphate de tripotassium, de 156 mg d'iodure de cuivre et de 93 mg de (1S,2S)-cyclohexane-1 ,2-diamine. Après 1 heure à 150\n0\nC sous irradiation micro-ondes et purification du mélange réactionnel résultant sur colonne de silice (gradient d'élution de CH2CI2 à CH2CI2/MeOH 98/02), on obtient 120 mg de la (8S)-2-(morpholin-4-yl)-8-(thfluorométhyl)-9-[4-\n \n The product is prepared following the procedure described in Example 12 but starting from 250 mg of (8S) -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido [1, 2-a] pyhmidin-4-one (Example 1 e), 313 mg of 1 -iodo-4- (trifluoromethyl) benzene, 349 mg of tripotassium phosphate, 156 mg of copper iodide and 93 mg of (1S, 2S) -cyclohexane-1,2-diamine. After 1 hour at 150 \n°\n C. under microwave irradiation and purification of the resulting reaction mixture on a silica column (elution gradient from CH 2 Cl 2 to CH 2 Cl 2 / MeOH 98/2), 120 mg of (8S) -2- (morpholin-4-yl) -8- (thfluorométhyl) -9- [4-\n\n\n\n\n\n\n \n(thfluorométhyl)phényl]-6,7,8,9-tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one sous forme d'un solide verdâtre dont les caractéristiques sont les suivantes : \n(thfluoromethyl) phenyl] -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one in the form of a greenish solid having the following characteristics:\n\n\n\n\n\n\n \n Spectre RMN 1 H (400MHz): \n 1H NMR Spectrum (400MHz):\n\n\n\n\n\n\n \n 2,42 à 2,53 (m partiellement masqué, 2 H) ; 3,01 à 3,13 (m, 4 H) ; 3,22 à 3,39 (m partiellement masqué, 1 H) ; 3,41 à 3,46 (m, 4 H) ; 4,37 (m, 1 H) ; 5,03 (s, 1 H) ; 5,05 (m, 1 H) ; 7,62 (d, J=8,6 Hz, 2 H) ; 7,81 (d, J=8,6 Hz, 2 H) Spectrométrie de masse : Méthode A \n 2.42 to 2.53 (partially masked m, 2H); 3.01 to 3.13 (m, 4H); 3.22 to 3.39 (partially masked m, 1H); 3.41 to 3.46 (m, 4H); 4.37 (m, 1H); 5.03 (s, 1H); 5.05 (m, 1H); 7.62 (d, J = 8.6 Hz, 2H); 7.81 (d, J = 8.6 Hz, 2H) Mass Spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,98 \n Retention time Tr (min) = 0.98\n\n\n\n\n\n\n \n [M+H]+ : m/z 449 \n\n Exemple 38 : (8S)-9-[(1 R ou 1S)-1-(2-fluorophényl)éthyl]-2-(morpholin-4- yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4- one \n[M + H] +: m / z 449  Example 38: (8S) -9 - [(1R or 1S) -1- (2-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9 4-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n \nStade c : \nStage c:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLa séparation des deux diastéréoisomères de la (8S)-9-[(1 R et 1 S)-1 -\nThe separation of the two diastereoisomers of (8S) -9 - [(1 R and 1 S) -1 -\n\n\n\n\n\n\n \n(2-fluorophényl)éthyl]-2-(morpholin-4-yl)-8-(tπfluoronnéthyl)-6,7,8,9-tétrahydro-\n(2-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (tπfluoronnéthyl) -6,7,8,9-tetrahydro-\n\n\n\n\n\n\n \n4H-pyrimido[1 ,2-a]pyrimidin-4-one est réalisée par chromatographie chirale (colonne Chiralpak AD 20 μm; élution 80 % Heptane 10% EtOH 10 %\n4H-pyrimido [1,2-a] pyrimidin-4-one is carried out by chiral chromatography (Chiralpak AD 20 μm column, elution 80% Heptane 10% EtOH 10%\n\n\n\n\n\n\n \nMeOH) à partir de 70 mg d'un mélange 70/30 des deux diastéréoisomères. \nMeOH) from 70 mg of a 70/30 mixture of the two diastereoisomers.\n\n\n\n\n\n\n \n On obtient ainsi 41.5 mg de la (8S)-9-[(1 R ou 1 S)-1-(2- fluorophényl)éthyl]-2-(morpholin-4-yl)-8-(thfluorométhyl)-6,7,8,9-tétrahydro- 4H-pyrimido[1 ,2-a]pyhmidin-4-one dont les caractéristiques sont les suivantes : \n 41.5 mg of (8S) -9 - [(1R or 1S) -1- (2-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6 are thus obtained, 7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H (400MHz) : \n 1H NMR Spectrum (400MHz):\n\n\n\n\n\n\n \n 1 ,62 (d, J=7,2 Hz, 3 H) ; 1 ,68 à 1 ,85 (m, 1 H) ; 2,30 à 2,39 (m, 1 H) ; 3,20 à 3,42 (m, 5 H) ; 3,50 à 3,65 (m, 4 H) ; 4,03 (m, 1 H) ; 4,22 à 4,36 (m, 1 H) ; 4,99 (s, 1 H) ; 6,05 (q, J=7,2 Hz, 1 H) ; 7,14 à 7,29 (m, 2 H) ; 7,35 à 7,43 (m, 1 H) ; 7,47 (m, 1 H) \n 1.62 (d, J = 7.2 Hz, 3H); 1.68 to 1.85 (m, 1H); 2.30 to 2.39 (m, 1H); 3.20 to 3.42 (m, 5H); 3.50 to 3.65 (m, 4H); 4.03 (m, 1H); 4.22 to 4.36 (m, 1H); 4.99 (s, 1H); 6.05 (q, J = 7.2 Hz, 1H); 7.14 to 7.29 (m, 2H); 7.35 to 7.43 (m, 1H); 7.47 (m, 1H)\n\n\n\n\n\n\n \n Spectrométrie de masse : méthode B \n Mass spectrometry: method B\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 4.02 \n Retention time Tr (min) = 4.02\n\n\n\n\n\n\n \n [M+H]+ : m/z 427 \n\n Pouvoir rotatoire : PR = +33 ; C = 2.543mg/1 ML DMSO. \n[M + H] +: m / z 427  Rotatory power: PR = +33; C = 2.543mg / 1 ML DMSO.\n\n\n\n\n\n\n \nStade b : (8S)-9-[(1 R et 1 S)-1 -(2-f luorophényl)éthyl]-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \nStep b: (8S) -9 - [(1R and 1S) -1- (2-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8 , 9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit peut être préparé en suivant le mode opératoire décrit à l'exemple 17, mais à partir de 500 mg de la (8S)-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one, de 1 g de carbonate de césium, de 391 mg de 1 -(1 -chloroéthyl)-2-fluorobenzène (voir stade a ci- dessous) dans 22 ml_ d'acétonitrile. Après purification sur colonne de silice (éluant : CH2CI2 / MeOH 97/03), on obtient 70 mg d'un mélange 70/30 des deux diastéréoisomères de la (8S)-9-[(1 R et 1 S)-1 -(2-fluorophényl)éthyl]-2- (morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2- a]pyπmidin-4-one, sous forme d'une poudre jaune pâle, dont les caractéristiques sont les suivantes : \nThe product can be prepared following the procedure described in Example 17, but starting from 500 mg of (8S) -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8 9-tetrahydro-4H-pyhmido [1,2-a] pyrimidin-4-one, 1 g of cesium carbonate, 391 mg of 1- (1-chloroethyl) -2-fluorobenzene (see Step a). below) in 22 ml of acetonitrile. After purification on a silica column (eluent: CH 2 Cl 2 / MeOH 97/03), 70 mg of a 70/30 mixture of the two diastereoisomers of (8S) -9 - [(1 R and 1 S) -1 - are obtained. (2-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyrimidin-4-one, in the form of a pale yellow powder, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,93 et 0,90 : mélange 70% - 30% d'isomères ; \n Retention time Tr (min) = 0.93 and 0.90: mixture 70% - 30% isomers;\n\n\n\n\n\n\n \n [M+H]+ : m/z 427 \n [M + H] +: m / z 427\n\n\n\n\n\n\n \nStade a : 1 -(1 -chloroéthyl)-2-fluorobenzène \n\n \n\n\n\nStage a: 1 - (1-chloroethyl) -2-fluorobenzene \n \n\n\n\n\n\n\n \nA une solution de 1 g de 1-(2-fluorophényl)éthanol commercial dans 20 ml_ de chloroforme sont ajoutés 767 mg de chlorure de thionyle. Après une nuit d'agitation à une température voisine de 20\n0\nC, le mélange réactionnel est lavé par une solution aqueuse saturée en bicarbonate de sodium puis séché sur sulfate de magnésium anhydre, filtré et concentré à sec sous pression réduite. On obtient ainsi 780 mg de 1 -(1 -chloroéthyl)-2-fluorobenzène qui est utilisé tel que dans l'étape suivante. \nTo a solution of 1 g of commercial 1- (2-fluorophenyl) ethanol in 20 ml of chloroform is added 767 mg of thionyl chloride. After stirring overnight at a temperature in the region of 20 \n°\n C., the reaction mixture is washed with a saturated aqueous sodium bicarbonate solution and then dried over anhydrous magnesium sulphate, filtered and concentrated to dryness under reduced pressure. 780 mg of 1 - (1-chloroethyl) -2-fluorobenzene is thus obtained, which is used as in the following step.\n\n\n\n\n\n\n \nExemple 39 : (8S)-9-[(1 R ou 1S)-1-(2-fluorophényl)éthyl]-2-(morpholin-4- yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4- one \nExample 39: (8S) -9 - [(1R or 1S) -1- (2-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9 4-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLa purification précédente (exmple 38, stade c) conduit aussi à 17.9 mg de la (8S)-9-[(1 R ou 1 S)-1 -(2-fluorophényl)éthyl]-2-(morpholin-4-yl)-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one, sous forme d'un solide ambre, dont les caractéristiques sont les suivantes : \nThe preceding purification (example 38, stage c) also leads to 17.9 mg of (8S) -9 - [(1R or 1S) -1- (2-fluorophenyl) ethyl] -2- (morpholin-4-yl). ) 8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyhmidin-4-one, in the form of an amber solid, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H (400MHz): \n 1H NMR Spectrum (400MHz):\n\n\n\n\n\n\n \n 1 ,69 (d, J=7,0 Hz, 3 H) ; 1 ,97 à 2,12 (m, 1 H) ; 2,36 à 2,46 (m, 1 H) ; 3,15 à 3,35 (m partiellement masqué, 5 H) ; 3,43 à 3,59 (m, 4 H) ; 4,09 (m, 1 \n\n H) ; 4,72 (m, 1 H) ; 4,93 (s, 1 H) ; 5,73 (q, J=7,0 Hz, 1 H) ; 7,07 à 7,25 (m, 2 H) ; 7,28 à 7,40 (m, 1 H) ; 7,51 (m, 1 H) \n1.69 (d, J = 7.0 Hz, 3H); 1.97 to 2.12 (m, 1H); 2.36 to 2.46 (m, 1H); 3.15 to 3.35 (partially masked m, 5H); 3.43 to 3.59 (m, 4H); 4.09 (m, 1  H); 4.72 (m, 1H); 4.93 (s, 1H); 5.73 (q, J = 7.0Hz, 1H); 7.07 to 7.25 (m, 2H); 7.28 to 7.40 (m, 1H); 7.51 (m, 1 H)\n\n\n\n\n\n\n \n Spectrométrie de masse : méthode B \n Mass spectrometry: method B\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 3,93 \n Retention time Tr (min) = 3.93\n\n\n\n\n\n\n \n [M+H]+ : m/z 427 \n [M + H] +: m / z 427\n\n\n\n\n\n\n \n Pouvoir Rotatoire : PR = -96.3+/-1.4 ; C = 2.812mg/0.5ML DMSO. \n Rotational power: PR = -96.3 +/- 1.4; C = 2.812mg / 0.5ML DMSO.\n\n\n\n\n\n\n \nExemple 40 : (8S)-9-[2-(3-fluorophényl)éthyl]-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \nExample 40: (8S) -9- [2- (3-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [ 1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 150 mg de la (8S)-2-(morpholin-4-yl)-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyrimidin-4-one dans 2.5 ml_ de toluène sont ajoutés 296 mg d'hydroxyde de sodium dans 2.5 ml_ d'eau, 33 mg d'hydrogènosulfate de tétrabutylammonium et 200 mg de 1 -(2- bromoéthyl)-3-fluorobenzène. Après une heure sous irradiation micro-ondes (puissance 100 Watts sur appareil CEM discover) à 60\n0\nC puis une heure à nouveau à 60\n0\nC et deux fois six heures à 70°C. le mélange réactionnel est dilué avec de l'acétate d'éthyle. Le mélange résultant est lavé par de l'eau. La phase organique est séparée puis concentrée à sec sous pression réduite. Après purification par HPLC/MS préparative du résidu obtenu (Méthode D), on obtient 43 mg de la (8S)-9-[2-(3-fluorophényl)éthyl]-2-(morpholin-4-yl)-8- \n\n (tπfluorométhyl)-6,7,8,9-tétrahydro-4H-pyπmido[1 ,2-a]pyrinnidin-4-one dont les caractéristiques sont les suivantes : \nTo a solution of 150 mg of (8S) -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyrimidin 4-one in 2.5 ml of toluene is added 296 mg of sodium hydroxide in 2.5 ml of water, 33 mg of tetrabutylammonium hydrogen sulphate and 200 mg of 1- (2-bromoethyl) -3-fluorobenzene. After one hour under microwave irradiation (power 100 Watts on CEM discover device) at 60 \n0\n C then one hour again at 60 \n0\n C and twice six hours at 70 ° C. the reaction mixture is diluted with ethyl acetate. The resulting mixture is washed with water. The organic phase is separated and then concentrated to dryness under reduced pressure. After purification by preparative HPLC / MS of the residue obtained (Method D), 43 mg of (8S) -9- [2- (3-fluorophenyl) ethyl] -2- (morpholin-4-yl) -8-  (tfluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrinidin-4-one having the following characteristics:\n\n\n\n\n\n\n \n Spectre RMN 1 H (400MHz): \n 1H NMR Spectrum (400MHz):\n\n\n\n\n\n\n \n 1 ,87 à 2,05 (m, 1 H) ; 2,29 à 2,38 (m, 1 H) ; 2,82 à 3,24 (m, 3 H) ; 3,38 à 3,50 (m, 5 H) ; 3,60 à 3,66 (m, 4 H) ; 4,11 à 4,25 (m, 2 H) ; 4,50 à 4,69 (m, 1 H) ; 4,99 (s, 1 H) ; 6,96 à 7,15 (m, 3 H) ; 7,28 à 7,41 (m, 1 H) \n 1.87 at 2.05 (m, 1H); 2.29 to 2.38 (m, 1H); 2.82-3.24 (m, 3H); 3.38 at 3.50 (m, 5H); 3.60 to 3.66 (m, 4H); 4.11 to 4.25 (m, 2H); 4.50 to 4.69 (m, 1H); 4.99 (s, 1H); 6.96 to 7.15 (m, 3H); 7.28 to 7.41 (m, 1H)\n\n\n\n\n\n\n \n Spectrométrie de masse : méthode B \n Mass spectrometry: method B\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 4,10 \n Retention time Tr (min) = 4.10\n\n\n\n\n\n\n \n [M+H]+ : m/z 427 \n [M + H] +: m / z 427\n\n\n\n\n\n\n \nExemple 41 : (8S)-9-benzyl-3-fluoro-2-(morpholin-4-yl)-8-\nExample 41: (8S) -9-Benzyl-3-fluoro-2- (morpholin-4-yl) -8-\n\n\n\n\n\n\n \n(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n(Trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n \nChiral \nchiral\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nStade e : \nStage e:\n\n\n\n\n\n\n \nA une suspension de 1 g de la (8S)-3-fluoro-2-(morpholin-4-yl)-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one dans 11.8 ml_ d'acétonitrile sont ajoutés 4 g de carbonate de césium et 796 mg de bromure de benzyle. Après une nuit d'agitation à une température voisine de 20\n0\nC, la suspension obtenue est filtrée et le filtrat résultant concentré à sec sous pression réduite. Le résidu huileux jaune est purifié sur colonne de silice (éluant : CH2CI2 / MeOH 98/02). Les fractions d'intérêt sont réunies et \n\n concentrées à sec sous pression réduite. Le résidu est repris par de l'oxyde de diéthyle, essoré puis séché sous vide. On obtient ainsi 600 mg de la (8S)- 9-benzyl-3-fluoro-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H- pyrimido[1 ,2-a]pyhmidin-4-one, sous forme d'une poudre blanche, dont les caractéristiques sont les suivantes : \nTo a suspension of 1 g of (8S) -3-fluoro-2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1, 2- a] pyhmidin-4-one in 11.8 ml of acetonitrile are added 4 g of cesium carbonate and 796 mg of benzyl bromide. After stirring overnight at a temperature in the region of 20 \n°\n C., the suspension obtained is filtered and the resulting filtrate is concentrated to dryness under reduced pressure. The yellow oily residue is purified on a silica column (eluent: CH2Cl2 / MeOH 98/02). Fractions of interest are collected and  concentrated to dryness under reduced pressure. The residue is taken up in diethyl ether, drained and dried under vacuum. 600 mg of (8S) -9-benzyl-3-fluoro-2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1] are thus obtained. , 2-a] pyhmidin-4-one, in the form of a white powder, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H (400MHz): \n 1H NMR Spectrum (400MHz):\n\n\n\n\n\n\n \n 2,17 à 2,30 (m, 1 H) ; 2,39 à 2,46 (m, 1 H) ; 3,31 à 3,52 (m, 9 H) ; 4,23 (m, 1 H) ; 4,55 (d, J=16,1 Hz, 1 H) ; 4,61 à 4,73 (m, 1 H) ; 5,13 (d, J=16,1 Hz, 1 H) ; 7,20 à 7,26 (m, 3 H) ; 7,28 à 7,36 (m, 2 H) \n 2.17 to 2.30 (m, 1H); 2.39 to 2.46 (m, 1H); 3.31 to 3.52 (m, 9H); 4.23 (m, 1H); 4.55 (d, J = 16.1Hz, 1H); 4.61 to 4.73 (m, 1H); 5.13 (d, J = 16.1 Hz, 1H); 7.20 to 7.26 (m, 3H); 7.28 to 7.36 (m, 2H)\n\n\n\n\n\n\n \n Spectrométrie de masse : méthode B \n Mass spectrometry: method B\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 4,01 \n Retention time Tr (min) = 4.01\n\n\n\n\n\n\n \n [M+H]+ : m/z 413 \n [M + H] +: m / z 413\n\n\n\n\n\n\n \nStade d : (8S)-3-fluoro-2-(morpholin-4-vl)-8-(trifluorométhvl)-6J,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one \nStep d: (8S) -3-Fluoro-2- (morpholin-4-yl) -8- (trifluoromethyl) -6,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit peut être préparé en suivant le mode opératoire décrit à l'exemple 16, stade b, mais à partir de 1 g de la (8S)-2-chloro-3-fluoro-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one dans 5 mL d'acétonitrile et de 1.6 mL de morpholine. Après une nuit à 65°C, on obtient 1.1 g de la (8S)-3-fluoro-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1 ,2-a]pyhmidin-4-one, sous forme d'une poudre beige, dont les caractéristiques sont les suivantes : \nThe product can be prepared following the procedure described in Example 16, stage b, but starting with 1 g of (8S) -2-chloro-3-fluoro-8- (thfluoromethyl) -6.7, 8,9-tetrahydro-4H-pyhmido [1,2-a] pyhmidin-4-one in 5 mL of acetonitrile and 1.6 mL of morpholine. After one night at 65 ° C., 1.1 g of (8S) -3-fluoro-2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H- are obtained. pyrimido [1, 2-a] pyhmidin-4-one, in the form of a beige powder, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectrométrie de masse : Méthode A \n\n Temps de rétention Tr (min) = 0,56 \nMass spectrometry: Method A  Retention time Tr (min) = 0.56\n\n\n\n\n\n\n \n[M+H]+ : m/z 323 ; [M-H]- : m/z 321 \n[M + H] +: m / z 323; [M-H] -: m / z 321\n\n\n\n\n\n\n \nStade_ç_L(8S)-3-fluoro-2-chloro-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H- pyrimido[1,2-a]pyrimidin-4-one \nL- (8S) -3-fluoro-2-chloro-8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLa séparation des énantiomères de la (8R,8S)-2-chloro-3-fluoro-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one est réalisée par chromatographie chirale (Chiralpak AD 20μm 80X350 mm 250ml/min 254nm ; \nSeparation of the enantiomers of (8R, 8S) -2-chloro-3-fluoro-8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyhmidin-4- one is performed by chiral chromatography (Chiralpak AD 20μm 80X350 mm 250ml / min 254nm;\n\n\n\n\n\n\n \n 5% EtOH 5% MeOH 90% Heptane +0.1 % TEA), à partir de 6.8 g d'un mélange racémique. \n 5% EtOH 5% MeOH 90% Heptane + 0.1% TEA), from 6.8 g of a racemic mixture.\n\n\n\n\n\n\n \n L'énantiomère dextrogyre est concentré pour obtenir 3.13 g de la (8S)- 2-chloro-3-fluoro-8-(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2- a]pyπmidin-4-one, sous forme d'un solide blanc, dont les caractéristiques sont les suivantes : \n The dextrorotatory enantiomer is concentrated to obtain 3.13 g of (8S) -2-chloro-3-fluoro-8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyπmidin-4-one, in the form of a white solid, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectrométrie de masse : Méthode A \n Mass spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,62 \n Retention time Tr (min) = 0.62\n\n\n\n\n\n\n \n [M+H]+ : m/z 272 ; [M-H]- : m/z 270 \n [M + H] +: m / z 272; [M-H] -: m / z 270\n\n\n\n\n\n\n \n Pouvoir rotatoire : PR= +19.6+/-0.6; C = 2.488mg/0.5ML CH3OH. \n Rotatory power: PR = +19.6 +/- 0.6; C = 2.488mg / 0.5ML CH3OH.\n\n\n\n\n\n\n \nStade b : (8R, 8S)-2-chloro-3-fluoro-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n\n\nStep b: (8R, 8S) -2-Chloro-3-fluoro-8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 6.5 g de (8R, 8S)-3-fluoro-2-hydroxy-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhnnido[1 ,2-a]pyhnnidin-4-one dans 20 ml_ de 1 ,2-dichloroéthane sont ajoutés 8 ml_ de thchlorure de phosphore. Après 4 heures d'agitation à une température de 65 \n0\nC et retour à une température voisine de 20\n0\nC, le mélange réactionnel, est concentré à sec sous pression réduite. Le résidu est dilué dans 150 ml_ d'acétate d'éthyle et 1 OmL d'eau glacée. A une température comprise entre 0\n0\nC et 10\n0\nC, est ajoutée une solution d'hydroxyde de sodium concentrée jusqu'à obtention d'un pH compris entre 6 et 7. Le solide formé est filtré pour donner 3.5 g d'un solide beige S1. Le filtrat est décanté, et la phase organique est séchée sur sulfate de magnésium anhydre, filtrée et concentrée à sec sous pression réduite. Après purification du résidu sur colonne de silice (éluant : CH2CI2 / MeOH 97/03), on obtient 3.3 g d'un solide jaune pâle S2. Les deux solides S1 et S2 sont réunis pour donner 6.8 g de la (8R, 8S)-2-chloro-3-fluoro-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one, sous forme d'une poudre jaune pâle, dont les caractéristiques sont les suivantes : \nTo a solution of 6.5 g of (8R, 8S) -3-fluoro-2-hydroxy-8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhnnido [1,2-a] pyhnnidin-4 in 20 ml of 1,2-dichloroethane are added 8 ml of phosphorus thichloride. After stirring for 4 hours at a temperature of 65 \n°\n C. and returning to a temperature in the region of 20 \n°\n C., the reaction mixture is concentrated to dryness under reduced pressure. The residue is diluted in 150 ml of ethyl acetate and 1 ml of ice water. At a temperature of between 0 \n°\n C. and 10 \n°\n C., a solution of concentrated sodium hydroxide is added until a pH of between 6 and 7 is obtained. The solid formed is filtered to give 3.5 g of a solid. beige S1. The filtrate is decanted, and the organic phase is dried over anhydrous magnesium sulfate, filtered and concentrated to dryness under reduced pressure. After purification of the residue on a silica column (eluent: CH 2 Cl 2 / MeOH 97/03), 3.3 g of a pale yellow solid S 2 are obtained. The two solids S1 and S2 are combined to give 6.8 g of (8R, 8S) -2-chloro-3-fluoro-8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1, 2-a] pyhmidin-4-one, in the form of a pale yellow powder, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectrométrie de masse : Méthode B \n Mass spectrometry: Method B\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 2,90 \n Retention time Tr (min) = 2.90\n\n\n\n\n\n\n \n [M+H]+ : m/z 272 ; [M-H]- : m/z 270 \n [M + H] +: m / z 272; [M-H] -: m / z 270\n\n\n\n\n\n\n \n Stade a : (8R, 8S)-3-fluoro-2-hydroxy-8-(trifluorométhyl)-6,7,8,9- tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n\n\nStep a: (8R, 8S) -3-fluoro-2-hydroxy-8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une suspension de 7 g de 6-(trifluorométhyl)-1 ,4,5,6- tétrahydropyrinnidin-2-annine chlorhydrate (exemple 1 , stade a) dans 35 ml_ de fluoro propanedioate de diméthyle sont ajoutés 5.6 g de méthylate de sodium. Après 3 heures d'agitation de la suspension à une température de 100\n0\nC, le milieu obtenu est concentré à sec sous pression réduite. Le résidu est repris dans de l'oxyde de diéthyle puis essoré sous vide. Le solide obtenu est repris dans 14 mL d'eau et le mélange résultant est, refroidi dans de la glace avant acidification jusqu'à pH 5-6 par ajout d'acide chlorhydrique concentré (25%). Après 2 heures d'agitation à une température de 0\n0\nC puis une nuit à une température voisine de 20\n0\nC, la suspension est filtrée puis le solide est essoré et séché sous vide sur P2O5. On obtient 6.5 g de (8R, 8S)-3- fluoro-2-hydroxy-8-(thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2- a]pyπmidin-4-one, sous forme d'une poudre jaune, dont les caractéristiques sont les suivantes : \nTo a suspension of 7 g of 6- (trifluoromethyl) -1,4,5,6-tetrahydropyrinidin-2-annan hydrochloride (Example 1, step a) in 35 ml of dimethyl fluoro propanedioate are added 5.6 g of sodium methoxide. . After stirring for 3 hours at a temperature of 100 \n°\n C., the medium obtained is concentrated to dryness under reduced pressure. The residue is taken up in diethyl ether and then filtered under vacuum. The solid obtained is taken up in 14 ml of water and the resulting mixture is cooled in ice before acidification to pH 5-6 by addition of concentrated hydrochloric acid (25%). After stirring for 2 hours at a temperature of 0 \n°\n C. and then overnight at a temperature in the region of 20 \n°\n C., the suspension is filtered and the solid is then drained and dried under vacuum over P2O5. 6.5 g of (8R, 8S) -3-fluoro-2-hydroxy-8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyrimidin-4-one are obtained in the form of a yellow powder, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectrométrie de masse : Méthode A \n Mass spectrometry: Method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,28 \n Retention time Tr (min) = 0.28\n\n\n\n\n\n\n \n [M+H]+ : m/z 254 ; [M-H]- : m/z 252 \n [M + H] +: m / z 254; [M-H] -: m / z 252\n\n\n\n\n\n\n \nExemple 42 : (8S)-9-(3,5-difluorophényl)-2-(morpholin-4-yl)-8-\nExample 42: (8S) -9- (3,5-difluorophenyl) -2- (morpholin-4-yl) -8-\n\n\n\n\n\n\n \n(trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n\n Chiral \n(Trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one  chiral\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit est préparé en suivant le mode opératoire décrit dans l'exemple 12, mais à partir de 250 mg de la (8S)-2-morpholin-4-yl-8- trifluorométhyl-6,7,8,9-tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1 e), de 276 mg de 1 ,3-difluoro-5-iodobenzène, de 349 mg de phosphate de tripotassium, de 156 mg d'iodure de cuivre et de 93 mg de (1 S,2S)- cyclohexane-1 ,2-diamine. Après 1 heure à 150\n0\nC sous irradiation microondes et purification sur colonne de silice du mélange réactionnel (gradient d'élution de CH2CI2 à CH2CI2/MeOH 98/02), on obtient 91 mg de (8S)-9- (3,5-difluorophényl)-2-(morpholin-4-yl)-8-(trifluorométhyl)-6,7,8,9-tétrahydro- 4H-pyπmido[1 ,2-a]pyhmidin-4-one, sous forme d'une meringue ocre, dont les caractéristiques sont les suivantes : \nThe product is prepared following the procedure described in Example 12, but starting with 250 mg of (8S) -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro- pyhmido [1, 2-a] pyhmidin-4-one (Example 1 e), 276 mg of 1,3-difluoro-5-iodobenzene, 349 mg of tripotassium phosphate, 156 mg of copper iodide and 93 mg of (1S, 2S) -cyclohexane-1,2-diamine. After 1 hour at 150 \n°\n C. under microwave irradiation and purification on a silica column of the reaction mixture (elution gradient from CH 2 Cl 2 to CH 2 Cl 2 / MeOH 98/2), 91 mg of (8S) -9- (3.5 g) are obtained. difluorophenyl) -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyhmidin-4-one in the form of an ocher meringue, whose characteristics are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H (400MHz): \n 1H NMR Spectrum (400MHz):\n\n\n\n\n\n\n \n 2,45 (m, 2 H) ; 3,07 à 3,16 (m, 4 H) ; 3,32 à 3,37 (m, 1 H) ; 3,45 à 3,55 (m, 4 H) ; 4,36 (m, 1 H) ; 5,01 (m, 1 H) ; 5,04 (s, 1 H) ; 7,18 à 7,34 (m, 3 H)\n 2.45 (m, 2H); 3.07 to 3.16 (m, 4H); 3.32-3.37 (m, 1H); 3.45 to 3.55 (m, 4H); 4.36 (m, 1H); 5.01 (m, 1H); 5.04 (s, 1H); 7.18 to 7.34 (m, 3H)\n\n\n\n\n\n\n \nSpectrométrie de masse : méthode A \nMass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,95 \n Retention time Tr (min) = 0.95\n\n\n\n\n\n\n \n [M+H]+ : m/z 417 ; [M-H+HCO\n2\nH]- : m/z 461 \n[M + H] +: m / z 417; [M-H + HCO \n2\n H] -: m / z 461\n\n\n\n\n\n\n \nExemple 43 : (8S)-9-[(2,6-difluorophényl)carbonyl]-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n\n\nExample 43: (8S) -9 - [(2,6-difluorophenyl) carbonyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [ 1,2-a] pyrimidin-4-one \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit est préparé en suivant le mode opératoire décrit à l'exemple 18, à partir de 300 mg de (8S)-2-morpholin-4-yl-8-trifluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1 e), de 47 mg d'hydrure de sodium et de 174 mg de chlorure de 2,6-difluorobenzoyle dans 4 ml_ de tétrahydrofuranne. Après trois purifications successives par chromatographie sur silice (éluant: CH\n2\nCI\n2\nZMeOH; gradient de 100/0 à 98/02 puis 98/1 et 98/2), on obtient 22 mg de la (8S)-9-[(2,6-difluorophényl)carbonyl]-2-(morpholin-4- yl)-8-(thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one, sous forme d'un solide blanc, dont les caractéristiques sont les suivantes : \nThe product is prepared following the procedure described in Example 18, starting from 300 mg of (8S) -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyhmido [ 1, 2-a] pyhmidin-4-one (Example 1 e), 47 mg of sodium hydride and 174 mg of 2,6-difluorobenzoyl chloride in 4 ml of tetrahydrofuran. After three successive purifications by chromatography on silica (eluent: CH \n2\n Cl \n2\n ZMeOH, gradient from 100/0 to 98/02 and then 98/1 and 98/2), 22 mg of (8S) -9 - [( 2,6-difluorophenyl) carbonyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyhmidin-4-one in the form of a white solid, the characteristics of which are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H (400MHz) : \n 1H NMR Spectrum (400MHz):\n\n\n\n\n\n\n \n 2,06 à 2,23 (m, 1 H) ; 2,69 à 2,79 (m, 1 H) ; 2,91 (m, 2 H) ; 3,06 (m, 2 H) ; 3,18 à 3,34 (m partiellement masqué, 1 H) ; 3,37 à 3,50 (m, 4 H) ; 4,52 à 4,61 (m, 1 H) ; 5,23 (s, 1 H) ; 5,62 à 5,86 (m, 1 H) ; 7,04 à 7,35 (m, 2 H) ; 7,50 à 7,67 (m, 1 H) \n 2.06 to 2.23 (m, 1H); 2.69 to 2.79 (m, 1H); 2.91 (m, 2H); 3.06 (m, 2H); 3.18 to 3.34 (partially masked m, 1H); 3.37 at 3.50 (m, 4H); 4.52 to 4.61 (m, 1H); 5.23 (s, 1H); 5.62 to 5.86 (m, 1H); 7.04 to 7.35 (m, 2H); 7.50 to 7.67 (m, 1 H)\n\n\n\n\n\n\n \n Spectrométrie de masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,93 \n Retention time Tr (min) = 0.93\n\n\n\n\n\n\n \n [M+H]+ : m/z 445 \n [M + H] +: m / z 445\n\n\n\n\n\n\n \nExemple 44 : (8S)-9-[(2,4-difluorophényl)carbonyl]-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n\n\nExample 44: (8S) -9 - [(2,4-difluorophenyl) carbonyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [ 1,2-a] pyrimidin-4-one \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit est préparé en suivant le mode opératoire décrit à l'exemple 18, à partir de 300 mg de la (8S)-2-morpholin-4-yl-8-trifluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1 e), de 47 mg d'hydrure de sodium et de 174 mg de chlorure de 2,4-difluorobenzoyle dans 4 ml_ de tétrahydrofuranne. Après deux purifications successives par chromatographie sur silice (éluant: CH\n2\nCI\n2\n/MeOH gradient de 100/0 à 98/02 puis 99/01 ), on obtient 24 mg de la (8S)-9-[(2,4-difluorophényl)carbonyl]-2-(morpholin-4-yl)-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one, sous forme d'une laque incolore, dont les caractéristiques sont les suivantes : \nThe product is prepared following the procedure described in Example 18, starting from 300 mg of (8S) -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyhmido [1, 2-a] pyhmidin-4-one (Example 1 e), 47 mg of sodium hydride and 174 mg of 2,4-difluorobenzoyl chloride in 4 ml of tetrahydrofuran. After two successive purifications by chromatography on silica (eluent: CH \n2\n Cl \n2\n / MeOH gradient from 100/0 to 98/02 and then 99/01), 24 mg of (8S) -9 - [(2,4- difluorophenyl) carbonyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyhmido [1,2-a] pyhmidin-4-one in the form of 'a colorless lacquer, whose characteristics are as follows:\n\n\n\n\n\n\n \n Spectre RMN 1 H (400MHz): \n 1H NMR Spectrum (400MHz):\n\n\n\n\n\n\n \n 2,20 (m, 1 H) ; 2,67 à 2,77 (m, 1 H) ; 2,81 à 2,91 (m, 2 H) ; 3,03 (m, 2\n 2.20 (m, 1H); 2.67 to 2.77 (m, 1H); 2.81 to 2.91 (m, 2H); 3.03 (m, 2\n\n\n\n\n\n\n \nH) ; 3,24 à 3,45 (m partiellement masqué, 2 H) ; 3,37 à 3,46 (m, 2 H) ; 3,52\nH); 3.24 to 3.45 (partially masked m, 2H); 3.37 at 3.46 (m, 2H); 3.52\n\n\n\n\n\n\n \n(m, 1 H) ; 4,30 à 4,48 (m, 1 H) ; 5,21 (s, 1 H) ; 5,53 à 5,67 (m, 1 H) ; 7,18 (dt, J=2,5 et 8,6 Hz, 1 H) ; 7,35 (ddd, J=2,5 et 9,3 et 11 ,2 Hz, 1 H) ; 7,61 à 7,71\n(m, 1H); 4.30 to 4.48 (m, 1H); 5.21 (s, 1H); 5.53 to 5.67 (m, 1H); 7.18 (dt, J = 2.5 and 8.6 Hz, 1H); 7.35 (ddd, J = 2.5 and 9.3 and 11.2 Hz, 1H); 7.61 to 7.71\n\n\n\n\n\n\n \n(m, 1 H) \n(m, 1H)\n\n\n\n\n\n\n \n Spectrométrie de masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,94 \n Retention time Tr (min) = 0.94\n\n\n\n\n\n\n \n [M+H]+ : m/z 445 \n [M + H] +: m / z 445\n\n\n\n\n\n\n \nExemple 45 : (8S)-2-(morpholin-4-yl)-9-(phénylacétyl)-8-(trifluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n\n\nExample 45: (8S) -2- (Morpholin-4-yl) -9- (phenylacetyl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidine -4-one \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit est préparé en suivant le mode opératoire décrit à l'exemple\nThe product is prepared following the procedure described in the example\n\n\n\n\n\n\n \n18, à partir de 300 mg de la (8S)-2-morpholin-4-yl-8-trifluorométhyl-6,7,8,9- tétrahydro-pyhmido[1 ,2-a]pyhmidin-4-one (exemple 1 e), de 47 mg d'hydrure de sodium et de 152 mg de chlorure de phénylacétyle dans 4 ml_ de tétrahydrofuranne. Après deux purifications successives par chromatographie sur silice (éluant: CH\n2\nCI\n2\n/MeOH gradient de 100/0 à 98/02 puis\n18, from 300 mg of (8S) -2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyhmido [1,2-a] pyhmidin-4-one (example 1 e), 47 mg of sodium hydride and 152 mg of phenylacetyl chloride in 4 ml of tetrahydrofuran. After two successive purifications by chromatography on silica (eluent: CH \n2\n Cl \n2\n / MeOH gradient from 100/0 to 98/02 then\n\n\n\n\n\n\n \nCH\n2\nCI\n2\n/AcOEt 95/05), on obtient 12 mg de la (8S)-2-(morpholin-4-yl)-9-\nCH \n2\n Cl \n2\n / AcOEt 95/05) gives 12 mg of (8S) -2- (morpholin-4-yl) -9-\n\n\n\n\n\n\n \n(phénylacétyl)-8-(thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1 ,2- a]pyπmidin-4-one, sous forme d'une laque incolore, dont les caractéristiques sont les suivantes : \n(phenylacetyl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one in the form of a colorless lacquer, the characteristics of which are as follows: :\n\n\n\n\n\n\n \n Spectre RMN 1 H (400MHz): \n 1H NMR Spectrum (400MHz):\n\n\n\n\n\n\n \n 1 ,91 (m, 1 H) ; 2,59 à 2,69 (m, 1 H) ; 2,88 (m, 1 H) ; 3,33 à 3,45 (m, 4 H) ; 3,60 (m, 4 H) ; 4,07 (d, J=16,0 Hz, 1 H) ; 4,16 (d, J=16,0 Hz, 1 H) ; 4,43 à 4,52 (m, 1 H) ; 5,30 (s, 1 H) ; 5,48 à 5,61 (m, 1 H) ; 7,11 (d, J=7,7 Hz, 2 H) ; 7,17 à 7,23 (t, J=7,7 Hz, 1 H); 7,28 (t, J=7,7 Hz, 2 H) \n 1.91 (m, 1H); 2.59 to 2.69 (m, 1H); 2.88 (m, 1H); 3.33 at 3.45 (m, 4H); 3.60 (m, 4H); 4.07 (d, J = 16.0 Hz, 1H); 4.16 (d, J = 16.0 Hz, 1H); 4.43 to 4.52 (m, 1H); 5.30 (s, 1H); 5.48 to 5.61 (m, 1H); 7.11 (d, J = 7.7 Hz, 2H); 7.17 to 7.23 (t, J = 7.7 Hz, 1H); 7.28 (t, J = 7.7 Hz, 2H)\n\n\n\n\n\n\n \n Spectrométrie de masse : méthode A \n Mass spectrometry: method A\n\n\n\n\n\n\n \n Temps de rétention Tr (min) = 0,99 ; \n Retention time Tr (min) = 0.99;\n\n\n\n\n\n\n \n [M+H]+ : m/z 423 ; \n [M + H] +: m / z 423;\n\n\n\n\n\n\n \n [M-H]- : m/z 421 ; pic de base : m/z 303 \n\n Exemple 46 : (8S)-9-[2-(3-chlorophényl)éthyl]-2-(morpholin-4-yl)-8- (trifluorométhyl)-6,7,8,9-tétrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one \n[MH] -: m / z 421; base peak: m / z 303  Example 46: (8S) -9- [2- (3-chlorophenyl) ethyl] -2- (morpholin-4-yl) -8- (trifluoromethyl) -6,7,8,9-tetrahydro-4H-pyrimido [ 1,2-a] pyrimidin-4-one\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nLe produit est préparé en suivant le mode opératoire décrit à l'exemple 40, à partir de 150 mg de la (8S)-2-(morpholin-4-yl)-8-(thfluorométhyl)- 6,7,8,9-tétrahydro-4H-pyrimido[1 ,2-a]pyrimidin-4-one dans 2.5 ml_ de toluène sont ajoutés 296 mg d'hydroxyde de sodium dans 2.5 ml_ d'eau, 33 mg d'hydrogènosulfate de tétrabutylammonium et 216 mg de 1 -(2-bromoéthyl)-3- chlorobenzène. Après 44 heures à 60\n0\nC. Après refroidissement, le mélange réactionnel est dilué avec de l'acétate d'éthyle. La phase organique est séparée et la phase aqueuse est extraite par de l'acétate d'éthyle. Les phases organiques rassemblées sont concentrées à sec sous pression réduite et le résidu est purifié par HPLC/MS préparative (Méthode D). On obtient ainsi 42 mg de la (8S)-9-[2-(3-chlorophényl)éthyl]-2-(morpholin-4-yl)-8- (thfluorométhyl)-6,7,8,9-tétrahydro-4H-pyhmido[1 ,2-a]pyhmidin-4-one dont les caractéristiques sont les suivantes : \nThe product is prepared following the procedure described in Example 40, starting from 150 mg of (8S) -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9 4-tetrahydro-4H-pyrimido [1,2-a] pyrimidin-4-one in 2.5 ml of toluene are added 296 mg of sodium hydroxide in 2.5 ml of water, 33 mg of tetrabutylammonium hydrogen sulfate and 216 mg of 1- (2-bromoethyl) -3-chlorobenzene. After 44 hours at 60 \n°\n C. After cooling, the reaction mixture is diluted with ethyl acetate. The organic phase is separated and the aqueous phase is extracted with ethyl acetate. The combined organic phases are concentrated to dryness under reduced pressure and the residue is purified by preparative HPLC / MS (Method D). There is thus obtained 42 mg of (8S) -9- [2- (3-chlorophenyl) ethyl] -2- (morpholin-4-yl) -8- (thfluoromethyl) -6,7,8,9-tetrahydro- 4H-pyhmido [1,2-a] pyhmidin-4-one having the following characteristics:\n\n\n\n\n\n\n \n Spectre RMN 1 H (400MHz): \n 1H NMR Spectrum (400MHz):\n\n\n\n\n\n\n \n 1 ,91 à 2,05 (m, 1 H) ; 2,34 (m, 1 H) ; 2,81 à 2,92 (m, 1 H) ; 2,94 à 3,04 (m, 1 H) ; 3,17 (m, 1 H) ; 3,38 à 3,50 (m, 5 H) ; 3,65 (m, 4 H) ; 4,09 à 4,22 (m, 2 H) ; 4,57 à 4,71 (m, 1 H) ; 4,99 (s, 1 H) ; 7,17 (d, J=7,8 Hz, 1 H) ; 7,25 à 7,38 (m, 3 H) \n 1, 91 to 2.05 (m, 1H); 2.34 (m, 1H); 2.81 to 2.92 (m, 1H); 2.94 to 3.04 (m, 1H); 3.17 (m, 1H); 3.38 at 3.50 (m, 5H); 3.65 (m, 4H); 4.09 to 4.22 (m, 2H); 4.57 to 4.71 (m, 1H); 4.99 (s, 1H); 7.17 (d, J = 7.8 Hz, 1H); 7.25 to 7.38 (m, 3H)\n\n\n\n\n\n\n \n Spectrométrie de masse : méthode A \n\n Temps de rétention Tr (min) = 1 ,03 \nMass spectrometry: method A  Retention time Tr (min) = 1, 03\n\n\n\n\n\n\n \n [M+H]+ : m/z 443 ; [M-H+HCO\n2\nH]- : m/z 487 \n[M + H] +: m / z 443; [M-H + HCO \n2\n H] -: m / z 487\n\n\n\n\n\n\n \nExemple 47 composition pharmaceutique On a préparé des comprimés répondant à la formule suivante : \nExample 47 Pharmaceutical composition Tablets having the following formula were prepared:\n\n\n\n\n\n\n \n Produit de l'exemple 1 0,2 g \n Product of Example 1 0.2 g\n\n\n\n\n\n\n \n Excipient pour un comprimé terminé à 1 g \n Excipient for a tablet finished at 1 g\n\n\n\n\n\n\n \n (détail de l'excipient : lactose, talc, amidon, stéarate de magnésium). \n (details of the excipient: lactose, talc, starch, magnesium stearate).\n\n\n\n\n\n\n \nL'exemple 1 est pris à titre d'exemple de préparation pharmaceutique, cette préparation pouvant être réalisée si désiré avec d'autres produits de formule\nExample 1 is taken as an example of a pharmaceutical preparation, this preparation can be carried out if desired with other products of formula\n\n\n\n\n\n\n \n(I) selon la présente invention et notamment en exemples dans la présente demande, parmi les exemples 2 à 46 et 48 à 56. \n(I) according to the present invention and in particular examples in the present application, among Examples 2 to 46 and 48 to 56.\n\n\n\n\n\n\n \n Les produits du tableau ci-dessous sont des produits de formule (I) tels que définis ci-dessus et constituent les exemples 48 à 56 de la présente invention. Ces produits de 48 à 56 sont préparés comme indiqué ci-dessus dans la partie expérimentale. \n The products of the table below are products of formula (I) as defined above and constitute Examples 48 to 56 of the present invention. These products of 48 to 56 are prepared as indicated above in the experimental part.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nPartie pharmacoloqique : \nPharmacological part:\n\n\n\n\n\n\n \n Protocoles expérimentaux \n Experimental protocols\n\n\n\n\n\n\n \n Procédures expérimentales in vitro \n In vitro experimental procedures\n\n\n\n\n\n\n \n L'activité inhibitrice des molécules sur la phosphorylation d'AKT est mesurée soit par western blotting par la technique décrite ci-dessous, soit par la technique MSD Multi-spot Biomarker détection de Meso Scale Discovery également décrite ci-dessous. Il a été démontré sur un set de molécules que les 2 techniques donnent des résultats compatibles. \n The inhibitory activity of the molecules on the phosphorylation of AKT is measured either by western blotting by the technique described below, or by MSD Multi-spot Biomarker detection of Meso Scale Discovery also described below. It has been demonstrated on a set of molecules that the two techniques give compatible results.\n\n\n\n\n\n\n \n Etude de l'expression de pAKT dans les cellules humaines PC3 de carcinome de prostate mesurée par western blotting (Test A): \n Study of the expression of pAKT in human PC3 prostate carcinoma cells measured by western blotting (Test A):\n\n\n\n\n\n\n \n Cet essai est basé sur la mesure de l'expression de la protéine AKT phosphorylée sur la serine 473. La phosphorylation d'AKT (pAKT) est mesurée par western blotting dans la lignée de carcinome de prostate humaine PC3 (ATCC CRL-1435), en utilisant un anticorps reconnaissant spécifiquement pAKT-S473. \n\n Le jour 1 , les cellules PC3 sont ensemencées en plaques 6 puits (TPP,\nThis assay is based on the measurement of the expression of AKT protein phosphorylated on serine 473. The phosphorylation of AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody specifically recognizing pAKT-S473.  On day 1, the PC3 cells are seeded into 6-well plates (TPP,\n\n\n\n\n\n\n \n# 92006) à la concentration de 0.8x106 cellules/puits dans 1800 μl de milieu\n# 92006) at the concentration of 0.8 × 10 6 cells / well in 1800 μl of medium\n\n\n\n\n\n\n \nDMEM (DMEM Gibco #11960-044) contenant 10% de sérum de veau fœtal\nDMEM (DMEM Gibco # 11960-044) containing 10% fetal calf serum\n\n\n\n\n\n\n \n(SVF Gibco, #10500-056) et 1 % Glutamine (L-GIu Gibco #25030-024), et incubées à 37°C, 5% CO2, pendant une nuit. \n(Gibco SVF, # 10500-056) and 1% Glutamine (L-GIu Gibco # 25030-024), and incubated at 37 ° C, 5% CO2, overnight.\n\n\n\n\n\n\n \n Le jour 2, les cellules sont incubées en présence ou pas des produits à tester pendant 1 à 2 heures à 37°C en présence de 5% CO2. Les molécules diluées dans du diméthylsulfoxyde (DMSO Sigma #D2650), sont ajoutées à partir d'une solution mère concentrée 10 fois, le pourcentage final de DMSO étant de 0.1 %. Les molécules sont testées soit à une seule concentration inférieure ou égale à 10μM, soit à des concentrations croissantes dans une gamme pouvant s'étendre de moins de 1 nM à 10μM. \n On day 2, the cells are incubated in the presence or absence of test products for 1 to 2 hours at 37 ° C. in the presence of 5% CO 2. The molecules diluted in dimethylsulfoxide (DMSO Sigma # D2650) are added from a stock solution concentrated 10 times, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 μM, or at increasing concentrations in a range that may range from less than 1 nM to 10 μM.\n\n\n\n\n\n\n \n Après cette incubation, les cellules sont lysées pour la préparation des protéines. Après aspiration du milieu de culture, les cellules sont rincées par 1 ml de PBS (DPBS Gibco, #14190-094), récupérées par grattage dans 200μl de tampon HNTG complet et transfert en plaque 96 puits (Greiner #651201 ), et lysées pendant 1 H sur glace. Le tampon HNTG est composé du mélange suivant :Hepes 50 mM, NaCI 150 mM, Triton 1 %, Glycerol 10%, avec ajout extemporané d'une pastille de Protease Inhibitor Cocktail Mini (Roche 1836153) et d'une pastille de Phosphatase Inhibitor Cocktail (Rochel 04906837001 ) pour 10ml de tampon. \n After this incubation, the cells are lysed for the preparation of the proteins. After aspiration of the culture medium, the cells are rinsed with 1 ml of PBS (Gibco DPBS, # 14190-094), recovered by scraping into 200 μl of complete HNTG buffer and transfer to a 96-well plate (Greiner # 651201), and lysed for 1 hour on ice. The HNTG buffer is composed of the following mixture: 50 mM Hepes, 150 mM NaCl, 1% Triton, 10% Glycerol, with extemporaneous addition of a Protease Inhibitor Cocktail Mini pellet (Roche 1836153) and a Phosphatase Inhibitor Cocktail pellet (Rochel 04906837001) for 10ml of buffer.\n\n\n\n\n\n\n \n Le lysat est centrifugé 10min à 6000RPM. 155μl de surnageant sont récupérés. 150 μl sont incubés pour dénaturation pendant 5min à 95°C en présence de tampon NuPAGE LDS Sample Buffer 4X dilué 4 fois (Ref InVitrogen NP0007) et de NuPAGE Sample Reducing Agent 10X dilué 10 fois (Ref InVitrogen NP0009). Ces échantillons sont ensuite congelés à -20\n0\nC. 5 μl sont dosées par la technique microBCA selon la fiche technique du MicroBCA Protéine Assay Kit (Pierce #23235). \nThe lysate is centrifuged for 10 min at 6000 rpm. 155 μl of supernatant are recovered. 150 .mu.l are incubated for denaturation for 5 min at 95.degree. C. in the presence of NuPAGE LDS Sample Buffer 4X buffer diluted 4 times (Ref InVitrogen NP0007) and NuPAGE Sample Reducing Agent 10X diluted 10 times (Ref InVitrogen NP0009). These samples are then frozen at -20 \n°\n C. 5 μl are determined by the microBCA technique according to the technical data sheet of the MicroBCA Protein Assay Kit (Pierce # 23235).\n\n\n\n\n\n\n \n Pour la séparation des protéines, 20μg de protéines sont déposées sur gel NU-PAGE 4-12% Bis Tris Gel 12 puits (Ref InVitrogen NP0322BOX) et la \n\n migration est effectuée pendant 1 h30 en tampon de migration NU-PAGE MOPS SDS Running Buffer 2OX dilué 20 fois (Ref InVitrogen NP0001 ), à 150 Volts. \nFor the separation of the proteins, 20 μg of proteins are deposited on NU-PAGE gel 4-12% Bis Tris Gel 12 wells (Ref InVitrogen NP0322BOX) and the  migration is performed for 1 h 30 in migration buffer NU-PAGE MOPS SDS Running Buffer 2OX diluted 20 times (Ref InVitrogen NP0001), at 150 volts.\n\n\n\n\n\n\n \n Le gel est ensuite transféré sur une membrane Invitrolon PVDF (Invitrogen #LC2007) préalablement perméabilisée quelques secondes dans de l'éthanol (Ethanol Fischer Scientific #E/0600DF/15). \n The gel is then transferred to an Invitrolon PVDF membrane (Invitrogen # LC2007) previously permeabilized for a few seconds in ethanol (Ethanol Fischer Scientific # E / 0600DF / 15).\n\n\n\n\n\n\n \n Le transfert s'effectue dans une cuve Biorad à 30 Volts pendant la nuit ou à 60 volts pendant 3 heures, en présence de tampon de transfert NUPAGE Transfer Buffer 2OX dilué 20 fois (Ref InVitrogen NP0006). \n The transfer is carried out in a Biorad tank at 30 volts overnight or at 60 volts for 3 hours, in the presence of NUPAGE Transfer Buffer 2OX transfer buffer diluted 20 times (Ref InVitrogen NP0006).\n\n\n\n\n\n\n \n La membrane est ensuite saturée en solution de saturation composé de TBS (Tris Buffer Saline 10x, Sigma #T5912 Sigma, dilué 10 fois), Tween 20 0.1 % (#P5927 Sigma) et BSA 3% (Bovine Albumin Sérum Fraction V, Sigma #A4503) pendant 6h après un transfert d'une durée de une nuit ou bien pendant 1 h après un transfert d'une durée de 3h. \n The membrane is then saturated in saturation solution composed of TBS (Tris Buffer Saline 10x, Sigma # T5912 Sigma, diluted 10 times), Tween 20 0.1% (# P5927 Sigma) and BSA 3% (Bovine Albumin Serum Fraction V, Sigma # A4503) for 6 hours after a transfer of a duration of one night or for 1 hour after a transfer of a duration of 3 hours.\n\n\n\n\n\n\n \n Les anticorps primaires sont dilués au 1/1000e pour l'anticorps anti- phospho AKT-Ser473 (193H2, monoclonal de lapin, cat#4058 de chez CeII Signaling Technology) Abcam), en solution de saturation composée de PBS, Tween 20 0.1 %, BSA 3%, puis mis sous agitation pendant la nuit à 4°C. \n The primary antibodies are diluted 1/1000 for the anti-phospho antibody AKT-Ser473 (193H2, rabbit monoclonal, cat # 4058 from CeII Signaling Technology) Abcam), in saturation solution composed of PBS, Tween 20 0.1% , BSA 3%, then stirred overnight at 4 ° C.\n\n\n\n\n\n\n \n Deux rinçages de 5 min en solution de lavage composée de TBS, Tween 20 0.1 % sont effectués avant l'hybridation des anticorps secondaires. \n Two rinses of 5 minutes in washing solution composed of TBS, 0.1% Tween 20 are carried out before the hybridization of the secondary antibodies.\n\n\n\n\n\n\n \n Les anticorps secondaires sont dilués au 1/10000e pour l'anticorps Rabbit anti-Mouse IgG HRP (W402 Promega) et au 1/10000e pour l'anticorps Goat anti-Rabbit IgG HRP (W401 Promega) en solution de saturation puis mis sous agitation pendant 1 h à température ambiante. \n Secondary antibodies are diluted 1: 10000 for Rabbit anti Mouse IgG HRP (W402 Promega) and 1 / 10000th for Goat anti-Rabbit IgG HRP antibody (W401 Promega) in saturation solution and then stirred. for 1 h at room temperature.\n\n\n\n\n\n\n \n Deux rinçages de 30 min en solution de lavage sont effectués puis un rinçage de 5 min à IΗ2O est effectué pour éliminer le Tween 20 restant. \n Two rinses of 30 minutes in washing solution are carried out and then rinsing for 5 min at 120 ° is carried out to remove the remaining Tween 20.\n\n\n\n\n\n\n \n La solution de révélation est préparée volume à volume selon la fiche technique du Western Lightning Chemiluminescence Reagent Plus (Western Lightning Chemiluminescence Reagent Plus Perkin Elmer #NEL104). \n\n La membrane est placée pendant 1 min dans la solution de révélation, égouttée, insérée entre deux transparents puis placée dans l'appareil de mesure pour la lecture de la luminescence et la quantification du signal. La lecture de la luminescence est effectuée avec l'appareil FujiFilm (Ray Test). \nThe visualization solution is volume-to-volume prepared according to the data sheet of the Western Lightning Chemiluminescence Reagent Plus (Western Lightning Chemiluminescence Reagent Plus Perkin Elmer # NEL104).  The membrane is placed for 1 min in the developer solution, drained, inserted between two transparencies and placed in the meter for reading the luminescence and quantizing the signal. Luminescence is read with FujiFilm (Ray Test).\n\n\n\n\n\n\n \n L'appareil FUJI mesure le signal total de luminescence obtenu (AU) pour chaque bande sélectionnée. Puis il soustrait le bruit de fond (BG) proportionnel à la taille de la bande sélectionnée (Area), bruit de fond calculé à partir d'une bande de bruit de fond spécifique, en vue d'obtenir le signal spécifique (AU-BG) pour chaque bande. La bande obtenue en absence de produit et en présence de 0.1 % DMSO est considérée comme le 100 % de signal. Le logiciel calcule le % d'activité spécifique (Ratio) obtenu pour chaque bande sélectionnée en fonction de ce 100 % de signal. Le calcul du pourcentage d'inhibition est fait pour chaque concentration selon la formule (100% - Ratio). \n The FUJI device measures the total luminescence signal obtained (AU) for each selected band. Then it subtracts the background noise (BG) proportional to the size of the selected band (Area), background noise calculated from a specific background noise band, in order to obtain the specific signal (AU-BG ) for each band. The band obtained in the absence of product and in the presence of 0.1% DMSO is considered as the 100% signal. The software calculates the% specific activity (Ratio) obtained for each selected band based on this 100% signal. The percent inhibition calculation is done for each concentration according to the formula (100% - Ratio).\n\n\n\n\n\n\n \n 2 expériences indépendantes permettent de calculer la moyenne des pourcentages d'inhibition obtenus à une concentration donnée pour les produits testés uniquement à une concentration. \n 2 independent experiments make it possible to calculate the average of the percentages of inhibition obtained at a given concentration for the products tested only at a concentration.\n\n\n\n\n\n\n \n Le cas échéant, l'activité des produits est traduite en CI50 approchée, obtenue à partir d'une courbe dose-réponse de différentes concentrations testées et représentant la dose donnant 50 % d'inhibition spécifique (CI50 absolue). 2 expériences indépendantes permettent de calculer la moyenne des CI50s. \n Where appropriate, the activity of the products is translated into approximate IC50, obtained from a dose-response curve of different concentrations tested and representing the dose giving 50% specific inhibition (absolute IC 50). 2 independent experiments make it possible to calculate the average of IC50s.\n\n\n\n\n\n\n \n Etude de l'expression de pAKT dans les cellules humaines PC3 de carcinome de prostate mesurée par la technique MSD Multi-spot Biomarker Détection de Meso Scale Discovery (Test B): \n Study of the expression of pAKT in prostate cancer carcinoma PC3 human cells measured by the MSD Multi-spot Biomarker technique Detection of Meso Scale Discovery (Test B):\n\n\n\n\n\n\n \n Cet essai est basé sur la mesure de l'expression de la protéine AKT phosphorylée sur la serine 473 (P-AKT-S473), dans la lignée de carcinome de prostate humaine PC3, par la technique basée sur un immuno-essai sandwich utilisant le kit MSD Multi-spot Biomarker Détection de Meso Scale Discovery : kits phospho-Akt (Ser473) whole cell lysate (#K151 CAD) ou \n\n phospho-Akt (Ser473)/Total Akt whole cell lysate (#K151 OOD). L'anticorps primaire spécifique de P-AKT-S473 (Kit #K151 CAD) est coaté sur une électrode dans chaque puits des plaques 96 puits du kit MSD : après ajout d'un lysat de protéines dans chaque puits, la révélation du signal se fait par l'addition d'un anticorps secondaire de détection marqué avec un composé électrochimioluminescent. La procédure suivie est celle décrite dans le kit. \nThis assay is based on the measurement of the expression of the phosphorylated AKT protein on serine 473 (P-AKT-S473), in the human prostate carcinoma cell line PC3, by the technique based on a sandwich immunoassay using the MSD Multi-spot kit Biomarker Detection of Meso Scale Discovery: phospho-Akt kits (Ser473) whole cell lysate (# K151 CAD) or  phospho-Akt (Ser473) / Total Akt whole cell lysate (# K151 OOD). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated on one electrode in each well of the MSD kit 96-well plates: after addition of a protein lysate in each well, the signal is exposed. by the addition of a labeled secondary detection antibody with an electrochemiluminescent compound. The procedure followed is that described in the kit.\n\n\n\n\n\n\n \n Le jour 1 , les cellules PC3 sont ensemencées en plaques 96 puits\n On day 1, PC3 cells are seeded into 96-well plates\n\n\n\n\n\n\n \n(TPP, #92096) à la concentration de 35000 cellules/puits dans 200 μl de milieu DMEM (DMEM Gibco #11960-044) contenant 10% de sérum de veau fœtal (SVF Gibco, #10500-056) et 1 % Glutamine (L-GIu Gibco #25030-024), et incubées à 37°C, 5% CO2, pendant une nuit. \n(TPP, # 92096) at the concentration of 35000 cells / well in 200 μl of DMEM medium (DMEM Gibco # 11960-044) containing 10% fetal calf serum (Gibco SVF, # 10500-056) and 1% glutamine ( Gibco L-GIu # 25030-024), and incubated at 37 ° C, 5% CO2, overnight.\n\n\n\n\n\n\n \n Le jour 2, les cellules sont incubées en présence ou pas des produits à tester pendant 1 à 2h à 37°C en présence de 5% CO2. Les molécules diluées dans du diméthylsulfoxyde (DMSO Sigma #D2650), sont ajoutées à partir d'une solution mère concentrée 20 fois, le pourcentage final de DMSO étant de 0.1 %. Les molécules sont testées soit à une seule concentration inférieure ou égale à 10μM, soit à des concentrations croissantes dans une gamme pouvant s'étendre de moins de 1 nM à 10μM. \n On day 2, the cells are incubated in the presence or absence of test products for 1 to 2 hours at 37 ° C. in the presence of 5% CO 2. The molecules diluted in dimethylsulfoxide (DMSO Sigma # D2650), are added from a stock solution concentrated 20 times, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 μM, or at increasing concentrations in a range that may range from less than 1 nM to 10 μM.\n\n\n\n\n\n\n \n Après cette incubation, les cellules sont lysées pour la préparation des protéines. Pour cela, après aspiration du milieu de culture, 50μl de tampon de lyse Tris Lysis Buffer complet du kit MSD contenant les solutions d'inhibiteurs de protéases et phosphatases sont ajoutés dans les puits et les cellules sont lysées pendant 1 H à 4°C sous agitation. A ce stade les plaques contenant les lysats peuvent être congelées à -20\n0\nC ou à -80\n0\nC. \nAfter this incubation, the cells are lysed for the preparation of the proteins. For this, after aspiration of the culture medium, 50 μl of Tris Lysis Buffer lysis buffer complete of the MSD kit containing the protease inhibitor and phosphatase solutions are added to the wells and the cells are lysed for 1 h at 4 ° C. agitation. At this stage, the plates containing the lysates can be frozen at -20 \n°\n C. or -80 \n°\n C.\n\n\n\n\n\n\n \n Les puits des plaques 96 puits du kit MSD sont saturés pendant 1 h à température ambiante avec la solution bloquante du kit MSD. Quatre lavages sont effectués avec 150μl de solution de lavage Tris Wash Buffer du kit MSD. Les lysats préparés précédemment sont transférés dans les plaques Multi- spot 96 puits du kit MSD et incubés pendant 1 h à température ambiante, sous agitation. Quatre lavages sont effectués avec 150μl de solution de \n\n lavage Tris Wash Buffer du kit MSD. 25μl de la solution MSD sulfo-tag détection antibody sont ajoutés dans les puits et incubés pendant 1 h à température ambiante, sous agitation. Quatre lavages sont effectués avec 150μl de solution de lavage Tris Wash Buffer du kit MSD. 150μl de tampon de révélation Read Buffer du kit MSD sont ajoutés dans les puits et les plaques sont lues immédiatement sur l'instrument S12400 de Meso Scale Discovery. \nThe wells of the 96-well plates of the MSD kit are saturated for 1 h at room temperature with the blocking solution of the MSD kit. Four washes are carried out with 150 μl of Tris Wash Buffer wash solution of the MSD kit. The lysates prepared above are transferred into the 96-well multi-spot plates of the MSD kit and incubated for 1 hour at room temperature, with stirring. Four washes are carried out with 150μl of solution of  Wash Tris Wash Buffer from the MSD kit. 25 μl of the MSD sulfo-tag detection antibody solution are added to the wells and incubated for 1 h at room temperature, with stirring. Four washes are carried out with 150 μl of Tris Wash Buffer wash solution of the MSD kit. 150μL Read Buffer revelation buffer from the MSD kit is added to the wells and the plates are read immediately on the S12400 instrument of Meso Scale Discovery.\n\n\n\n\n\n\n \n L'appareil mesure un signal pour chaque puits. Des puits sans cellules et contenant le tampon de lyse servent à déterminer le bruit de fond qui sera soustrait à toutes les mesures (min). Les puits contenant des cellules en absence de produit et en présence de 0.1 % DMSO sont considérés comme le 100 % de signal (max). Le calcul du pourcentage d'inhibition est fait pour chaque concentration de produit testé selon la formule suivante : (1 - ((essai- min)/(max-min)))x100. \n The device measures a signal for each well. Cell-free wells containing the lysis buffer are used to determine the background noise that will be subtracted from all measurements (min). Wells containing cells in the absence of product and in the presence of 0.1% DMSO are considered the 100% signal (max). The percentage inhibition calculation is made for each test product concentration according to the following formula: (1 - ((test-min) / (max-min))) × 100.\n\n\n\n\n\n\n \n L'activité du produit est traduite en Cl\n5\no, obtenue à partir d'une courbe dose-réponse de différentes concentrations testées et représentant la dose donnant 50 % d'inhibition spécifique (Cl\n5\no absolue). 2 expériences indépendantes permettent de calculer la moyenne des CI\n5\nOs-\nThe activity of the product is translated into Cl \n5\n o, obtained from a dose-response curve of different concentrations tested and representing the dose giving 50% specific inhibition (Cl \n5\n o absolute). 2 independent experiments make it possible to calculate the average of the CI \n5\n Os-\n\n\n\n\n\n\n \nL'activité inhibitrice des molécules sur l'autophagie est mesurée par la translocation de la protéine LC3 du cytoplasme vers les autophagososmes.\nThe inhibitory activity of the molecules on autophagy is measured by the translocation of the LC3 protein from the cytoplasm to the autophagososms.\n\n\n\n\n\n\n \nPour cela les cellules HeIa ont été transfectées avec un vecteur codant pour la protéine chimérique GFP-LC3. Un clone HeIa exprimant la protéine GFP-\nFor this, the HeIa cells were transfected with a vector encoding the GFP-LC3 chimeric protein. A HeIa clone expressing the GFP-protein\n\n\n\n\n\n\n \nLC3 de manière stable a été sélectionné. La translocation de la protéine LC3 est déterminée en mesurant le nombre de cellules présentant des granulations de LC3 après un stress métabolique, à l'aide d'un cytomètre d'analyse automatique d'images iCyte (Compucyte) \nLC3 stably has been selected. The translocation of the LC3 protein is determined by measuring the number of cells presenting LC3 granulations after metabolic stress, using an iCyte (Compucyte) automatic image analysis cytometer.\n\n\n\n\n\n\n \n Etude de la translocation de la protéine LC3 dans les cellules humaines HeIa mesurée parcvtomètre d'analyse d'images (Test C): \n Study of the translocation of LC3 protein in human cells HeIa measured paralytic image analysis (Test C):\n\n\n\n\n\n\n \n Le jour 1 , les cellules HeIa GFP-LC3 sont ensemencées en plaques 96 puits coatées poly D lysine (Greiner, #655946) à la concentration de 15000 \n\n cellules/puits dans 200 μl de milieu DMEM (DMEM Gibco #11960-044) contenant 10% de sérum de veau fœtal (SVF Gibco, #10500-056) et 1 % Glutamine (L-GIu Gibco #25030-024), et incubées à 37°C, 5% CO2, pendant une nuit. \nOn day 1, HeIa GFP-LC3 cells are seeded into 96-well coated poly D lysine plates (Greiner, # 655946) at a concentration of 15,000.  cells / well in 200 μl of DMEM medium (DMEM Gibco # 11960-044) containing 10% fetal calf serum (Gibco SVF # 10500-056) and 1% Glutamine (L-GIu Gibco # 25030-024), and incubated at 37 ° C, 5% CO2, overnight.\n\n\n\n\n\n\n \n Le jour 2, les cellules sont lavées deux fois avec de l'EBSS\n On day 2, the cells are washed twice with EBSS\n\n\n\n\n\n\n \n(Sigma#E3024).. Les cellules sont ensuite incubées dans de l'EBSS, 10μM d'hydroxychloroquine et des produits à tester pendant 2h à 37°C en présence de 5% CO2. Les molécules sont diluées dans du diméthylsulfoxyde (DMSO Sigma #D2650). Le pourcentage final de DMSO étant de 0.1 %. Les molécules sont testées à des concentrations croissantes dans une gamme pouvant s'étendre de 10 nM à 1 μM. \n(Sigma # E3024). The cells are then incubated in EBSS, 10 μM of hydroxychloroquine and products to be tested for 2 h at 37 ° C. in the presence of 5% CO 2. The molecules are diluted in dimethylsulfoxide (DMSO Sigma # D2650). The final percentage of DMSO is 0.1%. The molecules are tested at increasing concentrations in a range that can range from 10 nM to 1 μM.\n\n\n\n\n\n\n \n Après cette incubation, les cellules sont fixées avec 4% paraformaldéhyde (Sigma#HT501128 4L) pendant 10min. Les cellules sont ensuite lavées 2 fois avec du PBS puis les noyaux colorées avec 2μg/ml de Hoechst 33342 (lnvitrogen#H3570) Les plaques 96 puits sont ensuite lues avec le cytomètre analyse d'image iCyte (Compucyte). L'analyseur quantifie le nombre de cellules présentant des granulations de LC3. Une cellule est considérée comme positive lorsqu'elle présente au moins 4 granulations de LC3. Le pourcentage de cellules présentant plus de 4 granulations est calculé par rapport au nombre total de cellules. \n After this incubation, the cells are fixed with 4% paraformaldehyde (Sigma # HT501128 4L) for 10 min. The cells are then washed twice with PBS and the nuclei stained with 2 μg / ml of Hoechst 33342 (Invitrogen # H3570). The 96-well plates are then read with the iCyte (Compucyte) image analysis cytometer. The analyzer quantifies the number of cells with LC3 granulations. A cell is considered positive when it has at least 4 granulations of LC3. The percentage of cells with more than 4 granulations is calculated with respect to the total number of cells.\n\n\n\n\n\n\n \n L'activité du produit est traduite en CI50, obtenue à partir d'une courbe dose-réponse de différentes concentrations testées et représentant la dose donnant 50 % d'inhibition spécifique (CI50 absolue). 2 expériences indépendantes permettent de calculer la moyenne des CI50s. \n The activity of the product is translated into IC50, obtained from a dose-response curve of different concentrations tested and representing the dose giving 50% specific inhibition (IC50 absolute). 2 independent experiments make it possible to calculate the average of IC50s.\n\n\n\n\n\n\n \n Les résultats obtenus pour les produits en exemples dans la partie expérimentale sont donnés dans le tableau de résultats pharmacologiques ci- après: \n The results obtained for the exemplary products in the experimental part are given in the table of pharmacological results below:\n\n\n\n\n\n\n \n Tableau 1 de résultats pharmacoloqiques : \n\n\n\n\n\n\n\nTable 1 of pharmacological results: \n \n \n \n\n\n\n\n\n\n \n \n*\n Tests A, B et C : CI50 (nM) \n \n*\n Tests A, B and C: IC50 (nM)\n\n\n\n\n\n\n \n Test d'activité anti-paludique \n Malaria activity test\n\n\n\n\n\n\n \n Les tests d'activité antipaludique sont effectués selon la micro méthode radioactive de Desjardins (R. E. Desjardins, CJ. Canfield, J. D. Haynes, J. D. Chulay, Antimicrob. Agents Chemother., 1979, 16, 710-718). Les essais sont réalisés dans des microplaques de 96 puits (Test Plates Réf. 92696, Techno Plastic Products Ag, Zollstrasse 155, CH-8219 Trasadingen). Les souches de P. falciparum sont mises en culture dans des solutions de RPMI 1640 complémenté avec 5 % de sérum humain avec un hématocrite à 2 % et une parasitémie à 1 ,5 %. Pour chaque essai, les parasites sont incubés avec des concentrations choisies de drogues pendant 48 h à 37 \n0\nC en atmosphère humide et à 5 % de CO2. L'artémisinine, l'artésunate ainsi que la chloroquine di-phosphate sont utilisées comme molécules référence. La première dilution de la drogue est réalisée à 1 mg/mL dans du diméthylsulfoxyde. La gamme de dilutions des solutions filles successives est également réalisée dans du diméthylsulfoxyde. Chaque dilution fille est ensuite diluée au 1/50 ème dans du RPMI 1640 complémenté avec 5 % de sérum humain, l'ensemble des dilutions étant réalisé à 37 \n0\nC. Ces dilutions sont ensuite ajoutées aux parasites en culture dans les microplaques. Après ajout de la drogue, les parasites sont en culture dans du RPMI 1640 à 5 % de \n\n sérum humain et à 1 % de diméthylsulfoxyde. La croissance des parasites est mesurée par l'incorporation d'hypoxanthine tritiée (ajoutée 24 h après le début de l'exposition à la drogue) comparée à l'incorporation en l'absence de drogue. \nThe antimalarial activity tests are carried out according to the Desjardins radioactive micro-method (RE Desjardins, CJ Canfield, JD Haynes, JD Chulay, Antimicrob Agents Chemother., 1979, 16, 710-718). The tests are carried out in 96-well microplates (Test Plates Ref 92696, Techno Plastic Products Ag, Zollstrasse 155, CH-8219 Trasadingen). Strains of P. falciparum are cultured in RPMI 1640 solutions supplemented with 5% human serum with 2% hematocrit and 1.5% parasitaemia. For each test, the parasites are incubated with selected concentrations of drugs for 48 hours at 37 \n°\n C. in a humid atmosphere and at 5% CO 2. Artemisinin, artesunate and chloroquine di-phosphate are used as reference molecules. The first dilution of the drug is carried out at 1 mg / ml in dimethylsulfoxide. The range of dilutions of the successive daughter solutions is also carried out in dimethylsulfoxide. Each daughter dilution is then diluted 1:50 in RPMI 1640 supplemented with 5% human serum, all dilutions being performed at 37 \n°\n C. These dilutions are then added to the parasites in culture in the microplates. After adding the drug, the parasites are cultured in RPMI 1640 at 5%  human serum and 1% dimethylsulfoxide. Parasite growth is measured by incorporation of tritiated hypoxanthine (added 24 h after the start of drug exposure) compared to incorporation in the absence of drugs.\n\n\n\n\n\n\n \n L'activité du produit est traduite en % inhibition de la croissance de P. falciparum (hautement résistant à la chloroquine souche Fcm29-Cameroun) à 1 uM et 0,1 uM dans un test in vitro utilisant des érythrocytes humains infectés. \n The activity of the product is translated into% inhibition of the growth of P. falciparum (highly resistant to chloroquine strain Fcm29-Cameroon) at 1 μM and 0.1 μM in an in vitro test using infected human erythrocytes.\n\n\n\n\n\n\n \n Les résultats obtenus pour les produits en exemples dans la partie expérimentale sont donnés dans le tableau 2 de résultats pharmacologiques ci-dessous : \n The results obtained for the products in examples in the experimental part are given in table 2 of pharmacological results below:\n\n\n\n\n\n\n \n Tableau 2 de résultats pharmacologiques : \n Table 2 of pharmacological results:"
  }
]